<SEC-DOCUMENT>0001641172-25-010790.txt : 20250515
<SEC-HEADER>0001641172-25-010790.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515153522
ACCESSION NUMBER:		0001641172-25-010790
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		25952007

	BUSINESS ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GTBP="http://gtbiopharma.com/20250331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_GTBP_gtbiopharma.com_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000006" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantToSettleVendorPayable" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0522" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0524" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0613" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0615" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0731" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0733" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0735" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0737" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0739" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="xdx2ixbrl0741" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20250331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-04</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_InducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-20</xbrli:startDate>
        <xbrli:endDate>2024-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-112025-05-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-11</xbrli:startDate>
        <xbrli:endDate>2025-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-14</xbrli:startDate>
        <xbrli:endDate>2025-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-05-15_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-15_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000422" toRefs="Footnote000463"/>
  <ix:relationship fromRefs="Fact000423" toRefs="Footnote000463"/>
  <ix:relationship fromRefs="Fact000425" toRefs="Footnote000463"/>
  <ix:relationship fromRefs="Fact000427" toRefs="Footnote000463"/>
  <ix:relationship fromRefs="Fact000506" toRefs="Footnote000529"/>
  <ix:relationship fromRefs="Fact000508" toRefs="Footnote000529"/>
  <ix:relationship fromRefs="Fact000510" toRefs="Footnote000530"/>
  <ix:relationship fromRefs="Fact000512" toRefs="Footnote000530"/>
  <ix:relationship fromRefs="Fact000514" toRefs="Footnote000531"/>
  <ix:relationship fromRefs="Fact000516" toRefs="Footnote000531"/>
  <ix:relationship fromRefs="Fact000518" toRefs="Footnote000531"/>
  <ix:relationship fromRefs="Fact000520" toRefs="Footnote000531"/>
  <ix:relationship fromRefs="xdx2ixbrl0522" toRefs="Footnote000532"/>
  <ix:relationship fromRefs="xdx2ixbrl0524" toRefs="Footnote000532"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20250101__20250331_z6ZzhpUAsLX1"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000012" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentQuarterlyReport_c20250101__20250331_zOo3iWUNJ7ic"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarterly
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_90D_edei--DocumentPeriodEndDate_c20250101__20250331_z6yqfpINw0Oj"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20250101__20250331_znMOoBPi7zli"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000015" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentTransitionReport_c20250101__20250331_zPFvCDXzknl3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transition
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from __________ to ____________.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_900_edei--EntityFileNumber_c20250101__20250331_zUgwxUmMgIs7"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000017" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20250101__20250331_z011NACklB47"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000018" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20250101__20250331_z21MkjjBCwh3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20250101__20250331_zTNudvHEfWQ"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A<sup>1</sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--CityAreaCode_c20250101__20250331_zMZ7urCHYZH9"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000021" name="dei:CityAreaCode">415</ix:nonNumeric></span>-<span id="xdx_900_edei--LocalPhoneNumber_c20250101__20250331_ztD7xc7AorWg"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000022" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20250101__20250331_zKfl8JKtDHS9"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000023" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20250101__20250331_z3x1Xwcjdp6i"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000024" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20250101__20250331_zrGulrKa3Dy6"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:exchnameen" id="Fact000025" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20250101__20250331_z2wZtUj1X6W1"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000026" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20250101__20250331_zlKSRFinJ6Xk"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000027" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20250101__20250331_zuXqtTxtabff"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000028" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90E_edei--EntitySmallBusiness_c20250101__20250331_zTXp7dN8ayi7"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleantrue" id="Fact000029" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20250101__20250331_zSDmcHx59Pt1"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90B_edei--EntityShellCompany_dbF_c20250101__20250331_zE5xNvsCtg84"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="Fact000031" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 13, 2025, the registrant had <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250513_zvhBgaVeEcrg"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-05-13" id="Fact000032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,586,397</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><sup>1
</sup></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of July 1, 2024, the Company
became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements
of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required
to be sent to the Company&#8217;s principal executive offices may be directed to <span id="xdx_901_edei--EntityAddressAddressLine1_c20250101__20250331_zUoxb1Otkll5"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000033" name="dei:EntityAddressAddressLine1">505 Montgomery Street</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20250101__20250331_zzfr4dqZ4TPb"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000034" name="dei:EntityAddressAddressLine2">10th Floor</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20250101__20250331_zVNcrxY4odm4"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000035" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20250101__20250331_zANbu2euDBx5"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000036" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span>
<span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250101__20250331_zMT27pg4QtU3"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" id="Fact000037" name="dei:EntityAddressPostalZipCode">94111</ix:nonNumeric></span>, or by email to auditcommittee@gtbiopharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-Q</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three Months Ended March 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">Condensed
    Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Condensed
    Statements of Operations for the three months ended March 31, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Condensed
    Statements of Stockholders&#8217; Equity (Deficit) for the three months ended March 31, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Condensed
    Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Notes
    to Unaudited Condensed Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_008">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_009">PART
    II OTHER INFORMATION</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_010">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_011">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_012">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_zNcl90vSqW12" summary="xdx: Statement - Condensed Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250331_zJ8rl4WzBVz2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zMOlXN8ceu3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zoZsJEvdBmQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zVagspbJHWa2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACz3bi_zy9S5NZ8bTCd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,365,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,951,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCashCurrent_i02I_maACz3bi_zEGCna8E52xk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2025-03-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2024-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz3bi_zgrgIaJ411ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtACz3bi_maAzZ68_zUtmkqwH6KR5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,658,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_znj8pp6beoh9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    DEFICIT</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_z4D9ofNaUh88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCzqF6_zA4m98CcO7zd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,380,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzqF6_zBAVtquEDG5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,132,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,797,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_i02I_maLCzqF6_zXUVCnLJ8xUb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzqF6_maLASEzEek_z70VHCRW5Gwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,638,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,902,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; Deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_maSEzWnM_zVQxTE97cxI1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Preferred stock,
    par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zcyQTHIImxZ4" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zNIUC8QGtPAj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000081" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_zqk5QDYDSBpl" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zeiNMH7JGL2j" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized Series C - <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zub30jxWxRwb" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFQstNX0oOni" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zIxzyroKMM4a" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zuOwXd3vd2z4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2025 and December 31,
    2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_maSEzWnM_zX8JuiP9svt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_zFGpu6cYqFI9" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zoWuB0TgtHpi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_zUQNrW5UU0T" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zXO3D89ZAbMa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_zTdxvebEHnrc" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_z2SGtalGejOb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,536,397</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zHqTrJJLPOo5" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zhtfdb5myIh1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_maSEzWnM_z6PjY3NsDZx1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,019,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzWnM_zicHMan1RA9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">696,003,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_mtSEzWnM_maLASEzEek_zsajMFQs6tI8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders&#8217; Deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">980,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzEek_zj6FRcq69T7h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,658,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_z9fftw6jjBx1" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20250331_zIo7h4YpDcP1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240331_zo1m6hr7RiQ6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For The Three
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzeyD_zpgSpHzVWTd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0129">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILzeyD_zx5gSAiqcqgc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and
    development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,099,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">777,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_msOILzeyD_zMH2vna06m9e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Selling,
    general and administrative (including $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zuHWtkjNS69g" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zMyKB57DV6m3" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span> from stock compensation for the three months ended March 31, 2025 and 2024,
    respectively)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">833,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,314,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iT_maNILz6lV_mtOILzeyD_zZVs3RplfFDe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss from Operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,932,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,091,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeOther_i01_maNIEznFC_zBpVvKgoYgmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-01-01to2025-03-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-012024-03-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEznFC_z9R5HhglBYB5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value of
    warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-03-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">126,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">658,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEznFC_zlKGJjkvJl12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of vendor
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-03-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0157">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEznFC_zJ3cTXCiX1o1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0159">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_maNIEznFC_zuQsFHidN6g8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    gain on short-term investments</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0162">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-03-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01T_maNILz6lV_mtNIEznFC_zdHdJdxbIp9c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Other Income, Net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,156,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">825,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILz6lV_zY1oEMWUo7t5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,266,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Per Share - Basic and Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331_zECIEhWKXNLf" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331_zzE4oiP7ARKj" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-03-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240331_zrle9NtOQLIg" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240331_za6hWLrIMYOf" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-03-31" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.64</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331_z5L7mstbCpmi" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331_zE6Wn1YN2Zgd" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-03-31" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,345,087</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240331_z2Gcuqnxj1h2" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240331_zPQ34twi5WA1" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-03-31" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Three Months Ended March 31, 2025 and 2024 (Unaudited):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_zDgMPeHn8Gn5" summary="xdx: Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zKuLde0XecSj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zc7MJd0xEQyj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zCV7ypCk3sIj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z6DnzmOFhTqg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zsBGepFwBhmb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43F_c20250101__20250331_eus-gaap--StockholdersEquity_iS_zaula5flVZfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVa9fGw6ZJV5" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zw7VjhlrQ8Kb" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_z7qukCKnfzh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants for cash and inducement
warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpbQec5s7eF4" title="Exercise of warrants for cash and inducement warrants, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">615,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0200">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-01to2025-03-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_zKacv8hEjdf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of prefunded warrant to settle
    vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-01to2025-03-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zyYDZ99SNKOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0211">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-03-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z6bVdwt7Aool" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0219">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43B_c20250101__20250331_eus-gaap--StockholdersEquity_iE_zwnywWmCmACb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zsZZbyQIU0z5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvIQ75ML5YN" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,536,397</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,019,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">696,003,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">980,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_435_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zTWxI8nM64y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 30%"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhLVsnxQmMd1" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDgKhZaXJlwh" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43B_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zJkcp1w7u3xi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6w38RaqmqGi" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU8B883jbTHa" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zdWl4nBULYs9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zJcOOXpMx1k5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,266,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,266,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_432_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zdTA5X4r2dZ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5x5zrBLQoRa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4hDVvBA9xna" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,641,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,331,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,312,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43F_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zOObXHcOtoJj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPhN2HCDueLe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYDncsU8BqG9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,641,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,331,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,312,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_ziD9mrTDThJ3" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250101__20250331_zuIN9wyex0Md" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240331_zRQAImInf19j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For The Three
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_maNCPBUzkoF_z8wQ4Kldha65" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,266,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maNCPBUzkoF_zF1NoXnQNRu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzkoF_z1phkIwZMaYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value of
    warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-03-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">126,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">658,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DebtSecuritiesUnrealizedGainLoss_i02N_di_msNCPBUzkoF_zJHTzAs8UZOb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain on short-term
    investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-03-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzkoF_z0LvjelWjlU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Increase) Decrease in
    prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-03-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-03-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzkoF_zvBNJNXK27bd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (Decrease) in
    accounts payable and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-03-31" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,291,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-03-31" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,347,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInOperatingLeaseRightofuseAssets_i03N_di_msNCPBUzkoF_zeWVFAIQQDk8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Decrease in operating lease right-of-use assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="From2024-01-012024-03-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzkoF_maCCERCzk1L_zGTfcHI1xDOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Used in Operating
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,202,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-03-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,163,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsForProceedsFromInvestments_i01N_di_msNCPBUz7m2_zwfv52oD7XRi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Sale of investments</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2024-01-012024-03-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,034,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz7m2_maCCERCzk1L_zI02LC97QARg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Provided by Investing
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-03-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,034,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maNCPBUzWiy_zMhu6O3GTTq6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of warrants and issuance of inducement warrants for cash, net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-03-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzWiy_maCCERCzk1L_zMxsZEaxuXQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Provided by Financing
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzk1L_zzuHlCxdcHLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Increase (Decrease) in Cash and Cash Equivalents
    and Restricted Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-03-31" id="Fact000336" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,586,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-03-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">871,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zwbaaLACFySj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents
    and Restricted Cash at Beginning of Period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,044,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,079,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_ziV0kPHNimCf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents
    and Restricted Cash at End of Period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,458,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,950,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF CASH FLOW INFORMATION:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--CashPaidDuringYearFor_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid during the period for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaid_i02_zFnoA3KR6Ct7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_i02_zjTuzFl1xnYa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF NON-CASH INVESTING AND FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--FairValueOfPrefundedWarrantToSettleVendorPayable_i01_zi3RxZOpNYnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value of prefunded warrant to settle vendor payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-01to2025-03-31" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended March 31, 2025 and 2024 (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000363" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zM6PIFrYAEv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_823_z23uQagtjm6i">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible
debt instruments, and strategic collaborations. For the three months ended March 31, 2025, the Company recorded a net loss of approximately
$<span id="xdx_90B_eus-gaap--ProfitLoss_iN_pid_di_c20250101__20250331_zt99e9axnC3l" title="Net loss"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31" id="Fact000365" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">800,000</ix:nonFraction></span> and used cash in operations of approximately $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250331_zHl2q3qQWmh" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" id="Fact000367" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">2.2</ix:nonFraction></span> million, and had a stockholders&#8217; deficit of approximately $<span id="xdx_906_eus-gaap--StockholdersEquity_iNI_pn6n6_di_c20250331_z31Ufg8ARuT" title="Stockholders deficit"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000369" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">1</ix:nonFraction></span> million
as of that date. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year
of the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm,
in its report on the Company&#8217;s December 31, 2024, financial statements, raised substantial doubt about the Company&#8217;s ability
to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable
to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000371" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zRhOk7ZRSfae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zHweFq8hJnyg">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000373" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_84A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zmAmW8E5Bce8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z470qXIiS6Ld">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain
information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be
read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance
sheet as of December 31, 2024 included herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000375" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zqT8nlXirlld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zGi5OSuGphgl">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000377" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zI8cXo5tQFOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zjgXBdSxuVk7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At March 31, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds, amounted to approximately $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zYOreHHvbRKg" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000379" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zBl9ncHWQPD1" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000383" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zv9OsLVptJsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zMMvlSpaDnai">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement
with the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000385" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zacVsGESQNJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zUb8WajMASUb">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses
and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20250331_zOXvps7CxYa7" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_zspCPHqNOLEj" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span> at March 31, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000391" name="GTBP:WarrantLiabilityPolicyTextBlock"><p id="xdx_843_ecustom--WarrantLiabilityPolicyTextBlock_zn4R7s00VTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zmB5wSBctree">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000393" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zqoRcRrNaNji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zaJjXnbQV6M8">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000395" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zCvsGIiEXn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTSl9riVB5mk">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000397" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zbXPGAi80Qdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zRBQmeHnWnj5">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000399" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember" id="Fact000404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,769,894</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-03-31" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,894,494</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">431,227</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z81CU68N4GFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000410" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zzhLpyzj6El3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOEuKYc0ZAPb">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20250331_zS9GZTGTB3dj" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-03-31" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000414" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwwaByBJlAOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zPIXApcRV3ug">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000416" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEag9Q3NM2M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zHfJBoclPqT7">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

</ix:nonNumeric><p id="xdx_85E_znT4gC9gGuDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000418" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zOdI1DL8mQz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_821_zH2zM6gKBSR8">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000420" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcZATHE2dRq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zKWYRga3cP4g" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250331_zqW0YFXn3lBf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_z1WqoC6Zg8B2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXLwOEOvO1m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable
    to Cytovance, a related party <b><sup id="xdx_F4E_z4UeE58erEQf">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z1dMePmOYD8g" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000425" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z5FJlFZ8isvd" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zjUsN19m6ata" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-03-31_custom_UniversityOfMinnesotaMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zlDwu4Xead43" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31_custom_UniversityOfMinnesotaMember" id="Fact000432" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_ziZvvk7z22X5" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000434" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpehegdI0Lu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zztuRI6YJCde" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember" id="Fact000439" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjRO9z2vDVGd" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000441" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zrHzT4rPEdff" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjDQo3GCFERe" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember" id="Fact000446" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zB0I64IsCdH5" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zSNx52a28dp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2025-03-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zay1ppGKWtfh" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31_custom_OtherAccountsPayableMember" id="Fact000453" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2024-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z7TmpAgQIJT5" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember" id="Fact000455" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zajFcUgdrSBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,380,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331_zqLF4pMHeNXi" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-03-31" id="Fact000460" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_z4rDXvrJuaIc" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td id="xdx_F01_zZsdS1E3ZXe4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhrfQva32tsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000463" xml:lang="en-US">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8AB_znnEVNOy7KV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000465" name="GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zALwPRMOQmf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zdNKQsxVbiCj" style="display: none">Schedule
of Accounts Payable to Related Party</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250331_z8nrJ4FJXso4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zUA7eC4FzE6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zxID2R9FHfA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,515,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zUO0oBe3k6ni" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTpHmaiJX623" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zhYuxYYBTK39" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments in pre-funded
    warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zevZ2mD2owff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-03-31_custom_CytovanceBiologicsIncMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,984,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_ze56yxW8XcD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zd27Unshc0lk" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares of common stock exercisable
at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zDYAuT8VtyV" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000484" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share with a fair value of approximately $<span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgKhMJQaAxp5" title="Payments in pre-funded warrants, at fair value"><ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></span> to Cytovance as partial payment of accounts payable. The pre-funded
warrants were valued at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zzFXn5B72fE" title="Prior year unpaid fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember" id="Fact000488" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million. The Company classified this transaction as other income during the period ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000490" name="GTBP:WarrantLiabilityTextBlock"><p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zAPAMzLGFfWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zqbd1GKbxbQ6">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z9Wn8dAr8rt6" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember" id="Fact000492" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,667</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zmHfZSUpMuW6" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zrrIJOKaTQg4" title="Volatility amount utilized in the value calculation percentage"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000496" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zUINDY4eEwbj" title="Warrant  fair value"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000498" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember" escape="true" id="Fact000500" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zq3ZcIXqQcel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a BlackScholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqVMRczECXg3" style="display: none">Schedule
of Warrant Liability Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zxkZEcyMUNDg" title="Warrants measurement input" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000502" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.15</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zI2ZKBePaDPh" title="Warrants measurement input" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup id="xdx_F4D_zOwk5RhxxqZg">1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zE5vJQEuvXPj" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zoeM54tNwsCl" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000508" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup id="xdx_F4E_zZXqpXDLWypd">2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z0D7SRTuVGF9" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">112</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zdmOdN0ZZFDl" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000512" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup id="xdx_F48_zvGlUa57Zhfc">3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zHmVUjPWfAQ6" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000514" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.75</ix:nonNumeric></span>
                                            &#8211; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z9EC9wV3sDtl" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000516" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.25</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zIU4Ylbt9qG5" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000518" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.00</ix:nonNumeric></span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zZDwDxUEPSI1" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000520" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.50</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup id="xdx_F4F_zelfSlSVyIg3">4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zDUZHAFyOnua" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zX8IAhNPrhq2" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zaFbvcMFMlB2" title="Fair value of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z1VDfo10kQO" title="Fair value of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zYjOToFFH3vg" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F16_zTdv3qgvClSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000529" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0C_zvpQT0GH6Qs1" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1D_zAnmwhI4d9ah" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000530" xml:lang="en-US">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zIo5uGGv9OHb" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F12_zLN7PkjyPcej" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000531" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F05_zOgBl70L1kif">4</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1E_za3P2XSlLMx8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000532" xml:lang="en-US">Based on no dividends
paid or expected to be paid</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AE_zm8VVcez7oXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000534" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zRTHSBQwv64b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zCApsygI1Ndi" style="display: none">Schedule
of Warrant  Liability Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250331_zHEIIxNXu5Fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240331_z4UqUeGrsoh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zG7JU6ftL4me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zKClTktTjRU2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIhUaRRlmMC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2025-01-01to2025-03-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">126,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2024-01-012024-03-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">658,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zTwyAK8bjMql" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zVUwC9mOynhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A4_zb0HKYT3ZeLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000551" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHRGombDIUQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_823_zIGddV7QHat3">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of March 31, 2025 was <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_zcYP3SOb3O65" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_zLTVgR4WAM6j" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_z19uG5FLWC61" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zUNnKtJdz22g" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zLS9bHQh7zra" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-02-262025-02-26" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">686,000</ix:nonFraction></span>
before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_z1VPm9iHPPz5" title="Other offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-02-262025-02-26" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>
in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226_zXKpaejRaEC4" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span>
shares of the Company&#8217;s common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zblTL6afperg" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-02-26_us-gaap_CommonStockMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span>
per share. The holders agreed to exercise these existing warrants at a reduced exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z3pd9KePE9w8" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span>
per share in exchange for the Company&#8217;s agreement to issue the holders new warrants (the &#8220;Inducement Warrants&#8221;)
exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zeCdRkOxUqHe" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,138</ix:nonFraction></span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zCO0MtQqnK61" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zwAvPu6xgJr6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_z5IzWdtryvi3" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000577" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance, and ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zOvJ8KCsOzdh" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyNQ11svGdMa" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately
upon issuance with a term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_z6k5OlPMUh46" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000583" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen months</ix:nonNumeric></span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240523_zTkrCPQiDXnd" title="Placement agents"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-23" id="Fact000585" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zwb6XRnUYg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zoGPjdbEHp2k" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26" format="ixt-sec:durwordsen" id="Fact000589" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250331_zQz5MRAXQ7jf" title="Equity issuance cost"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-03-31" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJySguInM01" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqxVdC8cGGm6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></span></span> shares of series C preferred stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJMIh8i0dVvl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLvkRRo84uu4" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000601" name="GTBP:CommonStockWarrantsAndOptionsTextBlock"><p id="xdx_806_ecustom--CommonStockWarrantsAndOptionsTextBlock_zOx08Tl0c5w9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82A_zOJ5liIIBDZ7">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000603" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zNijWn5Oqb17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zQZzAJUiSHbk" style="display: none">Schedule
of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zaOszPndsBcg" title="Warrants outstanding, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,429</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zIS25OOpsxh1" title="Weighted average exercise price, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.85</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zDlP55hnZGb" title="Number of warrants, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-01to2025-03-31" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">951,534</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250331_zgmaCpNYvMPd" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.05</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250331_zV9d4w3rg8i8" title="Number of warrants, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250331_zKgEw1yv7Ym1" title="Weighted average exercise price, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331_zSi1crGnMMpj" title="Number of warrants, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-01to2025-03-31" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250331_z3pBqM9iRRL6" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-03-31" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.35</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zsv46KVXYRMj" title="Warrants outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,769,894</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_zHUFngovEUl1" title="Weighted average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.91</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250331_zIGjOpokraA7" title="Warrants exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2025-03-31" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,769,894</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zaaHhne0BtA7" title="Weighted average exercise price, exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.91</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zSvMFSa0S0oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, all outstanding warrants were fully vested and exercisable and had an aggregate intrinsic value of approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250331_zXrhk6maDCm1" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">780,000</ix:nonFraction></span>
based on the fair value of the Company&#8217;s common stock on March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember" escape="true" id="Fact000631" name="GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z15bp3jr1SQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zxvwGp0FxzI6" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXb3A1LpFlg" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zL6J8rmNonu3" title="Number of outstanding" style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zr1mXiK5iCHk" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAJWDXzR0JOf" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zti4BJe7frof" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,138</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHAXH1kSa6i7" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact000643" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.2</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVmX3O1lUOo9" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ10iRdr6i78" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zt047FzdD05i" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zErWXMrasQOi" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact000651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z12UvnA63y2f" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgEe3Fz09W3j" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zG3ojNL9m2S6" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_ziNZU4uDeHS8" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact000659" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.2</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTxNimT4MLA6" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTeOEsCSCMX9" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3y6w2gFVXj4" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zu6LytumgCfl" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact000667" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.2</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zaL2hyh1NTn8" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTGwkPz2xG48" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBX7fOKkWOIf" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4V6RH8XRZ" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember" format="ixt-sec:duryear" id="Fact000675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.3</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zgCjWH6wHzU8" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUMhdzPuOyF2" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zVBRnY2D73Pa" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zkpTu0a2QLS7" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember" format="ixt-sec:duryear" id="Fact000683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.8</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zZGgLYt84Ws3" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4Thc450ADql" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">102.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zfXP9059l2D8" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,867</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zL8GybeHIOrf" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember" format="ixt-sec:duryear" id="Fact000691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.3</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zg6Y8d4U2Wc1" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">102.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zwAdIiRn3P99" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zY3Hr46dtLjl" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJXkHQlANyLd" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember" format="ixt-sec:duryear" id="Fact000699" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z1z77Gq6krb5" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zgP6M7hcSRmf" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zy6wQpztR4Oi" title="Number of warrants outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,780</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQ4ge4H0Enel" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember" format="ixt-sec:duryear" id="Fact000707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.9</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZrzNVWbttfj" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUp7oXuCfEg3" title="Number of warrants outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,769,894</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zkk3adYBfwAa" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_WarrantsMember" format="ixt-sec:duryear" id="Fact000713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.5</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlr2WDuWOEI3" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.91</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zF2LG7OPp8dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zmgXZImSAPVb" title="Common stock awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,667</ix:nonFraction></span>.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under
the Plan. As of March 31, 2025, there were <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331_zPc73PT8vxSh" title="Stock option outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span> stock options outstanding and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250331_zz1TNoO99XNc" title="Rstricted stock granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-03-31" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,935</ix:nonFraction></span> shares of restricted stock granted in prior years
under the Plan, which left <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zAj24qQeubi5" title="Available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_OmnibusIncentivePlanMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,132</ix:nonFraction></span> shares available for grant under the Plan. The following table summarizes stock option transactions
for the three months ended March 31, 2025:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000725" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwX7pgJKqPTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zAFYiX5utv6d" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331_zoyRoudq3b57" title="Number of options outstanding, beginning" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_z06l8W2piFsh" title="Weighted-Average Exercise Price, beginning" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.69</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250331_z3b7CHLeCNgg" title="Number of options, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zUt0FrITAJs7" title="Weighted-Average Exercise Price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331_zPhtp7JDkKn8" title="Number of options, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_z95YfFOnKPt" title="Weighted-Average Exercise Price, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331_zv5tGuY6zQ39" title="Number of options, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zX4lrtnt3Yri" title="Weighted-Average Exercise Price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331_zD65Ylh3Gdia" title="Number of options outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_z57GoByABuV2" title="Weighted-Average Exercise Price, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.69</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250331_zFAS13N4juP7" title="Number of options outstanding exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-03-31" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,746</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zejkIcCibhig" title="Weighted-Average Exercise Price,exercisable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.47</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zYndHl2ev1X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of March 31, 2025 was
<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331_zUudQ9v3hJMa" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" format="ixt-sec:duryear" id="Fact000751" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.0</ix:nonNumeric></span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable as of March 31,
2025 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250331_zTsBkWN4XW7k" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-03-31" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250331_zeoTZW2zZsb8" title="Options vested and exercisable intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-03-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, in each case based on the fair value of the Company&#8217;s common stock on March
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the three months ended March 31, 2025 and 2024, was $<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250331_zVQPbU6eXn4a" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-03-31" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240331_zHgq2xdQxEef" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span>, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
March 31, 2025, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250331_zguKtE1oskkd" title="Stock option, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-03-31" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,746</ix:nonFraction></span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250331_zUcR6eAmqd38" title="Stock option, unvested compensation"><ix:nonFraction name="GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-03-31" id="Fact000763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000765" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zyjW5WJYy61a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zE9N8n3wJHgg" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSJscntedLyg" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_RangeOneMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zx9QbJXzLLpj" title="Options outstanding" style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-03-31_custom_RangeOneMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,482</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQ0kMtC25rCf" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact000771" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.6</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcO51nuYSHgj" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-03-31_custom_RangeOneMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmzqmTT8fNo9" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_RangeTwoMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z93huJfABi3b" title="Options outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-03-31_custom_RangeTwoMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zt6FOBpqvvu5" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact000779" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.0</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBNSj0IXaYZ4" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-03-31_custom_RangeTwoMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuSUHk5vpgY7" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_RangeThreeMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNbwl6Pt93j2" title="Options outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-03-31_custom_RangeThreeMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zA8tdYPN4d02" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact000787" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.8</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDW3rlOB6ZMe" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-03-31_custom_RangeThreeMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwhfLDvXzjNl" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-03-31_custom_RangeFourMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9BnGNSHZ0He" title="Options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-03-31_custom_RangeFourMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,598</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFOtwcsmrZjg" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact000795" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.3</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zncA8Sd9SxS9" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-03-31_custom_RangeFourMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331_zuBHkw7zoKO" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-03-31" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,746</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zmMKfWSNQ2de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000801" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zc8SMVyfROOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_824_zyzj1qzzqKfd">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his Employment Agreement, and that the
Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his Employment Agreement and Separation Agreement. A final hearing is scheduled for June 10th through
June 12<sup>th</sup>, 2025 in Los Angeles, California. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader
against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against
TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released
from all associated liability and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further
briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal
of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common
stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its
motion for entry of default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that
the motion for entry of default was mooted by the settlement agreement between Z-One and TWF. The Court ordered that the case be dismissed.
On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. Z-One
alleges that it was assigned TWF&#8217;s rights under the Notes and seeks enforcement and damages. The Company intends to demand a complaint,
and seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will continue to vigorously
defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#8217;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use
in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The Agreement also set
Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zfMcsPGWvxnl" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zkp7b1QCa1yf" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zTE98MUzPjo9" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025 and 2024, the Company recognized research and development expenses of $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztsFX4tZvack" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zO2EyNRGvkW9" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,000</ix:nonFraction></span>, respectively
and made cash payments amounting to $<span id="xdx_905_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEDoDKfhFJla" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zVY4YmLT5XXi" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember" id="Fact000815" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million, respectively to Cytovance. In addition, during the three months ended
March 31, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCurDIOPHccl" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares of common stock exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zpD7Rxv9VGS6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share
to settle accounts payable valued at approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zO2Ka33UbCR2" title="Fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of March 31, 2025, amounted to approximately $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250331_z53srMILBFR8" title="Stock issued during period, value, issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-03-31" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2016
Exclusive Patent License Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zh6DWCbwdbv3" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact000825" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span>
million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue
work with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zWZdkyXQkoZh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zXseZOlerf0a" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, pursuant to the 2023 Sponsored Research
Agreement, for the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately
$<span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zLZJIjB5Cgk3" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">431,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;
</sup>technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement,
the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology
worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses,
authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that
is responsible for the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and
the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaKAnwukyRc9" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>,
and license maintenance fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zrXh9Dhcofh6" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC4A8jhsmpf1" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> per year beginning in year 2021 and each year thereafter.
The agreement also includes <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRmu9QtmMku7" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8diRgQ6C1x1" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements
or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zYH1rcxPToIj" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
beginning in 2022, $<span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zTZtSEr2gjfk" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact000845" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in 2025, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zpsVCA0HSLgd" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember" id="Fact000847" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million beginning in 2027 throughout the remainder of the term. The agreement
also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC52exVIqrUg" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000849" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time
sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4cTs8f3Kws2" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0X3KFkdir5l" title="Sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000853" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGirNm8CUO4" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpDqzo0BCb59" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000857" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million
in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zeRgcHdKc9f9" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zR3YMluBFCzl" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzMEedMHqRi5" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z12AY91gMeh3" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_ziMp5TbXWo3i" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zM1KXx3x2d5c" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zdCC7QaRZ8dj" title="Royalty expense year one"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOne" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z2pNVMJjzdW3" title="Royalty expense years two through five"><ix:nonFraction name="GTBP:RoyaltyExpenseYearTwoThroughFive" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000873" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6S7suzfhzRe" title="Royalty expense year six and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterSix" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000875" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zAzVnZtiVoPf" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000877" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zK53mAG9qiv7" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000879" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zWzIY80Yh00c" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000881" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0jBDvMtM0h" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000883" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOOBR0g3DEW9" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000885" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2016 Exclusive Patent License Agreement, for
the three months ended March 31, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znLmoDlx0DWl" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000887" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zYdTsFu4Jvkg" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year beginning in year 2022 and each year thereafter. The agreement also includes
<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znbYlqDn5jzg" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zie4hXnFhB08" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9iERo7RCfw9" title="Royalty expense year one though four"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOneThoughFour" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXrhXuADoEI5" title="Royalty expense year five and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterFive" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000897" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zQRII04gULUf" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUgOqKOynOSk" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000901" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhYXIHztk9b6" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000903" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zECnFA4wSMag" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000905" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0PrTzZxhM3k" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000907" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJ2TWPY1a1I9" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the three
months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately $<span id="xdx_908_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zwfUhapHa0bf" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact000911" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zWhIClx7GmW7" title="Contigency minimum required"><ix:nonFraction name="GTBP:ContigencyMinimumRequired" contextRef="AsOf2024-11-21" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff has not, as yet, accepted our plan of compliance, and has requested additional information
regarding our financing plans. We can provide no assurance that the Staff will accept our plan of compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Staff does not accept our plan of compliance, or if the Staff accepts our plan but we do not regain compliance within the allotted
compliance period, Nasdaq will provide notice that our Common Stock will be subject to delisting. If our Common Stock is delisted from
Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected.
We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our Common Stock and could harm
our business and future prospects. In addition, we believe that, if our Common Stock is delisted, our stockholders would likely find
it more difficult to obtain accurate quotations as to the price of our Common Stock and it may be more difficult for stockholders to
buy or sell our Common Stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As a result of the private placement
of preferred stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#8217; equity on
an unaudited proforma basis of at least $<span id="xdx_90F_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zBlgubIXYp27"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember" id="Fact000914" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction>
</span>million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement, the Company may be subject
to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000916" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zymEbTqntKxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82F_zgmdGiGTFph7">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000918" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z6BajPcYxsb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zWidqRMLRzE7">&#160;Schedule
of Segment Information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zA4G2M2ZwHx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z1aFGXbjAcyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_z9cJNughFMI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,099,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">777,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zz8H0owUszgh" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zarglEP7naQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z9nTiw93Kmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zZJZjr6CJWP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,658,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zU0BPIoETkBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000935" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,156,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">825,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zWP7DprIbtAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_custom_SegmentsMember" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_SegmentsMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,266,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_ziN8c525UXb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-03-31" escape="true" id="Fact000941" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zyGbQyvFd9x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_826_zWnD1FqdvU67">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
Placement of Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with the purchasers
identified therein (collectively, the &#8220;Purchasers&#8221;) providing for the issuance and sale to the Purchasers of (i) up to <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zz972VTyQWZ4" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,056</ix:nonFraction></span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;), (ii) warrants to purchase
up to a number of shares of common stock of the Company (the &#8220;Common Stock&#8221;) equal to 100% of the shares of the Company&#8217;s
Common Stock issuable upon conversion of the shares of Preferred Stock (the &#8220;Common Warrants&#8221;), and (iii) warrants to purchase
up to a number of shares of Company&#8217;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities
Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#8220;Vesting Warrants&#8221; and together
with the Common Warrants, the &#8220;Warrants&#8221;), with an aggregate stated value of $<span id="xdx_900_ecustom--AggregateStatedValue_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z8mmq31JkZq8" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000945" format="ixt:numdotdecimal" decimals="2" unitRef="USD">6,055,555.56</ix:nonFraction></span>, for an aggregate purchase price
of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2cAQYuXz5Z3" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000947" format="ixt:numdotdecimal" decimals="2" unitRef="USD">5,450,000.00</ix:nonFraction></span> (the &#8220;Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Preferred Stock with an aggregate stated value of
up to $<span id="xdx_903_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zb2u2Ro1KElc" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000,000</ix:nonFraction></span> (the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zkK2ri3mtiW8" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,800,000</ix:nonFraction></span>, subject to adjustments, as further
described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its respective Greenshoe Rights for an amount
of Preferred Stock equal to the ratio of such Purchaser&#8217;s original subscription amount to the original aggregate subscription amount
of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. The Certificate of Designation
creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms and conditions on which shares of such
preferred stock would convert into shares of our Common Stock, as well as its liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Preferred Stock may be converted at any time at the
option of the Purchasers into shares of the Company&#8217;s Common Stock at an initial conversion price of $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zV3PxbyJaOvg" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>, subject to certain
conditions, as further described in the Certificate of Designation. In addition, the holders of the Preferred Stock are entitled to receive
cumulative dividends at the rate per share (as a percentage of the stated value per share) of <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znds67Q5LTbd" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-112025-05-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum until May 11, 2026, increasing
to <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z1ZxQIBGo3Hf" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date
of issuance of the Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in cash, shares of the
Company&#8217;s Common Stock (subject to the Company&#8217;s satisfaction of the conditions set forth in the Certificate of Designation),
or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right to require the Company to redeem
the Preferred Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser will be issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#8217;s Common Stock equal to 100% of the Conversion Shares underlying the Preferred Shares issued to such Purchaser and
(ii) a Vesting Warrant (the exercisability of which shall vest ratably from time to time in proportion to the Purchaser&#8217;s (or its
permitted assigns&#8217;) exercise of such Purchaser&#8217;s Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement), each
to purchase up to a number of shares of the Company&#8217;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined
in the Securities Purchase Agreement) applicable to such Purchaser, in accordance with the Securities Purchase Agreement. The Common
Warrants have an initial exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zkRxuMFo5CRc" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, are exercisable, subject to certain ownership limitations, immediately upon
issuance and have a term of exercise equal to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zlK1aofvSut9" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt-sec:durwordsen" id="Fact000961" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>. The Vesting Warrants have an initial exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zrJFqDRUCFo1" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, are
exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_z6770Fcc7XY4" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember" format="ixt-sec:durwordsen" id="Fact000965" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date that
the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $<span id="xdx_90E_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zNaBdThHfaPf" title="Floor price"><ix:nonFraction name="us-gaap:DerivativeFloorPrice" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.454</ix:nonFraction></span> per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the Common Stock issuable upon conversion of the Preferred
Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement within 30 days after the initial closing
and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met, <span id="xdx_900_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcZ3aywStsZj" title="Liable of liquidated damage percentage, description"><ix:nonNumeric contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000969" name="GTBP:LiableOfLiquidatedDamagePercentageDescription">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser pursuant to the Securities Purchase Agreement. Further, if the Company fails to pay such liquidated
damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registerable
securities.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_90B_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmnSTL5m2KG3" title="Common stock shares outstanding percentage"><ix:nonFraction name="GTBP:CommonStockSharesOutstandingPercentage" contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% of the number of shares of the Company&#8217;s Common Stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). In connection with the required Shareholder Approval, all of the Company&#8217;s officers and directors (each a &#8220;Voting
Agreement Party&#8221;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a result of the private placement of preferred
stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#8217; equity on an unaudited
proforma basis of at least $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zY4bT4X5pN59"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember" id="Fact000972" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction>
</span>million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement, the Company may be subject
to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Private Placement </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 14, 2025, the Company entered into a common
shares purchase agreement (the &#8220;Purchase Agreement&#8221;) with investors (collectively, the &#8220;Investors&#8221;) relating to
a committed equity facility (the &#8220;Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time
at its option to sell to the Investors up to $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTqv6CHtzxRg" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000974" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span>&#160;million of its common stock subject to certain conditions and limitations set forth
in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Sales of the shares of common stock to the Investors
under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion
and will depend on a variety of factors, including, among other things, market conditions, the trading price of the common stock and determinations
by the Company regarding the use of proceeds of such shares of common stock. The net proceeds from any sales under the Purchase Agreement
will depend on the frequency with, and prices at, which the shares of common stock are sold to The Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The purchase price of the shares of common stock that
the Company elects to sell to the Investors pursuant to the Purchase Agreement will be <span id="xdx_90E_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT8BiduZLyMj" title="Weighted average volume price of common stock percentage"><ix:nonFraction name="GTBP:WeightedAverageVolumePriceOfCommonStockPercentage" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span>% of the volume weighted average price of the
shares of common stock during the applicable purchase date on which the Company has timely delivered written notice to the Investors directing
it to purchase shares of common stock under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In connection with the execution of the Purchase
Agreement, the Company agreed to issue to the Investors a pre-funded warrant to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvKjJULH1Zpb" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of common stock as consideration
for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to the satisfaction of the conditions
set forth in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Settlement
of Vendor Payable in Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to March 31, 2025, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdUMIZJwVhO4" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-05-15_us-gaap_SubsequentEventMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of common stock and warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHWhc5W0n8Qg" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-05-15_us-gaap_SubsequentEventMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of common stock as settlement
of a vendor payable amounting to approximately $<span id="xdx_90A_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgruVu5MrxD3" title="Issuance of warrant to settle vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-04-012025-05-15_us-gaap_SubsequentEventMember" id="Fact000984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><p id="xdx_819_z5kLBpHXCVD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ar_006"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; within the meaning of the safe harbor
from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business
strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect
the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified
by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;foresee,&#8221; &#8220;may,&#8221; &#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221;
&#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe
our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn
out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations
for various reasons. You should carefully review all information, including the discussion of risk factors under &#8220;Part I. Item
1A: Risk Factors&#8221; and &#8220;Part II. Item 7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; of the Form 10-K for the year ended December 31, 2024. Any forward-looking statements in the Form 10-Q are made only
as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements
contained in this Form 10-Q to reflect subsequent events or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) fusion protein
immune cell engager technology platforms. Our TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics designed
to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells, or NK cells. Once bound to an NK cell,
our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific
type of cancer cell or virus infected cell, resulting in the targeted cell&#8217;s death. TriKE&#174;s can be designed to target any number
of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific
customization. We believe our TriKE&#174; and Dual Targeting TriKE&#174; platforms that activate endogenous NK cells are potentially safer
than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications. Our preclinical
data suggests that this is explained by the TriKE&#174; dependent CD16 directed IL-15 proliferation of NK cells but little effect endogenous
T cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE&#174; platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies,
solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational
new drug (IND) ready moieties in a timely manner after a specific TriKE&#174; conceptual design. Specific drug candidates can then be
advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKE&#174;s may have
the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr.
Jeffrey Miller, Professor of Medicine, and the Interim Director at the Center. Dr. Miller, who also serves as our Consulting Senior Medical
Director, is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive
rights to the TriKE&#174; platform and are generating additional intellectual property for specific moieties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidate pipeline is summarized in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was our first TriKE&#174; product candidate and its clinical development was suspended so that we could focus resources on second-generation
TriKEs&#174;. GTB-3550 is a tri-specific killer engager (TriKE) comprised of two single-chain variable fragments (&#8220;scFv&#8221;)
composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We
studied this anti-CD16-IL-15-anti-CD33 TriKE&#174; in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous
leukemia, or AML, and myelodysplastic syndrome, or MDS. The anti-CD33 antibody fragment in GTB-3550 was derived from the M195 humanized
anti-CD33 scFv. We believe the approval of the antibody-drug conjugate gemtuzumab validates the targeting of CD33.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously announced the interim clinical trial results for GTB-3550, which showed significantly reduced CD 33+ bone marrow blast levels
by 33.3%, 61.7%, 63.6%, 50% in Patient 5 (25 &#181;g/kg/day), Patient 7 (50 &#181;g/kg/day), Patient 9 (100 &#181;g/kg/day), and Patient
11 (150 &#181;g/kg/day), respectively. After the end of infusion, GTB-3550 and IL-15 concentrations declined rapidly with overall geometric
mean terminal phase elimination half-life (T1/2) of 2.2 and 2.52 hours, respectively. There was minimal CRS resulting from hyperactivation
of patient&#8217;s T-cell population at doses 5&#8211;150 &#181;g/kg/day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the positive interim clinical trial results, GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKE&#174;, GTB-3650,
that similarly targets CD33 on relapsed/refractory AML and high-risk MDS. A key difference between GTB-3550 and GTB-3650 is the incorporation
of camelid antibody technology instead of a scFv; our preclinical experience showed markedly enhanced potency of TriKEs&#174; comprised
of camelid components. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared
to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the
second-generation, camelid-based TriKE&#174; platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Second
Generation TriKE<sup>&#174;</sup>s Utilize Camelid Nanobody Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid
tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred
as nanobodies) are smaller than human immunoglobulin, consisting of two heavy chains instead of two heavy and two light chains. These
nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing
this camelid antibody structure for all of our new TriKE&#174; product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
develop second generation TriKE&#174;s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist
of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of
engaging without the need of a light chain counterpart (see figure below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-q_003.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability
to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation
against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFN&#947; with the single-domain CD16 TriKE&#174; (cam
16-wt15-33; GTB-3650) compared to the original TriKE&#174; (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr.
Felices M et al (2020) in Cancer Immunol Res.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CD33+
HL60 Targets in Killing Assays</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purple line represents the GTB-3650 and the blue line represents GTB-3550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3650</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3650
is a TriKE&#174; which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor
on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650. The TriKE&#174; approach provides
a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting,
in an anti-CD33-targeted fashion. We are advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase
in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We advanced GTB-3650 through
requisite preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA)
in December 2023. In late June 2024, the FDA cleared our IND Application for GTB-3650. We started study enrollment targeting patients
with relapsed/refractory AML and high grade MDS on January 21, 2025. This initial study is testing GTB-3650 as monotherapy testing administration
2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy, as agreed on with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-5550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-5550
is a B7-H3 targeted TriKE&#174; which targets B7-H3 on the surface of advanced solid tumors (figure above). GTB-5550 is our first dual
camelid TriKE&#174;. B7-H3 is expressed on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies
through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumors, including
head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer
(amongst others). We are advancing GTB-5550 through preclinical studies and initiated a GMP manufacturing campaign in anticipation of
filing an IND. A pre-IND packet was submitted to the FDA in October 2023 with a written response from the FDA in December 2023. The main
question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The initial trial is designed as a basket
trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion),
and is dependent on manufacturing of clinical materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_006.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-7550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-7550
TriKE&#174; is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKE&#174; is a
tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv engager against CD19 on malignant
and normal B cells, and a human IL-15 sequence between them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published
data shows that GTB-7550 effectively targets CD19+ malignant cell lines and primary chronic lymphocytic leukemia (CLL). Preliminary data
shows that GTB-7550 can target and eliminate normal B cells, which we are continuing to test in mice. We are currently exploring and
assessing potential manufacturers of GTB-7550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of our financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires
us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure
of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge
of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may
differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we
consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments
and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation
of deferred tax assets. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives
in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221;. For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with
changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of derivative financial instruments is generally limited to warrants issued by us that do not meet the criteria for equity treatment
and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing
model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends.
The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three Months Ended March 31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,099,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">777,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">322,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">830,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,212,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,382,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock compensation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(99,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Operating Expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,932,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,091,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,159,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(37</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by approximately $322,000 for the three months ended March 31, 2025 compared to the same prior year
period, primarily due to an increase in scientific research costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses relate to our continued licensing, development and production of our most advanced TriKE&#174; product candidates
GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA
with respect to our IND Application in relation to our next generation GTB-3650 camelid nanobody product. Study enrollment began in early
2025 and we are advancing into the clinic, enrolling patients, and performing tests for data collection throughout the year. We have
paused the final phase of product development of GTB-5550 to reduce costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling,
General, and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general, and administrative expenses decreased by approximately $1.4 million for the three months ended March 31, 2025, compared to the
same prior year period. The decrease was primarily due to cost reduction measures including a reduction in legal fees, consulting fees,
and salaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income (Expense)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">142,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(110,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value of warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">658,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(532,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(81</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss) on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">998,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">998,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(100</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Other Income
    (Expense)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,156,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">825,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">331,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
Income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income decreased by $110,000 for the three months ended March 31, 2025 compared to the same prior year period, due to lower money market
fund and short term investment balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
in Fair Value of Warrant Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant liability decreased by approximately $532,000, for the three months ended March 31, 2025 compared to the
same prior year period, resulting from a reduction in our warrant liability primarily due to the decline in the Company&#8217;s stock
price at March 31, 2025 as compared to the prior comparable periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
on Settlement of Vendor Payable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$1 million. The Company classified this transaction as other income during the period ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(776,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,266,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,490,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss decreased by $1,490,000 for the three months ended March 31, 2025 compared to the same prior year period, primarily due to a
decrease in legal fees, consulting fees, and salaries, and the reduction of prior year unpaid legal fees, as described
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that we will continue as a going concern. We do not
have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained operating
losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed our operations
through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and
strategic collaborations. For the three months ended March 31, 2025, we recorded a net loss of approximately $800,000 and used cash in
operations of approximately $2.2 million, and had a stockholders&#8217; deficit of approximately $1 million as of that date. These factors
raise substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are
issued. In addition, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s December
31, 2024, financial statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial
statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if we are unable to continue as a going
concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes we will continue as a going
concern, and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations,
which has raised substantial doubt about our ability to continue as a going concern. While it is very difficult to estimate our future
liquidity requirements we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to
enable us to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed financial statements
are issued. There can be no assurances that we will be able to secure additional financing on acceptable terms. In the event that we
do not secure additional financing, we will be forced to delay, reduce, or eliminate some or all of our discretionary spending, which
could adversely affect our business prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Statements of Cash Flow
    Data:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,202,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,163,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,034,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">616,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash and cash
    equivalents and restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,586,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">871,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    and restricted cash, beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,044,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,079,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents and restricted cash, end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,458,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,950,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $2.2 million for the three months ended March 31, 2025, and was primarily due to
a decrease in accounts payable and accrued expenses of approximately $1.3 million, and a net loss of $776,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $4.2 million for the three months ended March 31, 2024, and was primarily due to a net loss of
$2.3 million, a decrease in accounts payable and accrued expenses of $1.3 million, and a decrease in the fair value of warrant liability
of $658,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $5.0 million for the three months ended March 31, 2024, resulted from proceeds
of the sale of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $616,000 for the three months ended March 31, 2025, resulted from the exercise of warrants
for cash and inducement warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Capital (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes total current assets, liabilities, and working capital (deficit) for the periods ended March 31, 2025 and
December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/> 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Increase/(Decrease)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,658,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,232,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,574,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,638,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,902,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,264,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Working capital (deficit)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(980,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,670,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">690,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ar_007"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f)(1) and is not required to provide information
for this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ar_008"></span>Item
4. Controls and Procedures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act
of 1934, as amended), as of March 31, 2025. Based on that evaluation, we have concluded that our disclosure controls and procedures were
effective as of March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by,
or under the supervision of, a company&#8217;s principal executive and principal accounting officers and effected by a company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
    could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations on the Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective
control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a
simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become
inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_009"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ar_010"></span>Item
1. Legal Proceedings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his Employment Agreement, and that the
Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his Employment Agreement and Separation Agreement. A final hearing is scheduled for June 10th through
June 12<sup>th</sup>, 2025 in Los Angeles, California. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader
against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against
TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released
from all associated liability and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further
briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal
of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common
stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its
motion for entry of default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that
the motion for entry of default was mooted by the settlement agreement between Z-One and TWF. The Court ordered that the case be dismissed.
On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. Z-One
alleges that it was assigned TWF&#8217;s rights under the Notes and seeks enforcement and damages. The Company intends to demand a complaint,
and seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will continue to vigorously
defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Item
5<i>.</i> Other Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
10b5-1 Trading Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the
Securities Exchange Act of 1934, as amended) adopted, amended, or terminated a &#8220;Rule 10b5-1 trading
arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of
Regulation S-K.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ar_011"></span>Item
6. Exhibits</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Herewith</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated
    Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/15/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/ex3-5.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/30/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/1/2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/ex3-1.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000017/exhibitthreeone.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/4/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225008387/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Series A Inducement Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225008387/ex4-2.htm" style="-sec-extract: exhibit">Form
    of Series B Inducement Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/ex4-1.htm" style="-sec-extract: exhibit">Form of Prefunded Common Stock Purchase Warrant</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-40023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">4/4/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.6</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="ex4-6.htm">Form of Prefunded Common Stock Purchase Warrant</a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225008387/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Inducement Letter</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.2</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="ex10-2.htm">Common Shares Purchase Agreement</a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934,
    as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934,
    as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
    2002*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
    2002*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the
    liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the
    Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
    BIOPHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 15, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Breen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer and</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 15, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Urban</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>ex4-6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PRE-FUNDED WARRANT<BR>
TO PURCHASE SHARES OF COMMON STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">GT BIOPHARMA, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0pt; padding-left: 0pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant Shares: ________&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 0pt; padding-left: 0pt; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Original Issuance Date: &nbsp;&nbsp;May 15, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS PRE-FUNDED WARRANT TO
PURCHASE SHARES OF COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in full
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from GT Biopharma, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares of Common Stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;),
of the Company (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;).&nbsp; The purchase price of one Warrant
Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday, or other day on which the Federal Reserve Bank of New York is closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Agreement</U>&rdquo;
means the securities purchase agreement, dated as of May 15, 2025, by and between the Company and each of the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means the Company&rsquo;s registration statement on Form S-1to be filed pursuant to the terms of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Securities Act&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means the Company&rsquo;s current transfer agent any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) <U>Exercise of Warrant</U>.
&nbsp;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail
(or e-mail attachment) of the Notice of Exercise in the form annexed hereto as <B>Exhibit A</B> (the &ldquo;<U>Notice of Exercise</U>&rdquo;).&nbsp;
Within the earlier of (i) one (1) Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined
in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for
the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.&nbsp; No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required.&nbsp; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date
on which the final Notice of Exercise is delivered to the Company. &nbsp;Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder are permitted, <I>provided however</I> that any such partial exercise
must relate to a number of Warrant Shares equal to the lesser of fifty thousand (50,000) and all of the Warrant Shares available for purchase
under this Warrant.&nbsp; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases.&nbsp; The Company shall deliver any objection to any Notice of Exercise on the Trading Day of receipt of such notice.&nbsp;
Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the
Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to
deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00&nbsp;p.m. (New York City time) on the Initial
Exercise Date, and the Initial Exercise Date shall be the Warrant Share Delivery Date (as defined below) for purposes hereunder, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery
Date.&nbsp; <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
at any time during which there is no effective registration statement for the issuance of the Warrant Shares to the Holder, but only if
this Warrant is exercised for cash, the Company may settle the exercise of the Warrant with unregistered shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>Exercise Price</U>.&nbsp;
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company
on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.&nbsp; The Holder shall
not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for
any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.&nbsp; The remaining
unpaid exercise price per Warrant Share under this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Cashless Exercise</U>.&nbsp;
This Warrant may also be exercised, in whole or in part otherwise in accordance with the terms of this Warrant, at such time by means
of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a)
hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to
the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
(&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp; The Company agrees not to take any position
contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) <U>Mechanics of Exercise.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) <U>Delivery of
Warrant Shares Upon Exercise</U>.&nbsp; The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder
by The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then
a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to, or resale of the Warrant Shares by, the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical
delivery of the Warrant Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by the date that is the earliest of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the
&ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).&nbsp; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise.&nbsp; If the Company fails for any reason to deliver to the Holder the Warrant Shares
subject to a Notice of Exercise by the Warrant Share Delivery Date, without delivering an objection to the Notice of Exercise per Section
2(a), the Company shall pay to the Holder, at the Holder&rsquo;s election either (A) in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for
each Trading Day after such Warrant Share Delivery Date until the earlier of such Warrant Shares being delivered or Holder rescinds such
exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof.&nbsp; The Company agrees to maintain a registrar
(which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.&nbsp;
As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading
Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice
of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) <U>Delivery of
New Warrants Upon Exercise</U>.&nbsp; If this Warrant shall have been exercised in part in accordance with the limitations of Section
2(a), the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant
Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) <U>Rescission
Rights</U>.&nbsp; If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>.&nbsp; In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder.&nbsp; For example, if the Holder purchases
shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000.&nbsp; The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&nbsp; Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) <U>No Fractional
Shares or Scrip</U>.&nbsp; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&nbsp;
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) <U>Charges, Taxes
and Expenses</U>.&nbsp; The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <B>Exhibit B </B>duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&nbsp;
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii) <U>Closing
of Books</U>.&nbsp; The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) <U>Holder&rsquo;s Exercise
Limitations</U>.&nbsp; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any
portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as
set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&rsquo;s Affiliates, (ii) any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates, and (iii) any other Persons whose beneficial ownership of
shares of Common Stock would or could be aggregated with the Holder&rsquo;s for the purposes of Section 13(d) (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this
Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&nbsp;
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number
of outstanding shares of Common Stock that was provided by the Company.&nbsp; In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&nbsp; For purposes of this
Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares
of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;), as the case may be, (B) a more recent public announcement by the Company or (C) a more
recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon
the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder the number of shares of Common
Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding shares of Common Stock was reported.&nbsp; The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, at the election of the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of Common Stock
outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant.&nbsp; The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving
effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply.&nbsp; Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice
is delivered to the Company.&nbsp; The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation.&nbsp; The limitations contained in this paragraph shall apply to a successor holder of this Warrant.&nbsp;
If the Warrant is unexercisable solely as a result of the Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration
is owing to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) <U>Stock Dividends and Splits</U>.&nbsp;
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares
of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common
Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the
Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number
of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall
be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged.&nbsp; Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Subsequent Rights Offerings</U>.&nbsp;
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &ldquo;<U>Purchase
Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such
Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) [RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) <U>Calculations</U>. All
calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may
be.&nbsp; For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) <U>Adjustment
to Exercise Price</U>.&nbsp; Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) <U>Notice to
Allow Exercise by Holder</U>.&nbsp; If, while the Warrant is outstanding, (A) the Company declares a dividend (or any other distribution
in whatever form) on the shares of Common Stock, (B) the Company declares a cash dividend on, or a redemption of, the shares of Common
Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection
with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as
it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or
other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required
to be specified in such notice.&nbsp; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) <U>Voluntary Adjustment
By Company</U>.&nbsp; Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this
Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4. <U>Transfer of
Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) <U>Transferability</U>.&nbsp;
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto as <B>Exhibit B</B>, duly executed by the Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer.&nbsp; Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be cancelled.&nbsp; Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which
case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an
assignment form to the Company assigning this Warrant in full.&nbsp; The Warrant, if properly assigned in accordance herewith, may be
exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>New Warrants</U>.&nbsp;
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney.&nbsp; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.&nbsp; All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall
be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Warrant Register</U>.&nbsp;
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time.&nbsp; The Company may deem and treat the registered Holder of this Warrant
as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) <U>Currency</U>.&nbsp; All
dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under this
Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount
in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange Rate</U>&rdquo; means, in relation to any amount of
currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal
(NY edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>.&nbsp; This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section
3.&nbsp; Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c)
or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net
cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>.&nbsp; The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the
posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) <U>Saturdays, Sundays, Holidays,
etc</U>. &nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall
not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) <U>Authorized Shares</U>.&nbsp;
The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant upon the exercise of any
purchase rights under this Warrant.&nbsp; The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this
Warrant.&nbsp; The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and
delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.&nbsp; The Company covenants that all Warrant Shares underlying this Warrant which may be issued
and delivered upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment.&nbsp; Without limiting the generality of the foregoing,
the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) <U>Governing Law</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.
Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members,
employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) <U>Restrictions</U>.&nbsp;
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) <U>Nonwaiver and Expenses</U>.&nbsp;
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right
or otherwise prejudice the Holder&rsquo;s rights, powers or remedies.&nbsp; Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) <U>Notices</U>. Any and
all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of
Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at ___________, Attention: ___________, email address: ___________, or such other email address or address as the Company
may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the
Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service
addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the
next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth
in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading
Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the
party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) <U>Limitation of Liability</U>.&nbsp;
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k) <U>Remedies</U>.&nbsp; The
Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant.&nbsp; The Company agrees that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in
any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l) <U>Successors and Assigns</U>.&nbsp;
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&nbsp; The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m) <U>Amendment</U>.&nbsp;
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n) <U>Severability</U>.&nbsp;
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o) <U>Headings</U>.&nbsp; The
headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Signature Page Follows)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; text-align: justify; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GT BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; width: 50%; text-align: justify; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0pt; padding-left: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; width: 45%; text-align: justify; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; padding-right: 0pt; text-align: justify; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 0pt; text-align: justify; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; text-align: justify; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: justify; padding-left: 0pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: GT BIOPHARMA, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#9744; in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#9744; if permitted the cancellation of such number of Warrant
Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum
number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[SIGNATURE OF HOLDER]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Investing Entity: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing Entity</I>: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(To assign the foregoing Warrant, execute this form and supply required
information.&nbsp; Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON SHARES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>COMMON SHARES PURCHASE
AGREEMENT</B> is made and entered into as of May 14, 2025 (this &ldquo;<B><I>Agreement</I></B>&rdquo;), by and between Five Narrow Lane,
L.P., a Delaware limited partnership And/or its assignee and Bristol Capital, LLC, a Delaware limited liability company and/or its assignee
(each an &ldquo;<B><I>Investor</I></B>&rdquo; and together, the &ldquo;<B><I>Investors</I></B>&rdquo;), and GT Biopharma, Inc. a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the parties
desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investors,
from time to time as provided herein, and the Investors shall purchase from the Company, up to the lesser of (i) $20,000,000 (the &ldquo;<B><I>Total
Commitment</I></B>&rdquo;) in aggregate gross purchase price of duly authorized, validly issued, fully paid and non-assessable common
shares of the Company, par value $0.001 per share (the &ldquo;<B><I>Common Shares</I></B>&rdquo;) and (ii) the Exchange Cap (to the extent
applicable under Section 3.3); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, such sales
of Common Shares by the Company to the Investors will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act
(&ldquo;<B><I>Section 4(a)(2)</I></B>&rdquo;) and/or Rule 506(b) of Regulation D promulgated by the Commission under the Securities Act
(&ldquo;<B><I>Regulation D</I></B>&rdquo;), and upon such other exemption from the registration requirements of the Securities Act as
may be available with respect to any or all of the issuances and sales of Common Shares by the Company to the Investors to be made hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,</B> the
parties hereto, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms used in
this Agreement shall have the meanings ascribed to such terms in <U>Annex I</U> hereto, and hereby made a part hereof, or as otherwise
set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE OF COMMON SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.1. <U>Purchase
and Sale of Shares</U></B>. Upon the terms and subject to the conditions of this Agreement, during the Investment Period, the Company,
in its sole discretion, shall have the right, but not the obligation, to issue and sell to the Investors, and the Investors, <I>pari
passu</I> and in equal amounts as to each VWAP Purchase Notice (unless otherwise agreed between the Investors as to any VWAP Purchase
Notice), and without prejudice to the Company) shall purchase from the Company, up to the lesser of (i) the Total Commitment and (ii)
the Exchange Cap, to the extent applicable under Section 3.3 (such lesser amount of Common Shares, the &ldquo;<B><I>Aggregate Limit</I></B>&rdquo;),
by the delivery to the Investors of VWAP Purchase Notices as provided in Article III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.2. <U>Closing
Date; Settlement Dates</U></B>. This Agreement shall become effective and binding upon (a) the delivery of counterpart signature pages
of this Agreement executed by each of the parties hereto, and (b) the delivery of all other documents, instruments and writings required
to be delivered pursuant to this Agreement, as provided in Section 7.1 at or prior to 9:00 a.m. New York City time on the Closing Date
(the &ldquo;<B><I>Closing</I></B>&rdquo;). In consideration of and in express reliance upon the representations, warranties and covenants
contained in, and upon the terms and subject to the conditions of, this Agreement, during the Investment Period, the Company, at its
sole option and discretion, may issue and sell to the Investors, and, if the Company elects to so issue and sell, the Investors shall
purchase from the Company, the Shares in respect of each VWAP Purchase. The delivery of Shares in respect of each VWAP Purchase, and
the payment for such Shares, shall occur in accordance with Section 3.2, <U>provided</U> that all of the conditions precedent in Article
VII shall have been fulfilled at the applicable times set forth in Article VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.3. <U>Initial
Public Announcements and Required Filings</U></B>. The Company shall, after the Closing but not later than 9:00 a.m., New York City time,
on the Trading Day after the date of this Agreement, file with the Commission either a current report on Form 8-K (including any exhibits
thereto) or its quarterly report on Form 10-Q (including any relevant exhibits thereto) disclosing the execution of this Agreement by
the Company and the Investor (as applicable, the &ldquo;<B><I>Announcement Report</I></B>&rdquo;). The Company shall provide the Investors
and their legal counsel a reasonable opportunity to comment on a draft of the current report on Form 8-K, or the relevant disclosure
from the quarterly report on Form 10-Q, as applicable, prior to filing the Announcement Report with the Commission and shall give due
consideration to all such comments. From and after the filing of the Announcement Report with the Commission, the Company shall publicly
disclose all material, nonpublic information delivered to the Investors (or the Investors&rsquo; representatives or agents) by the Company
or any of its Subsidiaries, or any of their respective officers, directors, employees, agents or representatives (if any) in connection
with the transactions contemplated by the Transaction Documents. The Investors&nbsp;covenant that until such time as the transactions
contemplated by this&nbsp;Agreement&nbsp;are publicly disclosed by the&nbsp;Company&nbsp;as described in this Section 2.3, the&nbsp;Investors&nbsp;shall
maintain the confidentiality of all disclosures made to them in connection with the transactions contemplated by the&nbsp;Transaction
Documents&nbsp;(including the existence and terms of the transactions contemplated thereby), except that the&nbsp;Investors&nbsp;may
disclose the terms of such transactions to their financial, accounting, legal and other advisors (provided that the&nbsp;Investors&nbsp;direct
such parties to maintain the confidentiality of such information). The Company shall use its reasonable best efforts to prepare and,
as soon as practicable, file with the Commission the Initial Registration Statement and any New Registration Statement covering only
the resale by the Investors of the Registrable Securities in accordance with the Securities Act. At or before 5:30 p.m. (New York City
time) on the second (2nd) Trading Day immediately following the Effective Date of the Initial Registration Statement and any New Registration
Statement (or any post-effective amendment thereto), the Company shall use its reasonable best efforts to file with the Commission in
accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection with resales of the Registrable Securities
by Investors pursuant to such Registration Statement (or post-effective amendment thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of the conditions set forth in Article VII, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.1. <U>VWAP Purchases</U></B>.
Upon the initial satisfaction of all of the conditions set forth in Section 7.1 (the &ldquo;<B><I>Commencement</I></B>&rdquo; and the
date of initial satisfaction of all of such conditions, the &ldquo;<B><I>Commencement Date</I></B>&rdquo;) and from time to time thereafter,
subject to the satisfaction of all of the conditions set forth in Section 7.2, the Company shall have the right, but not the obligation,
to direct the Investors, by its timely delivery to the Investors of a VWAP Purchase Notice, in substantially the form attached hereto
as <U>Exhibit A</U>, after 6:00 a.m., New York City time, but prior to 9:00 a.m., New York City time, on a VWAP Purchase Date, to purchase
a number of Common Shares equal to the VWAP Purchase Share Request at the applicable VWAP Purchase Price therefor on such VWAP Purchase
Date in accordance with this Agreement (each such purchase, a &ldquo;<B><I>VWAP Purchase</I></B>&rdquo;). In addition, the Investors
may, in their sole discretion, accept a VWAP Purchase Notice after 9:00 a.m., New York City time, on a VWAP Purchase Date, provided that
such acceptance, once provided, shall be irrevocable and binding and the Company&rsquo;s obligation to deliver the shares that are the
subject of such VWAP Purchase Notice shall be binding; <I>provided</I> that, if the Investors (or one of them) does not accept a VWAP
Purchase Notice that is delivered after 9:00 a.m., New York City time, such VWAP Purchase Notice shall be deemed to be null and void.
The Investors may also, in their sole discretion, accept additional VWAP Purchase Notices within a Trading Day, in which case any prior
VWAP Purchase Notice accepted by the Investors in such Trading Day shall be null, void, superseded and replaced in its entirety by such
subsequent VWAP Purchase Notice. The Company may timely deliver a VWAP Purchase Notice to the Investors as often as every five (5) Trading
Days (and may deliver multiple VWAP Purchase Notices in any given day, it being understood that a subsequent VWAP Purchase Notice will
supersede and replace all earlier VWAP Purchase Notices delivered within the same Trading Day in their entirety), so long as all Shares
subject to all prior VWAP Purchases theretofore required to have been received by the Investor as DWAC Shares under this Agreement have
been delivered to the Investors as DWAC Shares in accordance with this Agreement. The Investors are obligated to accept each VWAP Purchase
Notice prepared and delivered by the Company in accordance with the terms of and subject to the satisfaction of the conditions contained
in this Agreement. If the Company delivers any VWAP Purchase Notice directing the Investors to purchase a number of Shares that is in
excess of the applicable VWAP Purchase Share Amount, such VWAP Purchase Notice shall be void <I>ab initio</I> to the extent of the amount
by which the VWAP Purchase Share Estimate set forth in such VWAP Purchase Notice exceeds such applicable VWAP Purchase Share Amount,
and the Investors shall have no obligation to purchase such excess Shares in respect of such VWAP Purchase Notice; <U>provided</U>, <U>however</U>,
that the Investors shall remain obligated to purchase the applicable VWAP Purchase Share Amount in such VWAP Purchase. On the date of
delivery of any VWAP Purchase Notice, the Company shall, prior to 9:00 a.m., New York City time (or as promptly as practicable thereafter
in the case of a VWAP Purchase Notice delivered after 9:00 a.m., New York City time, that is accepted by the Investors), issue to the
Investors a number of DWAC Shares equal to the VWAP Purchase Share Estimate (the date such Shares are delivered, the &ldquo;<B><I>VWAP
Purchase Share Delivery Date</I></B>&rdquo;). In no event shall the Investors, pursuant to any VWAP Purchase, purchase a number of Shares
constituting the applicable VWAP Purchase Share Amount that exceeds the VWAP Purchase Share Estimate issued on the VWAP Purchase Date
in connection with such VWAP Purchase Notice; however, the Investors will immediately return to the Company any Shares issued pursuant
to the VWAP Purchase Share Estimate that exceeds the number of Shares constituting the applicable VWAP Purchase Share Amount the Investors
actually purchase in connection with such VWAP Purchase. In no event shall the Investor purchase a number of Shares that exceeds the
specified VWAP Purchase Share Estimate included in a given VWAP Purchase Notice in connection with such VWAP Purchase. In addition, it
is acknowledged and agreed that the Company may not deliver any additional VWAP Purchase Notice to the Investors until all Shares subject
to a VWAP Purchase, and all Shares subject to all prior VWAP Purchase Notices, have been received by the Investors as DWAC Shares in
accordance with this Agreement. At or prior to 5:30 p.m., New York City time, on the VWAP Purchase Date for each VWAP Purchase, the Investors
shall each provide to the Company a written confirmation for such VWAP Purchase (each, a &ldquo;<B><I>VWAP Purchase Confirmation</I></B>&rdquo;)
setting forth the applicable VWAP Purchase Price per Share to be paid by the Investors in such VWAP Purchase, and the total aggregate
VWAP Purchase Price to be paid by the Investors for the total VWAP Purchase Share Amount purchased by the Investors in such VWAP Purchase.
Notwithstanding the foregoing, the Company shall not deliver any VWAP Purchase Notices to the Investors during the Post-Effective Amendment
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.2. <U>Payment
and Settlement</U></B>. For each VWAP Purchase, the Investors shall pay to the Company an amount in cash equal to the product of (a)
the applicable VWAP Purchase Share Amount and (b) the applicable VWAP Purchase Price for such Shares (the &ldquo;<B><I>VWAP Purchase
Amount</I></B>&rdquo;), as full payment for such Shares purchased by the Investors in such VWAP Purchase, via wire transfer of immediately
available funds, not later than 5:00 p.m., New York City time, on the Trading Day immediately following the applicable VWAP Purchase
Share Delivery Date for such VWAP Purchase, provided the Investors shall have timely received, as DWAC Shares, all of such Shares purchased
by the Investors in such VWAP Purchase on such VWAP Purchase Share Delivery Date in accordance with the first sentence of this Section
3.2, or, if any of such Shares are received by the Investors after 1:00 p.m., New York City time, then the Company&rsquo;s receipt of
such funds in its designated account may occur on the Trading Day next following the Trading Day on which the Investors shall have received
all of such Shares as DWAC Shares, but not later than 5:00 p.m., New York City time, on such next Trading Day. If the Investors (or either
of them) fail to pay the VWAP Purchase Amount when due, the defaulting Investor or Investors will return the DWAC Shares to the Company.
If the Company or the Transfer Agent shall fail for any reason to deliver to the Investors, as DWAC Shares, any Shares purchased by the
Investors in a VWAP Purchase prior to 4:30 p.m., New York City time, on the Trading Day immediately following the applicable VWAP Purchase
Share Delivery Date for such VWAP Purchase, and if after such Trading Day the Investors or either of them purchases (in an open market
transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the such Investor of such Shares that the Investor anticipated
receiving from the Company on such VWAP Purchase Share Delivery Date in respect of such VWAP Purchase, then the Company shall, within
one (1) Trading Day after the Investor&rsquo;s request, either (i) pay cash to the applicable Investor in an amount equal to such Investor&rsquo;s
total purchase price (including brokerage commissions, if any) for the Common Shares so purchased (the &ldquo;<B><I>Cover Price</I></B>&rdquo;),
at which point the Company&rsquo;s obligation to deliver such Shares as DWAC Shares shall terminate, or (ii) promptly honor its obligation
to deliver to the Investor such Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover
Price over the VWAP Purchase Amount; <I>provided</I>, that each Investor agrees to use its commercially reasonable efforts to purchase
Common Shares in respect of the Cover Price only in normal brokerage transactions at the prevailing price per Common Share then available.
The Company shall not issue any fraction of a share of Common Shares to the Investors in connection with any VWAP Purchase effected pursuant
to this Agreement. If the issuance would result in the issuance of a fraction of a share of Common Shares, the Company shall round such
fraction of a share of Common Shares up to the nearest whole share. All payments to be made by the Investors pursuant to this Agreement
shall be made by wire transfer of immediately available funds in United States dollars to such account as the Company may from time to
time designate by written notice to the Investors in accordance with the provisions of this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.3. <U>Compliance
with Rules of Principal Market.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <B><U>Exchange
Cap</U>.</B> The Company shall not issue or sell any Common Shares pursuant to this Agreement, and the Investors shall not purchase or
acquire any Common Shares pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of Common
Shares that would be issued pursuant to this Agreement and the transactions contemplated hereby would exceed ____________ Common Shares
(representing 19.99% of the voting power or number of Common Shares, issued and outstanding immediately prior to the execution of this
Agreement, subject to the Exchange Cap Allocation), which number of shares shall be reduced, on a share-for-share basis, by the number
of Common Shares issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions
contemplated by this Agreement under applicable rules of the Principal Market (such maximum number of shares, the &ldquo;<B><I>Exchange
Cap</I></B>&rdquo;), unless the Company&rsquo;s shareholders have approved the issuance of Common Shares pursuant to this Agreement in
excess of the Exchange Cap in accordance with the applicable rules of the Principal Market, unless &ldquo;average price&rdquo; of all
purchases under the Purchase Agreement equals or exceeds the Minimum Price, adjusted to take into account the Commitment Shares such
that issuances and sales of Common Stock under this Agreement are deemed &ldquo;at market&rdquo; pursuant to the corporate governance
rules of the Principal Market. If the Company issues shares above the Exchange Cap in reliance on this clause, the &ldquo;average price&rdquo;
of all purchases under the Purchase Agreement for the remainder of the term of the Purchase Agreement must always equal or exceed the
Minimum Price.. For the avoidance of doubt, the Company may, but shall be under no obligation to, request its shareholders to approve
the issuance of Common Shares pursuant to this Agreement; <U>provided</U>, that if such shareholder approval is not obtained, the Exchange
Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the term of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <B><U>General</U>.</B>
The Company shall not issue or sell any Common Shares pursuant to this Agreement if such issuance or sale would reasonably be expected
to result in (A) a violation of the Securities Act or (B) a breach of the rules of the Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.4. <U>Beneficial
Ownership Limitation</U></B>. Notwithstanding anything to the contrary contained in this Agreement, neither Investor shall be obligated
to purchase or acquire, and shall not purchase or acquire, any Common Shares under this Agreement which, when aggregated with all other
Common Shares then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act
and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor and its affiliates (on an aggregated
basis) of more than 4.99% of the outstanding voting power or number of Common Shares (the &ldquo;<B><I>Beneficial Ownership Limitation</I></B>&rdquo;).
Upon the written request of an Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent
is open for business) confirm orally or in writing to the Investor the number of Common Shares then outstanding. The Investors and the
Company shall each cooperate in good faith in the determinations required under this Section 3.4 and the application of this Section
3.4. The Investor&rsquo;s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting
effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.5</B>. <B><U>Upfront
Commitment Fee</U></B>. In consideration for the Investor&rsquo;s execution and delivery of this Agreement, the Company shall pay the
Upfront Commitment Fee to the Investor in the form of a pre-funded warrant to purchase Common Stock, in the form of <U>Exhibit B</U>
hereto, simultaneous with the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS OF
THE INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Investor, severally
and not jointly, hereby makes the following representations, warranties and covenants to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.1. <U>Organization
and Standing of the Investor</U></B>. The Investor is a limited liability company duly formed, validly existing and in good standing
under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.2. <U>Authorization
and Power</U></B>. The Investor has the requisite corporate power and authority to enter into and perform its obligations under this
Agreement and to purchase or acquire the Shares in accordance with the terms hereof. The execution, delivery and performance by the Investor
of this Agreement and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary
action, and no further consent or authorization of the Investor or its sole member is required. This Agreement has been duly executed
and delivered by the Investor and constitutes a valid and binding obligation of the Investor enforceable against it in accordance with
its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation,
conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement of, creditor&rsquo;s rights and remedies
or by other equitable principles of general application (including any limitation of equitable remedies).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.3. <U>No Conflicts</U></B>.
The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of the transactions contemplated
hereby and thereby do not and shall not (i) result in a violation of such Investor&rsquo;s applicable organizational instruments, (ii)
conflict with, constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give
rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture,
note, bond, license, lease agreement, instrument or obligation to which the Investor is a party or is bound, or (iii) result in a violation
of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any court or governmental agency
applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case of clauses (ii) and
(iii), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually
or in the aggregate, prohibit or otherwise interfere with, in any material respect, the ability of the Investor to enter into and perform
its obligations under this Agreement. The Investor is not required under any applicable federal, state or local law, rule or regulation
to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order
for it to execute, deliver or perform any of its obligations under this Agreement or to purchase or acquire the Shares in accordance
with the terms hereof; <U>provided</U>, <U>however</U>, that for purposes of the representation made in this sentence, the Investor is
assuming and relying upon the accuracy of the relevant representations and warranties and the compliance with the relevant covenants
and agreements of the Company in the Transaction Documents to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.4. <U>Investment
Purpose</U></B>. The Investor is acquiring the Shares for its own account, for investment purposes and not with a view towards, or for
resale in connection with, the public sale or distribution thereof, in violation of the Securities Act or any applicable state securities
laws; <U>provided</U>, <U>however</U>, that by making the representations herein, the Investor does not agree, or make any representation
or warranty, to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any
time in accordance with, or pursuant to, a registration statement filed pursuant to this Agreement or an applicable exemption under the
Securities Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell
or distribute any of the Shares. The Investor is acquiring the Shares hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.5. <U>Accredited
Investor Status</U></B>. The Investor is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.6. <U>Reliance
on Exemptions</U></B>. The Investor understands that the Shares are being offered and sold to it in reliance on specific exemptions from
the registration requirements of U.S. federal and state securities laws and that the Company is relying in part upon the truth and accuracy
of, and the Investor&rsquo;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the
Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.7. <U>Information</U></B><U>.</U>
All materials relating to the business, financial condition, management and operations of the Company and its Affiliates, and materials
relating to the offer and sale of the Shares which have been requested by the Investor have been furnished or otherwise made available
(including through filing with or furnishing to the Commission) to the Investor or its advisors, including, without limitation, the Commission
Documents and other documents filed with or furnished to the Commission by Affiliates of the Company. The Investor understands that its
investment in the Shares involves a high degree of risk. The Investor is able to bear the economic risk of an investment in the Shares,
including a total loss thereof, and has such knowledge and experience in financial and business matters that it is capable of evaluating
the merits and risks of a proposed investment in the Shares. The Investor and its advisors have been afforded the opportunity to ask
questions of and receive answers from representatives of the Company concerning the financial condition and business of the Company and
its Affiliates, and other matters relating to an investment in the Shares. Neither such inquiries nor any other due diligence investigations
conducted by the Investor or its advisors, if any, or its representatives shall modify, amend or affect the Investor&rsquo;s right to
rely on the Company&rsquo;s representations and warranties contained in this Agreement or in any other Transaction Document to which
the Company is a party or the Investor&rsquo;s right to rely on any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transaction contemplated hereby. The Investor has sought such accounting, legal and tax
advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Shares. The Investor
understands that it (and not the Company) shall be responsible for its own tax liabilities that may arise as a result of this investment
or the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.8. <U>No Governmental
Review</U></B>. The Investor understands that no United States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in the Shares
nor have such authorities passed upon or endorsed the merits of the offering of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.9. <U>No General
Solicitation</U></B>. The Investor is not purchasing or acquiring the Shares as a result of any form of general solicitation or general
advertising (within the meaning of Regulation D) in connection with the offer or sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.10. <U>Not an
Affiliate</U></B>. The Investor is not an officer, director or an Affiliate of the Company. Nothing in this Agreement shall prohibit
or be deemed to prohibit the Investor from purchasing, in an open market transaction or otherwise, Common Shares necessary to make delivery
by the Investor in satisfaction of a sale by the Investor of Shares that the Investor anticipated receiving from the Company in connection
with the settlement of a VWAP Purchase if the Company or its transfer agent shall have failed for any reason (other than a failure of
Investor or its Broker-Dealer (as defined below) to set up a DWAC and required instructions) to electronically transfer all of the Shares
subject to such VWAP Purchase to the Investor on the applicable VWAP Purchase Share Delivery Date by crediting the Investor&rsquo;s or
its designated Broker-Dealer&rsquo;s account at DTC through its DWAC delivery system in compliance with Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.11. <U>No Prior
Short Sales</U></B>. At no time prior to the date of this Agreement has the Investor, its sole member, any of their respective officers,
or any entity managed or controlled by the Investor or its sole member, engaged in or effected, in any manner whatsoever, directly or
indirectly, for its own principal account, any hedging transaction, which established a net short position with respect to the Common
Shares that remains in effect as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.12. <U>Statutory
Underwriter Status</U></B>. The Investor acknowledges that it will be disclosed as an &ldquo;underwriter&rdquo; and a &ldquo;selling
shareholder&rdquo; in each Registration Statement and in any Prospectus contained therein to the extent required by applicable law and
to the extent the Prospectus is related to the resale of Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.13. <U>Resales
of Shares</U></B>. The Investor represents, warrants and covenants that it will resell such Shares only pursuant to the Registration
Statement in which the resale of such Shares is registered under the Securities Act, in a manner described under the caption &ldquo;Plan
of Distribution&rdquo; in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities
laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS OF
THE COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby makes
the following representations, warranties and covenants to the Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.1. <U>Organization,
Good Standing and Power</U></B>. The Company and each of its Subsidiaries are duly organized, validly existing and in good standing (to
the extent such concept is available) under the laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries
are duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws of each other
jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such license
or qualification, and have all corporate power and authority necessary to own or hold their respective properties and to conduct their
respective businesses as described in the Commission Documents, except where the failure to be so qualified or in good standing or have
such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to
have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise),
prospects, shareholders&rsquo; equity or results of operations of the Company and its Subsidiaries taken as a whole, or prevent or materially
interfere with consummation of the transactions contemplated hereby (a &ldquo;<B><I>Material Adverse Effect</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.2. <U>Subsidiaries</U>.</B>
The subsidiaries described in the Company&rsquo;s most recent annual report on Form 10-K (collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;),
are the Company&rsquo;s only significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission).
Except as set forth in the Commission Documents, the Company owns, directly or indirectly, all of its equity interests in the Subsidiaries
free and clear of any lien, charge, security interest, encumbrance or other restriction, and all its equity interests in the Subsidiaries
are validly issued and are fully paid, nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.3. <U>Authorization,
Enforcement</U></B>. The Company has the requisite corporate power and authority to enter into and perform its obligations under each
of the Transaction Documents to which it is a party and to issue the Shares and the Commitment Fee warrant in accordance with the terms
hereof and thereof. Except for approvals of the Company&rsquo;s Board of Directors or a committee thereof as may be required in connection
with any issuance and sale of Shares to the Investors hereunder (which approvals shall be obtained prior to the delivery of any VWAP
Purchase Notice), the execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party
and the consummation by it of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary
corporate action, and no further consent or authorization of the Company, its Board of Directors or its shareholders is required. Each
of the Transaction Documents to which the Company is a party has been duly executed and delivered by the Company and constitutes a valid
and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws
relating to, or affecting generally the enforcement of, creditor&rsquo;s rights and remedies or by other equitable principles of general
application (including any limitation of equitable remedies).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.4. <U>Capitalization</U></B><U>.</U>
The Company has a capitalization as set forth in the Commission Documents (as applicable) as of the dates thereof. Except as set forth
in the Commission Documents and this Agreement, there are no (i) agreements or arrangements under which the Company is obligated to register
the sale of any securities under the Securities Act or (ii) Common Shares that are entitled to preemptive rights. Except for customary
transfer restrictions contained in agreements entered into by the Company to sell restricted securities, equity award plans or related
award agreement terms for restricted stock or as set forth in the Commission Documents, the Company is not a party to, and it has no
knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except as set forth
in the Commission Documents, there are no securities or instruments containing anti-dilution or similar provisions that will be triggered
by this Agreement or any of the other Transaction Documents or the consummation of the transactions described herein or therein. The
Company has filed with the Commission true and correct copies of the Company&rsquo;s memorandum of association as in effect on the Closing
Date, and the Company&rsquo;s by-laws as in effect on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.5. <U>Issuance
of Shares</U></B>. The Shares, if and when issued and sold against payment therefor in accordance with this Agreement, shall be validly
issued and outstanding, fully paid and non-assessable and free from all liens, charges, taxes, security interests, encumbrances, rights
of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof, and the Investors shall each
be entitled to all rights accorded to a holder of Common Shares. At or prior to Commencement, the Company shall have duly authorized
and reserved 25,000,000 Common Shares (such share amount, the &ldquo;<B>Share Cap</B>&rdquo;) for issuance and sale as Shares to the
Investor pursuant to VWAP Purchases that may be effected by the Company, in its sole discretion, from time to time from and after the
Commencement Date, pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.6. <U>No Conflicts</U></B>.
The execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation
by the Company of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation of any provision of
the Company&rsquo;s certificate of incorporation or by-laws, (ii) conflict with or constitute a material default (or an event which,
with notice or lapse of time or both, would become a material default) under, or give rise to any rights of termination, amendment, acceleration
or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, instrument or obligation to which
the Company or any of its Subsidiaries is a party or is bound, (iii) result in a violation of any federal, state, local or other foreign
statute, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries (including federal and state
securities laws and regulations and the rules and regulations of the Principal Market or applicable Principal Market), except, in the
case of clauses (ii) and (iii), for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges,
encumbrances and violations as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect
or that have been waived. Except as specifically contemplated by this Agreement and as required under the Securities Act, any applicable
state securities laws and applicable rules of the Principal Market, the Company is not required under any federal, state or local rule
or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency
in order for it to execute, deliver or perform any of its obligations under the Transaction Documents to which it is a party, or to issue
the Shares to the Investor in accordance with the terms hereof and thereof (other than such consents, authorizations, orders, filings
or registrations as have been obtained or made prior to the Closing Date); <U>provided</U>, <U>however</U>, that, for purposes of the
representation made in this sentence, the Company is assuming and relying upon the accuracy of the representations and warranties of
the Investor in this Agreement and the compliance by it with its covenants and agreements contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.7. <U>Commission
Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Since January
1, 2024, the Company has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act)
all filings required to be filed with or furnished to the Commission by the Company under the Securities Act or the Exchange Act, including
those required to be filed with or furnished to the Commission under Section 13(a) or Section 15(d) of the Exchange Act. As of its filing
date, each Commission Document filed with or furnished to the Commission prior to the Closing Date complied in all material respects
with the requirements of the Securities Act or the Exchange Act, as applicable. Each Registration Statement, on the date it is filed
with the Commission, on the date it is declared effective by the Commission and on each VWAP Purchase Date shall comply in all material
respects with the requirements of the Securities Act (including, without limitation, Rule 415 under the Securities Act) and shall not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading, except that this representation
and warranty shall not apply to statements in or omissions from such Registration Statement made in reliance upon and in conformity with
information relating to an Investor furnished to the Company in writing by or on behalf of such Investor expressly for use therein. The
Prospectus and each Prospectus Supplement required to be filed pursuant to this Agreement after the Closing Date, when taken together,
on its date and on each VWAP Purchase Date shall comply in all material respects with the requirements of the Securities Act (including,
without limitation, Rule 424(b) under the Securities Act) and shall not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, except that this representation and warranty shall not apply to statements in or omissions from
the Prospectus or any Prospectus Supplement made in reliance upon and in conformity with information relating to an Investor furnished
to the Company in writing by or on behalf of such Investor expressly for use therein. Nothing has come to the attention of the Company
that has caused the Company to believe that the statistical, demographic and market-related data included in the Registration Statement
and Prospectus are not based on or derived from sources that are reliable and accurate in all material respects. The Commission has not
issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Securities
Act or the Exchange Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The consolidated
financial statements of the Company included or incorporated by reference in the Commission Documents, together with the related notes
and schedules, present fairly, in all material respects, the consolidated financial position of the Company and its then consolidated
subsidiaries as of the dates indicated, and the consolidated results of operations, cash flows and changes in shareholders&rsquo; equity
of the Company and its then consolidated subsidiaries for the periods specified and have been prepared in all material respects in compliance
with the published requirements of the Securities Act and the Exchange Act, as applicable, and in conformity with generally accepted
accounting principles in the United States (&ldquo;<B><I>GAAP</I></B>&rdquo;) applied on a consistent basis. The pro forma condensed
combined financial statements and the pro forma combined financial statements and any other pro forma financial statements or data included
or incorporated by reference in the Commission Documents, if any, comply with the requirements of Regulation S-X of the Securities Act,
including, without limitation, Article 11 thereof, and the assumptions used in the preparation of such pro forma financial statements
and data are reasonable, the pro forma adjustments used therein are appropriate to give effect to the circumstances referred to therein
and the pro forma adjustments have been properly applied to the historical amounts in the compilation of those statements and data. The
other financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Commission
Documents, if any, are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and
records of the Company. There are no financial statements (historical or pro forma) that are required to be included or incorporated
by reference in the Commission Documents that are not included or incorporated by reference as required. The Company and the Subsidiaries
do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations or any &ldquo;variable
interest entities&rdquo; as that term is used in Accounting Standards Codification Paragraph 810-10-25-20), not described in Commission
Documents which are required to be described in the Commission Documents. All disclosures contained or incorporated by reference in the
Commission Documents, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations
of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included in the Commission Documents fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and
guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Weinberg &amp;
Company, P.A. (the &ldquo;<B><I>Accountant</I></B>&rdquo;), whose report on the consolidated financial statements of the Company as of
and for the years ended December 31, 2023 and 2024 included in the Company&rsquo;s annual report on Form 10-K and 10-K/A, are and, during
the periods covered by their report, were an independent public accounting firm within the meaning of the Securities Act and the Public
Company Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of the auditor
independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B><I>Sarbanes-Oxley Act</I></B>&rdquo;) with respect to the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) There is and
has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities as such, to comply
in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder.
Each of the principal executive officer and the principal financial officer of the Company (or each former principal executive officer
of the Company and each former principal financial officer of the Company as applicable) has made all certifications required by Sections
302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents required to be filed
by it or furnished by it to the Commission. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo; and &ldquo;principal
financial officer&rdquo; shall have the meanings given to such terms in the Sarbanes-Oxley Act. The Company and the Subsidiaries maintain
and keep accurate books and records reflecting their assets and maintain internal accounting controls in a manner designed to provide
reasonable assurance regarding the reliability of the Company&rsquo;s financial reporting and the preparation of financial statements
by the Company for external purposes in accordance with generally accepted accounting principles and including those policies and procedures
that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions
of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation
of the Company&rsquo;s consolidated financial statements in accordance with generally accepted accounting principles, (iii) that receipts
and expenditures of the Company are being made only in accordance with management&rsquo;s and the Company&rsquo;s directors&rsquo; authorization,
and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the
Company&rsquo;s assets that could have a material effect on its financial statements. The Company and the Subsidiaries maintain such
controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the
applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in
the Commission&rsquo;s rules and forms, including, without limitation, controls and procedures designed to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the
Company&rsquo;s management, including its principal executive officer and principal financial officer, or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to
the Company or the Subsidiaries is made known to them by others within those entities, particularly during the period in which such periodic
reports are being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.8. <U>No Material
Adverse Effect</U></B>. Subsequent to the respective dates as of which information is given in the Commission Documents (including any
document deemed incorporated by reference therein), there has not been any Material Adverse Effect or the occurrence of any development
that the Company reasonably expects will result in a Material Adverse Effect.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.9. <U>No Material
Defaults</U></B>. Neither the Company nor any of its Subsidiaries has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.
The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act indicating that it (i) has failed to pay any
dividend or sinking fund installment on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or
on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.10. <U>No Preferential
Rights</U>.</B> Except as set forth in the Commission Documents, (i) no Person, has the right, contractual or otherwise, to cause the
Company to issue or sell to such Person any Common Shares or shares of any other capital stock or other securities of the Company, (ii)
no Person has any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other rights (whether pursuant
to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Shares or shares of any other capital stock or other securities
of the Company, (iii) no Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the
offer and sale of the Common Shares, and (iv) no Person has the right, contractual or otherwise, to require the Company to register under
the Securities Act any Common Shares or shares of any other capital stock or other securities of the Company, or to include any such
shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness
of the Registration Statement or the sale of the Shares as contemplated thereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.11. <U>Solvency</U></B>.
The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to Title 11 of the
United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company have any knowledge
that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings
for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for the relief of debtors.
Except as set forth in the Commission Documents, the Company is financially solvent and is generally able to pay its debts as they become
due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.12. <U>Real
Property; Intellectual Property</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Except as set
forth in the Commission Documents, the Company and its Subsidiaries have good and marketable title in fee simple to all items of real
property owned by them, good and valid title to all personal property described in the Commission Documents as being owned by them, in
each case free and clear of all liens, encumbrances and claims, except those matters that (i) do not materially interfere with the use
made and proposed to be made of such property by the Company and any of its Subsidiaries or (ii) would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. Any real or personal property described in the Commission Documents as being
leased by the Company and any of its Subsidiaries is held by them under valid, existing and enforceable leases, except those that (A)
do not materially interfere with the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B)
would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect. Each of the properties of the
Company and its Subsidiaries complies with all applicable codes, laws and regulations (including, without limitation, building and zoning
codes, laws and regulations and laws relating to access to such properties), except if and to the extent disclosed in the Commission
Documents or except for such failures to comply that would not, individually or in the aggregate, reasonably be expected to interfere
in any material respect with the use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have
a Material Adverse Effect. None of the Company or its Subsidiaries has received from any Governmental Authorities any notice of any condemnation
of, or zoning change affecting, the properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or
zoning change which is threatened, except for such that would not reasonably be expected to interfere in any material respect with the
use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect, individually
or in the aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) Except as disclosed
in the Commission Documents, the Company and its Subsidiaries own, possess, license or have other rights to use, or can acquire the right
to use on reasonable terms, all foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations,
trade names, copyrights, licenses, inventions, trade secrets, technology, Internet domain names, know-how and other intellectual property
(collectively, the &ldquo;<B><I>Intellectual Property</I></B>&rdquo;), necessary for the conduct of their respective businesses as now
conducted except to the extent that the failure to own, possess, license or otherwise hold or acquire adequate rights to use such Intellectual
Property would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as disclosed in
the Commission Documents and except as would not be reasonably expected individually or in the aggregate, to have a Material Adverse
Effect: (i) to the Company&rsquo;s knowledge, there is no infringement by third parties of any Intellectual Property owned by the Company
or its Subsidiaries; (ii) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others
challenging the Company&rsquo;s and its Subsidiaries&rsquo; rights in or to any Intellectual Property owned by the Company or its Subsidiaries,
and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iii) there
is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or
scope of any such Intellectual Property owned by the Company or its Subsidiaries; (iv) there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate
any Intellectual Property rights of others; and (v) the Company and its Subsidiaries have taken reasonable efforts in accordance with
standard industry practice to maintain the confidentiality of all trade secrets and other confidential information of the Company and
its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.13. <U>Actions
Pending</U></B>. Except as set forth in the Commission Documents, there are no actions, suits or proceedings by or before any Governmental
Authority pending, nor, to the Company&rsquo;s knowledge, any audits or investigations by or before any Governmental Authority to which
the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries is the subject that, as would
be reasonably expected, individually or in the aggregate, would have a Material Adverse Effect and, to the Company&rsquo;s knowledge,
no such actions, suits, proceedings, audits or investigations are threatened or contemplated by any Governmental Authority or threatened
by others; and except as would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect, there
are no current or pending audits or investigations, actions, suits or proceedings by or before any Governmental Authority that are required
under the Securities Act to be described in the Commission Documents that are not so described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.14. <U>Compliance
with Law</U></B>. Each of the Company and its Subsidiaries: (A) is and at all times has been in compliance with all statutes, rules,
or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its
Subsidiaries (&ldquo;<B><I>Applicable Laws</I></B>&rdquo;); (B) has not received any FDA Form 483, notice of adverse finding, warning
letter, untitled letter or other correspondence or notice from the FDA or any other Governmental Authority (including, without limitation,
the EMA) alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B><I>Authorizations</I></B>&rdquo;); (C)
possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation
of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation
of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority or third party is considering any
such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental Authority
has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such
Governmental Authority is considering such action; (F) has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete
and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or
involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement,
safety alert, post sale warning, &ldquo;dear healthcare provider&rdquo; letter, or other notice or action relating to the alleged lack
of safety or efficacy of any product or any alleged product defect or violation and, to the Company&rsquo;s knowledge, no third party
has initiated, conducted or intends to initiate any such notice or action, except in the case of each of (A) through (G) above, as would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.15. <U>Certain
Fees</U></B>. Neither the Company nor any of its Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.16. <U>Disclosure</U></B>.
The Company confirms that neither it nor any other Person acting on its behalf has provided the Investors or any of their agents, advisors
or counsel with any information that constitutes or would reasonably be expected to constitute material, nonpublic information concerning
the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by the Transaction Documents. The Company
understands and confirms that the Investor will rely on the foregoing representations in effecting resales of Shares under the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.17. <U>Broker/Dealer
Relationships</U>.</B> Neither the Company nor any of the Subsidiaries (i) is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo;
in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls or
is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning set forth in the
FINRA Manual).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.18. <U>Disclosure
Controls</U>.</B> The Company maintains a system of &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule 13a-15(e) of
the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required
to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Commission&rsquo;s rules and forms, including controls and procedures designed to ensure that
such information is accumulated and communicated to the Company&rsquo;s management as appropriate to allow timely decisions regarding
required disclosure. The Company has carried out any evaluations of the effectiveness of its disclosure controls and procedures as required
by Rule 13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.19. <U>Permits</U></B>.
Except as disclosed in the Commission Documents, the Company and its Subsidiaries have made all filings, applications and submissions
required by, possesses and is operating in compliance with, all approvals, licenses, certificates, certifications, clearances, consents,
grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the appropriate federal, state or foreign
Governmental Authority (including, without limitation, the United States Food and Drug Administration (the &ldquo;<B><I>FDA</I></B>&rdquo;),
the United States Drug Enforcement Administration, the European Medical Agency (&ldquo;<B><I>EMA</I></B>&rdquo;), or any other foreign,
federal, state, provincial, court or local government or regulatory authorities including self-regulatory organizations engaged in the
regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials) necessary for the ownership or lease
of their respective properties or to conduct its businesses as described in the Commission Documents (collectively, &ldquo;<B><I>Permits</I></B>&rdquo;),
except for such Permits the failure of which to possess, obtain or make the same would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of
all such Permits, except where the failure to be in compliance would not have a Material Adverse Effect; all of the Permits are valid
and in full force and effect, except where any invalidity, individually or in the aggregate, would not be reasonably expected to have
a Material Adverse Effect; and neither the Company nor any of its Subsidiaries has received any written notice relating to the limitation,
revocation, cancellation, suspension, modification or non-renewal of any such Permit which, individually or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, or has any reason to believe that any such
license, certificate, permit or authorization will not be renewed in the ordinary course. To the extent required by applicable laws and
regulations of the FDA or EMA, the Company or its applicable Subsidiary has submitted to the FDA and/or the EMA an Investigational New
Drug Application or amendment or supplement thereto for each clinical trial it has conducted or sponsored or is conducting or sponsoring;
all such submissions were in material compliance with applicable laws and rules and regulations when submitted and no material deficiencies
have been asserted by the FDA or EMA with respect to any such submissions, which, in each case, have not yet been remedied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.20. <U>Environmental
Compliance</U></B>. Except as set forth in the Commission Documents, the Company and its Subsidiaries (i) are in compliance with any
and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human
health and safety to the extent relating to hazardous or toxic substances or wastes, pollutants or contaminants (&ldquo;<B><I>Hazardous
Materials</I></B>&rdquo;), the environment or the presence, release, generation, use, management, handling, transportation, treatment,
storage, or disposal of Hazardous Materials (collectively, &ldquo;<B><I>Environmental Laws</I></B>&rdquo;); (ii) have received and are
in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any disposal
or release of Hazardous Materials, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply, failure
to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.21. <U>No Improper
Practices</U></B>. (i) Neither the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary
nor, to the Company&rsquo;s knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has, in
the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution
in violation of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal,
or foreign office or other person charged with similar public or quasi-public duty in violation of any applicable law or of the character
required to be disclosed in the Commission Documents; (ii) except as described in the Commission Documents, there are no material outstanding
loans or advances or material guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any of their respective
officers or directors or any of the members of the families of any of them; and (iii) neither the Company nor any Subsidiary nor any
director, officer or employee of the Company or any Subsidiary nor, to the Company&rsquo;s knowledge, any agent, affiliate or other person
acting on behalf of the Company or any Subsidiary has (A) violated or is in violation of any applicable provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti-corruption law (collectively, &ldquo;<B><I>Anti-Corruption
Laws</I></B>&rdquo;), (B) promised, offered, provided, attempted to provide or authorized the provision of anything of value, directly
or indirectly, to any person for the purpose of obtaining or retaining business, influencing any act or decision of the recipient, or
securing any improper advantage; or (C) made any payment of funds of the Company or any Subsidiary or received or retained any funds
in violation of any Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.22. <U>Operations</U>.</B>
The operations of the Company and its Subsidiaries are and have been conducted for the past five years in compliance with applicable
financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively,
the &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;); and no action, suit or proceeding by or before any Governmental Authority involving
the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.23</B>. <B><U>Transactions
with Affiliates</U></B>. No relationship, direct or indirect, exists between or among the Company or any of its Subsidiaries on the one
hand, and the directors, officers, trustees, managers, stockholders, partners, customers or suppliers of the Company or any of the Subsidiaries
on the other hand, which would be required by the Securities Act or the Exchange Act to be disclosed in the Commission Documents, which
is not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.24. <U>Labor
Disputes</U></B>. The Company is not bound by or subject to any collective bargaining or similar agreement with any labor union, and,
to the knowledge of the Company, none of the employees, representatives or agents of the Company is represented by any labor union. The
Company and its Subsidiaries have complied with all employment laws applicable to employees of the Company and its Subsidiaries, except
where non-compliance with any such employment laws would not have a Material Adverse Effect. No labor disturbance by or dispute with
employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened which would result in a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.25. <U>Use of
Proceeds</U></B>. The proceeds from the sale of the Shares by the Company to Investor shall be used by the Company in the manner as will
be set forth in the Prospectus included in any Registration Statement (and any post-effective amendment thereto) and any Prospectus Supplement
thereto filed pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.26. <U>Investment
Company Act Status</U></B>. The Company is not, and as a result of the consummation of the transactions contemplated by the Transaction
Documents and the application of the proceeds from the sale of the Shares as will be set forth in the Prospectus included in any Registration
Statement (and any post-effective amendment thereto) and any Prospectus Supplement thereto filed pursuant to this Agreement the Company
will not be an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.27. <U>Taxes</U></B>.
The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be
filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested
in good faith, except where the failure to so file or pay would not reasonably be expected, individually or in the aggregate, to have
a Material Adverse Effect. Except as otherwise disclosed in or contemplated by the Commission Documents, no tax deficiency has been determined
adversely to the Company or any of its Subsidiaries which has had, or would have, individually or in the aggregate, a Material Adverse
Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been
or might be asserted or threatened against it which would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.28. <U>Employee
Benefits</U></B>. To the knowledge of the Company, each material employee benefit plan that is maintained, administered or contributed
to by the Company or any of its Subsidiaries for employees or former employees of the Company and any of its Subsidiaries has been maintained
in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, no prohibited transaction
has occurred which would result in a Material Adverse Effect with respect to any such plan excluding transactions effected pursuant to
a statutory or administrative exemption; and for each such, except as would not reasonably be expected to have a Material Adverse Effect,
the minimum funding standards applicable thereto have been satisfied and the fair market value of the assets of each such plan (excluding
for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using
reasonable actuarial assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.29. <U>Stock
Transfer Taxes</U></B>. All stock transfer taxes which are required to be paid in connection with the sale and transfer of the Shares
to be sold hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or
will have been fully complied with provided the sale and transfer is effected within the facilities of DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.30. <U>Insurance</U></B>.
The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and
each of its Subsidiaries reasonably believe are adequate for the conduct of their properties and as is customary for companies engaged
in similar businesses in similar industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.31. <U>Exemption
from Registration</U></B>. Subject to, and in reliance on, the representations, warranties and covenants made herein by the Investors,
the offer and sale of the Shares in accordance with the terms and conditions of this Agreement is exempt from the registration requirements
of the Securities Act pursuant to Section 4(a)(2) and/or Rule 506(b) of Regulation D; <U>provided</U>, <U>however</U>, that at the request
of and with the express agreements of an Investor (including, without limitation, the representations, warranties and covenants of such
Investor set forth in Section 4.9 through 4.13), the Shares to be issued from and after Commencement to or for the benefit of the Investor
pursuant to this Agreement shall be issued to the Investor or its designee only as DWAC Shares and will not bear legends noting restrictions
as to resale of such securities under federal or state securities laws, nor will any such securities be subject to stop transfer instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.32. <U>No General
Solicitation or Advertising</U></B>. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person acting on its or
their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the offer or sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.33. <U>No Integrated
Offering</U></B>. None of the Company, its Subsidiaries or any of their Affiliates, nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require
registration of the issuance of any of the Shares under the Securities Act, whether through integration with prior offerings or otherwise,
or cause this offering of the Shares to require approval of shareholders of the Company under any applicable shareholder approval provisions,
including, without limitation, under the rules and regulations of the Principal Market. None of the Company, its Subsidiaries, their
Affiliates nor any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require
registration of the issuance of any of the Shares under the Securities Act or cause the offering of any of the Shares to be integrated
with other offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.34. <U>Manipulation
of Price</U></B>. Neither the Company nor any of its officers, directors or, to the knowledge of the Company, its Affiliates has, and,
to the knowledge of the Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended
to cause or to result in the stabilization or manipulation of the price of any security of the Company, or which caused or resulted in,
or which would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security
of the Company, in each case to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company. Neither the Company nor any of its officers, directors or, to the knowledge of the Company,
its Affiliates will during the term of this Agreement, and, to the knowledge of the Company, no Person acting on their behalf will during
the term of this Agreement, take any of the actions referred to in the immediately preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.35. <U>Listing
and Maintenance Requirements; DTC Eligibility</U></B>. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Shares under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not received notice from the Principal Market to the effect that the Company is not in compliance
with the listing or maintenance requirements of the Principal Market. The Shares are, or will be after the Commencement Date, eligible
for participation in the DTC book entry system and deposit at DTC such that they may be transferred electronically to third parties via
DTC through its Deposit/Withdrawal at Custodian (&ldquo;<B><I>DWAC</I></B>&rdquo;) delivery system. The Company has not received notice
from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Shares, electronic trading or book-entry
services by DTC with respect to the Shares is being imposed or is contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.36. <U>OFAC</U></B>.
Neither the Company nor any of its Subsidiaries (collectively, the &ldquo;<B><I>Entity</I></B>&rdquo;), nor any director, officer of
the Company nor, to the knowledge of the Company, any employee, agent, affiliate or representative of the Company or any director or
officer of any Subsidiary, is a Person that is, or is owned or controlled by a Person that is (i) the subject of any sanctions administered
or enforced by the (&ldquo;<B><I>OFAC</I></B>&rdquo;), the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury,
or other relevant sanctions authorities, including, without limitation, designation on OFAC&rsquo;s Specially Designated Nationals and
Blocked Persons List or OFAC&rsquo;s Foreign Sanctions Evaders List or other relevant sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;),
nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with
that country or territory (including, without limitation, the Crimea region of the Ukraine, Cuba, Iran, North Korea, Sudan and Syria
(the &ldquo;<B><I>Sanctioned Countries</I></B>&rdquo;)). The Entity will not, directly or indirectly, use the proceeds from the sale
of Shares, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person (a)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions or is a Sanctioned Country, or (b) in any other manner that will result in a violation of
Sanctions by any Person (including any Person participating in the transactions contemplated by this agreement, whether as underwriter,
advisor, investor or otherwise). For the past five years, the Entity has not engaged in, and is now not engaged in, any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or
was a Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.37. <U>Information
Technology; Compliance with Data Privacy Laws</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Except as described
in the Commission Documents, and except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect: (i) the Company and its Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware,
software, websites, applications, and databases (collectively, &ldquo;<B><I>IT Systems</I></B>&rdquo;) are adequate for, and operate
and perform as required in connection with the operation of the business of the Company as currently conducted, and, to the Company&rsquo;s
knowledge, are free and clear of all bugs, errors, Trojan horses, time bomb, and malware (ii) the Company and its Subsidiaries have implemented
and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards designed
to maintain and protect their confidential information and the integrity, continuous operation, redundancy and security of their IT Systems
and data, including all &ldquo;Personal Data&rdquo; (defined below) and all sensitive, confidential or regulated data (&ldquo;<B><I>Confidential
Data</I></B>&rdquo;) used in connection with their businesses. &ldquo;<B><I>Personal Data</I></B>&rdquo; means (A) a natural person&rsquo;s
name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&rsquo;s
license number, passport number, credit card number, bank information, or customer or account number; (B) any information which would
qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (C) &ldquo;personal data&rdquo;
as defined by the European Union General Data Protection Regulation (&ldquo;<B><I>GDPR</I></B>&rdquo;) (EU 2016/679); (D) any information
which would qualify as &ldquo;protected health information&rdquo; under the Health Insurance Portability and Accountability Act of 1996,
as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &ldquo;<B><I>HIPAA</I></B>&rdquo;);
(E) any &ldquo;personal information&rdquo; as defined by the California Consumer Privacy Act (&ldquo;<B><I>CCPA</I></B>&rdquo;); and
(F) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any data related to an identified person&rsquo;s health or sexual orientation. Except as described in the Commission Documents,
and except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (x) to the knowledge
of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to their IT Systems or Personal
Data maintained or processed by the Company, except for those that have been remedied without material cost or liability or the duty
to notify any other person, nor any incidents under internal review or investigations relating to the same and (y) the Company and its
Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any
court or arbitrator or governmental or regulatory authority, external policies and contractual obligations relating to the privacy and
security of their IT Systems, Confidential Data, and Personal Data (collectively, &ldquo;<B><I>Privacy Laws</I></B>&rdquo;) and to the
protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) Except as described
in the Commission Documents, and except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect: (i) to the extent required by applicable Privacy Laws, the Company has in place commercially reasonable policies and procedures
relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data
and Confidential Data (the &ldquo;<B><I>Policies</I></B>&rdquo;); (ii) the Company has made disclosures to users or customers to the
extent required by applicable Privacy Laws, and none of such disclosures made or contained in any Policy have been inaccurate or in violation
of any applicable Privacy Laws; (iii) neither the Company nor any Subsidiary has received written notice of any actual or potential liability
under or relating to, or actual or potential violation of, any applicable Privacy Laws, and there is no action, suit or proceeding by
or before any court or governmental agency, authority or body pending or, to the Company&rsquo;s knowledge, threatened alleging non-compliance
with any applicable Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.38. <U>Acknowledgement
Regarding Investors&rsquo; Acquisition of Shares</U></B>. The Company acknowledges that while the Investors will be deemed to be a statutory
&ldquo;underwriter&rdquo; with respect to the Transaction in accordance with interpretive positions of the Commission, the Investors
are a &ldquo;trader&rdquo; that is not required to register with the SEC as a broker-dealer under Section 15(a) of the Securities Exchange
Act of 1934. The Company further acknowledges that the Investors, and each of them, and their respective representatives are not acting
as a financial advisor or fiduciary of the Company (or in any similar capacity, except as noted above) with respect to this Agreement
and the transactions contemplated by the Transaction Documents, and any advice given by an Investor or any of its representatives or
agents in connection therewith is merely incidental to the Investor&rsquo;s acquisition of the Shares. The Company further represents
to the Investors that the Company&rsquo;s decision to enter into the Transaction Documents to which it is a party has been based solely
on the independent evaluation of the transactions contemplated thereby by the Company and its representatives. The Company acknowledges
and agrees that neither Investor has made and does not make any representations or warranties with respect to the transactions contemplated
by the Transaction Documents other than those specifically set forth in Article IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.40. <U>Regulatory
Filings</U>.</B> Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect and
except as disclosed in the Commission Documents, neither the Company nor any of its Subsidiaries has failed to file with the applicable
Governmental Authorities (including, without limitation, the FDA, the EMA or any foreign, federal, state, provincial or local Governmental
Authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report
or submission, except for such failures that, as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect; except as disclosed in the Commission Documents, all such filings, declarations, listings, registrations, reports or
submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority
with respect to any such filings, declarations, listings, registrations, reports or submissions that have not yet been remedied, except
for any deficiencies that, as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.
The Company has operated and currently is, in all material respects, in compliance with the United States Federal Food, Drug, and Cosmetic
Act, all applicable rules and regulations of the FDA and other federal, state, local and foreign Governmental Authority exercising comparable
authority. The Company has no knowledge of any studies, tests or trials not described in the Commission Documents the results of which
reasonably call into question in any material respect the results of the studies, tests and trials described in the Commission Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.41. <U>Clinical
Studies</U>.</B> The preclinical studies and tests and clinical trials described in the Commission Documents were, and, if still pending,
are, being conducted in all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where
applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by
the Company; the descriptions of such studies, tests and trials, and the results thereof, contained in the Commission Documents are accurate
and complete in all material respects; the Company is not aware of any tests, studies or trials not described in the Commission Documents,
the results of which reasonably call into question the results of the tests, studies and trials described in the Commission Documents;
and, except as described in the Commission Documents, the Company has not received any written notice or correspondence from the FDA,
the EMA or any foreign, state or local Governmental Authority exercising comparable authority or any institutional review board or comparable
authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials described in
the Commission Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.42. <U>Emerging
Growth Company Status</U>.</B> From the time of the initial filing of the Company&rsquo;s first registration statement with the Commission
through the date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities
Act (an &ldquo;<B><I>Emerging Growth Company</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADDITIONAL COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company covenants with
the Investors, and each Investor, severally and not jointly, covenants with the Company, as follows, which covenants of one party are
for the benefit of the other party, during the Investment Period (and with respect to the Company, for the period following the termination
of this Agreement specified in Section 8.3 pursuant to and in accordance with Section 8.3):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.1. <U>Securities
Compliance</U></B>. The Company shall notify the Commission and the Principal Market, if and as applicable, in accordance with their
respective rules and regulations, of the transactions contemplated by the Transaction Documents, and shall take all necessary action,
undertake all proceedings and obtain all registrations, permits, consents and approvals for the legal and valid issuance of the Shares
to the Investor in accordance with the terms of the Transaction Documents, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.2. <U>Reservation
of Common Shares</U></B>. The Company has available and the Company shall reserve and keep available at all times, free of preemptive
and other similar rights of shareholders, the requisite aggregate number of authorized but unissued Common Shares to enable the Company
to timely effect the issuance, sale and delivery of all Shares to be issued, sold and delivered in respect of each VWAP Purchase effected
under this Agreement, at least prior to the delivery by the Company to the Investors of the applicable VWAP Purchase Notice in connection
with such VWAP Purchase. Without limiting the generality of the foregoing, as of the Commencement Date the Company shall have reserved,
out of its authorized and unissued Common Shares, a number of Common Shares equal to the Share Cap solely for the purpose of effecting
VWAP Purchases under this Agreement. The number of Common Shares so reserved for the purpose of effecting VWAP Purchases under this Agreement
may be increased from time to time by the Company from and after the Commencement Date, and such number of reserved shares may be reduced
from and after the Commencement Date only by the number of Shares actually issued, sold and delivered to the Investors pursuant to any
VWAP Purchase effected from and after the Commencement Date pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.3. <U>Registration
and Listing</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) The Company
shall prepare and, as soon as practicable, and in any case no more than 20 Trading Days, after the date of this Agreement, file with
the Commission an initial Registration Statement on Form S-3 (if then eligible) or Form S-1 (or any successor form) so as to permit the
resale of the Registrable Securities held by the Investors under Rule 415 under the Securities Act at then prevailing market prices (and
not fixed prices) (the &ldquo;<B><I>Initial Registration Statement</I></B>&rdquo;). The Company shall use its commercially reasonable
efforts to have the Initial Registration Statement declared effective by the Commission as soon as reasonably practicable following the
filing thereof with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) The Investors
shall have the right to select one legal counsel to review and oversee, solely on its behalf, any registration pursuant to this Section
6.3 (&ldquo;<B><I>Legal Counsel</I></B>&rdquo;), which shall be Ellenoff Grossman &amp; Schole LLP, or such other counsel as thereafter
designated by the Investors. The Company shall reimburse the Investors for any the legal fees and expenses of the Legal Counsel incurred
in connection with the transactions contemplated by this Section 6.3, in the amount of $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) If at any
time all Registrable Securities are not covered by the Initial Registration Statement filed pursuant to this Section 6.3 or otherwise,
the Company shall use its commercially reasonable efforts to file with the Commission one or more additional Registration Statements
so as to cover all of the Registrable Securities not covered by such initial Registration Statement, in each case, as soon as practicable
(taking into account any position of the staff of the Commission (&ldquo;<B><I>Staff</I></B>&rdquo;) with respect to the date on which
the Staff will permit such additional Registration Statement(s) to be filed with the Commission and the rules and regulations of the
Commission) (each such additional Registration Statement, a &ldquo;<B><I>New Registration Statement</I></B>&rdquo;). The Company shall
use its commercially reasonable efforts to cause each such New Registration Statement to become effective as soon as reasonably practicable
following the filing thereof with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) In no event
shall the Company include any securities other than Registrable Securities on any Registration Statement pursuant to this Section 6.3
without the express written consent of the Investors prior to filing such Registration Statement with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) If the Staff
or the Commission seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting
an offering of securities that does not permit such Registration Statement to become effective and be used for resales by the Investors
on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), or if after the filing of any
Registration Statement pursuant to this Section 6.3, the Company is otherwise required by the Staff or the Commission to reduce the number
of Registrable Securities included in such Registration Statement, then the Company shall reduce the number of Registrable Securities
to be included in such Registration Statement (after consultation with the Investors and Legal Counsel as to the specific Registrable
Securities to be removed therefrom) until such time as the Staff and the Commission shall so permit such Registration Statement to become
effective and be used as aforesaid. Notwithstanding anything in this Agreement to the contrary, if after giving effect to the actions
referred to in the immediately preceding sentence, the Staff or the Commission does not permit such Registration Statement to become
effective and be used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and
not fixed prices), the Company shall not request acceleration of the Effective Date of such Registration Statement, the Company shall
promptly (but in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant to Rule 477 under the Securities
Act. In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall use its commercially reasonable
efforts to file one or more New Registration Statements with the Commission in accordance with this Section 6.3 until such time as all
Registrable Securities have been included in Registration Statements that have been declared effective and the Prospectuses contained
therein are available for use by the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) The Company
shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the terms of
this Agreement and the intended method of disposition thereof, and, pursuant thereto, during the term of this Agreement, the Company
shall have the following obligations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a) Subject to Allowable
Grace Periods (as defined below), the Company shall keep each Registration Statement effective (and the Prospectus contained therein
available for use) pursuant to Rule 415 for resales by the Investors on a continuous basis at then-prevailing market prices (and not
fixed prices) at all times until the earlier of (i) the date on which the Investors shall have sold all of the Registrable Securities
covered by such Registration Statement and (ii) the date of termination of the Purchase Agreement if as of such termination date the
Investors hold no Registrable Securities (or, if applicable, the date on which such securities cease to be Registrable Securities after
the date of termination of the Purchase Agreement) (the &ldquo;<B><I>Registration Period</I></B>&rdquo;). Notwithstanding anything to
the contrary contained in this Agreement, the Company shall ensure that, when filed and at all times while effective, each Registration
Statement (including, without limitation, all amendments and supplements thereto) and the Prospectus (including, without limitation,
all amendments and supplements thereto) used in connection with such Registration Statement shall not contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case
of Prospectuses, in the light of the circumstances in which they were made) not misleading. The Company shall submit to the Commission,
as soon as reasonably practicable after the date that the Company learns that no review of a particular Registration Statement will be
made by the Staff or that the Staff has no further comments on a particular Registration Statement (as the case may be), a request for
acceleration of effectiveness of such Registration Statement to a time and date as soon as reasonably practicable, and in any case no
later than two Trading Days, after the Company learns of such fact in accordance with Rule 461 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b) The Company shall
use its commercially reasonable efforts to prepare and file with the Commission such amendments (including, without limitation, post-effective
amendments) and supplements to each Registration Statement and the Prospectus used in connection with each such Registration Statement,
which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep each such Registration
Statement effective (and the Prospectus contained therein current and available for use) at all times during the Registration Period
for such Registration Statement, and, during such period, comply with the provisions of the Securities Act with respect to the disposition
of all Registrable Securities of the Company required to be covered by such Registration Statement until such time as all of such Registrable
Securities shall have been disposed of in accordance with the intended methods of disposition by the Investor. Without limiting the generality
of the foregoing, the Company covenants and agrees that (i) at or before 5:30 p.m. (New York City time) on the second (2nd) Trading Day
immediately following the Effective Date of the Initial Registration Statement and any New Registration Statement (or any post-effective
amendment thereto), the Company shall file with the Commission in accordance with Rule 424(b) under the Securities Act the final Prospectus
to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment thereto), and (ii) if the transactions
contemplated by any VWAP Purchase are material to the Company (individually or collectively with all other prior VWAP Purchases, the
consummation of which have not previously been reported in any Prospectus Supplement filed with the Commission under Rule 424(b) under
the Securities Act or in any report, statement or other document filed by the Company with the Commission under the Exchange Act), or
if otherwise required under the Securities Act (or the interpretations of the Commission thereof), in each case as reasonably determined
by the Company and the Investors, then, at or before 8:30 a.m., New York City time, on the first (1st) Trading Day immediately following
the VWAP Purchase Date, if a VWAP Purchase Notice was properly delivered to the Investors hereunder in connection with such VWAP Purchase,
the Company shall file with the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act with respect to the
VWAP Purchase(s), the total VWAP Purchase Price for the Shares subject to such VWAP Purchase(s) (as applicable), the applicable VWAP
Purchase Price(s) for such Shares and the net proceeds that are to be (and, if applicable, have been) received by the Company from the
sale of such Shares. To the extent not previously disclosed in the Prospectus or a Prospectus Supplement, the Company shall disclose
in its quarterly reports on Form 10-Q and in its annual reports on Form 10-K the information described in the immediately preceding sentence
relating to all VWAP Purchase(s) consummated during the relevant fiscal quarter and shall file such quarterly reports and annual reports
with the Commission within the applicable time period prescribed for such report under the Exchange Act. In the case of amendments and
supplements to any Registration Statement on Form S-1 or Prospectus related thereto which are required to be filed pursuant to this Agreement
by reason of the Company filing a report on Form 8-K, Form 10-Q or Form 10-K or any analogous report under the Exchange Act, the Company
shall have incorporated such report by reference into such Registration Statement and Prospectus, if applicable, or shall file such amendments
or supplements to the Registration Statement or Prospectus with the Commission on the same day on which the Exchange Act report is filed
which created the requirement for the Company to amend or supplement such Registration Statement or Prospectus, for the purpose of including
or incorporating such report into such Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including,
without limitation, any supplement thereto) included in each Registration Statement in accordance with the provisions of the Securities
Act and with the securities or &ldquo;Blue Sky&rdquo; laws of the jurisdictions in which the Registrable Securities may be sold by the
Investor, in connection with the resale of the Registrable Securities and for such period of time thereafter as such Prospectus (including,
without limitation, any supplement thereto) (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required
by the Securities Act to be delivered in connection with resales of Registrable Securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(c) The Company shall
(A) permit Legal Counsel an opportunity to review and comment upon (i) each Registration Statement at least three (3) Trading Days prior
to its filing with the Commission (it being understood that such notice period has been satisfied in respect of the initial Registration
Statement) and (ii) all amendments and supplements to each Registration Statement (including, without limitation, the Prospectus contained
therein) (except for annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any similar or successor
reports or Prospectus Supplements the contents of which is limited to that set forth in such reports) within a reasonable number of days
prior to their filing with the Commission, and (B) shall reasonably consider any comments of the Investors and Legal Counsel on any such
Registration Statement or amendment or supplement thereto or to any Prospectus contained therein. The Company shall promptly furnish
to Legal Counsel, without charge, (i) electronic copies of any correspondence from the Commission or the Staff to the Company or its
representatives relating to each Registration Statement (which correspondence shall be redacted to exclude any material, non-public information
regarding the Company or any of its Subsidiaries), (ii) after the same is prepared and filed with the Commission, one (1) electronic
copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements
and schedules, all documents incorporated therein by reference, if requested by the Investors or either of them, and all exhibits and
(iii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in such Registration
Statement and all amendments and supplements thereto; provided, however, the Company shall not be required to furnish any document (other
than the Prospectus, which may be provided in .PDF format) to Legal Counsel to the extent such document is available on EDGAR).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(d) The Company shall
take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and qualification applies,
the resale by the Investors of the Registrable Securities covered by a Registration Statement under such other securities or &ldquo;Blue
Sky&rdquo; laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments (including,
without limitation, post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain
the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such
registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary
or advisable to qualify the Registrable Securities for sale in such jurisdictions; <U>provided</U>, <U>however</U>, the Company shall
not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction, or (z) file
a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and the Investors of
the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable
Securities for sale under the securities or &ldquo;Blue Sky&rdquo; laws of any jurisdiction in the United States or its receipt of actual
notice of the initiation or threatening of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(e) The Company shall
notify Legal Counsel and the Investors in writing of the happening of any event, as promptly as reasonably practicable after becoming
aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any
material, non-public information regarding the Company or any of its Subsidiaries), and, promptly prepare a supplement or amendment to
such Registration Statement and such Prospectus contained therein to correct such untrue statement or omission and deliver one (1) electronic
copy of such supplement or amendment to Legal Counsel and the Investors (or such other number of copies as Legal Counsel or the Investors
may reasonably request). The Company shall also promptly notify Legal Counsel and the Investors in writing (i) when a Prospectus or any
Prospectus Supplement or post-effective amendment has been filed, when a Registration Statement or any post-effective amendment has become
effective (notification of such effectiveness shall be delivered to Legal Counsel and the Investors by e-mail on the same day of such
effectiveness), and when the Company receives written notice from the Commission that a Registration Statement or any post-effective
amendment will be reviewed by the Commission, (ii) of any request by the Commission for amendments or supplements to a Registration Statement
or related Prospectus or related information, (iii) of the Company&rsquo;s reasonable determination that a post-effective amendment to
a Registration Statement would be appropriate and (iv) of the receipt of any request by the Commission or any other federal or state
governmental authority for any additional information relating to the Registration Statement or any amendment or supplement thereto or
any related Prospectus. The Company shall respond as promptly as reasonably practicable to any comments received from the Commission
with respect to a Registration Statement or any amendment thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(f) The Company shall
(i) use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration
Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an exemption from qualification,
of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal
of such order or suspension at the earliest possible time and (ii) notify Legal Counsel and the Investors of the issuance of such order
and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(g) The Company shall
hold in confidence and not make any disclosure of information concerning the Investors provided to the Company unless (i) disclosure
of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in such Registration
Statement pursuant to the Securities Act, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable
order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the
public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company agrees that it shall, upon
learning that disclosure of such information concerning the Investors, or either of them, is sought in or by a court or governmental
body of competent jurisdiction or through other means, give prompt written notice to the Investors and allow the Investors, at the Investors&rsquo;
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(h) Without limiting
any obligation of the Company under the Purchase Agreement, the Company shall use its reasonable best efforts either to (i) cause all
of the Registrable Securities covered by each Registration Statement to be listed on Nasdaq, or (ii) secure designation and quotation
of all of the Registrable Securities covered by each Registration Statement on another Principal Market. The Company shall pay all fees
and expenses in connection with satisfying its obligation under this Section 6(vi)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) The Company shall
cooperate with the Investors and, to the extent applicable, facilitate the timely preparation and delivery of Registrable Securities,
as DWAC Shares, to be offered pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations or amounts
(as the case may be) as the Investor may reasonably request from time to time. The Investors each hereby agree that they shall cooperate
with the Company, its counsel and Transfer Agent in connection with any issuances of DWAC Shares, and hereby represents, warrants and
covenants to the Company that that it will resell such DWAC Shares only pursuant to the Registration Statement in which such DWAC Shares
are included, in a manner described under the caption &ldquo;Plan of Distribution&rdquo; in such Registration Statement, and in a manner
in compliance with all applicable U.S. federal and state securities laws, rules and regulations, including, without limitation, any applicable
prospectus delivery requirements of the Securities Act. At the time such DWAC Shares are offered and sold pursuant to the Registration
Statement, such DWAC Shares shall be free from all restrictive legends may be transmitted by the transfer agent to the Investors by crediting
an account at DTC as directed in writing by each Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(j) Upon the written
request of an Investor, the Company shall as soon as reasonably practicable after receipt of notice from such Investor, (i) incorporate
in a Prospectus Supplement or post-effective amendment such information as the Investor reasonably requests to be included therein relating
to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable
Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities
to be sold in such offering; (ii) make all required filings of such Prospectus Supplement or post-effective amendment after being notified
of the matters to be incorporated in such Prospectus Supplement or post-effective amendment; and (iii) supplement or make amendments
to any Registration Statement or Prospectus contained therein if reasonably requested by such Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(k) The Company shall
make generally available to its security holders (which may be satisfied by making such information available on EDGAR) not later than
ninety (90) days after the close of the period covered thereby, an earnings statement (in form complying with, and in the manner provided
by, the provisions of Rule 158 under the Securities Act) covering a twelve-month period beginning not later than the first day of the
Company&rsquo;s fiscal quarter next following the applicable Effective Date of each Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(l) The Company shall
otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission in connection
with any registration hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(m) Notwithstanding
anything to the contrary contained herein, at any time after the Effective Date of a particular Registration Statement, the Company may,
upon written notice to the Investors, suspend Investors&rsquo; use of any prospectus that is a part of any Registration Statement (in
which event the Investors shall discontinue sales of the Registrable Securities pursuant to such Registration Statement contemplated
by this Agreement, but shall settle any previously made sales of Registrable Securities) if the Company (x) is pursuing an acquisition,
merger, tender offer, reorganization, disposition or other similar transaction and the Company determines in good faith that (A) the
Company&rsquo;s ability to pursue or consummate such a transaction would be materially adversely affected by any required disclosure
of such transaction in such Registration Statement or other registration statement or (B) such transaction renders the Company unable
to comply with Commission requirements, in each case under circumstances that would make it impractical or inadvisable to cause any Registration
Statement (or such filings) to be used by the Investors or to promptly amend or supplement any Registration Statement contemplated by
this Agreement on a post effective basis, as applicable, or (y) has experienced some other material non-public event the disclosure of
which at such time, in the good faith judgment of the Company, would materially adversely affect the Company (each, an &ldquo;<B><I>Allowable
Grace Period</I></B>&rdquo;); <I>provided, however</I>, that in no event shall the Investors be suspended from selling Registrable Securities
pursuant to any Registration Statement for a period that exceeds sixty (60) consecutive Trading Days or an aggregate of ninety (90) days
in any three hundred and sixty-five (365)-day period; and <I>provided, further</I>, the Company shall not effect any such suspension
during the three-Trading Day period following the VWAP Purchase Share Delivery Date for each VWAP Purchase. Upon disclosure of such information
or the termination of the condition described above, the Company shall provide prompt notice, but in any event within one Business Day
of such disclosure or termination, to the Investors and shall promptly terminate any suspension of sales it has put into effect and shall
take such other reasonable actions to permit registered sales of Registrable Securities as contemplated in this Agreement with respect
to the information giving rise thereto unless such material, non-public information is no longer applicable). The Company shall cause
its transfer agent to deliver DWAC Shares to a transferee of the Investors in accordance with the terms of the Purchase Agreement in
connection with any sale of Registrable Securities with respect to which (i) the Company has made a sale to Investors and (ii) the Investors,
or either of them, have entered into a contract for sale, and delivered a copy of the Prospectus included as part of the particular Registration
Statement to the extent applicable, in each case prior to the Investor&rsquo;s receipt of the notice of an Allowable Grace Period and
for which the Investor has not yet settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) All reasonable
expenses of the Company, other than sales or brokerage commissions and fees and disbursements of counsel for, and other expenses of,
the Investor, incurred in connection with registrations, filings or qualifications, including, without limitation, all registration,
listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii) With a view
to making available to the Investor the benefits of Rule 144, the Company agrees to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a) use its best
efforts to make and keep current public information available, as such term is used in Rule 144;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b) furnish to the
Investors, or either of them, promptly upon request, (i) a written statement by the Company, if true, that it has complied with the reporting,
submission and posting requirements of Rule 144 and the Exchange Act, (ii) a copy of the most recent annual or quarterly report of the
Company and such other reports and documents so filed by the Company with the Commission if such reports are not publicly available via
EDGAR, and (iii) such other information as may be reasonably requested to permit the Investors to sell such securities pursuant to Rule
144 without registration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(c) take such additional
action as is reasonably requested by the Investors, or either of them, to enable the Investor to sell the Registrable Securities pursuant
to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions
to the Company&rsquo;s Transfer Agent without unreasonable delay as may be reasonably requested from time to time by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix) Neither the
Company nor either Investor shall assign this Agreement or any of their respective rights or obligations under this Section 6.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) No provision
of this Agreement may be (i) amended other than by a written instrument signed by all parties hereto or (ii) waived other than in a written
instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy
under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi) Solely for
purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own
of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons
with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from
such record owner of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.4. <U>Compliance
with Laws.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) During the
Investment Period, the Company shall comply with applicable provisions of the Securities Act and the Exchange Act, including Regulation
M thereunder, applicable state securities or &ldquo;Blue Sky&rdquo; laws, and applicable listing rules of the Principal Market or Principal
Market, in connection with the transactions contemplated by this Agreement, except as would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) Each Investor
shall comply with all laws, rules, regulations and orders applicable to the performance by it of its obligations under this Agreement
and its investment in the Shares, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect. Without limiting the foregoing, each Investor shall comply with all applicable provisions of the Securities Act and the Exchange
Act, including Regulation M thereunder, and all applicable state securities or &ldquo;Blue Sky&rdquo; laws, in connection with the transactions
contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.5. <U>Keeping
of Records and Books of Account; Due Diligence.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) The Investors
and the Company shall each maintain records showing the remaining Total Commitment, the remaining Aggregate Limit and the dates and VWAP
Purchase Share Amount for each VWAP Purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) Subject to
the requirements of Section 6.12, from time to time from and after the Closing Date, the Company shall make available for inspection
and review by the Investors, or either of them, during normal business hours and after reasonable notice, customary documentation reasonably
requested by the Investor and/or its appointed counsel or advisors to conduct due diligence; <U>provided</U>, <U>however</U>, that after
the Closing Date, the Investor&rsquo;s continued due diligence shall not be a condition precedent to the Company&rsquo;s right to deliver
to the Investors any VWAP Purchase Notice or the settlement thereof except to the extent expressly contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.6. <U>No Frustration;
No Variable Rate Transactions.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <B><U>No Frustration</U>.</B>
The Company shall not enter into, announce or recommend to its shareholders any agreement, plan, arrangement or transaction in or of
which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its
obligations under the Transaction Documents to which it is a party, including, without limitation, the obligation of the Company to deliver
the Shares to the Investors in respect of a VWAP Purchase not later than the VWAP Purchase Share Delivery Date. For the avoidance of
doubt, nothing in this Section 6.6(i) shall in any way limit the Company&rsquo;s right to terminate this Agreement in accordance with
Section 8.2 (subject in all cases to Section 8.3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <B><U>No Variable
Rate Transactions</U>.</B> The Company shall not effect or enter into any new agreement to effect any issuance by the Company of Common
Shares or Common Shares Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. For the avoidance of doubt,
the Company shall not be prohibited from entering into a Variable Rate Transaction other than another equity line of credit, unless a
VWAP Purchase Notice has been delivered and the delivery of such Shares and the payment therefor have not been completed at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.7. <U>Fundamental
Transaction</U></B>. If a VWAP Purchase Notice has been delivered to the Investor and the transactions contemplated therein have not
yet been fully settled in accordance with the terms and conditions of this Agreement, the Company shall not effect any Fundamental Transaction
until the expiration of five (5) Trading Days following the date of full settlement thereof and the issuance to the Investors of all
of the Shares issuable pursuant to the VWAP Purchase to which such VWAP Purchase Notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.8. <U>Selling
Restrictions.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) Except as expressly
set forth below, each Investor covenants that from and after the Closing Date through and including the Trading Day next following the
expiration or termination of this Agreement as provided in Article VIII (the &ldquo;<B><I>Restricted Period</I></B>&rdquo;), none of
the Investors any of their respective officers, or any entity managed or controlled by an Investor (collectively, the &ldquo;<B><I>Restricted
Persons</I></B>&rdquo; and each of the foregoing is referred to herein as a &ldquo;<B><I>Restricted Person</I></B>&rdquo;) shall, directly
or indirectly, (i) engage in any Short Sales of the Common Shares or (ii) hedging transaction, which establishes a net short position
with respect to the Common Shares, with respect to each of clauses (i) and (ii) hereof, either for its own principal account or for the
principal account of any other Restricted Person. Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained
herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during the Restricted Period
from: (1) selling &ldquo;long&rdquo; (as defined under Rule 200 promulgated under Regulation SHO) the Shares; or (2) selling a number
of Common Shares equal to the number of Shares that such Restricted Person is unconditionally obligated to purchase under a pending VWAP
Purchase Notice but has not yet received from the Company or the Transfer Agent pursuant to this Agreement, so long as (X) such Restricted
Person (or the Broker-Dealer, as applicable) delivers the Shares purchased pursuant to such VWAP Purchase Notice to the purchaser thereof
or the applicable Broker-Dealer promptly upon such Restricted Person&rsquo;s receipt of such Shares from the Company in accordance with
Section 3.2 of this Agreement and (Y) neither the Company or the Transfer Agent shall have failed for any reason to deliver such Shares
to the Investor or its Broker-Dealer so that such Shares are received by the Investor as DWAC Shares on the applicable VWAP Purchase
Share Delivery Date in accordance with Section 3.2 of this Agreement, including, without limitation, within the time period specified
for receipt of such Shares by the Investor or its Broker-Dealer as DWAC Shares from the Company or the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) In addition
to the foregoing, in connection with any sale of Shares (including any sale permitted by paragraph (i) above), each Investor shall comply
in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements of the Securities
Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.9. <U>Effective
Registration Statement</U></B>. During the Investment Period, the Company shall use its reasonable best efforts to maintain the continuous
effectiveness of the Initial Registration Statement and each New Registration Statement filed with the Commission under the Securities
Act for the applicable Registration Period pursuant to and in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.10. <U>Blue
Sky</U></B>. The Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption for or to qualify
the Shares for sale by the Company to the Investors pursuant to the Transaction Documents, and at the request of the Investors, the subsequent
resale of Registrable Securities by the Investors, in each case, under applicable state securities or &ldquo;Blue Sky&rdquo; laws and
shall provide evidence of any such action so taken to the Investors from time to time following the Closing Date; <U>provided</U>, <U>however</U>,
that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction
where it would not otherwise be required to qualify but for this Section 6.11, (y) subject itself to general taxation in any such jurisdiction,
or (z) file a general consent to service of process in any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.11. <U>Non-Public
Information</U>.</B> Neither the Company or any of its Subsidiaries, nor any of their respective directors, officers, employees or agents
shall disclose any material non-public information about the Company to the Investors during any VWAP Purchase Period, unless a simultaneous
public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing
covenant by the Company or any of its Subsidiaries, or any of their respective directors, officers, employees and agents (as determined
in the reasonable good faith judgment of the Investors) at the time the Investors are holding Shares or will receive Shares due to a
pending VWAP Purchase, (i) the Investors (or either of them) shall promptly provide written notice of such breach to the Company and
(ii) after such notice has been provided to the Company and, provided that the Company and the Investors shall have not concluded within
48 hours that such information does not constitute material, non-public information or the Company shall have failed to publicly disclose
such material, non-public information within 48 hours following demand therefor by the Investors, or either of them, in addition to any
other remedy provided herein or in the other Transaction Documents, if the Investor is holding any Shares at the time of the disclosure
of material, non-public information, the Investor shall have the right to make a public disclosure with the Company&rsquo;s prior written
consent (such consent not to be unreasonably withheld or delayed) in the form of a press release, public advertisement or otherwise,
of such material, non-public information; <I>provided</I>, that prior to making any such public disclosure, the Investor shall consult
with the Company and provide the Company opportunity to review and comment on such proposed disclosure. The Investors, and either of
them, shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees,
shareholders or agents, for any such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.12. <U>Broker/Dealer</U></B>.
The Investors shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that it may purchase or otherwise acquire
from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be a DTC participant (collectively, the
&ldquo;<B><I>Broker-Dealer</I></B>&rdquo;). The Investors shall, from time to time, provide the Company and the Transfer Agent with all
information regarding the Broker-Dealer reasonably requested by the Company to effectuate the purposes of this Agreement. The Investors
shall be solely responsible for all fees and commissions of the Broker-Dealer (if any), which shall not exceed customary brokerage fees
and commissions and shall be responsible for designating only a DTC participant eligible to receive DWAC Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.13. <U>Disclosure
Schedule</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) The Company may, from
time to time, update a disclosure schedule (the &ldquo;<B><I>Disclosure Schedule</I></B>&rdquo;) as may be required to satisfy the conditions
set forth in Section 7.2(i) (to the extent such condition set forth in Section 7.2(i) relates to the condition in Section 7.1(i) as of
a specific VWAP Purchase Condition Satisfaction Time). For purposes of this Section 6.14, any disclosure made in a schedule to the Compliance
Certificate shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the contrary, no
update to the Disclosure Schedule pursuant to this Section 6.14 shall cure any breach of a representation or warranty of the Company
contained in this Agreement and made prior to the update and shall not affect any of the Investor&rsquo;s rights or remedies with respect
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Notwithstanding anything
to the contrary contained in the Disclosure Schedule or in this Agreement, the information and disclosure contained in any Schedule of
the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Schedule of the Disclosure Schedule
as though fully set forth in such Schedule for which applicability of such information and disclosure is readily apparent on its face.
The fact that any item of information is disclosed in the Disclosure Schedule shall not be construed to mean that such information is
required to be disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and the thresholds (whether
based on quantity, qualitative characterization, dollar amounts or otherwise) set forth herein shall not be used as a basis for interpreting
the terms &ldquo;material&rdquo; or &ldquo;Material Adverse Effect&rdquo; or other similar terms in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.14. <U>Delivery
of Bring-Down Opinions and Compliance Certificates Upon Occurrence of Certain Events</U></B>. Within three (3) Trading Days immediately
following each time the Company files (i) an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing
amended financial information or a material amendment to the previously filed Form 10-K); (ii) a quarterly report on Form 10-Q under
the Exchange Act; (iii) a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo;
pursuant to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange
Act; or (iv) the Initial Registration Statement, any New Registration Statement, or any supplement or post-effective amendment thereto,
and in any case, not more than once per calendar quarter, the Company shall (1) deliver to the Investor a Compliance Certificate in customary
form, dated as of such date, (2) cause to be furnished to the Investors opinions of Company Counsel along with a 10b-5 letter from United
States Counsel, in customary form (each such opinion or letter, a &ldquo;<B><I>Bring-Down Opinion</I></B>&rdquo;) and (3) cause to be
furnished to the Investors a comfort letter from the independent registered public accounting firm of the Company in the case of an annual
report on Form 10-K (in the case of a post-effective amendment, only if such amendment contains amended or new financial information),
modified, as necessary, to relate to such Registration Statement or post-effective amendment, or the Prospectus contained therein as
then amended or supplemented by such Prospectus Supplement, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDITIONS TO CLOSING AND CONDITIONS TO THE
SALE AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE OF THE SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.1. <U>Conditions
Precedent to Commencement</U></B>. The right of the Company to commence delivering VWAP Purchase Notices under this Agreement, and the
obligation of the Investors to accept VWAP Purchase Notices delivered to the Investors by the Company under this Agreement, are subject
to the initial satisfaction, at Commencement, of each of the conditions set forth in this Section 7.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <B><U>Accuracy
of the Company&rsquo;s Representations and Warranties</U></B>. The representations and warranties of the Company contained in this Agreement
(a) that are not qualified by &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; shall have been true and correct in
all material respects when made and shall be true and correct in all material respects as of the Commencement Date with the same force
and effect as if made on such date, except to the extent such representations and warranties are as of another date, in which case, such
representations and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by
&ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; shall have been true and correct when made and shall be true and correct
as of the Commencement Date with the same force and effect as if made on such date, except to the extent such representations and warranties
are as of another date, in which case, such representations and warranties shall be true and correct as of such other date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <B><U>Accuracy
of the Investors&rsquo; Representations and Warranties</U></B>. The representations and warranties of the Investors and each of them,
contained in this Agreement (a) that are not qualified by &ldquo;materiality&rdquo; shall be true and correct in all material respects
as of the Commencement Date, except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by &ldquo;materiality&rdquo;
shall be true and correct as of the Commencement Date, except to the extent such representations and warranties are as of another date,
in which case, such representations and warranties shall be true and correct as of such other date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) <B><U>Payment
of Upfront Commitment Fee</U>.</B> On or prior to the end of the Trading Day immediately following the execution of this Agreement, the
Company shall have paid the Upfront Commitment Fee by issuance of pre-funded warrants to each Investor, all of which Upfront Commitment
Fee shall be fully earned and non-refundable as of the date of such payment, regardless of whether any VWAP Purchases are made or settled
hereunder or any subsequent termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) <B><U>Performance
of the Company</U></B>. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Commencement.
The Company shall deliver to the Investors on the Commencement Date a compliance certificate in customary form (the &ldquo;<B><I>Compliance
Certificate</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) <B><U>Initial
Registration Statement Effective</U></B>. The Initial Registration Statement covering the resale by the Investors of the Registrable
Securities included therein required to be filed by the Company with the Commission pursuant to Section 2.3 of this Agreement shall have
been declared effective under the Securities Act by the Commission, and the Investors shall be permitted to utilize the Prospectus therein
to resell all of the Shares included in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) <B><U>No Material
Notices</U></B>. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or
any other federal or state governmental authority for any additional information relating to the Initial Registration Statement, the
Prospectus contained therein or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other federal
or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or
suspending the use of the Prospectus contained therein or any Prospectus Supplement thereto, or of the suspension of qualification or
exemption from qualification of the Shares for offering or sale in any jurisdiction, or the initiation or contemplated initiation of
any proceeding for such purpose; or (c) the occurrence of any event or the existence of any condition or state of facts, which makes
any statement of a material fact made in the Initial Registration Statement, the Prospectus contained therein or any Prospectus Supplement
thereto untrue or which requires the making of any additions to or changes to the statements then made in the Initial Registration Statement,
the Prospectus contained therein or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act
to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus or any Prospectus
Supplement, in the light of the circumstances under which they were made) not misleading, or which requires an amendment to the Initial
Registration Statement or a supplement to the Prospectus contained therein or any Prospectus Supplement thereto to comply with the Securities
Act or any other law. The Company shall have no knowledge of any event that would reasonably be expected to have the effect of causing
the suspension of the effectiveness of the Initial Registration Statement or the prohibition or suspension of the use of the Prospectus
contained therein or any Prospectus Supplement thereto in connection with the resale of the Registrable Shares by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii) <B><U>No
Suspension of Trading in or Notice of Delisting of Common Shares</U></B>. Trading in the Common Shares shall not have been suspended
by the Commission, the Principal Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the Commencement Date), the Company shall not have received any final and non-appealable
notice that the listing or quotation of the Common Shares on the Principal Market shall be terminated on a date certain (unless, prior
to such date certain, the Common Shares is listed or quoted on any other Principal Market), nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of,
or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the
Company in writing that DTC has determined not to impose any such suspension or restriction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii) <B><U>Compliance
with Laws</U></B>. The Company shall have complied with all applicable federal, state and local governmental laws, rules, regulations
and ordinances in connection with the execution, delivery and performance of this Agreement and the other Transaction Documents to which
it is a party and the consummation of the transactions contemplated hereby and thereby, including, without limitation, the Company shall
have obtained all permits and qualifications required by any applicable state securities or &ldquo;Blue Sky&rdquo; laws for the offer
and sale of the Shares by the Company to the Investors and the subsequent resale of the Registrable Securities by the Investors (or shall
have the availability of exemptions therefrom).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix) <B><U>No Injunction</U></B>.
No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify
or delay any of the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) <B><U>No Proceedings
or Litigation</U></B>. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have been commenced,
and no inquiry or investigation by any governmental authority shall have been commenced, against the Company or any Subsidiary, or any
of the officers, directors or Affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change the transactions contemplated
by the Transaction Documents, or seeking material damages in connection with such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi) <B><U>Listing
of Shares</U>.</B> All of the Shares that have been and may be issued pursuant to this Agreement shall have been approved for listing
or quotation on the Principal Market as of the Commencement Date, subject only to notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii) <B><U>No
Material Adverse Effect</U>.</B> No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall have
occurred and be continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiii) <B><U>No
Bankruptcy Proceedings</U>.</B> No Person shall have commenced a proceeding against the Company pursuant to or within the meaning of
any Bankruptcy Law. The Company shall not have, pursuant to or within the meaning of any Bankruptcy Law, (a) commenced a voluntary case,
(b) consented to the entry of an order for relief against it in an involuntary case, (c) consented to the appointment of a Custodian
of the Company or for all or substantially all of its property, or (d) made a general assignment for the benefit of its creditors. A
court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (I) is for relief against the
Company in an involuntary case, (II) appoints a Custodian of the Company or for all or substantially all of its property, or (III) orders
the liquidation of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiv) <B><U>Delivery
of Commencement Irrevocable Transfer Agent Instructions and Opinion of Counsel</U></B>. The Commencement Irrevocable Transfer Agent Instructions
shall have been executed by the Company and delivered to the Company&rsquo;s transfer agent and an opinion of United States Counsel relating
to the Initial Registration Statement and the removal of restrictive legends from the Shares shall have been executed by Company Counsel
and delivered to the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xv) <B><U>Reservation
of Shares</U></B>. As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Shares a number
of Common Shares equal to the Share Cap solely for the purpose of effecting VWAP Purchases under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvi) <B><U>Opinions
of Company Counsel</U></B>. On the Commencement Date, the Investors shall have received the opinions of Company Counsel, along with a
10b-5 letter from Company Counsel, in customary form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvii) <B><U>Comfort
Letter of Accountant</U>.</B> On the Commencement Date, the Investors shall have received from the Accountant or a successor independent
registered public accounting firm for the Company, a letter dated the Commencement Date addressed to the Investors, in form and substance
reasonably satisfactory to the Investors with respect to the audited and unaudited financial statements and certain financial information
contained in the Registration Statement and the Prospectus, and any Prospectus Supplement, except that the specific date referred to
therein for the carrying out of procedures shall be no more than three Business Days prior to the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.2. <U>Conditions
Precedent to VWAP Purchases after Commencement Date</U></B>. The right of the Company to deliver VWAP Purchase Notices under this Agreement
after the Commencement Date, and the obligation of the Investors to accept VWAP Purchase Notices under this Agreement after the Commencement
Date, are subject to the satisfaction of each of the conditions set forth in this Section 7.2 at the applicable VWAP Purchase Commencement
Time for the VWAP Purchase to be effected pursuant to the applicable VWAP Purchase Notice timely delivered by the Company to the Investors
in accordance with this Agreement (each such time, a &ldquo;<B><I>VWAP Purchase Condition Satisfaction Time</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <B><U>Satisfaction
of Certain Prior Conditions</U></B>. Each of the conditions set forth in subsections (i), (ii), (vi) through (xiii), (xv) and (xviii)
set forth in Section 7.1 shall be satisfied at the applicable VWAP Purchase Condition Satisfaction Time after the Commencement Date (with
the terms &ldquo;Commencement&rdquo; and &ldquo;Commencement Date&rdquo; in the conditions set forth in subsections (i) and (ii) of Section
7.1 replaced with &ldquo;applicable VWAP Purchase Condition Satisfaction Time&rdquo;); <U>provided</U>, <U>however</U>, that the Company
shall not be required to deliver the Compliance Certificate after the Commencement Date, except as provided in Section 6.15 and Section
7.2(x).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <B><U>Initial
Registration Statement Effective</U></B>. The Initial Registration Statement covering the resale by the Investors of the Registrable
Securities included therein required to be filed by the Company with the Commission pursuant to Section 2.3 of this Agreement, and any
post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date and prior to the
applicable VWAP Purchase Date shall have been declared and shall remain effective under the Securities Act by the Commission, and the
Investors shall be permitted to (and to continue to) utilize the Prospectus therein, and any Prospectus Supplement thereto, to resell
all of the Shares included in the Initial Registration Statement, and any post-effective amendment thereto, that have been issued and
sold to the Investors hereunder pursuant to all VWAP Purchase Notices delivered by the Company to the Investors prior to such applicable
VWAP Purchase Date, and all of the Shares included in the Initial Registration Statement, and any post-effective amendment thereto, that
are issuable pursuant to the applicable VWAP Purchase Notice delivered by the Company to the Investors with respect to a VWAP Purchase
to be effected hereunder on such applicable VWAP Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) <B><U>Any
Required New Registration Statement Effective</U></B>. Any New Registration Statement covering the resale by the Investors of the Registrable
Securities included therein, and any post-effective amendment thereto, required to be filed by the Company with the Commission pursuant
to this Agreement after the Commencement Date and prior to the applicable VWAP Purchase Date, in each case shall have been declared effective
under the Securities Act by the Commission and shall remain effective for the applicable Registration Period, and the Investors shall
be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto, to resell (a) all of the Shares included in such
New Registration Statement, and any post-effective amendment thereto, that have been issued and sold to the Investors hereunder pursuant
to all VWAP Purchase Notices delivered by the Company to the Investors prior to such applicable VWAP Purchase Date and (b) all of the
Shares included in such new Registration Statement, and any post-effective amendment thereto, that are issuable pursuant to the applicable
VWAP Purchase Notice delivered by the Company to the Investors with respect to a VWAP Purchase to be effected hereunder on such applicable
VWAP Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) <B><U>Delivery
of Subsequent Irrevocable Transfer Agent Instructions and Opinion of Counsel</U></B>. With respect to any post-effective amendment to
the Initial Registration Statement, any New Registration Statement or any post-effective amendment to any New Registration Statement,
in each case declared effective by the Commission after the Commencement Date, the Company shall have delivered or caused to be delivered
to the Transfer Agent (a) irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions
executed by the Company and acknowledged in writing by the Transfer Agent and (b) an opinion of Company Counsel relating to the removal
of restrictive legends from the Shares, in each case modified as necessary to refer to such Registration Statement or post-effective
amendment and the Registrable Securities included therein, to issue the Registrable Securities included therein as DWAC Shares in accordance
with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) <B><U>No Material
Notices</U></B>. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or
any other federal or state governmental authority for any additional information relating to the Initial Registration Statement or any
post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained
in any of the foregoing or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Registration Statement
or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained
in any of the foregoing or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of the Initial Registration Statement or any post-effective amendment thereto,
any New Registration Statement or any post-effective amendment thereto, or prohibiting or suspending the use of the Prospectus contained
in any of the foregoing or any Prospectus Supplement thereto, or of the suspension of qualification or exemption from qualification of
the Shares for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose;
or (c) the occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact
made in the Initial Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective
amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto untrue or which requires
the making of any additions to or changes to the statements then made in the Initial Registration Statement or any post-effective amendment
thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing
or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary
in order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in the light of the circumstances
under which they were made) not misleading, or which requires an amendment to the Initial Registration Statement or any post-effective
amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the
foregoing or any Prospectus Supplement thereto to comply with the Securities Act or any other law (other than the transactions contemplated
by the applicable VWAP Purchase Notice delivered by the Company to the Investors with respect to a VWAP Purchase to be effected hereunder
on such applicable VWAP Purchase Date and the settlement thereof). The Company shall have no knowledge of any event that would reasonably
be expected to have the effect of causing the suspension of the effectiveness of the Initial Registration Statement or any post-effective
amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the prohibition or suspension of the use
of the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto in connection with the resale of the Registrable
Securities by the Investors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) <B><U>Other
Commission Filings</U></B>. The final Prospectus included in any post-effective amendment to the Initial Registration Statement, and
any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 2.3 after the Commencement
Date and prior to the applicable VWAP Purchase Date, shall have been filed with the Commission in accordance with Section 2.3. The final
Prospectus included in any New Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto,
required to be filed by the Company with the Commission pursuant to Section 2.3 after the Commencement Date and prior to the applicable
VWAP Purchase Date, shall have been filed with the Commission in accordance with Section 2.3. All reports, schedules, registrations,
forms, statements, information and other documents required to have been filed by the Company with the Commission pursuant to the reporting
requirements of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the Exchange
Act, after the Commencement Date and prior to the applicable VWAP Purchase Date, shall have been filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii) <B><U>No
Suspension of Trading in or Notice of Delisting of Common Shares</U></B>. Trading in the Common Shares shall not have been suspended
by the Commission, the Principal Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the applicable VWAP Purchase Date), the Company shall not have received any final and non-appealable
notice that the listing or quotation of the Common Shares on the Principal Market shall be terminated on a date certain (unless, prior
to such date certain, the Common Shares is listed or quoted on any other Principal Market), nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of,
or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the
Company in writing that DTC has determined not to impose any such suspension or restriction).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii) <B><U>Certain
Limitations</U>.</B> The issuance and sale of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall not (a) exceed
the applicable VWAP Purchase Share Amount, (b) cause the Aggregate Limit or the Beneficial Ownership Limitation to be exceeded, or (c)
cause the Exchange Cap (to the extent applicable under Section 3.3) to be exceeded, unless in the case of this clause (c), unless the
Company&rsquo;s shareholders have theretofore approved the issuance of Common Shares under this Agreement in excess of the Exchange Cap
in accordance with the applicable rules of the Principal Market, unless &ldquo;average price&rdquo; of all purchases under the Purchase
Agreement equals or exceeds the Minimum Price, adjusted to take into account the Commitment Shares such that issuances and sales of Common
Stock under this Agreement are deemed &ldquo;at market&rdquo; pursuant to the corporate governance rules of the Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix) <B><U>Shares
Authorized and Delivered</U>.</B> All of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall have been duly authorized
by all necessary corporate action of the Company. All Shares relating to all prior VWAP Purchase Notices required to have been received
by the Investor as DWAC Shares under this Agreement prior to the applicable VWAP Purchase Condition Satisfaction Time for the applicable
VWAP Purchase shall have been delivered to the Investor as DWAC Shares in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) <B><U>Bring-Down
Opinions of Company Counsel, Bring-Down Comfort Letters and Compliance Certificates</U></B>. The Investors shall have received (a) all
Bring-Down Opinions from Company Counsel for which the Company was obligated to instruct its Company Counsel to deliver to the Investors
prior to the applicable VWAP Purchase Condition Satisfaction Time for the applicable VWAP Purchase, (b) all Bring-Down comfort letters
provided by the Company&rsquo;s auditors and delivered to the Investors prior to the applicable VWAP Purchase Condition Satisfaction
Time for the applicable VWAP Purchase and (c) all Compliance Certificates from the Company that the Company was obligated to deliver
to the Investors prior to the applicable VWAP Purchase Condition Satisfaction Time for the applicable VWAP Purchase, in each case in
accordance with Section 6.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi) <B><U>Material
Non-Public Information</U></B>. Neither the Company nor, in each Investor&rsquo;s sole discretion, the Investors, shall be in possession
of any material non-public information concerning the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 8.1. <U>Automatic
Termination</U></B>. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earliest to
occur of (i) the first day of the month next following the 36-month anniversary of the Effective Date of the Initial Registration Statement,
(ii) the date on which the Investors shall have purchased the Total Commitment worth of Shares pursuant to this Agreement, (iii) the
date on which the Common Shares shall have failed to be listed or quoted on the Principal Market or any other Principal Market, (iv)
the thirtieth (30<SUP>th</SUP>) Trading Day next following the date on which, pursuant to or within the meaning of any Bankruptcy Law,
the Company commences a voluntary case or any Person commences a proceeding against the Company, in each case that is not discharged
or dismissed prior to such thirtieth (30<SUP>th</SUP>) Trading Day, and (v) the date on which, pursuant to or within the meaning of any
Bankruptcy Law, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general
assignment for the benefit of its creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 8.2. <U>Other
Termination</U></B>. Subject to Section 8.3, the Company may terminate this Agreement after the Commencement Date effective upon ten
(10) Trading Days&rsquo; prior written notice to the Investors in accordance with Section 10.4; <U>provided</U>, <U>however</U>, that
(i) the Company shall have paid the Upfront Commitment Fee to the Investors required to be paid pursuant to Section 10.1(ii) of this
Agreement, and (ii) prior to issuing any press release, or making any public statement or announcement, with respect to such termination,
the Company shall consult with the Investors and their counsel on the form and substance of such press release or other disclosure. Subject
to Section 8.3, this Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of
such mutual written consent unless otherwise provided in such written consent. Subject to Section 8.3, the Investors shall have the right
to terminate this Agreement effective upon ten (10) Trading Days&rsquo; prior written notice to the Company, which notice shall be made
in accordance with Section 10.4 of this Agreement, if: (a) a Fundamental Transaction shall have occurred; (b) the Company is in breach
or default in any material respect of any of its covenants and agreements in this Purchase Agreement, and, if such breach or default
is capable of being cured, such breach or default is not cured within fifteen (15) Trading Days after notice of such breach or default
is delivered to the Company pursuant to Section 10.4 of this Agreement; (c) while a Registration Statement, or any post-effective amendment
thereto, is required to be maintained effective pursuant to the terms of this Agreement and the Investor holds any Registrable Securities,
the effectiveness of such Registration Statement, or any post-effective amendment thereto, lapses for any reason (including, without
limitation, the issuance of a stop order by the Commission) or such Registration Statement or any post-effective amendment thereto, the
Prospectus contained therein or any Prospectus Supplement thereto otherwise becomes unavailable to the Investor for the resale of all
of the Registrable Securities included therein in accordance with the terms of this Agreement, and such lapse or unavailability continues
for a period of forty-five (45) consecutive Trading Days or for more than an aggregate of ninety (90) Trading Days in any three hundred
and sixty-five (365)-day period, other than due to acts of the Investor; (d) trading in the Common Shares on the Principal Market (or
if the Common Shares is then listed on an Principal Market, trading in the Common Shares on such Principal Market) shall have been suspended
and such suspension continues for a period of five (5) consecutive Trading Days; or (e) the Company is in material breach or default
of any of its covenants and agreements contained in this Agreement, and, if such breach or default is capable of being cured, such breach
or default is not cured within fifteen (15) Trading Days after notice of such breach or default is delivered to the Company pursuant
to Section 10.4 of this Agreement. Unless notification thereof is required elsewhere in this Agreement (in which case such notification
shall be provided in accordance with such other provision), the Company shall promptly (but in no event later than twenty-four (24) hours)
notify the Investors (and, if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission,
or under the applicable rules and regulations of the Principal Market (or if the Common Shares is then listed on a Principal Market,
under the applicable rules and regulations of such Principal Market), the Company shall publicly disclose such information in accordance
with Regulation FD and the applicable rules and regulations of the Principal Market (or such Principal Market, as applicable)) upon becoming
aware of any of the events set forth in the immediately preceding sentence.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 8.3. <U>Effect
of Termination</U></B>. In the event of termination by the Company or the Investors (other than by mutual termination) pursuant to Section
8.2, written notice thereof shall forthwith be given to the other party as provided in Section 10.4 and the transactions contemplated
by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as provided in Section
8.1 or Section 8.2, this Agreement shall become void and of no further force and effect, except that (i) the provisions of Article V
(Representations, Warranties and Covenants of the Company), Article IX (Indemnification), Article X (Miscellaneous) and this Article
VIII (Termination) shall remain in full force and effect indefinitely notwithstanding such termination, and, (ii) so long as an Investor
owns any Shares, the covenants and agreements of the Company contained in Article VI (Additional Covenants) shall remain in full force
and notwithstanding such termination for a period of thirty (30) days following such termination. Notwithstanding anything in this Agreement
to the contrary, no termination of this Agreement by any party shall (i) become effective prior to the second (2nd) Trading Day immediately
following the date on which the purchase of Shares by the Investors pursuant to any pending VWAP Purchase has been fully settled, including,
without limitation, the delivery by the Company to the Investors of all Shares purchased by the Investors pursuant to such pending VWAP
Purchase as DWAC Shares on the applicable VWAP Purchase Share Delivery Date therefor, and the delivery by the Investors to the Company
of the aggregate VWAP Purchase Price payable by the Investors for such Shares, in each case in accordance with the settlement procedures
set forth in Section 3.2 of this Agreement (it being hereby acknowledged and agreed that no termination of this Agreement shall limit,
alter, modify, change or otherwise affect any of the Company&rsquo;s or the Investors&rsquo; rights or obligations under the Transaction
Documents with respect to any pending VWAP Purchase that has not fully settled, and that the parties shall fully perform their respective
obligations with respect to any such pending VWAP Purchase under the Transaction Documents), (ii) limit, alter, modify, change or otherwise
affect the Company&rsquo;s or the Investors&rsquo; rights or obligations under this Agreement as they relate to the Initial Registration
Statement or the New Registration Statement and the maintenance of their continued effectiveness, all of which shall survive any such
termination, or (iii) affect the Upfront Commitment Fee payable to the Investors pursuant to Section 10.1(ii) it being hereby acknowledged
and agreed that the entire amount of the Upfront Commitment Fee shall be fully earned by the Investors and shall be non-refundable as
of the Upfront Determination Date, regardless of whether any VWAP Purchases are made or settled hereunder or any subsequent termination
of this Agreement. Nothing in this Section 8.3 shall be deemed to release the Company or the Investors from any liability for any breach
or default under this Agreement or any of the other Transaction Documents to which it is a party, or to impair the rights of the Company
and the Investors to compel specific performance by the other party of its obligations under this Agreement or any of the other Transaction
Documents to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 9.1. <U>Indemnification
of Investors</U></B>. In consideration of the Investors&rsquo; execution and delivery of this Agreement and acquiring the Shares hereunder
and in addition to all of the Company&rsquo;s other obligations under the Transaction Documents to which it is a party, subject to the
provisions of this Section 9.1, the Company shall indemnify and hold harmless the Investors, each of them, each of their respective directors,
officers, shareholders, members, partners, employees, representatives and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls
an Investor within the meaning of the Securities Act or the Exchange Act) and each of the directors, officers, shareholders, members,
partners, employees, agents, and representatives (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding the lack of such title or any other title) of such controlling person (each, an &ldquo;<B><I>Investor Party</I></B>&rdquo;),
from and against all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses (including all judgments, amounts
paid in settlement, court costs, reasonable attorneys&rsquo; fees and costs of defense and investigation) (collectively, &ldquo;<B><I>Damages</I></B>&rdquo;)
that any Investor Party has suffered or incurred (a) as a result of, relating to or arising out of, or based upon any untrue statement
or alleged untrue statement of a material fact contained in any Commission Document (or any amendment thereto), or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising
out of any untrue statement or alleged untrue statement of a material fact included in any Commission Document, or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; <U>provided</U>, <U>however</U>, that this indemnity in (a) shall not apply to any loss, liability, claim,
damage or expense to the extent arising out of an untrue statement or omission, or alleged untrue statement or omission in a Commission
Document, made in reliance upon and in conformity with information furnished in writing to the Company by the Investor for the Company&rsquo;s
express use in connection with the preparation of the Registration Statement, Prospectus or Prospectus Supplement or any such amendment
thereof or supplement thereto (it being hereby acknowledged and agreed that the written information set forth on <U>Exhibit B</U> to
this Agreement is the only written information furnished to the Company by or on behalf of each of the Investors expressly for use in
any Registration Statement, Prospectus or Prospectus Supplement), (b) to the extent of the aggregate amount paid in settlement of any
litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever based
upon any such untrue statement or omission, or any such alleged untrue statement or omission; <U>provided</U> that any such settlement
is effected with the written consent of the Company, which consent shall not unreasonably be delayed, conditioned or withheld, (c) in
investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced
or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission
(whether or not a party), to the extent that any such expense is not paid under (a) or (b) above, (d) as a result of, relating to or
arising out of any breach by the Company of its representations, warranties, covenants or agreements under this Agreement, or (e) as
a result of, relating to or arising out of any other action, suit, claim or proceeding against an Investor Party arising out of or otherwise
in connection with the Transaction Documents (except in the case of subsection (e), solely to the extent any Damage is determined by
a court of competent jurisdiction, not subject to further appeal, to have resulted primarily and directly from the bad faith or gross
negligence of such Investor Party).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall reimburse
any Investor Party promptly upon demand (with accompanying presentation of documentary evidence) for all reasonable legal and other costs
and expenses reasonably incurred by such Investor Party in connection with (i) any action, suit, claim or proceeding, whether at law
or in equity, to enforce compliance by the Company with any provision of the Transaction Documents or (ii) any other any action, suit,
claim or proceeding, whether at law or in equity, with respect to which it is entitled to indemnification under this Section 9.1. To
the extent that the foregoing undertakings by the Company set forth in this Section 9.1 may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of the Damages which is permissible under applicable law,
provided that in no event shall the Investor be obligated to contribute any amount in excess of the fees it actually receives pursuant
to this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 9.2. <U>Indemnification
of the Company</U></B>. In consideration of the Company&rsquo;s execution and delivery of this Agreement and sale of the Shares hereunder
and in addition to all of the Investor&rsquo;s other obligations under the Transaction Documents to which it is a party, subject to the
provisions of this Section 9.2, the Investors, jointly and severally, shall indemnify and hold harmless the Company, its affiliates,
each of their respective directors, officers, shareholders, members, partners, employees, representatives and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) and each
Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act) and each of the directors, officers,
shareholders, members, partners, employees, agents, and representatives (and any other Persons with a functionally equivalent role of
a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling person (each, a &ldquo;<B><I>Company
Party</I></B>&rdquo;), from and against Damages that any Company Party may suffer or incur in connection with the claims described in
clauses (a), (b), (c), (d) and (e) of Section 9.1; provided that, such indemnity shall only be required if the Damages occurred as a
result of an untrue statement or omission, or alleged untrue statement or omission in a Commission Document, made in reliance upon and
in conformity with information furnished in writing to the Company by the Investor for the Company&rsquo;s express for use in connection
with the preparation of the Registration Statement, Prospectus or Prospectus Supplement or any such amendment thereof or supplement thereto
(it being hereby acknowledged and agreed that the written information set forth in a customary selling shareholder questionnaire is the
only written information furnished to the Company by or on behalf of each Investor expressly for use in any Registration Statement, Prospectus
or Prospectus Supplement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section 9.3. <U>Indemnification Procedures</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Promptly after
an Investor Party receives notice of a claim or the commencement of an action for which the Investor Party intends to seek indemnification
under Section 9.1, the Investor Party will notify the Company in writing of the claim or commencement of the action, suit or proceeding;
<U>provided</U>, <U>however</U>, that failure to notify the Company will not relieve the Company from liability under Section 9.1, unless
and solely to the extent it has been materially prejudiced by the failure to give such notice as evidenced by the forfeiture of by the
Company of substantive rights or defenses. The Company will be entitled to participate in the defense of any claim, action, suit or proceeding
as to which indemnification is being sought, and if the Company acknowledges in writing the obligation to indemnify the Investor Party
against whom the claim or action is brought, the Company may (but will not be required to) assume the defense against the claim, action,
suit or proceeding with counsel satisfactory to it. After the Company notifies the Investor Party that the Company wishes to assume the
defense of a claim, action, suit or proceeding, the Company will not be liable for any further legal or other expenses incurred by the
Investor Party in connection with the defense against the claim, action, suit or proceeding unless (1) the employment of counsel by the
Investor Party has been authorized in writing by the Company, (2) the Investor Party has reasonably concluded (based on advice of counsel)
that there may be legal defenses available to it or another Investor Party that are different from or in addition to those available
to the Company, (3) a conflict or potential conflict exists (based on advice of counsel to the Investor Party) between an Investor Party
and the Company (in which case the Company will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4) the Company has not in fact employed counsel to assume the defense of such action or counsel reasonably satisfactory to
the indemnified party, in each case, within a reasonable time after receiving notice of the commencement of the action; in each of which
cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the Company. It is understood that the
Company shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees,
disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any
one time for all such similarly situated Investor Parties. The Company will not be liable for any settlement of any action effected without
its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. The Company shall not, without the
prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened
claim, action or proceeding relating to the matters contemplated by this section (whether or not any indemnified party is a party thereto),
unless such settlement, compromise or consent (1) includes an express and unconditional release of each indemnified party, in form and
substance reasonably satisfactory to such indemnified party, from all liability arising out of such litigation, investigation, proceeding
or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any
indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) In order to
provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of
this Article IX for any reason is held to be unavailable or insufficient to hold an Investor Party harmless, the Company and the Investor
Party will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses
reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted) to
which the Company and the Investor Party may be subject in such proportion as shall be appropriate to reflect the relative benefits received
by the Company on the one hand and the respective Investors on the other hand. The relative benefits received by the Company on the one
hand and the Investor Party on the other hand shall be deemed to be in the same proportion as the total net proceeds from the aggregate
of all VWAP Purchase Amounts (before deducting expenses) received by the Company bear to the total compensation received by the respective
Investors from the Company pursuant to this Agreement. If, but only if, the allocation provided by the foregoing sentence is not permitted
by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative
benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Investor Party, on
the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action
in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by the Company or the Investor Party, the intent of the parties and
their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the
Investor Party agree that it would not be just and equitable if contributions pursuant to this Section 9.3(b) were to be determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein.
The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect
thereof, referred to above in this Section 9.3(b) shall be deemed to include, for the purpose of this Section 9.3(b), any legal or other
expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the
extent consistent with Section 9.3(a) hereof. Notwithstanding the foregoing provisions of this Section 9.3(b), the Investors, and either
of them, shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person
found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9.3(b), any person who controls
a party to this Agreement within the meaning of the Securities Act, any affiliates of the Investor Party and any officers, directors,
partners, employees or agents of the Investor Party or any of its affiliates, will have the same rights to contribution as that party,
and each director of the Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution
as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9.3(b), will
notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties
from whom contribution may be sought from any other obligation it or they may have under this Section 9.3(b) except to the extent that
the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution
is sought. No party will be liable for contribution with respect to any action or claim settled without its written consent if such consent
is required pursuant to Section 9.3(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) The Company
Party shall provide equivalent notice to the Investors in the case the Company seeks indemnification or contribution from the Investor
pursuant to Section 9.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The remedies provided
for in this Article IX are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Investor
Party at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE X</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section 10.1. <U>Certain Fees and Expenses;
Upfront Commitment Fee; Commencement Irrevocable Transfer Agent Instructions.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <B><U>Certain
Fees and Expenses</U></B>. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement,
except that the Company will reimburse the reasonable and documented fees and disbursements of legal counsel to the Investors in the
amount of $25,000 in connection with the entry into this Agreement and $5,000 per fiscal quarter in connection with the Investor&rsquo;s
ongoing due diligence and review of deliverables subject to Section 6.15. The Company shall pay all U.S. federal, state and local stamp
and other similar transfer and other taxes (other than income taxes) and duties levied in connection with issuance of the Shares pursuant
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <B><U>Upfront
Commitment Fee</U></B>. In consideration for the Investors&rsquo; execution and delivery of this Agreement on or prior to the end of
the Trading Day following the execution of this Agreement, the Company shall pay to the Investors the Upfront Commitment Fee in the form
of the pre-funded warrant. For the avoidance of doubt, the entire amount of the Upfront Commitment Fee shall be fully earned by the Investors
and shall be non-refundable as of the Upfront Determination Date, regardless of whether any VWAP Purchases are made or settled hereunder
or any subsequent termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) <B><U>Irrevocable
Transfer Agent Instructions; Opinion of Counsel</U></B>. On the Effective Date of the Initial Registration Statement and prior to Commencement,
the Company shall deliver or cause to be delivered to its Transfer Agent (and thereafter, shall deliver or cause to be delivered to any
subsequent transfer agent of the Company), (i) irrevocable instructions executed by the Company and delivered to the Company&rsquo;s
transfer agent (the &ldquo;<B><I>Commencement Irrevocable Transfer Agent Instructions</I></B>&rdquo;) directing the Transfer Agent to
issue to the Investors or their respective designated Broker-Dealer at which the account or accounts to be credited with the Shares being
purchased by each Investor are maintained any Registrable Securities included in the Initial Registration Statement as DWAC Shares, if
and when such Registrable Securities are issued in accordance with this Agreement and (ii) an opinion of Company Counsel as contemplated
by this Agreement relating to the Initial Registration Statement and the removal of restrictive legends from the Shares. With respect
to any post-effective amendment to the Initial Registration Statement, any New Registration Statement or any post-effective amendment
to any New Registration Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall deliver
or cause to be delivered to its Transfer Agent (and thereafter, shall deliver or cause to be delivered to any subsequent transfer agent
of the Company) (i) irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions
executed by the Company and acknowledged in writing by the Transfer Agent and (ii) an opinion of United States Counsel, in each case
modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities included therein,
to issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this Agreement. For the avoidance
of doubt, all Shares to be issued in respect of any VWAP Purchase Notice delivered to the Investor pursuant to this Agreement shall be
issued to the Investors in accordance with Section 3.2 by crediting the Investors&rsquo; accounts at DTC as DWAC Shares, and the Company
shall not take any action or give instructions to any transfer agent of the Company otherwise. The Company represents and warrants to
the Investor that, while this Agreement is effective, no instruction other than those referred to in this Section 10.1(iii) will be given
by the Company to its Transfer Agent, or any successor transfer agent of the Company, with respect to the Shares from and after Commencement,
and the Registrable Securities covered by the Initial Registration Statement or any post-effective amendment thereof, or any New Registration
Statement or post-effective amendment thereof, as applicable, shall otherwise be freely transferable on the books and records of the
Company and no stop transfer instructions shall be maintained against the transfer thereof. The Company agrees that if the Company fails
to fully comply with the provisions of this Section 10.1(iii) within three (3) Trading Days after the date on which the Investors have
provided any deliverables that the Investors or either of them may be required to provide to the Company or its Transfer Agent (if any),
the Company shall, at such Investor&rsquo;s written instruction, purchase from the Investor all Common Shares purchased or acquired by
the Investor pursuant to this Agreement that contain any restrictive legend or that have any stop transfer orders maintained that prohibit
or impede the transfer thereof in any respect at the greater of (i) the purchase price paid by the Investor for such Common Shares (as
applicable) and (ii) the Closing Sale Price of the Common Shares on the date of the Investor&rsquo;s written instruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section 10.2. <U>Specific Enforcement, Consent
to Jurisdiction, Waiver of Jury Trial.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) The Company
and each Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either party shall
be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to
enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other security
being required), this being in addition to any other remedy to which either party may be entitled by law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) Each of the
Company and the Investors (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of the United
States or of the State of New York sitting in the State of New York, County of New York for the purposes of any suit, action or proceeding
arising out of or relating to this Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient
forum or that the venue of the suit, action or proceeding is improper. Each of the Company and each Investor consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this
Section 10.2 shall affect or limit any right to serve process in any other manner permitted by law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) EACH OF THE
COMPANY AND EACH INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND EACH INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) The prevailing
party in any litigation between the Investors, on the one hand, and the Company, on the other hand, shall be entitled to their respective
legal fees and expenses incurred in such litigation, including the costs of any appeal and costs of collection of any judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.3. <U>Entire
Agreement</U></B>. The Transaction Documents set forth the entire agreement and understanding of the parties with respect to the subject
matter hereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral
and written, with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative
to subject matter hereof not expressly set forth in the Transaction Documents. All exhibits to this Agreement are hereby incorporated
by reference in, and made a part of, this Agreement as if set forth in full herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.4. <U>Notices</U></B>.
Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall
be effective (a) upon hand delivery or electronic mail delivery at the address or number designated below (if delivered on a business
day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following
the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever
shall first occur. The address for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GT Biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">505 Montgomery Street,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9<SUP>th</SUP> and 10<SUP>th</SUP> Floors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Francisco California, 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Five Narrow Lane, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">510 Madison Avenue, 14<SUP>th</SUP> Floor&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">backoffice@lhxcorp.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bristol Capital, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1090 Center Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Park City, UT 84098</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Either party hereto may from time to time change its address for notices
by giving at least five (5) days&rsquo; advance written notice of such changed address to the other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.5. <U>Waivers</U></B>.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such
waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such power, right or privilege preclude other or further exercises thereof or of any other
right, power or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.6. <U>Amendments</U></B>.
No provision of this Agreement may be amended by the parties from and after the date that is one (1) Trading Day immediately preceding
the filing of the Initial Registration Statement with the Commission. Subject to the immediately preceding sentence, no provision of
this Agreement may be amended other than by a written instrument signed by all parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.7. <U>Headings</U></B>.
The article, section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement
for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context clearly indicates otherwise,
each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms &ldquo;including,&rdquo;
&ldquo;includes,&rdquo; &ldquo;include&rdquo; and words of like import shall be construed broadly as if followed by the words &ldquo;without
limitation.&rdquo; The terms &ldquo;herein,&rdquo; &ldquo;hereunder,&rdquo; &ldquo;hereof&rdquo; and words of like import refer to this
entire Agreement instead of just the provision in which they are found.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.8. <U>Construction</U></B>.
The parties agree that each of them and their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents. In addition, each and every reference to share prices (including
the Threshold Price) and number of Common Shares in any Transaction Document shall, in all cases, be subject to adjustment for any stock
splits, stock combinations, stock dividends, recapitalizations, reorganizations and other similar transactions that occur on or after
the date of this Agreement. Any reference in this Agreement to &ldquo;Dollars&rdquo; or &ldquo;$&rdquo; shall mean the lawful currency
of the United States of America. Any references to &ldquo;Section&rdquo; or &ldquo;Article&rdquo; in this Agreement shall, unless otherwise
expressly stated herein, refer to the applicable Section or Article of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.9. <U>Binding
Effect</U></B>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors.
Neither the Company nor either Investor may assign this Agreement or any of their respective rights or obligations hereunder to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.10. <U>No Third
Party Beneficiaries</U></B>. Except as expressly provided in Article IX, this Agreement is intended only for the benefit of the parties
hereto and their respective successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person;
provided, that either Investor may assign its obligations and rights under the Transaction Documents to an Affiliate upon notice to the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.11. <U>Governing
Law</U></B>. This Agreement shall be governed by and construed in accordance with the internal procedural and substantive laws of the
State of New York, without giving effect to the choice of law provisions of such state that would cause the application of the laws of
any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.12. <U>Survival</U></B>.
The representations, warranties, covenants and agreements of the Company and the Investor contained in this Agreement shall survive the
execution and delivery hereof until the termination of this Agreement; <U>provided</U>, <U>however</U>, that (i) the provisions of Section
6.3, Article VIII (Termination), Article IX (Indemnification) and this Article X (Miscellaneous) shall remain in full force and effect
indefinitely notwithstanding such termination, and, (ii) so long as an Investor owns any Shares, the covenants and agreements of the
Company and such Investor contained in Article VI (Additional Covenants), shall remain in full force and effect notwithstanding such
termination for a period of thirty (30) days following such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.13. <U>Counterparts</U></B>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; <U>provided</U> that a facsimile
signature or signature delivered by e-mail in a &ldquo;.pdf&rdquo; format data file, including any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall
be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.14. <U>Publicity</U></B>.
The Company shall afford the Investors and their counsel with a reasonable opportunity to review and comment upon, shall consult with
the Investors and their counsel on the form and substance of, and shall give due consideration to all such comments from the Investors
or their counsel on, any press release, Commission filing or any other public disclosure made by or on behalf of the Company relating
to the Investors, their purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, prior
to the issuance, filing or public disclosure thereof. For the avoidance of doubt, the Company shall not be required to submit for review
any such disclosure (i) contained in periodic reports filed with the Commission under the Exchange Act if it shall have previously provided
the same disclosure to the Investors or their counsel for review in connection with a previous filing or (ii) any Prospectus Supplement
if it contains disclosure that does not reference the Investors, their purchases hereunder or any aspect of the Transaction Documents
or the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.15. <U>Severability</U></B>.
The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one
or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision
of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part
of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent
possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.16. <U>Further
Assurances</U></B>. From and after the Closing Date, upon the request of the Investors or the Company, each of the Company and the Investors
shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry
out and to effectuate fully the intent and purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 10.18. <U>Currency
Provisions</U></B>. The obligations of the Company pursuant to this Agreement in respect of any sum due to the Investors shall, notwithstanding
any judgment in a currency other than United States dollars, not be discharged until the first Trading Day, following receipt by the
Investors of any sum adjudged to be so due in such other currency, on which the Investor may in accordance with normal banking procedures
purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due
to the Investors in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment,
to indemnify the Investors against such loss. If the United States dollars so purchased are greater than the sum originally due to the
Investors or either of them hereunder, the Investors agree to pay to the Company an amount equal to the excess of the dollars so purchased
over the sum originally due to such Investor hereunder. All payments made by the Company under this Agreement shall be made free and
clear of any withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of
whatever nature (including any amounts that result from the payment of fees, compensation or reimbursement of costs contemplated by this
Agreement) imposed or levied by or on behalf of the United States or by any department, agency or other political subdivision or any
taxing authority thereof or therein, and all interest, penalties or similar liabilities with respect thereto (collectively, &ldquo;<B><I><U>Taxes</U></I></B>&rdquo;),
unless such deduction or withholding is required by law. If any Taxes are required by law to be deducted or withheld by the Company in
connection with such payment, the Company will increase the amount to be paid to the Investors so that the full amount of such payment
is received by the Investors, provided that the Company will not be required to pay any such additional amounts to the extent that the
obligation to withhold or deduct any amounts arises as a result of any present or former connection between the applicable Investor and
the relevant jurisdiction other than any such connection arising solely as a result of the transaction described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page to Common Share Purchase Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Agreement to be duly executed by their respective authorized officer as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT Biopharma, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five Narrow Lane, L.P.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Five Narrow Lane General Partner LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arie Rabinowitz</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bristol Capital LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Kessler</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Common Share Purchase Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX I TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON SHARES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>DEFINITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Accountant</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.7(c) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Affiliate</I></B>&rdquo; shall mean
any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with
a Person, as such terms are used in and construed under Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Aggregate Limit</I></B>&rdquo; shall
have the meaning assigned to such term in Section 2.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Agreement</I></B>&rdquo; shall have
the meaning assigned to such term in the introductory paragraph hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Allowable Grace Period</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.3(vi)(m) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Announcement Report&rdquo;</I></B>
shall have the meaning assigned to such term in Section 2.3 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Anti-Corruption Laws</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Applicable Laws</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.14 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Authorizations</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.14 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Bankruptcy Law</I></B>&rdquo; shall
mean Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&ldquo;<B>Beneficial Ownership Limitation</B>&rdquo;</I>
shall have the meaning assigned to such term in Section 3.4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Block</I></B>&rdquo; shall mean
any trade on in excess of 10,000 Common Shares on a single Trading Day to a single purchaser, as reported by Bloomberg through its &ldquo;AQR&rdquo;
function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Bloomberg</I></B>&rdquo; shall mean
Bloomberg, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Broker-Dealer</I></B>&rdquo; shall
have the meaning assigned to such term in Section 6.12 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Bring-Down Opinion</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.14 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>CCPA</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing</I></B>&rdquo; shall have
the meaning assigned to such term in Section 2.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing Date</I></B>&rdquo; shall
mean the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Closing Sale Price</I></B>&rdquo;
shall mean, for the Common Shares as of any date, the last closing trade price for the Common Shares on the Principal Market, as reported
by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price
for the Common Shares, then the last trade price for the Common Shares prior to 4:00 p.m., New York City time, as reported by Bloomberg.
All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations
or other similar transactions during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Code</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.28 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Commencement&rdquo;</I></B> shall
have the meaning assigned to such term in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Commencement Date&rdquo;</I></B>
shall have the meaning assigned to such term in Section 3.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Commencement Irrevocable Transfer
Agent Instructions</I></B>&rdquo; shall have the meaning assigned to such term in Section 10.1(iii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Commission</I></B>&rdquo; shall
mean the U.S. Securities and Exchange Commission or any successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Commission Documents</I></B>&rdquo;
shall mean the Initial Registration Statement (or any post-effective amendment thereto), any New Registration Statement (or any post-effective
amendment thereto) and all documents that have been and heretofore shall be incorporated by reference therein, including all reports,
schedules, registrations, forms, statements, information and other documents filed with or furnished to the Commission by the Company
pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act if applicable, any Prospectus contained in the Initial Registration
Statement or New Registration Statement and each Prospectus Supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Common Shares</I></B>&rdquo; shall
have the meaning assigned to such term in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Common Shares Equivalents</I></B>&rdquo;
shall mean any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Shares, including,
without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or
exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company</I></B>&rdquo; shall have
the meaning assigned to such term in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Counsel</I></B>&rdquo; means
Baker &amp; Hostetler, LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Company Party</I></B>&rdquo; shall
have the meaning assigned to such term in Section 9.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Compliance Certificate</I></B>&rdquo;
shall have the meaning assigned to such term in Section 7.1(iv) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Confidential Data</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Custodian</I></B>&rdquo; shall mean
any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Damages</I></B>&rdquo; shall have
the meaning assigned to such term in Section 9.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>DTC</I></B>&rdquo; shall mean The
Depository Trust Company, a subsidiary of The Depository Trust &amp; Clearing Corporation, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>DWAC</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.36 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>DWAC Shares</I></B>&rdquo; shall
mean Common Shares issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely tradable and transferable and
without restriction on resale and without stop transfer instructions maintained against the transfer thereof and (iii) timely credited
by the Company to the Investor&rsquo;s or its designated Broker-Dealer at which the account or accounts to be credited with the Shares
being purchased by Investor are maintained specified DWAC account with DTC under its Fast Automated Securities Transfer (FAST) Program,
or any similar program hereafter adopted by DTC performing substantially the same function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>EDGAR</I></B>&rdquo; means the Commission&rsquo;s
Electronic Data Gathering, Analysis and Retrieval System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Effective Date</I></B>&rdquo; shall
mean, with respect to the Initial Registration Statement filed pursuant to this Agreement (or any post-effective amendment thereto) or
any New Registration Statement filed pursuant to this Agreement (or any post-effective amendment thereto), as applicable, the date on
which the Initial Registration Statement (or any post-effective amendment thereto) or any New Registration Statement (or any post-effective
amendment thereto) is declared effective by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Emerging Growth Company</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.42 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Entity</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.76 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Environmental Laws</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.20 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Exchange Act</I></B>&rdquo; shall
mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Exchange Cap&rdquo;</I></B> shall
have the meaning assigned to such term in Section 3.3 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Exchange Cap Allocation&rdquo;</I></B>
shall mean that no Investor or Purchaser (as defined below) in the Private Placement shall be issued in the aggregate, upon VWAP Purchase,
conversion or exercise (as the case may be) of any Preferred Stock or Common Warrants (each as defined below), Common Shares in an amount
greater than the Exchange Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>FDA</I></B>&rdquo; shall mean the
United States Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>FINRA</I></B>&rdquo; shall mean
the Financial Industry Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Fundamental Transaction</I></B>&rdquo;
shall mean that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate or merge with or
into (whether or not the Company is the surviving corporation) another Person, with the result that the holders of the Company&rsquo;s
capital stock immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding voting power
of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially
all of the properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender or exchange offer
by another Person that is accepted by the holders of more than 50% of the outstanding Common Shares (excluding any Common Shares held
by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or
exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than
50% of the outstanding Common Shares (not including any Common Shares held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination),
or (5) reorganize, recapitalize or reclassify its Common Shares, or (ii) any &ldquo;person&rdquo; or &ldquo;group&rdquo; (as these terms
are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the &ldquo;beneficial owner&rdquo; (as defined
in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and
outstanding Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>GAAP</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.7(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>GDPR</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Governmental Authority</I></B>&rdquo;
shall mean (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory
or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator
or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Hazardous Materials</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.20 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>HIPAA</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Initial Registration Statement</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.3(i) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Investment Period</I></B>&rdquo;
shall mean the period commencing on the Effective Date of the Initial Registration Statement and expiring on the date this Agreement
is terminated pursuant to Article VIII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Investor</I></B>&rdquo; shall have
the meaning assigned to such term in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Investor Party</I></B>&rdquo; shall
have the meaning assigned to such term in Section 9.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>IT Systems</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Legal Counsel</I></B>&rdquo; shall
have the meaning assigned to such term in Section 6.3(ii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Minimum Price</I></B>&rdquo; means
the minimum price as defined by the listing rules of the Nasdaq Stock Market, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.20 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>New Registration Statement</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.3(iii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>OFAC</I></B>&rdquo; shall have the
meaning assigned to such term in Section 5.37 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Post-Effective Amendment Period</I></B>&rdquo;
shall mean the period commencing at 9:30 a.m., New York City time, on the fifth (5th) Trading Day immediately prior to the filing of
any post-effective amendment to the Initial Registration Statement or any New Registration Statement, and ending at 9:30 a.m., New York
City time, on the Trading Day immediately following, the Effective Date of such post-effective amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Permits</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.19 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Person</I></B>&rdquo; shall mean
any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust,
unincorporated organization, business association, firm, joint venture, governmental agency or authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Personal Data</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Policies</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.38(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Principal Market</I></B>&rdquo;
shall mean the Nasdaq Capital Market; provided however, that in the event the Company&rsquo;s Common Shares is ever listed or traded
on the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, or the Nasdaq Global Market, then the &ldquo;Principal
Market&rdquo; shall mean such other market or exchange on which the Company&rsquo;s Common Shares is then listed or traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Privacy Laws</I></B>&rdquo; shall
have the meaning assigned to such term in Section 5.38(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Private Placement&rdquo;</I></B>
shall mean the issuance and sale by the Company pursuant to a Securities Purchase Agreement, dated May 12, 2025 (the &ldquo;Securities
Purchase Agreement&rdquo;), with the purchasers identified therein (collectively, the &ldquo;Purchasers&rdquo;) of (i) up to 6,056 shares
of the Company&rsquo;s Series L 10% Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;), (ii) warrants to purchase up to
a number of shares of common stock of the Company (the &ldquo;Common Stock&rdquo;) equal to 100% of the shares of the Company&rsquo;s
Common Stock issuable upon conversion of the shares of Preferred Stock (the &ldquo;Common Warrants&rdquo;), and (iii) warrants to purchase
up to a number of shares of Company&rsquo;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities
Purchase Agreement) issuable upon exercise of the &ldquo;Greenshoe Right&rdquo; of the Purchasers to elect to purchase shares of Preferred
Stock with an aggregate stated value of up to $22,000,000 for an aggregate purchase price of $19,800,000, subject to adjustments, as
further described in the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Prospectus</I></B>&rdquo; shall
mean the prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;
shall mean any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under the
Securities Act, including the documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Registrable Securities</I></B>&rdquo;
means all of (i) the Shares and (ii) any capital stock of the Company issued or issuable with respect to such Shares, including, without
limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares
of capital stock of the Company into which the Common Shares are converted or exchanged and shares of capital stock of a successor entity
into which the Common Shares are converted or exchanged, in each case until such time as such securities cease to be Registrable Securities.
Any Registrable Security shall cease to be a &ldquo;Registrable Security&rdquo; at the earliest of the following: (i) when a Registration
Statement covering such Registrable Security becomes or has been declared effective by the Commission and such Registrable Security has
been sold or disposed of pursuant to such effective Registration Statement; (ii) when such Registrable Security is held by the Company
or one of its Subsidiaries; and (iii) the date that is the first (1st) anniversary of the date of termination of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Registration Period</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.3(vi)(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Regulation D</I></B>&rdquo; shall
have the meaning assigned to such term in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Restricted Period</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.8 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Restricted Person(s)</I></B>&rdquo;
shall have the meaning assigned to such term in Section 6.8 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Rule 144</I></B>&rdquo; shall mean
Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the same effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Sale Price</I></B>&rdquo; shall
mean any trade price for the Common Shares on the Principal Market during normal trading hours, as reported by the Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Sanctions</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.37 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Sanctioned Countries</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.37 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Sarbanes-Oxley Act</I></B>&rdquo;
shall have the meaning assigned to such term in Section 5.7(c) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>SEC</I></B>&rdquo; shall mean the
U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Section 4(a)(2)</I></B>&rdquo; shall
have the meaning assigned to such term in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Securities Act</I></B>&rdquo; shall
mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Share Cap</I></B>&rdquo; shall have
the meaning assigned to such term in Section 5.5 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Shares</I></B>&rdquo; shall mean
the Common Shares that are and/or may be purchased by the Investors under this Agreement pursuant to one or more VWAP Purchase Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Short Sales</I></B>&rdquo; shall
mean &ldquo;short sales&rdquo; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Staff</I></B>&rdquo; shall have
the meaning assigned to such term in Section 6.3(iii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Subsidiary</I></B>&rdquo; shall
mean any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary voting
power for the election of directors or other persons performing similar functions are at the time owned directly or indirectly by the
Company and/or any of its other Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Threshold Price</I></B>&rdquo; shall
mean with respect to any particular VWAP Purchase Notice, the greater of (i) 90% of the Closing Sale Price on the Business Day immediately
preceding the VWAP Purchase Date but not less than $1.00 or (ii) such higher price as set forth by the Company in the VWAP Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Total Commitment</I></B>&rdquo;
shall have the meaning assigned to such term in Section 2.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Trading Day</I></B>&rdquo; shall
mean any day on which the Principal Market or, if the Common Shares is then listed on an Principal Market, such Principal Market is open
for trading (regular way), including any day on which the Principal Market (or such Principal Market, as applicable) is open for trading
(regular way) for a period of time less than the customary time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Transaction Documents</I></B>&rdquo;
shall mean, collectively, this Agreement (as qualified by the Commission Documents) and the exhibits hereto and each of the other agreements,
documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated
hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Transfer Agent</I></B>&rdquo; shall
mean Computershare the sole transfer agent and branch registrar of the Company or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Upfront Commitment Fee</I></B>&rdquo;
shall mean a pre-funded warrant to purchase 300,000 Common Shares, divided equally between the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Upfront Determination Date</I></B>&rdquo;
shall mean the last Trading Day prior to the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Variable Rate Transaction</I></B>&rdquo;
shall mean a transaction in which the Company (i) issues or sells any equity or debt securities that are convertible into, exchangeable
or exercisable for, or include the right to receive additional Common Shares or Common Shares Equivalents either (A) at a conversion
price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the
Common Shares at any time after the initial issuance of such equity or debt securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such equity or debt security or upon the occurrence
of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Shares (including,
without limitation, any &ldquo;full ratchet&rdquo; or &ldquo;weighted average&rdquo; anti-dilution provisions, but not including any
standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction),
(ii) issues or sells any equity or debt securities, including without limitation, Common Shares or Common Shares Equivalents, either
(A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Shares (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split
or other similar transaction), or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or other similar
provision or mechanism (including, without limitation, a &ldquo;Black-Scholes&rdquo; put or call right, other than in connection with
a &ldquo;fundamental transaction&rdquo;) that provides for the issuance of additional equity securities of the Company or the payment
of cash by the Company, or (iii) enters into any agreement, including, but not limited to, an &ldquo;equity line of credit&rdquo; or
&ldquo;at the market offering&rdquo; or other continuous offering or similar offering of Common Shares or Common Shares Equivalents,
whereby the Company may sell Common Shares or Common Shares Equivalents at a future determined price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP</I></B>&rdquo; shall mean,
for the Common Shares for a specified period, the dollar volume-weighted average price for the Common Shares as reported by Bloomberg
through its &ldquo;AQR&rdquo; function. All such determinations shall be appropriately adjusted for any stock dividend, stock split,
stock combination, recapitalization or other similar transaction during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;VWAP Purchase&rdquo;</I></B> shall
have the meaning assigned to such term in Section 3.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;VWAP Purchase Amount&rdquo;</I></B>
shall have the meaning assigned to such term in Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Condition Satisfaction
Time</I></B>&rdquo; shall have the meaning assigned to such term in Section 7.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;VWAP Purchase Confirmation&rdquo;</I></B>
shall have the meaning assigned to such term in Section 3.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Commencement Time</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, 9:30:01 a.m., New York City time, on the applicable VWAP Purchase
Date, or such later time on such VWAP Purchase Date publicly announced by the Principal Market (or, if the Common Shares is then listed
on an Principal Market, by such Principal Market) as the official open (or commencement) of trading (regular way) on the Principal Market
(or such Principal Market, as applicable) on such VWAP Purchase Date; <I>provided, however</I>, that if a VWAP Purchase Notice is delivered
after 9:00 a.m., New York City time, on a VWAP Purchase Date, then the VWAP Purchase Commencement Time shall start only upon receipt
by the Company of written confirmation (which may be by email) of acceptance by the Investor, and which confirmation shall specify the
VWAP Purchase Commencement Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Date</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, the Trading Day on which the Investor receives, on such Trading
Day, a valid VWAP Purchase Notice for such VWAP Purchase in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Maximum Share Percentage</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, fifteen percent (15%) such day&rsquo;s trading volume, unless
mutually agreed in writing (which may be by email) between the Company and Investor prior to delivery of a VWAP Purchase Notice in respect
of such VWAP Purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Notice</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, an irrevocable written notice delivered by the Company to the
Investor in the form set forth in <U>Exhibit E</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Period</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, the period on the applicable VWAP Purchase Date for such VWAP
Purchase beginning at the applicable VWAP Purchase Commencement Time and ending at the applicable VWAP Purchase Termination Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Price</I></B>&rdquo;
shall mean the purchase price per Share to be purchased by the Investor in such VWAP Purchase on such VWAP Purchase Date equal to ninety
three percent (93%) of the lesser of the (i) lowest sale price on the VWAP Purchase Date and (ii) the VWAP over the applicable VWAP Purchase
Period on such VWAP Purchase Date for such VWAP Purchase. Notwithstanding anything herein to the contrary, in the case where the Sale
Price falls below the Threshold Price at any time on a VWAP Purchase Date, the VWAP Purchase Price shall be calculated using the volume
weighted average price of Common Shares as reported by Bloomberg through its &ldquo;AQR&rdquo; function sold during the portion of the
applicable VWAP Purchase Period that the Sale Price is not below the Threshold Price, and, as applicable, using the Block with the lowest
Sale Price that is not below the Threshold Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Share Amount</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, a number of Common Shares equal to the least of (i) a number
of Common Shares which, when aggregated with all other Common Shares then beneficially owned by the Investor and its affiliates (as calculated
pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the
Investor of more than the Beneficial Ownership Limitation; (ii) the VWAP Purchase Share Request; and (iii) the VWAP Purchase Share Estimate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Share Delivery Date</I></B>&rdquo;
shall have the meaning assigned to such term in Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Share Estimate</I></B>&rdquo;
shall mean the number of Common Shares set forth in any VWAP Purchase Notice, representing the Company&rsquo;s good faith estimate of
the number of Common Shares equivalent to the VWAP Purchase Share Request during the VWAP Purchase Period on any VWAP Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Share Request</I></B>&rdquo;
shall mean the number of Common Shares equal to (i) the total volume of Common Shares as reported by Bloomberg through its &ldquo;AQR&rdquo;
function during the applicable VWAP Purchase Period (provided that in the case where the Sale Price falls below the Threshold Price at
any time on a VWAP Purchase Date, this volume shall be calculated using the aggregate shares as reported by Bloomberg through its &ldquo;AQR&rdquo;
function for such portion of the VWAP Purchase Date that the Sale Price is not below the Threshold Price) multiplied by (ii) the lesser
of (A) the VWAP Purchase Share Request Percentage and (B) the VWAP Purchase Maximum Share Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Share Request Percentage</I></B>&rdquo;
shall mean the percentage set forth in any VWAP Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>VWAP Purchase Termination Time</I></B>&rdquo;
shall mean, with respect to a VWAP Purchase made pursuant to Section 3.1, 4:00 p.m., New York City time, on the applicable VWAP Purchase
Date, or such earlier time publicly announced by the Principal Market (or, if the Common Shares is then listed on an Principal Market,
by such Principal Market) as the official close of trading (regular way) on the Principal Market on such applicable VWAP Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Breen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Alan Urban, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Urban </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT
Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Alan Urbani, Chief Financial Officer and Principal
Accounting Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Urban </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-q_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $^ HH# 2(  A$! Q$!_\0
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MZ5]6TI*FI\OLH[1=[O[5M/A_KY$Q4G&_,]WTCT;7GV/D[_AK"V_Z-Y_:K_\
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M/[5?_ACO$/\ \>I/^&K[7.?^&>/VJOK_ ,*.\0Y_]'5]944FJ:_Y=1^]^?\
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MW_D5RR_G?_@,3Y._X:PMO^C>?VJ__#'>(?\ X]1_PUA;?]&\_M5_^&.\0_\
MQZOK&DR,XR,^F>:.6E_SZC][_P @Y9?SO_P&)\G_ /#6%M_T;S^U7_X8[Q#_
M /'J/^&L+;_HWG]JO_PQWB'_ ./5]8TF0>A!_&CEI?\ /J/WO_(.67\[_P#
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MT<M/_GU'[W_D/EE_._\ P&+[GR=_PUA;?]&\_M5_^&.\0_\ QZC_ (:PMO\
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M_P"06E_._NC_ )'Z_?\ #6%M_P!&\_M5_P#ACO$/_P >H_X:PMO^C>?VJ_\
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MPMO^C>?VJ_\ PQWB'_X]1_PUA;?]&\_M5_\ ACO$/_QZOK&BCEI_\^H_>_\
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MHMXJ\8Z%X31O[1DMKM8!:-K0O&!@;S1 8@5+[A\C?\/1_%7_ $BU_P""G/\
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M._8V[?\ =Z53]1QJVPM3_P "H]E_T]7Y#^MX177UFCN[^_'N]-SY(T__ (.
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M"?\ 031_\&1_S/ZCE(VKDC[H/I] /IR*=E?4?F*_)'_AZ3XI.!_PZV_X*<G
M '_%'?L;DX QW_;3.2<9)/)/)/6C_AZ1XIQG_AUK_P %.",@9_X0[]C;\O\
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MKOPI\,>$-/\ %_P.\9>$;_7HOVEOA;\6_CK\/M<MK?Q%H]DE]X*\=:#^S_\
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M] :TN^[^]_YDVCVC_P" P_\ D!GE1_W?U;_&CRH_[OZM_C3]R\<CD CGJ"0
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M,9_X9\B_^3#_ (F[SG_HBLI_\/F;?_*3^]__ (:1_9H_Z.%^!_\ X=/P7_\
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M]N9M^M'^MS^]W_AI#]FC_HX3X'_^'2\%_P#RXH_X:1_9H_Z.%^!__AT_!?\
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M,V_^4G][_P#PTC^S1_T<+\#_ /PZ?@O_ .7%'_#2/[-'_1POP/\ _#I^"_\
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MWN_\-(_LT\$?M"?!')8#/_"T?!9.2>,_\3?KQD@$>F<'->C^%/&'@SQ[H_\
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MX  ']..OYG'N/0&O-?\ A8'B3_HW?]K3_P ,+J7_ ,NZ/^%@>(_^C=_VM/\
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M%_PA_B[_ *%/QE_X2'B7_P"5E'_"'^+O^A3\9?\ A(>)?_E97][O_"P/$O\
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MVK?_ !'^^_\ EQ1_PL'Q+_T;I^U;_P"(_P!]_P#+C_\ 5WI?\3!UO^B5P_\
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MH]WIMOJ)U.UF:RAMI$OK2Y:.*1;>Z%R"L$P>2)U(,C"L?XVZGX!TGX9>(?\
MA9_AZV\6> =:N?#'@WQ)X>O$TZ6UU.#QUXITCP;8Q7$>IWEA;-!%?ZY:W,NR
MYCOUCC=],WZBEK!(WX-ZA?ZIX=UV[U/P?X\\$7$OB_50NA_$?PM/X1\1&W%E
MI1AOQI%Q<73-IMYF06=XLY^T&&X(BC\L@[7Q,^%?ASXT^$)?A[XL34Y]$O/$
M?@OQ')#I%ZME>S:CX$\7:+XWT,+<"&<_93K/A^R-_'Y+K+:)/$\D*R^97FXN
ME)T\10IJG5J2I3Y(UFHT9K3GYWJE:+;BWNW;0^CX:Q678;/LBQF;UL?A,IPV
M<9;7S3%Y7.O2S3!8&AC(5JV+RVMAIT<5''T?9P>'AAZM*K4<IVDG&*E\<1^-
M?V!?A#H^@ZEX.G\!:OH7@+QIXM\:/KO@W5Y_%5[X,\7Q>!]1BUKQ%JZZGJS^
M)-1U/5?"^@W>BV,<,6IRR"T-N8[9+>>:#H/@?JG[$?A!-<O?AGI7@7X>6?C'
M5M'\,V^KZ_Y4<GBV74= _P"$OTS3]*>ZO=8O= AALO$5W<V6D7:^';\:I<74
M.EVTUU/"TV9X(_8M_93\>6]_J7@Z7QKXFL?"]WXA^$FMK'KFLVD0UGPYIWC#
M0]:T>[AU#P_I-[>:EI\'Q(U;=JUBC:7=.FEW&FWMY;V<DTFW;_\ !.KX%W.L
M^$]=GN_BIJ^I^#O$WA3Q78&X\:V]Y;:AK_@9_#D6C3:GIL&C/9S26J>&=*L=
M5GL+:VNKF"2[L]1OHHIXDA^7I4L^7U>K2P/#LH1HPIT522E"G.M+DQ=:E.57
M23<*<91=/EER<RE%S:7[[6S7PG6 QN69UQ[X]87%XJ2?$-3'99B:V)Q<(K^T
M<%1QN2_VCALMCC88_"X'VU;,9SRS#QQT:]/+*N;T9X^7&>#;;_@FU\0O ?@N
M:QM_A*_ASQ+J7C#XOZ!9?$'4K_1M=U6ZTRSEMO&?B/Q6/$^IB]NM*FT/X;O;
M7^G^*+R?0]:T'P$ZV]E>V'AV=8-+X>Z#^PI^T-_PMKPUX;\$^%?%XMOBMK>L
M^(I]0FU.\U;QSKWPY\(>#I+[Q[X9U6YU4Z[?>%/#ND?'T>"+>WFGLH;>[U_Q
M/I,^CI!J-VTG/Z%^P+^QI\0/^$RT'3)/&'C2R\#:7XX_9O\ 'VE7^NW9&@Z9
M/H/BHW7@^TUK4_#FFZKI=QX$T+XPZRF@>*_ 6M12-I^L6T&M>(_$4]BT%M]4
M?"3]FKP]\%M0\8W?AOQ-\4=<O_&^J>*?$?C:W\9^+(M5_MGQ%XST?X::#J'B
MF^L+'1+!+75K;0?AGH5KX>GM+>UTRRM-6UZS@AFT^_LH--O"4,;6J4O:9?PZ
ML+.%>%:MAJ3F\1.E@,53PLI35:+I2E-9ASOV=1*<7=U)RL<O$W$'"&6X;.YY
M1X@>.<.)J6)R'%Y?@^(?[<RZGD=2MG.69]G$ZF98'&U,2IK)Z^2UZ6/Q=/ 6
MS"IEN9X;#SHU<-A:'S]\._VI_P!DCXEW6F_%U-/T_P #6NH?"G6?".G>/_'=
MSX)TM+/X96^M>&["Y\&BU\/>+?$=YHEO>ZGJ&C06NF7-C9:C;-%%:W,-G'-:
MQW.%=^$_^";OB/QO\+_"47AGX:^+O%/C35YO#/P[?0;'7M6TPZM\+=(T'58]
M*EURTDBTZW&CZ98:$MN!-=)Y^G&UN]MS"T;<5J/@+_@G%X4TBP\-:M\9?#OA
MRR_9:TG1/A[K,-QXS?3;BQN)?'_AK6;"'6WN/#\"^/\ Q7J/C/2M!\.ZC-X6
M?79DO9I?#MY%;:A*\-=QKW@?]C/]GKXDZ/\ $#Q5\5?$7@KQQIGC+5_CU]IO
M)]?.A:;8_$[2#X.U.XUO3_"_@>7PKX>\#:S8Z7;S:C>:G;:1J*2Z=%X@\0:W
M%;M<:I)B_K,HJGC*7#%:E"5*.-KUGA:N(H156,*S4E63M&I@JF%;3;?U;FC=
M/D7LSH<.8"O6K<+U/I)Y%FE?*\SAPKD^%P&?X6>*6!RO$U^&Z,\;A)RS2.%A
ME^8</YSFF'RK$1R_#9?GWL*%#*XX^KF4^HL/!W_!/GP[XJU?4=/7X0V'C?X.
M^(=8\;^)+RWU+5;CQ/X8\1KXET#0]?UC7(K9[G5-3>U\5Z)X7T[5;*6#4([7
M4K/2_.@266U:ZZ[3?VBOV7+[X\ZK<Z!KVD:S\4;?2O#GPF\3_$&TN[*VT'2_
M DOPLU[]J;P^TGB;4KZTTKQ'X0D\.VE]K@U;PZ-0>._O(9Y(_P"QK:YOT^6K
M+]G/]DG7M4_:AUGXF_'ZV\6:K\*/&'Q(^+GQ,N/!WCFXL?#O[/WPZ\;_ !!O
M/CWJ-EXELX;?4M&:>]TOP'8WGQ%@U.76)+B'PJ%M]$\/--;)/D/\*O\ @FKX
M=\/ZQIVL_%G6H_#/PKT3X9_";QCX1UGQ'XZL9_.L?V?_ !M^Q%X.U9O#DO@G
M3_&GBG4O$?PMTWQ9X0UOQ1X,M+S1/^$O^%VKZG+%I>L^&?%<-@H5\RI*$J.#
MX8P5&-=8E*6+P5*C5>&K8W"0C4BI-T72P4Z<8R<Y.;C*Z@Y&E;(. \QKSIXW
MBCZ0W&694LDIY5SX;A;/<92RV&?Y9PAGM*A@:N)IT<RS3+\\S-^WR[)*^#R_
M+ZE#)<KQT\1F^#6!JU_H" ?\$ZK6TU"&RUCX*M#X[M=4U^ZTJVUN\GNO$$,G
MB^Y\=7JVNEO.)K>>Y\>:?<ZNNCA+2XDUC]Q%9L]VL<GHO[._PG_9.O=&\(?'
MG]GWX?\ A_3;#Q/;:MKWAOQ-::=JNG:A(OB&TM]'UB<V&J3/+I\EY8Z=;6DD
M15D$$*>2 K&OERT^&?\ P3O\(?;;1_BE/J%WX'TKX?:[J\>F-JD]WK>EV/B>
MVU[PCX@T#1_ /PVBM/B0FO:CKVC:3J6K?#:QU^34XKG2[74+F'5IQ+/^AGP;
M\&>%OA[\+?!?@WP3J7B/5O!VC:4/^$6O?%IOAKPT6^EEOK*SOX]5TK1-6M6L
M([G[)#8:UI-EK5C#'';:G$ES&177E5&=?%TUB<!PY&G0I/3+X4J]:E5;E*G)
M5:=5.FJTE)*3IVFXZ),^8\1<1@<JX:KT\@XG\>9O.\WHX2K/CVGF/#G#V=9#
M#)LPKXJD_P"SJ4\%CLSJTL)PXZ-3'/$5ZN45,3&4J4*M.C0/B6 ;'PC@8QXR
MM0,D?]"_XC)[C /7C@_4URP [>G'/48 Z8]AG_Z_&G\9M0U+2M'\(76F^"OB
M#X\G_P"$VM4FT?X;^%;CQ=KMK;'PYXC\S5;S3;:XM&M]&MY3#;7-]YKF.YN[
M. 0R?:#+%Y%_PL'Q&>1^SO\ M:8;YES\ ]30[3R,HVMY1B""R-\R-E3R#7V-
M%KV4=D[RNFU=7;OJY:ZW5]GK8_G6JI.K)J-KI^[!/EBW*_)%6=E'9:MVIPU:
ME*_IE!. 3Z<UYG_PL#Q)_P!&[_M:?^&%U+_Y=T?\)_XD_P"C=_VM/_#"ZE_7
M6ZTNNZ^]?YF?++^67W/_ "/1?@M_R>CX-_[-F^+1_P#,L?" ?TK]1EZ#Z#^5
M?DM^SKKNHZY^V?X6DO\ X=?%SP$MO^S/\5T23XH?#^^\$0ZI*?BK\(Y98M"E
MN[V[.IR6:&)[^/9;M:17=A(!(ETI7]:5Z#Z#^5<>):^L)W5O84]>GQ2[7.C#
MZ4VGNJE3=-;R36C[IW1^</[5X+?M0?LVKRV_X%?M7QG&0Q$GC']EB-@I7:ZG
M#85U974X97#@-7P)^RE;?L<?#G6_'_P:_94^)FKZGJ'@^YU.?QI\/KC]I7X]
M_&KPQX%N7\375UX@/AG0OBS\2_'7@GP#=W7B_6+^7Q7'\/H="FO-;O)V\1"Z
MNXAY/WO^UM$D_P"TY^SE#)O5)_@-^UK!(T3&.58Y_%G[+UM(T3@C9*$F9HW'
M*2A) <H*_(?_ (8J_:=LOV7H_P!C[2_BI\ Y/A-X-U9$^'FN-H/Q!T7X@:_X
M2NO'.M>*]4T;XC_8M-U#0-/\126FNW-M-XD\.Q:\-:U6UM[[4+&+>TL7J8&,
M986$76=-RY(M.IRP<'*KSSE#E_>.%ERQYH?$[;M'%B'..(<E3A/EI2:<E:?.
MG'DA"?V/:/FYIZ_"M#],O'?@WPA\3_!WBCX>?$KP_H?CGP)XRT.[\.^+O"/B
M@1WVC:WH-^J/<V5[;23QSPP@K!=6EY93V=]I]S%;:A87EK=0V\Z_%OQ!_9-_
M8E^"?PQ\<?%#Q_IOQ(\(>'/AC;:A\:_%_P :W_:E_;'O?C3X*TKPI\.9/AIJ
M6KZ=\<+#XWZI^T#IOA/3_A?Y7@H>"_#/C.+PK/X>LM/TBW\-RM::>;/Y;TO_
M ()8^,[QO#MS\2?B_H'CK6-.F\(Z?K6J3:_\8+:?7O!_AS]GKQ)\*M2\,W?V
M75=.CN8M4\;ZAX:\;BYO(O.N++P_%!>3F^2"V/'>+/\ @E-\;_%W@KXO^&M<
M_:/TSQ/K/Q%_9"UW]GG1_$.O>)_B3;V.A>)O$/[.N@_ VZL-?\+?\(]JUGXK
M^%*ZOI-[\2[&ZN=6M_$FG>*Y[/5TT2[U9;^\O>F,*-.,^7&)73O'2GSM1DXJ
M]Y-*Z479IVDKW2TR?MIN*J86FTK7YYJ32;C=KW5=KWI6V?+?K9_:7Q(^#G[
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M%I?B,_A?X.Z?XD^-7P\\&?$;QWIWPFT7P9IWQ#UWP_91>.;+Q%I)NM,NOK[
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MY?4?F.]?"FE?M7>.T\0QQ>)/AKH-AX*UWXH>,_@KX8\1Z7XKN+Z]TWXA^%-
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MP.>*:-9HW7Q=$0T<H#JZ_P"C<A@P((_A(QQ4G_#V+_@FM_T>3\#_ /PK(O\
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M%3G1EAJG+EN0QJ2PSHT,(J49SR;%R@_J>%H8:;A-2E3IJ,ZN,A&7USX!T/\
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MT4VU"$='HE>23_F3^UI9VNK.^FVQ]H>$_@+\./!/B'3_ !5X>TB^M]<TR_\
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M\3_]B]KG_IIO*\6_9,_Y-J^#7_8CV/\ .>O2_%WBCPY+X6\21IK^B%G\/:X
M!K&F%BW]E7>  +LD]3G .."<+DCQC]E+Q'H%O^SC\'()]<T:&5? NG[HI=6T
MZ*969[@8>*2X5EQZ[B,[E*@C);3=-VC+XX?9EU3\C-VYXNZMRRZK^:/F?55%
M<]_PEGAG_H/Z)_X.-+_^3*/^$L\,_P#0?T3_ ,'&E_\ R92L^S^Y_P"1I\U]
MZ_S.AHKGO^$L\,_]!_1/_!QI?_R91_PEGAG_ *#^B?\ @XTO_P"3*+/L_N?^
M0?-?>O\ ,Z#:/0>O2C ]!^0KG_\ A+/#/_0?T3_P<:7_ /)E'_"6>&?^@_HG
M_@XTO_Y,HL^S^Y_Y!\U]Z_S.@P/0?D*,#T'Y"N?_ .$L\,_]!_1/_!QI?_R9
M1_PEGAG_ *#^B?\ @XTO_P"3*+/L_N?^0?-?>O\ ,Z# ]!^0KY1_;& 'PS^'
MG '_ !E?^Q3T]?\ AKCX+XZ>]?1Q\6>&NVOZ)U'_ #&=+Z=_^7ROEG]K_P 0
MZ!=_#3P L&MZ/*8OVJOV+9Y FJZ?(4BA_:U^#4LLC!+EL)''&[NQP%16;HK8
M(QE[2#LTK.ZL^SZ<OGOY$R:46[K3\-5N?8H .#@<C/0=\=Z7 ]!^0KG_ /A*
M_#0X_M_1../^0QI>./K=@_F ?84?\)9X9_Z#^B?^#C2__DRBS[/[I?Y#5M-5
MLNJ[+S.@P/0?D*,#T'Y"N?\ ^$L\,_\ 0?T3_P '&E__ "91_P )9X9_Z#^B
M?^#C2_\ Y,HL^S^Y_P"0_FOO7^9T&!Z#\A1@>@_(5S__  EGAG_H/Z)_X.-+
M_P#DRC_A+/#/_0?T3_P<:7_\F46?9_<_\@^:^]?YG0;5]!^0I:Y[_A+/#/\
MT']$_P#!QI?_ ,F4?\)9X9_Z#^B?^#C2_P#Y,HL^S^Y_Y!\U]Z_S.AHKGO\
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M*=^53<8\RBUS6?+JE=<VVC6]R/:83;E?WQ_K9&]_PSQ^SG_T;A^SK^/P&^$
M/_J&"C_AGC]G/_HW#]G3_P ,-\(/_F,KQ/Q'^W'\%O#%O^U#JE_IOCZ3PU^R
M1XC\2^#OB?XJM- TR;0[WQAX6\7Z;X'U'PQX4E;7([W4-4D\0ZG%;6/]IV.C
MV5_%!>7%K=O':3,MZ;]M?X.:?XP^''@;7](^)/AG7_B);^#YI?[4\%23:/\
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MU"WDM0FL4]ZE;3^]']:3!2P\M%33:W]]6^7+)7VZ['-_\,W?LS?]&T_LW?\
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M>+__  L?$G_RRH_X2[Q=_P!#5XO_ /"Q\2?_ "RH_P"( XK_ **V/_AJA_\
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M37M@X 'I16/M:W_/VI]\/_E1I:E_SY7_ ('+_P"2/$_^&;?V9_\ HVC]F_\
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M/OP;_P#F)H_X9M_9G_Z-H_9O_P#$??@W_P#,37ME%'MJW_/VI]\/_E06I?\
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M_P!$WC?_  ZY+_\ ,Q'_ !*-G'_1<9/_ .&G'_\ SR/X!]T/_/6W_P# F/\
M^*HW0_\ /6W_ / F/_XJO[^/^&1?@E_T:O\ "G_PR/AC_P"9RC_AD7X)?]&K
M_"G_ ,,CX8_^9RC_ (F#RK_HF\;_ .'7)?\ YF#_ (E&SC_HN,G_ /#3C_\
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M '2<?;_U9'\!!>+C]Y;X/()N(AD<KD?-RNY2,@X)!/.*3=#_ ,];?_P)C_\
MBJ_N0^&/[+7P>U#XE_M66=Q^S1\+[R#0OCEX(TO3;6?X-^';J#1K2Y_9-_9I
MUR?3K&V;07CTVUGUG5=6UN:UMQ%&]]K5W>2(TUP\TWM(_9$^"7!/[*WPG''/
M_%C_  L&!_'PZ&/XX/;MS4_I!Y3"7)_JYC9+W7S?VGED;\R_Z>X2*>M](WM9
M/1--G_$HN<?]%SD[\UE&/U_\R9_ -NA_YZV__@3'_P#%4;H?^>MO_P"!,?\
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M23MS4E_BC!=>7HOYM/73NR3_ (=P?\$]?^C$OV+O_$5O@?\ _,31_P .X/\
M@GK_ -&)?L7?^(K?!#_YB:^UES@9_NCV.<<Y%+4^]O[2K?\ Z^S_ /DF/D\H
M?^ 1_P CXI_X=P?\$]/^C$?V+?\ Q%?X(_\ S%4?\.X/^">O;]A']BW(Y'_&
M*_P0[<G_ )DK]>WO7VM2-T/TS^7(H<II-^TJNR;M[6>MDW;<?)Y0_P# (_Y'
MY._!7]@;]A37?B-^TKINJ_L3?L?ZG9>&_BCI>G:!97_[,OP5N;?2-/D\&:+/
M)8Z=')X**6EJ]P7N6A@$<9N))YV1III9'^C!_P $X/\ @GKMW']A#]B[I@G_
M (98^!W!XSG_ (HKUX _,'BO!?B7X3\:^._!?[<'@[X=ZSXL\-^,?$7QZ^#N
MFZ1XD\#W-U:>)?#AFUKX8->>(;.6TF@F>TT.P2[U76K3S1#J&AVFI6%TLEM=
M31OYV/%W[8P^(GBKXSZOX8^(G@-=4^''PS^&-UX6NM$G\8^'OAQX?\&_'V/P
MM\3?BQIO@NSU"VT[Q9XKUZPO?&?Q"TO4X)H;U?A%>>#]4N[2^E\*OHNI],Z<
MISDUB&FE!6E4E%N].E)-:N][RC;7X4FO>1E[L$HJDGK=.-.+2;E+>Z:C:]V[
MZW>R6GU__P .X?\ @GI_T8A^Q;Z?\FL_ [KV_P"9+]<_ECK1_P .X/\ @GKD
MX_80_8N[]/V6/@=A>#U/_"%?GD^O'/'SIX(^+/[=.J:WIFK:UX>AD\,Z5-\#
MK.U\/R_##^Q[GXEZ%\0?VI_VI/A=KOC?6-3EU\W7@35+;]G?PM^SS\;-9\*P
MV-PO@C6->U#2]2,]IK;?V3P#^//VS?'OA[P]=:]=_$'1])2VAC\9P:5\(?\
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MB?NIM:.SU2;2DM[).[U.=7M[&6ZU]E3LKM)Z];:7MT3[6/H3_AW%_P $]/\
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MP3T_Z,1_8M_\17^"/_S%4?\ #N'_ ()Z_P#1B'[%WU_X97^"'_S%9_G7VM7
M^(?B3X6\+Z_;^&=7O)HM8N?"7B?QQ%;0V=S<*?#?@]].37KQIHD:-'MGU6Q2
M*!B)+B294B!(."\O^?E7YU)O\&V5R^5/T<(_Y'S,?^"<7_!/0?\ -B/[%O\
MXBO\$!_/P4*3_AW%_P $]#T_80_8M_\ $6/@?_\ ,7782_M>_"L0>(=1MM-^
M(&I:!X9\)^%/%NI>)]-\#ZI=^'FC\<6VC7?A+P[9:@K*;WQ;K<6OZ2+70;>%
MKA9;M8IGB96P^T_:[^$EWH_A3Q 4\766C>)_'W_"J[S4M1\(ZG9V?@;XDR^/
MK;X4:?X(^(<\F4\*Z_K/Q2OM/^'VDVLWVE;KQ+>VUL7CMI?M0KEK[<U1:_\
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MJ[T75+'5K:VU.R=8[S3;B?3Y[B&#4+.1MMY92.MQ;%HQ-&A=01N:N_:5M/\
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MQ;_XBQ\#O_F,KXT_X37QG_T.GB__ ,*/5?\ Y+H_X37QG_T.GB__ ,*/5?\
MY+I?\17PG_0JS/\ \+<-_P#+A?VKAO\ H'J_^"H?Y'V7_P .X/\ @GK_ -&(
M?L6_^(L? [_YC*/^'<'_  3U_P"C$/V+?_$6/@=_\QE?&G_":^,_^AT\7_\
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MMJ?%/_#N#_@GK_T8C^Q;_P"(K_!#_P"8FC_AW!_P3T_Z,1_8M_\ $5_@C_\
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MC$?V+?\ Q%?X(_\ S%5]K447G_S\J_\ @V?^8<GE#_P!?Y'Q3_P[@_X)Z?\
M1B/[%O\ XBO\$?\ YBJ/^'<'_!/3_HQ']BW_ ,17^"/_ ,Q5?:U%%Y_\_*O_
M (-G_F')Y0_\ 7^1\4_\.X/^">G_ $8C^Q;_ .(K_!'_ .8JC_AW#_P3T_Z,
M1_8M_#]E?X(?U\%8K[6HHO/_ )^5?_!L_P#,.3RA_P" 1_R/BG_AW#_P3TZ?
M\,(?L7=.O_#*_P #^OK_ ,B5Q],5\V_M2_L#?L*^&?A[X)OO#_[$_P"R%H=Y
MJ'[2W[(?AV]O-(_9G^#&GW5UH7B/]J3X0Z'X@TB6YM?!L4S:?KFC7M]I&L69
M?R-0TN]N].NXI[.YN+>;]9\<YSQZ8[],YKY1_;&X^&?P\]_VK_V*?U_:W^"X
M_P#K_6G"4_:1]^IW_B3W][^]VMK^=DTW%<K4HTW>WV(]UY=SF/\ AW!_P3US
M_P F(_L7?^(K_ _&?_")S_/O@CC!_P .X?\ @GI_T8C^Q=^/[*_P/P/;CP3G
MU]>W/K]J#).<\$ X_#UIU+WO^?E3>_\ $GN_^W@Y.RA_X!'_ "/BG_AW!_P3
MT_Z,1_8M_P#$5_@C_P#,51_P[@_X)Z?]&(_L6_\ B*_P1_\ F*K[6HHO/_GY
M5_\ !L_\Q<GE#_P!?Y'Q3_P[@_X)Z?\ 1B/[%O\ XBO\$?\ YBJ/^'<'_!/3
M_HQ']BW_ ,17^"/_ ,Q5?:U%%Y_\_*O_ (-G_F')Y0_\ 7^1\4_\.X/^">G_
M $8C^Q;_ .(K_!'_ .8JC_AW!_P3T_Z,1_8M_P#$5_@C_P#,57VM11>?_/RK
M_P"#9_YAR>4/_ %_D?%/_#N#_@GI_P!&(_L6_P#B*_P1_P#F*I#_ ,$X/^">
MO'_&"/[%OO\ \8K_  0_ \^"?\^]?:]%%Y_\_*O_ (-G_P#)(.3RA_X O\C\
M[/ _[.O[/GP#_;.\!1? KX#?!;X*CQ/^S7\:5\32?"+X5^!/AM+XC&F_$SX'
M1Z4FNR>#-"T:35H])%Y?-IL=^]REF]]>M;"%KJ=I/T3KY1\1?\GJ_"CU_P"&
M:_CGSUZ_%#X#?Y]^E?5U*7,_9WD_X,+[;J4E?7FZ;+IJ.&]3_&]/E&Y\E^/+
M6"]_;(^!=C=*7M[S]EW]K>UN$5F0F&?XC?L@13!74C:QCD=0PY7=N7GFOS^^
M$_\ P21\2?##7KZS@_:;US5?AGX7_9O^-_[,_P )/!Z>$UTF^TWP+\7;OQ'J
M.A+\2KJQUI-&\>:A\*KWQ7K4/A36H]"TG7+^RN<:[J%[<@3C]"O&2.W[:/P#
M(5F"_LR_M8EBJDA<_$K]CY5)(!"Y+!>3@L0J\GGZJQUQQGOCD<>V._/-6JLX
M4H0@TN>E%M.-TFISL]G9V;6CB[-J^MR>2$W)RC>TW9W?\L4]K75]^EUU/Q)^
M*?\ P2.U7XA^*OV:];A^.>GZ$GP+^ ?[-OP1N-=/@%M2\<VTW[.WCZU\?VWC
M3X<:K/KR:1X6USQE-:CPYK)UG1O$<=EH%Q<KIBV]^XNAZ+^VC_P2OTK]JJTT
M)]-^._Q$\->(;*T_:+\+7/B7QU>ZA\4=3\*^#/VH]%^'FD^.[OX23:GJ6FW'
MPZ\;^ )OACX:\2?!34M.N)M#\%^(I-6N[C1-3CO(8[;];]I(Y.?<C)!Q]2./
M3D&EQDG([@\A>G'''KSU]?I6BQ%=<G[QMP4TGHK<]^9+[5G=[2TZ6>K7L*-I
M1=-<LG%R7=PMRNS[67>]M5W_ ",UK_@F?J^K?$_]JSXIMXY^%@N/C[X3UOP5
MHWPXE^#P/PGU&TU_XSZ9\8+KQE\=_!Z>)%A^*_Q-LQI%GX.TKQC:3>&;JSTJ
MYUK57CN-:UFZN5X;P3_P2'/@_7O@Q*_[1GBG7_"/A1O@YJ_QA\/:YX;L=0O_
M (B^(?V?_BYX]^,WPMM/"FOW5Y-J/@'P7HVN?$?6_"K^'8)=3F3P7I>@:?9Z
MA!>V<MW)^UU-VCVZ^@Z<\>WIGKQ2C7KJZY[)VV2O:,>57WU2V:>]F[M63="E
M)IR@G9NSZJ[3=O5]-NFB;;4<@'&,@?XX_6EH P,#H.!16*T7]>OSZ[&H4A&0
M>WX9_3O]*6D(SVS@@C/UZ]NG6DW=-+>SZ/L_(#\Z7^(5]\+8?VV/&6C1VMQX
MCM/BYX3TKPKIUVCRIK/BKQ-H'A3PUX>T2"!)[-;F_P!5U35K:STVWN+VRL9;
M^:V74;ZSL/M-U$WP#^VCK*?LY?M%?%SQK\/]5USQ1^RM\-?'7BKXG>%O#<2V
M6N7'CWX?^&/%WCG4O@P=%5M7M=/^)VG^#M)\'7.N+H6H>(?"C:OXWL(O#>I:
MKIT$=Q/Z5\+O!GA[QQXR_:^\*^-O#>E^)_"NN_%?1HM4T#Q%I5MJNC:Q:Q>#
M- N8XKJPOX9+6ZCCN8K:YB9D?RKB&&:,J\:L/?/ OP4^%/PON-0N_AM\.? W
M@*\U:PTS2]5N_"7A;2- N-3L-&DNI=*M-1ETRWMFOX=.;4+]K5;KS!$UU)MX
M)%=%24.><)0U4J$U+6[7L*5U>]K6NM%S)N]W9(GWG:SMWLD[ZOK>Z\[)Z77I
M\\M\8/BQ\+]*\!P>-KKP5\<O'OQI?[1X#T+X7QQ>!O!UM;>&_ NJ^.?'UYIG
MBOQ%J>O3:YX=71]/27P6TZ7^O:U+=VB74L>ES:CK6C>7K_P4:\/:B+?6/#/P
M>\9ZYX+U*21=&\3R^(/#6E3WEMIOP>^'?QW\02W.AS337=B]A\._B):2Z9"M
MS=)K/B+2[W2!/86DMMK#_3]K^R3^S+8^'KKPG:? #X.6WA>[UC2=?G\.6_P[
M\,0Z++K6AVFI6.C:HVGK8?9A>:3::WK5GITR1QO:6>JZC:PE(;VY67N9?@O\
M*YS.)OASX$E6XN=2O) _A'1"'N]7\-:7X-U6ZE'V8(T^I>$]$TCPS?.J*MSH
M&EZ?I4B_9+2WB2(RH:^Y.36MVG!6UV2;3>RMK:R>O-91RU'U44ET;FV[^?+H
MNG76VEM?A+PU^VWXBN?#L\WBSP[?:0=;\?ZII/P]\::(-"U"R\4:#HOQB\&>
M!M3L[OPW,[SZ!+;Z7XUT:1[Z]:>6]2>^FA2TO[-(&TM3_P""C?AO0OA+XE^*
M^M?"W7M&32/AYX<^,>A>%+OQ#:WOB#QI\+-<\(?%#QI)J7AZU\.Z-KUS+XPT
MO1?@Q\1Y;OPE-9C3[6'2+34]5\6:3H=S>ZII?UYI?[.7P(T*ZUZ^T7X-?"[2
MK_Q/<:=<^([[3_ /AVTN==GT?5K37M*FU2:"UC>^ET_7+&SUBUEF9C%J-I;7
M:XN8$D$/B/\ 9G^ ?C#0K3PQXK^"WPH\2^';#2]*T6RT+7O 7AW5=(L])T+3
M?%6BZ+IEKI]Y82VL.G:5HWCOQOI=C8I&+:VL_%WB&WB06^KW\-Q?M,,[7I55
MJ];=[::?--OR<;:BDJVEI1??3;1ZZRUZ.UNZ=U8^(+O]JKP[X<UBZ\.^+O@]
MI&A^#/@[\6OB%X"^"_ACPS+H6NP>)8?AI\/OA?+\.M=LQJ^G:-8?#C4KN\^*
MFD:/H4%I,UAX?%ZQU>^L8=#:_N/4+_\ ;LLM%\1W7A/6/@]XCMM6\%SZY%\8
MIK+Q+H=_I?P^C\/^)?AEX?O;C2;TPVLOCE9H/BYX,UVRBL;/29Y=-DU>">*U
MU72I-/E^H;_X"_!C5+WQ-J6I?";X>:C?^,H;N'Q9>7O@O0;F?Q''?^#='^'=
M[%K3RVKG48;OP#X>T'P5<QW!<W/A;1=*T*Y:73["V@1=-^ WP;T728=#TGX5
M_#W3M'MM&N/#UOI=GX+T.#3XM$O-<M/$]WI:VD4 B^PW7B.PL=<N;8!8Y]5L
MK2_E!N[>.=!NBU\,D[.^O7Y:M\MT[[NS5K6&HUEO*+3MT2LDM;*_>UK[+N]3
MS6V&/VV[L'JO[*FFJ?JOQ=U<''MD<5]6U\J6R2?\-LWDA1]G_#*VF*7*' =O
MBYK#!6;[H<J"VTG<0&/.#7U77-M*+UM[*%M'WF[;%QWE_CE^40KY4^/'[*_@
MC]H7Q-X?UCQTMKJFE^'/ 7Q'\(6&BW<5^$BU;Q]#I5O%XACN=.U+3YO,TNVT
MZX@%G(9(KA+QFS'+%'(OU732!D$#ISQ@<X(YY'8FK4FM8.TK:-IK]%^=QM)M
M?=^OYJY^9*?\$_IU?QII$WB;P1=^'_&_PL^$'PVU'6;CPOXD'CBWL_A38>#-
M/&G07$/BR/PTWAW78O"DKSPOH2ZW:M?@1:PPA^?L=&_8_P#&7@K7?AUH'A'Q
MMX&U+X&?#+QOJ/B_PM\+_&_AGQ1J,NE7>J>.K?QA;:K)JFE>+].B\3^*O D!
MO-+^'6L^+[36O['O(['Q+J46J>(!<7S_ *#<^_/;CCKSU[_CTHP.N!G.>@_S
M_P#7JW5JN[E).[N[):NUKM;7M=*UK:]R53A&UE9+1:Z+6_Y_?\D+12 GN,?E
M0<]L=>^>F/YY_3CWK/9VM]W_  /^&Z>1>Q\N?ME<?LT_%7_L%Z9^OBWP\*\X
M^-'[*6L?'7Q=X7\1#Q[;_#[0(?AWXE\&ZSX@\$:3>:-\8[K0O&_PU\8>!M4\
M*6_C>#4UTN3PDM[XJTSQUI]MJV@:CJ>B>,_"VE:AH]]:(98V]*_;'BED_9K^
M*:1QN[OI>E!412[,3XM\/D*%4$DD*2  <CD9P<?1^D*5TG2U965AIUB&! !!
M%M$""&Y!!&"" 01BM(N4::E'22KU&FUI\%-7UT?ENM-MC)Q4IR35_P!W&ZNO
M^?D[=5T\T?FAJG_!/;5_$MGJUQKGC_P=H>L:SI>M:!=:?\/OAQ:^$_ MOIC^
M ;3P)HFI6/A.VOW@@\4W>-1UKQCK1F=]:#^'_#UK'9:#X0T6WC]I^"?[*NH?
M";XO7OQ+N_%/AG4[*'PQ\4O".DV>C^"X-#\1ZS9_$?XN:7\53KWQ!\2I=SS>
M*?%6F/8/H+7Y@MH+V(MJOD0ZA?:DUQ]K$9&,$=\\'D'/3)YSS1V *YQ[+S[X
MSQGZ4.K5DN2<E*/56MIKU^;O[S>U]4F6J<%+F44GUL]_7778_//Q1^Q5XBU"
M]O[KPU\3]+TL^)=<\0-XK&K>$O[59O"NK_%;PK\6(-/T(1ZG:I9:U::IX9;2
MI=0O1?6<^GW[2BPBN[:*8X?A7_@G9X=\+7>BZG9^)M'AUK1]$_9LTZ+7+#PA
M8V.M1ZI\#/VC/%OQL\1^(;'58IC?:?K'Q(\,^*IOAMJM_;3+=QZ1 /M,]]9%
M=/3]*,#^[^B_XT<^A[_W>YX[]AQ[]^:3J5K6C)+7FUM=R6B?3HWO=>3#V<>R
M^^W9VT?<_-'X;?\ !/*Q\)>*/A!X@\4>)O"'B6U^#NI?"NRLM%L_AY8:;IGC
M;P_\&?@M^U-\+/"OBKQK837M]9WOQ<U_5?VF[GQ5XO\ %%K!#IDLO@+PY;Z/
MI>GSO<7=?3O[+GP.U/\ 9^^'-WX#O_$>G:Y:_P#"27FJ>'=-T729M)\/^"O#
MC:/H&CZ=X.T 7]YJ6NWNDV!T2;4X;GQ!JFJ:E!)J\^E07ATG3=,M[?Z2R?0_
MI_C2TI5*DHN-1IQ?V4GTOZVOS/JM^JV.1)IJRM==V[V\_)=!H)(4XZ@$^V1_
M2G4F/RXP/3'?^7TQ2U":7>WH_P [?+Y%!UKXQ^-&/^&D/A%C/_)#?VDACM]S
MX?$^W&./;/O7V=7R?\0K-;W]J_X$PSVQGLYOA#\?+>YC>)I(7CN+SX:1212D
MJ%Q+'(8RC8WA]O.1E3BZM.O26GM<+BZ*>NDJN'J4XW5D[)U+NW:W4B:O&W=J
M-_\ %=?^W7[;GYS6P'V># X,$/)&?^6:>W4\\]._/-6,#T'Y"OUE'P/^%( "
M_#OP@J@!5']BVZX5> ,<8P.!QT]J7_A1_P *_P#HGGA#_P $\'^-?A?_ !"G
M,G=_VIENK;_@XQ[MO_H'\]=];_/P'DM>_P#'H[O[$^[\^UC\F<#T'Y"C ]!^
M0K]9O^%'_"O_ *)YX0_\$\'^-'_"C_A7_P!$\\(?^">#_&C_ (A3F7_0TRS_
M ,$XS_Y0']BU_P#G_1_\ G_F?DS@>@_(48'H/R%?K-_PI#X5_P#1//"'_@G@
M_P :4? _X5=_AYX0_P#!/!_]>G_Q"G,O^AIEG_@G&?\ R@/[%K_\_P"C_P"
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M]_\ DI';K_*O%/$WP"^$"?M"_!G3HO".H):77PY^-%W<1?\ "Q?B^[23V8\
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MV:ND[HX_KF&W]E5C?6W(G^/.3?\ #/'P8_Z$S5/_  Z'QE_^>31_PSQ\&/\
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M_P#SR*]MP/0?D*,#T'Y"CVL_[O\ 7R#DC_)_Y,_\SQ+_ (9V^#'_ $)VI?\
MAT?C+_\ /(H_X9V^#'_0G:E_X='XR_\ SR*]MP/0?D*,#T'Y"CVL_P"[_7R#
MDC_)_P"3/_,\2_X9V^#'_0G:E_X='XR__/(H_P"&=O@Q_P!"=J7_ (='XR__
M #R17MN!Z#\A1@>@_(4>UG_=^[_@!R1_D_\ )G_F>)?\,[?!C_H3M2&3S_Q=
M#XRY_P#5D]OJ>F!7B/[0'P#^#^G^!_#,UEX0U"&:7]H#]E.PD9_B-\6[H-9:
MG^TU\)].O8/*O/B'=6ZO<6-S-$MU'$+VTWB2QN;:=?-'VWM'H/R%>!_M&<^
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MJW=I[/I]_P"%MB'2I/>*;[II6[OYDC.9'>1N&D=W8>C.Q8C\"2,=J;29'O\
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MGK?]!%?_ ,&/_P"1#V,/^?5'_P  7^1\2?\ # '[._\ T%OVI?\ Q/7]NO\
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M -#Q>_\ @LTK_P"1*/\ A?\ \9?^AXO?_!9I7_R)2_XBQDW_ #YS[_P71_\
MF@/[1P7_ #YG_P"$T/\ (^B_^& OV>1_S%_VIN>.?V]?VZ_T_P",CNOTYH_X
M8"_9YSQK'[4I R#_ ,9Z_MU^X_Z./X_+(/YU\Z?\+_\ C+_T/%[_ ."S2O\
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MVZ*.>M_T$5__  8__D0]C#_GU1_\ 7^1\2?\, ?L[_\ 06_:E_\ $]?VZ_\
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MS."E)VMJF];M^?XWL?ID/ASJ)_YKK^U5_P"),?$\_H-0S^F3V&:!\.M0./\
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MC^&O&'[0_AKX47 \ Z7#K1F^,)\0:9-J[FZ\%RS7/A>WNK/4M2M8S$4'[2N
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MBKHSZS>V+7Z7CZ MSJ(DU**T?2K\7D:HE[:QPK<S6BVEQ:W$OL0^'6H$ _\
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M;1.\NO3=:?UN;7_"NM1//_"]/VJQGG'_  TO\3N/RU"C_A7.H?\ 1=?VJ_\
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M !)?XG__ "PKP[]H;X?7D7@/PJ\OQF_::OA)^T%^RE;I'JG[1'Q%U&"%K_\
M:9^$]@;R".XO_P!QJ%DMRUUI5[&5ET_48[6_A_TFU@=/L"O OVC/^1 \'_\
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M:U^91NIX?<=4(5YXGA3/\/'!X?$8K'^UPD(O X?!8&GF698C$1CCJLZ>'RW
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M^S>CHDL<GP*_:P66*1!)')&_C#]EJ*2.16(4QO'*\4BL&5D=DQN*NOYNS_\
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M-;^(7B>7Q=XY\6>)?%?P1O-:\3:O)\$_A[\ H+F[TR+X 6W@K3;K2O OPO\
M"\GAK7/#WA/1/$GA36O[;7PSK6D^&-=U+PQ-UGC?_@FU\!/'WC.]\<:WXD^*
MYO[KXH:G\5[;0[L_!CQAX-T;6?$WA'P[X+\=Z)I?A3XG?!?QYI+^'?'VF>$_
M#U[KK:Q%JWB/0M;TU-4^'GB+P2SM"&IX)_\ +S&>=FW^'/\ Y=AQEBV_>I4(
M*/PWI1=TV[]5;3UT=D?07@R#]E[XG/=Z/X#\/_!_QO\ \*@U>;PZ_P#8O@?3
M-0TCP/K5O?QW]SI>@>()?#Z>'Y;RVU2UBN;P^#]8U.&TU"&-[N:"^0*/H-<]
M22<@')SSG)!YY^Z5'X8R<5\W?!+]F#P#\!O%_P 7?&_@W7/&.I:O\9]7TS5_
M$VG:V? .C^%M'DTF-X+.+PWX2^&/P_\ AWH$5X]N5@U3Q;XBLO$GC_Q!!;VR
M>(?%NJO"CK](@8_R0/PR3[ $D], DAL<5:4'-QA5G5@O@E.5[WWM'>-M%N[O
MTUUIJ6MZ=.&J2]FDE)];IR^Y[+5=1U-;[IIU-;H?\^_^?\*QU\_N?9KR[]T;
M6?;\8_\ R9\KZ3XCT3P=<?M?^,O$]C_:.@>$?B1I'B34;7;9-O32/"GAZZM9
MPVHO%9VQL=06TOSJ-Q(L6F?9?[0);[+L;7\*?%?X&^.OA7K_ ,2-0TWPWH7@
MS2/AKJOQ/\>+J^D6.JZ7HWPP@O/%_C;4O&<]WI6G7%CXD\+ZA-X)\4>.M)U'
M2$FN];CMX_$<%E!JU[ITKY&C^!]+^(^K_M2>$]6U+6]&@NOC7X-U:UU?PW<Z
M=:ZWI6K^&=$\,^(=$U&Q_MC2=?T.]:TU33;2633M=T35]#OX?-MM2TR\@D"#
MIO!?[-W@3PAI?QGT#4=7\4?$/PW^T'%XAC^+7AGQTO@.WT3Q/<>,_#E[X1\>
MSPVOP]\"> ;C0;;QKX6OCHNL^&_#USI7A#2XX7U+PAX?\-:UJ>LZGJ'3S1U<
MYS@I<FD))7Y*4:=GKKJN;2V[6NLCFLY*\4F[O1Z6M?9^]WZ$-C\0O!7AGP]8
MZ[\1_AHOP*TN67P9I?@O2O%.GZ3K?B?6!X>M-<\7^']+_P"$/^'.G>)=2T36
M/APL>MZ_>:- -:LO!TEUXAU=]:C@BU.2#+F^*_[(NC37'A*7Q5\*+2,ZW;:G
M=Z;IWAB^N]*N-7N-(TK68=6M[W1?"]YH>H7-MX>\5Z)K]]>:??7-KI'AK7$U
MZ^GTO0IKBZCW9O@3JEW;^'7U+]H7X]:MXC\'W%\WA+QSJ4GP,G\6Z%IFM^$]
M4\%^*M#FD3X%Q:%XNMO%NBZE%)K>N?$'0_%_C9=8T;1-?TKQ7INLV^H7VJ8=
MC^R;\+=,T6'PYI=_XTT[1+,^*UT^P@UK2)UL;;QA\(_!OP7O[.*YU'P]?7MQ
M#9>$O VD7.ES:C=WEXFNS:A?ZC<ZE!.EI$U*A]JI4\N27)ZWUE?2UOF%JG_/
MJG+_ !KF?RTC;S,S3/C)\!/&>FZJLFB^#O[=\*>+]-T";PMX@LH[22)_#OBO
M3OAQHNM:/KDWAFXT?48---]96^GV&ASZG=:7;2V.DZI+I<5Y9W%=59?%W]F2
M\TIOB';ZYX#UWP]\,]4T_P 6R>(%\"^(=4LO"\NI7=SXUL_&0MX_"-S?VOAR
MXO\ P_>^*KSQ[;6TOA."Y\/:CJNI^(+)=$OKRSYFP_9%\ 6MI%IMUXZ^*^N:
M/IVHR:MX7TO5M:\!I;^#;J\\6>&_&6L?V#<Z-\-]'O\ 4(M>U/PGHUI?CQE>
M>++BSTJ*6VT*XTF>47*XWCC]B;X6>// =O\ #O4?%OQ/TS0(?AOX:^%5R=,U
M'X=W\FJ^%?"OA+XO>#=-?5M+\6_#+Q-X5OM:_L_XU>*=2CU=_#J7.A^)-)\(
M^(?!A\*ZIHUW/JJYJ"^&K7CW_>)W^=M!<M3;V5.7^-<UO2S5K[,Y30/^&5M'
M\(V_P1TJ[71/ 7P5\7_\(;\1KG78=2\,+XLU+]F#P[X5\8:<OBG4M0\.*_Q=
M\.17&J:'JM[?Z9J;PZAJ-JNH"'4XO$D?]J?1;?M$?!2XOM%M'^)FB?VIXHFN
MAIEK>:?XHT^^EN(=9L="OAK=KJ/A^TG\&M9Z]JVE:;?'QLGAX6E]K&EQW1@7
M4;.6XXG7_P!E3X?^)+S5;G4/%7Q(CAOO$&O>+=)L;'6_"=M!X/\ %?B/P3\-
M/!=_X@\,7A\$3ZR][#-\)?!?C6PMO%&J>)M-L?&5KJ @LT\'7P\'6]E_V8O
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M4M19EI-J]OQC^LE^044446?9_<_\AV?;\8__ "844446?9_<_P#(+/M^,?\
MY,****+/L_N?^06?;\8__)F3KO\ R!M;_P"Q?\0?^F>\KRS]GG_DA/PG_P"Q
M$TW_ -&W5>IZY_R!M<QV\/\ B#]='O?\#_G./*_V>?\ DA7PF';_ (033?S\
MZYP3].OZ]JV@[4:W^.@]U?XY/OY?\,2]TO3JO\VOQ/:J***QL^S^Y_Y%6?;\
M8_\ R844446?9_<_\@L^WXQ_^3"BBBBS[/[G_D%GV_&/_P F%%%!Z'/?C\Z+
M/L_N?^06?;\8_P#R85X%^T9_R('@_P#[.)_9$_\ 6IOA!7OG&1U]!U_S^)ZX
M]*\#_:-'_%O_  CVS^T3^R)^'_&4OP?SGD8XZ9S]>.-*7\2F_-OIV:MOZ>E]
M;(RJ_P .7IY=4_/I_6NA[[6SX#P/%'B G_H :-GH./MMX>OUY_7(/-89Z$'.
M<D=^G7'UQZ\ 'V(K<\"'_BJ/$!/3^P=&SDC_ )_;WH20,D9ZGGH1R:PQ"_=U
M+]7^'-O>_G?2^FMS:C\<+=4]=M''O?JM>E]M]#UPJQ56P%W2"%&;">9-L:00
MIN*AY=B-(8@=PC0OMV*6KY=^.7[(/PS_ &AO$=CXE\67OC/2[]?"5OX"\10^
M$=??2K7QQX#MO%VG^.M'\,>((D$DC#1_%&GV^LZ/JNGFTU2TEO[]+>X-MJ9C
MKD/VJOV1KW]IW5-$O8/BJGPR30?A7\;/AK;7-C\/6\8>(/,^-7@K5O!U]JUO
M?ZI\0-+\,Z=8Z#=7'A_Q)9P:=X)M_'GVWPW-I6C_ !-\-Z)XF\0:?/\ '%S_
M ,$XOB1=?%/QEXT\0>,/#?C6UT.ST7XD^#=>L/!-EX-\2^,/BO+XWM?$4G@G
MP;#=_%C6[7X$>&?"?@CX"?LU_"V;QKXEC\9ZKXL^'MWXQM= U#1KQ/$NNP_(
MYG7QS=7#3X=_M'!/$T52G]9IU8UJ<*5>J\34I4.;V7LE325-U'SRJWYE[.47
M^]^'>6<*8".&X@P_C=2X#XFCE-:AB<'#AG,<3B*7]IYCA<JQ>54,;.:RO,%+
M!U<FQ]>%>:BZ<:E6.$I5<@H8S"?6OQV_97^!7C(W6B?$'QMXM\,7_P =_P!H
M33O'=FFG2VL\WB?XB0>"K7POHGA&TMY-'U*S30-(\/Z2VI6,6H1Q0:9=R7-^
MUW$67/:>)/V+?A3XN^&>G_"#37\7>'?"!L?#F@>(SH>N&YU;Q]H?ANT@L=(T
M[Q%?:LVHL;RU6W"6VJZ9#IVJ6<TEP8)M[Y7XZ^''_!,;6_#?@CP<US\;;3P7
M\1#X>5O'A\%_#.67PPGBJ_\ A=K?@W4M5TJ.X^*0OKGQI'K'BK7=0\4_$.75
M3#XS@CM[+1O#_A*SMK2YBU/"O_!+#PWI6H:=K?B'XJ:7KVI:?XBTW7K4Z/\
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M O\ [M1?_;JVO;\.MM5\]'_K1G:_YC):W_YAL&ORH];>6SU1\G?\(5^U0?\
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MC !SC!&#N.<#!YSUP,9QTXH_LG+_ /H$I=?LQZ?(/]:,ZV^NW\OJV#_^5/\
M(^5/^$)_:HZ_\)#^S+CU_LCXQ_\ R32?\(5^U1G_ )&']F;@=1I'QCXST/\
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MY"G)&TK!(HVE<YPD:&1CQDX5 2>,$\=,57]E8'KAJ7_@*_R(_P!9\Y_Z"_\
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MM*N?AQ)\3K;P*DVBQ?'4^#)+:U\1P:CJ47P!MOAMHOQJO?C?=V^F)>&+6?\
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M57X,?\1"?Q2_Z-;^%_\ X<[QK_\ ,]1_Q$)_%+_HUOX7_P#ASO&O_P SU/\
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M_,]1_P 0CXD_Z)^C_P"%F _^7!_Q,/PM_P!%/6_\1ZM_\R'[S_\ "%?M4_\
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M(3^*7_1K?PO_ /#G>-?_ )GJ?_$(^)/^B?H_^%F _P#EP?\ $P_"W_13UO\
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MO_YG#_B#_B+_ -"&M_X<L!_\O/YS_D_V?TH^3_9_2OZ,/^(>+Q=_T>#X+_\
M$>O$/_SY*/\ B'B\7?\ 1X/@O_Q'KQ#_ //DH_XB-P9_T.H?^$>+_P#F</\
MB#_B+_T(:W_ARP'_ ,O/YS\CU7H0.G3\^@Z8_7FC(XY7ICJ/P_\ U>_7BOZ)
MKW_@WK\765C?WI_; \$/]BL+^^\D_L_^(8C,+&TFNS&)/^%PR+$95B,:RNA2
M-F#,& *US'PZ_P"""'BSX@^ O"'CN/\ :Q\%:-#XOT*VUV'29?@5KFHW&GQ7
M+S*EO/<Q?%VU6=E$)8S+;0QODB,,J[RO^(C<%WM_;5._;ZGC/O\ X%OQ^12\
M'_$9[</U_7^T<!;M_P _U^NSU[_@!\G^S^E'R?[/Z5_1A_Q#Q>+O^CP?!?\
MXCUXA'_O9*/^(>+Q=_T>#X+_ /$>O$/_ ,^2G_Q$;@S_ *'4/_"/%_\ S.+_
M (@_XB_]"&M_X<L!_P#+S^<_Y/\ 9_2CY/\ 9_2OZ,/^(>+Q=_T>#X+_ /$>
MO$/_ ,^2C_B'B\7?]'@^"_\ Q'KQ#_\ /DH_XB-P9_T.H?\ A'B__F<7_$'_
M !%_Z$-;_P .6 _^7G\Y_P G^S^E'R?[/Z5_1A_Q#Q>+O^CP?!?_ (CUXA_^
M?)1_Q#Q>+O\ H\'P7_XCUXA_^?)1_P 1&X,_Z'4/_"/%_P#S.'_$'_$7_H0U
MO_#E@/\ Y>?SG_)_L_I1\G^S^E?T8?\ $/%XN_Z/!\%_^(]>(?\ Y\E'_$/%
MXN_Z/"\%#W/[/7B' ^O_ !>2E_Q$;@S_ *'4/_"/%_\ S./_ (@_XB_]"&M_
MX<L!_P#+S^<TJ@'&.![8YR>Y"D]QGTZ\Y'[F_P#!):W^/R?#_P"(MU:NR?LM
MS?M'?L9PW4&KK.T=U\>;?]J_X"FVD\ G?Y:36WA*8)\2WC!@E%UX0MIX_P"U
ME"V?LX_X-X?%ADB#_MC>$(;=GC^TFU_9]UMKQ;8O'Y[6:W'Q=EMS=B!I/LIN
MHOL:W!B^URK S[OVK\;_  F^'WP&_9N^#GP<^%FB)X=^'WP_^/G[&>A^'-,)
M62^F4_M;_!V[U#7/$%XI']J>*O$6J3WFM^)M9D2*75=<U&_O70M+Q\-Q]QUD
M>9Y'+*\HY<SJXRK36(JU\'5A1P%*A7I585X^U5-_6IR7)AJD'^YBZDYJ7.H/
M]*\+/"_BC)>)L-GN>T\1E%#+U-TJ,,92G5Q\ZM*I2E0J1P_M?]GBI1E5A4Y?
M:)I0E>[7M][8_&ZZOKD:9XS\):#IAGD^S16_AFSU&]PSG#RW&H&9FG;)RX W
M#!P!P=KP):>-]/UO7;/Q?XTD\6C^S-.N;.(Z58:7#ILTE[<QW+1"QACWK.%4
M%9"RQA!MPO%>@./F8'!&XYR%X&>@&1G!Y!XYZ'!KA_%?A?7M9DBNO#GC75_!
M5Z(UM[JZTBUTRXEO+:)RT$$HO["]!\MVDP55<[OF=Q]W^?\ '9/A:V&JT\-A
ML-&M4^&O6O&I%\TF^;$7:CS.5T^7=)76Y_6V4\1X_"8W!3QV,Q,\OP;<?JE*
M$N1T_9UJ<8QHJE>3BZJE=27PV;N[KTT$!.IZ')(( XP"<X'!&>>V3VS7YV?M
ME_$3]H+PIXZ\*Z#\./#?Q;E\!7?@.\UC27^"FF3Q:SX]^,UU\0O#>@1>$_&'
MC2V\-^)U\#V'AGX=7-]XJT9?$&G:?X=\:W@_LCQ!XDLQX=M;%_I<> /B;C)^
M/'CC/?\ XE?A;Z]/^$=('7UZ>O%*/ GQ/3.WX]^.E##! TSPL 1SP?\ BGN1
MSGV/(ZFOD\;P9FN+H*C#$0P\E6HU/;4ZG[Q1IN\X1E%IQ=5/E=2]HW;:?-8_
M7>#/%SA_A//J.=8KAR'$M&E@,RP3RK-J>(IX1U<PPD<+1S*G*C1Q/)F66-XF
MK@*U7!XNG26:YNHT\-B<1A,RR[\\_P!H7Q+^U=X*G^.WB#P-XY_:+U.SD_:!
M\(_#CX:Z3IND^+M5TRR\%1>$[7Q=\1_%>F0>%_">KZL/#U[J.I0>#O"6LVNF
MSV.GW=A=V\<L*M*P]E^(WQ*_:4T']CC18[GP]\4;;X^:UX2\+V7ASQ1X4M[_
M %?QQK?C2^LI;N_/B/1/!GA+5K;P+>Z7/<V%JZ>(KR/1/$;6$T6KZQH:S7:K
M]4CP'\4%PP^/GCM2  "-,\+ \-G&?^$? "Y[#@')VD<T@\!_$]2Q7X]>.E)S
MN*Z;X74G).=Q'A_Y@<GKGN>O->53\.LVI5<=4IYMB5'&87ZK[-5HP6'?/BI?
M6*#^L5[5XO$I0FHTVO9Z\RDHP_0,9])?AS'X3AK"XWPPX8KU.'<]I9S+&0RY
M8'$9O1PF0Y7DN"R;'3RS(\&I972JY?5S3'8>I1S*EF^+Q=2.,IX:7-CH?FGX
MC^+/[;7F_M$6?B"3XM>%M5\/Z?HWA_X>:GX<^''CR]\.Q3Z3\1=&,.E6.D>#
M?#.HIK/C?XO?#[PQXCFL_B?X<O-1T3P'?>.HK/Q%+;)'8VD?N?[/WCC]K#Q#
M^T?IGA[QWIWQ:\/> /"WAEHO%_ASQSID.H>$8_!LGP$^!^M>$M6;XB_V=!:?
M$?XW^(?V@?'7Q'M/$&IZ%J%VFC^$_AGK.GZGIMA;'39+OZY'@7XH@ #X^>/!
M@$#&F^%QA2> ,>'^AP>G7/&#F@^ _B<5"'X]>.BJL=JG3/"S*I(Y*C_A'\9(
M/;J,<XXHP_AUG-&I3G4SK&UXPJQJNG/&**FX5HUE3E)2E*5&?(J=>E+W:JU7
M*U%QO.?I-<,YGEN:Y?A/"?A#)WFN5XO+XUL%EU?V>7XC&9/3R>MFF"PW]A)0
MQ7+]9S&$9XQ.CF];#X[#8O#5<'4GF7O@8#@D>F%W$ $<8/91V89SVKD]8_Y#
MWAKU:VUWIW_=6N< \GG_ #VKRW_A /B;V^/'C@>W]E^%1^7_ !3H''MZ'C'-
M=/X;\)>(])N_MGB7Q[KOC9HXI4LEU6UTJU%D+@*9_+_LO3K .)-BY$WG,Q&2
M5&7KZO+\@Q^#QV&Q=5T.2A4G4<(U'S3;IU(<L(I.]E/F>VB6KO=?SYG7%F68
M[*<7@*%/%QJXBE"E3<Z$XTTX2H3O*7+)QNJ%M;_Q:KN^9FCX$_Y/*^'O_9LW
MQB_]6E\%J_1%/N+_ +J_R%?G;X#&/VR_A\#R?^&9/C!DCCG_ (6G\%QTZCC.
M._'6OT37[J_0?RKR.(?^1M77_3G!_P#J.T?1<'O_ (0<*_YJ^/EI=[XR3WV_
M7K8^+OVBOA%\8_%7Q2^#_P 4/A#:_"[5Y_ W@/XR>!/$&A?$SQ=XN\%PSVWQ
M-UCX1ZU8ZIH^I^%/ /C]KF739OAE<6]YI]_8V,3QZG!<1W4C6[POYT/ '[:>
M.?A]^RMZG_B_GQ@/N>#^S6"?TQCI7W/X^\=^$?AAX+\5?$/Q[KNG>%O!/@?P
MYK'BSQ9XEU>1HM,T'P[H%E+J.KZK>R(DD@M[&RAFGD6-'D<)LC1W95/Q7H'_
M  48^".MZGX.T6[\$?'?P?JOC_2(?%'A2P\>?"J^\&W6J^#;GQ?X5\%67C*.
M#7-2MIH_#M_J7C+1[NTEF5+^72?MMW_9Z/9R6]883-,UPU&.&P,_W,')J#I0
MJM<WO/65F]KNW-W=NO5F'#V3YCB'B\?AW/$3C"$JD<16HJ2@FHIJG.*;BF[-
MW:OZF9_PK_\ ;4S_ ,D^_96)'_5>_B_GV_YMKI3\/_VU#_S3[]E<CW^/?Q?_
M /H;#7NJ?M?_ +/5UKN@Z+HGQ,\(>*;761XX-_XI\,>)_#>K>#?!2_#[0]+\
M1>(&\=Z^FL10^&HQI&KVEU8S7$4L-PHF+O JH\F3\1OVW/V;OAO\/[[XD7WQ
M$TCQ3H5CI?@GQ ++P#)%XK\0W_ASQ[\0/!OPRT7Q)IFBV<R7%]H-KXJ\?>%H
MM=U"%FBT2PU6TO[\117=D+K;^W\^ZS79?[)3U[;I6OLK]?D</^J/#>G^S-VV
MMF&+VWT_?O97>EEN_(\?_P"%?_MHC_FGW[*_?_FO7Q?[9S_S;9[&E_X5]^VD
M/^:??LKCT_XOU\7^O_B-E=M\0?V_OV=_A7^T-'^S7X_U7Q+X:\8^5X#%]XQU
M'PQ=P?"G1=5^*6A_%'Q'\/O#^M^/GG6PTW6?%.C?!CXC7ME!+;-:V\7AVX^W
MW=IYMN9?9=-_:>_9WU:YAM=-^.'PFO;BX\)W7CN".#Q[X<;S/!=BUVMWXJ#-
M?JAT.!=/OIFU'=Y)M;*[O$+VMO+.K_M_/THMS:4HJ47]4I--/9IJZVLVM[-.
MUM1OA'AR[C]7E=.S3S#%IWVV=9:7T^]'S+_PK_\ ;4_Z)_\ LL?^'Z^+_P#]
M#91_PK_]M/\ Z)_^RQ_X?OXO_P#T-E>T?"O]M+]F[XS:;XAU3P/\3?#<]EX>
M^(&J?#<RZGJ5AI_]N:WI_B!O"MK?^&P]W(=7\/>(?$$=QIGAC6X0+;6KFUN8
MK4%X)472\/\ [8/[-WBWXL^#_@?X2^+W@CQ7\3/'?A;Q_P",O#'A_P ,ZO!K
ML.J:'\,=9T70?&DL.KZ:;C2FN=*U/7;6);/[9Y]S#;:A=P+);6,LE#S_ #Z+
ME&52SBKR_P!CIJRLG=WV233=[:,2X1X<=K89N[LK8_$MM]E^\U>CMIJ>"_\
M" ?MI]?^%?\ [+&/7_A??Q?_ /H;*0^ /VT\'_BW_P"RP>Q_XOW\8/ICC]FP
M\_A7IO@/]N;X"_$6?Q[J6BZCXBTOX:> M>USPJWQV\6>&[KPQ\"_&?B7PMXS
MUGX=^+=&^'GQ$U.:/3_&$WA/QMX?UO0-=O-/MTTJ)]'U+4[/4;W2+8WI]-F_
M:<_9YM+KQ;97?QN^$]M>^ 4\WQO:S>/O#D=QX3B%U8V!;7(7OU>Q+:AJ>FV$
M23*&FNM2TZ&,,]];>:O[?SZ]E.^UTL)3>^G1-+5J][-72:3:0_\ 5#AS_H&?
MSQ^*7I_R\ZV?EV;6I\3>#?@/^V?X2\1?$[7QX2_9:OV^(_B^T\5-:?\ "[_B
M];)HPL]#M=$%BDR?LYS&_$@M?M#7,D=NR,YA$9";SWQ\ ?MICI\/OV5QT'/Q
M[^,'H.__  S7[<],8'3H-31O^"EO[*>K?!7QO^T!<^+=2\,_#3P5X;?Q.=4\
M7:?8Z#J/B^UCT+Q%XD72_ 6D7.JM?>)M>GTWPSJ1M=&@BM[JZE>S-N)(+R*<
M>J^*/VU?V:/!6E>%=5\4_%/P[H[>,OB!\(_A=H^C3O+-XAA\>_'2:2#X9^'=
M7T>TCN+O2IM>:TU<B[NT33X#H.NQ/=&XTF]ABMYWG\;^])6G*F[X2+M.*3DM
M;JZ6N[\[=1\*<-3LOJ]TO^H_$K1RMTJW^+35^G<\6_X0']M3_HG_ .RM_P"'
M\^,'U_Z-KYH_X0#]M,]?A_\ LK8_[+W\7SS_ .(U]?UKZGT[]HGX&ZSJ%CHV
MD?%?X>ZKK.J^++KP-I>DZ;XJTJ_U+4?%EC!#=WVAV=G:3S7%Q<VEG<V5Q<S1
MQ/8Q1WUDS76VZMWD]LPH4G &03C X)&<9'I_GM6;XASM?%6A%]%+"TTWLM+I
M=6M=E>SV''@_AMW<<)-M*[Y<=BG:]^JK.VB=KK76RT/SL_X0#]M'K_P@'[*P
M]_\ A??Q>'7_ +MLI/\ A _VT/\ H0?V5_\ P_?Q@_\ H;*^:O\ @K[_ ,%&
M/BY_P3]T;X'7_P */!G@'Q=)\3-6\;V6MKXWDU:.*QB\,Z=I=Y:KIPTLAFEN
M'OY%G\W@!5VY8U^(K?\ !R5^UOA0WP.^!Y! (Q>^*,<Y!X+>HXK]#X=X/\2N
M*,KH9QE$,KJX'$NLJ-2OC,'AYR="M+#U5[/V-:2Y*\)PO)Q32NKW:7Y%Q7Q_
MX.<'9WBN'\^JYI1S3!1P\L32H4,RQ-*"Q6'ABJ/+76)I0G>C.,FHK1NS74_I
M._X0/]M'_H0/V5O_  _GQ@'_ +[6:/\ A _VT3G_ (H#]E;TY^/?Q@QSUS_Q
MC6./YU_-?_Q$D_M:?]$-^"'_ (&^)_\ XJE'_!R3^UL<A/@;\#P<?Q7OBC'M
MG#9ZGDY&!SGBO<_XA;XN_P#/G).G_,SPB_\ =/\ R\WNU\ZO&?P$V^LYRK]?
MJ.9>7;'O\C^A/_A1/[:'_"UV^*)\)_LL[F^&$'PV_L,_''XOR1!4\877BQM8
M&H-^SH&9V-R;!+$6@1%C%Q]HR?)'??\ " ?MHG_FGW[*P]C\>_B_Q^?[-@/O
MTZU\$_\ !++_ (+.?\-G_$#7_@E\>/#W@OX:_%:[A;6/A7<>&+V]7P]XZTVS
MA_XGGAY?[999[7Q?I39OK:T&Y-5TLR26N9;65*_H*0 J#C/ Y('H/_U'WS7Y
MSGSXOX8S*KE&=1AA,=2ITZW*J%.K1K4:W,Z=?#8F,?8XFC4L^6I2F_>4E*,;
M)'Z_PK#@'C;)Z&>\.2J8W+ZTZM&4GBL70Q&'Q%";IU<-BL+*LZV'K0M&?LZJ
M5X3C.#E%N1^=?_"O_P!M'_HG_P"RM_X?KXO?_0V4A\ ?MI9P/A]^RM_X?OXO
M_P#T-9'ZU^B^!Z#\A2%?0+^(]C_7%>-_K%G*NWB:6W_0-2_R/H_]3N'_ /H$
MK?\ A;B__EI^=0^'_P"VD?\ FG_[*V?;X]?%X_\ OME'_"OOVT^WP]_96(_[
M+W\7_P#Z&LUZ_P#M3?MD_!_]D/3_  CJ'Q8MO'-W;^,CXON;$>!/!U]XNFTS
M1/ .BP^(_&_BC7X[2:#^R_#OAG1)5U+5-08RLENL@@MYI%V'M=!_:C_9Z\2R
M:1;Z%\9?ACJ%QKNOVGA+2K*W\9:,;ZX\6WSZ=#;^&#9-<B>#73=ZQHFFG3)T
MCN1K.NZ'HC1C5=;TJTO*6?YZX*HJGN2;49?4Z=GR_%JKVMU7SV,WPEPXI<GU
M>:GHW"688N+2>UE[=-WZ?=J]_FO_ (0#]M,8S\/_ -E< ]/^+]_&#_Z&L4?\
M(#^VGG ^'_[*Y_[KW\7^O;_FVS![=\_E7H>J?MZ?LXVOQ#\/?#30O%4_C[6_
M$EII]Y:ZK\/8M-\5>$K);WX\?"3]G:\MM2\46NJQ:5;WVB^/_C9X&N-:L8I9
M[N#PS-J6M6D5\MHEO/V$?[8_[.=Y>^$X-#^)_@WQ5H_BJZ\36\GC3PQXG\-Z
MQX(\(_\ "+?#Z]^)]_<>.?$,>L10>&K6?P=83ZA83W$<D<Y4B3R(X;F:!?V_
MGZ5Y2Y;KF5\)2>C;L_ATZ6O;FNFA+A'AKIAG?9K^T,5H^G_+Z[?7KYGRC\4?
M@5^V?\2OAWXM\ MX0_9:TA?%.GVMD=2'QP^+U]]C^RZMINK"4V;?LXVRW(=M
M-2'RS/$%\TR[FV>7)W*?#W]M1(8HF\ _LLN(H(("S?'OXP980PI%NP?V;?EW
M!2< D+DC/!->X>-_VROV>/ G@FY\=W/Q#T3Q+I,&G^#]:BL?!EU;>(]>U+0/
M''C+1O >AZ_I.CV\\5SJ6C_V_KM@E_>6AD33[8S7-SM2,!^"\??\%!?V=/A?
M\>W_ &=_'FJ^)_#'B>WET^RU+QMJWAB[M/A)HNLZO\)_B#\<=*\/ZW\0)9ET
M_3-6O?A7\*?B)XP5+BV^R6^E^$=8>[NX&AC$A_;N?W?(VW9R:^JT[\L.5-VW
M=E))))OLKE2X3X;E;_9G:*7_ #'XG2]TM55MK;=VV=]+''?\(!^VID@?#[]E
M?V_XOW\81TQR1_PS9@\_H3C&32_\*_\ VTA@?\*^_97&>@'QZ^,'7&"?^3;/
MS/'X#BOIG3OVH/V=M6O;K3M.^-OPGO+VR\(7GQ"NH(?'WAHBW^'^FP27FI>-
MKF5]02&#PY8:?!/JUWJLDBVL&BHNL22#3)8KI^*^%/[:G[.'QEL?$.H^"_B7
MX=%GX>^(VL?"\R:[J%CHS:[XBTK7]"\+0WOAV*>\:35?#NM^(_$FCZ)X>UF,
M1P:MJERUC;I]ICE1'_;^?6E+VCM'EYG]4AHY:1OI>[::5U?32Z)_U1X;LO\
M9M'?;'XK6V^JJN^_X_=XW_PK_P#;3SC_ (5_^RQZ_P#)>OC!WSW_ .&;,<\T
M?\(!^VGQ_P 6_P#V6.3@?\7Z^,'7_P 1LKWKPU^V!^S=XU^*NC_!/P7\7O!/
MB_XE>(?#OB;Q7HOA_P ,ZQ#KD=]HO@[6(M!\331ZIIQN-*$VDZK*MI<6WVOS
M=P9T#1JS#D? O[<_P"\>MXWU:PU3Q#H'PU\%:ROAX?''QKX<NO"?P2\8ZW#J
MFK:/JMAX ^(>KRPZ;XI&@W^AZDNM7UO%!I=I:6TFHB_ET])+I#^W\^_G6R?^
MZTMF[*R>NNMDDV[-);V/]4.&MOJS^6/Q6]KN]JEM+J]WHGJ[VOYI_P *_P#V
MT_\ HG_[+'_A^_B__P#0V4G_  @/[:7_ $('[*_./^:]_%_OT_YMLKZ8G_:>
M_9ZM+GQI9W?QM^$]K>_#@7 \?V-QX\\/17O@YK?Q8_@.>+7[5[U9K&YA\;JG
MA![>5//;Q+<6.BI&;_4K&"?YV\.?\%*OV5_$7PC\2_'!_%.I>%_A]X<T'2]=
MAU+QC9Z=X?N_%G]KW/CZWT_2? ^FW&L27?B379T^&GB>^CTNWCAFFTF.UU6%
MI;"2XGMJAGF?S5XS;7-"%U@Z;7-4O[-;7]_E;6]TKH7^J'#*=I8>SM)_[_BO
ML_%_R^^SU[/3=V*/_" ?MIC_ )I_^RQZ_P#)>_B_V_[MLI/^$ _;3_Z$#]E?
M_P /W\7QU&?^C;/0YKV36?VV/V9?#F@>#/$'B/XJ^'-%A\=Z_P##'PIHVDWL
MY/B*W\1_&#3+75? .CZWH=L)KW2+G5[6[A622Z06EI=[[.XN%N%:,>A6'[0G
MP0U?5+'1-'^+'PYU?6=4\0WOA/2M(TOQ9I&H:IJ7B/38+.ZU'3+/3[2YFNI7
ML;;4M,FNKE839PQ:II4DERJZE9F:7G^?+7VEE=J[P<+:-I_9MIYM+IYC7"/#
M6J^K2TM?EQV)=KKK^]NO3UOJ?+/_  @'[:0Z_#_]E?U_Y+W\7QD>W_&-A_/!
M^AK@=3^!7[9^I?$SP)\17\(_LM1'P3X6\?\ A@Z/_P +O^+LBZDOCI_#4ANF
MO1^SC&]K_9A\/!5MA;W N_M67EB,&V3]4&7(!VCC!(P#SP0..N#[^XKY$\;?
MM20>$/%OB'PJW@ZYOCX?U :>;T:I;P+<L;2UNMXA92Z +<E,'.2I/?%>3FO'
M-?)J-&OFF94,-1K571A-X1R_>>SG4Y5[*$FFXPW=ET3;M9U.%.&\/#GGAJD4
M^KQF+Z:]*GG=WNDM=[6\F_X0']M/C_BW_P"RP3S_ ,U[^,'Y_+^S2 <X.< +
MD @"E_X0']M3_HGW[+'_ (?KXP__ $-5=@/VR+8<?\(#=$9)_P"0S:]2#CC9
M]<]>><^I_P -E6O_ $(%S_X.;7_XW7A?\1BRFROQ#1=U?3+Z_D_^?7F<G^KG
M"#_Y<W]<3B6];OS[_CYW?'_\(#^VI_T3[]EC_P /U\8?_H:J/^$!_;4QG_A7
MW[+&/^R]?&'_ .AJKKS^V3;D';X N0W\.=9M1R.0,^7W/%?6?@3QGHWC[PWI
M_B?1)/\ 1+Z(>?;2E3<Z=>QJ!=Z=>(.8[JTE.QUP%DC$<\1:&:-V]/*_$BGG
M56I0RO.</B:U*"J3I/#2HU'"[3E3C5C#VEFDI<E^2Z<K)IFE+A;A.M+DI87G
MEORQQ6(O;O9V=OO\[=?AS_A ?VU/^B?_ +*__A^_C#_]#51_P@7[:?\ T3_]
ME?\ \/W\8?\ Z&JOT6 4\@#\O\X_R>]+@>@_(5[RXBSEZ_6::_[@1_SWZ/S.
MG_4OAS_H G_X55S\Z/\ A OVT_\ HG_[*_\ X?OXP_\ T-5+_P (#^VI_P!$
M^_97_P##]_&'UQ_T;5Z\?6OT6(7T'Y=SP*0A0,X''.,#GK@>W/3W%-\19PK_
M .TT]%?^!#_,7^I?#G_0!/\ \*J_^?WGYU?\(#^VGCGX??LL$?\ 9>_C#CMC
M_FVH_P"<?BG_  @/[:?7_A7W[*^1T_XOW\8._;_DVH\''XX'7I7NFJ?MD_LT
M:-\;X?V<=5^+7A[3OC3/J>A:*O@>[L_$$3C6_%&G7>K>&="DU\Z.?"T.O>(-
M.L;RZT;19M<BU+4H[>86=O*Z[1[K:^-_"5XF^S\2^&+M!+;P![7Q!H]PGFW>
MLR>'+./=%>N/,N_$44F@V\?WYM8CDTR,-?HUN#_6#/%R\U;E4H*<>;#):-V_
M2[:TLUJ*/!W#3O;!MV>J6,K.SV::NK/372_W'YL^$/@/^VCX3\4_&'Q,/"/[
M+5\WQ9^('A[QT]FWQO\ C!;#0SH/P9^%'PA735N%_9TF.I"[7X7KK[7<D-J\
M<FMOIQBE%@M[=][_ ,(%^VF?^:?_ +*_/8?'OXPG\!_QC7GZ9ZU]9W'Q[^%%
MIXXT;X=3>./#O_"4Z]X!^*/Q/L;>'4;:?3!X(^"WB7P!X2^*&MWNOQRG1=/3
MP?X@^)W@K3M7AOKZWGLYM94W"1K:W1A[-?'?@^2XL[1/%?A-KK4=+37;"W7Q
M%HS3WNB365SJ4&L6<"WIENM,FTVSN[Z/4(%>S>TL[J[6=K>"214L_P [BDG7
MII6]U*@MM==M%JV7+@WAQVO@9?\ A56_SO\ UL?#/_"!?MJ?]$__ &5^W3X]
M_&$]>G_-M5'_  @/[:G_ $3[]EC_ ,/W\8?_ *&KWK[BMOB#X&N[>[N[3QAX
M0NK/3[&XU6^NK?Q-H<]O8Z79RB&ZU&[FBOGBM[&UF989[R9TMH92$EE1R!6+
MXL^,?PL\":!XE\5^,OB#X'\.>'?!WA2^\<>*-8U/Q-H\%KH?@_3K2&^N_$FH
M*+MIH='CM;FUE6]\IHI?M=FD+2O=6XD?^L.<Z_[1'3_J'6C\].O3\"?]2^&_
M^@&7_A57^[?<^./^$!_;4_Z)]^RQTS_R7KXP]/\ Q&JC_A ?VU#T^'W[+!_[
MKW\8?_H:J^I/B!^TA\#_ (5V7PBU/Q_\3/"7AO3?CY\1_!7PA^#6H7%^]Y8_
M$CXC?$:VN[WP+X9\+W6F0WL%[<^)K:RN9=,NVDCTV1$C+WL9G@66;P=^T'\'
M/'>E^,=:\.?$'PM-IOP]\<^,_AMXUN;_ %BRTA/#GC/X?^.=<^&_B;2M3759
M[22T2W\:^'-9T"SN[A8K35+NR<Z=-<HR,R?$&>I)JM3=_P#IS%6Z=5WTWWTW
MT)7!W#3O; RNK7OBJ^[^?KYV3>VI\J_\(#^VI_T3[]ECKC_DO7QAZ_\ B-5)
M_P (#^VI_P!$_P#V5_\ P_?QA_\ H:J^[?\ A-/"JW>H6#^)/#,=_I-J]_JM
MB=>TH7FEZ?%'#++?:A;_ &LS6=I''/#))<W,<4*1RQ.[A9$+>>_#G]H3X/?%
MC1QKW@/QYX:UO2Y=?\:^&[.X.JV5D=2U7X=W]SIOC2+2H;R:&;4K;P_=6DPO
MM0L4N+&.W4W9N!;L)*?^L&=O55Z=M+WH15F_.UG?H_)O:]J_U,X;_P"@&7_A
M57_SW/E3_A OVU/^B?\ [*__ (?OXP^__5M7L?R-+_P@/[:G3_A7W[+&?3_A
M??QA_P#H:J^Y8/'G@ZZ@L;JV\4^%9[;5-;7PUI=S#XBT:6WU'Q(T;RCP]8SQ
MWC17FM^3#<2_V5;/+J'EV\K_ &;8 U<QX4^-7PS\;?$OXA_"'PSXLTG6_'_P
MK\.>!?%/C[0]+N%O3X<TKXCZU\1O#?A,WM[;&2R6]O=;^$GQ L+K3!/]OTR?
M0G6_M[?[1;F52XASM;5X/O\ N(I)723;M;79+1MV2U8?ZF<-_P#0#+7_ *BJ
M_P#F?&U]\.?VTKRQU"R;P'^RO"+^POK S'X\?&"1HA>VDMJ9%0_LVH&V"7S"
MFY=^T+N3(9>5^&_P1_;1^'OP_P#!W@5?"'[+.K+X2T.VT4:B_P <OC#9_;OL
MTDSBY-F/V<[E;9I!* \:3R#<"X;)Q7Z'>/->O/#>BQ7VGI#+*U[#;XN49X]D
MOWB A#!L@;3V!( XKQ__ (6IXE[V^E@^GD2_UDR/R->G@\5Q/CJ'UG#U\+*D
MYRIQ<E3A4YH)<UX/X=[1O>^NQXN8X+@G*L0L)B\)BXU73A42I/$58.G)M1?/
M&6FJ::MY[;^"_P#"!?MI_P#1/_V5_P#P_?QA_P#H:Z/^$"_;3_Z)_P#LK_\
MA^_C#_\ 0U5[W_PM3Q+VMM,QV_<R_P#Q9H_X6IXF_P"?73/^_$O_ ,779R\6
M?\_<-_Y1_P CS^;P[W^JX_\ \!Q/_P F>"?\(#^VH>GP^_98]/\ DO?QA_\
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M;2;;=M.K;=N_W+%86A9_N::NTW:.C:22;UZ))>A\)?%+_@GU\!?B[\3?C_\
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MD[M;>7DNG38TITH4N90A""D[OD5KVO:_HGIZGX0?\%K/V!_VA_VZ-#^ .G?
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M!U6+Q/>R_%O]AKXJZ'?>.M"U+[5I'B#2=4'[#7A3PC\4/"8M[70/B+X9\?\
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-q_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +# E@# 2(  A$! Q$!_\0
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MU+Q3\++YK37_ !I=^,O&GB6'2+_Q5?6\%QX#U#4-,&F-Y,,H6W\1/CE^U_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/0]N/K^E !GK[?\
MZZ*^:_VP/$^F^#/V:OC'XHUSXA^,OA/H&A^!]<U+7?B'\.=+M]:^(/AG2[2T
M>:ZNO!&E7>G:K:W?BJY138Z&+BPNXHK^Y@G:VN1'Y$GXD?#S3OB[\<_AI^R1
MH&D?M/\ [2%GXK^,W[0OBK_A$/$?A?XBZ7=ZM\*_V?O UE<_%CQ#I'QCU4?"
M\Z1XC\=W&C^$(O &GI/ID5I'K7CRSA^V7,%D6E /Z2Z!G'/7OCIFOPL_8O\
MB_\ %9?VG/CE8^+/&GC/X\2^(_#_ ,5OB/8VOA[Q-K#>%/AE'X1\4V%CX?\
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M[QZMYXQ^(/C#X>Z;H>OQZ?X>NM./@2"ZNM9\3Z]=W!EM=&M+5;62?-_)]H3
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M4[>ZTJQ2PCGCNIX+I())1 )#X)^U!^R5\,?B#K.K?&3XF?'+Q5\*? ]K\/\
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MV(9$:YW (#\NTDEB",?>)/KBK5,84444 %%%% !1110 4444 %%%% !1110
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MOB-90Z_H^JZ'::9<^&_%-A<S/8W6I/>VT'V37Q>2Q3E'GM@Y>)A+E6&/@_\
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M_@F!N QQ\3OVALC#;A@_V#D?-AA_M<\'FFMXM_X+O-PWP._X)A$$QL0WQ/\
MV@B,QN)(S_R+X^97&]3@A7PRG(R?V5*#!V@ X./0'MQSW]J^*_V=?VM=&_:(
M^*O[5'PHT;PQKOAN\_94^*=A\+/$.LZE<VES;^*M0U+PS:^(6U'38VM_]&M[
M>2\6V12S9 &PJ@V4^>6O[C"?^ 3_ /DOZV+Y_P"Y3_\  7_\E_7H?()\7?\
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MZ7'>SP1H(H99VA0!8@3^YBPQ.%=HD+D;\X!PSA=Y# #.2!DX&<9Q4H50Q8
MMU/<]Q]>Y]L?7%?U_P -Y?H2?C0/%_\ P7CX9_@I_P $P"X4QE_^%G_M"!L.
M09!G^P" KN 67!R>H)&2Y?%__!>0'CX*?\$P,DYW#XG_ +0N?N@ G&@ GY55
M<XSM4 9  'V'#^UQX?D_;=US]BC_ (1+63XBT7]G?3_VB)/'?VVU.CW&@ZEX
MOOO"2Z&FG&U5OM\=]:%C)YW,6UF7()K[.B13#'NVN3&A+ +\QVCY@5 '/48
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M W7V.N>2U '[.5%,&,;!2P)P,I]\ L 2O;(&>N.,G/%?C-+_ ,%A))D/V?\
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MN1UIT'_!5KQ]&I%K_P $J_\ @I*$)W&-?@EI4:YP!\H.N J&V_=4J">2 Q-
M'W]^UW<?$>/]EG]H"7X2>&K#QW\09?@]X]M_"7A'6;J>QM->OYO#&IQ?83/;
MD3RW%P6$=JBX9Y61%X?:?@[_ ((8'XVP_P#!,+]E72/CU\-M-^%'B[0?"-UH
M&B^$;+4;^ZU+_A%+'6[R/1M2\2P:GFXT[Q!KD-O+JEWI"A1I%I]D@CR)V:J[
M?\%5/BC-D1_\$F_^"DDA:(Q8;X/:/$=A."JEO$)50< [MR]LXQ21?\%2?BU
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M5>-O!_AQ_P!H3X%B&\\+>"&1/$]Y/=1ZHUM'=V\DT"6L,C++)]IA*1.I9Q[
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MI,O_  ISX:;)8W$D<B'P+H6'CD7Y9$<899!PRD,."* /8DC!1"2V2JD_,>I
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M&)A(\326M[?12QAXAN574,0<XP.,\_'KX($?+\8OA@".3GQUX9QC_P &?TH
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MR:UN]1DLD<RVT9164#&?T9COG9$E0*8Y%!"L&0HS,5*^:Y"R212*Z2QC#@\
M<<@&M16"^J21AY,PL8U>1H7,4#&-$0;1))-L4--YBI-)B(GY>,;C8L[RXN-A
M*H\+R QW,)5XIK>2+S(Y %=M@RP17#,DR@31G9(M &M1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %59U&Z)LMNA#R*0Q .
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MWU":R\)R7,=G=0&ZN0WHGP2^ _[;.J?MT?!'XM?&3P/XYNK2_P#VF?A1X_\
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MBBB@ HHHH **** "J=T_E@,<; DVX#E]H53\BCYF;(R0 <+DG%7*IW2,YB
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M'<F13\JAU^5HPV6$BL!(IR%&U R'<"=V2,#'(!;HHHH **** "BBB@ HHHH
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M=US4++2=%TJ'XB:4;K4]3U"18;*TMD8JTKWMQ(EM:&-7$TSHHP6P #]$:*^
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MTBT%_>0VEE/]FM))U66Y,.]UC#HWZBZ?"UG8:;;R$?Z#8V-K*PP3YL%OY!
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M\(:=#I=WJ9'AO6;NPUO4K#4]2LEMS!$\!!\RT44 ?'?[?5Q\._BG_P %&?\
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M;O=>*/!OPN\<>)/#D,2)-/\ VUI>@7ESI[)#(CJRK.B>8VQRJ9PH)!/\B_\
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M+ZTO[JR46IDCG !^D?\ P3BU+X6? 3_@H9\+O"/Q2_X)?:;_ ,$_/VC?B?\
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M&/\ PA]LE[I$5SHMO)H%]J6G:TNM Q2.E]=0WB&Q:.*W>%(78 _>+X9?L/\
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MWPQ_9XU?X;_&G6]1\-?"X>$OA'<>+?&'C37]#M[Z\\2Z/HW@30=)O/%-Q?\
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M2;+3?"VD>'?LR:3IWA73K=-.\/6VEI9%[ :1_8UO8FS%M(08_+/S $U\$_\
M!3SX4_M/_%7]DGXL>'OV:?B5I?@G6)OAC\3;;Q3X<G^'$/CO5_B+87WA>^MH
MO"?A46^HVKZ!K&KS,+>"]MIIMCW$1E9 LNRE_P $G?A=^T_\*?V0?@)H/[3?
MQ-T?QCK<7P,^"%KX9\&6W@,> =:^%&EV_P -=!BN/ GB<I?7R^(_$&CRQBPU
M349!%(VH6ERRM(FV20 _4>BC/.._)_+&?YBB@"K>KOMID!"EXV7<1G;D=?;W
M]L]Z_/\ _P""A_QI\??L]?LG?$_XH?#6ZL[?QGX>LK;^QI]2MQ=Z?#-%)%YK
M36SC$JR><GR.-I5&W$ X/Z 7B-);RHAVLRD DG /7)P"<  ].?2ORX_X*P:;
M/J?[$'QHM/E<&PMD"DX+/Y]KYC;\%4#(?O,0W/.,\?.<58^65Y%G.8^V5"EE
M_#_$>.K5VVHT:F%R?$U<!*35Y>_C8PC#E3;G9/E2YE][X2Y9DV:^+7AEEN>4
M?K.79WQWPOD694)+FI/*\?F^"IXV=6+33@J-6IS?$[*RBTVGXG_P27_:&_:%
M_;+^"GB#XN_%WXE6VF:IX2^-6N>!UT#PIX7T:V\/ZII&G>&/".L6T5RUQMNT
MGDN?$-ZLS1@_>!3G&?T6L/V1O@YI?B6P\2Z5HMSI,^F?$^^^+]M:6.I7J6:^
M.]9TB#1-7U,PM(0T5[9VMB&M\^6K12X7#C/Y$?\ ! +^V-)_9R^)_AC_ (12
M^?P^?VAO$NICQ@NJZ#_9BW<_@'X:&*P.ER:DOB03KL=3-_90LR<$7!!%?T+;
M&Q_M$Y'(P<;.>_3#''6O*\.,RQ.;\#<+9OC)3EB<TR3!XVM*<N9NM6^M<[W?
M\D&_6.KUMZ_CGDF5<,^,?B5PYDF&6$RS).,,TR[ 8>/*H0P%&6&>#<5'11G0
MJ2DEH[/6,7>)8HI!P /0"EK[@_*PHHHH **** "BBB@ HHHH **** "BBB@
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MP_\ "U/AI\/?"7@Q/A7-ING75KJ6D^!_'^D^(=,GMUOR?"TUA/>WXTU;R+S
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MA1VW/^Z)B601N5\S8LB,9#J$2[U\N9I(V"M$J[I2"H*R",?,T3.3&)0"A<$
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MTU=-1ULG9VNU?6R!W6ZMZ^1_I(_\+6^&7[O/Q$\" R.44?\ "8^&\D@9./\
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MV6O!>KZW\0=+U."Y\5ZQI6GZ7K#:I)?^*->;3[.]O+<PZ7%++)?E3--,<A"
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MY-!NXM2O((?$FOSVNS33-+%!<$ZI\KW!&SRL')P Q)P #_2=\,?LD?\ !/\
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M7QOC9YEQ=Q'F%6ZKXS.<=B*D9+WN2=6BZ$WJWRU:,54@V]8W:-*BBBOZ$/F
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M0?\ :S\"^)? WQN^)WA+7-.6VU )%;/"CMNCCO&BN89C,F%N?W,3L^.(R-C
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M%VHP/ON>O!^51^8&3ZX(P<FOICX?@C]E3]I5R25_X2GX+@$\G_D8+_G\1P2
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ME27<5(;D]-N02/G[_@O/\7-5UCXF^"O@+80&5((AK+VC$M_Q/-<G;3K&\1P
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MOP5X#\+3MX<>^AU:]O(+[5C+,WF75U=0J7FN3/(RR>4LDAA*'@2,.> /X?\
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MXM?#74)[;0?$6JV^FFTU^TFL]8T2"6./RKO['AXKA TK;$C$@8D#@ X_1O\
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M%-72OHU>]MK];>2ES;=E;2QY>Y_>7^SI\'-*_9RLK/Q9X6\6>)K/0OB-\.O
M6@WGPNUB_FE\!>'M5\/VRK:^(O#-L79=#N;^UG,=Y;6R(+NX(DD !#'](-7U
MJVT+PR5BN8+BVBTR&[9MX8B6[0E=AR,!IQ*B@'JO;''\K/P;_P""J'A.X^)7
M@G]F[XGW<'B;PWX:TC3- M?B-:QW,2ZI\0K":*"=+V52BII]Q;JEO9C!BWE<
M$<$?JIKO[:_A'P_K%QH_Q$O+#PIX1UO5=)\.>&9M1>.U-TZ6TLR"%Y6!D1<9
M#MA"5X?& ._&9E/,\1'$U$U*"C%)W3M'E2>J7\JMU"O_ +0K3[6V[)_U]R/R
M\_X+6ZV_B+PE<ZPUS&B:?IMGIEO8,Z^:\UR&RL2Y.6?8S?\  <$@'%?/7_!
M?X1ZAJES\4_C#>P2G21=Z1X:\/W$MK(8+J&P<MJ45M<[#'OM9I52=6=&$A&
MP!KXD_X*<?M2ZS\<_BYXG\.:;H=_H'@7P3=W5O;7"HSV_B!+#,%EJ\=S$9;9
MX;Y]UQ$WFDJ),%5&:_<#_@W6^(^B^(_V.OC1\'KJ2&+Q#X UZ]\2K9F*V26>
MPU@SW OH9-PNIV#K#O,89=[  [2,<3ZOU?YO]1)6279)?<K?H?T=^ -/TS6?
M#$-W-'%/'(\"6\L.Y\10A!'OVAFW!%!<=5.01@FF_'C4/!L/PG\<0:UJ6E:5
M:R:7%IK3:I?6]FEYJ5W;@6UA;&YDC\V>Z+ 1Q(3(6.TJ"#7FO[/6JS>&-.D\
M,S)=7%S*ES=Z$\UPOGB:?=)=^?"Y!*AW(1-K[,8'*Y'P+_P4>^'GPX^-/[-?
MQ-L_B+J7BS2;3X.^*]/^)OA_4M$UN?2KR?Q#I]T+V:SO_(DB-U81^4O^CEG(
MB.&CY&>C+8Y=BL?3PN=XC$8+#2G!.KA(SE:G?O3]U2<5%WE)6;DW?8Z<+2IU
MY<M22BM/BDH_C)I?CL?ES_P3H\)^#_'W_!1OXT-X9\%>'KGQ)X&T*ZEM=7UM
MI L?A_1X)DN;+1AM9!=R/N5\$,&.Z0[<8_JW^$<EAI7P].LK(;>W5;E3"CB>
MXL3,6C$,Y3<RL'\Q1DG VDD<$?PY?\$L/V[_  O\)OVSO&,WCO['::)XUEU\
M>&_$3JBM]EUA'BUG3[Z\<J)'>,%K0,2%9L@C-?U?_L__ +6?P7\;6WC+PCX>
M\3I:6.J^'-<UW1]:9TETF02.UI]EEN26B%Y9LH8PJWF!F4[1SF,?3H0K5Z6%
MG*KAJ=:K3P]25^>>'IU:D*-2;U?/4I1I2DFOBE*_4QFE&<XQ=U&4HIIW349.
M*::NGMTT9:_:)_:T\8>&/^%U^%]-^&&JM\//AQ\&HO'D?QIGU>T?2]6UFZ>]
ML]3\(6>E!O,^WV,8@N95F2-?+<.CLZH!_!O^RSXRD^(_[5UWXUU;3!<VWB_Q
MMK-UK$CA)[73(;J7RK2^D\UB59MJ!A&'"RYP!M4C^I+_ (*I?MO_  [^#G[!
M_C#X5>&=>T[6/BC\68'\,W5C$T,SI'YLRRZM/(I,L-IY0C#+@?,<8()!_BD^
M%/C;Q%\.M4TSQ'X9OFCN-*U"UDO[61 B7<8=9+TQ#!+1M+O\HD[BH7(Y +G5
MPLZ%.G1I2IUHTXJ<W?67+'F=WO[REIM;56NTI/\ 34_9K2SGTCPIHE_>O%I=
MMX3T^VT^: @)(BHLDI62,%2"P PQW L"%&#7JX\47/@WQ/KAN)FUO3EFB.E:
M>P>XO39SRF%KL*%.(1,"J@D8!.4P<C\+/^"=O_!1S3_BK\/_  G!I6F"SC\+
M>+;>Q\;6-\D;WNGZ#:Z.9+N^$KG]S:33?O%9V"Y*A?02_M7?\%E_@]\#_'-[
M+\&9]'\:7&M3&Q\7:AK,GVM/#\,<5S#'::/Y#2PM<PN5DF0<JX&X\D#"*:BD
MW=I:_P"?S _%?]LKQ1:?%#_@K/XOTWQ1>PSZ-8:CI&C6,=Y*BQV5THEGCL5,
MAV"82D)L7=AB!PPX_K6_8!L+'_A2>GZ9;1000Z3YR64_ \QFNW:4)\PX64NI
M+8/'IAJ_STX?C:/$OQX\?_&#Q;;RZZ?$GQ#O-7750\JWNAS3:D]YI^H6D+.'
M86T)595R550%'&<_VF_\$_?VM_".N_"_X.:I9ZF^I:#XNAN]%UZ2W@$4FF7^
MG7+QRWU_!'S;I)&Z2AV4!R"1P33 _8+5O'^GV6LZ]IUU<R27-B@6VCV*L4AD
MV*T(8@+N!!8X*@<9)YK^![_@L-\3=9\<_MO^--+U(+'IG@ZY>VTRRWJ8U,L)
M9&"HQ0-F0@ D8P.G2O["_CK\=OA%\&(?B!X[\7^/="ETG0M&FO;>T?4+;?->
MO$9K2W:1I S7$JM%B)"9 &5BH+<_P-?M+?%J/X\_M"?$7XJQ1/#:>)M>>ZMH
MW7#QVZHJQAE;O@9R1R#@# )(!]T?\$="!^W=X1Q\J+\-_BFQ4=(W;P;J#2*>
MX(/;V)'7)_GGU65U\0^+C&NXR^+/&.WIAL>+-8W %L 'IU(SD'L*_H:_X(Y%
M&_;R\+*K*4;X;_%=F(!(X\&ZC@9'4GHP_B;/(S7\[FM2,NN^+%7<[0>+?&K+
M"ROY4DC^*=75%+ $[RWW4R/[P;B@#]DO^")/[.WB_P"*G[4<GQC@TUQX!^'M
MC/9WFHS[XK:_UL@7(L;>90"YMTA?SEYC#.I#9K^ZSX3ZNNKZPFH6%Y!:+ @M
M[B2.8/ L@WJ+(AA^[E41$$;0')'S'G/\SO\ P08\6>&3^Q+XLTW3]T?CC0/'
M'B%]6$;1I*T6J%&L2X7]Y*@$4D:M(0 Q(7J17[Y?"J_&C:)!/J4\-I#/,)KZ
M%0()A?HV8DGWD,69)=PZJZN2"<L* /</VE=*C\;?!7XIV%HTJW>G>%-=EBA5
MMSAVA19V=5+8CF=80@8@;@-JC+9_@5_8P^#;_$3_ (*R^';'QAI-Y::1H_C'
MQ7)97UU:2Q64FMZ?9VUS:VR2L@1YVBD20$%E(.-W2O[D_BI\4U^&_P (OVA_
M&FO36EAX<M_AV\=U.[#?,TJ7DR1V_F88SQ+&I81 Y,J;QC:*_A>_9L_X*">%
MO"/[?6@>,=562#X6^,=5%O!J>L[()O"NMQW,EK<:ZLQ5&@@U*"2**5Y1B2.S
M0* 0VX _T(OV?(M.NK32;1S;W>GZ9->1S(T(NE"6EK&Z":-@3$%E#@EP"SG@
MG&:]J\1_&_P19^'/%;3VEO)/H&DWDLI%JBP0M;)*\,0*J5#DH" ,E00.P _&
M?]F+]NSX8:=J7C9M.UE]>\*>++[5+*Q\2Z+<1WEI%JEHC[K4NA,<"3VC17$#
M( &9W+[6SGKO&/[67P7\#?L3_M0_''4M9MI+/1+/7;"PL]5OH$OK[6Y+*Y6P
MCL\MOF+714;(BW& 0 #D _@O_;D^,>G?'']L/QUXLU(O)X:@^)1L=<CA4*DV
MA#7X;76K<.< -_937+8)! 4@ G K_2$_8EUSX<>&-.^'?AWP=%;6WA:Z^$'@
M]?#!MY(C9/IRZ?:1VD4,D+&)[J,3NLQ!WAR"S':<?Y<?PBO/AMKGB76_%OQM
MEUJ[T;4M;UWQ0^AZ#<+#X@UK6O$>OQ2:;]BD8B)+;3;*:6643,(B8T4@DJ*_
MJ<_8V_X*F^ ?A7X"^%_P='Q%\:>)]>T34?\ A"_AY>^+/#5E:7WACP[K0>;1
M=(UC4;,F'4)K6_MHK%+ASNS<0*2%=J /[-/&OCG7Y_&R> O"-\MM)?6"WM[>
M?>\FVTPK=7, .-P=BL8& 2ZAE4GD5_FS?\%SM)\0Z9_P4F\4:'K>IR:S)=>#
M5\06T4[22E)-1O'=;.%%+D.J6VY(\#AL'!)S_5%^US_P69\-_LJZIX)\<6>B
M:9JWQ#U'P,$U_2;F1'NK6\@A,<-U+I_/EQ:F!)M."#L(8+E*_AJ_:)_:T^*'
M[3_[5WB;]ISQ=?6,?BC5=0O#X9MDL8)8=&TYRYLU-LZ^3(UB"=D,H,9,FX@[
M10!_1O\ \&[?BT>%_ O[0VD?8I+7Q-X?\:>%O'E];36_D:H_AZ\B^S6:FWG5
M+E[(31.!M1@#@$!2#7]=OC>^B\?7'P5U2XNHO[%U[Q$]OK-PLX:S@)M4_P!$
MN0C8\]%;:JN-VYL@$GC_ #AOV5/^"AWQ/^!'BSQ+XIU[3_#WC76M2\':IX4M
MM?N+5= \5:='=Q$I)>SZ:J:5K=E"5W6Z3H9[(*/*/+"OW.U7_@H?K?PZ_9G^
M"7QDN?'VL>%H/$UQ%XA\.?#ZY5=0U76==TV$V.H:Y/;NQE72YYXQ/92*5B8#
M/ XH ^N/^"O'BOP;\%?A;^V/X3O=0@6ZU;P.^GZ%IUQ=QQ7(@N(6B5[1?-,B
M#,@ 55'&"1C-?'G_  ;_ 'A:+X8^$O&'QVT^V']O#PMI4+,DWV@Z?H<-C;SB
MR:(EE$MPJM+(3RR$G);BOYKOVX?VF_BK^UK\1?$_Q.^(OB/4KY];GF0P1SR6
MED]A.62*&6R4A&\L8)!#8P&X)P?T*_X)"?MM7'P[M]:^!>HZFFGCXC:YIND6
MUQ<RA8EL85C@CAMB^0S!$"JA"[\;20"* /[P-,\;V'C:/Q-XNDUG3]+O[S3[
M36=5TB"[036L5S9A[%;N,L%A^TLT13)X=TW8SQ_.7_P6<^%5[\2_V//%OQ5T
MF.*+1/ ?C"QU-6ER;B^6>Z6VNGMY<;9$$\O+*Q3Y3\Q[_I7\6_VF/V>?!6G0
M^"M)U^P76=1TCPY9ZKXWE,.EV6L:F8[:TM_#LWFS+'<3M<,(%B1=V_D8  'X
MB_\ !<+]N;P1'\-_#'["7PGDU*WO+233/$OQ)UB8/;6 M988;\Z#:&3 N[22
M>17#H[C*  D!C0!_,7J,L<NGPE64HMN&9^<*$:,DX&TD C!&<XZ<5_IX?"JZ
M6Q_X([_ B8\&/X1^&F!RH4YBG '[T&/)$D;98XPXX)!%?Y?^J M!.T1'E10"
M&-(R<2)@;Y P^4J,#Y@1U[8K_3I\"DG_ ((W?!-/O$_!_P +(!NVDD6\;@ @
M?>*D,#P2!U-?G/BY06)\+/$J@]74X'S^R5F_]PQEDEUNX]O2[V_-_&3$_5?"
M#Q1Q*NI8/@3B+%1:W<H9;C'%1[M\MK6OJE'5V?HO_!*S3?$-[X>^,/B>#QYJ
MS>'!\7I-+;X>2:3H[Z5!?Q^"OAS(VNQZY!'_ ,)*7GB8P_9IY6T\X!,:(H+?
MLUS@#/4-GL3]WKQQUS]:_%;_ ()%:KK_ /P@GQ>T[_A&YW\/Q_&6^EN/%4VI
MVBVBW4?@3X=%K-=&R-369412LY4VN5/)W';^T@N("=OG+N5A&1SD.Z[UW#^$
M.J$HQ^5B" 2W%>%X 4W1\&O#NDXRAR<,X*-I1G&WO8IMI22T^&[2LW=J^K/G
MOH[YC+./!#PTS2HK5,;PK@IRNWS<U.>+I)RB]4[)._7HO=9='08Z8&*6H3/$
MH!>1%XR2S!<#GYFR1M4D$ G )X'/%9&D>)_#WB".>;0M:TW6(K6^N-,N9--O
M(+Q+?4+5S%<6D[0.XBGAD!1XVP00:_8S]I-VBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J":5(POF.J;Y840L< LSKM7)P-S$$*.YQZU/6??I)(L:H/D
M+.TCF))6A*QGRI4\QU5&23:?N2;AN&U2=X /\_;_ (.#?$5UX;_X*E:WK>DW
M5I;ZMIOPJ^&-UI\M[92WUL)X5NXY<QJC1LT*R;F#9"Y&1S7Y+P_M*?'(7EQ>
MW'Q;U8F[34+:9+718+=(+6^C-I-;::UM;)<VRSP2R1^?YA5(B^1P#7]=?_!2
M3_@KY\ ?V5?VM_&OP)\>_L%>$OC[XE\(^'O"U[=?$C7KOP:FI:A;:Y:27=I8
MK%JG@N\F$%BD<B-C4) CM&HC^;*_!+?\'"G[+-NSM)_P2;\ ^4 %9XKGX=(!
MGY5+,? VW:<;?4L1WH2NTE=MO9)MO=V22;=]=E<#\L/V)/CUXM7XF>$?@WJG
MBC4F\-^,M;6WTHWUYJ%S-HNNVN^]TR."]D0-/#JEQ&5D#G:C;4&.E?2/[7O_
M  57^-;?$N+P%X5UW[5X \%6A\/:[HDMG=VCZ[J\5PEMKB'4T4NEJ(+006V!
M]^5\9[?9%A_P<2_LSV=[:WFC_P#!*3PG::E:[KRQN['6/A]97T$L=M-+#<V-
MY%X#9[62%E6=[D[52V2=@RD9KW3XT_\ !9?X$?"G0_AYXS\:_P#!++X;:E??
M%+0=5\5#3EU'P.^KZ396U]%;6MQJTUSX&,=[_:4\LDB7D8C#D9 8\U4H3BKR
MA.*WO*G-*W5OFC%;=7IJM>S49.]DW;5M1;5N[=FE]Z/Y/M=^,ZV7QDN/BM\(
M;>[^%^N7>JW&JV5M!%-JC:5<SVZV]SY=Q>P.5DN7W.LR!IXAAH\EFS]1>#?V
MQ/VB?"?BKPEXYU?XH:QK,?@'6)]6BMK.";2X=4MM4M;(:JEZEM"IUMY@9(UE
MNXHVAD!,>6&#^RD__!PI^RE%+9H/^"2/@!I;E92@>^^&ZR%T )"$^ ]S ,0&
M)Y)/:KUG_P '#'[,^J3P6&G_ /!)CP+>7=U=KIUM:V^J?#UV:X;[\(2#P&[O
M(@4,84C#!0#D$<9\W*N:-KQ]Y6UU2W]W6WFNH<LG9<LKRT2Y97;>UDDVWVLG
MY7/2_B1_P4#US]DKP3X=^(%KJ_\ ;?Q$^/?A:Q\9^'?"%_'<WUMHPU"!9+2?
M551<06UH7$YBD $VWR\#.:_&7]L/]OFP_;=\ 6,'QGN?&'ASQ;X @L4\-Z%I
M3SS^!-=U) QU74WTV. 26%W=2F1(XY681P2 ]@!^S\W_  7_ /@AXIT?5?$W
MB#_@EQX6O]/\)O9^%;235/$7@B[N$OD5?+T.&WNO S"P6) 9(+<-EXT&T#''
MD%Y_P<+?LKP++!>?\$C_  +&(1'<SK-?_#A&03/M1B#X%W_/G@E@K<G&W-9P
M=)7JTJE.HYNTU3J4JC@I;J<:<YRBM7?G4;/KT#E>ONR36_NNZ[WNKI66K=K'
MXL?LW?MC3_ 'X;Z1:_"SP#H_A[XOV6LW4^O?$Z[EU34'UK1KYID@T6WT^W\F
M%6L+6;R[:ZF#^3=11,^[:Q/ZN?L+?MZ_$3XN>5^S9\=-8UOQQH_]A^(/$&G>
M+5N+JQU>W@T*>XUU8/$5P$$>H1LJ-96US$$"J%C8&O2(/^#B7]E&*:[AM?\
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M>EM8:8J6LLC*)8;2'S$9FD8]5^]R6.<?WO\ B[_@MK_P34^'_B+Q!X'\7_\
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M6VJ:2J&:"+51_P (3Y<R[B)+-) R;P[*F68F7QC_ ,%L/V*O"&E>#]=\3?\
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M#X:_#VX62*1A'+Y 31 TDFW<(]AR& ;/%)2B[6E%WVM*+OYIINZTZ ?S2?\
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MQ(:ZS)!ID\31Q6]Q;K*MDT:M L37()DCD!V[O,98MI&1YF-PQD]596<,NEZ
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M@JN%J58X>,W%TJ,IU84XS<_Z/XOX!XNXIS;@?&97FSX8P/ 6-QLZ>8TY./\
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MKN^T[5GAA=66%E +_(&W+\YSGV;'0U_3V;GPE]FN)=;:X@O;]2(YBC"-98T
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MO >*&6\5<3YEQ5GCS'AO'3Q-/+^&'>V!JUE5A1FE)Z>QG4BWRV5XVV/Z5O\
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MY^)GA/1]?35O&D4NE3:G;Z=%)J5II#:;&+62&_NRJ_8[JV:<K<0##0,K #8
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M)C,?4CE695Z55X/6GBK?6*<O9-N&(;BH^V3TJM-WDM$?RX_M(_\ !6S]J_\
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M,0^&#X@DU#P!;R:!:HS%Y;94\3@O-,LC+D%1@@,2.O@T/_!NY^S1;P16T/\
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MN\5>)6\/74$OB?7=J-$SE=?UX7! =5.V1=1'0D$@?>P,GKC]T/\ @XZA+_\
M!6WXR27!C6W'P_\ A6 7!^<C2+U@BE<$/M0E2",*&!SG-?C9I6D#Q+ -.AT=
M=4TBXGMK2^LK8F*\=6N$$#QW!Q)$$NQ 9"A!,>Y#E78']K\./#S'<=/#X&A"
MES5ZM&G2<\+/%1NJL:JYL/02K5HR5!IQA)2?,G9QA-/W<)EE.>'^L5\/7Q5%
M>S=7#X9TX5JT)U:<)4Z<JT*E&-XU+U)U*<XQI*LU'FC%JAX8\*?$'6];@CM=
M1\16.E#4+.^^V7/B+Q!%#%;0+:&:1Y6U)=D960[]I((8@J2S"O9_C!H<L_\
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M[%P#]&--U_1];6YN-"U[2-;2S=H)I=)OX-4%M-&GF 79L+EXX\G,QB<(TD9
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M?@76QU#V="*F^;^;OI;?23^CWQUXA>"^)H<>\0\?^*V/XQRW'\9\29[P+BN
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M:^$]4>]6PEF0+KFGM;?V3<W%T=K0);(TCPF(A0SLW5R:^D_@=X @^)_C/7/
MVFG5;[P+\/K#6/%?B>WM8II+O6-%\-RWD6B:):M,1/<W>H3M:1ZLRG_2+>,L
MQ\O!-W]H;3[K7?@U>>)4\/\ A;P--H<6N>$)-'\)^%8_#-SJ>F7_ (?OM:%_
M>OL1[[^QKG3+33;RY;<HN+V0%BSBOZN^D5X_^$F1^(W#_@7Q;BN(<RXOXFX<
MQ'&/#V7Y7E+Q.#PE; Y%Q%1EC\=6YL6\#A:U11G7A3JSI1ITI1E6J7J7\?@?
M/N,^.>&^+^(^#Z> Q7#_  ?C>'<DXOQ$L[R/#YS5J<69;2S?#0X6P3<:V9PE
M.JJF,PK=>>&C*3JTXRC=>?\ [-GPM^+NL_ F\^,'@[0_^$A\&^&]:U.VOM/L
M[NT@\7):V1@CU77[32<AM4TC3#*9+J^E5Y57YE8AJ]NU#XP:I\1/ _@^ROSX
M2M-.\$:7<V.GZOHN@:=IDFKO/--)<ZCXIO+.")]4N$B12LMT9&2ZPV=^36!_
MP2K_ &M-"^$7@X_"[QO9Z-=>!?%K^,7&OR:=]HU3PWJ.H:,T#Z9!J.&>&PU"
MYBCDN(0?)=E3*@"O((-;M[WP[\0=)TY;2X8ZGX@%A=0L56:S_M0W%M%& %7R
MBFUF  &,YX-?0?1<I>(^?Y/B<)XAY-D53(.'Z7#=7PAQ^1UHK!9EEF;Y+BYY
MD\SKX9PH4*^&Q+IT,7A91E'"2JU%*C1<KO\ #>'_ !=XVP?B%XJ< 9YDN+GE
M,,II9EE6(J556^M8Q1KU,/24X2E3JQE4I4[.G>D]7!<B27AO[4/PH\77?AOP
MA\7(?#4D&B>(!<V-I<C4+>\N4BED:SMKW7M-4C6-.MKIHC<:;<2[8Y%;S(!@
M&N/_ &=] T37KWQ?::W8Z=<W6EZ397&F&[:-H8I862RO$0,,W'F31LTJSAI)
M&;$F=PKZ-_:W_;!\2>,?AAX0^$NO> ? FF-;1^'YM1E\/6$5MXNU^V\+V4*V
M-UK%];HCRV<#()&A=E#A2"&P2?GC]E/Q!8VVI:YXT\2:9/XETVP73M3U/0;:
M(6RZSIEQJ@DO-.L@H1D+1@_*"&:4$YYVG^'N(,CQD_I3>PS#+.':7B=BL-XH
MULHX%X2PV%Q>4QE@<FS:IP9C,YS/$T)Y?3S3,YT:.(Q=-<L:]>5.I5564G,_
M9N".)<=FF6Y'GG%^ Q-'$4LQS#&Y]D&%PW)F-+):=.I*KB\OJ4Z4,16KTL/1
M<Z6 A)TN91C&C'F=_N_QM\&]/T+0/AAKUAJ8U;P!\0;R?P[;2_V8FAS^&O&V
MA@M?Z'H]O;) /[-N8)8EDGC7_3!-,DC,!@6;4ZC9ZO#X \+>'KOQ)K6L30)I
MNFZ5I,$NH6@M9-]S]C*Q&.#>X,<DCE5(&&8\U[W^U;\6O@##\+_@7X?^!][J
M4OAK2O%GB'XFWVG:[>F_U3PQJ]]I[1MI<\LC22;!=>6;>+'[B6)7PK)7MO[)
MO[./Q"UCX/\ Q,\::WJ<'P\\9?&RS\/K\-KG4[U(;RWT!R=2OK2]U!_GL+#Q
M;!(8+FX213(9"H<8#5_3=#QQ\7_!OZ(E+Q/\7^"LPQWB?DLLSR>OPA.G@OK/
M$.8SS+%4L%FF24<IH8?%QRK*,%'!_7/84EAW3A.4DE)RE^*YEX_^!>6<83S#
MACCO,.%L@X\\0LIX)\/^.O$GA2I2S_ANCC,5]2XBJ9WEE#!O,(X2&9J6+IU<
M0[T<LP2J*5.C5:E^9OC_ $'XC>%/B58Z+XV\*:[X2UAH[NY32?$EFJ/-97 2
M(R1-%_H[);PDR)Y+$(P4@J0 /@77HT_X2SQ5Y3-)"OB'4HT9CN,@A=4,A8Y/
M[QCG/5L*3SDC]VOVB?"^I?#/X4_!S0/B=XMT?4_BGX9UGQ1:V/A6SU.+7M>T
MGPCJUHT=G'>:Z'FGN].M[[+V=O--(8(R$4D"OPIU]5B\3^(UCV-NUO491)"I
M2)Q+*K*$CSE?**LN,?>'JN!_%GTI_&C&^.G@)]'/C[BG@G,>!\TK97GM2O@,
M33QU"CA\;4IY-&7(L9*%64*LG+$P=2\E3QRLW2J0YOT3AO!?V5F_&5"'%W#_
M !W'#9YBZ$.-.%'7I\.\20A7:6;91#%3EB*>"QD4IQA5DN2HJZ25-0B;?A#5
M+'0/''P^UR_\E-/T_P 6:?<WQ=PF8</#D)T;+.HP3@$'@ELU_I6_L(>#M0U'
M]G3X:7,%Y:V<=SX:AN8[3_5W+17MPUY!<W ;$DCW%M<0HDCL69(@@.U%-?YP
M_P"S/\/]$^,'[3'P1^&7BF95T#Q/XSMHM1-Q*@1H;7-S' ZG:ICFN4C$F6 ,
M>4&,FO\ 0B_8@\)?M,_"@Z]X2^/GQ+\/>/M)O?$]A!\)&\/64>G1^$OAK86S
MV=CX<N/*AA69K"&&T&29"HW;I&+9'\*X'(<)C\HSO%8_,Z%*G@L2W++*4E3Q
MN8U:C=2A5P?(X58T*5.5&%2-)QA>G/FC9N_W4:#QD*DZ:25.$7:*LFE!-N\$
MM=W?=[W=]?TA^(?@*YU/P9>:5?WACM$EO"7CD",9?LMN$BB(.3Y[*=X'+E >
M>!7^7;_P4U\"0^"OVO/COH>EZ<\+7GB2'61 B%)-0U2YFNK<;5C&9)YV2".1
MVW.R&-<L*_U(_B?J]B^A>2EW''+%>-# DN63=]E*/JD8SAKF%_*<(<>=C[I(
M-?Y\W[67@GPEX8_X*-Z3;?&_QMIOQ$N-<^):>(;^_GBBT[/AW^TH&T+2-5T\
M!%C5)XYD$S@"X:/!XC"BLMRBCC\MS26:9Q@Z.*PD:<L+&FZ=.\'3A*A3DXN+
MYX4N2%1N[E44W)N3;<X6GA)8>=1U;XC]XI1;T3@W&-HMV5XI-Z)M_,_HZ_X(
M(_L\O\ _V4_A_P"&]=L'C\3>(]&;Q?JR2QLFH:9K'B S:@T-T\BB4"WMIX;:
M%6.$1%10J!17[>>%+B#PZNI3Z])-Y4-Y=W<-M;JP>69=YCG(4 M(I)&[)QDG
M/ KA?A]X<M-"G\&:AX4LM/MK;QWX/L-8L8+&6(PI:6^G6XMW1H_W>_8=A"\A
M1COS[!J^HGP-X>_X2;QI%9V7A[2-/U/7_$>IS6T5QY&@Z5:37FJ3LS@[$MK>
M)IMX^9S\HYX/E4:=3%5Z."K2P4\944:6$^ITL1''UN1*-&]1I8&I)QY>7E4Y
M24K5.:;9YL:-3$2IQ4I*3JR3M)JZYVE:SVL[;75NK/XR/^#CZ)Y-2^&FK:UH
MWV3^U8)SI5U=H5C2"XG,$,@5QS*'F1E'4YXP3BOT!_X-6/AY<:5^Q_XR^(K:
M5)9Q^//&.I1+J<-LT37_ /9]X(8VDRBF2(".11(22JLT>[YB#^3_ /P6)_;W
M^%?[?W@_3-2\)^ ]4\--\+=1MM/M)Y=4M-5LKKPU;>)H;;3_ !,+FU=KZSN-
M8Q'<16LB>7!!N#D2*@'V?^P[_P %</'O[)O@WX _ "+X"> / G[/FJ>(?#N@
MIXCL['7AK&K6GB2]MK6[UK20]H+"_OY]2G@,MHD[7#+-+<!=L+,/T_+/!7Q&
MSG%YGDN58++(<28;+\'Q+CL'QCF>$RRI'(\-A*M?"U<O=-T:->6(P<*E2G0I
MQ4ZDU&-9RJ.,E]%#(JU:JZ*4E*%.C5:::LIPD_>:4K[7=KW[K5G]?-_I5RNF
M>,[G4N#-;/;6LCQ ELQOY3%@ <QCE<=.<=#C^,;_ (.)?@]9ZY\.]#^(T$]]
M=:A\/O$VGPW@A,GD-'J$,NW[00,%$:-<%O5>3@&O[0-<\3Z5=^ +G7;&6[-G
M<Z?:7<DD\CVL4D5Q\R-=%^;7:LJD6Q -TZQVIR)2*_EZ_P""U'Q>_9@U_P#9
M@_:"^#-I\9M%D^/6F+X+\51^#+>WE%]J-O<:HJ36TS^68XG:W<0/9E@MJC*R
MJ#,37YG@<HSC,<9GE?!Y96Q=?*E/&X^&'A4J8:BJD??A248U(JC3]A)P?NJ[
MG;6+9P+ SGB*N&7Q44I2W;TNUM9O1/7JK:69_/O_ ,$D_ %M=?%WP;\2YH5E
M@MOB/X9T2:(YBD7S+N&1Y(IDVO!%!&TL\DN0J-DG!P1_79^V?_P4D_;"^"G[
M3/PV^$_P'_9N;XC?L^>)KKPSH%MXONM!U6^/C&\N[F2U\0Z;HGBG2T-OI4^D
M6ZBX2ZNYHY&;_5ONK^,W]B']I#X:? 76_AUIOQ"\2V_A2WO?BAHNOJ9;:2>U
MTZ.$F&6+5U@5FCM9R0$NBNV!0W0'C_04TG]HSP%I/[-WAKQAX=\2^$8M/NA+
MJ,FH7#F73+])U:YBNM-N;]-H:6VN(5D:,QL415Y/7T.&L\R3)J]3%9MP2N.*
M->-22R7'9G5RY8+$54X5,33KQJPG>G*G3E2I>TC3CRS2C%U')/!UL/A:E1XB
MC1K<K<?WU*%11G!VNN>#:=WI;3R9^"7_  <>_'31?AI^R_+X$TEK:VUOXMZE
M8V]G#936PNH-/66(7HN'?_B921V,L)MY>2KW+-<ON+N6_-W_ (-N_P!GVZUO
MXM_$[]H*YEA33?"/@JX\):1$\:)#'=HL4$DUN0/W4MPX5973!F. QP=M?G=_
MP6H_:[NOVJOVJK>PL;VWN?AY\(+=M#T:Z@E#6NJZJY\V]N2B?+<11Q!847D3
M1H(@?F)/[9?\&\/BU= ^!_Q?\+W5W#IWBF+5H;^?1+]5LK_[#>W$%S;:G+;2
MA1%I]XI1(40'[RD8R:\><U5GB*T:#PM.K7E.E@Y5/;/!TVHI8?VO-/GY&FW)
M2<6Y.W<YZTU5K5*D8J,92;C%:**>R222272Q_6=H>CZ/:>"[N^=;73)9+5;W
M6]9O[D+::+:+";B]N8/.8(B6T:/=,J@$F(O][D?@U_P4(_;L_98UOX%?$?6_
MA9\9]*^(5UX6MYM/U9;&WU'2TOM<"R6%FT*7Y2&\_P!)7S%GM 59D#*Q 5A^
MSWQ+\6Z%XH^$4&CVL>G:C9>)R/#VHVUO.JP7L%S9-;:S!*\3#E87N;4-D,I?
M!.1D?Q=_\%NOV>/V<_V2OAIX5^'GP>LI--UWQWJMKK%YI=SXBNM=U.PTY)C<
MV^C!#+*++1+=W,EM:OQ&I0YZ&OI,DP?"V(X3XTQ>=TN*I9[EF$PN)X0GE6*R
M:AD^+S.I7C2Q&#QT,9-9C7KTJ#5>5/#J5#V#C[CK7:VI4\).A.=6;C6C-\D5
M.R<%"ZO'9WE=:W^77^>Q+^YU:;5O$,UL4N-;UJ]UJX:60DQS7EQ(6FD8L&$D
M\8&^0D,X 4\ 5_I#?\$:M*\'>(/^"+OPSTWQY/KEGX.N?^$N76KC0H))]3%I
M_;$"R&V\E7G:4N62-XU9SD%<E,#_ #AA#':Z(KL4#R6@:3(S@I&-A=>G[L@[
M<@8&T$DEMW^CA_P1VN+R;_@B'\.[C1=-U+Q%J5KI_B:>#2?#]K:SZI?W$7B"
MTD-M8V.H,ME?WCC+0VURRP7# 0M][GYJK%0JIJK&4IT,+4J05U.A6J8:+KTJ
MMK1]I&HY<W):.C31R:W?17TU_P CZT@^"_[$$ESX9U9/A#\5VU'PK96-EHNI
M6'@WXBIY<FGVFHM:ZJ%CMUT]KY[;69I+B\2,3/=R*"Y9%KH+?P!^PW<W\UU+
M\"_&FNZU=#2XKE-3^'/C74[Z.ZTE+*2&6[LI[1EM-2NUM;34KZ?RXY]0B6.:
M5I.2/'?A?\+6^+%OK/B3Q;X%_:_\(W'A'6-;U1/#^J^(;338_'>FW.L^&)(]
M*MKO2-1,=M'<W-L+J.SC:/\ LRQ@U7P_\D=LP;8_:)^''B4>(/C-XC\-^'OC
M/87?C?5?AL(WT#6])T6'4-+?P5<Z7JWB/2;>WU07%E>>%8+/3_#=WXBN8H(3
M*5#.6&ZH6UGLM$NB71+R5_O; ]LTG1?V3?#/C!_'.@_"OXH:#XA&N:+XA:\M
M?AKXW^SI>>';2;3;2TMH+BR>*."87'G/;A '>-7*X0@_:WP]^*?ASXH:3<:K
MX5N]6,6G:W>:!?Q:SIMYHNK6NM:=<".>RO-/O[2$P)(H#!2BAAM(&:_,7]C3
MQ?J7PI70O"^GZ/\ %VZT'Q%\13X:\<>-/C?XP76--T6.'3F'AM/ NM:AJ=Q8
M:A)J4D<\VKQW,CZT\M]:V-G _P!AE$?WO^SVHEU3XZ2S+YYE^.?B9X_-)8JT
M<%L8V'H8\':.P]33 ^HQSSQTQVR#GYN1[@ CU'Y+2 8&/S]R>2?S[=NE+0 4
M444 %%%% !1110 4444 %%%% !1110 53NY B*2 /F*\CIN7D@?WL' &>YZU
M<K+U-',2&-_*;S"%E(WI&\@V(TB##,-S <$!>I[FDXN5TI<K:=FTFKVD[.[5
MT[<K5UH[]"*KE&G*4%S25FH]_>C?_P EO_5S_.;_ ."\?CK6=$_X*[?%;PV]
MK8S:3/X%^&6I/-=(995>'2+]@+9 =L=PR[E5WW+L+*<YKX8BUE=:T32_'6ES
MS:-<:=?VNIVMY<M'&FEZOI4Z/97$[)\\-A)*JP7F%??:32Q[0LA=/[:?VS_^
M" /[*/[=?[2OBK]J'XF_%7X^^&_'?BC1-#\/:EIG@3Q#X5TWPY:V/AZV:T@2
MTM=4\,ZE?QRRB1F:=[HC!8# (%?/&E?\&O7[%'ABWFM[/XZ?M42Z3<AHYM'U
M'Q?X0N=/E9G69I"@\(>;OS$1Q)Y9#$% ,$_Z.?1L^FAP5X<\ PX)\1\LQU3)
MX4*N42K4<-4QE-9=C(8C UZ=/">UITZD:]'&2I*E&=*,YUD[OEU^MCF^%K97
M'#5*KPN(H4*GU?$4\-"O/#8E4IO#8JE2Y91=:CB%AZL-+JI",M'%-?SDZ!H7
MP?\ B'IGPRN]"^*.F_#'QA\2+Z[L-;T+XD6Q_L+2]=BFADOM1L=2T1[^)/#&
MILSS:-;ZB]E,9!*9&VKQ^@WBCX1>+O"=WX!_9EO_ (@W&N_LFI\.-<\>^._B
M18P:,NBCQ1=,98;E?$J3-&+.RU,VSV>GR7*2N (UMY"&%?K!IO\ P;>_L5V$
M4D%A\2_C]#;LK+F3Q#X5N8O,8865;8^%8!N095&\S8@9L*"VX=Z?^"!OP'D^
M'L7P<N/VE_VH[KX6QSKJ0\$CQ%X-@TV26WN1>11/<'PG+?RVPNBLYMIKR2%R
M@79M+"O\UO';Z,?T1^.N,<LXI\+^/?$WPYR:GQ-GN(XCX4S;@;+<]JX>&.K2
MKQSCA3,*N)QCK8K K$5I93E^9TJN#P]2I*2HJ4%%?>8?Z7WTO<!PQP=PYFG'
M^0^(> X;P.,PN1YAXB9+0_M?A;-Y4Z6'ROB#+)4,-76;YUE>'H16"J9M*K4<
M8QI.IRP@H_RF?''Q/^S7\/O!>B?#GX::O<_%+XM^,S<7GB;XNZC9W4/AGPSH
MB3R6<6D^#]%.+>#6WAB7S]2F:1;EW9XT48 ^1=2T^7P];M=:)XMU;P=K$UK'
M:SSZ)J+Z;(UA;C%O%K-K')BY%T_[YOE\U?,.7"CC^Q+7?^#:']CGQ)I3:.?C
M5^T_IDR7XO4OM+\4^!XKH7!8-#S)X':"."'!_=*BIRI"C))RO$'_  :[_L.^
M*+FRU#5?C1^U6;V.%8KF:V\:>$$^WW*1K ][=;?!KHSRQ#:T<21PC^&/<#G_
M $M\!/I ?1<^B=X8P\.?!_ASC?.\NQ;HYQQ-F/&.79=#B'BS/L-1A&E&%'V+
MH4(SBJE'"2Q4)T<)'DA2]G#;\PXKSG.O&"IF.:>,_&=?Q/SC,,+B\-1S?,<)
M6]AEU7%7Y\%A\HQJK4*-+VTHWQE+#PDY4X5'4YK27\FOP]_:O^,OAW0+JQU#
MQ[9>(/#GAXW*)HOB]Y)M-U&XOP88[C1EB1#]H29TECDEE98Y5#\@8KL_&'_!
M1GX]:]\.M(^&%]KVBZ*HAFTC6?$.FWA&O:GI#L1?:0;R3S'^UM;,D=XT1B)M
MU8(Z8K^K2V_X-A/V%8-#N- N/BI^TEJ%E=0-;B6\\4^#&GA+*N'A>/P?'M<=
MF4*P(&6['SN]_P"#3[]@>Y\AI/C+^U3*\9FD)7QEX+19&N2!.6SX,+JTBY5I
M!)OQM&_JS?8>)OTS?HX\38KAC,L+X&9?QKG.7XNCF,L+QAA\+@%PMBL2J4,9
MG.54\+2^IXG%TXN?MFZ5-XY0^KXEUZ%1I_RYD/T5O!W+<VJ\0NEC,OS2.,DL
M!B,IISP=&#G6E-4:U/+:^5RK8.K.=L3A/K>'IUX>Y.<+*2_DP\$ZI)I1N_&7
M@UTTR>-55=+O]UWX:\1P1%DCM-:TJ-T6\M[UY#;R7:[9X%E$WV@)'D??G@S]
MHW]CK2O^$,UJ_P#V=O$VH_$/0+:";78]!%W9>#M"U&,B6^O](@DO'G\31Z5/
M\UK<6\BF($\DKFOWXTG_ (-?OV+-.-I#:?'K]K*"#2BUMI]L?&/@EH(;%D9!
M:D#P23.G.0TI:4;1AB:WQ_P;0?LBPW=A<6'QY_:GM7L8OLH:/QCX,!$;!A)&
MD3^""J+*&(D6+9O5CDL3D?FOCQXF?0I^E"LMAXT>%_$.'Q^#P-.G_:_#^.KX
M/'JEAL-3I0I?6,,Z.)K4L/1IJ%&C*M*G&E&-&"5.*4?Z:I8_BC)L%2I<*>,7
MB]X9TL/A'EDLB\-:^%R7*\QH5*$L*\PQ66XK^WLOQN*A"?MHUL=*<_:I.IB8
M)U)+^9O]J/\ :Z\ :IX+7X:?L^:S\0_#_@&/Q&/'WQ"UK7;V\L=:OO&.IS":
MTT7PS<SRRW2:!8W$:&6#SF0N#NRH53\(>#?$N@>-[O6-?U6S72;BTUA(K^YU
MF^BEGNM6U(+$;ZUC#(7FO4"?:, H[*,+@$G^TWQ5_P &Q?[$OBR&PL[SXQ?M
M*VJ6&T-+IOB;P?%//SN(N/M'A&YB9@QSO$0()RN=I5?))O\ @U%_8-L];L=0
MMOCS^UPA34K2]E@D\;^!Y+2>XMY5D3[1#_P@2[E4J 0CQL%) ;)S7H^&_P!+
M#PE\#<;D' G@=PI/+?"7(LKP]'+\5B,MPU#/\VQ:4:56.=U:$88O-U@(U,35
MHT<;BL0W><:?LY5IM?(<!\(<+<)/.\;GV69IQEQ#G.9TLQQ'&W$-/!8SBK-*
ML,53QD:V=4<E_L_ N$Z\%7Q<H4:W(W6JP4I*+G^"'PA_;?\ &G[-/@#3OA]H
M_P )O#6OWOA6^\1W?A#QJMO;PZU)H^L7,,^HVEWJ*A;E=/,DS.\+NR['D&W!
MP/JOQ_\ M#)!^SG<?'[QQ!H'ACXMOJ&E)\,K/2/$,>KNC/&QCN+"*&1I+JPL
MY)V&K0,IDA@=RSC:N/V9UO\ X-E/V0]6\21:Y%^T%^U9IT<5O!'_ &7:>,/
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M%XM5*F)R^C6C6G2K8N#PN&EAZ^(I))5Y4YT'2G*FXOV,YPE.G!PC3E!1BE_
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MEC6*:\L;Q5O(IGB4Y#Q)A" 2RX%?3PMX@V_:=V[>27<Y;;MY!;!&.BD8!R0
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M![@\&I**T6BMVT7HM$ODDE\A[ZLB\F/;MP<<\D\X.>,]<<G Z#M@<4>3&!@
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M@ W:*IVL[2&19%970KE2!]ULA7W@[7W!=QV]!TSD9N4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5DWFH2P7*VL43.[P-,)#%-Y*!21EY=GE2<CYK>%WO"/FC@=>1^#7Q"_X*9_\
M%)?C-J^I6?\ P3N_X)8?$/QQX T?Q+J?AV;XY?M:^-O"?[,GA/Q#)H4UU::M
MJ'@KP+XUUG3_ (DZQX>:^MFMM*\1W'ARUTW4XA]H@8!X@X!^_=!. 2>@Y-?S
M\>"?^"EW_!3_ ."FK6UO_P % ?\ @E'\0/#OPZN?$.GZ/<_&W]D?Q[X0_:/T
MK0(-:>""SU#7/A?X2U>_^**:'IU[/';:OXBM/#D^G6<;^=.8DC:1OWNT758]
M9LK;4;<A[6ZL[6YC)62&XC>ZA6X^S75I.D<]I<Q0R0--;W"1S022M#*BO&P
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MMQ$LFL:WI6@Z6#:VS-<3W%SJ.L6-L_V:.6UMWE^TW$D5C'//'^&0_P""R?\
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M=AI&F:CH7QC^'7C+P19^'O$$URC-J-FNGZC?I?6<VGMLC9)D$TK.'CA>/YJ
M/V9N)?(AFG.-L43NVYD10J LSM(Y"*J+EF+$*J@DU\_^ _VC_A7\3_&WC7P#
MX%^(?AGQ#XE^&VN67AGQGI.GW$<ES8ZUJ/AW1/%=K:6H9Q_;$O\ 8NM65W/-
MHXN['38[@PZI-;7BI"?PYN?^"PG_  4UNK>>VN?^"!W[6TMO<1207$4WC?P
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M*6[R3HR_SS>+OVU/VA+?XW_LLV4W[2/Q%T7Q/=_ C_@GW>_!'X'V.GO<Z/\
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M\(W5[);S7OQ!U ;M%UJ[5);!-**6L,DB1@#\BO\ @M7^U_\ &'Q5_P %O?\
M@EW^Q'XM\ ^$-)^#_@+]K3]G;X^_#/QY8WM]<>,_$EYXDU!?#VM:=KUI+<MI
MUGI]E>W<IM8EM(+I1&@=Y%+  'W5_P %&O\ @NM^T;^PS_P4^^"?[*(_9DT&
M[_9D\8ZS\)=,\9?'+Q?=:OX>M;JU^(^NV^A:AK>B^-+N*U\":!9^&)[VV6Z&
MNZBX,C*DC1B=#7[#^+?^"JG_  3T\(:+X_U6\_;7_9<U6[^&GA_5?$WBOPSH
M/QO^&VL^*[;3])L[K4;NVTW0=-\37=[K6K1V]E-#:6.GI*=0O3!;Q2(\T8/P
M[_P5'_X)<_';]J?PU\9O%/PE_:B^-_B/6_&EEHMAX=_92UWQOX3\+? >\9-9
MTB/41=:UJ'A37]:T2TTVT6?Q*GV:.Z=M2L+:"&%6F#1_Y_7[=?\ P33^)/\
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M352YTJWNX&M;@R2V\B[)(I&+HZD[B&5L@@OASTY10/E&*TZ* &H"JJI8L54
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M&3XAT7PYXBL=<UKPA_PE>E'^T/#CZO9V+>1>Q I>3PII=UML[V=U^;/V$_\
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M#\*>&/&WA=CJ7AKQ?H&F>)-%U!87@:?3-8LX[^R>6WF(E@?[-/"9%(?Y]X!
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MX>TC5YK/7=3TG1M?D\ 6UE&^J6+-IZR7+P7LKJ?%?^"WW[<WA?QS_P %7_\
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MD%LE^J8VQ2,#ELX  10&9VR> %=& /+!AM!YQ7U68P_9W$9=8V>61B!Y2QJ
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MH.K6GPT\7SW1U#5=3\!VOC"77-+T^U$ZSR:';I'"8QL0>0>'?CI_P44^+?\
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M6GW*H\P@U]GD.98_ 5XX;"XNAAZ;UMC:5'&15W%-N6*A5FM$E)IK1-I-VO\
M:< YSF^%Q<Z.69C@\OA6EBIU)<38++W2;Q-/V.):EBJ%3D]M3DTN5Z*TH14K
M*7K/[/'_  1;^&7PQ_:+T_\ :^^*?Q.\1_&7]H*WUO6?%$VK2>'?"W@GP4_B
M#5["TTJ+5;?PCX7TJQM[&ZL=,LH(U%G-% ]ZT]P81YA4?MA' RA2SDGRP&)R
MQ;(R22?F+$CDDY.<G)JOI"RG3M/DF;,CZ?9&3&0OF&VC,N%(7 +Y8?(C#.W
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M-8^O@*/ML9"4N3V&'ITU+GBU4@I<M)Q?+J[KELVF?KS',SR%"H4;=V0<\G
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M5;R'4=8U"""WM))C%#J%]-<RJ-DC#^E>!N.<_P GX$R_(ZN3YE3RS$<5XR/
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MA:KK \HW^JZ9HDLMS_9<4UQ$9+:$S226JLR+(WS9]6YX[G'3 P?E7/'N"?R
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MY<^I8 =\ 'QS^R!^Q)\(_P!AKX:ZK\-OA!?>--;A\4^++[QGXS\<?%+Q5?\
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MLY9)4"20LSF!P,E!Y2X$(C.75XW#ER=WR\5T(&,_R].3].N?_KF@Y[8_'/\
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M/AIX&N+^\UJ_T;1+5A<ZEKE\$%QJNHZE,7NK^9D1(HQ<2%((8Q'"JACGZ@'
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M6SU23M9=M&^NK6^NWEH)ZI)VT^]]=>_;T*\<<BR%F(V[2.#U.<Y(P!D]S[#
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M*,@) +;]V0 $.:L+XO\ "K$#_A)-!&5#?-K.F@[3@J2OVK<-X.5R!D YQTH
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M9P>E6['7]*U+S3I][;7RP.\4[V=U:7B02J ZQ3-:W$PBEEA9+B*-\.\$B28
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M^+'[1/Q:\0V.L_"N&>,^*_#N@VMMK4\6G>(Y8"8K*_DCVP3*P>5?E=?K1_\
M@V0_X)UWEV\:>,/VP$MWS+!;G]J?XJN\,99R)YFDU[$T5PQ0P"..-U'$BAMP
MKL_VB_\ @L9=_"+XZ:G!\+/"W@CXD_L\?""W\#W_ ,5['3/$$5]\</BWX.^)
M5G?2P?%O]E3P;I<TTGQ1^'_PK?1;^#QU+H<=_>WLXNH]/AN);"]$7[B?#GX@
M^"_B?X)\$_$[P#XCTSQ/X#\>^'=)\5>#O$.GW1FM-:\/^(K2&_TJ_@.%<S7$
M5P@GAE5)+:4M;RI'/%)&H!^!<G_!K_\ \$Z(T:1_&/[7P5%+M_QE%\4<@ ')
M_P"0YS@9X_+)JA<_\&QG_!.J.WN1:^-/VMX;YH+F/3FO?VG/BQ);O=M"QM9V
MA@UWS+FV6=T9UC(,J!HP0>O]'5S?VPB=A.BB)_GD8X1#&=\@+DA=\*Y9HSDX
M R,5^;O[=O[;MC^R]\/FL?!NN_#=OBUX@U_PAX"TZ^^(?B1=-\$_!R\\>3ZI
MIGAWXL_'0632ZSHWPQM=>LC;37L-J;::[$-NTBF1@H!^(_['/_!KI\)] ^#E
MGHW[;7QI^./Q&^-TWB?Q/-<^(O@_^T+\7_#GA-_"LFJW+>%+&XTR]UBW:'5-
M)TDVT>JJL1'VDLGVB[*">3ZR_P"(7S_@G5_T./[7O_B47Q1_^7E?H7_P3I_;
M\\-?MM> ?$,&KV%GX/\ CW\&->N/!/QT\$6MRFHZ%<:O87$^GZ1\2OA7XFL3
M/I'CSX._$J"!?$G@'Q?H=Y?:;J.E:C!;27"W5O(@_2=KN!(S)(6C4*68.CA@
M ,L"N,[E7EEQD+SC'- '\Y;_ /!L#_P3I@1ICXS_ &O$\M6(<_M2?%) I*E5
M;<-=!7!(.0>G'>OE?7_^#7/X/7W[77P^\1>&_C=\<M-_8WT_X9:UIWQ&^'6H
M?M!?%^;XJ:W\4KEIQX=U?0_$DNL/'::"B>7/?67G*'1&*I-N!7^J;QY\2O _
MP[\,7GBOQIXGT;PQH-M+:6BZGKNI66D65SJ&IS)::1I=M=ZE/;6LFH:[>2QZ
M?HUL90VH7TT5M;[Y'"G\//V=?^"Q]MXS_::\)?#[XP:+X.\-_"3]HO5]:\,?
M &_\&ZK<Z_\ $7X#?$GP;XJU'PEKGP?_ &R_#L7FR_#;Q9\3;Q=#UGX4:OL_
MX1_5;:Z.D/>K>7<"  X7_B%\_P""=6#CQC^U[R#T_:A^*(S[C.N\$]>3W/3M
M$?\ @U^_X)V(-Q\8?MA *"V1^U'\3R1MR>,:]D$XXP#C(YSG']'1N(@P&[.Y
M6<$ E=J<-E_N@Y!QDC/T&:HSZI:!)$#%MVV.-S%.;>665)F6))HD82.! WF)
M$6DB+Q!@#(@(!_*'^U)_P:_?L_\ B?X$>.=%_9"^,7Q_\ _M"7":5+\/_%WQ
M1_:(^,&N>!]*AM]3A&L-JVE0ZU<?;6U&Q\^.SNC$\<<Z*$B;:VSVGP9_P;#?
ML+VG@[PE9^.?B#^U9JWCB+PWHEIXQU30/VGOBS8Z3J_B2'2;:/7KK0;.;7B]
MII.H:I]JN5MKC<T,3*BA550/IC]N'_@J?JGP2^(NC?#?]GO3_A/XSN_#?@N^
M^,GCBX\>^.[/PUI/QB\+>$O%VH^#?'/P'_9\UJ&Z\G6?VB-.O(TU>+PY=20B
MU^R0:5=1I?:A;QR?I=^S9^T5\-_VJO@KX$^/OPLO]0F\$_$#2K>[MK?7M/O=
M!\3Z*UO,;/Q!X=\5:/J44%YI?B?PUJ\5QIFK6;QB6*Y@D0@J-U 'XS?\0OG_
M  3J _Y'']KTX';]J+XH\_3_ (GG]:A/_!L)_P $Y4R7\8_M?$(HD>/_ (:@
M^*9;:#\P.W6V&3C 098>A-?T;"[AS@EPYR0C(R.W\( 5@#R2$7IN?"C+<5\;
M?MG_ +8_@+]C[X,^./B7JT,?B_Q7X1\(ZIXXTKX8Z7JEI;>*]:\/:)<V]EXC
M\5KI4TT>H2>#/!4=V=<\=^(((9;#PQX9M-1U[5Y;;3K">XC /YV?V;_^#7+X
M3^'_ !)^T#<_M-?'3XS>/O!VL_$V_P!7_9R@^&G[0'QBT#5/"'PI:XE?3M!\
M<W,VMQP:QXK%H8S/J2"XCC$<T\LC)C9]?#_@U]_X)U, 1XQ_:]P0#_R=%\4<
MX//)&N$$D=3D@GFOKO\ X)W_ /!0P?M,^+?'O[.WQEO_ (8/^TI\)U.OMXJ^
M"FO2>+O@'\;? M_';+9_$GX'^- )+;4;72H]3LM'\3Z'-/'JWAW5+E;75K6"
M?>J?KVLT8RI8@H2"7!&2,YY/T(]R.,\9 /YQ?^(7S_@G9G'_  F'[80'M^U'
M\3L8S_V'R<=^03GGGI7R?\=O^#7KX0:I\4?V>K_]GOXZ_&GPG\)/#_C'4KK]
MIWP_X\_:)^,6J>+/&G@=H8XM)TOP->Q:W+!H=_9WH=YKUWB67?'^\*J87_K'
M\3^-?"?@S0-4\5>+?$&E>&_#&B6#ZKKGB+6KR'3=$T32X59YM3U?5+IH[/3;
M"!5+37EW-%;PC#2R(IS7X+>,O^"R^B?#[]J6?2O&]EX!M_V3[?XF:C\!M7N=
M&U675_C]X!\2V]IX=U[PW^T3XJ\#:4+K[1^RK\0+;Q+96&C^+M-BNTM+F/\
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M @\.Q3HH6X2P\F.1=J%=@5$_?>HGFBC8*[A6*[L'LH.-Q]!DXSZT ?S=7/\
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M^"=MTQC?Q=^U^HCR5_XRE^*@"*%C7][#+KQ=;F<YDE=55,J00"RU-_Q"^?\
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M&/C_ ,6ZO::5%IFE6VO^)+B59-0TSPMIT1TC0+9T\R'3U5+BYG+KY7M_Q/\
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M(#$ D<D G%/H **** "BBB@ HHHH **** "BBB@ HH_S^?2H)+B&-@DC@%L
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M"L?C1+:G1M>^('[,/@CP_J-]#H?PNU_P2UMI\T'BZ75KF&_CFNM.<B]FE?\
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M:E>_L_\ A#3_  _9VQ^*>O\ V>RDCBT?3KW7K5KO4K:XBNM%5&O197BVT_E
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MM\??B7KGPJ\4_ WQW\"?%GPX^+.B&37O"/B\^']9U5/&?PI\-^,?A5'J&M^
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MY%C'RJJC;P10!'8"*V@,#!H@A=MDKAL@X:5TS^\,1D<_-*2Q)))P<5POQ/\
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M<Z!X$L6/AWX?1^+]8%QK6K^'?!5AH7AM-4GFN;33(6E9F^P+4,J%2@09!55
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M_P +V^M^(KQWEO-5U6.SB1[FYD>60VZ,WDVD3/%#&@8Y^@O\_P#U_7_]9H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-q_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ B8# 2(  A$! Q$!_\0
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MKK6EF33+.WLY]-DB#HQ=)(=I)+%3@4+?QQXF_9^_X*0_M5>.O%WP6_:'\6^
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MV=K'';PK"F54QHN268\L20#\=O\ @GS\&=>^'MQ^UUH?B_X1^)OAG\4OBZ/
M'BC4/B#J/@34M.L/%9\1_ #P'H>I7U[XD:);7Q!XET?QO%XGDU_01+)>V>J"
M>2X0,V:Y[X ?%#XW?L]_L]>%?V2[_P#9$^*?C;XU> O'FJ>%+>6;P%J$OP#\
M5^%]7^)MYXJM/C5?_$FSM1X;TVRB\/ZDVJW6DM<QZK'XF@N[2?<=BI^YD]C9
MW41@N;6WG@*QJ89H8Y(RL3;HE*.I4K&WS(",*>1@TLUG:7,?E7%M!/'NC?RY
M8DD3?"VZ)MK C=&WS(V,J>00: /YL_$7[''Q%\+I\4/CMX1^!7B:^_:1O_\
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M[3JS:C==K7OIJS^$K_@H!^T1^VC\7?\ @X8_8L^">O? GPGJWQ _9UU(:?\
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MZ2:Y+.SA&STLGH6Z*A,Z [2&S]!V&<]>F.:8]U%&K.^Y47;\Y'RDL2 ."3U
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M+=KJEZD5)*,)2=-U5&+;I1^*HE;W%JM7TU6QB[XIX9@-L8"$G><K[$DXP.H
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MUW1117^CA_FH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOJJVK>'?!6A0R?V+X&MIENI-(F;EM>U>2$LNIW.HGYY[>(-);<@A0,5]9?\
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MU& .\[H0SEV&7E15R!,^3O8<L<$\U]C?\$B?V]/B)^P?^U%H'PWU&TU+Q?\
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MM\EH^RE[JJ^[I=?SCZ) K_#Z\C+J87B^S@,3O=9X@K97IE0QX'![^E?T"?\
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MU6/5]+M9].FTF,DRRWL5PT$47SR.!D#_ $R/,FEB#QA'1E&8Y$#$*>0%*@X
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ME5J0JTE[&,DE!Q<W_$!X+.+9(UYE6, @YZA23SVP0,\<CUQ7WS_P2BLUN_\
M@I%^S;NEDC,OC.&XF,9*F2<VD(9VYR$<Y)B!V')'3BO@7P:O^CI(/]8R D]L
ME><\YYZXZ<_G^@W_  27_P"4D?[-7_8VP?\ I-%7YEP74E_K1@(.5W3S/&3]
MU1=%3GB:;DZ4G%RDFUUE*WNVM?7^O?&^*H?1MXVPD/J\*7^IG$N8.G@\PI9A
MAUB.?$JG5AB(T*>(I5^6I46)HO$RHRE*WU>*@D?Z'-I&88;>/>6*P(C':J!R
MJ[=Y11M4G&<#@9X[5K0+MB !SRQY]V)K/B4E$8?PHO'<YR!6C"<QJ?\ >_\
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M+?B9X;^,W@^\\%^!KK3!XPO+G[?IMWX>GUJ>.UTB/7=-OEMKV/[;//"EG=-
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M,P^9F(W \8/3G%4/^&3OV=/^B1>#?_!?%_A0![1_PEWA7_H:O#__ (.=)_\
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MJC_A+O"O_0U>'_\ P<Z3_P#)5>+_ /#)W[.G_1(O!O\ X+XO\*/^&3OV=/\
MHD7@W_P7Q?X4 >T?\)=X5_Z&KP__ .#G2?\ Y*H_X2[PK_T-7A__ ,'.D_\
MR57B_P#PR=^SI_T2+P;_ ."^+_"C_AD[]G3_ *)%X-_\%\7^% 'M'_"7>%?^
MAJ\/_P#@YTG_ .2J\S^)WQQ^&'PUTJTU_P 6^,=$T_1Y+I+-=6%_97=MIMY*
MP$=Q=Q6TSR&(!DSN&P $D@FL/_AD[]G3_HD7@W_P7Q?X5YY\2_V&_P!GWQ_H
M$7AR/P-H_AJTEO8Y]3N- MX[.^O+%<"2S>Y4;E@?!W+TY)/6@#Z<\/ZSH?B;
M1;#6_#^M:?KVEW\$=_#K&DW$-Q87ZSQAA/"\3R!=XP3$2I7N V:MZEJ%K:V,
M\TY!CC4@!BL8=D4O\SR'8H559V9L+\ISZCA_ 'PV\"?![PGI7@'X?>'[3P]X
M;TY!%;:?:J<O@8-W--DF5IL98DYR#R!7D/[7GA[Q?K_[/OQ$TSP#=W%EXGGT
MJ5]-DM03<.$4BYMH>I,DL)<#&2<"O)S;%U,NR_,<X>'EB5E&%K5J&%A)QEB6
MJ,JL[SC&<J;C+W5RPFVE=*[1T95EU',,^RK*\2X87"9[BZ.'Q&8SJ.V&4:E.
MCS>P]V-1<KV=2";M=J/,U^-_[>/[8=Y\5/$U_P#!CX;ZU<S>"](U!AXF\0Z<
MTD3>*-8C0*^F6[Q-LCL]-*/!*4&R=USECR?B70;.VT+2UN[B O(=QL[5EPZR
M$$R2/(P!+;@22>2>_/%#PSX7FT24?;H+FSBTV46MPUT-E[<7<:L5-Z" ?+,[
M7)4$<L!R*Z?2M!\3?%GQKH_@#PC87.H:EJ;Q1B6)2T5G&\R1"ZEZKY5OO\QR
M?X(SGW_Q0X\XSSGQ:\0\WP$WF>84\;F,\#A,CE2KVRS&.K>G"#?-*K0A"<).
MM*A2]_F3ZL_VOX2X3X*\.N \IR_ U*6&R3*<+#.,US&ECH8)9MC845&IC,5*
MG*SJSHTX4OJJK5(JE""6BBC1^%_PI\9_M&_$C3?!?A6-Y+,R17WB;6?G6T\-
MZ#;_ /'\Q?:8O.DQ]PL&8?PL>O\ 3;\(?@UX8^"_@#0/!/A.QCAT;38Q,3%
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M>?%W_L9?!O\ Z73U_"U\'_\ D5[[_KBW_H"U_=+_ ,'#?_*+SXN_]C+X-_\
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M9;RO\OC3/^1MU_\ [#NL?^G'4*_U!_C5_P DK^('_8F^)_\ TRWE?Y?&F?\
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MPMZD%;#<KO**M*4K1B]=).VB>KL?JS_P;\_\I2--_P"R3_$+_P!'Z!7ZQ_\
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MPG3C7_UFX-J>QE.,G%5>2G4G[-M2Y83E:T7;_/>\%_\ 'DG_ %S_ *U^@_\
MP2=_Y2/_ +-__8TQ_P#I''7Y[>"WC^PHS2PH@M_-9WFCC1(P>6D9V41_[KE6
M)X SQ7Z#_P#!*!Q'_P %'?V<6<.JQ^+8(I6*.%ADDLXBB3L5 A8Y'$NPC(R!
M7Y+PE6I5..\'*G5ISBY9?23A.,DZE'#Y?3JP33:YZ4X2A4CO"491DDTS^_\
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MDOI02,"WW\[: /J 2Q%!()$*'&'# J<G P0<')X&.IIC75LIPT\*D0M<8:1
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M!6&2/,#,;#Z5!(69I)@\D0AE=)&B>4"1)"[M'M)D.S8)!AE1F52 3D _ /\
M9L_8&^)=CJ?[(7_"]?A#X:UC0?A;\4?VI/%WC2R\0WVD>(M-T@?$+P+JFB^%
M=?&F7*3V&J7>HW%R8YI9+>0QR%;M<31QNOZ/?\$YO@WXR^ W[,/@;X8^/= L
MO#GB/PW)XBB;1;&\M[NTT72;O6Y;K1+"S\G/DVTU@R7'D(1%$RA-H8 #[=AT
MFVMY99H6D1YI#*[;MS-(4:/=*S9:?:C$1K,76/)V!:O10B+(#LP(4 .=Q&!@
MY8_,V>N7+$= 0.* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JA<6*7,_
MF2?,A@\EHF>8QL-[/DP^9]G).<&0Q>=MX60  5?HH ^"_CS\ _VK_%'B3_A)
M/@5^V'>?!>,QV\%OX N?A)\.O%GP[-K;OOU.ZO'OO#Y\:OJ][$X6*XB\4PVL
M3H"UI(F(Q\Q?M2_LXZ+:?'O_ ()V?%/4_#%GXZ^+_A?XY^'=%\>_&"'0K>TO
MK;2['PTUK?ZBD5A%%:^%],U"[53(-/2S58F2*]EG49/[%31&4 9&T!MR'^/(
MX!;!*@$9. <\5E/I]QDNJ0,K_O)+:1F^9I04N8EF4J0DD>P$.LD3E1OB;"[0
M#^=KX:SS> _VM?#^A?LN>,/VEYOB?XZ_:Z^*FN?M'_!/XF:%8+\,],^%.HR2
MIXR\:6&J6VBV=K8Z)/)9^#KWX?Z];WDOB'4[:^N[?[<L4=TLVK^UKH?[1&C?
M\%!/'7Q.T"R\6C]DKPYX&_9EOOVC=$\'V>IZ9X_\>6K>-?BWHVEOX+\4Z=<I
MJ;67@2XO]'OO&_AG27MY-2TC61-)/$L#^;^_UMX:^QR#[*_DVSHJS6[.9"_D
M&1;4F;"2E;:!D@LH%=+>V17+12E@5TY;2]$D;PL"_E>6)97C9[1 $WI%^Y#2
M-=.%>>1FP!$%1 [+(@!_+9X'\>>%/&7['GQ:_8<T+X>_$/Q;^T1\0_VJ_&FK
M> ?#*?#R_A/A#1C\8-,\;>&_B??Z[J$"6.F:)I/ANQEO$\1?:I-3:.5;&5I"
M)&.[^S7XQ^*VH?MU_ .1H/B+HVJ:A\0OBQX&_: \-:IK_P 4O&M_/X9\,?#Z
M8^'/$'Q"?6M>7X8>%-#U;Q/X:L[OPVOACPG;7LUM-&EQ=RO([M_3H]A>& H+
MB1V,@RAD0((G8><D8:.1#AAYRM<K<2[2T'F ,S%+BQO)$52SRB.9451/%%YD
M"QLGG,3;2+!+B22/;:);ETQO<@XH U;-_,M87RQW(""ZJC8).!M0*H4# 3 &
M5"GJ:LU7M8Y(;>**5S)(B[6<A03@G;G:JJ<+A<A1G&3R35B@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-q_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D E@# 2(  A$! Q$!_\0
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M[QIX(AUR41%K_2K">VU2"WN3#''$=1T&WO%T&\(0%9[*5<_>)^N1*$78/F4
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M^ /V1_VC[*V^ &B7'PCT;1[;PU^T1=_&B+QI<^/O#>HZWX3\$W/Q4UCQ9>^
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MG3G.E"TJBC>3=--.:5F]X7UM][/R9\(_\%G_ -@/QO\ $'P_\+=%^)WBN_\
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M=\/[,&B-H5M=/<6)TTM%J+73I+%/M-M:S#,@_C%M/!?_  66'[;</B.+PO\
M'T^-XOV@GNUT[^V/&\G[/TFL#4\6MA+=->R0VO@$O^\6X:V$OV$[S:;\QC_1
MS-H&.6<L>?F9$WD%0"&D4(S'<-X;@Y]A1]E W;2%8DL&"G ;^$L/,RQ!Y)!4
MDG.1S7VW#O&;X;P^(P\<EP&:K%PE3<\52@YT.;F][FGK**YKQ45=6>FJ/T+A
M'Q!GPI@L9@/]4^%L[CBJ=2,<9FN'KSQM)U7)OFG"\91IMI4E%1:@K-MGYB_L
M0:A_P4]N_%/C=OVZ_#W[.7AWP>FD:>G@*S^"^L^(=9\03:V+Z:;4D\07.J0V
MUK'8PP.([9H[<S%]PF' >HOVA/V9_CGXV^/&L?$?X>S?#[Q!I>M_#C3= \'Z
M_P"/_%'C/3)/@/XGT&#6H[S^P/#W@W4[.U\2VOQ$34;*UN+VXDLGT^2&1[]=
M0B2-&_3L6*@$._F9.[+(,J>2=CY\T GJ&>1.VWK5@6>?+(<* #G8I1RAVE(P
MR,JA,C$J[") ?X#S7RF88I8O%O$QPM&'/4E4E&C%4Z4')WY:<&[Q@M5&-W;O
MK<^,S#'+,*];$/"87!SK5)U)4L'!PPL'.3;AAX2;G&E'104I<R5UV1^ ?PW_
M ."87QRU'2(H/C5XHT"[CT7Q4NH>$_"FB>._%5OI'@SPYJGBO2_$7B?388](
MN+'[1)K-E;ZGH21I>QI_9UW$)6+O*B_:LO[(OC/4/V4?AQ\#/$5YX0U[QS\,
M_B'I?B_PUKWB5[O7++0['1OBEJ'BO0SH]YJ$(U*"?P_X.FLO#.E7,L9GCDCD
M):18XFN?TLDM5<##%2"#@EC$Q!!R\:NH<C'R[B=N .1Q0UL&;=OP2 &;:GF$
M @@*^,HHQC !ZG!6N<X#\<O@M^P;\;OAC\8_B-JFE_&&;X:^!=:\5?$#6[;Q
M+X9U"#Q9XF^)MO\ $7QU%X[FL_$WASQ-9SZ!X0&F";4="=M$MH)Y[8VUY;WG
MGO,J>%:]_P $R?VG_$?_  N72_&GQ:\(_$+X=>)M&\0V/@OX<:[JGC$:;+-X
M-U*V?X#VFHN;DVUG=Z3HE[XDT_QEJ-E!#_:MU?6LLK7L<*M%_0%]E3KD G)<
MJO+MSM9MQ8,5SC+!C_=*@D%#9PE67:N'!60%5*R*PPRL,#Y7'# 8)  R* /R
M?^)'[%OB+7]1^+?BO3?AC\#_ !9!\4/A;\"-"UCX6>+9=1T?0_$?C#X97=S>
MZI+KGB/21'J/F:7YMM%H%[)+<)Y5C;QO)&5J&P_99_:6\-_LT?\ "NE^(VA_
M%_6;SPW+X8OOA5XMU.3PUX3\)Z9K,=_;ZGI?P^^*5I87?C^+5],MKZ*'3/$E
M_?S0FPL&L[>P6&]81_K,+2/"KQA$9$P -H*[ NWE&15P$617V@#D]F"Q0*J!
MB44!%C;>T84$$,$\P*)E(^250NT?*%"C% 'Y%_#G]C/X\^'/&_P3M_$&M_#F
M?PK\"_@EKOPYT/Q_X?FU72=?\6?\)-\/+;PI>:%KGA.+S-'M+C3M=M(;VP^(
M<9EUB/3H/(C5FF>)?#+']E/]J#4?A5I%K\.;#P_X%U'QU\#/AG\#_B'>^)=5
MN_#/C?X2>./@7XLUM[[Q]X8=;2^M?B#X'\>SZAJ6LWGAUUL+O5;B72;^^D2X
M$T4'[TM: @ 2L"HVAMD9D YQARN2?4.'0]-G3##81F1)2Y,B!@7*1[GW"/=G
M:JA=TD2R.L81&.05P3D _(S]I+]BOXQ?$?1?VB[GPM>^%-<U+XG^)_V</%7A
M^T77M1\ 7NJS_!"%]1U=+CQ1I]G?W&C:CXJU8B2#4((;K^S9'$JNDT29D^!W
M[*/[1_P8^#/BFUT?Q?X2&IZ[XE\9^,+']F_7)QX@\!6;>-M8@U*^TS6_B_-%
M=^.=;\<A6O!#XUNI1##?W%N\-G&L09?UONHD6,D[ JIU=%VQQH5:3&,$;P <
MY.,< @U^9_\ P4B^,?[6'[/'P5U;XV_LT:)\&O%.B_#3P_XH\8?$[0?BQ<>)
M;>^U#0-%LFU"V'@VX\.12VD5U$$::4:F%CDCB;)$FS.V$PTL;BZ.%A4Y:E5V
MA%M1C)Z[SDU!=M9+H=F5X*IF694,O@X0EB4X49U*M.C"5;5\GM*C4(NUFG)I
M-M*_4^,_A[_P3.^//@?Q)X-OH?%'@5!=>'H&\5W-_P")?$>H6OP_TVWA\3PW
M/PH&C(UG!\2O"WB2WUZ.+Q!XLOWTG6I;^.>XF+*+=Y-+3O\ @GG\?M-TC5#H
M-E\'?!.C>-M%UCX1W7P?@UOQ!XI\"_!'X:>(XO#D>I>/?AW?ZE%=W%SXAFN?
M"\_B.W\.1_V;"]]?6%DVIQ?8Y)IOO/\ 88\=_M3?$OX*Z+\0_P!J6R^#D'B#
MQO8>'O&/@&V^#B^*AHMGX)\4Z!8Z]86WB9_$2QO)KJ+J*+.MNR:=.V<284"M
M#]KK]N/]G?\ 8H\&+XN^.GC>UTS5[Y4MO"O@+0T.O_$3QYJ\\DT>G:+X1\':
M5'?W^KW<UPC6]M/;P)964T@,MSE91'M4P=?Z_++80=:<)1IJ5.]2CSRMS)UD
ME224G:3E-1BU*[LKC_LO%4\QJY?3C+$UZ=9TG.#YJ?/&;A).M_"4827)S.:A
M97YK:GD_@+QG>?LF_LQ?M,_'GXAZ#XAA\(^&_&?Q:^+>D>$9(H%\0_\ "#Z%
M/+'9W,<=RP9-2\3)H\FNQJ9OLYDU:$O+"QG2#\%O^"8/_!<#]CWX4']J#1_C
M"OC;X8GXP?M'_$/X_>%/[1T.]\0+-H'Q"ELI[+1[^31VN[FUU33[@/;7RS62
M62R8\J\DP0/O0?!C]NS_ (*V72ZM^TT_B7]B/]A74D,^C?LX^$;Z*/XY_'+2
MK]%CMC\;O$8:)?"VC76GB*:X\)V"2S6[M'%.WGB4)PW_  1*_8'_ &:OAEKW
M[:'C;1O!<OB#5/#?[1_Q1_9[T:3QW=IXPMX/A]X%UB"XT8PVFL6*^1JLR2Q1
M7EWY2RS-'O*#S"@^^RW"\+93P_FU+B"G4S''TI\_U3 5G2]C!3:C!XN-\-*4
M7S<SIRDFEJY-WC^H93@^#<JX2S^AQ+0J9GG<*RJ4\%E]5P]E3=22C&6,@Y82
M4U+F<^2<KKW6Y-I1].G_ ."^OP:\0^3:? S]D/\ ;/\ C9=""XU*>72O@QJG
MAK28=$@C>2#5HM9U[=:WMO=,NVU@@<W$K[0T29X@7_@HE_P5Q^**0O\ !?\
MX).:UX/T]=+FUP:Q\>_BS8Z'!>6LS&'3?[(L]%A:6'4FBD2:;3KY(5QNB,H+
M$U_0!I&A:5I$5I:Z9I>FZ7:QI);+;V-A:VL"6D*$Q6R10QI''#&3\J*HVD#U
MJ[<QIM,MPX$-KOFF!CC%L<*<.P*R/$J*1YKK(5$>YB$X(^5CFV44YQCE_#LJ
M%)RA>&/Q,,5)ZK1>RFE&^VC:L[M733^-AF_#.6MK*.#,J5.3CSSQV*QV+J02
M:;E2C)QASK>*=H.27,FC_.L_85T3]O&\_P""O?PLU+XC:'\<M,\=Q?'R'Q!\
M;-(EOM?FTSPYX"U/5O$%S;Z?JDMQ.PO/A\LEQ?0>&G>$6A"P+'L61RO^C'!N
M!"N0S*(E9U "NV0S,,=>6P20#D$XYK\0O@[XX\))_P %C_VI[B'Q1X6GT_4O
MV5?@)I$-U#XHT9X[G7+?Q+XJB?3(E2\9Y=0M8Y(WMK:UD>=S<F":-6V25^W=
MG'+R)#M7,?E1K'L1$+;PN#EO,0,J2!NCJ1Q@Y]GCW.X9WB\HG3RJEE-/"Y?1
MI15&4)+%3]G[SER>\E%)M*HD]-5%N*?TOBEQ++B/,LEK0RK!9/1P^28.BJ>$
MIPMB9>SBY.3IQBX*+BFO:*+:]U)-J+VJ***^&/R\**** "BBB@ HHHH 0G )
M] 3QUXJK,P,6T?Q_-D] 'W-SSG.,_P"-6FZ'Z'^54V&Z-23@*B^YP$.?3^][
M]/?@>S]'^0'P+_P45_8<\'_\%#OV3/B)^S#XL\3:CX+E\57.@Z]X-\=Z9:&_
MO?!/Q!\&W)\1>"_%*67GV@O$TK5H%EG@CND::#,6[#D+^#'B[_@G;_P<,?M(
M>![S]BW]IG]NO]F[3/V/]4TBS\)?$/XO?#CP:UO\;?B)\/-.DL[>?0IX'TV.
M?2]1\2:;;O#?W,E]'$\<TBS32 R(?W"_X*<?M,?'O]C[]F&\_:,^ ?P5NOV@
M;KX<>//!NL_%CX=Z6SGQ+>_ ZWF>+XCZQX3CCC,LFM:+HTC7-O!':2232;E5
MXP"S?F!^T#_P<2?!'Q3X(^&7@K_@FGX%\3?MP_M=_'/PQI^L^!_A)X1TG4+;
M1_A+-K=E,UIJ/QV\0"W:ST*?PQ=1O!=>%KBXCN;E[:8W=U9P1F0X8;]VXJEK
M!M7>UD[+9Z["EJFNZ9^U=OX"NOV4OV4],^'?[-GPPE^(-[\#/A!IGA#X1?"V
MYUBUT*/Q/)X1TG^R] T2_P#$EU:W<%E'=L4N;^6W@FN2GGQPDL4)_%NP_P""
MQ?[4MK+\0OV;;_\ 9T^ VI?MOZ#^TMX"_9H\(IX2^*/B'5_V7[[Q=XZ^&VL_
M%;4;'6O&+6EQXJM/%'P]T70-0T3QEHE@)95U>\L9K1/LT%S"?UATOPQ^V7\1
M/V%;3PMXC\9>"OA/^V[XT^"LFEZYX]T_27U'P3\-/BQXBL9H-2UFQLK&:6ZN
M7\/O-<)916U[-"MW912B7=L6OR+^#G_!&C]J;X5?LQ_"OX::3\:/V==+^/O[
M,_[0EC^U!\)OC'H_@SQWK=M\6?BWXAT'Q-X8^*?B/]HVS\37,-UXCU7Q+I?B
M)FT?4=(<II5S;P1R)+#&J#2?\5=O>[=F"_A./VGRZ>CUUV/J_P 5_P#!13X,
M_&W_ ()3>+?VB/BOK_@[]GB_^-/PD^/?PYM/"'C#QEI:V\WQ2\(6GBSP3XB\
M,^&M7E-I'K_VC6=(N;S2O(@2Y?3+FV-Q!'<I.HO?\&\<;#_@C+^PC$L<B%_A
MAJI99!AA_P 5UXA 8 9^5T/F(W!*D-W%<O\ %?\ X)9?LV>!O^"5.J?L\?'+
MP9X:_:/N_P!GGX7_ !P^+.B^*O'FCR+*OQB\3Z=XJ\7>(O&>DVD-VD>EDZMJ
MES;:=;(9EBL(+1VWNKK76?\ !N^TS?\ !&G]A%I7+.WPQU7&"'*I_P )UXA$
M<;$8V"-%6.-"#MA"#)P,V]4X])*S]#/D=G%[25GKTZGW3^U1^P_^SA^V+I'A
MC0/VC?AEHWQ+TGP3JUYKOA.#4;G4K5M)U+4K:.UOI<V%S;B93$BF-)"R9R=B
MDEF_$#XW_P#!L1^RC\3/BI)XZ^'?Q1\>? _P7)!X<C;X2^#--T6\\+A]$BMH
MKZ6&[U.WFU.W?71 ZWK)<$Q+(3%Z'^H?RQ(@+8+%?O8&>><8]@<=LX_"J7V0
MC& 1C_84]1@X);/^/<<FO9RKB/.\E:_LK&?5%%.+NG)34ENK1G:RNM;7YF['
MU>2<9\2<,1<<BS3&Y?&<7&K#"QP\HU=&HN:Q%[."E)1Y.DI-ZNQ^9_[/7_!)
MW]A?]FCXC>&OBU\)/@9H>@?$WPO8WMOI'C*.[U:6:*:]M8[6]NY;>74&ANII
MHED=Q+&V)G_<H!EA^CK7$%G'&T]S';0L8+>)IIX+=7F5'(A5+B2,_:9B6DDC
M#L5 5CE1N%NXMVBA/EDQK@QCJK)YJ-&S1/O(2;Y@8G*D*_.ULFOA?]L+X!?$
M#XSZE\(]>\'V_@3Q;I?@;6]1.L_#GXG:YXH\-^%]5OM8^QPZ=XT6\\)S0WU_
MXC\&2VI33M&N0MKK)OYB+B&2W6)_.Q6+Q>.KSQ6-KO$XBJ^:=1Q<7JVU'6U[
M.3ULKWVT/%Q^8X_-<54QN98W$8_%57>5?$JFJJC>3C3M2]SEBY2:MK[SUT5O
MMQ];TM3.K:C9L+9H;2\8WMGML;F[SY$-P?M&$DDS'MC&YVWA@I57*<_XI\;>
M$/"'@_7/'GBGQ/HWASP?X6TR_P!6\2>)=5OK--&T;2])@DGU*]O[MYC#:160
MC*W+JQEC<KE,8-?B?H?_  37^/OB3Q[XWU[XR>,_AG>> M?NI;NZ\&>%?$7Q
M&TS3M2UBVC\<VGAGQ7<POJ9N])O4C\4:'*UJ;O8X\/H7BC:7]S]B?L[?L=ZW
M\(_@G\;/A'XAUSPYXC\-_$W1[&T\,Z.UUJ?BGP_I%Y/\-=&\&>+=4OAXI%XU
M[#?^)K.\UJ^1&F2>VD>X:U\\A9.<XSZ6T_\ :2^"VH^+? GA'3O'-IJ'B;XE
M^$[+Q5X.L=/@OKZSUWPYJ\"7/A_49]3AMFLM-EUR*3SM&MM2GM;K4[>.2YLX
MI;9#+7MRWEO&EY-)=11PQ+(6E,T:P6T5J2E]+/,SB.%;11YETK-YL$)666-0
M5)_(2T_X)\_&G1/C#\/_ !EX>\>^'_!D ^'GP(\.>*O&GAO7M:36/A_J'P4\
M#7?@HZ%\// UW;2>&-7\.^.8[I-1OIM72WNM,OH5EM@\3&VC@\:_\$\_VA_%
M7QYTSQM:_M%/>_":RU#PVNL>']=N?$-EXA\=:1XGTV>S^/LVKQ:2Z:19ZAXP
MOK+0CX3BBM3;Z790W\*O&D@D !^EUS^T+\#]/U7PQHS_ !2\(RZOXM\+>*?'
M/ABQM==M[V?6_!_@F%Y?%/B6PCMVE\[2=%19!>W?"1R(R9W  TO _P"TG\'?
MB;\*]2^-W@[QI!JGPHT&WU>ZU#QK]@U.TTP66CPO-J&H6@N[2"XO[2,(5C>T
MAG:Y=E6W63<#7P[\/?V%_$_@_P  ?LY^'1I7P;T36O@1\.?CG\--02WL]1UG
M2=5T7XBPZE:^'[&">[M8]732=;AO89O&=C-J#%9UD2P^TIMN4=\ ?V0?VA/A
M+X.\:2Z1XZ\!?"MM2U*XOO!/[,/A>RF\;?L\^&DM_!>G>&[33)]1\101^)HM
M!UW6=.F\6:GI]BMI%IUU?O90F8P1WK 'U7I7[97[-NLKX%N]/^+&E+%\1M6N
M=!\*":TU6W>]UB"\&GR:=>+-9+_8]S]M=+:)=5-F+B62..#S'=<]-\0OVH?@
M3\+EU!/&OQ(T_3+CP]K=MX<UBP@@OM2U.UUW4=(76;?2O[+TVVNK^6]M],D@
MU'4(H;>5M-L[B&YO?L\+B0?FUI7[#/[2\?@WPEX&EN_@SH&E:A^T)8?M ZT+
M'7_%VK>(_@SXEL?&FF>*Y=+\%>)-3TR!_B?X<\0"VU%A;>,X4DT1-3CTZV^T
M0VD#UTNJ?LU?'9OBY\3_ !_X"M]#N_&?A7XW_$GQ=H<'Q!N-3\,>&_B#\/OC
MO\.?#WA2\O\ 1/&>BV&M:AX3\4>"+K3K[3]+EMM.O+F.&!$D,,<R!0#Z]N_V
M[OV6+'Q;X=\"77Q:23Q/XH\*2^-=!BM="\0SZ7J_A2UTV35+GQ#::\FF'13I
MT%I$WGO)?)+#/MMY8EF8*?6O@=^TO\%?V@;+7)_A#XYM?%\?AU=+EUV'[#JN
MDZEIUMKM@-1TB]FT_6+.QN_L>HV6+BTNTA:&9/F5B,$_$OA3]CCXRZ7X9\ :
M=XI\:^'/$FK^&/V5/CC\#[S4]0EN3='Q)\3]3;4]&ABUI;2UO[_0_#>F0:;I
M$^O31V]_<RVDUXD,!NWB3@?V+?V%?CS\#M8N_$/B3XD6/PFM;C1_A1I&L^#_
M  )XCU?XKR^.A\+_  VNBRZEXC\6>.H[:YT#1M7MXMT7AC0[-H+6*7RXKV<(
MI< _9>!?E!+!\_,I'H<'./\ ZPQDXX(JQ698RM)YC%>!CRSG 9&(^8 C"@#'
M R!C&>M7)7."H&1M!R#T(.<9X]/8\Y]J/Z[!UM_PWWE74" H!/) 4#(&6+ @
M') QA6/)'W3WXK\=?V*I%A_X*0?\%6&97*GQ=^S_ + B-*SK_P *SF!:-45B
MP!)5L99#@NH4AC^L'C#6I-&T77=4$'VAM%T'5-9^S><\(NFTW3[N^CM3*F70
M3S011ED$IVG_ %14$K_"5^R]_P %A/VJ_BY^UM^T;;?LJ?LQ^ 1^T!^VKXAT
M./PO8>-_'=_+X>\!W/PP\,7N@7?B#4[=M.MIM8MX-/LYM72ULOL2F6/[-<Y0
MQRO];PUP_F&=83/98*$?9X?"4Y8NM*M1HQITXSYN92JS@IN,(R;C!N2LE97N
MOO.#.%<RXDPG$?U)4U1PF I3KUJF(I8>G3BJBG-\]6<%+EIQG-J+<O=6BOS1
M_MP^,_QT^$/P#\(WGQ$^-7Q(\+?#CP3I%FUS>ZKXIUFSTRVD$:LS1VRSRI-=
MSJB\V]HLLQRH5"Q('\_WB_\ X*<_MA?\%"/%FL?"#_@DC\,I=-\"VJSV/BO]
MLSXT:#?:5\/M%@FG^S7$WPXTJXA>[\27HB\XVDZJP-Q&#Y<'*CNO@S_P1$UO
MXR>,M&^/'_!4OX\^)/VO/BK#=V^OZ=\*?M6HZ5^S_P"!M0\J)FL].\'_ &M8
M-5BMW\R-8YXEA "L9)B=H_??PKX,\)_#_P /Z;X4\%^&M$\(^'-(@2UTO2/#
M>F6NEZ786\4?EPQVNGVT*V\1B7[A"YW ,Q8DFN95,GR2+6&2SK%S@E.I.$Z=
M+"U+VDH>V455<+?%"3A?X;W=N>B^'>$U*>&DL\Q]2[JU<73J5,#A:B]VU"E-
M-U8QY$TXKV;E=QC)/7^,[Q3_ ,$3+T?\%*?V9O WQN_:U^+GQ:^)7Q2\,ZY^
MT3X^^)=[H'A]$?Q7\&M>\+74/A;3+:YMKFZ@T#4[J67[")GFETNU01E]RKG^
MUG3]D4D8W%A#';IL8H9 'C&UG1>4^X<A]G)R 0*_'+XP_P#!)76_BU^T3<?M
M'P?M_?M;^!_&L1UJR\%IX:O_  L+?X<>$O$LT<^L>"_"DMQIY,&CW;111L;R
M"ZN!%'&)'D=2Q_7_ ,*:,VD:%IFDRZQJ>NRZ1IME8RZQK1BFU;57L8EC:^U&
M>&.%9KJ=@9&.P(K.2 PR*7$.<ULYHY3&6+=1X2@H5::IRA[-I:Q3<4FN54Z:
M46TE3O?WKFG&7$M;B##9'%9E1QOU3)7A:M-82M0CAZ\L4ZJI1]K2@I15&2C%
MP<J<%",4TT=;:@B(Y[NQ'TX']*LU#!_JQ_O-[]S4U?.'PX4444 %%%% !111
M0 57N!_J^O#$\?[C#GU&"?QQ]*L5%*BL!N&<'W';V(I-730F[*[/QK_X+,_
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MW4HXBBH2K8:O2I5/X5:<+4JC5KJ$K:M76U]&GHM3H+X,T+J-HW (&+%1EFC
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MF"$J[@;Y0-FP.Y&X_+L#$E5 .*M44 5/L=N"^5!WMO8':1N\M8E(4C"[8U
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MHO+O8/A9X OYUT_QA\6O%5NL\,UI8:-HUS=3V/F(B2S.H5BP7/P__P $@_\
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M^"^P$?\ P1N_;V7/3X&:P..<9OM-QD\=1S[ @5]G?\$]/^3$/V.O^S:?@O\
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MFV^K6SQ_!GX#I<9O3X2^#_@61YM.LCHD3QP3^)KZVEU#4;F-KF"6)6P?3?\
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M(R$0$<>AX-3U1L0 LJY&X2 2!5" 2!%#D1\F,.P+A69B=V[)SFKC.JY+' 4
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MS-.(L/GU6CDKJ4<-EOUM8K$UU0C1FJE/FDU**4U&'M&X)-Q233NS^L/]L_\
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M4;R9V-U))X?\C6)R$E$Q=RV5&3^M27RVZ:)[^OKVN*6S]&?T$?\ !#_]J_\
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M\&_LD? O]I/]M'6=)@L='M]4^%/PSU?3O"6KZN";&WCLM<N[&'2WBU-;=[J
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M^2_-**492O=Q23;22&M+VTNK.VEUO9VM=7;=G=:O35WH+:QQQLI12@V!01T
M;!'4G&"!DG-:,*JL:!5"@JI.!CD@4U8 N<LQ!QW!Z9]1C'/IUJ55"C )/.>3
MGK^5$8P@K0C&"5[*$5!:N[TBHK5ZO35ZN[U#;162[))+\+#J***Z(_#'T_S
M****H HHHH **** "BBB@ HHHH **** "JD@S$X]9)A@]#]_K[9JW5.?I,1D
M_NT(V\DG?D[0",MQD8Y)I/9^C_)@?#_[=7PW_:X^*'P'OO#/[%7Q*^%OPK^.
MTWB3PI>VOB[XP>"+7Q[X.C\+Z5?S-KNGOX>O;2_@-],LCBSOOLC/'YDFR0%@
M5_FY_:3D_P""RG['NB^'];_:E_X*I?\ !+#X&6'C"\ETWPM-XT^!D-FVLWR
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MAO"D,YM9O$:^'5F_M)M$ANU-J^I"%K,7(>%9FD214P)?^#KWX/6D7Q2GO/\
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M'*B,/J>LVYA ^X2&X*@G(+88J#_%C*@':0V#P00#0!^0?P,\%_\ !+[X=_\
M!3/XN^&_V=?#7@7PK^W'>? \:O\ &?2_AE'+;:?I?@B7Q8;R1O&>G:2P\-Z5
MXYU'7;^*:_6ZC;6)[;[&]RD>(:_8&$236\;>:X)4YSL8L2",OE<$$$\8P.#R
M0#7XG^ _V.K[X3_\%I/%/[0GPX^"D'A/X+_$3]CS6X?B!\4=)M+&SL_&7QWU
M;XFQZG<OKUX)GU/5O$5SH(8_OXH[.WM8$,(#*0W[96FY(HD.&#(6##' &  <
M$@]>OJ>.^ #@F^$WPX7XC/\ %]/ _A@?%67PY'X/D^(B:+8_\)D_A6*<W*:
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ML[@.I8QS*00T7!-?QX>)/V.?VU=!\1:W^U];?LH_$;Q1<_M-P?\ !1'X?1?
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M2%8&"K&6VL/TUH \A\+?!;X6> #X^E\%?#_PEX3;XIZ_=^*/B2?#^@:?I/\
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M81?W>G64H62&VEF:-64;5'->'_L+_!?Q1^SS^QU^S%\"O&U_::CXR^$OP0\
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M?'-[=_#S6_%UU#<3Z?XA^%/Q(M;3[)>^&?&MM-HM]H>NWRR):6]VT3*)P[
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M0 L1D6,@']%,<8M9)@T\8B=PQ@"NA^53@.4(W\??!)#DY?)K0MFC :50(68
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M+Z:T^PZ#X(T#7Q8Z9X6DTX%ETR)Y45-Y2IE+E5[7U2^]V _O,GD,TOE(@
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M2Q)/4DY.<?\ UC^I/.:GH+()PA #@$D.%R<8R "1WS@D9&" 2 <FJ,MJYCF
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MPU/Q9I,WA^^\5_%*>Y;38M6N3I5PSBP$5RBW* HZIE9/"Y_^"&G[?8^!LO\
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-q_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? E@# 2(  A$! Q$!_\0
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MONI;>3Q;J,OAH-JWV73E5IKDZ>K3JB[E63&QOU!\6Q^:="CS(-_B"W!,3!)
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M9;1ZEX"\J#0?#%];3&7=HT%O!'&@@7S%BQDYYH XC]M']J#]LKX/>/[+PY\
M_P!GOX67_P +=+\ Z[X\^)W[4/[1?Q</PY^!_@M='G:"U\%)966=:G\3ZFNV
M0WMP/[)5&$BAP-M=!_P3)_;;U_\ X*%?LO6/Q^\1_"#6/@U=S>-/&_@^VLY=
M6FU[PMXT3PUJITFW^('PXU75=-T6ZUSP#KC_ +[PO>ZAI*+>1!2K,,D>5?\
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MC_2_A/)=6-Q=_P!B>)]>DU/3=+3Q+8Z<!=7WAS1-1U;4K)H;J.U%PPD!^?\
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MR)Y;C5[BX,I4IB@#];'&-?TS_L#Z]_Z6^'**)/\ D/Z9_P!@?7O_ $M\.44
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M/QA\/I?!USX@U!U\,3RI_;K:QH\NC1VNH+'<P"YBT]G&H013EHTD+N6AWM(
M#WR-XG,80QC[1&[ I-:SN47<'\U4E;S3EB1+"LD<66,F!NKXT_;QU?XE>"/V
M>O$/C[X9?$G7_AOXE\+ZAX=O)+[0= TKQ"=2BU;7=#\/W=M=1:Q#/9VRI#>3
M2"<+B)B7PQS7C_P0_84\7?"CXE_#_P >ZA^T/XN\7VGAN?6KRZ\,3Z7>6.D2
M)=Z+/HMMI6@^?XBU9=!\*7%U,NK>(M+NK?7YM0UM%NK.\T[2R]O7EG_!0?\
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MW)Q_K"!GID\#WKY0_:R^%/[17Q@^']OX;_9U_:7O/V7/&-OXA@O[OQQ:^ ]
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MK5\8YJ;K8_\ VNDZL5!JI".)CB*49*T4I1BI)QNG?8L?*)G:,$%F0R94*&<
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M &05E5K2248SGB$HI)17^UJ*Y8I)))*RLE97225T7****DL**** "FO]QO\
M=;^1IU-?[C?[K?R- 'P;\%?^3\?VV?\ L3_V9_\ U%O$]?>E?!?P5_Y/Q_;9
M_P"Q/_9G_P#46\3U]Z4 8\__ "'],_[ ^N?^EOAZBB?_ )#^F?\ 8'US_P!+
M?#U% &Q1110 4444 %%%% !1110 4444 %%%% !1110!$8(B,;.Q&06#8+%B
M-P(;&XDXSQVI[*K*5;)!X/)!_,$$=.QIU% #514&%! QCJ3Q^)/Y]:^9OVI?
MVF_A)^R!\'/&WQ[^-OB^'PQ\/?!%F;V[$S(^HZWJC'R=,\)^%K$%KOQ!XG\1
MWKPZ=HN@6,;WES>2H -@..[^,'QC\!_ CX>^-OBU\6/&6B^ /AO\/M(O_$7C
M#QAXBD^S:%H.BV%OO>YFGP);J93Y8CTRU5[[4[N>.QL#Y_!_#O\ 9L^$_P 2
MO^"JWQW\'_\ !0#]K+P9J7AC]DCX3ZA<ZI^P5^RYXJLYK>?Q;>>8PL_VJ/C5
MX<98XIM9U5DBU#X;Z!J"S1:'ITD%]=6)O &(!W'[%?[-'Q=_:S^.>F_\%0?V
M^?"X\/\ BR&UO_\ AB+]F'5XWN='_9B^&.KQ(VF>/O&NCL!:W/Q\\<6!BN-0
MOIEN;KPO97<&F:=]BN[>XD/[P0VL(4DQKO8_.02<E)&;/7C+DLXZN6;S"Q+$
MPVL,-S;P32)&9?W;R&+S%C-S"S[V7=M9PL[2LLC#,A(EZD&M!$5%"J, >I))
M]22<DD]2222>M #(88K=/+A01QAF8(N=JEB6(4$D(N2=J+A%'"J  *EHHH "
M >M-**>HZ'/4]?SIU%2X0DU)PBY+:3C%M>C:;7R8>73L,\M,@[1D=*#&AZK[
M]2!GUP#BGT4W&+U:3?=I/\TQ65K65NUM/NV_ :J(F=J@9QGKSC..OU-.HHH2
M25DDEV6@PHHHI@%%%% %6[8I#D2/&#(BEHT,DF"V,*!G:2< L00HSQW&1J.J
MI8Q++=WL%A$MPT;2W,L-O;.A&(XFN[B2**.5R!\Z[BIW#8>*U+ZX%O$CEE#/
M-%$BLXB#M(2I7S&!52$+NF[AG54ZL ?Y"_\ @O;XAO?VA_BE\'_V9E\/_M)^
M ?&U])XZ\-?".*X\'Z5K7P*^.6I"TM;R[\=>$E\.?'+P-JH\8^ 1$]WX9N/%
MIETAVGN%ETZ5BH !_7#INH?;)+>6*[MKJVN%F='M;I;F&38%426\VQ!+ I#H
MZIN=9&BD)",:Z"OY]O\ @WX\00:S\%/V@[&3XH?$_P"('B_PU\=%\+?$CP[\
M0M#A\*:!\,_%?AGP1HV@S^&OA?X=/Q&^)M_;>%[JUL-/U/46N]6L(YO$%WJD
MMI"84\D?T$T %<QXU\5:5X'\)>(O&&N2SPZ/X9TB^UK4Y;:&2YN$L]/@:XG,
M%O"DDL\NQ"$AC1I)6(1%+,*Z>JM]866J65UIVI6=KJ&GWT$MK>V-[!%=6=W;
M3H8YK>YMIT>&>"5&9)(I49'4E64@D4 ?!7PF_P""AG[/OQL\8>%_ O@^]\>_
MVUXKEFTR"'6_ OB+18;/5'M7U*UTS67N[&$Z/>7]C$]QITMZ\,<UIEA\Y!KY
M<_X*$_M=_LQ:Q\-?B/\  ^\U@W?Q=T?Q?X#T'3[+4?AKXDO+6P\41_$#P@UY
M_9OB2^T"72+,RVQ$<.H6=_"L<I$JS*REQ^I>E_!/X/\ AF_TG7M ^&?@C2-8
M\-V5Y9:%J=AX=TNUO-*M+X%;J&TN$AC>%)(RT.?,!CMF>VC9+=FB/R'_ ,%)
M?'N@^&_V8/%FB:U/J=O?>+-=\!Z/H#6V@Z]KEM=3Q>/_  HYENK[1=)OK32!
M*6\AKO4KJSM$1_,N)TA64H ?H%:_\>]AGK]FML_]^6K1K.M?^/>P_P"O:V_]
M$FM&@ HHHH *R7&92&Z!@0.PR2<\>HQ_49K6K)D^\['!.$./3AB._L#^7H<S
M)M<K6CYX*ZT=G))J^]GLUUZG/B%[L;ZP_><\7K&5J-:4;QV=I14E=.S2:U2/
M,?BC,+7X=>-;HG"VWAOQ',W' V:1?/DD^FT8'3@#O7X;_P#!*"0I\;M0=25D
MU_\ 9]T_6=X_Y:M<_$6^G,A!SDE2,[0%QC &>?VO^.]TEC\&/BO=,=JP^!_%
M4ZGH K:+>1KWZ;VX)['TY/XH?\$O+<Z=\?/"-F!L#_LCZ#,4Y);/B4SJ<L?[
M\A;K@EO3&/D<]D_];<@IIVBI5I\E]+SHTE=Q3Y;Z--VONFS^F?###RCX+^/.
M(DY>QK8'+5&#;</:X;+,MQ-.HH.\?:4I5YSA-+GA*<Y1E&4I-_T*V9+R3*Q)
M"L^T'' 7H.G0>_\ A6JH 4 <#'_UZRK+B6X'H\O\ZUEZ#Z#^5?93_B5.W-'\
M819_-?\ R]EYQ@WYOV6'U?=ZO7S?=W6BBBI+"BBB@ HHHH **** "L[4%;:C
MH<,F[D8R 2H.,^HSZ>]:-4+QL% 3\I#9'J> /H1DG/X'-1.4HPE.+LX1<^NJ
M@N9K3NDUV=[/0<4N9.3M&+YY=G&'O2BUUC))QDFFFFTTUH<9XEUJU\-Z%J6O
M:K<F#2]%L;O5=2E"EC%86=O+--(  3N3"NN <D8Y%?SJZEXVM?$]I^U#<Z5,
M;C0_B)X\TV[TJ[>)@;V&XOKFW$LZ$=2L"H!&J9" XYR?WF_:&G6'X&_%.<-@
MQ>"/$+'!QP+-P=W3<.N5(((_"OYS_@C'-<>(?AGHB1&:#Q9KDFIWL3_-;NFD
M7-S<[Y(FRBI^] "HJ+D$XR<U_2G@)P]A,1DG'?$DZLO:X;/,BI86/-:--4,+
M4S"JZ2:;IR=3+U4;A*"YHJ3BY)27^6'T\^.LVR_BWP@X(P5*<5F>!S;,YUZ;
ME&HHYGBX9'0:G"2DE3J9G3C35_<;M&U[&UX6^&MAXCUCX9>';6SMXCK?P_\
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M44 %%%% !1110!2O_-$&85C:0,Q02R/%&'$,OEERBOE?-V;@PVJN9/O(H/\
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MZGXOM/V7_&4&A>$(?$.E:GK/@&/Q)JQ\3Z?I,GAB"W^('A(_:5M9;6:?7F8
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MWQ?TC1K?4=8U_P &^,/ VI#Q'\.?B?X-NVT_Q?X!\1Q*!I^I:'J,*"7^R]2
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M068 ^HO^""MW:WW[/OQ3:UU%;Z&/XJ2SK(/B)\$/B5++)-IDBS-/K_P-C30
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MZ8;C^8..@QU]JOT %%%% !67(_F&1" -H!R.<C 4#MCAL^YS6I60OS-.<_=
M7\BI_P#91^=5!)R2>VG_ *5'_APC9U8Q>ONRDEYQJ46G\K^G>Y^67_!3N?S_
M  O^S]H;' U3]H#PVS8.6*:=8WMZI"GA@9;= V?N]5R0*^)OBQ)]GU[X)7&?
MDL?VD_A3.9"<9A-_!;L3V4;KMSZ94#."2/KW_@I3+Y_C#]E/3-Y'_%W)]2=.
MNZ*ST+4][D= $+ $]N>,5\6_M!W TCPEX7\229:'PW\5OAMJUT0-K)]F\6Z8
MA;O@&(.Y?! "D8.<C\GXEG*IG%>4WS.$L,H.R]U*JK)62O\ B?W;X+X6=/PL
MX+IQ;C3QU/C5U%HU4J5\9Q+0K-MJZYJ#]E:+BDG>*4O>/Z,=.U%[R)6,:H-J
MD!6)XVQD'D#J6_(<&M]#E%/J!TKA?#TZOINGS("RW6GVDZD\';+!"ZL>#R0>
M>G [=:[2V?=$HQ@!%QSD]QSP/3TK]4IPBJ&%FDDY8:DD[O5<L5W[KL?P?:<)
MQA._,_K;=[)MTLRQM"-TDK<M.E3ATT@F[MR;L4445184444 %%%% !6#J\DZ
M2)Y2*RK%O;>^Q<ASCG!Y_EP>O3:9V!P #P#R3W)]/I6/JK 1/*YQM@D&#S$6
M"L4W @_,"<CH#P#QR)G.I"+=&G"K4=HQC.W+[\H1<G??E4KVZF->WLI2E9PI
MJ56K3>BK4J,*E:I0;7O156%)Q<H.,XV3C*+;9^='_!2+5+[3OV>-5<2I;37&
MKZ*0%N&VY>^A/EJ\6UB6C5S\W?H .*^$/V.M,O5\(^*M4U!)EFU>XTT6\LI9
MC]D>WN;K$3.6+('F9%]ADX-:?Q+^.?Q!_:DUK6/@AJ&@V<.@Z5XSNTO?$-K%
MNCL;/2+BZBMGFA*(L\DA@R ]Q%M&X#<,8^C/ OA6V\'>%M&\/0[9)K#3;6UN
M;Q(Q$EY]GC>WBG$:LZABB[F42-MWA<D<U_8O#.!K<(<"5>%\RP&%6;9OFF&Q
M\\72:E5ADE;!4<?A*;E",5&,JJI-V4:BY^24IQ3M_CQQOGV5^,OTB,R\3.%\
M=CZ_"O#G#E;A'&T,74KTJ$>),KS*K@Z^ H87VRP\Z6#M.K#$>Q=6I[*+G6GL
M=:$W(<_\M#G'8 (@ ]3US['GGI3U!& 2" 2<XP22,8QD],?Y[*HP ,YP,?HH
M_P#91^?M3JQC3A",81C:,)-P5V[;I:MMO1O=O[S[:4G.;G+6;BHM[>ZK:65E
MT6MKOJPIC#D>XQ^O7]?\G!#Z:V,K]>/S']/Y54DG%IJZ:V]+-?BE]Q,DVFEO
MHUZP<9Q?RE3B_EJFKIQF-F5PK*#Y9;+DKD'@HN,Y8J3@'J :R/ D\EC^U'\.
M[J!0\=WX'\8VSEFV%R9;.X1%QG=Y1=@HP6QR,9(&T"RO&5"Y Y++N RC@?+D
M<Y_ITKQWQ[JA\#^*?A9\5QJ4FG_\(GXC2PUAMF^&71-3\V*^5P6&QL1Q;!M?
M<P'(/->9B<!/,<-FN%I1Y\5C\OQ6 I[I3C4IN4:;2=K2=&W.DI:_%L0LPIY9
MB^&<XK5W0PF7<793GF9U5:]\NQ3<J[<DU%PHRG'ECRTVI-R@VDU^QMO=,/LB
M[,1O$QD<YW(V2X4+CYN0 3CCKZBM:TG>1HQL54(.#N^;A6[>N1@_G7C7P?\
MBQX=^-/@R/QCX;,TFD2WT]A%+=1/!-+<V,C)<,D+!<Q. 623(. 1MS@GV6R9
M0L:+C;AL'D$_>XP>GTY]N*_ES%X7$86IB,/4BXXC#XCV=52M>,8R?/!VTNHW
MB]+V2:UNS_3_ "?.<ESS*LNS/)\:ZN79HJ6896H+F@\OJ4H1I1C-Q;E3=5.:
MG*3F[Z3Y=%I4445S'NA37^XW^ZW\C3J:_P!QO]UOY&@#X-^"O_)^/[;/_8G_
M +,__J+>)Z^]*^"_@K_R?C^VS_V)_P"S/_ZBWB>OO2@#'G_Y#^F?]@?7/_2W
MP]11/_R'],_[ ^N?^EOAZB@#8JAJ4:RVDBL5V94N&CCE5D# LK1RJZ,&'!RN
M?3!J_44RETV\8)7<",AER,CV)[&IFXQC*4XJ<$KRA)*2DM+IQ:::?9IE1=I1
M>FC3U2:^:::?HTUW1^?W[:.AG3=,^%GCDYM]/\)_$0:-JTR &W32?'6E77AL
M2SN^Z2VLT\0:CHE[* _D1+8-E09A)%\M/\G[HDY#2EN,?+'(T*M[YF295&?N
MQK)DB0 ?K)\3OA]HOQ.\">+? /B"(3Z7XIT2]T>XQCS;=KF,BUOK4DYCN[&<
MQ7%LZE6$T2$.#\P_'_38=?T:\U;P-XS%O#XZ\!7D&A>(Q),88=3AF@,NE>+-
M-#1/)-X?UVT2!+6Z4.L6LF[TZ=UFB:5OPGQ6R&M'%8+/J*G5FIPP\E14J4:-
M%22GSTZ7+3G",&VY5(RNKW;/(QF&E*HZJC&<7[\E5A&O&FXZN5*%53C1DK7C
M.DHR@TG%II,W"O R <<X'KG*D$\\, 2.AZ'(X,;01M,+@11QS+YK":.&V>X$
MDV&D;[1<12RK')(JN]JC+:2*"LD#9R)68*P4E@Q'S*Z%-C_\\MV2&D(^8!<@
MC/((Q3J_)G'WW.\E-K5QG*+^7*U;Y?H<5E)=]+??V??SW*<-E9VP"VVG:791
MI.]Q!'I^G6MBMO(Z2Q[HI($6Z#P)<7*V@,YBMA<.$C*D@V?+@$JRQV-@AAN+
MFZL]MG!";.XNWNDNI+=[06\D)O;2[DAU(P/$;^<"YG)/R4^BA<R_Y?8C_P *
M:_KM[2WR_P V3[*/][_P.7^93^Q6WE+!]ELA!YGVJ:!-.TQ8+G4@JI_:%Q ;
M-HIIR 7$LBM<0S;9;6:W(8/8*#@ $#^(%B=Y'0DDDX].,GOCO)1^!/H!U)[
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M:0\6)HVN:I;+(9_#/PPT*1-4\<:]>"$J(HQIUK=:=IS/>6H>[NWB60FYPO\
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MQYDG '#.(S;B"M*C@<7.C@Z-6,N25.>81QF#HS4E*+?)7JT9-W?9IIM/Y4^
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M]/PS2T4-7T>S JW<#SP211LBLZX^<':PR-R.5.X*ZY1F7YE!R,D"OE3]H/\
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MGGUK\P/VY?\ @G)I7QWOK/X_?!#5++X2_M=>!DDO] \>:9:A-&^*5K:1&0^
M/BQI5N%7Q+H%\%^SP7,\;:A82.LD4F%X_5RJKVV\,"58%S(H*D%7/<.#D?4
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M"YB\N53)(R!92&GME5W,GV-9(XIH(FF8&56+@*<4X%\89M[$99R &DD8'S&
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M_L7_ !;:QN522'7/B796OPP\/&)\9GBN/%5]IUU*JY#G;:$L.8U>O])#X??
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MQ,JF!RJMF"J?4:2JRPU6M2G&&"J8F%25+"U*MU.JW):4)<WAWP8FGU:R\?\
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M^"J5M!8Z/=_ C]G.[F'B+4/#XUF;XB>)[9WT^SM//3QG-#%;-$NCW61%!I*
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M].QCS_\ (?TS_L#ZY_Z6^'J*)_\ D/Z9_P!@?7/_ $M\/44BC8HHHH ****
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MT78^#]<\-Z/\67O5T^ZL_&'AR]L+G3-+U&PU%+QIY(#>W-C).\]U+]H>'?\
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6 )&#3!W_ +'UW_TM\._XBBMBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-q_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G E@# 2(  A$! Q$!_\0
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MC4C'(Y!^\3T8-WR.2.>.G3!YKR9%'_"\Y5Y"CX5VV%!( (\67PSP<Y(8@\T
M+_PE'Q7_ .B?^%?_  OS_P#,Y1_PE'Q7_P"B?^%?_"_/_P SE>L^6OH?^^F_
MQKY\_:4^+VO? KX0^*OBEH7A33?&!\)6R:AJ>DZIXGM_"L']F@HLTL.I7<5R
MDUZTLD<-EI\4+37MQ+'!&59MP .J_P"$H^*__1/_  K_ .%^?_F<H_X2CXK_
M /1/_"O_ (7Y_P#F<KYQ\#_M8^-?$7Q>\,_";Q;\$-5\!:AXC^'UQ\0'DF\7
M>&_$VI^&K:PT:UU6YLO&VCZ#?W#>$[34KJY?0]"U34KM9KS4[.Z633(80LE<
MG\-?^"D'P3\?VW@VPGTKXB:#XW\:>*(O">B>";OP%XANM6U>XN+_ %:S@\0:
M+/I\=UIFJ>$PFCWUU<ZY:WTEK;6]N[NVX[5 /KAO%/Q77'_%OO"YSG[OCY&Z
M>N_0H?7L6]P.,T[[QS\3]-L;S4KSX?>&Q::?;RWEV4\>H9A:P(7E:")-!E$K
MJ #AY(5' !8GCUFSE:<.LHC66()YHB,CQAI%$BB)YXD,B>6R$N%!#ED(!4UE
M>+H4/A7Q,3DX\/ZP< E 0MA.^"(]@8$J <Y(&0" 3D ?X3UN7Q'X>T/79;<6
MIUG1=*U<6RL)%@&HVB7/EB8']Z%W8#&.,XP<'/'1UPOPR51\// S@ ,W@[PT
M"?\ 9&DVSJOKA3*P&2>/?)/=4 %%%% !1110 4444 07.W[/+N"D%2"',87D
M@#)E5H\@G*[U92P *GI7\4O[4FEVW[./_!3OX?>#M0T[Q=\1-/L_C;\,[F7Q
MF?AMIWA?PCH-Y\0=?M-<TKPIIFJWWQ3EO_$M_HT.JQ7JSVNB7EK-*;LQ6.FK
M8O%7]K5T$-O,'^[L).$\PC'((3:VY@0"HVGD"OY2_P!K6Z\7>*_^"R%CI>I0
M>(?%'@/P7J/[.=UX4TF^/QMU3P_X4UB2V,VHZCX?_P"%6Z'?>$M-U"5I))]6
MMOB#>6DT;OYD$JV>\4 ?TP?$'X6?#[XOZ5!X6^)GA6P\8>'H?$WAOQ;9Z+K$
M2O8V7B3P;>VVKZ%J\8@=$FN-/U:UM;^"-WGB\^-6=70;*^;/&7_!-3]B#QN/
MB9/XK_9[\)^(;KXMZO:ZSXUO-0N];GU*ZOH=0_M,G1-5GU8W_A.UGU%Y;V[L
M?"]WHUG<RSW(DA,<\D;?9MCYHNA&LML\(E9RL/F?.!!&1*\DA)EG+2D.(7EA
MVX,C+( M;%V=MO(<;C@ *%WLQ) "JO0N3PN2!DC) R0 ?E=X.\,V?@G_ (*C
M^$_!OA?2O$.A_#[PG^P=K/ACPCHOG^'T\!:%I^B?$WX?6EMHWA33[.)/$,$T
M5JL37TFL7-[#+]G1H)4?=O\ U:K\I=*DT9O^"Q#QVX\+/KB?L*^(6U"?3['7
M(_&)LI/BW\/#;0^([N\QH$NB&10^BMI"#4I)XY1J)6)$5_U:H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3/S$=@%/YEL_R%?,7Q\_:F
M^''[.=]\/[3XAQ^+I&^)'C'3? _A\^%O!FN>*HX]7U7>+>;59=%MKK^S+*,I
M^]N;H)$ P)=54U].#[[?[J_S>L::TM[N51/$)O(N$EC5HQ(()L-Y=RA(RDJ$
MY212&3)&><5<*M*E+FK1E*%G&T;7YFO=>NFC6NWJ95H3G"T&D^9/5M*RO?;7
MJ? ?[7O[;6O?LM>./V9=/M_AG/X]\ _%C7_&7_"V]>TZ:XB\0?#/X>^$]%L]
M0O/B#IOAX0R7.O:?HEQ?V\WB>RC"3Z;HWG:@H<1E1XQ\ ?\ @K/\.?BKH'@/
M4-1\*ZQ=V/B?Q1H/A;7?B#X)%MK7P[\-ZA\0?$&L:;\*HYKB6YAUG4/^$WT_
M38;J.;2K"[M=,N+J"WOI8B[[/N;XO7WP \,ZSX'\6_&G5/!&C:]I>G^,;3P7
MKOC"Y\J6WL-1TE++QS9:>)9-LD.H:'+ FJ0S1O'/:L89$DW #S[P_P#LA?L?
M>!%\%^*O"?P4^&7A:Q^&MEI]_P"$;C38#I7AS0K+3FN=8T75KFW;48M VZ.N
MJ7.I:5JNKVMW=:7%=2"RDM@$V1*2G+FA=0=]&K.[\O)%4U-*TK?)_ALK^O\
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M+CP$OQ"\&^)X-,LKJ]75--\6:*LKVD:SQWD&P^; ""#^GME,UQ:P3MM/G()
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MCYS&G<L3P%Y!_$YS6AYDG]P_FG^-?B#I_P"T-\>+&!'_ .%DZU<VL;APAL[
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MMP?[.PO"I+_VE>AC*LA/VAQTV@?GQ!^T%\9YK9WNO&NKV9&0DYAM0KL.HV&
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MV?<$ U5/^"MVE&XF\9MI$W[$/B\V*:MJ.A3^"?MB_%;X<_;1X7TNR)U[3]9
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M^2U;L9K,<,E4G5<Z%*E&4Y5ZT)1I.,=W&45-R^4;OH?KMD'H0?QI:_&W0?\
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M?!7P/?0>,/AE\0M(DTJTTRVU;Q3K.MZ/9:[9W0B ,=C:!$:-3$7E4G=\E?\
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M[QHNGZ^DWCOQS?\ Q3UO]H#2M2M[[PW!'/=Z%IQ\!7MMI=S;K9V-A>02&6$
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MM5U36=%T>;4)8K"Q?5;VRM9KN9V+KI]E'//:3W4UT5!6&WG>0E 5CX.>LM4
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M& V"#C'K]6(^2?CQ\!-'^,&FS:??R3VU_I\02UU1V26 18+*DB_= #'EU'F
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M;;2_"GQC\2:AX.ETR!O&VG'[;*MI>SV[1W<FD16-V)I(YVEPD@;])'@1EP%
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M.CV-\.[BWT#4'TT65@@"X,@ /Z08"^%EN 4NFV"82!9%=EW-&BK:[XO*:-Y
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MZL=2%IXG2Y^P:E;VJ7EU:7VVS?\ L^:VLY+>X:)Q$565F,?'(!]Q45\(0_\
M!2#]A[^R1XE?]J7X1C1;@0M;ZK)XLA30[BWN[GR--FCOVM6@5KK[1:H?+< R
MS(N7;:3=O/\ @H7^Q=83V-I=?M+_  QAO-4DFM=/T^3Q$WVR\:"%[Z_&G0+:
MI-?O:VL+W*/")";>.5OE0' !]Q4QXP^,]L]@>OU_SZU\/)_P4+_8R>Z?3O\
MAIGX8#4[.TMM0O;5M=,>IQ:=+(D O7TQK5W6WDD$T)G,0 F54R#]UB?\%%/V
M))HKR>V_:?\ A9<VVGWE]::E-;^*(YX["\LP7O+74)5LV%C+9Q_O9(9F1HT
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MNDP=-KJMD]GU2?ZG](WPY4#X?^!R  3X0\-@D=PND6F!^!)Q]:[2N)^'!/\
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M8M^*^NJ* /CBZ_8:^!EUN,FG^(BQ#8)\2W><D'&6%L& R>H(8=0<UX[\4?\
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M8V^#,@&=/UP$'.1K\X/XD6H/^>E5_P#AB[X,G=NL_$!R,#_BH;GCG.<&V_\
MU>M?6]% 'QQ)^PY\#[@_Z1I_B!@C+)$T?B2Y1D=6R<_Z(4<-QD.K G/')-?*
M?BG_ ((N?LI>+=:UW6[[QM^TQ9R^(=1.HWEAI'QUU_3-)MY#-:W AL=/@L#%
M;VJRVJA;:)HT$,LT><2'/ZYT4 87AOP_9^%]%TG0-/ENI=/T72=,T:Q:]F:Y
MO#::5:K:6[75TVTW$[0HGFRE$:1PSMDL<;M%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>gtbp-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSPSbP9z5Z86ekhvWB6bfmazyslnJRHTygV8m4mAWYL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:GTBP="http://gtbiopharma.com/20250331" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20250331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
          <link:definition>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" id="OrganizationAndGoingConcernAnalysis">
          <link:definition>999008 - Disclosure - Organization and Going Concern Analysis</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" id="AccountsPayableAndRelatedParty">
          <link:definition>999010 - Disclosure - Accounts Payable and Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>999011 - Disclosure - Warrant Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
          <link:definition>999012 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" id="CommonStockWarrantsAndOptions">
          <link:definition>999013 - Disclosure - Common Stock Warrants and Options</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999014 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999015 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999016 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" id="AccountsPayableAndRelatedPartyTables">
          <link:definition>999019 - Disclosure - Accounts Payable and Related Party (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>999020 - Disclosure - Warrant Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" id="CommonStockWarrantsAndOptionsTables">
          <link:definition>999021 - Disclosure - Common Stock Warrants and Options (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999022 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" id="OrganizationAndGoingConcernAnalysisDetailsNarrative">
          <link:definition>999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
          <link:definition>999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
          <link:definition>999026 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" id="ScheduleOfAccountsPayableToRelatedPartyDetails">
          <link:definition>999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" id="AccountsPayableAndRelatedPartyDetailsNarrative">
          <link:definition>999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" id="ScheduleOfWarrantLiabilityAssumptionsDetails">
          <link:definition>999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" id="ScheduleOfWarrantLiabilityTransactionsDetails">
          <link:definition>999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>999031 - Disclosure - Warrant Liability (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
          <link:definition>999032 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999033 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>999035 - Disclosure - Schedule of Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" id="ScheduleOfOptionsOutstandingAndOptionsExercisableDetails">
          <link:definition>999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" id="CommonStockWarrantsAndOptionsDetailsNarrative">
          <link:definition>999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999038 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" id="ScheduleOfSegmentInformationDetails">
          <link:definition>999039 - Disclosure -  Schedule of Segment Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999040 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="GTBP_OfficersEmployeesAndDirectorsMember" name="OfficersEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CytovanceBiologicsIncMember" name="CytovanceBiologicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UniversityOfMinnesotaMember" name="UniversityOfMinnesotaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LegalServicesFirmMember" name="LegalServicesFirmMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OtherAccountsPayableMember" name="OtherAccountsPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" name="TwoThousandTwentyThreeCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" name="TwoThousandTwentyThreePlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeWarrantsMember" name="TwoThousandTwentyThreeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InducementWarrantsMember" name="InducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesAInducementWarrantsMember" name="SeriesAInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesBInducementWarrantsMember" name="SeriesBInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OmnibusIncentivePlanMember" name="OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeEightMember" name="RangeEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeNineMember" name="RangeNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTenMember" name="RangeTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" name="TwoThousandTwentyThreeSponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" name="TwoThousandSeventeenThroughTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyTwoMember" name="TwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFiveMember" name="TwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" name="TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SegmentsMember" name="SegmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" name="SeriesLTenPercentConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GreenshoeRightsMember" name="GreenshoeRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_VestingWarrantsMember" name="VestingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" name="StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" name="FairValueOfPrefundedWarrantToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" name="DisclosureCommonStockWarrantsAndOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockWarrantsAndOptionsTextBlock" name="CommonStockWarrantsAndOptionsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" name="ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" name="RepaymentsOfPrefundedWarrantsAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfWarrant" name="ExtinguishmentOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOne" name="RoyaltyExpenseYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearTwoThroughFive" name="RoyaltyExpenseYearTwoThroughFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterSix" name="RoyaltyExpenseYearAfterSix" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOneThoughFour" name="RoyaltyExpenseYearOneThoughFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterFive" name="RoyaltyExpenseYearAfterFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ContigencyMinimumRequired" name="ContigencyMinimumRequired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AggregateStatedValue" name="AggregateStatedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiableOfLiquidatedDamagePercentageDescription" name="LiableOfLiquidatedDamagePercentageDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockSharesOutstandingPercentage" name="CommonStockSharesOutstandingPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" name="WeightedAverageVolumePriceOfCommonStockPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyOneScientificResearchAgreementMember" name="TwoThousandTwentyOneScientificResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>gtbp-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20250331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysis" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20250331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformation" xlink:href="gtbp-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20250331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformationTables" xlink:href="gtbp-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20250331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfSegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999008 - Disclosure - Organization and Going Concern Analysis" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999010 - Disclosure - Accounts Payable and Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999011 - Disclosure - Warrant Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999012 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999013 - Disclosure - Common Stock Warrants and Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999014 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999015 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999019 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999020 - Disclosure - Warrant Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999021 - Disclosure - Common Stock Warrants and Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999022 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999026 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999031 - Disclosure - Warrant Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999032 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999035 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999039 - Disclosure -  Schedule of Segment Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999040 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>gtbp-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20250331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysis" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20250331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformation" xlink:href="gtbp-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20250331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformationTables" xlink:href="gtbp-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20250331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfSegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999008 - Disclosure - Organization and Going Concern Analysis" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999010 - Disclosure - Accounts Payable and Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999011 - Disclosure - Warrant Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999012 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999013 - Disclosure - Common Stock Warrants and Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999014 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999015 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999019 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999020 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999021 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999022 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999026 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999031 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999032 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_230" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999035 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_330" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_330" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_330" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_330" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_330" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_330" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_330" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_330" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_330" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent_330" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_330" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance_330" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_330" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_330" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_330" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_330" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_330" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_330" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_330" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne_330" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive_330" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix_330" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_330" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour_330" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive_330" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired_330" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockholdersEquity_330" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999039 - Disclosure -  Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999040 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPAggregateStatedValue_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquity_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_140" xlink:type="arc" order="15" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>gtbp-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="GTBP_CytovanceBiologicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CytovanceBiologicsIncMember_lbl" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="GTBP_UniversityOfMinnesotaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UniversityOfMinnesotaMember_lbl" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LegalServicesFirmMember" xlink:label="GTBP_LegalServicesFirmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LegalServicesFirmMember_lbl" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OtherAccountsPayableMember" xlink:label="GTBP_OtherAccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OtherAccountsPayableMember_lbl" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_InducementWarrantsMember" xlink:label="GTBP_InducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InducementWarrantsMember_lbl" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="GTBP_SeriesAInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesAInducementWarrantsMember_lbl" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="GTBP_SeriesBInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesBInducementWarrantsMember_lbl" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantsMember" xlink:label="GTBP_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="GTBP_OmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeOneMember" xlink:label="GTBP_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeOneMember_lbl" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTwoMember" xlink:label="GTBP_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwoMember_lbl" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeThreeMember" xlink:label="GTBP_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThreeMember_lbl" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFourMember" xlink:label="GTBP_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFourMember_lbl" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFiveMember" xlink:label="GTBP_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFiveMember_lbl" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSixMember" xlink:label="GTBP_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSixMember_lbl" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSevenMember" xlink:label="GTBP_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSevenMember_lbl" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeEightMember" xlink:label="GTBP_RangeEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeEightMember_lbl" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeNineMember" xlink:label="GTBP_RangeNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeNineMember_lbl" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTenMember" xlink:label="GTBP_RangeTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTenMember_lbl" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Patent Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="GTBP_TwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="GTBP_TwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="GTBP_TwoThousandTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentySevenMember_lbl" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SegmentsMember" xlink:label="GTBP_SegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SegmentsMember_lbl" xml:lang="en-US">Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="GTBP_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GreenshoeRightsMember" xlink:label="GTBP_GreenshoeRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GreenshoeRightsMember_lbl" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonWarrantsMember" xlink:label="GTBP_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_VestingWarrantsMember" xlink:label="GTBP_VestingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_VestingWarrantsMember_lbl" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PurchaseAgreementMember" xlink:label="GTBP_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="GTBP_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 250,000,000 shares authorized, 2,536,397 and 2,234,328 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative (including $3,000 and $102,000 from stock compensation for the three months ended March 31, 2025 and 2024, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) Decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Decrease in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sale of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Exercise of warrants and issuance of inducement warrants for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" xlink:label="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable_lbl" xml:lang="en-US">Fair value of prefunded warrant to settle vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Going Concern Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="GTBP_WarrantLiabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xml:lang="en-US">Common Stock Warrants And Options</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xml:lang="en-US">Common Stock Warrants and Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable to Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding and Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Accounts payable interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Invoices, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payments in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Prior year unpaid fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Liability Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_WarrantLiabilityCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="GTBP_ExtinguishmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfWarrant_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_WarrantLiabilityCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility amount utilized in the value calculation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Placement agents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Equity issuance cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of warrants, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Warrants weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants outstanding, weighted average remaining contractual life (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xml:lang="en-US">Schedule Of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-Average Exercise Price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options outstanding exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price,exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Range of excercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Common stock awards granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Stock option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Rstricted stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options vested and exercisable intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Stock option, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock option, unvested compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued during period, value, issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Aggregate research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US">Unbilled and unaccrued amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Proceeds from upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">License maintenance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">Royalty fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">One-time sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cumulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="GTBP_RoyaltyExpenseYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOne_lbl" xml:lang="en-US">Royalty expense year one</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xml:lang="en-US">Royalty expense years two through five</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="GTBP_RoyaltyExpenseYearAfterSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_lbl" xml:lang="en-US">Royalty expense year six and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xml:lang="en-US">Royalty expense year one though four</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="GTBP_RoyaltyExpenseYearAfterFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_lbl" xml:lang="en-US">Royalty expense year five and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ContigencyMinimumRequired" xlink:label="GTBP_ContigencyMinimumRequired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ContigencyMinimumRequired_lbl" xml:lang="en-US">Contigency minimum required</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceCommissions_lbl" xml:lang="en-US">Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_AggregateStatedValue" xlink:label="GTBP_AggregateStatedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AggregateStatedValue_lbl" xml:lang="en-US">Aggregate stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Issuance of shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Percentage of dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFloorPrice" xlink:label="us-gaap_DerivativeFloorPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFloorPrice" xlink:to="us-gaap_DerivativeFloorPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFloorPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xml:lang="en-US">Liable of liquidated damage percentage, description</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="GTBP_CommonStockSharesOutstandingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_lbl" xml:lang="en-US">Common stock shares outstanding percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Warrants to purcahse</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xml:lang="en-US">Weighted average volume price of common stock percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_2_lbl" xml:lang="en-US">Issuance of warrant to settle vendor payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityCurrent_doc" xml:lang="en-US">Warrant liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_doc" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xml:lang="en-US">Decrease in operating lease right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during the year for [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable_doc" xml:lang="en-US">Fair value of prefunded warrant to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LegalServicesFirmMember_doc" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CytovanceBiologicsIncMember_doc" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UniversityOfMinnesotaMember_doc" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OtherAccountsPayableMember_doc" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xml:lang="en-US">Schedule of Accounts Payable and Related Party [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xml:lang="en-US">Repayments of prefunded warrants at fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityTextBlock_doc" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfWarrant_doc" xml:lang="en-US">Extinguishment of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InducementWarrantsMember_doc" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesAInducementWarrantsMember_doc" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesBInducementWarrantsMember_doc" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xml:lang="en-US">Common Stock Warrants and Options [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of warrants oustanding and exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeOneMember_doc" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwoMember_doc" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThreeMember_doc" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFourMember_doc" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFiveMember_doc" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSixMember_doc" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSevenMember_doc" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeEightMember_doc" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeNineMember_doc" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTenMember_doc" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OmnibusIncentivePlanMember_doc" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options non vested in period fair value 1.</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyOneScientificResearchAgreementMember" xlink:label="GTBP_TwoThousandTwentyOneScientificResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyOneScientificResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyOneScientificResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyOneScientificResearchAgreementMember_doc" xml:lang="en-US">2021 Scientific Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyTwoMember_doc" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFiveMember_doc" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentySevenMember_doc" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOne_doc" xml:lang="en-US">Royalty expense year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xml:lang="en-US">Royalty expense year two through five.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_doc" xml:lang="en-US">Royalty expense year after six.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ContigencyMinimumRequired_doc" xml:lang="en-US">Contigency minimum required.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SegmentsMember_doc" xml:lang="en-US">Segments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xml:lang="en-US">Royalty expense year one though four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_doc" xml:lang="en-US">Royalty expense year five and thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AggregateStatedValue_doc" xml:lang="en-US">Aggregate stated value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GreenshoeRightsMember_doc" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_VestingWarrantsMember_doc" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_doc" xml:lang="en-US">Common stock shares outstanding percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xml:lang="en-US">Liable of liquidated damage percentage, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xml:lang="en-US">Weighted average volume price of common stock percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseRightofuseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilityTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilityPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_4_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>gtbp-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20250331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20250331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20250331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20250331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20250331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysis" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20250331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformation" xlink:href="gtbp-20250331.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvents" xlink:href="gtbp-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20250331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SegmentInformationTables" xlink:href="gtbp-20250331.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:href="gtbp-20250331.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:href="gtbp-20250331.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20250331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="gtbp-20250331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:href="gtbp-20250331.xsd#ScheduleOfSegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="gtbp-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPFairValueOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999008 - Disclosure - Organization and Going Concern Analysis">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999010 - Disclosure - Accounts Payable and Related Party">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999011 - Disclosure - Warrant Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="loc_GTBPWarrantLiabilityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999012 - Disclosure - Stockholders&#8217; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999013 - Disclosure - Common Stock Warrants and Options">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999014 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999015 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="loc_GTBPWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999019 - Disclosure - Accounts Payable and Related Party (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999020 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999021 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999022 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999026 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="loc_GTBPExtinguishmentOfWarrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPExtinguishmentOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999031 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999032 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999035 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999039 - Disclosure -  Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999040 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPAggregateStatedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250331.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Montgomery Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,365,000<span></span>
</td>
<td class="nump">$ 3,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL ASSETS</a></td>
<td class="nump">2,658,000<span></span>
</td>
<td class="nump">4,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,380,000<span></span>
</td>
<td class="nump">3,853,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,132,000<span></span>
</td>
<td class="nump">1,797,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,638,000<span></span>
</td>
<td class="nump">5,902,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 250,000,000 shares authorized, 2,536,397 and 2,234,328 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">695,019,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(696,003,000)<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Deficit</a></td>
<td class="num">(980,000)<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="nump">$ 2,658,000<span></span>
</td>
<td class="nump">$ 4,232,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,536,397<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,536,397<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,099,000<span></span>
</td>
<td class="nump">777,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including $3,000 and $102,000 from stock compensation for the three months ended March 31, 2025 and 2024, respectively)</a></td>
<td class="nump">833,000<span></span>
</td>
<td class="nump">2,314,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(1,932,000)<span></span>
</td>
<td class="num">(3,091,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">658,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of vendor payable</a></td>
<td class="nump">998,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income, Net</a></td>
<td class="nump">1,156,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (776,000)<span></span>
</td>
<td class="num">$ (2,266,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">2,345,087<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">2,345,087<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 689,539,000<span></span>
</td>
<td class="num">$ (682,065,000)<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,266,000)<span></span>
</td>
<td class="num">(2,266,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">689,641,000<span></span>
</td>
<td class="num">(684,331,000)<span></span>
</td>
<td class="nump">5,312,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">615,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">616,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(776,000)<span></span>
</td>
<td class="num">(776,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 695,019,000<span></span>
</td>
<td class="num">$ (696,003,000)<span></span>
</td>
<td class="num">$ (980,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,536,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of prefunded warrant to settle vendor payable, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (776,000)<span></span>
</td>
<td class="num">$ (2,266,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(126,000)<span></span>
</td>
<td class="num">(658,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) Decrease in prepaid expenses</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase (Decrease) in accounts payable and accrued expenses</a></td>
<td class="num">(1,291,000)<span></span>
</td>
<td class="num">(1,347,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">Decrease in operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(2,202,000)<span></span>
</td>
<td class="num">(4,163,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sale of investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by Investing Activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Exercise of warrants and issuance of inducement warrants for cash, net</a></td>
<td class="nump">616,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">616,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="num">(1,586,000)<span></span>
</td>
<td class="nump">871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</a></td>
<td class="nump">4,044,000<span></span>
</td>
<td class="nump">1,079,000<span></span>
</td>
<td class="nump">$ 1,079,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">2,458,000<span></span>
</td>
<td class="nump">1,950,000<span></span>
</td>
<td class="nump">$ 4,044,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable', window );">Fair value of prefunded warrant to settle vendor payable</a></td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of prefunded warrant to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Going Concern Analysis</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zM6PIFrYAEv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_823_z23uQagtjm6i">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible
debt instruments, and strategic collaborations. For the three months ended March 31, 2025, the Company recorded a net loss of approximately
$<span id="xdx_90B_eus-gaap--ProfitLoss_iN_pid_di_c20250101__20250331_zt99e9axnC3l" title="Net loss">800,000</span> and used cash in operations of approximately $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250331_zHl2q3qQWmh" title="Net cash used in operating activities">2.2</span> million, and had a stockholders&#8217; deficit of approximately $<span id="xdx_906_eus-gaap--StockholdersEquity_iNI_pn6n6_di_c20250331_z31Ufg8ARuT" title="Stockholders deficit">1</span> million
as of that date. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year
of the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm,
in its report on the Company&#8217;s December 31, 2024, financial statements, raised substantial doubt about the Company&#8217;s ability
to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable
to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zRhOk7ZRSfae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zHweFq8hJnyg">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zmAmW8E5Bce8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z470qXIiS6Ld">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain
information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be
read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance
sheet as of December 31, 2024 included herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zqT8nlXirlld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zGi5OSuGphgl">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zI8cXo5tQFOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zjgXBdSxuVk7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At March 31, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds, amounted to approximately $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zYOreHHvbRKg" title="Cash equivalents">2.2</span> million and $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zBl9ncHWQPD1" title="Cash equivalents">3.8</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zv9OsLVptJsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zMMvlSpaDnai">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement
with the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zacVsGESQNJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zUb8WajMASUb">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses
and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20250331_zOXvps7CxYa7" title="Warrant liability">126,000</span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_zspCPHqNOLEj" title="Warrant liability">252,000</span> at March 31, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--WarrantLiabilityPolicyTextBlock_zn4R7s00VTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zmB5wSBctree">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zqoRcRrNaNji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zaJjXnbQV6M8">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zCvsGIiEXn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTSl9riVB5mk">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zbXPGAi80Qdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zRBQmeHnWnj5">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">304,962</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,894,494</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431,227</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_z81CU68N4GFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zzhLpyzj6El3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOEuKYc0ZAPb">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20250331_zS9GZTGTB3dj" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwwaByBJlAOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zPIXApcRV3ug">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEag9Q3NM2M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zHfJBoclPqT7">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_85E_znT4gC9gGuDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Related Party</a></td>
<td class="text"><p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zOdI1DL8mQz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_821_zH2zM6gKBSR8">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcZATHE2dRq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zKWYRga3cP4g" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250331_zqW0YFXn3lBf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_z1WqoC6Zg8B2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXLwOEOvO1m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable
    to Cytovance, a related party <b><sup id="xdx_F4E_z4UeE58erEQf">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z1dMePmOYD8g" title="Accounts payable interest rate">25</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z5FJlFZ8isvd" title="Accounts payable interest rate">31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zjUsN19m6ata" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zlDwu4Xead43" title="Accounts payable interest rate">26</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">712,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_ziZvvk7z22X5" title="Accounts payable interest rate">18</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpehegdI0Lu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">597,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zztuRI6YJCde" title="Accounts payable interest rate">25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjRO9z2vDVGd" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zrHzT4rPEdff" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">597,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjDQo3GCFERe" title="Accounts payable interest rate">25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zB0I64IsCdH5" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zSNx52a28dp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">554,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zay1ppGKWtfh" title="Accounts payable interest rate">24</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z7TmpAgQIJT5" title="Accounts payable interest rate">12</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zajFcUgdrSBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,380,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331_zqLF4pMHeNXi" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,853,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_z4rDXvrJuaIc" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td id="xdx_F01_zZsdS1E3ZXe4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhrfQva32tsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td></tr></table>

<p id="xdx_8AB_znnEVNOy7KV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zALwPRMOQmf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zdNKQsxVbiCj" style="display: none">Schedule
of Accounts Payable to Related Party</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250331_z8nrJ4FJXso4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zUA7eC4FzE6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zxID2R9FHfA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,515,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zUO0oBe3k6ni" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">532,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">269,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTpHmaiJX623" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(268,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,800,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zhYuxYYBTK39" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments in pre-funded
    warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(847,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zevZ2mD2owff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,984,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_ze56yxW8XcD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zd27Unshc0lk" title="Issuance of pre-funded warrants">326,251</span> shares of common stock exercisable
at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zDYAuT8VtyV" title="Exercise price">0.0001</span> per share with a fair value of approximately $<span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgKhMJQaAxp5" title="Payments in pre-funded warrants, at fair value">847,000</span> to Cytovance as partial payment of accounts payable. The pre-funded
warrants were valued at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zzFXn5B72fE" title="Prior year unpaid fees">1</span> million. The Company classified this transaction as other income during the period ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zAPAMzLGFfWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zqbd1GKbxbQ6">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z9Wn8dAr8rt6" title="Warrants to purchase">216,667</span> shares of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zmHfZSUpMuW6" title="Warrants to purchase">13,000</span> shares of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zrrIJOKaTQg4" title="Volatility amount utilized in the value calculation percentage">100</span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zUINDY4eEwbj" title="Warrant  fair value">5.8</span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zq3ZcIXqQcel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a BlackScholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqVMRczECXg3" style="display: none">Schedule
of Warrant Liability Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zxkZEcyMUNDg" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">2.15</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zI2ZKBePaDPh" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup id="xdx_F4D_zOwk5RhxxqZg">1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zE5vJQEuvXPj" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zoeM54tNwsCl" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup id="xdx_F4E_zZXqpXDLWypd">2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z0D7SRTuVGF9" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zdmOdN0ZZFDl" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup id="xdx_F48_zvGlUa57Zhfc">3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zHmVUjPWfAQ6" title="Expected life (in years)">2.75</span>
                                            &#8211; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z9EC9wV3sDtl" title="Expected life (in years)">3.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zIU4Ylbt9qG5" title="Expected life (in years)">3.00</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zZDwDxUEPSI1" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup id="xdx_F4F_zelfSlSVyIg3">4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zDUZHAFyOnua" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zX8IAhNPrhq2" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zaFbvcMFMlB2" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">126,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z1VDfo10kQO" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zYjOToFFH3vg" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F16_zTdv3qgvClSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0C_zvpQT0GH6Qs1" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zAnmwhI4d9ah" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zIo5uGGv9OHb" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zLN7PkjyPcej" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F05_zOgBl70L1kif">4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_za3P2XSlLMx8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<p id="xdx_8AE_zm8VVcez7oXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zRTHSBQwv64b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zCApsygI1Ndi" style="display: none">Schedule
of Warrant  Liability Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250331_zHEIIxNXu5Fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240331_z4UqUeGrsoh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zG7JU6ftL4me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,052,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zKClTktTjRU2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIhUaRRlmMC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(126,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(658,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zTwyAK8bjMql" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zVUwC9mOynhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p id="xdx_8A4_zb0HKYT3ZeLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHRGombDIUQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_823_zIGddV7QHat3">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of March 31, 2025 was <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_zcYP3SOb3O65" title="Common stock, shares authorized">250,000,000</span> shares of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_zLTVgR4WAM6j" title="Common stock, par value">0.001</span> per share, and <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_z19uG5FLWC61" title="Preferred stock, shares authorized">15,000,000</span>
shares of preferred stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zUNnKtJdz22g" title="Preferred stock, par value">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zLS9bHQh7zra" title="Proceeds from private placement">686,000</span>
before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_z1VPm9iHPPz5" title="Other offering expenses">70,000</span>
in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226_zXKpaejRaEC4" title="Issuance of warrants">302,069</span>
shares of the Company&#8217;s common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zblTL6afperg" title="Share price">4.35</span>
per share. The holders agreed to exercise these existing warrants at a reduced exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z3pd9KePE9w8" title="Share price">2.27</span>
per share in exchange for the Company&#8217;s agreement to issue the holders new warrants (the &#8220;Inducement Warrants&#8221;)
exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zeCdRkOxUqHe" title="Issuance of warrants">604,138</span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zCO0MtQqnK61" title="Issuance of warrants">302,069</span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zwAvPu6xgJr6" title="Exercise price">2.02</span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_z5IzWdtryvi3" title="Warrant term">five years</span> from the date of issuance, and ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zOvJ8KCsOzdh" title="Issuance of warrants">302,069</span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyNQ11svGdMa" title="Exercise price">2.02</span> per share exercisable immediately
upon issuance with a term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_z6k5OlPMUh46" title="Warrant term">eighteen months</span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240523_zTkrCPQiDXnd" title="Placement agents">21,145</span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zwb6XRnUYg" title="Exercise price">2.8375</span> per share exercisable immediately upon issuance with a term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zoGPjdbEHp2k" title="Warrant term">five years</span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250331_zQz5MRAXQ7jf" title="Equity issuance cost">1.1</span> million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJySguInM01" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqxVdC8cGGm6" title="Preferred stock, shares outstanding">96,230</span></span> shares of series C preferred stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJMIh8i0dVvl" title="Preferred stock, par value">0.01</span> per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLvkRRo84uu4" title="Preferred stock, shares issued">96,230</span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockWarrantsAndOptionsTextBlock', window );">Common Stock Warrants and Options</a></td>
<td class="text"><p id="xdx_806_ecustom--CommonStockWarrantsAndOptionsTextBlock_zOx08Tl0c5w9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82A_zOJ5liIIBDZ7">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zNijWn5Oqb17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zQZzAJUiSHbk" style="display: none">Schedule
of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zaOszPndsBcg" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,120,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zIS25OOpsxh1" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">18.85</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zDlP55hnZGb" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif">951,534</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250331_zgmaCpNYvMPd" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250331_zV9d4w3rg8i8" style="text-align: right" title="Number of warrants, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250331_zKgEw1yv7Ym1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331_zSi1crGnMMpj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"><span style="font-family: Times New Roman, Times, Serif">(302,069</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250331_z3pBqM9iRRL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zsv46KVXYRMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_zHUFngovEUl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">11.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250331_zIGjOpokraA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zaaHhne0BtA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">11.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zSvMFSa0S0oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, all outstanding warrants were fully vested and exercisable and had an aggregate intrinsic value of approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250331_zXrhk6maDCm1" title="Options outstanding intrinsic value">780,000</span>
based on the fair value of the Company&#8217;s common stock on March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z15bp3jr1SQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zxvwGp0FxzI6" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXb3A1LpFlg" title="Range of exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zL6J8rmNonu3" style="width: 22%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif">326,251</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zr1mXiK5iCHk" title="Warrants weighted average exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAJWDXzR0JOf" title="Range of exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zti4BJe7frof" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">604,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHAXH1kSa6i7" title="Warrants outstanding, weighted average remaining contractual life (years)">3.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVmX3O1lUOo9" title="Warrants weighted average exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ10iRdr6i78" title="Range of exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zt047FzdD05i" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">21,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zErWXMrasQOi" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z12UvnA63y2f" title="Warrants weighted average exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgEe3Fz09W3j" title="Range of exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zG3ojNL9m2S6" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">437,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_ziNZU4uDeHS8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTxNimT4MLA6" title="Warrants weighted average exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTeOEsCSCMX9" title="Range of exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3y6w2gFVXj4" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">88,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zu6LytumgCfl" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zaL2hyh1NTn8" title="Warrants weighted average exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTGwkPz2xG48" title="Range of exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBX7fOKkWOIf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">216,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4V6RH8XRZ" title="Warrants outstanding, weighted average remaining contractual life (years)">3.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zgCjWH6wHzU8" title="Warrants weighted average exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUMhdzPuOyF2" title="Range of exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zVBRnY2D73Pa" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zkpTu0a2QLS7" title="Warrants outstanding, weighted average remaining contractual life (years)">2.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zZGgLYt84Ws3" title="Warrants weighted average exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4Thc450ADql" title="Range of exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zfXP9059l2D8" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zL8GybeHIOrf" title="Warrants outstanding, weighted average remaining contractual life (years)">0.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zg6Y8d4U2Wc1" title="Warrants weighted average exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zwAdIiRn3P99" title="Range of exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zY3Hr46dtLjl" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">52,316</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJXkHQlANyLd" title="Warrants outstanding, weighted average remaining contractual life (years)">0.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z1z77Gq6krb5" title="Warrants weighted average exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zgP6M7hcSRmf" title="Range of exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zy6wQpztR4Oi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">7,780</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQ4ge4H0Enel" title="Warrants outstanding, weighted average remaining contractual life (years)">0.9</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZrzNVWbttfj" title="Warrants weighted average exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUp7oXuCfEg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zkk3adYBfwAa" title="Warrants outstanding, weighted average remaining contractual life (years)">3.5</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlr2WDuWOEI3" title="Warrants weighted average exercise price">11.91</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zF2LG7OPp8dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zmgXZImSAPVb" title="Common stock awards granted">166,667</span>.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under
the Plan. As of March 31, 2025, there were <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331_zPc73PT8vxSh" title="Stock option outstanding">124,600</span> stock options outstanding and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250331_zz1TNoO99XNc" title="Rstricted stock granted">25,935</span> shares of restricted stock granted in prior years
under the Plan, which left <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zAj24qQeubi5" title="Available for grant">16,132</span> shares available for grant under the Plan. The following table summarizes stock option transactions
for the three months ended March 31, 2025:</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwX7pgJKqPTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zAFYiX5utv6d" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331_zoyRoudq3b57" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_z06l8W2piFsh" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250331_z3b7CHLeCNgg" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zUt0FrITAJs7" style="text-align: right" title="Weighted-Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331_zPhtp7JDkKn8" style="text-align: right" title="Number of options, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_z95YfFOnKPt" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331_zv5tGuY6zQ39" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zX4lrtnt3Yri" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331_zD65Ylh3Gdia" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_z57GoByABuV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250331_zFAS13N4juP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"><span style="font-family: Times New Roman, Times, Serif">107,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zejkIcCibhig" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"><span style="font-family: Times New Roman, Times, Serif">37.47</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zYndHl2ev1X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of March 31, 2025 was
<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331_zUudQ9v3hJMa" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term">8.0</span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable as of March 31,
2025 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250331_zTsBkWN4XW7k" title="Options outstanding intrinsic value">1,000</span> and $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250331_zeoTZW2zZsb8" title="Options vested and exercisable intrinsic value">0</span>, respectively, in each case based on the fair value of the Company&#8217;s common stock on March
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the three months ended March 31, 2025 and 2024, was $<span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250331_zVQPbU6eXn4a" title="Fair value of vested stock options">3,000</span> and $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240331_zHgq2xdQxEef" title="Fair value of vested stock options">102,000</span>, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
March 31, 2025, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250331_zguKtE1oskkd" title="Stock option, exercisable">107,746</span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250331_zUcR6eAmqd38" title="Stock option, unvested compensation">29,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zyjW5WJYy61a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zE9N8n3wJHgg" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSJscntedLyg" title="Range of excercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zx9QbJXzLLpj" style="width: 22%; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">6,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQ0kMtC25rCf" title="Options outstanding, weighted average remaining contractual life (years)">9.6</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcO51nuYSHgj" title="Options outstanding, weighted average exercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmzqmTT8fNo9" title="Range of excercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z93huJfABi3b" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">16,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zt6FOBpqvvu5" title="Options outstanding, weighted average remaining contractual life (years)">8.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBNSj0IXaYZ4" title="Options outstanding, weighted average exercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuSUHk5vpgY7" title="Range of excercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNbwl6Pt93j2" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zA8tdYPN4d02" title="Options outstanding, weighted average remaining contractual life (years)">7.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDW3rlOB6ZMe" title="Options outstanding, weighted average exercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwhfLDvXzjNl" title="Range of excercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9BnGNSHZ0He" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">34,598</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFOtwcsmrZjg" title="Options outstanding, weighted average remaining contractual life (years)">7.3</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zncA8Sd9SxS9" title="Options outstanding, weighted average exercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331_zuBHkw7zoKO" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">107,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_zmMKfWSNQ2de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockWarrantsAndOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants and Options [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockWarrantsAndOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zc8SMVyfROOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_824_zyzj1qzzqKfd">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his Employment Agreement, and that the
Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his Employment Agreement and Separation Agreement. A final hearing is scheduled for June 10th through
June 12<sup>th</sup>, 2025 in Los Angeles, California. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader
against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against
TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released
from all associated liability and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further
briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal
of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common
stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its
motion for entry of default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that
the motion for entry of default was mooted by the settlement agreement between Z-One and TWF. The Court ordered that the case be dismissed.
On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. Z-One
alleges that it was assigned TWF&#8217;s rights under the Notes and seeks enforcement and damages. The Company intends to demand a complaint,
and seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will continue to vigorously
defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#8217;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use
in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The Agreement also set
Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zfMcsPGWvxnl" title="Equity method investment, ownership percentage">4.9</span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zkp7b1QCa1yf" title="Equity method investment, ownership percentage">9.9</span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zTE98MUzPjo9" title="Equity method investment, ownership percentage">5</span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2025 and 2024, the Company recognized research and development expenses of $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztsFX4tZvack" title="Research and development expenses">532,000</span> and $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zO2EyNRGvkW9" title="Research and development expenses">269,000</span>, respectively
and made cash payments amounting to $<span id="xdx_905_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEDoDKfhFJla" title="Cash payments">268,000</span> and $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zVY4YmLT5XXi" title="Cash payments">1.8</span> million, respectively to Cytovance. In addition, during the three months ended
March 31, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCurDIOPHccl" title="Issuance of pre-funded warrants">326,251</span> shares of common stock exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zpD7Rxv9VGS6" title="Exercise price">0.0001</span> per share
to settle accounts payable valued at approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zO2Ka33UbCR2" title="Fair value">847,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of March 31, 2025, amounted to approximately $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250331_z53srMILBFR8" title="Stock issued during period, value, issued for services">340,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2016
Exclusive Patent License Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zh6DWCbwdbv3" title="Aggregate research and development expense">1.7</span>
million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue
work with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zWZdkyXQkoZh" title="Research and development expense">216,000</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zXseZOlerf0a" title="Research and development expense">0</span>, pursuant to the 2023 Sponsored Research
Agreement, for the three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately
$<span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zLZJIjB5Cgk3" title="Unbilled and unaccrued amounts">431,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;
</sup>technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement,
the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology
worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses,
authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that
is responsible for the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and
the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaKAnwukyRc9" title="Proceeds from upfront amount">200,000</span>,
and license maintenance fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zrXh9Dhcofh6" title="License maintenance fees">200,000</span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC4A8jhsmpf1" title="License maintenance fees">100,000</span> per year beginning in year 2021 and each year thereafter.
The agreement also includes <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRmu9QtmMku7" title="Royalty fee percentage">4</span>% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8diRgQ6C1x1" title="Royalty fee percentage">6</span>% under subsequent license agreements
or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zYH1rcxPToIj" title="Annual royalty payments">250,000</span>
beginning in 2022, $<span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zTZtSEr2gjfk" title="Annual royalty payments">2</span> million beginning in 2025, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zpsVCA0HSLgd" title="Annual royalty payments">5</span> million beginning in 2027 throughout the remainder of the term. The agreement
also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC52exVIqrUg" title="Performance milestone payments">3.1</span> million, and one-time
sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4cTs8f3Kws2" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0X3KFkdir5l" title="Sales">250</span> million in cumulative gross sales, and $<span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGirNm8CUO4" title="Sales revenue">5</span> million upon reaching $<span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpDqzo0BCb59" title="Cumulative gross sales">500</span> million
in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zeRgcHdKc9f9" title="Proceeds from upfront amount">145,000</span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zR3YMluBFCzl" title="License maintenance fees">50,000</span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzMEedMHqRi5" title="License maintenance fees">100,000</span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z12AY91gMeh3" title="Royalty fee percentage">1</span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_ziMp5TbXWo3i" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zM1KXx3x2d5c" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zdCC7QaRZ8dj" title="Royalty expense year one">250,000</span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z2pNVMJjzdW3" title="Royalty expense years two through five">2</span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6S7suzfhzRe" title="Royalty expense year six and thereafter">5</span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zAzVnZtiVoPf" title="Performance milestone payments">3.1</span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zK53mAG9qiv7" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zWzIY80Yh00c" title="Gross sales">250</span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0jBDvMtM0h" title="Sales revenue">5</span> million upon reaching $<span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOOBR0g3DEW9" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2016 Exclusive Patent License Agreement, for
the three months ended March 31, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znLmoDlx0DWl" title="Upfront license fee">20,000</span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zYdTsFu4Jvkg" title="License maintenance fees">5,000</span> per year beginning in year 2022 and each year thereafter. The agreement also includes
<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znbYlqDn5jzg" title="Royalty fee percentage">2.5</span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zie4hXnFhB08" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9iERo7RCfw9" title="Royalty expense year one though four">250,000</span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXrhXuADoEI5" title="Royalty expense year five and thereafter">2</span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zQRII04gULUf" title="Performance milestone payments">3.1</span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUgOqKOynOSk" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhYXIHztk9b6" title="Gross sales">250</span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zECnFA4wSMag" title="Sales revenue">5</span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0PrTzZxhM3k" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
three months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJ2TWPY1a1I9" title="Annual royalty payments">2</span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the three
months ended March 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately $<span id="xdx_908_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zwfUhapHa0bf" title="Unbilled and unaccrued amounts">1.9</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zWhIClx7GmW7" title="Contigency minimum required">2,500,000</span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff has not, as yet, accepted our plan of compliance, and has requested additional information
regarding our financing plans. We can provide no assurance that the Staff will accept our plan of compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Staff does not accept our plan of compliance, or if the Staff accepts our plan but we do not regain compliance within the allotted
compliance period, Nasdaq will provide notice that our Common Stock will be subject to delisting. If our Common Stock is delisted from
Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected.
We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our Common Stock and could harm
our business and future prospects. In addition, we believe that, if our Common Stock is delisted, our stockholders would likely find
it more difficult to obtain accurate quotations as to the price of our Common Stock and it may be more difficult for stockholders to
buy or sell our Common Stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As a result of the private placement
of preferred stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#8217; equity on
an unaudited proforma basis of at least $<span id="xdx_90F_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zBlgubIXYp27">2.5
</span>million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement, the Company may be subject
to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zymEbTqntKxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82F_zgmdGiGTFph7">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z6BajPcYxsb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zWidqRMLRzE7">&#160;Schedule
of Segment Information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zA4G2M2ZwHx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z1aFGXbjAcyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_z9cJNughFMI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,099,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">777,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zz8H0owUszgh" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">281,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">478,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zarglEP7naQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z9nTiw93Kmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zZJZjr6CJWP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">488,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,658,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zU0BPIoETkBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,156,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(825,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zWP7DprIbtAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,266,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_ziN8c525UXb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zyGbQyvFd9x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_826_zWnD1FqdvU67">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
Placement of Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with the purchasers
identified therein (collectively, the &#8220;Purchasers&#8221;) providing for the issuance and sale to the Purchasers of (i) up to <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zz972VTyQWZ4" title="Issuance of shares">6,056</span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;), (ii) warrants to purchase
up to a number of shares of common stock of the Company (the &#8220;Common Stock&#8221;) equal to 100% of the shares of the Company&#8217;s
Common Stock issuable upon conversion of the shares of Preferred Stock (the &#8220;Common Warrants&#8221;), and (iii) warrants to purchase
up to a number of shares of Company&#8217;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities
Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#8220;Vesting Warrants&#8221; and together
with the Common Warrants, the &#8220;Warrants&#8221;), with an aggregate stated value of $<span id="xdx_900_ecustom--AggregateStatedValue_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z8mmq31JkZq8" title="Aggregate stated value">6,055,555.56</span>, for an aggregate purchase price
of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2cAQYuXz5Z3" title="Issuance of shares, value">5,450,000.00</span> (the &#8220;Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Preferred Stock with an aggregate stated value of
up to $<span id="xdx_903_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zb2u2Ro1KElc" title="Aggregate stated value">22,000,000</span> (the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zkK2ri3mtiW8" title="Issuance of shares, value">19,800,000</span>, subject to adjustments, as further
described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its respective Greenshoe Rights for an amount
of Preferred Stock equal to the ratio of such Purchaser&#8217;s original subscription amount to the original aggregate subscription amount
of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. The Certificate of Designation
creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms and conditions on which shares of such
preferred stock would convert into shares of our Common Stock, as well as its liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Preferred Stock may be converted at any time at the
option of the Purchasers into shares of the Company&#8217;s Common Stock at an initial conversion price of $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zV3PxbyJaOvg" title="Conversion price per share">2.043</span>, subject to certain
conditions, as further described in the Certificate of Designation. In addition, the holders of the Preferred Stock are entitled to receive
cumulative dividends at the rate per share (as a percentage of the stated value per share) of <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znds67Q5LTbd" title="Percentage of dividend">10</span>% per annum until May 11, 2026, increasing
to <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z1ZxQIBGo3Hf" title="Percentage of dividend">12</span>% per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date
of issuance of the Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in cash, shares of the
Company&#8217;s Common Stock (subject to the Company&#8217;s satisfaction of the conditions set forth in the Certificate of Designation),
or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right to require the Company to redeem
the Preferred Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser will be issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#8217;s Common Stock equal to 100% of the Conversion Shares underlying the Preferred Shares issued to such Purchaser and
(ii) a Vesting Warrant (the exercisability of which shall vest ratably from time to time in proportion to the Purchaser&#8217;s (or its
permitted assigns&#8217;) exercise of such Purchaser&#8217;s Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement), each
to purchase up to a number of shares of the Company&#8217;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined
in the Securities Purchase Agreement) applicable to such Purchaser, in accordance with the Securities Purchase Agreement. The Common
Warrants have an initial exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zkRxuMFo5CRc" title="Exercise price per share">2.043</span> per share, are exercisable, subject to certain ownership limitations, immediately upon
issuance and have a term of exercise equal to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zlK1aofvSut9" title="Warrants term">five years</span>. The Vesting Warrants have an initial exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zrJFqDRUCFo1" title="Exercise price per share">2.043</span> per share, are
exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_z6770Fcc7XY4" title="Warrants term">five years</span> from the date that
the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $<span id="xdx_90E_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zNaBdThHfaPf" title="Floor price">0.454</span> per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the Common Stock issuable upon conversion of the Preferred
Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement within 30 days after the initial closing
and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met, <span id="xdx_900_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcZ3aywStsZj" title="Liable of liquidated damage percentage, description">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser pursuant to the Securities Purchase Agreement. Further, if the Company fails to pay such liquidated
damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registerable
securities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_90B_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmnSTL5m2KG3" title="Common stock shares outstanding percentage">19.99</span>% of the number of shares of the Company&#8217;s Common Stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). In connection with the required Shareholder Approval, all of the Company&#8217;s officers and directors (each a &#8220;Voting
Agreement Party&#8221;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a result of the private placement of preferred
stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#8217; equity on an unaudited
proforma basis of at least $<span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zY4bT4X5pN59">2.5
</span>million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement, the Company may be subject
to delisting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Private Placement </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 14, 2025, the Company entered into a common
shares purchase agreement (the &#8220;Purchase Agreement&#8221;) with investors (collectively, the &#8220;Investors&#8221;) relating to
a committed equity facility (the &#8220;Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time
at its option to sell to the Investors up to $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTqv6CHtzxRg" title="Warrants to purcahse">20</span>&#160;million of its common stock subject to certain conditions and limitations set forth
in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Sales of the shares of common stock to the Investors
under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion
and will depend on a variety of factors, including, among other things, market conditions, the trading price of the common stock and determinations
by the Company regarding the use of proceeds of such shares of common stock. The net proceeds from any sales under the Purchase Agreement
will depend on the frequency with, and prices at, which the shares of common stock are sold to The Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The purchase price of the shares of common stock that
the Company elects to sell to the Investors pursuant to the Purchase Agreement will be <span id="xdx_90E_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT8BiduZLyMj" title="Weighted average volume price of common stock percentage">93</span>% of the volume weighted average price of the
shares of common stock during the applicable purchase date on which the Company has timely delivered written notice to the Investors directing
it to purchase shares of common stock under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In connection with the execution of the Purchase
Agreement, the Company agreed to issue to the Investors a pre-funded warrant to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvKjJULH1Zpb" title="Warrants to purcahse">300,000</span> shares of common stock as consideration
for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to the satisfaction of the conditions
set forth in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Settlement
of Vendor Payable in Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to March 31, 2025, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdUMIZJwVhO4" title="Issuance of shares">50,000</span> shares of common stock and warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHWhc5W0n8Qg" title="Warrants to purchase shares">50,000</span> shares of common stock as settlement
of a vendor payable amounting to approximately $<span id="xdx_90A_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgruVu5MrxD3" title="Issuance of warrant to settle vendor payable">200,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zmAmW8E5Bce8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z470qXIiS6Ld">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable
rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain
information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be
read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance
sheet as of December 31, 2024 included herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zqT8nlXirlld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zGi5OSuGphgl">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zI8cXo5tQFOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zjgXBdSxuVk7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At March 31, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds, amounted to approximately $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zYOreHHvbRKg" title="Cash equivalents">2.2</span> million and $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zBl9ncHWQPD1" title="Cash equivalents">3.8</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zv9OsLVptJsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zMMvlSpaDnai">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement
with the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zacVsGESQNJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zUb8WajMASUb">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses
and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20250331_zOXvps7CxYa7" title="Warrant liability">126,000</span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_zspCPHqNOLEj" title="Warrant liability">252,000</span> at March 31, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_843_ecustom--WarrantLiabilityPolicyTextBlock_zn4R7s00VTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zmB5wSBctree">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zqoRcRrNaNji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zaJjXnbQV6M8">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zCvsGIiEXn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTSl9riVB5mk">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zbXPGAi80Qdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zRBQmeHnWnj5">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">304,962</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,894,494</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431,227</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_z81CU68N4GFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zzhLpyzj6El3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOEuKYc0ZAPb">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20250331_zS9GZTGTB3dj" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwwaByBJlAOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zPIXApcRV3ug">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEag9Q3NM2M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zHfJBoclPqT7">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
                                            31, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&#8239;&#8239;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">304,962</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,894,494</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431,227</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcZATHE2dRq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zKWYRga3cP4g" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250331_zqW0YFXn3lBf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_z1WqoC6Zg8B2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXLwOEOvO1m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable
    to Cytovance, a related party <b><sup id="xdx_F4E_z4UeE58erEQf">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z1dMePmOYD8g" title="Accounts payable interest rate">25</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z5FJlFZ8isvd" title="Accounts payable interest rate">31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zjUsN19m6ata" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zlDwu4Xead43" title="Accounts payable interest rate">26</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">712,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_ziZvvk7z22X5" title="Accounts payable interest rate">18</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpehegdI0Lu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">597,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zztuRI6YJCde" title="Accounts payable interest rate">25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjRO9z2vDVGd" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zrHzT4rPEdff" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">597,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjDQo3GCFERe" title="Accounts payable interest rate">25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zB0I64IsCdH5" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zSNx52a28dp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">554,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zay1ppGKWtfh" title="Accounts payable interest rate">24</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z7TmpAgQIJT5" title="Accounts payable interest rate">12</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zajFcUgdrSBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,380,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331_zqLF4pMHeNXi" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,853,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_z4rDXvrJuaIc" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td id="xdx_F01_zZsdS1E3ZXe4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhrfQva32tsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td></tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock', window );">Schedule of Accounts Payable to Related Party</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zALwPRMOQmf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zdNKQsxVbiCj" style="display: none">Schedule
of Accounts Payable to Related Party</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250331_z8nrJ4FJXso4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240331_zUA7eC4FzE6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zxID2R9FHfA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,515,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zUO0oBe3k6ni" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">532,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">269,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTpHmaiJX623" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(268,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,800,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zhYuxYYBTK39" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments in pre-funded
    warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(847,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zevZ2mD2owff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,984,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Payable and Related Party [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Warrant Liability Transactions</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zRTHSBQwv64b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zCApsygI1Ndi" style="display: none">Schedule
of Warrant  Liability Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250331_zHEIIxNXu5Fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240331_z4UqUeGrsoh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zG7JU6ftL4me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,052,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zKClTktTjRU2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIhUaRRlmMC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(126,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(658,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zTwyAK8bjMql" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zVUwC9mOynhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Warrant Liability Assumptions</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zq3ZcIXqQcel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a BlackScholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqVMRczECXg3" style="display: none">Schedule
of Warrant Liability Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zxkZEcyMUNDg" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">2.15</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zI2ZKBePaDPh" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup id="xdx_F4D_zOwk5RhxxqZg">1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zE5vJQEuvXPj" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zoeM54tNwsCl" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup id="xdx_F4E_zZXqpXDLWypd">2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z0D7SRTuVGF9" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zdmOdN0ZZFDl" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup id="xdx_F48_zvGlUa57Zhfc">3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zHmVUjPWfAQ6" title="Expected life (in years)">2.75</span>
                                            &#8211; <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z9EC9wV3sDtl" title="Expected life (in years)">3.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zIU4Ylbt9qG5" title="Expected life (in years)">3.00</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zZDwDxUEPSI1" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup id="xdx_F4F_zelfSlSVyIg3">4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zDUZHAFyOnua" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zX8IAhNPrhq2" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zaFbvcMFMlB2" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">126,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z1VDfo10kQO" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zYjOToFFH3vg" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F16_zTdv3qgvClSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0C_zvpQT0GH6Qs1" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zAnmwhI4d9ah" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zIo5uGGv9OHb" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zLN7PkjyPcej" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F05_zOgBl70L1kif">4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_za3P2XSlLMx8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zNijWn5Oqb17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zQZzAJUiSHbk" style="display: none">Schedule
of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zaOszPndsBcg" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,120,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zIS25OOpsxh1" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">18.85</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zDlP55hnZGb" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif">951,534</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250331_zgmaCpNYvMPd" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250331_zV9d4w3rg8i8" style="text-align: right" title="Number of warrants, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250331_zKgEw1yv7Ym1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331_zSi1crGnMMpj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"><span style="font-family: Times New Roman, Times, Serif">(302,069</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250331_z3pBqM9iRRL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zsv46KVXYRMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_zHUFngovEUl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">11.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250331_zIGjOpokraA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zaaHhne0BtA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">11.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwX7pgJKqPTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zAFYiX5utv6d" style="display: none">Schedule
of Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331_zoyRoudq3b57" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_z06l8W2piFsh" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250331_z3b7CHLeCNgg" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zUt0FrITAJs7" style="text-align: right" title="Weighted-Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331_zPhtp7JDkKn8" style="text-align: right" title="Number of options, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_z95YfFOnKPt" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331_zv5tGuY6zQ39" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zX4lrtnt3Yri" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331_zD65Ylh3Gdia" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_z57GoByABuV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250331_zFAS13N4juP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"><span style="font-family: Times New Roman, Times, Serif">107,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zejkIcCibhig" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"><span style="font-family: Times New Roman, Times, Serif">37.47</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Options Outstanding and Options Exercisable</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zyjW5WJYy61a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zE9N8n3wJHgg" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSJscntedLyg" title="Range of excercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zx9QbJXzLLpj" style="width: 22%; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">6,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQ0kMtC25rCf" title="Options outstanding, weighted average remaining contractual life (years)">9.6</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcO51nuYSHgj" title="Options outstanding, weighted average exercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmzqmTT8fNo9" title="Range of excercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z93huJfABi3b" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">16,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zt6FOBpqvvu5" title="Options outstanding, weighted average remaining contractual life (years)">8.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBNSj0IXaYZ4" title="Options outstanding, weighted average exercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuSUHk5vpgY7" title="Range of excercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNbwl6Pt93j2" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zA8tdYPN4d02" title="Options outstanding, weighted average remaining contractual life (years)">7.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDW3rlOB6ZMe" title="Options outstanding, weighted average exercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwhfLDvXzjNl" title="Range of excercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9BnGNSHZ0He" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">34,598</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFOtwcsmrZjg" title="Options outstanding, weighted average remaining contractual life (years)">7.3</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zncA8Sd9SxS9" title="Options outstanding, weighted average exercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331_zuBHkw7zoKO" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">107,746</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z15bp3jr1SQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zxvwGp0FxzI6" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of March 31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXb3A1LpFlg" title="Range of exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zL6J8rmNonu3" style="width: 22%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif">326,251</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zr1mXiK5iCHk" title="Warrants weighted average exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAJWDXzR0JOf" title="Range of exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zti4BJe7frof" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">604,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHAXH1kSa6i7" title="Warrants outstanding, weighted average remaining contractual life (years)">3.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVmX3O1lUOo9" title="Warrants weighted average exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ10iRdr6i78" title="Range of exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zt047FzdD05i" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">21,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zErWXMrasQOi" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z12UvnA63y2f" title="Warrants weighted average exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgEe3Fz09W3j" title="Range of exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zG3ojNL9m2S6" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">437,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_ziNZU4uDeHS8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTxNimT4MLA6" title="Warrants weighted average exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTeOEsCSCMX9" title="Range of exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3y6w2gFVXj4" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">88,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zu6LytumgCfl" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zaL2hyh1NTn8" title="Warrants weighted average exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTGwkPz2xG48" title="Range of exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBX7fOKkWOIf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">216,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4V6RH8XRZ" title="Warrants outstanding, weighted average remaining contractual life (years)">3.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zgCjWH6wHzU8" title="Warrants weighted average exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUMhdzPuOyF2" title="Range of exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zVBRnY2D73Pa" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zkpTu0a2QLS7" title="Warrants outstanding, weighted average remaining contractual life (years)">2.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zZGgLYt84Ws3" title="Warrants weighted average exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4Thc450ADql" title="Range of exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zfXP9059l2D8" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zL8GybeHIOrf" title="Warrants outstanding, weighted average remaining contractual life (years)">0.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zg6Y8d4U2Wc1" title="Warrants weighted average exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zwAdIiRn3P99" title="Range of exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zY3Hr46dtLjl" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">52,316</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJXkHQlANyLd" title="Warrants outstanding, weighted average remaining contractual life (years)">0.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z1z77Gq6krb5" title="Warrants weighted average exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zgP6M7hcSRmf" title="Range of exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zy6wQpztR4Oi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">7,780</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQ4ge4H0Enel" title="Warrants outstanding, weighted average remaining contractual life (years)">0.9</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZrzNVWbttfj" title="Warrants weighted average exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUp7oXuCfEg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,769,894</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zkk3adYBfwAa" title="Warrants outstanding, weighted average remaining contractual life (years)">3.5</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlr2WDuWOEI3" title="Warrants weighted average exercise price">11.91</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrants oustanding and exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z6BajPcYxsb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zWidqRMLRzE7">&#160;Schedule
of Segment Information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zA4G2M2ZwHx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z1aFGXbjAcyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended March 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_z9cJNughFMI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,099,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">777,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zz8H0owUszgh" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">281,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">478,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zarglEP7naQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z9nTiw93Kmcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zZJZjr6CJWP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">488,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,658,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zU0BPIoETkBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,156,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(825,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zWP7DprIbtAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,266,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">2,202,000<span></span>
</td>
<td class="nump">$ 4,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders deficit</a></td>
<td class="nump">$ 980,000<span></span>
</td>
<td class="num">$ (5,312,000)<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
<td class="num">$ (7,476,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,894,494<span></span>
</td>
<td class="nump">431,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">124,600<span></span>
</td>
<td class="nump">126,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,769,894<span></span>
</td>
<td class="nump">304,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 554,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,853,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,984,000<span></span>
</td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember', window );">University of Minnesota [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 629,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 597,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,505,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember', window );">Other Accounts Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Invoices, net</a></td>
<td class="nump">532,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">269,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments in cash</a></td>
<td class="num">(268,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="num">(847,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Ending balance</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,984,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">326,251<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Prior year unpaid fees</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (126,000)<span></span>
</td>
<td class="num">$ (658,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">3 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on rates
established by the Federal Reserve Bank</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Determined by the
remaining contractual life of the derivative instrument</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Based on no dividends
paid or expected to be paid</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(126,000)<span></span>
</td>
<td class="num">(658,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfWarrant', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liability (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>May 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember', window );">2023 Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">216,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember', window );">2023 Placement Agents Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility amount utilized in the value calculation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering expenses</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember', window );">Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="nump">604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember', window );">Series A Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember', window );">Series B Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted | shares</a></td>
<td class="nump">951,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of warrants, forfeited/cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited/cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised | shares</a></td>
<td class="num">(302,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">$ 1.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, ending balance | shares</a></td>
<td class="nump">1,769,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 11.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable, ending balance | shares</a></td>
<td class="nump">1,769,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending balance | $ / shares</a></td>
<td class="nump">$ 11.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">1,769,894<span></span>
</td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 11.91<span></span>
</td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">437,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">88,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 102.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 102.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">52,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">7,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">1,769,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 11.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning | $ / shares</a></td>
<td class="nump">$ 32.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, forfeited/cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeited/cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending | $ / shares</a></td>
<td class="nump">$ 32.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options outstanding exercisable | shares</a></td>
<td class="nump">107,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price,exercisable, ending | $ / shares</a></td>
<td class="nump">$ 37.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Outstanding and Options Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">107,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">6,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">16,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">34,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Rstricted stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock option, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1', window );">Stock option, unvested compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options non vested in period fair value 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>May 13, 2024</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Jul. 18, 2016</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,000)<span></span>
</td>
<td class="num">$ (658,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period, value, issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099,000<span></span>
</td>
<td class="nump">777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ContigencyMinimumRequired', window );">Contigency minimum required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(980,000)<span></span>
</td>
<td class="nump">5,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember', window );">2023 Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Aggregate research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Proceeds from upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOne', window );">Royalty expense year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearTwoThroughFive', window );">Royalty expense years two through five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterSix', window );">Royalty expense year six and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | 2017 through 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Beginning in 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Beginning in 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Beginning in 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOneThoughFour', window );">Royalty expense year one though four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterFive', window );">Royalty expense year five and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember', window );">2024 GTB-3650 Clinical Trial Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,000<span></span>
</td>
<td class="nump">269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532,000<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ContigencyMinimumRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contigency minimum required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ContigencyMinimumRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year after six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOneThoughFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one though four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOneThoughFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearTwoThroughFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year two through five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearTwoThroughFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong> Schedule of Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,099,000<span></span>
</td>
<td class="nump">$ 777,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,156,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(776,000)<span></span>
</td>
<td class="num">(2,266,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember', window );">Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,099,000<span></span>
</td>
<td class="nump">777,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="nump">281,000<span></span>
</td>
<td class="nump">478,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Insurance</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">488,000<span></span>
</td>
<td class="nump">1,658,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(1,156,000)<span></span>
</td>
<td class="num">(825,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 776,000<span></span>
</td>
<td class="nump">$ 2,266,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 11, 2025</div></th>
<th class="th"><div>May 15, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 23, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (980,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,312,000<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of warrant to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of warrant to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LiableOfLiquidatedDamagePercentageDescription', window );">Liable of liquidated damage percentage, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser pursuant to the Securities Purchase Agreement. Further, if the Company fails to pay such liquidated
damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registerable
securities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockSharesOutstandingPercentage', window );">Common stock shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series L 10% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,055,555.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,450,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage', window );">Weighted average volume price of common stock percentage</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AggregateStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate stated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AggregateStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiableOfLiquidatedDamagePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liable of liquidated damage percentage, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiableOfLiquidatedDamagePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of prefunded warrant to settle vendor payable, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average volume price of common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WeightedAverageVolumePriceOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &A\KUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( &A\KUK,6'L^\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
M"J5,7K5::0##.'W)$Q+#W(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]
M7BQH0-!445IO7R"TY1\S^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!
M;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=
M6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38
M]MJND::JC5-/T_=]W^N;:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K
M:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8
M[CF)$?[&Q036:=(9EC1&<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:
MR('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYP
MO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR
M([O=]EA]]D]';B/7J<"S(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQ
MEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1
M]E6\W*.76!4!EQC?-*HU+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^
M*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=
M F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9
MK#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++
M9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>
M/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>
M1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+
M@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A
M=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9=
M=N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8
MT='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7
M\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I
M=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4
M%Z9*HO,94[[G*TG$53B_13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;R
MWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z
M;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,
MN2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#
MB<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >
MLX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[
MM'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ
M#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1.
M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( &A\KUIF(Y7UZ 4  +P?   8
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M%KB[WK)_<KE3+@NF<2JK[SPSY=C[X$&&.5M6YDZNOV"7SYGE2V6EW2^L.]_
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M&U4I2 SDNL.0(/$R*=Q$$,RO3%RUJHRN*L&\BL#V2&]GI+>MT347U/^IUZL
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MT+2&U_MI-R'O!ZH=+C."+5FKG8I:<9#M=M'#.?4-"GK4(@W=4.HO*?),7)8
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MK ^G7HO06/:,A)N-D:],).@#HY91$RT=T1!.8!@$?A $X#!/(/3#4>P.XO
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MDV@$JGW_M0-3K^V;:UX;?,'9SQ4^F:4B!9Q?U'C5[@:TP/ (O_P74$L#!!0
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M(&&1'VEWFDS#+-ADA5WVLK4A+-3,$,4:=CT?E@\[LXI2++:;(4D87[,IR=N
M$R]UT:XXM:RH"6*E80,"-34K,BX&/;<4=M<MYMZD#>FO;&!!V$B0+HH'3#Y3
MA1$%OGG_N2MR8RE.05@[! ?&9T]6S ZL2%H']PEUEY \8.)<U0[<<O&9G#?S
M!I*&[<-DK]EN>L$#*[Y%G>SKK8W/E@&E;84W&<B8>R1MTCQ)(QDQSZL[RKI@
M<M;4U#ZD=AB#0BK2F$8L5^/L7=.X%Z?,H+V(#^]J>,7'-G<;M0L9I;=9RWU%
M"R4;L.)I4^P<X1:\:[S#)M(O[!+U0&'KT ZHU?'P&2L2^^Y<37960IMZQ':0
M%-)/?=^J65NFCNL6]8#UY-=8Q]+/A'7>7QZ-(N?=&K2C0#C6;0P*988/67WG
M$M3\,F3N$W7)CL9I"GM90\F*>]P"AVO&;FQ1L^ /54>5$D+3OS#^4;BWC3_8
M_CMU<C09C$8C-3E]%C[/^',\/%-'D]/!Y&2L1D,\&:NSXZ?\ZMQ3B;/%SV,H
MBCU>6XI:@BZ;$C6B=-0R?.'>*;YU4&=A1(T7"XV-CGI/:=5+IZ2+M%R4Q<C8
M]0=I [LVE*P-+5Q*1M8L]";G@] \E9RAEP@%]]PI1=#Y3AT=CUCFOY:6M[GU
MFF6W96E\56O>A"8W*#BQUP:%CU'I'1!CQV'TZU!7OB7466\3T33Y(W)VB'KT
MM6--;;#V/;T, 7$R&I\F;^[3O/$8C!S$C>@K* U(Z)CM\H.9S0P?9(7]=MQN
MDVT (!NKL=[;DR'HKL7:-1C@VGM;G^,A'0&,GQX__^:/_H& M-ZE,1MP34D:
M)0QWC;7?&_6WF9N,3]G8ORO$8ZM>SB7VV&_9. K2J%LEZI$!U%ZH_9Z^D'RG
MCC&,0\37@4F]B1B2OOKX;,!3]P=[T])="MT\T/T_. )5M9)4!\F64ZC?XA3@
M,&PV(Y)"R[- 24)QG?KA?+C!%8?32^HC--S@_>3LG]\$"">;@)Z,1D&O\CD.
MG\?J%!DRO$-^.!J.U9B>X.\3/.OT2P%F?/0UN306%\0W7*/F /L?T?E&7)2:
M0;>).S30*+9C>P[HTR&#! M)0^/C$Y;S9%,%8XBZ7PG]:! [E_% CN3_34%A
MT#J=:IWNJS R(-_[S9D;;"S%@KET3'M>M<^=A""2,T_Z6G_Z#SC2AO-LL/OK
MSD.BTIXI:O;UTY^/5*W=W! $^^Y!N9*Q($8?PM ]"/S7 3 9JSUF&<3]1?*M
MEA_RL^1/GUX_.3J%6!=QW_&)]AV;E437*SGK>_O'T(C</OV"_:4XIG-8;NW:
M6IITCR[2M_$#*S)BDF]$3#>F T5?V]RY&6R3\PMJ+X;":%,@Y%F=)]33N'3-
MO-W\O7UWV1UP+)> O6Y[/GBGQJ<G)\>GJM5WG\<VJ7YPU=SIHG]2$EFA:Q9\
M.M!R97LZYH(4R7M!/9_QUB8R]O&R05RPX^+B<GQZ^/;JR?CD\.+RZ.@'LLR3
MF^@T?Z92PJDWY5S/\?D]^TNWM_V$?4T=H^G/=KY(/EI_JZ[7 ':V]DN OP:5
MFW69H>R@\Z#KRQOH_Z.9T4ENY=:'U)]8TM[HG/;9,A7N=&6:6U-8F/+\^NH'
M*0!A7TLGZM"6S1K\<6D][:NH L*H03SBS8RTDI+03NN9M:_TF[K)6DQ(YMBV
M S4OY7 _K4K:J8?3OU:]K4,WL5,TI0YM=Q#'BPRPKZ=K%D0H]H.Z/9Z'+S=R
M=2&DQZIQW/&0\W 3V@/+71N%R7\A$!T_ZK9M%)+\DWQ+%/I_6O,^+O3O6N_R
M7N59[UK2.HE7E]Z=WUR>_R6<*/N-L-RUS.5>D+$K[N+FAD^?^ZBG7NXLQJ8K
M?M^UK**>WFF?Z2_(.M()^DM#1X)A$G? 9K,M5\*32"8I:8DU'XGT&J4B<KSN
MQ"T>.4AN^^E4K,$R"PTGHQ9QV5Z_,83TP4FHS@CQ.\0 *#)Z$EO@4 61.CY1
MF5XC]-BA&0Z CMKFZA==<@]<:IF3'\@.OID"7Q1$<UV&\RNZYL6M8KMY=XA#
M45,D-SO$>"-B?)3:4]R$5!*/8>P,2P$-O P"#-!*5R3D&DY0+EVDFG-B;;R4
M4W6X*0K]2208GXU$,+(:)\<LM.!# _J!?C#)4#PA23JA^#Y)///D"+4PO-<@
M:#)K;##BML]A;&++^1@+5"_H$EPBC2<$N%N3VT55]4XD6&2>B1A 9Q\[U"O8
MZWF]],GI@$_0F#I+=X#T0/C2H04<:"PP"GE%=EQR$4WB)PV.M\7*JGS2S0$A
M%A@Q<UDY4B("(K<3B&^Z^\-WXIB]T%UV4"0* #X=SX01.C2C1#UK;UM1SN!;
M.GS$P,PVTYPZWNT]3#]4GTTBR.,+=:(B.4V+(L7V(^N=KWZEX4)-Z_9R'YF;
M(\%6-"LDK< F%@[K$SM+9U<DJC<0C4^>$89GQLD]QAW@E_0F3*#*($CS,39"
MWJ#%<+?\A@B2OQ><>+XT*%I(U'"%"8JRI5R_)E71NBZ+D@1ETAT.$&5ML6^$
MS$@GBTAKC>N:K5L(W4+P)EN OMR]D E995BL_9,&=))O9[V%9+COQD\;CCY9
M%9+QKC 2@$2]=;)\TGL=416B,,O1"<Q'<>U=S@OIF',<DI'4CF^F_T2"E0.O
MX#8DZ\,9UH<15-A0')$U!='Q/)W0H.E.:ZJ7EHY=PY6G"*<.-S&XMYB*AS9B
M1R.. OE")DFK)J=+E@ #Y67*?YJWFW16^=E(SS^<N8G,K3SJCN=RE%GWPDEF
M8K-=+ON$"P&'<ILVO%KQ_386#E,>:"5<*,L)LJY(^M=SY9*-'(+ )ES(;%[)
MXQS<YWE :-FG^<&#C+@I')27)<A,1<5W@>@.)PD+M593OHBL*3R1,W]IJE!3
M<OM?X@8\/6VO&3^0TTJ$FYIM\ESE]'FJJV3:K!47/\#90VH2APW=8^$K+.[6
MU+*Z9Z?1?*6,*CX^K&"+A705HQ'<1TYS$SX=,P 6%5&^9Y;>Y9$[[2A'AD =
M+B[S92[N3$UBM;5YC22<X-J: ]*>0H0#-Y63J-SY7,55'*?H=Q)6KHG5=&<3
M">@[ZA?LNOQ^V/OM0F'<G'^AX>6ZHOR,H7W:_@CD7'[[T V77Y"@AIQ;6#8W
M,TP=#9^>',@!>?Q25TO^)<04$:4J^,\%7Z>B 7@_HTL&X0LMT/XTYM6_ 5!+
M P04    " !H?*]:Y'5MR(X$   #"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R-5MMNXS80?==7#+3%8@,XMBQ?DS@&<MFBP2*;($[;AZ(/M#26
MB%"D2E)QTJ_OD)05%^ND?;$I<BYGSES(Q5;I)U,B6GBIA#3G<6EM?3H8F*S$
MBIF^JE'2R4;IBEGZU,7 U!I9[I4J,4B39#JH&)?Q<N'W[O5RH1HKN,1[#::I
M*J9?+U&H[7D\C'<;#[PHK=L8+!<U*W"%]M?Z7M/7H+.2\PJEX4J"QLUY?#$\
MO1P[>2_P&\>MV5N#BV2MU)/[N,G/X\0!0H&9=188_3WC%0KA#!&,OUJ;<>?2
M*>ZO=]9_]K%3+&MF\$J)WWENR_-X'D..&]8(^Z"VOV ;S\39RY0P_A>V038]
MB2%KC%55JTP(*B[#/WMI>=A3F"?O**2M0NIQ!T<>Y36S;+G0:@O:29,UM_"A
M>FT"QZ5+RLIJ.N6D9Y<K+(AB"S<R))B86@PL&7;'@ZPU<AF,I.\8&<&MDK8T
M\%7FF/];?T" .E3I#M5E^J'!6Z;[,!KV($W2R0?V1EV4(V]O]!]1/F"MM.6R
M@#\NUL9JJHD_#X4;K(T/6W-]<FIJEN%Y3(U@4#]CO/S\:3A-SC[ .NZPCC^R
M_G\S\J&1PQ"_*XO1'#Y_FJ?#X1D<< 2/)497JJJ9? 5J?,TL&F RIY*3U*,&
MN#6P;@RY,W1@0$FDWG2LLK5 +QKT',ETSB C;#QC HPE"[#FJBX9^<NPL7X_
M:_UM%-4[DKX$2S!R?*:147N(SBR)5:@SS@3_.X!5&Y"*A(!752/Q6$GJ!E6\
M0JU5WF0.*6L-JD:[W5ISM#1[X%'S8U-CQC<\@V]<"-14O 4!U/"%#K]]I7S.
MQF='O<CY?D2JE?<5KAL*XY'I GW8^_I0"V8=OZ;OR(4*F6DT.NRFY9\9@X25
MFY;(C@*"+YC,$'Q[1\2F598\!87^?K)\3F=G!J[NKF_)SK.;7K#ADO2),>![
M.?8%(9T;%UI.,>64V)*JU"I@0JB,LDXV#)&6X1Z)DNX(3AQ7"%^$,N:H#]^[
MK2ALN3!\%LD?X#,332B%-RA4'1X+!=:'%2^DHY1)&^WXP!>Z<8RK-9F))O=0
MD.FL;/%V9=$#0P112DV/9(E69[/GI6AN9D_' ;FK+S+H@^_#75>=/_BAV".-
M[B9SQYDRE!6)1(%Q)4/DM!WAJVG7!#W8EIRP46G1K<;%:V<.7RQJZ2+6:D.2
MY-YU ?4BS]JN4I1E#2RGP<[=.'(W5(>K'[F"V2C*R-8!"AW69L_X C%O],$/
M]+TYV!UQBY6KLJ(AV@AIJ!.B:/WJ8W+%<PHKNOCS1F!$-7I@1A JC1CM3WRX
M]>FA@1VY@>VF]CAZ>"=K\!,,>\G)22])$EK/9C.WBE9M*B&=#_W1>#;W!S>[
MS,(T',RF0>&=%,/(2PV3U(L=R/=X/@\BO>DD^+CS-.UJ>]@;3KP/.((O\W02
MEA'5>N1JW(.>MO#37CH-ZT.C?[!W,=/P*OSSPQ#<1MIP1W>[W0OG(ESL;^+A
M>404%U3D('!#JDE_-HE!AR='^+"J]M?\6EEZ-/AE2:\TU$Z SC>*QG_[X1QT
M[[[E/U!+ P04    " !H?*]:7F(6%3 )  #)&0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6RE65MSVS86?N>OP*C;CC.CE2C92N+X,I.D23<SS=93
M=].'G7V 2$A"0Q(, $KQO]_O'( 4)5FR9_?!%D7BW&_?H:XWQGYU*Z6\^%X6
ME;L9K+ROWXS'+ENI4KJ1J56%)PMC2^GQU2['KK9*YDQ4%N-IFKX<EU)7@]MK
MOG=G;Z]-XPM=J3LK7%.6TCZ\4X79W PF@_;&[WJY\G1C?'M=RZ6Z5_Y?]9W%
MMW'')=>EJIPVE;!J<3-X.WGS[H+.\X$O6FU<[UJ0)7-COM*73_G-("6%5*$R
M3QPD/M;JO2H*8@0UOD6>@TXD$?:O6^X?V7;8,I=.O3?%GSKWJYO!ZX'(U4(V
MA?_=;/ZAHCTSXI>9PO%_L0EGIY<#D37.FS(20X-25^%3?H]^Z!&\3H\03"/!
ME/4.@EC+GZ67M]?6;(2ET^!&%VPJ4T,Y75%0[KW%4PTZ?WO?S)WZUJC*BP]K
M_'?78P^V]'"<11;O HOI$1;GXK.I_,J)#U6N\EWZ,=3I=)JV.KV;GF3X6=J1
M.)\,Q32=SD[P.^]L/&=^Y\^U4?S[[=QYBXSXSV/F!FX7CW.C*GGC:IFIFP'*
MP"F[5H/;GWZ8O$RO3NAZT>EZ<8K[\^)QFL4_C5?)I?CIA]?3R>1*'%I_9_5:
MXLQ= 2M*>F 6N*D6REJ5BWMOLJ]"5KGX4UHKB>*W*ODL'\1D&F(R%'ZEQ'M3
MUK)Z$&"@B$Y7W@@I[E766.VU@J#&9BN4C'B[M"I(.B-*4FV:7IT\R6<F5R]0
M#W[%\NIXQKI$YSBA%QI2\<0J78DS5 *7^EH5#T'!*.:NH^MXUM:L=:ZKI4!;
MX[/:N496F6*[G2R4@#'T8$M-7CK3+T13T[.7PW3VDO_/AK/9;(0OL^'%+!VF
M:3I*4Z(CCCZ)?$X:.Q1*9JNM+%0X_$KFD*C6<.%6$AGW6+3821)-;@F62P17
M.(__N5C+HE&@2(+6?Q/3*6E(?V)R.7P=+T\&>*$+<)+BO;+D](S80X>?E=/+
M2G)S[512\*$;"F[NCIWYJRZUYU.L^;VRY(-?Q23]$1*J-3&=P]^=24DPJ9\I
MQR4?I@D<;97'@&%I/I+P$]_1%W(#5X[$'V3F4>8)..%NL,/5*J.4<\S+!@.?
M95"(T1 %DA4-9QUQ0-&4@7-FJEQ'!U5BL])(A6VH79.MDKKCY4*\35,P(4D+
ME;>E,(VEV)5@%B5+)S88?/2IH76AOS4Z#Y&KN["-#G+V1,#9(\W\KYBB&4X"
M 0BSJ5 I*UU#1A?VD$W[*4LI/E>M#91@7E"V><Q\N@9-8NHVN_9*<<_B7K9R
MVWMUY78\$'B#"FZ6193I@ODZ8^-0&:/TXAQ11!7\G]6[T?#U/#05&$9-0[;Z
MQ)X::?K5'2I4BJHIYV!"H6\-3)XT$!T>AH%^DB(-.Y=T=MX'5@U&M"T>VASL
MQ20\CQJ3<YL=DQ#OY$RS(5^4\\0@6A(*57U7-M-.SG6A/9=>E\?PQ1HDP@*?
MS NT$VO*$&5R+GUJBH.IC>5H[S?>SN S]&JD;U*C<K3GE'&4D2Z>>-%JH=JZ
M>83)+PA:Y59&M3VJCJ$FN?<1*TY'%_M)MPWWBQ"[Y)FQ>SHYN]C1R2V'K::'
M<3Q#)0-[8O+G";SW9(HB;G5=H)+G8;+M.H=:$_!Q9FS.,[#?2X_SC-V3+4DZ
MJ+"2:]6OM2XD!Y6VP*@6#TJBG ]N@'-RD)P[D&1NH",+6S3(,"07]A4?I2";
M? O[003J?K,RA!F$S/\"O"9#'#?(16/Y?JY<9O6< 0TWH5-C+X"'5BGFLW7T
ML!6*"U, E@3'PI0Z:M+3@:2A+U51[2X$K?^2G8P(N0MY8E$8:-%S;CJZF%VP
M ]OY32[8ZY][F V801,@9M%QM,D.L_4K)%1U'QWP.6X9A!/VF3$,(2[)8TE%
MFGWX#J6J9<@D]!^BR@SRO6U2=3.'0\EM!,NV!;4M( 9OE-E-S<1=M;0UO <M
M2"P?[?>+?B"[U&8+5](]UTJ.&R)YGHI</H!L 3\'@-G.GL(X6)9P7O)3'@3Q
M=JM(7S&Y'_?_J5J'I/M<90;]5BT6 2DGE1&%#"JB9B]WM(:AT&@D/K%*X)5C
MZ:=EPW%!5<:+4OE=J-A.OD)S/ A=MV #WLMEB46?F^)D-&O'5((JH9(+LUZ6
MIJ&<DSH7\X?]R=I/Q6<TJ(^AIM'?=MJP6$A=.!Z^ "'<"[=:)JV6,92O@D_"
MU (/.D1TH<(/C">.FJO+^;"<D%$^9+*E:6>90=$X (T?20FV<66*//1]AI><
M7<J2D,1U1AY"M*=B_FBADBRD5:F4CSE'J)"195##M1JC&1>:+*EI6T9;*X+]
M75XGR-2LZ:.TT_M?NV\AD+4)^6WF!!U)D9X&U$:QI$'>_H8VC'UYN^L,J3>6
M!CG)63RY'%U>BK>.B]0UA6\UJ\/>"]_W]MX.62>NZPU9:"X1:K<3!\Q!D<$Z
MZIQX?GQCFBMX;4UXRG/WZ+LV8@":^HR4:$0!ETEL!I1]L)I?M=&[)LVE JF%
MDH@!#<Y9$K=WL=W>?XNJ7#QC.P^F)1&==/A%/KJ@/[65ZXJ G4&Z'-^^/[5G
M.E*+[8OSSILD*!3 7'3(0F8!0_8U^1AOMDRVA; /%X]E/X6A6]P.,6@"+U,1
MQ(V#(!(M3)%Y9X3HUNA4W&,<=0!O"_=VDF>?/F$ ?E3A=E)#HUB8I#K-/<SZ
MMK?FBE9'@G[4('?:VF/(FDL;\$/DVM%F3'LMR6%VN:I5Q<DLQ5IBD0W8'3$@
M;7LKZY :,ZG$&(D:XQ*/2VF_ G1M%]C@<XQ%7G,[5$(W=_Q""K1VA"4QV;.%
M2MMVRW(36@6*(T,/Z_;B(VX/X[MB.!@)V#6=,\6I,"1[GJ%3"\NOT+( X4*@
MV#KJE,,>*CJ2!XQ J>LB,'_T$R*HVM7ACL>.Y13Z4+)3XE1Y[GC.[@_-1]IR
MFUN7YZ [AD-W^WS+)7ERW/!2>:B6I-[[]P6%(F^[[,Y"?!Y?3MTK[XL0&LC^
M@K!@)-R%"4P9'D#=]CTGS<;/$DRZE\B[FL4E-[RK:S^F0=ACKW#'O=?KI;)+
M_A'!P4L *N%->W>W^YWB;7@]OST>?N2 6DM=.33T!4C3T:O9('2D]HLW-;^L
MQWKC3<F7*\ N9>D GB\,-IOXA01TO][<_A=02P,$%     @ :'RO6M*7;F,#
M$   ERX  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK5I;<]NX%7[G
MK\"X.YUD1K8EV7&<FV=L)VDSW8LG2KH/G3Y )"2A(0DM0-I1?WV_<P"0D$UQ
MVYV^)#(!'!R<RW<NP-L'8[^YC5*-^%Z5M7MWM&F:[>O34Y=O5"7=B=FJ&B,K
M8RO9X$^[/G5;JV3!BZKR=#Z=7IQ64M='5V_YVYV]>FO:IM2UNK/"M54E[>Y&
ME>;AW='L*'[XK->;ACZ<7KW=RK5:J.;K]L[BK]..2J$K53MM:F'5ZMW1]>SU
MS>P%+> 9?]?JP26_!1UE:<PW^N-3\>YH2ARI4N4-D9#X[U[=JK(D2N#CMT#T
MJ-N3%J:_(_6/?'@<9BF=NC7EK[IH-N^.+H]$H5:R+9O/YN&O*AR(&<Q-Z?A?
M\>#GOC@_$GGK&E.%Q>"@TK7_7WX/@D@67$X/+)B'!7/FVV_$7+Z7C;QZ:\V#
ML#0;U.@''Y57@SE=DU86C<6HQKKF:N&U(<Q*+/2ZUBN=R[H1UWENVKK1]5K<
MF5+G6CGQ+/YZ_O:TP=9$X#0/V]SX;>8'MCD3/YFZV3CQH2Y4L;_^%"QW?,\C
MWS?S48(_27LBSF83,9_.7XS0.^OD<,;TS@[0&SKP/ZZ7KK&PFW\.'=C3.Q^F
M1\[TVFUEKMX=P5N<LO?JZ.K/?YI=3-^,<'O><7L^1OWJ1CKM2&=W1+MN)%GX
M$).C9(:99-K9(]KBRT9E$C*JMK+>D91R TW63A5BI6M9YUJ6PF&R@LLV3DBK
M1%O+MM"-*DYHN4L^"%TWRNKJ]ZALY+T22Z5J ?ZVH%EDFCPY-[; ; 5G:3;\
M=]#=UFH0V9;0WEK5RLJRW-&XVOI=1;-1XFO-/"QH'Y;B=05F<BF>_?E/E_/Y
M],U?KJ_O^.?LS7,AZT+([18V(9>ERFQ+Q.FC5>NV9.DP$:*\4'EK=:/#C _?
M\XVLUTK<FJK2CI$L[K'X<-MM 4K2%L1_E$LO#9S;6#K;B;A5M@'.0@0>C1G5
ML$UM&B4*[?+2N!9*PP<,T\DAC+(M^I,/"CF*5@R(EB21:*%35V:L,)5N2([;
MUKJ60*,Q /=\(P9%=,*8PJ<L=Q/BYH\8A-N8MBS 3$8AB#C&@G^UM8=X9OG@
M.:.H'$VQ"MQB+0FTE\^MMV]2S.SE&R>NZ[H%D<^L X$=*!*(V?3X;P(JR/Q6
M+L>4G9)6* (W\5[EJEHJ&^'I''-*?.^X@^J9EEK:EK!W'F!,/*/18!^\<&__
M:"[L30A%):DI\[%;L@D^W;DS #JQKB?B 3,+2/J>)&Q-Q0Q%)0R++5BW;$2!
MCR?B4\T'-UM=D] Q6,D:$9RF3SR]%"AZ'?^.;H,V!"Q7R.)?B'W^>XU3.4>"
M@LI64EL8]M9C4S:DM)[XUCC=>0E6(%+S89#3V."X4".S'.T/(]H4CA(.2AP(
MN^#%@ ^2 UE/,7G,8-:;D9<R@Q^VD<$100RP8$D8M6S@H2?0Z!@SP:8B+^&P
M^_3!2R<97>X "@40BE(<(II8Y;'J#W\B1H+/BR[XO!@-/DFH_. :71&*#L6>
M42K#L:<GG76D.?1XC/*0Q\<;L!\/!@2-NMDE\&75;ZTF6.S-E"RIDM^44-TN
M#/,.R>G6ZX(-7JY6, +6B<=A()^LB$56'>:K "REEDM=]M#?PS%-) O!H6CG
M0VO\+N1A,9@<!#$,9I$=D;!CU;VJV\" ^KXE7X.WMVQY_1DX3K)I$28W+1NH
M-\><T;70.+:-\&!<(J:3-$O,>ND%G$E$W+EC/XG,VTNB571ZJ 7 @&  O  2
MEG[&%DZ&.> JD<]D3S>M\Y#-0$;&PN(",HA[6;8L0![R[K!'AB9T9D2&T5"4
M1)K7!B/"-@108*10RX9%2<:I\RZDR5+_NR.! D!9"IZ-_)YYW8XZV47G9!>C
M3G8KW49\ ']@F!@;<K!1"L,.1F2SA"P[5P!0THW3$!SR+M0R0%FO(LCG7D4P
M9K>J",6\W;*M6@7-^_P><D/P?V+/,@>E",:P,SJ=2MC0/J;\H< !*VX$Z@%D
M'K$@8$T]B88(3J;!TB>[/VPT%O/Q74.I+PZC=CBF_8;8NFKK@@R0'8TT;2@?
MM.8[FS7$](.8G\S%V<GEF.)?=HI_.:IX1(8&R2AM1,H:TOLH@6&]]U0SMJQK
MSO#WA39)4R D?5!3"8N&LY,*?.[I91=R#\X-;,\OCV&.ADB'E!>6"4Y9W$GV
M92!X/R%'Z0K'\9"@)B9 ?JN;MHOP&U42AF,.JF*DG93^LR?C UQ4-R!I,6,-
M>R7+R;J,S,E*#1,>=>;+3J>7HSK]2-#T]PA-'[M]/O7 ,Z3G4:+#>J:=LO&=
M^J]9$LE1#-4%I./$C2$AQ3+EX_7BIJM3!N??FH+C09-6-]>+OKJYG$^/9],^
M#!.Z,W; D4*85 ,(OJ^.P/Q$+ U5?,-!%'F6073Z-X5%G^RGGXS/\?>LD,W#
MN[]N,DVY%O6)N-0C_F+P2G@#W"QNXZ$ _U"+$T_9?VRH_@!DG@QT#":$DGYS
MGX+&65D>JAQ$<5]!!MNG-)+3%RMK)WW1LU3- ]5F#[HL.;1+2\+@*B'SV%PB
M,2B[(C7A<Z/A(\" ':>4D@)P69H']UK\2$NR&5MMR$ZI^<52A&]S]HN_?FL-
MEX"6XZ..7;8 G3Z@(Z34)-(RJHUB1*(USK2(,38,CSPL(YZQRPAO<TIT3P)7
M\T&N]EFAC9VN=(FR;'#;R5/>(],^]0LYMC_0A%8;JALQ<=LBZ>\FF27Y'AL,
MY3>2- ( LM8L#3)6PKU=.@DA47KVVB6"&*<Z""*LF1:5!6"KBJH:Y#R*X6Q0
M#)Z]_@QMW>\]P9[;D#<N*;PWC>>Z-C'8\7%)"S[1#$1<TAJ$.O:M*!MGELP0
MN&LYIB?9ZE#IYB7<.\ZPGT]\FR'F$33Z.*1/?%=#]WEP1M,\_>A%GOHD]H_@
M_'+GQ<3% "6EJB<P2:,^<8_S]T* !E0ND9C&H[D-M0Q"ID3]U<RW/!(P&Y3-
M(=$\8!J)/\J!6[8_B-G\8C*=3L7\Q9S_'XE6K[IH]6HT6OT:=OHQ[C04FT9)
M#,>F0#?KZ.XEG\IGYN2)C1L&?PX8BOP#VPF]\F:03B!;[3-_ML7855@I+KV#
M9_R&<D.O=F1#E",6!1*C=.% *XQ0_XO9ZEQ<SI KA4"'++-?16;S5U6L29O)
MV3H=!O-(:I/A<^JT>UD"Q4+:&6R@JU*6N[V4S?=H#,-61<&-!G.8'_:3&4%.
M*'@:%#&-#T=DZ%9QF+34)X) ]KSW5Q4I$O/#['*MU$N!,RYBQTKN:6Y;BP1.
MC==%LVE_83$=-<]%8_)OQS>,=W1R..?!]O<XJ6$S3>AG*?T]:_7U,P4UZK*2
M-APJ$EKH@3A/%T)S9@7T1&4U0<8#63>&?JIJ6YJ=8FBI.5&F*IP5S/$AEIV6
M^HJ66E$+-GA'[58,9%26Q6)?6Q5,EJM]PW&$JV] FD:R4\2:+*X/[;Q%SW8&
M .P\[7]E&2X3LQ5F?VVH=Y76SY.8:85FP=H;,Q7B@:R7869\G3_I3#-D<&-=
M["X >F1FVK[\3$'Z@%^_G%U.]HSIF*6RK_\QZTVNVV:_5]XIKKI\A8HX;K;L
MB1]"F!DTXU&:!RL^WB@[M!'.ZY#'0!DM-S!(9S;EKD@6D2)"(&2,B*M\+]HA
MI;8<F)> K95N@GF8>V4WU*?/:2M2-/S&F;I6)9>%;<ZUA$U937<]$ H1A6FI
MA_OTBN,@^S&&GXB[%N-L*A3&@8NEV\--NNL 'T*6&*T#2+<4.1@ .4TNG>F$
M,0YJ\]XLYJ-F\3/0^D?CG+A#?K+88)M!.Q@E,FP'H)SM4Q9TPY=GD%0-Z3OQ
M# 68>TZJ0=+"(G6,7RU%G=;%YN$#7W"KXA@2LA).7K?<7>'V9E7!07@UU(S\
MDZI#6I@T'V/+\;TNF7+</_M_[Q]:I( M;$3Z4[Z+N]^'?<IL-L#L76Q& N8[
M>D^H1&!#*5%Q-S[VDFA/AC0/NI3^MUM#0*ELKGTVX,<#Y!'S61?F^XLW(*NW
M\N[.I@AB).$ELD-$RL.56Y>1>D0,4M"T1Z./XVE\$NKK/G^OZV7)7.TUR11C
MP/Z%HM=3UPVE3S5,^1%3_Q4CK\4B1Y1J2RXHKM.AY%XUXYY5UC7ZGGV-C:;G
MA ]GK]Z$_\3>Q//#$[-?8L??4*K"Z+ OA=G\?'*!W)IR[?G%B^S7J)^G*[*P
M8O+RXM7D\M6Y.)N>3UY=S+,OW'G<.W#F^MOB&4V>G&/!.3B>SU^.PDK_J&$V
M^@KAZM8@S-6-/9P@_8%7#'M$N4F9/>[2F?I@.RVYNW2A8T=IB7Z<\W>-/8SJ
MBF]O=E19^S2#6LS4X%(%-_G>^\VS3TA'+(?V6X.DT^XWI3Z^_]1WI70WE1-L
M)M=N2:4_H)B:<C'U4W]AM%2E1D )=?]^%I*P&X+)QI3%8.CR!:M-5@,L'.H^
M[EA-^@R.[LA1YFBZ/@S-2ZL=//([8"54CFFK5N[5Z/F>BBC!BD&_#_<$)*'.
MW:M^202WN\;<DW# $:)JR6T,:BSM)AV\?JUAP]91AX9:R1I1W<'(49PCC_N9
MGB2<<9$TF[V)C4,$H; '$?D<Z-X1W?$XVK^+F8T_C%FH-:OK4_]$8M#L_\"[
MF$ Z2T@/%GFW&ZU6R++@W(Q=O_@\FH],3VJX'=;9Y.V'7WJ3I'"$BI4)A&MA
MBJ$*H8)VHQM+VZ_\Y?U/<2EG3GT%C:7,(UDWC=!"-T 19K-$ *0+;9/+F(N!
M!_+-+J'N#9U;5_UMM.&6),B84E.F761+>CMT(FYB*P2G(383UI++^83))Y0$
M4WIZ(]&5_Z$Y!;?PQ_*7$>0%\)UX/<JFYH))4*@R?*3'UZO)RX"_?!$WVFP1
MM2I8\J<Z'[?+_LI\-GYG_EF1/^X]J[.FQN]<'6S__U<DLX,DZ9W&S\C .4D*
MUU\X-C7T8__@>O&51XZG9WQ84RG_*HH(''_N;HM) U9MZ"TF#-I// YU!/(Y
M)]=K>L+$+O$^>8?T;-$N&VJ99##8X_/I\]>/9T/DC_?M"I1)N#+P/004L?G@
MU8&01<$7BXS$R<LH-FVWA:VO:*FGFL'.U=I0M1)SF/ FR!RN+?E^J7LBPJ#I
M'^8$>T_D2$[L$QRN'(Q-GV)0DW -H*1D4ZY K;^CI)822%QX?.6V^:,7*=U2
M,;STY<37L]B'WKP5/J.DY?Z=E@^]T9DHQ_9MT'*7!?>,R:_&%)\O>RKXG)SP
M9!#UDK<5Y*?1X0M^+./?'N2\6; ]E(K0#E5<.^2+G<0FZ6,^U]TQD4S6K?95
MNX^P5*=Q:AQLF5X.6.,]//3%V-2[OGU'[=BIANDO3>'O'ZQIU_'A&-^A),\P
MW,A#C,(@(: SA.P@-/&Y6NP40&*$P+E7N=WW4+JR\4F^[,K1KEH9?I$V_+@I
M&WS<=#($7:?)6^%*V36_B.:7'W7CGPUW7[M7U]?^K7$_W3_91H8-DW2B5"LL
MG9Z\!&!9_PK:_P'?YY?'2],TIN*?U Y0EB9@?&7@>N$/VJ![BW[U'U!+ P04
M    " !H?*]:Z3*L-^@"  !N!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q]5=]/VS 0?L]?<0H2 JDC:9H6*&VEEFW:'M 0A?$P[<%-+HV%8P?;
MH>R_WSE)LU8K?8E_W??==_;=9;)1^L7DB!;>"R'-U,^M+<=!8)(<"V8N5(F2
M3C*E"V9IJ=>!*36RM 85(HC"<!04C$M_-JGW[O5LHBHKN,1[#:8J"J;_+%"H
MS=3O^]N-![[.K=L(9I.2K7&)]JF\U[0*.I:4%R@-5Q(T9E-_WA\O8F=?&_SD
MN#$[<W"1K)1Z<8OOZ=0/G2 4F%C'P&AXPUL4PA&1C->6T^]<.N#N?,O^M8Z=
M8EDQ@[=*///4YE/_RH<4,U8)^Z VW["-9^CX$B5,_85-8SN,?$@J8U71@DE!
MP64SLO?V'G8 5^$'@*@%1+7NQE&M\C.S;#;1:@/:61.;F]2AUF@2QZ5[E*75
M=,H)9V?+YC% 9;#D:\DSGC!I89XDJI*6RS7<*\$3C@;.'ME*H#F?!)8<.WB0
MM$X6C9/H R<#N%/2Y@:^R!33?7Q @CO5T5;U(CI*>,?T!0SZ/8C":'B$;]#=
MPJ#F&WS =RC<7_.5L9JRYO>A@!N^^#"?JZ2Q*5F"4Y]*Q:!^0W]V>M(?A3='
MU,:=VO@8^VQ)E9E6 MVCS4GUIY2+RB4W+#&I-+<D_Y#FHZR'-3_FZ&5*4.FZ
MNTE445 E45(F+X"O%7]C J4UL$&-@.^)J.A]@4NP.3KKLK*L+CY2ZK8D=1FA
MC($2J3'DC% K3%AET!US#9AE5*[ #;#=P,:PC=D[$K-':9'DWC8OX.Q)LBKE
M%M/STY.K:'!]TPZP9QA_;.C]*)U\ U9!61&&ZG__%OI1W!N%(8VC7C0:>L],
M:^:NY'^$UR)ZEZ/KWM5U#(,P[EV/(N]162;V _9,%Q4!R+@7$R FQ5%T"8=R
M*-CI 07J==WI#-1YW;2#;K=KIO.FA_PS;SHQW<Z:4] ",X*&%Y=#'W33W9J%
M567=45;*4G^JISG]$% [ SK/E++;A7/0_6)F?P%02P,$%     @ :'RO6LK;
MA $R!   [@D  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULG59+;^,V
M$+[K5PRTR2(!7.MARW;B!V!G6S1 TP9YM(>B!UH:6<1*I$O2\>;?=TC)BITX
M/O00AZ1FOGE^0TZV4GW7!:*!'U4I]-0OC%E?!X%."ZR8[LHU"OJ22U4Q0UNU
M"O1:(<N<4E4&<1@.@HIQX<\F[NQ>S29R8THN\%Z!WE054Z\++.5VZD?^[N"!
MKPIC#X+99,U6^(CF>7VO:!>T*!FO4&@N!2C,I_X\NEXD5MX)_,EQJ_?68"-9
M2OG=;FZSJ1]:A[#$U%@$1O]>\ ;+T@*1&_\VF'YKTBKNKW?HO[C8*98ETW@C
MR[]X9HJI/_(APYQM2O,@M[]B$X]S,)6E=K^PK67[ Q_2C3:R:I3)@XJ+^C_[
MT>1A3V$4?J(0-PJQ\[LVY+S\Q@R;393<@K+2A&87+E2G3<YQ88OR:!1]Y:1G
M9O,TE1MA--RS5[8L$9C(X %+9C"C,V5>X>+)?M"7D\"00:L6I WXH@://P'O
MP9T4IM#PL\@P.]0/R-'6VWCG[2(^"7C'5!=Z40?B,$Y.X/7:Z'L.K_<)7A.T
M=E%3*M2&E1K^GB^U4=0O_QP+N4;L'T>T'+K6:Y;BU">2:%0OZ,^^?HD&X?B$
MO_W6W_XI]-DC<3+;4)5D#N\K=\S7TV@[!&_=U#Z51#9-D 1O"H1<ED1:+E;7
ML+/L';'LS9V&^_6H1&GA[6H$Y_ -4ZR6J'9G?3CW6H3&LF<DW+P:^<)$BAU@
M1/>Z ]>N R,X@T$8=L(P!(=Y!E$G&O7<02\Z @@$^"R([TIS B#O[K@0J*5A
M,(BO:J0!(0VCV&VB$:'\ABM6@BT:3ZDI<JXJ2*Z&;W:C3A(FM=6K8U9/"?]!
M&54TA=ZK)/U:A?("_:2.*8I)X8F<+3\JG$'<Z8WJ9$3T9[/1ZXQVFO;$B]H:
M>?=O"6DS# LN2[GBJ>[ K4B[</'URRB.PW$KX?;1^-+6XF :=$!SB]!*>G(K
M-*SH0C 4GBF8@.1\UT WLEHS\6K1HN%8 ]=Z0TB6;71!:$,+ZB[JNZJB"4W#
M+OW>A4=$^%T:](;@%*.QQ:FXH;O U%2]H;%"BBA2CA3#(U\)GO.4"0-S<@6=
M9/<$X9*6<,G_)IQ-Z4%NCC'P)/SQ:?%4H)>A8;S4G^7Q0U,<5'>+BN:X;NBK
M3Y/W0Q3>4T$9]-XF-R7Z/:L/MGWOXEFP3<8)XA+VUMX"5\0Z6^$E*YUK^\2U
M;9M$CB'>K7B1EG,=$/0027IQPU#'5-O#=>VY@)3I B[BP<A)D+VH,VI&P^6!
M("7TIWQC+QYORY2BWB!T9B!G7,$+*S<(%Z/^L(%QJ8W'7AWOGK^[N6,]OQK5
M7#W66,'>'5RA6KF7A@:7[/HZ;D_;Q\R\OL/?Q.N7$&67\J:AQ)Q4P^Z0FDC5
MKXMZ8^3:W>A+:>A]X)8%/<A060'ZGDNB3[.Q!MHGWNP_4$L#!!0    ( &A\
MKUJ,RH$45@0  !T+   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+56
MVV[;.!!]UU<,U L2(+4E^98FMH$X:=  #3:(T^U#L0^T-+8(4Z*6I.SX[W=(
MV;*R<5Q@+R\V+S-GSI!SJ!FNI5KJ%-' <R9R/?)38XJ+=EO'*69,MV2!.>W,
MI<J8H:E:M'6AD"7.*1/M* CZ[8SQW!\/W=J#&@]E:03/\4&!+K.,J<T$A5R/
M_-#?+3SR16KL0GL\+-@"IVB^%P^*9NT:)>$9YIK+'!3.1_Y5>#$96'MG\#O'
MM6Z,P68RDW)I)W?)R \L(108&XO Z&^%URB$!2(:?VXQ_3JD=6R.=^BW+G?*
M9<8T7DOQ@R<F'?GG/B0X9Z4PCW+]%;?Y]"Q>+(5VO["N;+L='^)2&YEMG8E!
MQO/JGSUOSZ'A<!Z\X1!M'2+'NPKD6-XPP\9#)=>@K#6AV8%+U7D3.9[;2YD:
M1;N<_,SX!U.*Y0:^<3;C@IL-G#RQF4!].FP;PK=6[7B+-:FPHC>P.G O<Y-J
M^)(GF+ST;Q.OFERT(S>)C@+>,]6"3G@&41#UCN!UZF0[#J_S!MXTE<I\>D*5
MP0W.#/S\1@9P9S#3?QQ*MT+K'D:S<KG0!8MQY),>-*H5^N./[\)^<'F$:[?F
MVCV&/IZ2_))2(,@YO+ZD)YIKY@I;'V)^%/LP\Z<4O00-XT+;F.MM3%''-(V8
ML$:%P#3,I2!=ZPO8\?5^R==[2A6BMZ\5GB\\NNHX]79W#2^F7>_D>\[*A!M,
M3J$Q]B:XX'E._J1,P?(8X3U$O>@L" (:A6=!-?;NM"[=]CXQ#<S G'$%*R9*
MA(_OSJ,PNMS]>]<IRQ<(/&\:G811WX$3C7[OO!IZ7YX-42BY3NFU,J^0J@P;
M#'<@[Z'SN>M&1^JE5]=+[VB]T#EU=@>OX><]9C-4!ZOZ*,X_K.I^S;+_GRJP
M_S]P'=1<!_]"@5=44EGQI@"/0UNM-2^LH3*NJUI+H-2V;!A,!(N71$;2JPR_
MN9!0*![;W4PF:#\9)@63XE:-SFU/[U?:;&3B2'F[*OJ[*&\P=E5U4)?>U,AX
MZ8@Y%;;"GBWP5M#S'KE>?IJ3YDE-AMX-;4 Q@Q#2]OEG^ #=5C2 #Z2C@K[5
ME/E*"F8J<A&$840F8=AM6@@^)S62.#?(E#Z%#@4<] @OLC^DJ$ZK%^S-$[[B
M">8);#B*!+JO-'J[UWCSB6AJ=?NN>"%,J M(P#8EE(7V*!_Z8I+Z:7&V<?=P
MBPDJ)N"Q*DKRR)=>!%\Y?<_I@&AGGZ*]%.MS+;."Y1O':'"I(9991C&T.U:J
MBM(&-1(H',_L\;D++TU)#W'CP B-FY?>7H>NC@Z>VH>:HJ?0MFRV5&)ZB!6]
MS271<N>Z)40I\!6S31/=FS:JM*^;U]VGG\OZ8+57,$Z+"G!WYD1UAF"7#VFQ
MW6A9,E0+UYA9VF5NJNZE7JU[OZNJY=F;5XTC52E]!30(G)-K0'7@@ZJ:L6IB
M9.$:H)DTU$ZY84K]*RIK0/MS*<UN8@/4'?'X+U!+ P04    " !H?*]:4.;@
M.KT$  !$#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6S-5VMOVS84
M_<Y?<:$610((>E#OU#&0I-E6H&F#I%LQ%/O R+0M1 ^7I./TW^^2LA3'M95D
M6X%]2"P=\AX>DN=>D:-5(V[EG',%]U59RV-KKM3BR'5E/N<5DTZSX#6V3!M1
M,86O8N;*A>!L8H*JTJ6>%[L5*VIK/#+8I1B/FJ4JBYI?"I#+JF+B^RDOF]6Q
MY5L=<%7,YDH#[GBT8#-^S=7OBTN!;V[/,BDJ7LNBJ4'PZ;%UXA^=9KJ_Z?!'
MP5=RXQGT3&Z:YE:_O)\<6YX6Q$N>*\W \.>.G_&RU$0HX]N:T^J'U(&;SQW[
M+V;N.)<;)OE94WXI)FI^;*463/B4+4MUU:Q^X^OY1)HO;TII_L.J[1O%%N1+
MJ9IJ'8P*JJ)N?]G]>ATV E)O3P!=!U"CNQW(J'S'%!N/1+,"H7LCFWXP4S71
M**ZH]:9<*X&M!<:I\5E35;@XUZK);^$+$X+52@*K)_!IH9=-PL%G=E-R>3AR
M%8ZGH]Q\S7W:<M,]W %<-+6:2SBO)WSR.-Y%G;U8VHD]I8.$%TPX$/@V4(]&
M WQ!/_G \ 7[)E\R*:&9=A.'1H"Q)7S]@%WAO>*5_&O7Q%O><#>O3J0CN6 Y
M/[8P4R07=]P:OWGEQ][; =5AKSH<8A]?8V).EB7?%'ZBS5VH[[NT#K+MUFKL
M0%9K<H7_)<M;.V = #7G^"<XAZK=8*XW&'![\GF_/[#B@@/3$26FOCR"3CC9
M(9Q\UGQDTS!;?.3CLKKAPLS:Y!KV.+GC DL'Z8U[?L]%7DA.+D61;^!8CJ1"
M5Q?U#)B"=SSGAFQ-'H)O^]2S0YK!:_!3)XW(KSH2Q\@BWXZ"$*CC100KP907
M"+LYJW.L)=CAS:N4^O1M]TLZ#1,X"#QJ>W$&A^ [0;17SM;"^7829W::A5J+
M[V3^0R!ON75&/B<0!NP6]7:+GFVWKB8,V6V0;8_=-HRQ/<2_,T;'MN6+#G[:
M%C2T8\_#]0RH$V>]*;;W_&6^V&[9(V=[=[>T=%%/>,)+["2,=53BA,F0(^+>
M$?&+'?%I4_K&U^/\0=PNLPP.M-LL:V;R:+%,%=^:.</R\VAM]I2B%TR!M(5Q
M1\M.">2*U3,S1K?W8/P':\=NCMA9EZRM"U=<GZFPB9RA]P76WR4KX4,QY7#P
M)V="'OX8LV7SUUBT?!]B.TPI9(XV@0:([SF1!WYLQW$,J8./&B TTG#DV1ZZ
M+'%2, !)0B?T( CM*$L1#L  I#/6@*&2WE#)H*'Z\O;UPN3?SD_N(,4__.2F
MO<#T)QT4TI^@.NM59R\]*/SH\B<2='"$W?J[H?Z[#'V.^/X;208Z_4^SU',P
MXWPLZ[%-(Q\^NB?0@02/'11B+[3]((7 H?H<0A%-@R0"BL>6,(+0R:!%2(CG
M# B#Q,X"'W$*&B"1$^KN:6JGF-H:;A$2Z%&0IBT% 2:W00A^*W2%"$PI0&HP
M .8\U?U].XT3%!A "Q _CC0>43OP8VS(H$4(]6('-QHK1>H9O 7(PTDE<**!
MLXJ[<;.IN)B9^YN$O%G6JKWD]&A_13QI;T8/W=O[)6[ZK,"B7?(IAGI.@@<5
MT=[9VA?5+,P]Z:91>.LRCW.\YG*A.V#[M&E4]Z('Z"_.X[\!4$L#!!0    (
M &A\KUI9%>V7L0(  /(%   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;(54VV[;, Q]]U<(WC"T0%;?<G&[Q$"S"]:'KD72;0_#'A2;L87*DB<I3??W
MHZ3$RX T>XDI\?#P4 PYW4KUJ!L 0YY;+O0L;(SIKJ)(EPVT5%_(#@1ZUE*U
MU.!1U9'N%-#*!;4\2N-X'+64B;"8NKM[54SEQG FX%X1O6E;JG[/@<OM+$S"
M_<6"U8VQ%U$Q[6@-2S!?NWN%IZAGJ5@+0C,IB(+U++Q.KN9#BW> ;PRV^L F
MMI*5E(_V<%/-PM@* @ZEL0P4/T_P'CBW1"CCUXXS[%/:P$-[S_[)U8ZUK*B&
M]Y)_9Y5I9F$>D@K6=,/-0FX_PZZ>D>4K)=?NEVP]-DM#4FZTD>TN&!6T3/@O
M?=Z]PT% 'K\0D.X"4J?;)W(J/U!#BZF26Z(L&MFLX4IUT2B."=N4I5'H91AG
MBB74^,2&W C?8/M29P]TQ4&?3R.#&2PN*G=L<\^6OL"6D5LI3*/)1U%!]6]\
MA,IZ>>E>WCP]27A+U07)D@%)XW1T@B_KR\T<7_:?<A?02668J,F/ZY4V"O\<
M/X^5Z]F&Q]GLP%SICI8P"W$B-*@G"(LWKY)Q_.Z$UF&O=7B*O5CB %8;#D2N
MR9$V'9-[DO"X7+)/$QQ/$SPT"B X["O!KI2-;4M@VV)[,PP62.BNJ:AP+)YP
MW#O']9HD@_CR<A#',=J3R<1:P9)RJAAHDN:)<PTGN7/<"+U15)1 QMXQ&?L
M(\O'MW8 *U+*%I>2]O_6S*&2.'6PNPX4=8V%9XO!#,,\]Y#!>.1SW)D&%&$"
M>8"<)8-DY'*0<W*6IR-O!E_ !%QJ[42/=_+303KV]K$&1P=SV(*JW;;1*'<C
MC!_)_K9?:-=^CO_"_3;$)ZZ9T(3#&D/CB\DH),IO&'\PLG-3O9(&=X0S&US*
MH"P _6LIS?Y@$_1KOO@#4$L#!!0    ( &A\KUI9]Z6M$0,  %\*   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U6WV_:,!#^5ZQLFCJI;2 )H6,0
MB5_=]M .%75[F/9@DH-8=>S,-M#NKY_MA!1*RJ@$#\1V[OM\]UWLN^Z:BP>9
M BCTF%$F>TZJ5-YQ71FGD&%YR7-@^LV<BPPK/14+5^8"<&)!&76]1B-T,TR8
M$W7MVD1$7;Y4E#"8""2768;%TP H7_><IK-9N".+5)D%-^KF> %34/?Y1.B9
M6[$D) ,F"6=(P+SG])N=<6CLK<$/ FNY-48FDAGG#V;R+>DY#>,04(B58<#Z
ML8(A4&J(M!M_2DZGVM( M\<;]FL;NXYEAB4,.?U)$I7VG"L')3#'2ZKN^/HK
ME/&T#%_,J;3_:%W:-AP4+Z7B60G6'F2$%4_\6.JP!= \]0"O!'@O <$K +\$
M^,<"@A(0' MHE0 ;NEO$;H4;886CKN!K)(RU9C,#J[Y%:[T(,]_)5 G]EFB<
MBKZ+!6;D+RZRQA+TA1.V0$/.8A ,]1FF3Y)(=#8"A0F5Z!8+@4UR/Z(+=#\=
MH;/W'[NNTJX80C<NMQT4VWJO;.NC&\Y4*M&8)9#LXET=0A6'MXECX!TDO,'B
M$OG-<^0UO%:-/\/CX4$-?'08/H+X('Q\/-P_((9?)=6W?/X123TWN92<DN0Y
MQQ,!$I@J%O@<71.&64PP15.]"/H:4!+]ZL^D$OH@_ZY+;^% 4.^ N=PZ,L<Q
M])S<["56X$0?WC7#QN>ZW)R2;'1*LO&)R':R&%19# ZQ1[>Z2E N99W\!3*T
M2%,*5M%5P_RZ[FI;V(,;O%784Y*-3T2V(VRK$K;U7V%C+%.TE) @HH] #N9.
MT_>>K5M$$:A5O:!M;:GNZ1.[+WMK+SM!,_3W[$8'W7RKHB<BVU$TK!0-#RHZ
M53Q^2#E-0$A3IDE,5)V X9XPGZYJ/MM]LXN6W]P7>K1OV S;^X3C&L)VT ZW
M#8NXW:U*FH%8V!9&HI@OF2J*4;5:=$F#9F=HNXD7Z[I[ZMNFP7VF*5HO76H6
MA$E$8:XI&Y=MG3A1M#/%1/'<UNL95[KZVV&J.T 0QD"_GW.N-A.S0=531O\
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M2.ML*$FQTA>6$T%S;:W65$BCIH>Q]-+ 5(#\OJ%4'"9J@]J=!_\ 4$L#!!0
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MMI,4OTN*OX\]GF"9(WBNR!I38$H.I:%A&-4,IB:O8T^7:/V+[/6VPGT[_W+
M+MF[HH^*=R2R'?&"3KQ@KWB/IDCH2D()7A!*U.N0>@U%N*6*ZXWZX@5]D4.O
MKUW?S/\6],RF?3/7V:7;"3CL @[_NUO.T&UR-T&$R4K $N'"'.JAP,.!B 9V
MS5Z/'SV7QR2;'HFL4=K>NK_,ZT07YY76$%'(-+US?J&]B>;&;SJ*E_65MN!*
M7Y!U,]>/)!#&0,]GG*NWCKDENV=7_ ]02P,$%     @ :'RO6L/8<TV3!0
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M89%+V-P1K)*B09FB0:/)SY2&0:T@][QZU9G9 SU 4XJOZVP(!_52=?,S\,@
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MC=$"<VV@SB^94KW8T0'*MUTF_P%02P,$%     @ :'RO6@ R)H[F P  ; L
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK59M;^(X$/Y^OV*4O5NU
M$B5OO!>0"NSI*EU7J&CW/E3[P20#6$ULSC:P_/L;)R$+);!;Z?JAV..99YZ9
MC#W3WTGUJE>(!KZGB= #9V7,NN>Z.EIARG1=KE'0R4*JE!G:JJ6KUPI9G!FE
MB1MX7LM-&1?.L)_)IFK8EQN3<(%3!7J3IDSM1YC(W<#QG8/@F2]7Q@K<87_-
MECA#\V4]5;1S2Y28IR@TEP(4+@;.@]^;^)XUR#2^<MSIHS784.92OMK-8SQP
M/,L($XR,A6#TL\4Q)HE%(A[_%J!.Z=,:'J\/Z']FP5,P<Z9Q+)-_>&Q6 Z?C
M0(P+MDG,L]S]A45 38L7R41G_V%7Z'H.1!MM9%H8$X.4B_R7?2\2<61 .-4&
M06$0O#4(+QB$A4'XUJ!QP:!1&#2RS.2A9'F8,,.&?25WH*PVH=E%ELS,FL+G
MPG[WF5%TRLG.#&=42/$F09 +>(@BN1%&PY3MV9QD1L(S)LQ@3")E]G S0<-X
MHF_A#L9[([=,1 @C+A.YY)&&1Q'!RQ.F<U3?2.7+; (WO]_V74-,K3\W*EB-
M<E;!!58A/$EA5AH^B1CC4WN7(BS## YACH*K@$],U2'T:Q!X0;."S^37S1M7
MZ(1EUL,,+[R -\$%26(8H:"5@6G"!$RXCA*I-PKAY6\ZAD>#J?Y6E;T<O5&-
M;I^*GEZS" <.O04:U1:=X<</?LN[KPK]?P([242C3$3C&OIPA$LN!!=+NKR)
M+::J:'.(5@9AW['MT/<[H>=Y?7=[I#>^[NK%KTKEY!P\;/K-8_"3P)IE8,VK
MWA[%5O((=0T$FJJ@<O/FD=]F&)S%-#E7"UK=B^Q:);O6579TP>GMIIO.!41,
MKZH(MLX\WP6MSCG#"CW?JEWBV"XYMG^9(U7>W6)CWP+8,:48B6O #"P85[!E
MR::R;MKGS#J-]GD$5WE47P"X4ON=,L#.U0#I;?M)X7?.:K-UFMB\[J^[N5#W
MY]A^M].X^-6ZSAN![_WH,-[/"!PZRV_PCK^C+E31:VJVV=3AYN.'3A!X]Z5&
MMO?O;ZD^3IM7#32W"*7FN\C(G="PI,G*H *SHN>Z^8?MF69%B#)=,[&WGOWV
M/16LUAORRD0,-&EIP_(/'<DTI4F'6GKT6H<9(GR6YGTLVI Y\>^MSY2;_()8
M1V/JE^0$1<3MHS/C2\$7/**; @]$&S/->E75ND?#0XIJF0UA&K(/EK]WI;08
M]+J]2=<.'V_DHZ W#JKD=C"LD%/='";&LY/>0X;D_B"4SZ'4B*EA:$AP0>2\
M>IMNM\I'NWQCY#H;=N;2T.B4+5<T#J.R"G2^D)3S8F,=E /V\#]02P,$%
M  @ :'RO6BB8(]CB P  'A0  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&ULM9A=CYLX%(;_RA&[JEJI#1_Y;)I$F@1&':FSBF;4W8NJ%PX<$JN L[9)
M)O]^;6"8),N@I'7G8F*,W\?V>\ V9[)G_(?8($IX2I-,3*V-E-NQ;8MP@RD1
M';;%3-V)&4^)5)=\;8LM1Q(5HC2Q/<<9V"FAF36;%'5+/INP7"8TPR4'D:<I
MX8<Y)FP_M5SKN>*!KC=25]BSR9:L\1'EU^V2JRN[ID0TQ4Q0E@''>&K=N./
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M)EIW.PID<A O:\W.75_'IXUWVH?6Y<@J:5=YO'22@]I[5[KJ2C<^]9N[3@Z
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M+T#9 /P^D])L.G:"^H<E^0U02P,$%     @ :'RO6D;Q&]$L P  2 T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK9==;]HP%(;_BI554R=MY),
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MDZHA-<-,?0( UQO4^R5C<C_1#NJ/BO@?4$L#!!0    ( &A\KUI'9C:K*@0
M % 5   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,58VV[C-A#]%4(M
MBA9(+9&V+DYM \EN%UV@08RDEX=%'VAI; LKB2Y)7P+TXTM*LJA-9,8V'$0/
MUHTS<V:&/$?F:,OX5[$$D&B79X48.TLI5]>N*^(EY%3TV H*]6;.>$ZENN4+
M5ZPXT*0TRC.7>%[@YC0MG,FH?#;EDQ%;RRPM8,J16.<YY4^WD+'MV,'._L%#
MNEA*_<"=C%9T 8\@_UQ-N;IS&R])FD,A4E8@#O.Q<X.O;TFD#<H1?Z6P%:UK
MI%.9,?95WWQ.QHZG$4$&L=0NJ#IMX -DF?:D</Q;.W6:F-JP?;WW_JE,7B4S
MHP(^L.SO-)'+L1,Y*($Y76?R@6U_@SHA7_N+62;*7[2MQH:^@^*UD"ROC16"
M/"VJ,]W5A6@9],D! U(;D!)W%:A$^9%*.AEQMD5<CU;>]$69:FFMP*6%[LJC
MY.IMJNSDY%&U.5EG@-@<W:]TH02Z7TLA:9&DQ0*I4_/\UQWP.!5TIH;_^!$D
M33/QT\B5"H9VYL9UR-LJ)#D0LH_N6"&7RE^10/*MO:O@-SF0?0ZWQ.KPCO(>
MZN,K1#SBH^^1B\22<A#UR1*AWU2I7T;H'ZJ2=O3SK>I^@J;T2<U*B6XXI\4"
M]/557:*K?8D 37D: WK0(]"7WY4[]%E"+O[I*E<5>] =6R_+:[&B,8P=M>X$
M\ TXDQ^^PX'WBR6S09/9P.9]LN\M:_7\O\["55@K;W[I3:_XS01[83@(1NZF
M X7?H/"M**HZJ2GXK'[WJFY?[B"? >^LG-7KF94+&LS!.\Z)X TR"YO,PN.Z
M ;NXAK[2T+MP5I["UGP@/8R[9T/4Q(\N.B>C%W,R&$2D&\.PP3 \%<,5VI8<
MK_I--\"59BE9TL*G\<6*TKB2F#7-4);.%4$^ >7=]&B//$2E)0I17M%D@!+Z
M9&,Q[!FR]RZ0%>Q>ZWH=YKBVXY86X;-HX(\ML]* W>V9JP43 YN\(Q/4P2^<
MG%$^;)6?D\B@=A5^HPX]_\"T,!*%+ZM1N$.D G4<P&%$"MM5ZBTYX970444*
MMHX:W<)6\;@<"02G=-N(#SY2?9Z3P)*#_6O [OC<E6)4"T?O20-6S3PW.2.'
MV*Y*)]' \*4Z^(<F!C'B14X6+RL-U.[:-.![ZCB PZ@4L:O46]+ *Z'#^MM@
MN/\VP-%K'P?$R!BQ*LG%>*$.<V3[C1"1(X7HV?+YQ-;<2@MVOV>N'&+4BPS>
MD1:(53K/3<Y((CGRC]L1M%"[:L^+<- ;>*WCP!<D,=I&3M8V.T<$+SBB/_"'
MT0$<1L2(7<3>E"/LH?<<T3^!(XS&D9/_FIW'$=')<\%M;7+EP!?E5IY0E5L7
MLMKO:IXVVX4WU2:9&5[M-=Y1ODA5%AG,E:G7TYMSO-J^JVXD6Y5;9C,F)<O+
MRR70!+@>H-[/&9/[&QV@V42=_ ]02P,$%     @ :'RO6C'^[OKE!   ^QL
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULQ5G;;N,V$/T50BV*72 ;
MB?(M26T#OFBQ 9IND&"[#XL^T-+8%B*)+DG;R=^7I&19LA76*EC4#XDN/&?(
M,T,.1QSN*7OA:P"!7M,DXR-G+<3FSG5YN(:4\&NZ@4R^65*6$B%OV<KE&P8D
MTJ T<7W/Z[LIB3-G/-3/'MEX2+<BB3-X9(AOTY2PMRDD=#]RL'-X\!2OUD(]
M<,?##5G!,XAOFT<F[]R2)8I3R'A,,\1@.7(F^"[  P70+?Z(8<\KUT@-94'I
MB[JYCT:.IWH$"81"41#Y;P<S2!+%)/OQ5T'JE#85L'I]8/^L!R\'LR <9C3Y
M'D=B/7)N'!3!DFP3\43W7Z 84$_QA33A^B_:%VT]!X5;+FA:@&4/TCC+_Y/7
M0H@*0/(T _P"X%\*Z!2 SBF@^PZ@6P"ZEP)Z!4 /W<W'KH6;$T'&0T;WB*G6
MDDU=:/4U6NH59RI0G@63;V.)$^,935/IKV=!PQ?TG3!&,L$1R2+T=:,\R=&'
M.0@2)QS]KMXJMWY$G]"WYSGZ\//'H2MD)Q25&Q8&I[E!_QV#&#W03*PY"K((
MH@;\S(SO&/"N''RI@']08.H;"2<;=HTZWA7R/=]OZH\9_D 4'&MXKP$^OQS>
M;8 '9O@<PO?@-3$Z93AT-%_G';[G-6'P:2IG7H1D:,CEB!,]H2<J,E8@EPB!
M%F^HVNZ1O.G'DSUA$?KQFZ1$]P)2_F=3=.3VN\WVU;)XQS<DA)$CUST.; ?.
M^)>?<-_[M<DU-LGF-LD"2V0U)W9+)W9-[./#S)5Y@0LYE>-LA>),L%@N[R':
MD60+39XQDK;U3$[6UV0J6>W&@QM/_H;NKJJY39N!);*:YKU2\YY1\V(=Y7H=
M)6HF<+12BVGC&C<UDK75^E^0H:8)8+-3@26RFC/ZI3/Z1F?DV8SJ:5"=!4V>
M,#*U]41.UJM$/?:[_;.HMVDS^$>;-0D'I80#HX1/7*X7H8S>(J0-L6PD:JO@
MX&PT?N^VTSL1T*;)P!)93>:;4N8;<Z3J/+K0>32LYEM2S[>\TFY3Y%N]REP5
M8<ZO$+P""V-.%@E<H;W>(<O69 =,[OCEIEZ5#2H5A'+_Q.0&?4L2)("E33XU
M]KJM3\T2W* W((PW+4@V>Q%8(JNY^;9T\^U_D9&-I&V]<'N6D?%Y/K9I,;!$
M5E,<>\?"QKM(\QUP/0]D25.9(9?(;S;05O^"K;JTG:IOU6!@BZVN?Z6PQ$;]
M/Y.8Y=HBNCQX@5<R<].4GYI)6VN.SX*^<Q[T#:VPYY^U"VSUK2ZH?Q34OWA7
M4UOM&W4T<K76T3_?9'B#0;=_JJ1-JX$MMKK>QU(8&XNT$[VW61'"U33=J+S5
M"K=@J\:F?]L0PE:+5UML=>&/Y2LVUZ_J0PSZFF;Q8LO1?1;*S4Z\ _28D S]
M>(!T :SQTX*9MK7R-MGF5MD"6VQU!QUK7=S[G[\28:L%LE6VN56VP!9;W97'
M2AF;2^66WRUP0[79E[]!?3V:F:VV5MQJP6R+K:[XL;#&YLIZLB-QHK>@2\IR
MK1N5MEI6X_.Z&O=QQS]-(U8+:UMLN=!NY9 C!;;2ITM<IN-M)O*O_>73_ 1K
MAN_F^J#GY/D$WTWT>8Y[I,F/Q1X(6\F: "6PE)3>]4#JQ?*3IOQ&T(T^2EE0
M(6BJ+]= (F"J@7R_I%0<;I2!\KQO_#=02P,$%     @ :'RO6NZ X2J?%@
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M:+Y_79;UXR?M!-_+ZH_]T[[\#U!+ P04    " !H?*]:@=Z&:* #   >#@
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M%VK@]YJ09R_?TX$?QI]]S\J-BI0._(>+CW_FA;K^X-GKV:>SL];#Y?5N_,(
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M-E$/3MX#_Q><X_DZJ3>>,ZZ8J'LSEJ94O#@8:GE%QOH/UBU]/3ZE&9ES==^
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( &A\KUK FI 4LP,  $D;   /
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MU?H,VJ;FJQ7UYDO0YBO6R1]02P,$%     @ :'RO6CQA]1J- 0  3Q@  !H
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MCM=K_>/VM^5]$Y\7Q0UG!_\/EK]02P,$%     @ :'RO6IC$(26B 0  IA@
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M0E:)0E:)0E:)0E:)0M;Q?Y+U7>O57W\Y;]>D5F5S]&?=[XGY)U!+ 0(4 Q0
M   ( &A\KUI&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ :'RO6LQ8>S[R    *P(  !$
M     ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ :'RO6IE<
MG",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " !H?*]:9B.5]>@%  "\'P  &               @($E
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ :'RO6EHM
M"U*/!   RQ   !@              ("!0PX  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( &A\KUK 1+_DZ0(  +(*   8
M  " @0@3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !H
M?*]:<30N?N4$  !1$@  &               @($G%@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ :'RO6O )\7>= @  #P8  !@
M         ("!0AL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( &A\KUKJOC!F"P4   L;   8              " @14>  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !H?*]:4Q4 ZWL&  !,(@
M&               @(%6(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ :'RO6I41Y<-B"   B!0  !@              ("!!RH  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &A\KUJ=%+G.$0\
M /XG   8              " @9\R  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !H?*]:G1ED>Z8$  #S"@  &0              @('F
M00  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &A\KUIM
M]TRF @4  ' +   9              " @<-&  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ :'RO6HJH)S<F!   /PD  !D
M     ("!_$L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &A\KUK2EVYC Q   )<N   9              "
M@1MW  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ :'RO
M6NDRK#?H @  ;@8  !D              ("!58<  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !H?*]:RMN$ 3($  #N"0  &0
M        @(%TB@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( &A\KUJ,RH$45@0  !T+   9              " @=V.  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ :'RO6E#FX#J]!   1 \
M !D              ("!:I,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !H?*]:617ME[$"  #R!0  &0              @(%>F
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &A\KUI9]Z6M
M$0,  %\*   9              " @4:;  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ :'RO6J:BT!(: P  J0L  !D
M ("!CIX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !H
M?*]:93J/A;8"  """0  &0              @('?H0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &A\KUK#V'--DP4  /DB   9
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M970S,"YX;6Q02P$"% ,4    " !H?*]:1O$;T2P#  !(#0  &0
M    @(&!O   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M &A\KUJMT(\UAP8  &0U   9              " @>2_  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ :'RO6B0==U]0 P  \0L  !D
M             ("!HL8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !H?*]:(JD4,Y<(  "H40  &0              @($IR@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &A\KUK.!?V;,0,
M & ,   9              " @??2  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ :'RO6D=F-JLJ!   4!4  !D              ("!
M7]8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !H?*]:
M,?[N^N4$  #[&P  &0              @(' V@  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( &A\KUKN@.$JGQ8  -Z1 0 9
M      " @=S?  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ :'RO6H'>AFB@ P  '@X  !D              ("!LO8  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !H?*]:2MM$R^D+  !1G
M&0              @(&)^@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( &A\KUI&F?W850,  -(5   -              "  :D& 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ :'RO6I>*NQS     $P(   L
M         ( !*0H! %]R96QS+RYR96QS4$L! A0#%     @ :'RO6L":D!2S
M P  21L   \              ( !$@L! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( &A\KUH\8?4:C0$  $\8   :              "  ?(. 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &A\KUJ8Q"$EH@$
M *88   3              "  ;<0 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     P #  !PT  (H2 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - Organization and Going Concern Analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</Role>
      <ShortName>Organization and Going Concern Analysis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Accounts Payable and Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</Role>
      <ShortName>Accounts Payable and Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Common Stock Warrants and Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</Role>
      <ShortName>Common Stock Warrants and Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Accounts Payable and Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</Role>
      <ShortName>Accounts Payable and Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiability</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Common Stock Warrants and Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</Role>
      <ShortName>Common Stock Warrants and Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SegmentInformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative</Role>
      <ShortName>Organization and Going Concern Analysis (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails</Role>
      <ShortName>Schedule of Accounts Payable to Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative</Role>
      <ShortName>Accounts Payable and Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Warrant Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>Warrant Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiabilityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails</Role>
      <ShortName>Schedule of Options Outstanding and Options Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative</Role>
      <ShortName>Common Stock Warrants and Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure -  Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails</Role>
      <ShortName> Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>gtbp-20250331.xsd</File>
    <File>gtbp-20250331_cal.xml</File>
    <File>gtbp-20250331_def.xml</File>
    <File>gtbp-20250331_lab.xml</File>
    <File>gtbp-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
    <File>form10-q_002.jpg</File>
    <File>form10-q_003.jpg</File>
    <File>form10-q_004.jpg</File>
    <File>form10-q_005.jpg</File>
    <File>form10-q_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="419">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gtbp-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 171,
   "keyCustom": 38,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 38,
   "hidden": {
    "total": 52,
    "http://fasb.org/us-gaap/2024": 37,
    "http://gtbiopharma.com/20250331": 11,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 151,
   "entityCount": 1,
   "segmentCount": 58,
   "elementCount": 379,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 419,
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "shortName": "Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
     "longName": "00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:DebtSecuritiesUnrealizedGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis",
     "longName": "999008 - Disclosure - Organization and Going Concern Analysis",
     "shortName": "Organization and Going Concern Analysis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty",
     "longName": "999010 - Disclosure - Accounts Payable and Related Party",
     "shortName": "Accounts Payable and Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://gtbiopharma.com/role/WarrantLiability",
     "longName": "999011 - Disclosure - Warrant Liability",
     "shortName": "Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficit",
     "longName": "999012 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions",
     "longName": "999013 - Disclosure - Common Stock Warrants and Options",
     "shortName": "Common Stock Warrants and Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "longName": "999014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://gtbiopharma.com/role/SegmentInformation",
     "longName": "999015 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://gtbiopharma.com/role/SubsequentEvents",
     "longName": "999016 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables",
     "longName": "999019 - Disclosure - Accounts Payable and Related Party (Tables)",
     "shortName": "Accounts Payable and Related Party (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityTables",
     "longName": "999020 - Disclosure - Warrant Liability (Tables)",
     "shortName": "Warrant Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
     "longName": "999021 - Disclosure - Common Stock Warrants and Options (Tables)",
     "shortName": "Common Stock Warrants and Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://gtbiopharma.com/role/SegmentInformationTables",
     "longName": "999022 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
     "longName": "999023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)",
     "shortName": "Organization and Going Concern Analysis (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "longName": "999024 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "longName": "999026 - Disclosure - Schedule of Accounts Payable (Details)",
     "shortName": "Schedule of Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails",
     "longName": "999027 - Disclosure - Schedule of Accounts Payable to Related Party (Details)",
     "shortName": "Schedule of Accounts Payable to Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CytovanceBiologicsIncMember",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
     "longName": "999028 - Disclosure - Accounts Payable and Related Party (Details Narrative)",
     "shortName": "Accounts Payable and Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-012025-03-31_custom_LegalServicesFirmMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
     "longName": "999029 - Disclosure - Schedule of Warrant Liability Assumptions (Details)",
     "shortName": "Schedule of Warrant Liability Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
     "longName": "999030 - Disclosure - Schedule of Warrant Liability Transactions (Details)",
     "shortName": "Schedule of Warrant Liability Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "GTBP:WarrantLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "999031 - Disclosure - Warrant Liability (Details Narrative)",
     "shortName": "Warrant Liability (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
     "longName": "999032 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-262025-02-26",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999033 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999034 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_custom_WarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "999035 - Disclosure - Schedule of Options Activity (Details)",
     "shortName": "Schedule of Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
     "longName": "999036 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)",
     "shortName": "Schedule of Options Outstanding and Options Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
     "longName": "999037 - Disclosure - Common Stock Warrants and Options (Details Narrative)",
     "shortName": "Common Stock Warrants and Options (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999038 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-21",
      "name": "GTBP:ContigencyMinimumRequired",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
     "longName": "999039 - Disclosure -  Schedule of Segment Information (Details)",
     "shortName": " Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_custom_SegmentsMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999040 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-15_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Related Party",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r44",
      "r614"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "verboseLabel": "Total accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r511"
     ]
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableInterestBearingInterestRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable interest rate",
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r40"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r511",
      "r671"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r564",
      "r565",
      "r566",
      "r567",
      "r620",
      "r672"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AggregateStatedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "AggregateStatedValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate stated value",
        "documentation": "Aggregate stated value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangement, expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r102",
      "r115",
      "r191",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r313",
      "r317",
      "r335",
      "r511",
      "r584",
      "r585",
      "r629"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r98",
      "r479"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r77"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents and Restricted Cash at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents and Restricted Cash at End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r59",
      "r112"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r59"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r638"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CashPaidDuringYearFor": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CashPaidDuringYearFor",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:",
        "documentation": "Cash paid during the year for [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r99",
      "r100",
      "r101",
      "r115",
      "r133",
      "r134",
      "r136",
      "r138",
      "r144",
      "r145",
      "r191",
      "r219",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r245",
      "r246",
      "r249",
      "r252",
      "r258",
      "r335",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r416",
      "r436",
      "r454",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r545",
      "r561",
      "r568"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase",
        "verboseLabel": "Placement agents",
        "terseLabel": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of pre-funded warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r211",
      "r212",
      "r475",
      "r576",
      "r581"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r564",
      "r565",
      "r567",
      "r620",
      "r670",
      "r672"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r416"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r416",
      "r433",
      "r672",
      "r673"
     ]
    },
    "GTBP_CommonStockSharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CommonStockSharesOutstandingPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding percentage",
        "documentation": "Common stock shares outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.001, 250,000,000 shares authorized, 2,536,397 and 2,234,328 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r359",
      "r511"
     ]
    },
    "GTBP_CommonStockWarrantsAndOptionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CommonStockWarrantsAndOptionsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants and Options",
        "documentation": "Common Stock Warrants and Options [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r89"
     ]
    },
    "GTBP_ContigencyMinimumRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ContigencyMinimumRequired",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contigency minimum required",
        "documentation": "Contigency minimum required."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License maintenance fees",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CummulativeGrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CummulativeGrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative gross sales",
        "documentation": "Cummulative gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CytovanceBiologicsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "CytovanceBiologicsIncMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cytovance Biologics Inc [Member]",
        "documentation": "Cytovance Biologics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r41",
      "r42",
      "r78",
      "r79",
      "r116",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r510",
      "r562",
      "r577",
      "r578",
      "r579",
      "r625",
      "r626"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r116",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r510",
      "r562",
      "r577",
      "r578",
      "r579",
      "r625",
      "r626"
     ]
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain on short-term investments",
        "label": "Debt Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r556",
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFloorPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFloorPrice",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "documentation": "Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "DisclosureCommonStockWarrantsAndOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants And Options",
        "verboseLabel": "Schedule Of Warrant Activity",
        "terseLabel": "Schedule Of Options Activity"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "verboseLabel": "Schedule Of Warrant Liability Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r538",
      "r539"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r131",
      "r133",
      "r136",
      "r137",
      "r138",
      "r141",
      "r307",
      "r310",
      "r327",
      "r328",
      "r355",
      "r366",
      "r480"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r133",
      "r136",
      "r137",
      "r138",
      "r141",
      "r307",
      "r310",
      "r327",
      "r328",
      "r355",
      "r366",
      "r480"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r140"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r93",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r143",
      "r192",
      "r193",
      "r204",
      "r260",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r365",
      "r383",
      "r384",
      "r385",
      "r396",
      "r454"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r303",
      "r546",
      "r547",
      "r548",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment, ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ExtinguishmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ExtinguishmentOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment",
        "documentation": "Extinguishment of warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value of warrants",
        "terseLabel": "Fair value",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r506"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r506"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r506"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "GTBP_FairValueOfPrefundedWarrantToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "FairValueOfPrefundedWarrantToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of prefunded warrant to settle vendor payable",
        "documentation": "Fair value of prefunded warrant to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of vendor payable",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29"
     ]
    },
    "GTBP_GreenshoeRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "GreenshoeRightsMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greenshoe Rights [Member]",
        "documentation": "Greenshoe Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_GrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "GrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross sales",
        "documentation": "Gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r332",
      "r333",
      "r334",
      "r380",
      "r382",
      "r439",
      "r478",
      "r505",
      "r641"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r332",
      "r333",
      "r334",
      "r380",
      "r382",
      "r439",
      "r478",
      "r505",
      "r641"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r111",
      "r299",
      "r300"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in operating lease right-of-use assets",
        "documentation": "Decrease in operating lease right-of-use assets.",
        "label": "IncreaseDecreaseInOperatingLeaseRightofuseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) Decrease in prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "GTBP_InducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "InducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Warrants [Member]",
        "documentation": "Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceCommissions",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants at fair value",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "GTBP_LegalServicesFirmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "LegalServicesFirmMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Services Firm [Member]",
        "documentation": "Legal Services Firm [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r80",
      "r361",
      "r511",
      "r563",
      "r575",
      "r624"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r97",
      "r115",
      "r191",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r314",
      "r317",
      "r318",
      "r335",
      "r511",
      "r584",
      "r629",
      "r630"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LiableOfLiquidatedDamagePercentageDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "LiableOfLiquidatedDamagePercentageDescription",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liable of liquidated damage percentage, description",
        "documentation": "Liable of liquidated damage percentage, description."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r218",
      "r296",
      "r495",
      "r582",
      "r583"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r218",
      "r296",
      "r495",
      "r582",
      "r583"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on short-term investments",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r265",
      "r296",
      "r331",
      "r353",
      "r379",
      "r381",
      "r388",
      "r408",
      "r409",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r476",
      "r477",
      "r493",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r586",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r506"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r506"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r265",
      "r296",
      "r331",
      "r353",
      "r379",
      "r381",
      "r388",
      "r408",
      "r409",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r476",
      "r477",
      "r493",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r512",
      "r586",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r61",
      "r82",
      "r95",
      "r103",
      "r104",
      "r107",
      "r115",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r135",
      "r191",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r307",
      "r310",
      "r328",
      "r335",
      "r364",
      "r435",
      "r452",
      "r453",
      "r522",
      "r584"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering expenses",
        "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income, Net",
        "label": "Other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OfficersEmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "OfficersEmployeesAndDirectorsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers, Employees and Directors [Member]",
        "documentation": "Officers, Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "OmnibusIncentivePlanMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Omnibus Incentive Plan [Member]",
        "documentation": "2022 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r481",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Going Concern Analysis",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r62",
      "r63",
      "r76"
     ]
    },
    "GTBP_OtherAccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "OtherAccountsPayableMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Member]",
        "documentation": "Other Accounts Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year unpaid fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale of investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "GTBP_PerformanceMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "PerformanceMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance milestone payments",
        "documentation": "Performance milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of dividend",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r461",
      "r463",
      "r464",
      "r468"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r670",
      "r672"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r245"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r416"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r245"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r416",
      "r433",
      "r672",
      "r673"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r358",
      "r511"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants and issuance of inducement warrants for cash, net",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r390"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invoices, net",
        "verboseLabel": "Research and development expenses",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ProceedsFromUpfrontAmount",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from upfront amount",
        "documentation": "Received upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r103",
      "r104",
      "r109",
      "r115",
      "r120",
      "r126",
      "r129",
      "r130",
      "r191",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r307",
      "r310",
      "r312",
      "r315",
      "r316",
      "r328",
      "r335",
      "r356",
      "r363",
      "r395",
      "r435",
      "r452",
      "r453",
      "r503",
      "r504",
      "r523",
      "r553",
      "r584"
     ]
    },
    "GTBP_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r263",
      "r265",
      "r290",
      "r291",
      "r292",
      "r296",
      "r331",
      "r351",
      "r352",
      "r353",
      "r379",
      "r381",
      "r388",
      "r408",
      "r409",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r476",
      "r477",
      "r493",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r516",
      "r580",
      "r586",
      "r622",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "GTBP_RangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeEightMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Eight [Member]",
        "documentation": "Range of Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Five [Member]",
        "documentation": "Range of Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeFourMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Four [Member]",
        "documentation": "Range of Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r263",
      "r265",
      "r290",
      "r291",
      "r292",
      "r296",
      "r331",
      "r351",
      "r352",
      "r353",
      "r379",
      "r381",
      "r388",
      "r408",
      "r409",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r476",
      "r477",
      "r493",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r516",
      "r580",
      "r586",
      "r622",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "GTBP_RangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeNineMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Nine [Member]",
        "documentation": "Range of Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeOneMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price One [Member]",
        "documentation": "Range of Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeSevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Seven [Member]",
        "documentation": "Range of Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeSixMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Six [Member]",
        "documentation": "Range of Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeTenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Ten [Member]",
        "documentation": "Range of Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Three [Member]",
        "documentation": "Range of Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Two [Member]",
        "documentation": "Range of Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r264",
      "r346",
      "r347",
      "r357",
      "r362",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r432",
      "r434",
      "r459"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r264",
      "r346",
      "r347",
      "r357",
      "r362",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r432",
      "r434",
      "r459",
      "r628"
     ]
    },
    "GTBP_RepaymentsOfPrefundedWarrantsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RepaymentsOfPrefundedWarrantsAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments in pre-funded warrants, at fair value",
        "negatedLabel": "Payments in pre-funded warrants, at fair value",
        "documentation": "Repayments of prefunded warrants at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments in cash",
        "label": "Cash payments",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r478",
      "r487",
      "r637"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r560"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r67",
      "r360",
      "r386",
      "r387",
      "r394",
      "r417",
      "r511"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r192",
      "r193",
      "r204",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r319",
      "r321",
      "r322",
      "r324",
      "r326",
      "r343",
      "r344",
      "r383",
      "r385",
      "r396",
      "r672"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r142",
      "r151",
      "r152",
      "r173",
      "r179",
      "r183",
      "r185",
      "r186",
      "r261",
      "r262",
      "r354"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual royalty payments",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "GTBP_RoyaltyExpenseYearAfterFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyExpenseYearAfterFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year five and thereafter",
        "documentation": "Royalty expense year five and thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearAfterSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyExpenseYearAfterSix",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year six and thereafter",
        "documentation": "Royalty expense year after six."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyExpenseYearOne",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one",
        "documentation": "Royalty expense year one."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOneThoughFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyExpenseYearOneThoughFour",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one though four",
        "documentation": "Royalty expense year one though four."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearTwoThroughFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyExpenseYearTwoThroughFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense years two through five",
        "documentation": "Royalty expense year two through five."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "RoyaltyFeePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty fee percentage",
        "documentation": "Royalty fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time sales milestone payments",
        "documentation": "Sales milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SalesRevenue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales revenue",
        "documentation": "Sales revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable to Related Party",
        "documentation": "Schedule of Accounts Payable and Related Party [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Transactions",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r303",
      "r546",
      "r547",
      "r548",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding and Options Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule of warrants oustanding and exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r142",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r209",
      "r210",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r484",
      "r487",
      "r488",
      "r494",
      "r513",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r142",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r162",
      "r164",
      "r165",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r186",
      "r482",
      "r485",
      "r486",
      "r487",
      "r489",
      "r491",
      "r492"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r182",
      "r185",
      "r483",
      "r484",
      "r490"
     ]
    },
    "GTBP_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SegmentsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Member]",
        "documentation": "Segments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative (including $3,000 and $102,000 from stock compensation for the three months ended March 31, 2025 and 2024, respectively)",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesAInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SeriesAInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Inducement Warrants [Member]",
        "documentation": "Series A Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesBInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SeriesBInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Inducement Warrants [Member]",
        "documentation": "Series B Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r587"
     ]
    },
    "GTBP_SeriesLTenPercentConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SeriesLTenPercentConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L 10% Convertible Preferred Stock [Member]",
        "documentation": "Series L 10% Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rstricted stock granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility amount utilized in the value calculation percentage",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "label": "Number of warrants outstanding",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Share based compensation arrangement by share based payment award non options exercised weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited/cancelled",
        "documentation": "Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Warrants weighted average exercise price",
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding exercisable",
        "verboseLabel": "Stock option, exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price,exercisable, ending",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, forfeited/cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Common stock awards granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning",
        "periodEndLabel": "Number of options outstanding, ending",
        "label": "Stock option outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Exercise Price, beginning",
        "periodEndLabel": "Weighted-Average Exercise Price, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price",
        "verboseLabel": "Range of excercise price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, unvested compensation",
        "documentation": "Share based compensation arrangement by share based payment award options non vested in period fair value 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r113"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r94",
      "r142",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r209",
      "r210",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r484",
      "r487",
      "r488",
      "r494",
      "r513",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r99",
      "r100",
      "r101",
      "r115",
      "r133",
      "r134",
      "r136",
      "r138",
      "r144",
      "r145",
      "r191",
      "r219",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r245",
      "r246",
      "r249",
      "r252",
      "r258",
      "r335",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r416",
      "r436",
      "r454",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r545",
      "r561",
      "r568"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r49",
      "r50",
      "r93",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r143",
      "r192",
      "r193",
      "r204",
      "r260",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r365",
      "r383",
      "r384",
      "r385",
      "r396",
      "r454"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r143",
      "r344",
      "r354",
      "r389",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r517"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r143",
      "r187",
      "r344",
      "r354",
      "r389",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r517"
     ]
    },
    "GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net, shares",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r67",
      "r390",
      "r454",
      "r470"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r67",
      "r276"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, value."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of prefunded warrant to settle vendor payable",
        "verboseLabel": "Issuance of warrant to settle vendor payable",
        "documentation": "Issuance of prefunded warrant to settle vendor payable, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period, value, issued for services",
        "verboseLabel": "Warrants to purcahse",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficit",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "negatedLabel": "Stockholders deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r64",
      "r418",
      "r433",
      "r455",
      "r456",
      "r511",
      "r524",
      "r563",
      "r575",
      "r624",
      "r672"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r114",
      "r244",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r325",
      "r457",
      "r458",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r627"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Patent License Agreement [Member]",
        "documentation": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandSeventeenThroughTwoThousandTwentyMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 through 2020 [Member]",
        "documentation": "2017 through 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Patent Exclusive License Agreement [Member]",
        "documentation": "2016 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2025 [Member]",
        "documentation": "Beginning in 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 GTB-3650 Clinical Trial Agreement [Member]",
        "documentation": "2024 GTB-3650 Clinical Trial Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2027 [Member]",
        "documentation": "Beginning in 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyThreeCommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Common Warrants [Member]",
        "documentation": "2023 Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyThreePlacementAgentsWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Placement Agents Warrants [Member]",
        "documentation": "2023 Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyThreeSponsoredResearchAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Sponsored Research Agreement [Member]",
        "documentation": "2023 Sponsored Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Warrants [Member]",
        "documentation": "2023 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "TwoThousandTwentyTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2022 [Member]",
        "documentation": "Beginning in 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled and unaccrued amounts",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_UniversityOfMinnesotaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "UniversityOfMinnesotaMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Minnesota [Member]",
        "documentation": "University of Minnesota [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront license fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r87",
      "r88",
      "r90",
      "r91"
     ]
    },
    "GTBP_VestingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "VestingWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Warrants [Member]",
        "documentation": "Vesting Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Warrant liability current."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability Policy [Text Block]",
        "label": "WarrantLiabilityPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Text Block]",
        "label": "WarrantLiabilityTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant fair value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (in years)",
        "verboseLabel": "Warrant term",
        "terseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623"
     ]
    },
    "GTBP_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "WarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r138"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r138"
     ]
    },
    "GTBP_WeightedAverageVolumePriceOfCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250331",
     "localname": "WeightedAverageVolumePriceOfCommonStockPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average volume price of common stock percentage",
        "documentation": "Weighted average volume price of common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001641172-25-010790-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-010790-xbrl.zip
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M43JJ<%EZD%F!V36?Q7H+U[5T(10<$EDXZ:_@-2.3O*E7H@'A &(@3FYL$,_
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M.,W(7)0IC,,S>%C3Q>OC; E7B(()Q77"C!.!<H5KO=B*:%N4RP+#K? BYQG
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M.-!@FR_B]&&8\R+<&B5CT*+07QTK @K6@8\-!:*%9FT0H_9^8")<BD?0+/,
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MC'F<2V!R[W)X0W1G*6)OLM>^*?KOQ(."I;LB4B8Y4?S9_TAV%%D,3KZD#\N
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M\[J,3ZG+M'')X>0"2<],7"+669*.D?BO_W&Q0&$I:,3.F&@$A,"R 3A@J.!
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MOM(^5<<?#=+K)Z@7!^V#-UCS3&:UAY*)%)_8#,NT&G_;!EVCKYMZ#J,E.XI
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M'#V ,>T('62G' Y<^<C\QV_8X0$%.I+4]1-T9Q?ERNVR6!%TFO*P:YEEL->
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M@T4-E3WLY=GX7KHQIX?+C SD]>9D/1;OY3HS+*WS"+RY=M A49 KQ2JVWEJ
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M>BF8"?/&N(\#^!3K!N>2X9-T)P0'2]L]LBMJ^FJO&8=-$(MSOD*\"5U1Z6[
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M=[J+>)P8@4^X'>'1$DGD.)S$&$IW3)< UP@?RDBU9!Q=0NE#D_9!--NX*+"
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M,+S(DS;O>[Q]+R@"[-<\N3N9#AU!U,S+.=&"!0<UM<RVA*UX5UYE6&FN'H>
M.(O3BSY/@B'@,&3PC>3JW)R^'&ZEH26'0>6!SZ]=%=-F\M;<<AP2Q<0:/@?9
M4 $EP&F/FCA=8&-=Y"/C!:K]X^U"BS= ]4F: @5"SRU*>:YC@_<?G:KHL4#7
MD52'1SZCPM/U3C4[U>R7XVI"W6=J3#  :533+JV#1I8?\KJAJ.<(_BBUCAEC
MHA8%#\^-HWHI3(/\G.J*L/7>\\P?\;P8\\[X&JTF9)H&/3D(&Z QI0B4NTX
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MH1R8RP;(-0 J[#=]:%U_C"T@EL<Q.T*Y$AF//@K)V(O&LFRH2]3:K%ETG?V
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MJCCELY3ZL\A=4VWW*548<58)V+K/ZFQ*]?Y(6S%8A"(B?A!B[X7+O8G"BE:
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M H&2WZ#,+,)#3:M5-,I%6GTK\(*CP0FODV@\*7)*__A;G!BY'JHL"J"&05W
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MI=/=[[VS[)^*R>9$9V<ZF#=O#7EU!P.,2M#QB#18]$LJP]^Y@(K=%/-'"%C
MU^V<G4$;/:.Q<"IRA;Q!MA:L>7U_5>9U<UY,$S=9B2'AVX'#C7($_9Y[L+6D
MH?Q_0XXHM;-4(Z7 I%C*+S9?#%K/IIV?M"*D<$0F^#[S:OLUO;TM.48#$CBO
M)L"M8F-)X*(15YY0>WEIM1:U0;0B#_ )GX<JQJ3GW5& YBT5$NFZD*^O^>VL
MI +G,J_!3C-*8&AK?B"<!KRR+>:$7,&;W8B1H8&(KU#$Q+'Y>U$6%_,+& &P
M9&4C. Q<F T1[**D@D780\X8(4XA,6*PB([T.LFPL;N_<>*$OCN5L8GC!8XU
M1#K-?]M2IPP:G( L9+KA@3'2-2Z=2VRBI!=*=>WU:$Y96CVS0WSJCSV)-R\B
MV/M"+:: R7-@1K(C(")9T',6Y>.6V56S*H.!8A \+(V;P*.!=V8<1QMWYL7>
ML+:WQ#=#"$]T%Z]F "^J&6S#J<,03AO:'1#F=(UX:4WL^G@H3M8WD'%_ME==
M&;WU?A$1BOMBP@P>"1%XD!*,5RDV86W<(M8.!K#W>^I5=D@QLA7<13;GY\)D
MP$=)E>FT6P2 B Q X3-TM66KOOH^-KK_X]3"T=6LARQ@HAC!<7 5I^^PVOL?
MJ3Z$T+SSI#1?='"#RO?.7R-P<DASZM@5#@9IDWQ!;6Q[$7E6BL?K+B:UZB)Y
M,$TPC+O"Q5!;NU8PFM)6HQC+9Q^(7^? 1<45J#$O.*OL]D$);;=%^K+FSNZM
MS%*-BF9H;%T;-E(D.S;089Y@W#MC/$KP !T]&_&&D LS_^AXO?%0A\;BDBRL
M7,7WQ!TRS('V$6E"9 G?_'+_[]HY.CG8?;>?_'%P</!UWGBR?_3[P>'.R<'[
MPWM\X3(JEGN7\:I<,#]M;B,7C#%0*]AX0Z-I77]V=SP^DJN49_6D@%/B8G>Z
MSM_"'=+0:N/XFOP,S%%Z'\+O.59(3V^HX@'A<& -;!2$CQL7M?EHE-E,O/%W
M9E I]7FF8,CPP8L?GM%G65F"WD8;5UQ(FWG<8\3<"OG@?@]K\^&;&("L2G7U
M1PT+<1C)[SVI )JLO+HK)(VP7(,+N+*1=X/>W>^U7QX+=>, QAGFI<C?CX5$
MNX+<W:%2&,KE@ DUS@MSI>9F$ALOMOYY_/'#+[/S?_X=_G=@H_%[9JDBJ^--
MXO8DP#0.4=7"!MRTV( M3(/XC_47%Y,>!Q>O!%4A.@1:WTC\#'P8H,<M&L@=
MZ.@\^^LK"8DRWH"^_P+Q>!S02)*L*72A80]1ZS+)NI;=;0AU]>\992H$Q<8^
MN0%#\;?0?S>JY?MIG9[\MA'EVUYL1'+&B*+HI7;L^+S<SUZDP>:^5M?6#6K+
M%;G'%-1M;DR_C>TM[^0W;$RRWH!L@?F>Y&!:SL8"I,CVUN;+%6F X#(;1/)!
M=&]E!5U9'Z?&3S)S49?6VSPRI@"$@[^/XC2V-K>%#0FDJ**FJ:-*LOH3@E^H
MEQ%!#Z9'G4]R=(?,%QB;C1^2Y=SX^,#2.-A#?G@(V235[/9#<).0,+ MTF3F
MHLJMOET%(/_)C:]47:%'J0F3)<"_G@)6,1 2Q]PCDZJ9U[G=C.AC!KO1VW/<
M9$-;8#.4!%"LB8]^,9\!5;!L*&:M%VL'.K<5F'!S,"P;T*7[9PSMRJ&"(/X@
MCISC+*Z*)O>HGO"'P2\6'[:H"86((H!=D]O==0;;YRRYU3&SMSX95Z6.I9X2
MG#N:<M G,$9>5(RIVBU+WAK3..,R-=W0)E(RYRJ1;#(1CS]<!,"C $9'/LY@
MAS*L3@&H:*>SU207;G69EYF0KV8RO,9R$MI8A7\L8?RTH/3JQ+W92,,\-YMB
MR,*\AM*L9OR05XK_1.PG_)+8,N/":%%<M5?^JK%Z=4U;%HRCB\*]2Q=%ENHU
M1H[,ZD^@;*$+&;IZN4;14HY Z\&88O?3,+K?49_:(O=((.5&Q3WQ"EG6:RVP
M]H(RWJ732^SL)MFTX=HI*MX$>#F46H1-'/N]L(NCS@)FNB2N!<49)%(Q]:5@
M<'2?OKP;NE-XI[GQ)#!'P:T6)ZW+T1J_#NR-(>8VZ'MA77-'FK-CGZ1\ QF9
MX1+!O.P8J1VD\($UB!D%/PCY8[!ZS/BEU\_&(,2-EZ^XW0ET%+W,_:/)LW-,
MQ_!_-MUMGF1<D]R\:^/G0!6+OB)FY'.C$K&:'P==?+8O?_'#J\$S\/6GS&VC
M:CY&2&664(LAG_KU-39,F2V"@W6YOAL ,RIB2*:"BXK$B\;)MIWC96_%-6G!
MCUJY)@5-LRNI\"!V\9+6VJ'@%BS::T02Y+%[Q=X>$>VZXD42,':W]N2"FR19
M[2+QK[U[N$F252X2ST"+WR0V7$:X(*XZG5$=CW<OY),FOT+064MH6+9&M@C1
M3<W9*I$'"H7GJ6]]A;H"?T>G![^&>C6&!X,>I-.9\?DW3N=H5I05EQ$!2DKJ
MK:[,'\PAK>9F*SU_.3"WD)'+@(""XU9G6EEW.V%N(>1R'1,(52QI_7MDNZXF
M;_=TK]0(/2)N$@?2:(%!8->JQLI=, 9LJKNJ-F@K \W\M<H0XKHANDKH[P!3
M,_D.O#%TYB#&?.&+4&R)+Y).=,PI>!+NL8,!6>5X6V)A0'8%,!2G4]!$8>H(
MGRC;G GC4X^@W^0$G< AA>JP_Q:T[GOH4+C;!BY>8."" M6H?J/!BX/2R0X%
MZ;X4UFZP&:([1KO;U'R7G3SUA$',;N[W?MI\GK;<)U9KM#UQ_7#'&;5T!E:G
MZ%%60=0T/,X-C-I4]N:RJLY(>L%WBT63C.<UOIJ]+?-C3O7A6(P@6Z8V'/%X
M@L,-%H2Q#9)5 :>.K >9BLEE51#Z!ZRCR@[+2(R1C&3 ^@TJ)%1C53>>R1WC
MOP\A4=SO;1SE$%P KY(*@9(_L[J&^&TNX BYL'U0C]$N\IB#_TXV#LR&O"CM
MY:(^-1_^;G1-/IED95[-FP$O$<R4OM+O0?XNV3C1&\CC,H3+>4[;PYLLMD(9
M VD"G'&SHV#1('9")SV,U) =@9&BIDJP.TZ&%=2RM<UQN2K)*1)0,<'8.HR6
MH%^!9\-8(9N9[3@,LY7GHBE*1]_%\VF9<)@PN(9LP0 278W*G(2_!1H>_^EF
M F %G;5-"8M;@/G5V)VWK+R!M-U-[CA,YY4F"GN1][)R7S4 PIB=%83RGI<C
M/PVD-#DX'9WI(-KK$HIP^;$6":G'Y@OC9 X2'W<!:&LJTIHCRQ<658^TO4'7
M8VAPX+B8 FYI23A#1%TFCQ-_"\=,44$U:..=6A"+CRECAV4) ED8ZRCXC$IY
M#/ %4:?A=+QF&6I^UCUUWIS_.@2QFGUQC4-I/<URG$1)QCI\657M[EKJ=#01
M>+'Y/+)=-XH9^PTP<]B\FG#-GOH1:=6ENY\V/&X)8,^9S""EC0QIYNPP!EFB
MN!@.R$B=*:,FA$F%E[#$)#'$B1^[CB8:9JPBA?V>[7W=)B+H/ 3,EDK^4G 0
M:'<P_(G#PG*3XS>-;L*P-@6\^7U8N:]'&QM,:X>[$44GY_IZ<Z\)%G^R7/K0
M,8;+4^Y*[G[H#4W^:X*^JC!/&S, ^&L5FX*O+:F*QF@]Q 7S4F)BDEP@1W_D
M1_!22<ERM1BN53.O+S'PQ7(W"E_?FN#V(XA B:DCOR/GN@UT6Y33673XZ"K4
MIP_-5C,YJ [ N@DY,AUCLL8=;<D\J\N8>G4$RMB%JWQF-"!$W&$Z66/UFKQD
M+]<J@&I[0>'5HPD'2HUC3H:CD6K8$HD)7J@#/1XF36@K18&6-U2]B@?BQPO,
M7>Y=W<H9<'-B[#Y2,E(B::&1CSA'^&122.1/HK61>$ITXPL<9*PL^.B1A4'1
MABS0?,[(<""H -8W947M,CJAX45[I'4M 3%,/G$-VE@9:6(V[55PA&KI<5XR
M*ZUEX].Z;Q#>O?JA%@NW2FWVSVOPP_<+JCSX[Z_SOH/#O?W?#P_>'NS>-ZSR
M:PITU7C-SXR@#!QH5/-6FWEA&XC/%\ ;J4MM6O8)L0D+<X<UW^.)P6P(\55Q
MJ=AQ4.13PK_";JS4[G29JJ@2EYJC*ZA_OV,>UQ+8,(9WU1DYQN*=!8N5:)0A
MYVELV?I"RA$UX%KUW[OP_N59KLG(&!Y#_ 6LD5FOG-':MHK1&)LYM&"&BF S
MCQ+_"\)/U75.S"LNY'*92U !!;$AY#4,H430(1O(F3%@RB&%$<".,4MVF4W0
M/Z\KS@\*3!%&XMS^8@;!V3"< --'+2L!9/R>C^'$/U'$!@5"C\>8/(,=J#^0
M&4 #V\0E+^-(0]Q>+7XV^*MF=U$O%%2)%7JR3.9FE\2$3@)..43M+\"MI)XL
M%+HQH;]8ZO(-%C 068$-@XER$ Y,QN^(:*7_ <Y/V/802'[(J!M9P"KZJ5A=
MD%I##[$]ZOBF4,M; #D0.15&DD/\SBB[,&+%OS<<' -BN!),W V?H.??\]$9
MLPJ1T0Z500#V L"/==_A2?-Z1L]+'>F<L<"-66#L=H?%&>=\<NC=1E;&%(57
M,UD4"((G,$@VAD9\='XG9M=Z,MNC283" O0#(Z-\J:(OW,R!\)7I $KFJ4:8
M#F@OL[G )@::!UWN"&M<%XUK (SV[2E&>S#- 2]C5E$+2"/JS F0L(]:'T;8
M6-O$<XIQ230N)F RC[Z9(0H#"\^M-&,QO=^,1?Y($2+839$A!+B5!7R<"U@X
M\;L1_DL6H1G+W**4VG*YF<Q"*K*(R.Y"+F[:*["0$I7]4O[01-&'(F)'\8>F
M@?Q6;_2(:7V\.6<X6-C:CMT 8HG7$J@![>%TQS4KBQ2J#>!@43$[*@5+!L),
M ]Y9 %T66\;*TNHL7%/W15Q#M8+.'TLMKZXYE539Q\=NQ#R+X!["C%'SZYSH
M>%Z717/N-U\(,OQA-7* DQ?S"!H]$)YS3A'-&+^C^8*YQ3P+KPMRY5/1QO%'
M-J( !*(!UJQJ\;8S6.EF,5$8HJ3VM.1<$-;\ _*2GY%.,WD#^XU[D[2R9W#,
M2N!TC3S0+45;_A5V SK-S4X=@]RT">%" RS_"04TYE(5J9!PMY#Q@*IA_2W>
MBH5SP*I]\]DR#+A_SUS@C8A@U&7&'.I2>,)YEE]U#X,=H8U/;;G*B+27N5#-
MN)@4A'4G'E>C/[)94X$>H NIW[,W$NZ:Y4?3[J\5SFA+$27VLB7 DI4+HC,M
M'ZX]'QW(Y "$*Y\ZS34O'9$M-X3)KD$>E@V=1 4O.C<.?HJ@3M@>:A'@(J(#
MRA1#:'EX=4 4-[N7E42#(%C*[G5,[G,9^[T-"7)6-=T,Y+D-TN @^,LK]P&#
ML/ TT#7&9(Q85WYJ))$B(&^Q405]*H.;1$*4+20#A?CJ,.=]97/>J4KV@CA<
MKC<6"TP%$@<!XM7M/F7J9\P(U<PA5T%KZ.\+MZ5"0S1XJ)_2Z+A8XOZW\-$%
M/#ZN)35,,L62Y<EU>(V7D#3$J[[PR*E.(2[+!KUY&$9C\1=^4P38 <K/MW +
M9)%++?4'R99JY"[,S"?DT9-C"*I<RO)/LQ%4+\X0F7=F5+59FC(_,Q94KDLJ
M?%D^?&*L&T273EI1$&-+7IS.:TQUM1T:B]Q#76&L/JRG(>]W.*0'H>^I#@TZ
M7+Q_P*#-094;^0YL+:!RWHPF87Y VO3HLE%4R?J+2B];A^KT.K96,9N)&J9?
M+S].J4O+ ##Q"K4IY)B-QP)JUFRWO"28R= 10,3(;*FTB.-1<@'%CQ<ET ;Z
MV(=C[?=6&&SBCS5,F^H0&B3(9A/A$/%"BUJ3>5'($VX4IW7V[%Q3EN,O9U@]
MU81"">!W_L.E[&A>LG1Q7_CH?R]\)^A4ZQQ=9)^1! N#(<7I7.*0E'F^MJ',
M1C-D!"8@N_HBJ(:ZFIJKS+&=!=!215]"!;P*UFHY']W^-#/TB#_L8'/VMM'Z
M:_&282S#K)L9]1RC3,PKTRSJ3'O7&NLVO+Q/E/7@9RX.C<7LU1Y>'K4/(^<W
M"MI'F M7#MFWV$B^4<S^>8OVY-]09<Z7>P-V+!R(=,5HOBN]AW#D>%Q, #0&
M,>$5POE+(\MW%,UG2/4M \MW&,WO]Q:%\ULWWOU&\U'AKRST>XOF@\EZ/U)?
M(9KO!Z;M31@/YB>M6+Y<;];9DM4CLPFN8(I;VZAU5_B)XOU& 35#<WUAU L-
ME#E&]C.*=:3$[8D.&AB,-$=UZ;].O,LSE5(#B2O2F<9 SVGN@L:%?UF[-I#F
M;$%G /:Q[BU@F*P0+Q3_ZFL$#"5>I:)5:M%4:]*O$31,%L8,@1O@;H.&N#9#
M("*YR)#!F0Z.TA4)MOTTORJS EN5T[5S=_%#NSZQN*%70-LM970SXG'#.T<#
M?4W#J?TN[RT+L$$OM];8H.]O=9UV?Q&S@&&+,_S:&K\/-Z1R.W; ; "SI( )
MUH7ZN >Z:ZT#YVI&,Q>.P"M6,[[0;<8FML\,VHI]S+ 9-]0 Y/FGT+>7PL$6
M*B9XS%5! 7&IN8QPSDNR408=#A@3&RJ$X8<N7IOU62G7"$1C\QIS@Y'QR#CQ
M!LXO?<@J&D .G1J9.?&,<"5T+'A9S%R1A^1JJ5KPW_-1,70X835,*$MSY;1#
M++B0\)?[?E6/\V(VIV)%^J.C]N?8*O)D7>8*2\X8AL9OUH=2.,V]H ZB[:%T
M<F8[A0H 0B=VT@5K!$Q;RHT+CK+M?-!4<S,\LK4+SV_5EWOC]RO(E2^I8U#7
MD=UHQL$6K/$_+OQ=QV<"!E/S./0 P*;%>F.[4;0E.:L@,M\88\Z3CR9K\X4$
MK#6AE,BV$ZX>&UZJ"+Q0S#:3'4WCQ,R?V-"AB1V]-ETL6".X$&ZL_9Y>S.5+
MF<9/#7+W>:$V":]32%92!BX,JV.O.([EL=?51!L9M-  ;6Q3D2+Y=Z)?1.(=
M [''UC&3ZQT8=,=)-IX/8HL!3U&19R!-)2#(!F7/P-H?7;(&YQ$)- AM7@EL
MDCSE^"8>J4?!MC2).K8=D%J_0$@1D-XA?*0.PS=FFB!A>;)N6,)S? $T0>"5
M3 IRQ:<5:#G G]B_8A_H9M'\6CPDE"$QLYQ=H<##V\[![V4#!MP#T;WIDS0A
M33*&!4)51OZ'=(91QCE\SRHMR(M2ZA&C[2]]E@HI7X(B2P#B<"1AI*<<413A
MVQUEE]HS@4:@$+H:E\3%="%;*@&53*=)D(&+J";(?H"-[ R(F-7@+N'7]@52
MW ,=/QK60>HM8PR@C(H&$T(4RU.I&>2E;/1VD-M'2F\X>>N',#>3 PP#XB5L
MMD;E/#QW[=D\?!K3(YQ0$>50U5PP-5)_M:U&&N.1!HE$7]G%9FVTZO)I.TZ:
MJH320G2ID3[V(MF83HSS-JF&>*)(&Y@#= %>)MW*-:S&,+<\9GJ(S+0&OBDO
MMN3*"/107)B37<.6,H8#3MP[9T74+(BK^1:P1/:P!Z5 >B7BYM3$9@R;Z$91
M8")''0&'EF \!1T5BZB(M1[&72#%LQPHC@S">N&1$T639-L4DIA%P_^BGXJI
MA[V?6 R"0[7M1!FXX6$J.!F7JH.O-J9.[5-FBEH)>#VAA&/ YL]#H 0:V\&4
M5!Q=(BH#Y +!:S) QJ0=LX;;E/&,6-LNT2/8[//2K@I2O3&?8+>(B]+2$H)M
M)+R$W>K/B_'I)U&T$JMBQ6 /\ M$.J5 ,QY:)O4,5Y@OFH@8>31W^ZC*1<7C
MU)$9S!9*-@+#*/&T-I*RQ=HU(\CY9"J#@F]I:Q^NBTAD",]Q:YJ/SMD]'4#N
M2J"J-AN*>@9^2:%]R$>C^O&2LZ#B/:1JH:OT0W?#AHK'9/GXB6=0PF=U-CUO
M,$:OV2. ?B*@D2L@$S81^+&F6,-G0Q#<N$ZL(C"+U/;@):_D6]9AG2$'YTD5
MJVROD/$A<;?@ZP5%[^'LK>6-&3^.>6OPO \; TA4"*>01T!PO VB:-^TKD7R
M(CABV@(I!'K0PYT9ZRFOC>(;X#9I-S9IT0^ZG 0@Q#EG*+<F<$5#*V"X,QM7
MP8K-P,PUP574=3Z>B,%(2OG2,D4W[39!UOFFS067\#D)8L2/L$E!Q<[ 7T9!
MP]?I+NM^70MR9M_6[WFO"R31>E&L</<T]^P?7TQNPY7Y3!9*]2NQ*%3B9#//
M]LOJJ0D=N 88#S6O'<V'>-')!AMTSO(TSVI_TR/<JVSH<(<_TT0 0<6Q?FHW
MK3W0[AB+#RX.B/,78SJF9E)5J$]<0(9UB1! 6?@A@$!FP@P4<HL%CT6[6"DY
MC^"U8_\2>WILY\+K<0)Z"YMAN$UE7,):4#Q=\P Q9).F\@\"U66'P-A@\Z<=
MVQ&^2)Z,VY!MP!%N1%>TH'-J:/Q;S)[(A6H%V+A2)0/6IZA9!:8N]H.I-OM2
MRCXA3=A5;B2?-2K3"@;-949]]-R-Y& 7;:8)8K<#Q]M(%$B&A^>A!&6%(22C
ML(VT-BA_;#I_ 6Q"PHL%GHH#;X&8. %YP[H4+=%XN4E%#XB4X$RP6Q%N')58
M@[Q3$=%2=703T$6MH>Q"\H$&X8S!%"PO&PND]JU-Z^UX94WA9,PQ 8P(J1J=
M?KQ:&%>%=FXL4^O[$;QS6Y$A3##2!BR@5<9\,A*O)6*R%/Z!CO324#D/L(>P
MNH9T<0!V-4<\,1LM\_1%+<!NVAL79DL069/Z$H[56K#QGHZ=6UKK"*H:VNSW
M0$[Z<@?Q.LH=Z.C0\CU\D#4A&Q8?US1Z7A-W7&V%2>J-$I'=$90@BC=RZ[%)
MGUJ_WBP1-KQMXXE>("X!T?=>@!.+;I8#32,>63M.X54"!/!_FR]W$2,TCP0,
MQ6D'7,(&_],C 8<)9(.$A-:FZ ILXD7 *A*$/M.,EB'R.H&J7:2^6Z\K]U8$
M+PXM<,(W@HH.4A!B-F/H"[!YF6\E9_-B0A0<XSJ;C^8(R3&/]9'Z!$INXY L
MH<SVQG@0!R8-HDD4??)M<>RUP'( #77%D4,W0%S?1:/<3-["<:,]VKTVP8M4
M%;5$ $*C9V44%ION%O\6HOY$40I.RN+>=&U[!'=%%1&Y8KX+C5A+C1( \$CZ
M-N2+UBMGO8)E($LVFW'<@%'B$)Z0P04VC4:7X3S"ST&ZT%"&FREUD"FM/$#*
MFFF;2GDOJM\/0Y/=(953O6-Y\;JV8NH@^2H</$6];./!_5X[A6S#?)*'(6M4
M-)GB]B</37+28XH?N45@OPR-VBA<G/8P",UR]UKE-Y6](,8"'BS,[<5>(OG%
M4PH$)IYQ8[/"D4RP;!+U*C[$2][EN(U"V&MBVVR3;XH;HE, EFJS5>M$MK,*
M([F):$)E]H%C>6?<A0MSQ-HDN^Z0,9;/T:3A.N'OBBI406-/6#$^MO!&$]HJ
M">'"@0]CMX6#/#92RV=OF!@CF'__K5M10O&A,GDEVF0)MS$6IT"L"SK_X%4=
M)N, 0M*T0G'A=K!^N8MZQ1?O^7K)?J'H$-"5YH[XESHE6&)5%[B$Q"\H-:-(
M)O.&./A&RB1##D,*;=KS;Y]..AS4E.XKX>>>=;F7;)](,=&3H21[N;V&'7XW
MZ^FXR+X2%=GO!\>[^^_>[1SNO_]X_+T3D76C-X%X$^&;T-@:R*??"IG./GO)
MK_N].)OF:[]5W8%QGR\K"I=BF1!4%^R<X4?<N1QLWTU!@Z[OAPW;7)J%W^^U
MI.\*Q_8S:T]+8"2KB:;RJG0<2"JX,9':0PS%=Y'@V_RT*V6'X(0CCF]!=FP)
M<8BLP+P55TQ ^D[&Y$,MC*U*$9D.D)'8*,:[LIRN?WW^*MW:VNK"G%%>'P-E
MD1##7^FW4Z#(+QH ;/S/W,@Q[ZQY"4OB *9!@19H&#0JI("<2HXN"[-%D'0*
M:_1 $HTN??-ZJD?@#].,FJ-^W#S>-#*#<-XDE5BN>0-A3,R_+Z;D I/'P!@1
M6M@Q%A++1[/L<^ZW9BA*)%O'#ZA&9S1'?VP"PX]E!KW>6AA7\/L+]WN$2EC;
M>;]@03<=9-:4B'-2JG)!^><XB+??G+514"F*/3_'WA#D>6KR?)\OW[VA]=!H
MOY@L0ED/_^H@6W99J@M;#FN\VF= I0S>(A%M4(@,4VO0UD)VW*B:G_(H\CLG
M>&84>"?#<_B2^R-X)DJW3H;G]L*LC]LO1$!.YTT9'?W> JOC=?)^6I0LT5VZ
M=]RA?$\[]38-W?%PVK.G#:)H,U@^QNA70PFES1ZI5F%PI0=3V> $E[EKQTAA
MO_K3B$!![2Y[79RI7)[KY )&2:%,N4))D35&.V>H-%2KF,Y=HL&K-^!+89GK
MC>W)L!B68\.BXX)? B(%+K9(8(2T4% 1GD.T&*VD-W7UR7B >WDV(1(.!VR1
MW!SFO8:$G*"5H.;DFJU*NI#DB%WS6GSX%8:D-FR73UU;V-7FD17NL@WK]02!
M@F]2AU?G>>EWR S>D]74<#/>'"YB=S'125+IHT<;AH\@#&990Z808[G">22S
M]**ZS)#EP$QS5A>THI U+S44AL2PF?RI IV(I\>D3&<WT%7&0KF7!5T;JJ4=
M8*LECPB:HHSRH3$)O::PK;YVBUJ-QZY]/M<$M/QJ.BOI5%DAM<9@L<I25H@+
MHF.$W1K055L8*RH?<)2Z-:)7[]PN2 F>VW%B/I:H0'#%&SDW_K+W>]C1I*#"
M>(]0%7/M%MW2O0T[-[H<IQ5;S*:X9UG#KOZSL%'1S1K51DQ(W"1L0ZJ62HR;
MLTHLZ'#M@^ .*8+>NM>LBN[&I"FD$+\LYN-V]?^&OD1FC]#E(1=9RS^P5XVY
MB_9.=EMZ/2C$$18E"ROQ,SE8R>@='#Z'"^T%%VWV'5N;!2?_GTW]QM;$6!$2
M&01URFZ3?]H-B5W&U.AT#U^JA6K!XU2&CIO+%"[QC^T$6VC0J![35(APL*IZ
ML4CBT#C>?XZG W5P8"XN.6O 1EAK;V;A/;CD;DDL'(>_&-XQ0?^AY<_QNG6*
MMO>R$6.SM!.WHPB%3>KYM*H^2<]0.!3B@KF"(<:*8(]ONP#>AE7X2V<VJ2)$
M^ZN9I-\]"!EL/,8;!*6MD+MM4+&15XEL<->:H;<3?:.W'@,V )$&Y7F1KL+P
ML'83.Z<S( 6M:,A@;%[0R8;K/*N6>U0RRD?2WQK>(^G#@ 6CJJ/W.C$$#6+^
M30K*R./IL\PECG_#+EGJ^O.U\HJHM?UVN<Y81D.;AP]HNU6U,LJ'2=&Y2""T
M#!-62I3NQXEY.P[S0(W>8@0^J"OD,B8.P8MI/LJC>RYQ+T;UP.MUAN5&N$:V
M3:>(9LI=\HI6',-UR/,%M8$4I*YSKC,M<,$F%9;:' -G&+7@<QJLW=U\Y+G"
MRQ?U004HEB0 GZ\3@ ^"R71A>HKX]8ZE<]<^D4:2\[,K:!)SUO^/5P'Z9T9>
MQAC^?FUTF+DJUZDG+_7DH4DL<LXI8.>].+(FOA]KHI>""YRI_0E;C01=XG(1
MA-LRD-D(<.NR5-UE$5'-E1C@LG7%&B!.8YNYL5M0$QY;F1Q(_ PUIU203(\Q
MNF]R[5%/Z2;.=(]!W84'R<,4RK^9+X[@$O*OAFY0[IYMO%J >?&KFU5F'6M
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MA&$YZ";2L7*;R8X18$XMY9I(\!<F(<Z1,9%KD*U #EP!/S1:!/D@8HO*+Y$
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MN14YI P)+02LR: ?X'^YQ1A2S2C;C%, Z..=$8DV5+SGF3'GQFCZOQJ _>E
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ML2G)::U.92?^B#OQMQSW@]Z'&) @'IG4DLQ3<-GV;#_GGSGB&2\NRK1/A!J
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M)G\QVJ[YH:E?*:'Z-;L_DS6<FV%C&P)$YA-TGU,+5#ZK$/J<[8X-2,HQX"N
M8<HP;:?H]0'<-H(=A=^VO6)FU?"3,4FGDP(2C?A/B&V?,A^!_=NHP"YW(\S^
M#<D1+OXCWS&'OS[+2OF#0A)ZI"7"1H,+2=!A)K>F7HI^^8%?\;=3^EF[5JE'
M);IHSRC!#,KF2!F9Q_,'?Y4_D1X%&E5<X$EV-9Y/$DS6E\-K6V_J5V*:/QJK
MT"Q2%@RF4>_F(]E^-_.^R0?M\?/Z<;\7>Z<A>;'D16>89F+5K)5IKJGK12V8
MEPO;W#VR2MQ7J<;+=3CVIE'NAW4E_8Q7TINB)&5'7!L:D1&MGTU.Z0>VV[8Y
M*DRC"MN<NR.$( P.%44O,5O&V8 +Q\@$#6LM7<F<!;:"-Y,UX*&$Y]31'+?>
MY&@:':ELHP($#).G%O-KJV5KT_P?809@-]0CX:A\@XL\++*Z\/C0B*(L:Q14
MQ)9&&H7JJ#5;Z V -F/S7,S(<Q/O[OTD5%?+-A3W127$=_N1&.^AK51>*SN6
M S*(*\- %=CKJ?*C:(>\=I6?J5>W$MNE2 NG=AU6UM)^% KC+@045;OL"&$W
MG3R/3=:6(*PWK=FT1)_X*Q1GEZC:WF57R_7:&7Z?XQV$]V(7KH/[ (U1:-4V
MY;[:# G4Q-#&<G&%TY%B"RGRX5"XV-&D2X?G%8>ZH03'+UAR?3AHYU&U%_-W
M.'-#F\D\%JJ)H'VL2QW66\=L'2YMG->7P-H<N&@!JBY5F+H4N0#*3/@5'#@P
M5J.A$ZA2_2Q.3F1S-C@<;CW<04+'*FMN1C.QY6B=G&6OD]7Z?]O29V_OL<#Z
MO1\V7Z16J_]Q<'"0;)RXUPY23::\$72C'[ D%.6R^=+O13/,C7> $$OI-U+G
M4-QM$7U4?X>^'!X7:O4W+L 9F""4S>O+@2=%20/OA)2JKYLJF4!K(&Q4Y):D
MNBJI<Y$P=U!\:^$"^U5@7L6]O\1.7LG&SLCV>]R5QP_2U:8=G:AQT=2ZHQ,)
MP+R"NMH8:</UO?%BBW)L(1A-_7:M#8PV>,%!FSF&'8SIX0=Y8^%URSX$A_D*
M^UIBSUKPS6>%M*:5QQ$5CNWXX(4/@9 2K:'<Z@QL?.%!GR59=9HCFZA#4")W
MF'X5T2=@4VX7U\\=@VV4,$ZE45LJ@Z,]T-$*8PCF!!#0DM-U[A_NL?#*9XC;
MQ-0AN]Z;TY&-3%(_*@@R9)!"R34.'PZ7PG^Z%Q#]A[2#IS"%YFY-]H\/?CV$
MYBL@Z^=;6UMIDF^>;1H-?G6U"?RX\"P 3=!?<G/SXE^R476:T]_SV7 SC:X0
M,-#Z6ME!6CUG"9<0!XWM6-F$M?8$KF[KE%/<V/T4YHM5U1#>,P9D <K#?O2
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MX>,@;GQSRY]")$/8JE^?7N2!"1.-BCN+Q+]X*JDV3X0'=9U?5A1B1O:Y,7(
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MR-A-!89#L,PHN<PF<QP%B>^OSY]#=R?L\$0L\>HG]D44$34_^NOVS^E/]'5
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MP1^\,KG82L$'U-,=H#8US5J]Q$6!OI._2Z0=B.$1XNMC!P!02P,$%     @
M:'RO6LS?PX,Q"   1U0   H   !E>#,Q+3$N:'1M[5QM;]LX$OY>H/^!%Z"+
M!)#CI+W<!]MKP(Z=K8$TR27:P_8C+8UL;B11)2D[OE]_,Z3DESAID]LDM;TJ
MT"26^/*0'#WSS)!RZ[/_Y;S]_EWK<[_3P]^,_K7\@7_>;[?J[C?>K1>W6]W+
MWE=VXW\][_^Z%\G4--CQ46:8+Q+0[ *F[%HF//7<!8_=@!+1'E;$JE?/K==D
M"5<CD388%9W_;S(#=Z;&8S'"6W_FVHAHMM=NG5U>^,M=U"*>B'C6^%$GMJP6
M_P6'::_]2SK46;-5IP9Q$JY>$[X2H[%Y2?"M;KM_-Q9#8=Z_^W1\>-RJ=]MO
M,Y0 4@-J6Q?BY='C2ISVK_W!V>"TXP\N+]Z_N_K]^N;W#C;O7[*;_BE=9)^.
M/K++,^9_[K.;SG6W<]&_J5W^<=[_RCJG?K5X/XT$!M[[=U]$,.80LZX"P!H!
M*.J%F3$WC=<:V.LO@=_IGO?9:?_\_.:J<SJX^.W7O:,]^_FJT^N5GY\]FJD(
MS9B*'GUHLJ%4(:A:(..89QH!E7_M61_3\J^?W\&$IC_@<;GH1F9[A<=J^;W_
M&_#1X8E(7W'6_=XF@N2'+P3PM1]#!VW,)\ 43 1,(<0'4&C\E$EEF$S9F50)
M%J_]F\F(_>:SKI#9F*N$>VR0!H<K2X$_KC?%!#?4Z#84UEO+OLI8WAK6<$LX
MJ<LUA X>LD\R8[>IG,80CL!;H:908K.I-.C\4L-%RG@Z8WEJ5 Y,&VX@0=%%
MG,51"J#Z$CQF$0_PDF(R$08MQI5;*Y!" %IS-7,HL%S";P$[7VI8X[40$6&_
M,049U!$5"(0*\@2+I=@&PD$_S:9C5#I,Y_1C47\*"HI&:!2)T#'P4*0C]$IF
MC*/4&02$LD"!C6<(4H8X8#1^).KA;'E"JF=K)V!51+R)J_*2L(*=(&)@D4B1
MY8@U%ZSF(0N'3.)MM71?I!&*2&X$MB/2(,Y#9"]DSB7V\I!ZA8IG+$/B(^(F
M0H_C.3,[' 4IZGO]HP<(!;7N48D\Q@)(QQ+ITO:I+:B ZS&+8CG5)5<K& EM
M%,?>.%UTX!&JM\2VND1D(9=<7+'N;L&J6'<35^4E885;PKI%2,X32W9(7F(8
M Y$2 Z3982STF#0B,56"JI>4+WT.A0YBJ7/4E*2'E8P=ZV5*!A#B9<WVD>1"
M0-9TY-N_"\8\'0'KH,J\SF,L<?R)UXY/]N& JCH<QR>ANV2O83VDX]11+G7"
M2(HN,;$C10+TY-XBUW+1$7ZBL:[2<S$E6(HR%8V'GZ*ZS;RUJV1AE2S<KF3A
M5H 4!]M!GSW0V'2I6VW,_6-J]"@G$/ <]>Y3JU!68 C(<*Z[(M*7N<(&4#A.
MA"8Y.D\@0&H;H[V-1;)A618KB+GE32R\2GY>(9GIID!EBX"TC$7(C44[U"(4
M7 D:A7!9"2O44VHIUY0DL')<.RR46[#*6VI 5 9E,]7,.#W0><Q)@N, +9)%
MQ@%KN"3&<@(&_QH"%42!C/4AK.1-!:N2Z)4-[Q@LL<6^[\EZ?<T%/EWI/^8)
M2Q@+=TA%T85.1$@.CFN9<@INN$;G2 ES\GI<A:7S09\H^%#$PLPH9?-0W^24
MK9^R+LBYTI6BB]24@V,#J;MB:%FN,O2#VB:;@@"%LD5A\^\C2$'Q&-TAWH&,
MG"T5R5/C7!XZ99%A&%,11@6K<GJ5#>\8++$U7J\_X7%.P=!BGQ2B" (C)DCA
M^H%L_R]*?\ME4S\ES',?%QL JZ=C,-S#BAB=:;?-,)2Y^0&,IT2C?%X::#<E
M^O'F+QO29@WMTUCG#6Y.$%1SGCNKGO$*5N6G*AO>+5ABLB5NJN=XOW13]SP)
MG5TJ-DCLG0?=U3-",LHSRB#(%;F*I7S>>JL.3B*UP9MT3AT;U/A@L&\Y5]@?
MVW\$383>#^.D>Z4+] &Z(WOVBHYEI?D<W(&#-N9ZG@:E",LZ2@B+?"F&:'9F
MB@!QQF)Q"_C+'L2Z5\G[RY/5?-PY5EM*N[&E]!.\TP9NX<!V[8#;0^EAR9K>
M0N&2ZE[FJX78)<9Y1L9K;:ME3AX\#X61Y9Y)F62R5['=)!'& 'PGL.A*KJQP
M[PD$22VQ?60UE/":X@3\33L_)2G#MUS@&"SWYFE@CRP=5+O<.TU)?SOVV0J0
MVY+S0 %49->Q!Q&AD2)WT&F;0 #27)&WF&\T3X'?4@["9;IM%L)FZ^U1^/*4
MY+/(L]@.Y@K*@YD/B#4>8FT-<ZWV*-L6.7ZL@FR)#[+GLB$:9T#G";(6#MV.
MJ%#+#YXLK3(=%:PJTU'9\*["VIJ$/$^+%Z<BA8K90U<!]GT =#;V1:?"*WDN
M%2#2B8PG0/F E(^*E[94\0H!)%DL9X!WIV/I(@*^XO/01WTG8U*F6I[HU XK
MR;VCDOODZ,.+YO+0A!L.U1<^8\<G'OMX]/'D9<7MR8?7?\-GUO@NYF*%A](8
MF318-^;!+3O&$=@#B*[!9XWIGV\PJ-:@7=?U8G66OV*B51^T*[>Z6;[B@B?P
M?1O<&*B%+3F A4%5QK1)*^0+$Y>\O!V(3\<"(@>O?P=!3H<%V&6$X@85"@6\
ME8EMUH)M$]:Y13F(IV,N%-8KT]8V1UW9UV:MV39AW;]RAV#+E[/7&.S@K>*I
MG_.=A3B ?]1J[$Q '#;8%0:O36S@6PYI0!6;[#*S6SD-=LZU8;5:N9:]P7]*
M5&XX<X7]K\S,XZI'5#<.:Q'<+0=S]X.]50V_'J7=B^;6=?2"!1YXME>G/(;(
MUI@;Z?J7WZUTMYC1TC)*JVC5<7;*B5J:WCK-KYO#;3*<-9-9!C^'M)B.(GRO
MTQ>!MNTW@](7B/X/4$L#!!0    ( &A\KUKQ.'=&!P@   12   *    97@S
M,2TR+FAT;>U<;4_C.A;^/M+\!R_2CD!**<PL]T/;6ZFEY4XE+G AL]KYZ"9.
MZ\6Q,[;33O?7[SEVTA=>9F 7F*8*$I0D?GG\]ISG'+OI? [_/.^^?]?Y/.P-
MX)/@3R<<A>?#;J?I/^%ILWC<Z5\.OI*;\.OY\/>]1$G;(L='F24A3YDA%VQ.
MKE5*9>!O!.2&:9[L04;(>O7<?&V24CWALD4PZ?*W32S[;AM4\ D\^G=N+$\6
M>]W.V>5%N%Y%(Z$I%XO6SRIQ:0W_#_.8]KH?Y-AD[4X3"X1.N'I-^)I/IO8E
MP7?ZW>'W*1]S^_[=I^/#CYUFO_LV38F8M$Q7=2!>'CV,Q.GP.AR=C4Y[X>CR
MXOV[JR_7-U]Z4'QX26Z&IWB3?#KZ2"[/2/AY2&YZU_W>Q?"F<?FO\^%7TCL-
MZ\'[920P"MZ_ZPDJR1<]QN01TU@%L5-J6Z_5JM?O_[#7/Q^2T^'Y^<U5[W1T
M\<?O>T=[[OJJ-QB4U\]NS9S'=HI)C_[>)F.E8Z8;D1*"9@8 E?_M.0/3":^?
M7\$,NS^BHAQQJ[*]PEQUPL'_#/CH\(3+5^SU<+"-(.GA"P%\[37HH4WIC!'-
M9IS-60P+D!NXRI2V1$ERIG0*R1M_$960/T+2YRJ;4IW2@(QD=+@Q%/#G>ENF
MX)9.NBV%]=::KYXL;PUK7!%.ZE/#8@\/V"==D%NIYH+%$Q9L4%.LH%BI+!@_
M:2F7A,H%R:75.2/&4LM24%S(612D $@O3@5): 2W-%$IMS!C?+I["22+F#%4
M+SP*2)?26P:5KQ5LX%X,B*!>@1X&5H0)(JZC/(5D$LH .&"GR7S*HRDQ.?Y9
MY9\SS8I"L!4I-X+1F,L)6"4[A5::C$6(LD !A6< 4L708)C\0-3CQ7J'U&MK
M)V#51+R-H_*2L**=(&)&$BZ!Y9 U5ZP6  O'1,%CO?:<RP1$)+4<RN$R$GD,
M[ 7,N<9> 5 OUV)!,B ^)&XD="&6S.QQ%*1H[M0/%B#F6'J *7(!"8".%="E
MJ],X4!$U4Y((-3<E5VLVX<9J"K51O.G! ]1@C6U-B<A!+KFX9MW=@E6S[C:.
MRDO"BBO"NH5+3E-'=D!>?"P8DA)A0+-CP<T4-2(R50JJ%Y4O7L?<1$*9'#0E
MZF&MA&>]3*N(Q7#;D'T@N9@!:WKR'7Z/IE1.&.F!RKS.!:0X_D0;QR?[[ "S
M>AS')[&_Y>Y!/J!CZ2D7*R$H1=>8V),B GIR;8DON:@(KK"MF_1<= FDPDA%
MZ^%5U'21MVX=+*R#A=4*%E8")#^H!GT.F(&B2]WJ?.Z?4V. ,8&(YJ!WGYH%
MHP)C!@SGJRL\?95K* "$XXP;E*/+  *3KC#<VU@%&]9EL6:".MZ$Q)OD%Q22
M&1]R4+8 R"C!8VH=VK'A,:>:8RNXCTHXH2ZQI-Q@D,#)<>.Q8&S!*6]E&*"R
M()LQ9T9Q0>>"H@2'!CHDJX@#Y/!!C/4 #/PW9I@0!#+D9W$M;VI8M42OY_".
MP>(5MGU/UNOW3.#3E?YCEK"$L3*'F!1,Z(S':."H49*B<T,-&$<,F*/5HSHN
MC0_81$['7'"[P)#-0W6C479VRID@;THWDJY"4QZ.<Z2^%TW+<IV!'30NV!1%
M()0="A=_GS#)-!5@#N$)R]#88I)<6F_RP"CS#-R8FC!J6+71J^?PCL'BE;%Z
MPQD5.3I#JWU2EB0LLGP&%&X>B/9_T.9;KMKF*6Z>OUQM &R>C@%W#S*"=V;\
M-L-8Y?8G,)[BC=)E:H:[*<G/-W_)&#=K<)_&&6_F^P1 M9>QLWJ-U[!J.U7/
MX=V"Q6<5,5,#S_NEF;IC2?#L4K%!XIX\:*Z>X9)AG%%%4:[15*S%\^Z7ZN&D
MREAXB(?4H4 #"X-\RZF&^LC^(V@2L'[@)]U)7:"/P!RYLU=X+$OF2W ''MJ4
MFF48%#TL9RA97,1+P45S/5,XB LB^"V##W<0ZTZFX/_NK/;CQK'>4JJWE"JY
M6\.JM=GMSI_')4$&*S&+ GN=FE:Z%LGE&<&M>[LJ2YZ@><RM*K='RGB2NPOE
MIBFWEK$?^!!]1;73Z ,.(+$DL@\$!FK=H$L G[C)4_(O^Y9S:(.CV5Q&[G32
M0;VA7;//+K%/)4!6);P!6J<(I$,-/(%)"MR!!VLBSH#FBA#%<D]YSN@MAAM\
M4-L%'%Q@WIUZ+P]$/HL\BYU?JEEY!O,!749CR&W84I8]RK9%.!^R %O"0@Y\
MX,- #Y@\!=:"IKL6%<+XP4.D=5"CAE4'->HYO*NP*A-[I[+XCE2B03$'8"J8
M._H/QL9]IZFP2H'W^KF<*3%CZ/I+.BF^GZ6+;PNP-!-JP>#I?*J\1T W;![8
MJ!\$1\JHRA.-VF$MN7=4<I\@WM>.Y<&\;GFH?](%.3X)R,>CCR<OJWA/7K\=
M_47KAYB+81\K:U7:(GU!HUMR#"UP!Q!]@<]JTS_>H%&=4;=IFKXMJ_=+P-H>
M=;?5TOX"H;&]6"]HRGX\+;<&*DXOC\[-L7IZ56#,0FY%5>;7Z92SQ,,[6VJ8
MRP0$$:B:#S3-VI UTLQ2O:@G7P4&M$I8]Z_\&<?RN[?W9N#!6VGH7_,^.FC
MWQH-:#83<8M<@<."J^U;SF2$&=OD,G/A^Q8YI\:21J,<R\'HGR4JWYRE@/HM
MLTLM_8BH@F:M!/VZ@+\K\#<EVGUE?D?!WY=)*VIX8,%O=KE@B<NQG*3W7VRV
M4=VJ1\N94<Z*3A-ZI^RHM>YM8O_Z/MR%B=/$MSCZUSKBVQ__"U!+ P04
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M\ EHX6*2RN]_+V!G16<PIB4J?=K8< W8Q6,PCNL5GA]T5@P'?"D?)/;3Z*2
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MQ]BP]:1]<L]?4"8^MN83?\.!O6#KQE;HGP)6>=#.\94\=X)L(7%W9$PY!DZ
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M3>4*5Z^_@,WGL<(*MO,K\0NH-7@%:H'A0-:@#^A<O 3LBCEHL$(E:5:Y@)*
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MZ#.E<&TQDA>TC=Q=P_GAXF1VRW1=)S'&COD.MJC,3T=4: >&YI_*^6@\5T4
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M &II&EQ-?OI&Y_I8^1!=:5'_B^'@B<-/Z@BOQ*$<L,-3L"KVBZ8[@H07]MA
MM +%D^S0[9G1V6@%C'AR7-6]">X@X<AN0@+7$AV9CX+/SD82.XL#6DD^2[60
M&S&SW-04R#HEZ&1FPM[J#4Z\;WTTW+J+]:ZHL+O=*>CB.-HS&&F=N,CL>[#Z
M,\>;HA,O'=X*]DG.V7M'_\EZ729=M&F*9[Y?+X+(BQP<WI5O\EZ49%BDM<N"
M933,FH<Y]<.DZMI@E(%M:+L($/9F@@<206>,F#:>;;#5"H_CU9:CA1Y/(YG5
MPNIH1Q!3U2Y(=IX+OY7@>U87O)KEL6K0P:C1=%%9$? /7*Q:M3\;%_ETQ&-N
M)%_P(PE->_H;W:(/A]L4#@5'1:@8G@ICNC >*6>>>K1T*^+3ECA*,?V,J5:*
MS.=3";8P.DLJ9?U(22Y9:I:7&O)=VK=<P'Z4U,L2@9)P.T2BXA_>$A)LA2O5
MU!,N?N%A"F$<P3=1^HM%D1)_*[+'VGA [1).9.R[_<5GU2(MW1)RAXA7M' =
M(8%].Q>)BTD6(]'1?ZGZ9$RZM.'E6"1C+FT5+C]#OO+!=\L%CTUXB>64*QG5
M ^[2>N N;3L68CP5'=8;*POU=-P!^-(*L45U4+,.P.AZ"2<Z!;(H4.T'0(HH
MEZAK'S-=HMM*MLJ.F"R7NLO;Y7D!I3:Y[)F+R=MO.WM?<]<XFZH1<VC92FAU
MG7*S9<G>?'C:I1)F[J(%L'AKASBDK)056+TB.%]*!AEF(TKJJ49A#>X)JWH.
M3)>,G,1'N>R#HQONXKINOGJ0I&J]N8MV]#9:K$GW9YD%I,H)Y^";OE.K'Q?E
MU2OJ.N]:"37&:E,1KG+,G2V4@%6-/$2[V&S:65ID@5Y24/$L.>?&CQ8F%.OJ
M -9<;(EVHH=(@,.!STP&2%X9<8:AV.DE[*'$9R0ZEVS0159G9T@DW [&P_0O
M/;>NKY,-=0<MVC#;VT$2N/8VPT'S/C@TVS36,2@TLQH]J55,NB"\PJN/F#'"
MV<KEQW"[K#CLAH_*8<55%:XMF&06S Q3S*2*R!E 0 464)B<TW*\CZH(Z=?K
M=LR_NU6R<4#F#=T&F, :X2](G7BP-;91D::QU"6F*!W,UZ>KZ G?>V']HT?W
MH:A;#44]N@]%?:^A*,[@V%:"^=1'<:CP ,N@SI/TS*:K<]&Y&!_7>?VN6@ R
MD5?*ZE8<.#T@/="US! +NCGTLC!)H+M5D_54%LN34SGVBO(DR=-_6?H5#ZT4
M5JG>HI*@.JW-5!>P.))*9+7IR]OLRQ%K,WO*YC-9!_0!"J88HUEI.?NDT[8U
MJE1Y1=@]PG?!68IY*@<N9E8K2IN<%&#8SA*"<U38#\+[W65)1S#*&!]B;1NA
M=O3 ->4?V6OXC:I.JX?]+(?TQ1I3^%MM"V%\$,Z6V+7:4^HC]@2+4VKLO9&D
M)57P]D7X\.8G)C=EDJDZ&]=FMH'B(&EAP$V"#+Y?S"(I\21>.M'W$4-1^S-*
M-W-^R"(9Z?A$>\ 7,#DS0Q$TH5@D*BIP/]\EQ8U!J+=#ZW.-R=D0/A4J=;:_
MQ%^*O<&F1&9.&"5*"WR=Z=$GD![;K&$P,>TWEF!2?4TI?4^]14U=;6 QD#-4
MC(D@W[^ZF$N)U.W!H^9"K>;53R4F$0:>N7>8F,(8A!H7TY7%HOT..[>:IBS.
MVO)PL5P1V1*'QKS)[?PZ,:*_QIN5/1G7;J[3K_H6FOO;G1F[0D#&ZD/%5@1D
MV>322G)-"F 1)7UP(=Q@UD7I[Y7IR_3"XH7@.++ T_6+39J5V>7FEHM>=X)8
MBCOWYD6+$LLAX0]XDJQ9G]_<=+YU9IN_@YXM">7Z+CE7U#;44,_V!YK()8*R
M46%J6WD)R@)K&:6!()]O<-:!?U<GG4%TAU8XH0$(^A7=*MT6"JN,Z;:=;2\9
M4D>M?S+TRYW+37@-_ O*[+>B_.P-'L\:J H&,B$ */(9K!T^0-'/MZMB.-A/
M"/*.5;3)"?B%RO\FW8ZA! D9MB062J)JBPJK7W/O)BM.R2K234';3O*&;6D[
M)F/,'^F)#%8J$#C:E9;6P<2T6>+Z^,6^0BAV\:*83R(I8X[I?CG]:6Y0:U!
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MW]$YN-_L=VRS7WFJVV'./]/H__/HX.\?=HY_/J0@Q-N/[_;V#__K?L]?-7>
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M)VP4]0.NPL%-9T@Y-J[X3ZV6_._.S1\.D9G[YP@TOA@2S#,RS0KF-+,T8VJ
M>+R3E6.&!EX\4-%$ 6?&23 ^(D90B+\RX419A[]PJ7]]_SES!6X)N!E317-
M.95$\$X08WHO4]S3G&3+W*MOJ=7%Q/D:(N@'& :0B9TD<W4O0 >,Y9MFYLP8
M*Y* B%,U,61[!XV]")&RUD60Z2.Y&&77.Z_;W  \FN';!7@4\?/T54/*+N@O
M:].$]<\-6&O6IY> \C)@._H?22KN9.TBGU^UF![$G%V YF1NX04C98*7E;JZ
MBO"*OZ<97>VC5-DPVISW:%^':D'X^ZO0NQOL9K2%(*/-X0Z% -$K25'\4CBK
M0ZQY#1%O;.BH/>59]A[@]S:OOOPL*,(DNFNT,,"B[P#GI)Q==(%R,"" 7XU7
M H\PYS5"LDVPH][AT (FM_<P:^V!D4-&X_(E.FI#;3#.>ZR)>Q-\=E$'Y0\/
MET7.K]1EF1%77HRX4X BZ9<X7;.)II<K3T>%;_I#]'W6"Z/T6'CTH@;O=67Q
MD;\^@@95#>$% LTN857%&8*H8[V(EX31_QOI U&9@G<QX<[A4^I%)*"]MJM=
M=L &VTY#[MUU;*+MM7>)HP4@8?9]A$?A(V-X3"'A)<E7KN+"MWQ]"60E,LKY
M"J9[Q7)Y17/Q#:M+D4M+EJO,G&?3/7+DBWR0T)#<X21BO7;H+DP.6TYVNM3.
ME5JG#*SP247<G\P @14  J>$M^X9:3)FNCA9B>CFKYHN/-R-][U#?3_MRXZ)
M]23I!*^F1TG=UVFW$3<;="=Y%%;OO=X8PA02MXPA."2Y]7FS5[-A:H)'V<-*
M#4?,=>P\0O2<W-&<3"W--F4SGMOA/,VCTQ.VO..>L+O<;Q%\.(=U_?>ZT<][
M&YQ+8B"P?4\F[''LK(1A-8'YW_5ZLWEUY4(Z?('?]N]9+L)\]*R1V"$S:O<]
M0FB+N6JU:^UZJW8#9AK;N5J/G,&R"ZS[B?W0NZ-V+&HK5[T[ONQ8N"T=30AQ
M[/E^Y'@(]71EK]I;VSMQ2WO3FE-DAE!"<</F+DWI,6#YB6/ >Q[^>_;?G-K/
M9EF\"1EWP-*L"L=+3B++.=TQ0KIF+3 M>M?,NP>99!.1\ ]9KFD@WCPDU[JB
M\.D]MZ-]J,?!>?X-*]\3 WAN&>!S38R1W9DBL]'A?(>@3J)+:\\3\H@N">8Q
MS-T3(>F0+U"M?CJ@SZ\'?7>^4JY9*]],\Z\AZC/F70,-\:'D_[SQZ5"D%N!4
M)D-A_62H<QHI"GA^ZQ:@1"W Z8"^B/<OZ4@C@] 5QH$IX\P%QHE0%Z+39(.X
M_(;UMI,VR24X;;*$XQ(^QT_F1@2=3E=2/**&J/$&.=2':..:S$DS320J?0YL
M#'9SQP6^YAYIAK3L]R<=\6SE3>MM!_3YTP%]^0R?S(H+OSA<@&INC@;\PH>2
M]1F!OZ1H!JX.KPT40[?:-3'WHO8GZ9C.O67WVT%TX70072$^N*XJDN:@^4Y5
M>"1@ "<>KM1U3K+KO$_Z$[DNXRF$S8K462_.AUXOWJ/JJ;H7BUM,I_>Y>;^X
M4KRH?-[<]#V)U=9%H;/9LXL;-++67HFA(<W,DF]I:'P+?TJG U3V[*+Y,A8'
M8O)3+[FW'8A2+^C8 #QXW52<"^26]$SN[*+;NF[7>@_WS6[B-4UU3ZUS-FS5
M.GBQ]-K=0;F/3&=*4I@?\%NLCB\?F>_XW #XFFX>6MA9Y^*DS<./3&\VA??7
M5&X@\A\9W"#=Y'-;P=S++>SXL>\BN_Q.9Q-2W#"?F,T-"R?OV<5TUE!.;/O0
M?/U\L3PPN8,ZVK[A8+K4WI6>S^;[+,OV7]N\5,T^=?\^LMC7,";PXAFYY,-\
M\9;)N!9W%P45P3\)IL>7-]0$/2]HA]+U=/P6G9G,,Q)'8QV3(PF>6UAV^G9/
M!]$6::%:<C4/^%)1I<+CZ^7WU]RR!5V[;65I1#ME)ZEU,=?4G/UTGJSUW JT
M0MW;$6P6"[; YDA7B([THUWAD9$78R-8NT[;+=M"C&2[&JTE0)WL'V#^>-_I
ML!=*V8XP]D_X[V%8N7^X[&M>.,H&-VHVM,R(XZ:93$W3P,C7!KBS'J_WQ<O^
MJ_)+^])\$BXGW[BS];/)*].AC@;O<ME".I>OI'/%XC_>>;=]HK'6[39[W4/@
MPP,35GBY%P7B?H^*V7>(%^UC0%08L1&&IX*HK"@(Z[R:N9[(LJ IOG,C;3KX
M\OF1RT70%(_>BT8['*]%-<.1,5 0QA6$5!@Q$H:G1LB[- +>]E"3!?P/WOKS
MQ$FX_+NFUSE5Q=W(2189-$2NU9]PM?IK?B#V7V?5;K']JS+HU86].!5VT('Y
M868IG&1#:?E8[&VU"M[V@<O0>/B!T('F;/ 1F7.&]7Y\_L6WL+L=[_^L'Q-;
M6GK=MMCW[K]LP>]#(/3YM6%>;9E8* 9LPYQU-6%^Z#9P!^9\J9B&1_AU8/;C
MUVZELU934-@='W:%#)M;A5TI*NSRZ6J1C27L/ W'I<MPW"/P'D7< !FST3Z2
M<<E0-*_K,E=I%G,O?W;G4WI9AQTR8SXP8A.H;[/%1/,$20A]7HDZL:KY,+.*
M.L3)!(VW-JZ> F@VAO)W*IIRHM!\F>*%/K!F'7QFS$* OZR-1^JHQ7TIL"PW
M.IC;OLRE72_.6&PP/7>3%QKQYQ5RA Z_+FFP9HUCKR[6IO6?0TWI,'3L=\H'
M '-PJU%D(T<!V6P8#>"Y-G8HX5'0)A6TGE:K&/0$H170LI5*S$'K:<M8O[0T
MMEH],%NZ9;; ?KW^*E7ZKP_ZY,_?Y\^EK_?%?043N:SG\G80,Y;#3?FWX%NO
MTZO=$.H\E[S\Q+?M:R-.?/):1E",@80.DB@(2<5^9WY4PU2(GIXJ%;>:Y813
MQS-.%*6Q1*FW)8J<1,6Q02[V* U:710N!J(9@U-=0J/"B)$P/%W)@LN5O!&Y
M@2B1\P+!(W=W.#0[&RX41\F_*]-I:8"4<75W'N6^*Z)N6K7+UDVKUVIVF5J[
MP71[G?K7SYV;1O.^:W5&,ALC-:]:]5:/8CFN6*;"B)$P/!5+W5NQ>-=/%1I5
M9=CF'L:5REZRJWLHI9+F8Z+(C"LRJ3!B) Q/-5%UI[)X'J:UKMUQ,[S#:VDE
MYJ;^^O>JU'^M%2;52IWOE%^C%% =9UW<'ADS-8>63)#Z1>X'#,L]$1(\BU3*
M;U'D5 FUP$$56_(PXYG3*47./.;3E6+<E\5+B_I7-9"PZJTMJ^#+VG?]K]%L
M7!<'1UL,WTX;XW$Z:][)G%DQJ3CQ!4T(K1RY!I!-L^&RIE0K)Q<[WMJY'!T[
MY6HY/MCQU,[E/N(-#?1H)O/(J2HGZS:O9CZJ^<?#][I\\Z7R\A!%-6_A'>^Z
M.,D:+R'%CK5GM)XC9O4<U[W+NP\^T QA "*7';*Y4LP+."A*$XA23U-3SD8.
M'HM;+>T>J\QH?0H7IVY)K9%E>L &U;K-UR;ZTW\M9[]_KM\_%J^?#U$MNT7E
MT79SL*?H5G]<.RM\XYL5IEK@V%K ]CJW"57*D4L-\^E2/N[%AA2EB4.IMZ6*
MG.8LIJO9!-FJ;0,<&OV?ZF(3%4:,A.'I7>9<WN6Z6J,L>QGWF@"OPV"M0V I
M*.,*2BJ,& EC8VWBG8J&"-P@LRQQH;,*!)V/\FW_]?NWEUZS6N9?6FQB"@/J
MBDQ(Q UMG2'"@V",:4+*E%.9)SQ:YG_,E]CLJ2[L EIDSQVG=E32TU8@G+I#
M:G?,J<"Q5G\J"GU^WCR5GWWK?6ZU)B^_"F>,+NIX ,N$S(FP1SHG(KL5$5:C
MSW;KH5[Y=JW?U7X'(V+3WK( 9 2/^2I!]T2VVE>+_O0=>9.V1X(]W?]*4/??
MG^#L>9;U" '\8@+R3YI9!D?)%QSF>VJ&/E94\14)'LC\^Z?XK?&ST;V<2OZ@
MT,AS&,YYT"I"FY&(L)")Q/;MY_*7ZYO<&F1Z$1%"X,MDA$!FT.TFBX*.@LI
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MJHZ<5I5DM)D!'BX(:$9J/\D1[B,R@C2#+(NZJ0M0(/:M<PD]3\@(PRB3%_T
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M\74]*.<=* -&]KGL=NL ^2P$^*5J4/^"SM8#*]K0H(SF9NT4DVPU<K8IU,H
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M=[>-AXV7,O&JAV@12CQN[&RZO,9-OC:Q*<]C$3PPHH,G>.'!>H:*G.478E3
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M%'F4P4QP(5/&!]2:.5,L28^Y,<?"">EC4CZ&7HAUOUA7H%RF!<J[*U N)Z5
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MD5LY,&?DGDQV<D\>K,6<<$G!$5<*ER=.1%TGF645KR>:N__Q^J@GBU;S9%$
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M$[(:D[D-2:=RL^OT5<",!5E --1=[IJZ#280MI;!''>K+DDTK6P3"T\Q6WW
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MY_IV>&;<;RDI1^_!+)I>+ )KT70^LGAQ*9*VE\6Q=4T1]R<RPRE*''GO2(9
M?O[[/SL[W*%().$[=P$<^P-&>C7 ):$C_.!HI/4[5^!V=LP[<D$<Q<V%\L%G
M5J@E,Q=@UFS,*X;;.6TPA<,UZ,HP\(HW&I/(];IOGEVS]NL'=S,>POL;*EC.
MG1_<.3 LV]-S!7<OGW,_]8_U&/YI&L7PWW]@FP,V7"7\RTZ; !/!V$-Z7F[(
M4K;#-G&Z2,ZAA*%G</>4<*YL.BX"V0"Q;S]+;<_D$84P2(E3W8U2,5H<<G\A
M [)K HF%EMUB=-HD&*K*2!0(BGV.-Z_"@!<[AL2C\,[@YSB*;288FA5J9.+D
MNM-7)%CB0!&(A+=+^"<R,J]).L#;/'R(ER(\3IB7W)%,C<4\7==PKG=;<],R
M;')=28'_FM<E(P6_A XPQP_P)H8S\-<)6.SF'*;'X_4ID\9=,TS5V!XH=P%U
M$X$YXE,-7'>/;O;>V/F*&71NP+X(]HU7 UR&P9 N[. =+VN(<&?/DR)S#T7!
M"\UM&D"K-H5\>G^BJB>_6K_YF\M>R;9K[A;8PB%14>""()IE 6U@-P,C_::5
M%-=>\FZ4SQQ:4;_T""3R_W) TB;TKS?^#U8FO $^'HBR=0= &4)#MA1E757P
M@D@#[0@*%#4#F*=X:,".H)(U=CW840Q)P*M#0]+Q5"T6IW]\HW]L$R_V,(ZA
M$1U(A'D)C#3PRI/KBN]$V($MV:$_911Z.A9+^BTZY4WF"*5=T_2C"U2I<LRB
M)8W9*3I.NW'=Y&IY7XX.;H#G$L24?8Y$U/"6S8J#P99P(GQJ9M_"*PG1V99:
MHW08#9L&J&>P+%ZE@#Y%V?;6)_1R!?X/9VYMDDHZ:.P(^%[[K7A\\#M;)@RB
M90AN,(4Z-6]G"4(U=SG"=_HPQE!1,:9LWM-\(JMU>R9OJUB;DN@5O0A,*X(_
M-G:=M.[-$0E*$7([Q782A"PP/\Z7"3:4R^8=ZUJ%_>W)^?YCB1R\M9_]3BP7
M(\G#DN!1JUG<08T4N+'O6<OA]ZSEW=JLFU:+-7MT2P38>A8;,8:F*.M("C5S
M,''.,K4P^*?9M)&ATJ>C:,S,X8<BF#93UDR0J'$+-:\(L]2N7Y :%OH7;KH
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MXBX,B$WK<1QN: TT6ZW$F4[857QAIU!Q?O(J&#0X%@N\5&J1,<),F\"XB,L
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M;$@:"L3D*F5Q7;"U:&Q6"P.CJ3@P=_&>?YJTWG.U&RG7*;_5MPZ(IA(*1-.
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M)^'V.9C+%\-Q\-@F^=UZ:/%[(KA\C9&0E=LD;EC5U":)9Y,45BG POQZ/)&
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M8NCHE+"]A(>9U8P&.,^I5HJSVP-XQ\;,L$3T$'"F(C7*=[D;UR3 SA;)" A
M1$-;,WT;)J5HZUR@;7 5+&<G@]OEF.R?J0GKMFO_F_O#S)$$5"-QJ0WPP3;
M&:@8E(T@,$!.PLEP[&2RW.EID_O+5&?PN:G(_K9, \J7(/9 GIG2PQ$OW+4Q
M)%33-,&S97$*)D] 6HZ1^5UR"2/#3/>Z=!:H#-(%9YU'J6A) ?8V7I)(SXI&
MX(1%)JSZBH0J%F7.FX(13^J(H<BZ &TC:AHJ*8RC:O:RZ&_VPCSA"VLF@BA0
MV2> ]($!.8W>M3+[8C!0\!RP#;9@@$R3T>: +VDHU6%3#DD;)!&\%38WOTOG
M^@8K0Y6(PAVV"(8G TX27PU1H&$.4U%F:*H1CHAS06E+7\F6+K!54"U'3;B\
M?7X!)APW4"R-+8@:[@,+&PU08L(,F!IM$VJM>%Y'3X2^*HL'8KX\"X(7IJL2
M'&YHZ"R&U";F^V#92'^/BOJ"ND5G3="[1* Z%@,=NL:V8J1(0 V@YZ2Q-3-\
M'DQ YZR9ZYF)IBX?.6'P!A00Z"4")@G8G5XUHAEMC?K"NN3LT;6!9VG%RJVW
MXSZ=H'H?@H4$"\A81BE.'[_Z9Z<%2A 9A4V466D&O'E G,G1#^E6P"_VYCB\
M8'V$NTP)8WH4M]+-B,$62@AE8O")';6$QF1/U)B]"$/B,F")]BKH,5.KB,T:
MZ &C7-2VIJ&M >P"TGA7$CL8A,L(U)!G%,7&5GEWN"QX3I1R;>8H1_@?%O'B
M^# 5E>X72 ;>D'3;%H-E9&VF LE(8SA 4F @Z-9V6N/"JJT]B)B@)='PS@K_
MQG;(;:*[K!*,=!)DUPRU:H%-W'%+231M(V8N4CO1(D@\6;0Z\3304&%KG:)?
M9N.BD2BP^<,):*)@KL#W5!<&[0.IME5PP7#UQM"4(K"EIHW/ Q,,@:;1YL3H
M-*_B],!'$_B1J-/30;50MPZ&+3_@2#1@&]XT_9EI:QV#R=!@AIF4P%)14'C
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M]@*R5;,S3U?(39]&'EUS7\O2W5,KZEE4M "Y&*X"T!+@#_2L1T?P%N$<^9?
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MLA2/ZPOU5A1%5OBM4MG4'96/8M$S:F50=GRKHWWI% %RX$: 6"*56[CK6]Y
M!B\=JG 0+!S#RC_]YIPBL^@GIWUIF\@4#E]E4;_Z+;1;O^_O?KD\.CW9/?_;
M.#F]/-I_9YZ_>[][?G!T\MX\/#W_"O]</SX]_81_7USN7K[[_.[D\F*%U[S2
MY_LBZ%$R;*R*PNKT60HT^T,7"CP76-@*G0@Z^(S<CS)(1:8DKGM!<,61[6HL
MU9!.YG3@BWK"\C-189'5%B:H1W"3&N10Q106CH,1$5XV;M1-O=(JBBD3=G\,
M_^EP0M@Y7CP]<]>F",WJSDZSC!.>,#?IB,XM77N(#2ROSB7Y8@[+; ,A.P$
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MJV0>^78)Q)C5\0.8AHV5N/G3,IQMB\"R&D@7=XY4JZ5]6 *<9=^U\*OJSB8
M[^&Q#!Q+7B8.AQ+H(3,E<Z/A]DV(4K6HJX&HJ^YLU3C=*C,6&O]QB(.#(_.,
MEF2+A,QJ$:^"$Z]"NVM4:8QMF.*I#Y3KQSST%GZZTRA-&:(G0GP?!?H<H=F-
MXTQ!M ,A]SW7QQ_+W^($X=,?@U@ .+TH[Y:S<S:R<S[]Z^@B/YX< ^;'M=BW
M4,#C_Y_XTW&T&-G@0A0^D2B\Q@!_<;/"8O YV*>^"@/EB67:\JBBL.D(LZ4.
MB3KOE%G&^ 10G= 1VPY #"_HDZ*K\CVQ8HRNO81RRP_@1U@W-_&#=="& R\
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M&8 J:+-S5.<EK$2,\7@= 6<;R&T;&-=MRNI;GMFG%&"!U=ND1;!K>>UU]">
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MN-I<K]??:GMQ:B)6L;1!Z';(-Y5['B\+>+YG9I]OXO-C1"\;E2G;!AT-5-)
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M)&(Y$ZDU;NS9J,=!%/JE1H8Z+$]D8TX6*9:#HI._)M+V$+Z#] )FM$446>'
M=-NYX \W0E&(!^.6B:RHX%_Y6VOFB^K^_"";5D_E T,SY*Z-(@X^0OF.K/20
MJQ3ED-FR(E=.D*Y6H-&42U7-1-Y679>ZT_OPDKY'MR@#:"SO9RD(#<,*%"@$
MMF,W:EL:7:O(1U=$^A9Q)<UDN",M%VD%,B3DCMJM!.Y.H&!Q+)Y@\E\%HRB!
M$;>$AT@[@]>Y<.VI2Y]9$S@%T4^,>*EC$=_2Y94R*#*M.ZE7?$9*]X3@>R^
M&Z7#MW3)8/[K GO><@?,?F.6L;P)'$2XO^%8 ' !O=)MP\I <<1'!1 4KW->
M!\$NPU.Z!ZP _A7*$W>#Y\US 2F./>=!"VFC+U;4*9DL?J<$(!#N4)H6@A,
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M@-W 0K%) R6EG;X&,.,*)DP87N]06YA8Y\@'O971\EGXDN+[.GNJ6AAF[A[
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M?#EA.3*@CM7#!Z@/KUGQ&-D+&M\1$Y>-^INT$#4.C^2N1-^\<UXB.80N'_B
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M5 @%>/,P@Z#A/OV]UYZ]^:5L!SY:RH5M6&,[Q$("PQ<^\82QITMXA:=/QS<
M2VA3@?AZDC5T^IXL7:N9YP)? +F-#L"B<N["0Q$QHK0:3RYF,OD@IZZ/P#+P
M*NV*4H9(B4DAH+*R..]-7-$AYCYZQR[E-<8%B3E18Y0*NK-A&Y>,E! 9(9VY
M.<QYK8R=@"[HGE97>(0O#J=:.)L^H:?5SYT/Z!H$]C"-&?NR^_I$&.!H1\7M
MG)%\+CY&T[M#9#$%\=J-M7"<PH!*SY-&I_6C"S"(TCQ2WH7:##._:Y\>FN*;
M,U:VG^-B;-X0"+E*B,UO* ?A@+QA/KC/*7*+6(5+?HP2&7KP"<BJ$5T)4R,E
M+B&-3"+XY_;FQ-AC+F_:?IU]L-KENSU] :)&X*O")E#^[0'!'R-^X0@ (.I3
M?N(6Q BS!R'I_$@B1E?/K 5X=;A%XM+I/S'&D; O;1],K5DM';51X4SI5?)<
MY<UI;E]J1QW!\'Z69YR!Q%&0;O,#V)(ZI4/0C-C^HMM>Y\T\99 FO:IJ+$/L
ML\W4YK<0K54AEEW(JV',IY6YYT &N^&J,UB_82P>_QR^(66R(5?Y.;@=)4.%
MZ3P=N*<I>Z*)V.LG9J6J<"'L!)(]=+)"RH:_VUL<)WUSU@,.D $&PTRK%Y!&
M]B7H<VFQIY1CEAXKN%;_R&T68Q&\)^0'P*NYB.%H1C[L*-]:[_P+!7'(W'RV
M\^B-7+$TR,!0A?LDP'0CYU>F:!IC8[T/":.'@&]*;P8V;-$D?@49RO$CR\-C
M0K0P_;OZK*\ZB$V9WVG+O$DC> T'W$\S<%/L>R.;$P&G@'KWZX?Y(3D4O<++
M[$3@)PKL^::$+_BPYQOR@P%JOGB(>[?FZQW;(-L3%2L>NJVB%#S>84V:)8N+
M+-<Z8UQ6 H@+G2=5N)6T,=K;&,(WEPU3@_%-+;VH9'0/X>LDON(3!LPJ7,EV
M^ZAE>RU>5/DO47[,K.HJ,)^:) =\=7%WV4P6VF.2&IN9=53!1#R_G#N^">R7
MI\#J8B*.H:[,0E:+"<G,+? ;"2?= &YL,F/%\[9AB*#O; ^NF!*QHH/4P4_Y
M02L@XR*PQ\?2H6.:8-(;EHNOY)7FZH8$'-[K1(-CR*G\86,^Z,-!K(!@!I,*
M]E$Y3[0*&)[0RQ8RYD#&\5(@.7<+7/ OR?PL/,@&SHL$'?J;F"O P114$];R
M)8-O_47I49B0ZC'3G,'V'P,K\Q=@P<"EA\@.Z%CG!F?'-;>L4R*C**7T*R.5
MF?*V79D&!MV7L[\6)<7YQ8P5IC0"PED@5KEO9FX-(;,AVO:,,E%&3"%MK#+#
MUW^(V-WI; 1Z25FIY7RC$8+EXXQ[8&%]T-+.<P ^T#^<O!@)")M?<"9$')TI
MHJ;V[^JF/;$-[A@+&H?LN/ &+<2@/Y /^]T+I1HX>SZB\V76K*CTLW7HO(1Z
MLQK+[36=ZV](0\&)^ GG30_M,PM#9/SD*KX6:<403PV4"29'8@;8A</5OU6[
MM:0R5F;/?&QA(Z8@LT-,J@)I\C L8@I0[T;2':EFI:+J<*LK1!%0\'0K:4:.
M6!DM/UOVLIVW=#37E(PGBY\0<.@ZV$N 6K9SOXQ-J7 &=!L9(9'[4VS*YYX;
M@4EAXEA^:4L\<P'Z:KM?G>YI/+S& S$2MHB6,1?2M<D:$2(3<8[\ FB< UVW
M[T*7T^.[J:E\'3L\_-T!= &<^ ".. 3GR<)XA&&L$^[""8]@AQZ?LD,,-P H
M>!]^K:<3,G^T^=EY=(V)VR#:UO]6^. /JC]6_B&,\D"RZ^P&91H0;H&7MREO
MH1IHEZ4YZ)A.,@\E6) L0H'%YSCS&3N?!CHVF=D_>'K]U.%KY#-%H3T\/WE6
M(L/KI'YC$V]I3;NS5V&C;F:11O PZ/%0EG&7\S6F1T(<^Z0X!M/D/K UJ)!?
M@#'KHO$0*QTW#-#F&8<9P+%U_L2T#<!)88H9EU5CUW<'S2NDAXLP Z7"T0@&
M\+/!1M0<0PX%OB';35YQ]H2$K?,^%#5K.U[6=BZ=]%;4CQ7*JHDZE88Y72&Z
MA%_*=XDC1Y)!-(JX,#4ZJ,%7A>/^2D.IV,+ 82QC>"YC_#,5[A3WFP,G]5<,
M<W\:=L&;DM:#$Y2]@)+)V3TD 'X*.\+^-O\]9K@*#Q6#C?);6,PWZ9PFSCQT
M92BF:^W)XCQT:65-^]0G#A4RN<S_Z5R;W>\2R#+%\3;C'-"O=:CKO-<ZMPC"
M^ZF7W8>_'-_<?#7KELN#5E0[1?KP\6.)"L<Z M1[?_IZ:GRE?F$"$'SQV:.
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MY0WC$IF%HU_W[8G7LP^L@&-DQ_&-?53AJ'%9%;#F:EP$YA_)1<HY>.JC7.:
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M%I6F(*!(4<1DJYLN1$1ZR59$2H2(M  A49%>HJ"@M*B 2 D1"$5*(EU%I(.
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MC>5>42]@_%!_#7YDSIEV\U6FPNOPVB"0BS-@5ET@@GA&L^VU\+?#6 +=N-%
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MP-T;0O6H\+1UD/U#<W8M0M >]AG4B,U86O2&_%@E9E790@ [FJZ1"ZS@B$D
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MT@(!#.4.:4@(L7[?6D:-0?!1&[>$5 =O<E!XLG6- >_-#1(/0A"7J?&2N<A
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M2%W3?B8Q9ZC&7W@9ZEP,PT'#IE=K"/EKDEU\0?3-ZIO!"56?GJF8:Q0^^H$
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M=K];E8(KIGT!)A2P-D_VO^*=6LLC4XB5_?=Z8!'6^(*$8'N1-G,$L)^)#EO
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MK2(T!4TAXD_ZYNS=5Y)90J#.9'1:I;D^<]5[V^0RT32G;N987E Z?H/ZG3!
M):SCMD;B7'RV> 0L3P0FC<A&P!H3N?DL/"NJ/R>\&#^/W03NGOQ<LGNN-ODZ
M]=.,XEQ$ET/0M93/JYDZV*F6YSOFC=2M>%O;*_:_(."[8#V',7W@ON&!)%;
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M-P!2NB!")<I,,6<[_Y*L?S?SO\OM?VI&VO>B"$5)8'#]K>'+6C<8B108Q?@
M/D<"50_X&3/8PH NXD<D#_0@2$:X'_C9$.YG0^,(E_UKF+1)G.=YDPG R >I
MB_!98LN=OTMKE!DD]??G&H3>P2O$57)\Z#\.1\:. @F1! IW@Z\T?9.$5@&/
MN0&1P% JP+7N0TMZ+B927I=.7=_<DAV9[^S8C)XJXAYW.#[4Z9T98:+V?CI<
M\54!YD)<N=7%/P@I?#R2T@!</;@'7,7-<6$RKJ*_S%WNT<&*XYD.L5FYQ$^4
M-30:S3LR4?5=>?E;[H766X91+Y7M[;]Z918=/T[KP,D!'[*& 8$LO56H/6@7
M!3<]P1;956>(4#9&#Q?&F&@FQ:, _\IZ,>'FJ^H^ECG;W">@U/)'PK1G=M+!
MBQD_+GBWNIA S18.@U71;8BH^SOE$7!49O"B$(\&+R)2>,]_%39$),-(\5GY
M"[ 41:._S/UOJ$&OT+YU(M1CGO7/C!W_RZ$_^?+6E1V^Y'^+O:%4$UD*!/U/
MC_Z_VX3D/YJ L"N*@5E]&;'DQ=Q*E '<FTB+QPW3_XZ-OV#3BL*M01<&6#&X
M2)2)+2^+4!\2&CMEYGRF+01BQ)HJ.3!D*&5&$JX3H=YL)P6])':PWZ!)/C[:
MY%[*4 /%WS\]D,S/!$^E@^&G$[\SJPO/LHCO,ES8>/GZIX#*N8X9[_G)MSE%
M[]Z6IBQ0%$<-@UT99[]7G1<6O@7=N'-L/DT8!>!8[*&WB%P2XFLN\!\O3@3
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MM/_1'[<65,A6QED-YA]^2.X*OM6H7+&PL&P;O=7Y-I%7ND8[+:I_\;O%M/W
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M?D"Z1RN65Y<LXV+\\,K+"SF)"VI5R=+%C*+3"A8(2PZ+ 7U.@A;#N*AE9LU
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MM/MF;Y6\B*-F9<FR+8N#)S6"#1S+ FPQ.\N%KRH,."U7)VNK-$&C3'?B)M"
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MM->C:!*=GS[S<Q<9$LUNF?QHE\"/-FA,<GGK;6P*G)$YH2BMBNC[N/6B.\J
MH'#TF0]6X_GDO2<R4F\6_S@(F]]*E7T^DL#/3#&[%D3HRQP8^+RK/(;GZW"@
M_L,*]:0XU*/YGQ6?E>'L49DG_EW?_*;UE>?''6UIT]"X$PX6QC-FBZW:VO<6
M55 &4QAD9@:SS2(J>+W<ZL\R3$61GM@UW<AP&+X2Z!#OQ+JQR;7)A!H!)JH
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MSN=_+"HNC/9_F1KC?%VTFY< 1KEJ2&!Y(1<EL"[;'UCJ%+0.NWNXON*ZD!V
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M;:Z^E'I/K $Z<"&3SWPX3WAD)$^J3[##'^.A(Q(MB*JB%_1SG\(8#F[W\6^
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MA7J@Q9_9O;;(YKT>7A,"IF^("Y5LU@X!"&"O%R%2P#"H$MA&:)P2V/X]*+E
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M-L4$?PCY4"_6O/F2*6QMP+0#%822MD%F*S-_.!"/5@9P08L+E 4"&#L\)N/
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M;0[="(]]U %%D*H'2C<&M-4MB_OK'58'6EPZOS',N: ))]UJ)PU&R71.OHN
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M]<,G29T4F+CG*$LW2_+1",G6R^#18^-NEWTA#!<@[7<@_ D+3L.U<$&T')V
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MSB/7830?(V^ <Q#]-Y#?R@6)E')! IY<D,*C05)4HX)JW[JZ)$?\&\N6'D9
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MW8P3XTW!<>16>,1QS<#XWPU=V&XC_!X;QSGP'VGP_R5V^.OA1).=$!'L=YX
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M*CYT!7;$,U"WZ>@YP(,BY$2!-D;)_P_>WC.LJ:S]%XYC81Q*5*0(2,9!145
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MVYY?=06;W[YI#*F[8'7X&7^O%): J?:6PNSNC=!%=J0M4MC"-]+$.)A<]\;
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M-#O)CW6)Y030%-\4?_*>Y.OPEOBA/&1%#JI_V2NHB:*/R.L+NBF(\ J-^#W
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M>\:Q>P0.DLU+?!7N7",;\M4JU7Z%PX$X2W"5[]: _&7.^&.W8U45&,D!Y$&
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M^B?!C'K_A/^8KCE6.[+TOKG530P,Y_J_FBE@[D-PGT?.<$MZ/TZ\E-HDNST
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MA'8M"E=M;QS]C.+M?AP25;A*0T62@<$VKSL+<$+&U$T"[4'^8_>VO/+TW=M
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MMTR$5!Y*9UG_:(D=(;G<.?Z*TQ RY7,3VZW#/P-N=7@8 +""L#"O$M00^WM
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M"#YWN)]=+%M\JU^AN9I+$"JT]QSK7VE(K]W+;1?%C+A*1Y6B;*W 'K("4B;
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M-2LHU,VEM@_ICC]P\0F?BCA$EL3/<*,/[GWXBYQ>(_UF>DVAU2M1<P[(1*@
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M!VE5AYJ)UL3S:/-A3]<?^+5N5JP;]Q->.KQ'&$T@(X80<S2J-DDD<B<&>(L
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M.[G6@H."^=2\3K(B,L$D.AZNN$!<\&K(:+FQ^QA8&"Y)/%A?\C?&PZ-69;E
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MKRT9"ETV";_/1C(0'B\9AGDEAJD,Y1>A7#4X_L6;]J-G:\H]WG5G3)\4':-
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MI#YH/61W:>( IQ2[#]>KA[N"Y\=<F^8:]U(]].8C*#_B$4$UZRE/EQ?TVX
MMO:83,5@);/MX=)??%RK3C ".A)0W_UU]'5";I0\H9BN9HF8)#"O88,_?!_Y
MONM2XQ4[F8SCCY\\P6X<S[(YFG!9COU>Q'&*K5\68A3MCJVIG LV,HX[^*J%
MT!*W08QJ=][@&Y4]I.:JSI_NUQXDU:(K7:8:^!1*U7+C)"+(Y27*B?W*DJA=
M;%OP$7!_8 8/."+2O/<U<V?2S5! .!4_,!)3O&N2\F J*_CER NT(O7PW"5T
M,V5QK?G\7^>_Z=-Y!3<J3\9I<&[L+"][C "G!A&@V)#)E>*4L56K,><X969.
M@ 7%.LUL+\LEA('<A@BTIT0JZ;_),T$E$*X6.YWKG I'WFO%W>M19^EFOPAD
M'G%W!U..5\Q^+_1X* %;.J9S\ !1XOMJ\)G]-ICO,JF"S8]I,JE))],51^0<
MW(^\& Z^JUIDZ29U.SK?8;1.L7QEGFB<E(#4V??0YIU\WGZC<Z<+>.;?\F]D
M4A'I*,"M W'U3[V9?#CKG/&0#R.Q5R&<SO,"[*3P]XU8 &/(5Y-L'WAG!??C
MD26C75M#7 '\D,O"KO:95AUODD/A2-]-S^& *)[7'2)+^-T]O-QYDTKZ.&!-
MG1U"\H+?5R:V(<P"T)&V#4G!:DSTS)6"RG9*"*8,^(,2ZNH9*MVJ=L] $95B
M4IFHHQLYN?N3!_K^A<8.CQO:XEVHR<^38FJ.?S:H>@;E*;>^',HZ\OY\N8F8
MW+HJ/.@C.^&R)S%XW\M'.:>?N9QQ>&X8)/UC(]_4U_C Z;,.PAG69EG0'Q&#
M"P=WYJ"5R X&YZAZ@BLDB76V''8_=W:!9V?5+K/Y@1F]W8$E I\(_O2 00+$
M++J2]!S/::\+(58.C=CIR)[K8?#]7DQG+6Q#KJX8Y0PBE'5>8#QV^AS"!.0.
M38"G9VFD-_B]RW>,&E^@;18PAT"W"C!O=0 KQ'FB8UADKT[M=YQLZ")!=VCJ
ME$Y9W?18\>T(D=$9(TFWN="]G#,6%=K"'Y0&WI^[,5]U@<?.QF]3)?%>HI_.
MX6129*_?946Y7:BU)6:U/.S*DWC'5IX]%GWW[R(?1\.HPV8Y-OR,=8;=J1UA
M7H9P#W&>='DQ@D>81;,5X F&=(\*8B S?ALBBI7M96B<SJ?*KM$N8Y!/&^+K
M=&J[-*A(D4"2++7M4VGKM,'(R+S=C>OO?XX7/?BM!*,2V+*][!@J"R>]1!Q.
M+$UE^KZ>9A\J"X()FRG5+RD?8,3#A,HZ)ME6A?\"XA))P0?,-9\([I$K6<:8
M&F2K'76SVY6+FBZ8R/6EOWKEYG=IQO9<&H7==C#ZS/#(M4.:'?S!]"'!*H'"
M<Y>?QJ0F9_ODR;AY-A;X/2J'8Q)_/!09\,D<Q:$'" 8\[$F8!*[W'!S&1G,>
MLD48R!WFK\@UX7[DZG.>L'E#6<ZX(%"/LA[/1E ($N!8[^NZK2&\##@Y]/?J
M_<O,&6_A*0TC&>*>^P>?UU4.0U*T.L+$#R)>$ ";U?4DA0:V9 /3=@JKYA4<
M73A%$+F@)+@-<7?+:'[!-FJ=:A5"QN??>3)K0<^/^((Y>K]ODM/TJWMMW%9R
MP>[@_.CZWP-1S]Q(;E^"VH.D/Q9'A9B7_XT$+'72/GW9XW:E9+HW)28Z;2V'
MZ "\%Y*]X-94&';/IVP^Z-8=YR/+,^[V#^KS WS]PZ7;\*'/W4XQ8SR$%.5.
MNW]V]QAJ+!<C#B0+'[7>[>-K">$-^S_9&J[ZBLCCW7=MKQ'Y1.PS9W8*_.JU
MM"R>OF]/+KZOC$S[OA\RO,YK(R Q)'_]G#G\VC[EO5K9'VV?0K.XO-G&0WCB
MS((E3@=[ 'W^,N.M[\-<"F/_:<*JU*[[)QR:-(^;49L(X6.\_PJ@KU4Q>/N4
M]TY$K4N25NX,]Z_BQ=#Z_<96_2@&X5YD0Q)69KHKEOQ5/?)5<W8 0^]^K6&Q
MLLW^U^TY&\25&-11RUYIPQ^]B$P3_IWI3.8:@1Z,U#=WU+,9QDX3AD4D4;"=
MTK6P'V_3.1&YOO:IC5C<D!3Y3M?WU6D_'P/-EXU'XR/:3CU?X.<T?JE?S\#S
MJWZ.YN7O97V[1KZ7JY=:B7I8O'0ZP4W:XX;#VS>P71A3P#BUA?2YG39[]SOG
M"<:6:L3 MC-0P[CF@!V K;B\9QMR%OB8^P)=9C?)E0)Q;FT=4S,AIO8PUVD=
MMON"=,SSDME^(OQ%JME-NN-F90K.%R6)'8.)XP)B]<F$?A0,G3] $,'*@U#;
MB7/*DI-L)%"O9/7#??HW*5U9[24#7D.UGL) &;+G8T^%L8UO1_O>:C>^'G0K
M6_S:EKWLF@FHRASRJN3*9O8F>Q]4V5L/AP9+("77!/TW51GQ@GX%35L'?=/L
M^H9>\HPBR7KS G_FL49LR=&)HYL'P1/5737B@5\OJ\,4/2PUK:W\<RZY??SF
MNI THLF_"$V&BV/G\,H(?T2JMS*GLH60NG ('"&/I2-$NVX#*,M)0Q']/BR,
M %CET[IUPX6V(:'N:(4_*@SU;A]*>0\!3"X/CDC=V\K7ND%[9#SEOK46RC"E
M_J#+,CQZ%=H?=,60D6+H66K[<#>.6DGG/_B5" 908;TH\>4928P((%,0I?QT
M'.E?CBKM7,J[$UL K.7)JAG4F:5L0VI10!SVL\S*6<QU\)B*_ 5=K-A*Q.%3
M(P_AJ+3]5SZ>2Z Z7*P0CD,TUYZ4L2#CYZ7G_._3AGO[-TRJD/$*=U&'K4E*
M3V[:4;]+G'R9-'IYP#]58L^KK/-G[\:X]D%YO=G'P0@R@C?89*ID?S> >_!K
MQP]^624$;"0\._CP<*ZM9&?X7E6>CGF=).<;62&#<"U]7/\%[ON*\W;N&.\+
MP\;[!R*+M=G-&N^4S];O_09QV'PR!Q?@-!6:9[-O@Z=>Y<']4 *Z-+CMUQ:K
M!NH[B6--5XRU#RYT/YS6$V6+@A0< T?Y,3"6"I,U4Z(J0A-FE _?/_L)<Q#8
MXHJ_^&W+OA@4%&+ZE31&5=R*_YQJF2U^( K_\::+KATDMOC X;1^>5Y5L[0,
MZS_T&8(*@5Q 9V:F;T, Y[FDSZY,#B.]7O9)7>6#R-TNVE:VL=^RTS3_6%D;
M_IW7GK-RD)+I^_9.'J(/0;X?>+++9E^ TLEWL!P8<"Z_#2:'(U?IEU/^W2)^
MAA"_4JB2*1\7:" BR&>_4:T==]'Y.B/O5,=#?>EW$,Z=TJ>;PT^W(81LUIUV
MPE+@YN8;H=S)8]9IS(\S&K#$U9.2XQ?AG\B/_%S#W,Z%"=Z^?$,U;_]^G4=#
MYZ_;D!V5WF4CWS^;70SL]X]/>6-3><!J2CCQNL8MFS?#^V66_C^]Z/;_?SML
M?'KQ-D3X6]9-GMU*:0*'A]-*T$-'[KRSA%PT6CO:=O(Z9#3%+4F)QU_31NF>
MSE]AC6R]+>J.!F[B&,1V2XCSQD$N&[7U$\DUM?[/WUSU'#S<-_#VGC5),$.H
MYE#:\W4#VH'DC\?WB[_[5_ _F"#T&3T\@&A&W?O=T9H S! 8;O36#P@KAD8R
M1C-*RUS/LO#2 ;P#T-90'DSQ+9:YGAU\U$*55VG4:>@S+'@'=PQWX1,WI3=P
M='X"5R9ZK5YUAX+TS4Z_"SN2RDF&_SAL(WRBU^O][;<GI'BH/::@#TN(;<!X
M?A]@#1O_G4W$^%,?M>#/3$3I9:"4:;(S=TA)JI]:AB2'&1)V:.Q<[9=3E8,_
MF@Z4^#E#8-J;W". *UMRD[*>P-5#UPP5)G0\14>0S;EX7X:OVVMPE<'=8=:%
M&8WA_M&5EX)GQ3"G\M_W&"G4/XJ.#=TG(235DZIN.7]@@O-\&^+KY<2,!_NI
MF3*>JX56V921L;E*%.CT[(N 6RM,A.V:..2.2V>+T 1<1XZ=*9&?JJUK*'V5
M</WJP7YK.?NZ]Q[802QBAN"#E,$H,(9JR.DXYCV01I7C'L:.N_^>*=8'50<)
M$NQ3-'/$X(+I^)6X2[I77P$_4\L]+('UOO&1Q:>?S!"E6H\/VA;<-?K9);O#
M>+>:&.?@>WNFU]<P%C=?:_ST _\PAM?B8%+H *ZDDDS4U-B \^0"<:M/^_5R
MM]VS4)'<VE2#Q)0?+?@'*, ^4PAS<':'TG=+#%\8[Y%G6S*,GE'-[0;S$%)<
M^'([0KPK*#KRKUVPRZU,VMLHA/2J^^^UTR-G8NQ"BM+=K9 O"Z1[$0?095R!
M^3HT:Q AAN&CKJ=0<7,X%[ .&',  TH#"^L[*+CDGEW@*3+J02-X;)Z2Q; C
MKNB'!%%0,H<2^UTO>%N+MI-#0A&VTRYG; >'YQ;V<PIV9$+(8#]N0YH)B;^_
MAE#4RQ@DIA]80<$IH$\+V<5TZU%D!]/UWT3K+]\QKTSZ%:.C\I?6ZZJPE< X
M;F)>\BR @I 8EJG8%7PTL?VR:!$EL0_W.9<&NU_+O@&P;!EAE:6>JZ_S'X2I
M3&,-V;' Q\;GZ!J[#<L=_M=J+SL AT^V*IEZ-H4\5MBTZTX0^EQ6:)P@E+Y2
MY]%+@"(NCRD'F\SDDUEUKA>F,4=%NF>3=%"TRN$1^4BT7I2.Q<G&D$PZ5-G#
M*N#UK,'\JF8HIE>MT>/=#=G'D+-_G&B$-3N6%W:\1QW@'T H!>,%,<;5[L'P
M$\VO0!@9IA#"%0,(_=VJ PH+B=7H$*IY>\8:Y@2\F8&@&A5&QJ3&AGLD]F]#
MH.NZY"X;@VYKB_1PU:Y-:!(,.+M.5(Z5=?;B'=B)A98-R-M/44$1(U2"V)*.
M[XOEPLK,>I37C,OZR9G(!EFW?]=\O,H_W*9PPMX5<NBZ_@"SCA)JI8_;S_]U
M&]*2OS8-Q%!^O-F&R&). GR9Z08HZ24A2LP'5<=,&G0HY%=+"6E0(7*/3T 5
M^_2KQLY[[#^(J)B0J)#K8GOIB^E)B#(3LW#=W&?-HP,CY<MCVL7J>4&AH=]O
MES\4[RA'7WJW(3*_F9WF.DAHR4PTQ MC!Q7:$S&.MP/JT:D6@&M_'6Q (:\H
MD*D ?U:W7+(?F(I^G5?P_/8LS"_.KM]@)<Y:,\'@MD>()',A/G[I->\WL<BZ
M(Y=9063NB0^0\/]M__D46>'[;X+T4HGBRZ[IKE-5RT29W$K5GF<U(:[,UU<+
M*E5"X?Z_.5\:YT_M2U4+E5DV/HZ]+]+"6U[:U="+D^]1Q%B'C(&N"R8 ,N/
MRRNS$6CKP3O()/L6(8.\)C,@*-<3*=7H;:$M8:E2S2.?.R;_^9 ]8YW"UY&G
MB$]!"->%D6_[=+2]8FPE4$,\:H*$78W:>1K,?N4=DJ;M]S@B'-]V0I!GS<#U
MT1BCF6+?5A109\]0?..X%#W;%)3W^E?)T4]EX_6_+XE]N%$^MR*"OOQJVN>N
M8N)+T6:!HZH^M^M@4+83P)]:F3?6YVT$!"0WD-,^&.8E4HM5+W:D'.0K)X54
M?O'TJK%4*)!3O%D9(D)[ ?EEHG78W+[B<NH>I8);>Q[=>OQ%QO8QWZ;$B;M:
M>P/[S9YE/=W;W9$*35J0G(Z*68<&P0\ WZNH2GH1P0NPR2Z+BH75.V>UDTJN
MEE40QPSI73%RG<VGS]FWJ9\>%8%$/W0]%$O3$UW."&W5B>G_&[J>EU/75E;G
M=NE=8S[V>P;U3+'%F28[^:,B2XD/^L7:E8\!G+JZ.OK'QK(Y8K!PS?.OI& 7
M9E[^-N10=B'Q^\VLT=(#70+N%N^_^=Q[*EJ=LDCO<JT@>:"\E]M?>U?Z5SZ+
M*>H4<1_Z_E71IVCD-BU_#1!XIOA3[77>[@>GKFH3#)T 4J:9,4T(28<*AA3R
MIVA+LY.CH"*KKV]U^/)]E^(4AA2;! WXQ0UZ35]*+Q^HU#JI5"'MO7#CNOQD
M>-Z^^/U/FA[TZM:F.+;_5(R%F':HU/XOB?H+G9U&'P0^"W9<^3G6>-%9N)J=
MX?>H^6$:WUL7[94]BN2Q3 3@C/^LR+S"&,"+P$VY4[B]/4KLDRF:5_%][H2D
M^,(AO-)HPG$/UX2A!7IDXY/;0XOW[O+KPCT=^)?XI#?"TW!AR#D+RE8?7@AS
MD]$PO V)[U$ S6DQG5ZF?3!)0Y3"L@M7B"%3&2M>,M-_;J:]Y<(7N>FT;)ML
MF_B;!;NA^R<(Y%H28$^/N3CQ2T21.<XIB1*)]IS2;BF6/9M(57\8UFJ.=,CV
M:6IILSH\T4T?2 X-]'65/+=4QO<2@C@3V' 7X[L-X?M7/2$&8\H(3^[BIVU#
MB"RR\?VN #+')51V "L_B[G]?"[X+[PRS(DN(\O,?3P0G4?.C1"TT\BZI64J
M*_T;U:^7#A/&&J MSH/W@-1A91DPGQQZ^<0$VY7\(6S,<US7W6BO6GA,@%KC
MH'880^M,A*;HI2&(REWS\RE 0SJL);,W?&ZR=_+?PU"5 V.[,9I I"QI+I2J
MIX2.F^\G^A%S?=\W-Q5R'!O*8WLK/"XMYFCZEOCL2Y4,'0>L=Y1VGR2!5=0;
MW(;PL,\">BD]\K$)/RX4#1.MDUM6"?S$2W/JK/G4[ELGL"/7\JKEG^M?VWCC
MJ/Z!\H)W3K.AH&<O]S.I&4H_6+U*A+U!9."$X3JKRC)9E<D&A%T@P7:V541J
M3V _B>A^_FJ*1H&"0;&+S;%C&[I6:#J2*PAE20<NJ'8!>74L1XSP),:N,D0"
M#'?\%(X]L'1]Y5_-]K5+[TJ_!M&-\7S :W4>H;MCFANS:C\A,']'E![["J>9
MX/_OSA <!E0.-V20!+EB8.9@1*VRPJ>N*)J7XIGIJ(9C+BGR==J511]D9D7N
MA9OU2>591O+S:BS9ZWFUS%QIZYKT5OP _TN<80XQB53%)+UKX:$^72U3H?[)
M)8I%0JFWJ>@PG<5':J("QY=X.OZ;E;SX/$C@5B[ O=)CRRF-PR?CF_)^^%T$
M^[%_Y'L/E7F*I:>%62%N(X7YU7@*_RXLVPVHRHUF5.6<Y-4XL65VG1_EB%+!
M3G'%P6FJ(NI!SQ&0CT+8#0X/;4.$V;?5>S#ZM'4Q%!IE.?6+U1EDP%KT"D"F
M4&-"5FV^R<H4/2U<H$R5ISBIWX67>MSNL'[UYTK.L1P5Z;Q;F=]R3#L>9VN?
M7\YZ(3YP>>#CEXOVY_DSWE],=7C5?"7[5'B4E%W4K?RFP\3YC_L?CP1$["\N
M*P[]T7[$[KK^37<5,EL0KH;K=3QBP1TA-9_X\SF-'<7@%=9OE(<^_=W+G\'K
M[\S7*X)+(@'.ZEYU+!WNJ+^=1@$^PWUY]/:?OFW(()S0143FV?&)Q*&7>( +
MW&E2*VQM''#M<_GD!>8R'S"N=K(N8R+!4"I.BNT,7*TS3OI%B"\,'Q Y_0D3
MG##<M[<LB%DB"B(JWK_HV=?8U!SKWEM+OSP%_?R]^]4R(3!<&ONI1)JQ#:%[
M,Q$*6%U/MOZ4(7*.W[EQZE?Q"0,=#0JB+U/"J$AVL  KCZ3L&,B%A#V3WK%.
M[M/U?H1I2LY2OU:X[=Z_FUQ)/?!04>HSQ%H%2\?D2]'3]P3%UL&%]FNDX$T_
M$YZLNC7_"QM\G%&*3>[-G#I-!H$M-54Q=1/['M4T7_'EM+P$,OWO8I]-_"*E
M6 /XX]KL $EX=_(!A/A,\BX/&?4RH'\L<\&<@;I'"())L,\R^%-[8+;EX'"O
MLD0WF!E= Y4FL76![ZVQ/F36'[9Q!%\ET;!!_EVD89WU8+N3JJ5RLH\_)S=U
MK,5U[5GK=3\?-6T_/]\>E;6$XXL.60U/Q,7>LOI>V_:_K\QW07[T0"C@>NUU
ME-)P395KW5*!&X9/KN]XSUU_$($V[-]$HNJ@E)ZV8Q-QOO240I7F<ROMR.&!
M3/"P,N[;+.+J^;GA89UHLX!]._#(?%YC\RDTD--J 9W#4S&IJIJ7,,>KCOE^
MN(SQH$RJ>3QNP3J_\HNZ-/5 K6'T%,)AR3Y=]J0G] ]?$*[N+BQ_7^063?I/
M#./P/%?0EE'4.XL79MNRS+D?N%+ 5HI>I(=7]( +3@YSJM9KB>C?GA19?';K
MPLL)WPD=/LXWHSPG3N&$[;1_QY'UJ#03XQ5=O)#;YZ"V#7'N?5_?$"UAR>^]
MX=_$(&HW!XR]>8;TGT!"Q_\+[!&#HC;G_\YN%.]X</>F640H'M0:7K/=X0Q-
MC/8,,W\R8<YNA[M0$41)&BR>?: >A;ZY25-:3*BC*L;L!$N%]/BL8-AG8!MR
MV<R?KJ>2?F!J_9-'2U;?-.?2#S9N;!'U89TM/<*,:02S66<Q_)PZG-].<-@B
MRZYM0W;^<P\GY\!K@(FG(-)*CHZW$(0Q%F 4]03,K0/0RXC\TT";BISW6-+S
M[WC9XW=I8<2YTU]P8L"&_PUQK(\ JN:O9>_T80@>WX8T#M-;<%=0&20^N+H;
MYB"XSCJ.QIUAS&:R=1AUOY_MP5>B+;SL(P:0Y8'$XJE\7[K"<JA+2&HJOL6P
MUJE*=6 ;0FXG 6>AG_.9@6 JBQ?,I,CV%^/ZB>UT#U9D8(\P.!D5Q9 <-MY
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M0MP?#!;+?*EFO+M[Z,%8;GS"L^=H!V6_F2_C#&]O'R^]@L:,2=I_>H^D.$C
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MT7D*(4@8=?OA>D0\>1V264"6:]7A.8IEHTLD_T4B QG)__IDIU81K_0K"_7
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M3K1[O!VC&'06%5+<E^?Y0WE]X;?^..(6ZYV$"=A6"5?)]E/ZTNH@$;@V(\A
MQ(2=>'.;>9J5#2M]LTA(!'IL>;#[IABJ,DZU6_QC"F[:,((U^CFX:_3WS_K8
M.>>4L$NWQP[^!UO]=\!B+;1M!@^PR%J2"1L3$$+D($6;\(7X!O^I.7PA07@T
MO!!WD!\+PBNGG:*82%*S?M5KB:!"8\2[[XG;.2V.Y0SN5[P#)CP,7DM'J?3&
MX",K)2-5$0%[K?4KQX;"N7;L:ZE$#MPET!I61P7+S!Y-&XRIFG <!G>_-83S
MBU[3KGA[[URTTU!_@J\W0MI()D>& ;:HKW-BV2Z>6C=#A7KM/!A_E8W8@?.#
M;0S^V36]OWF,.^;X9EA)M,7U8]H%MUMYOLGK"EW<(-^$*_^.C43QU!"):JC'
MSH?Q=%A0KB-/QP8P2*0@)W&QBZ>^"&696EX]_+!:E$QO*9)DVEMY=MG8ZO28
MN[QU)CQ]U6$#],;BB32-,^)YO!GPNYZ%V( +ZZ3H\L)72,+C13,-HUYCZ<N&
MFD?-77C.Q1N"5$9KHTIGUB"_LG/4'I;=N91X._!XY^482T.<]6>MXV<KOL6\
M27J\:=/(>9\RJ9)3D[=[5*[]7^4EOJ/HY6ST_$^6K_([F!PQ:->+8#]-4:$P
M_"J [<A7X*DF'Z*^P UU6Q0_&WU3&FCQ.-?62-&K5_6Q577XG1KZ$9T4\QN#
M>G@SGC^3*E1", ,RLEC578CQ,>:%>(XY:,Y9R. %?L'O<7RB [H";04H3; D
MZ&(MQJ-@8,$X)?KQCDFG#=G]&H\OJWV@,INLU7G5:;^IS*?:VT L[] <LR=C
M61+Z"SM4K;7 X@!6"W&[$U,R5Y8\[RBM<8Z5QU$EE]65K??>16GZ5RYKPX><
M]=1#_U*ZXLAUJ/;JB1R:!HHK)W"?(]8[%[,E <B<^SV,5<ZU81$3*=O7(!VP
MZSG-)]TMX*VY&_G%I1C'2JEM&3EC+M.[W@2R&W%GU2Y"IQ$):(G+"95MV&,2
M#;H![P) YTL!-6_ CH:5^S6- !(JU3I#]@V$^RK[U))<A["?W#IJ)_+R/ ?N
M'WS^Z.+R=W<:,9@4+PG*=J2O+9V$'3QDSQID?(*)35#K7OV6KP$@$DU1]Q.[
MK<UYE&ILZ%C.Z+0J$)EH.F7C-T*MK7!=6#:H?X.K,+H<5?[DK(K1$=1793X=
MU"D7MQ-K^COZQQ?9:Y!WY#1T_=8\ 0+<"2*91_N[J%MQ89X\9+(I6L:SZ^9S
M="_E]]RI_ [<M&$7QLWLY88/"K[WQ9?$HW=_2E0M$=RC-K^1)\=G\PP2B,S_
MO"(:@0!^#A@4PH.R^FE(J-!GR)2D\E=QSB70 DJ+=G>L W[&M(:PR5MMK-#T
MM!>K<W;>SS1&OC7E?=P)*] VX25*@G4[<KVUFGA@C+&%&)".9E&[GV%=@;$.
M%@MQ/U(;SDM,-Q-MG5Y=I#5;IS.=I!U:>4X2+(XW6JH\L=@E ?GQ>TN:&,OD
M\%VA20ZKC<R>^7^'=I6B HHZZ,^1;B>-4_FW>2N="^J>CG>>X^+L >T'#8W(
M:\\JJRM^BP="-&?HZ?$?Z^O%S^YF^HY/%K;?U+ O@G9 QY4Y4_E/! [$]OW4
M(!(]S \(30=23]=)8E$J7A5 <-4C66WFK,1.Z@Y<+O_WD L0T!5R=]"U-(B@
MQ0OH1JP/).Q+Y0ZU8P^5'6T;5HS-K?)>+A7+Y#1*H.1?G?4=N*.5E01-H8.H
MAAA(U<1O:4GXZ*BU2RA5A2N[-% ? K-_MC/P]C-OMY0?XL]TLX2C]I/E[,/7
M@K9)S;V13%"B_V(C?#"WP%#$N#D_FNS14-](;1T<>Y>[825BU-QIG_>4W_@=
MPG75K%:3/.\G R&_I^DX[M3W^&Q*!/@3D/"O1<%!L)R)CK.VPDN+\H1291+%
MJ5!EK8;?1?8"[Y3:%8*)W3<]4I<'C,.O-8K[@)5\BE-][6RMMY<O&H4)VI&/
M!\KQF4#I_YS1%WPEME\0&PE/\-!<+99E-61*N!G<>ZD2]Q<9<*>.(8U;Z: '
MT!:VS;JO061O[VX6]+#6("HXHJ.:>=8<\'X-$FKQRBCYC8^=!*O;@Y$!U8FP
M>B)713+1,M$SBM$XPP=WD)W3)1&RMDW#M\?U:X:%ENR-H&YS3IS0NVC*.TXE
M^PV+O&TFU[FML*+Q1FIYY>'QW_HN5>N6B-VP>!A@1[V7K\=KC"48B/O)$,EG
MT8G4#<MHNF97\UW\[D:JN!=$%03/%/B!20Z7_/7JJK>^F%L_KE/_[56W;?*C
M@]K$GOS-DFGN%YJWBLBWR0KX=:#:33:2GO3+'2DEW,5:D(A$(!,L[%H]U%3B
M&<P7&S4 /S+]PU[.3*O6U0S#\SQX>O.JJWY/#CR<GOWY*7GNKXA'I/63[I:F
M4YD%Z-J?7-\7LR3!"7$/ [!'I) WXGUY>SR+FJ$]_9M[.()H;Q:I2PMV:3&@
M;:S5FH[C;3%7/#93-A&\03TOS'U4\MVH%JPVL=V*&(0:KV4'< 7LZJU"__I_
M1RB$3V3)$P)N_*;6+T.H>E$^_@YK(7'UR"#URG#->D?B%IP-34-^.B^L8"[B
M#9W8X5#=%6$6].+)K6/(YTXHL>RX9!$6&VM;HKWYMN Z[%65RC%^>M?/F+I=
M_AC,%K^K']I: K-UD^&+.K7-KZK./SN0N_KSG89[@BE40EH[_>1JOBR1-N.(
M#C5#>'@1+G+^0]',M,I0Y9 SL-R0G6T[ORE3E(Z]?+VK[OYV8>TBQ FO+ %'
M*]!-@!*>%STD&.&B^$'@XV+0P"./1:)-8+>!MXB)"N"".YAZ*9H5-1?8:L!R
MQ;ZD4^Y5!"_N;XSETX,:CM).73A6,U_\KXX^Z"L9::_H 6%](+*.09N"=5M,
MHJ6L9;S @/;L:2GM=:.4;4$1:Q#YV]NKK&39MW+&>ME(A< _W49F3J>.;TM_
MZ>534Y?<X !!NOXJM.)0#?YT$_][$;-ONDH0]$"AF'-U\E3$MW#^"K__KO#?
M'7!LHC"(MS*_+## H\ "8'3V,Z.;H%W3(.XFGVU4NXL_:*OKAW&ZSE&JR+^%
MSSCT^-3DL</(YVI)@]X?DR)J]T(>WH#Z/%U_ W+TR%)U+PDTW)1G72I0P ?6
M_?71E+NRV5D.2<;\."14.?:>L*@PN9C&6WQZGI3MGAEPA-1P;N]5(9*&FQV9
M"#8-OG0+[^2SH6CD^P+'7Z;S\:&?5_Z>_8&.8AE[9EVCP'%7LW\^(M3F!. C
M._ZJ7CWAF)OUD?>7LCG_4/CE(>?-Z5Y/&<HU-:E.I6PBX$"D:_+C137BS;@X
M]D(7(_D"_5H9"Y'N]?/>V#&@-'X)@X7.YIYZQB+)S*D.^-1W3]3E.Y(5IBOZ
MMB-QVWZJBU1?BS(I6X,(>J]YQH]?3,X<G"$K+U 0$UX>L^YEURB6H[>33)W0
M;OOK[INZ-T0T[*I<_%YN:ZRV]>!?1<D2KA=_'20&()+%$B2^?_:OT)H8B%6:
M]>^6>_4+.9X:B8PA:&ROV)JC7T315:[J<3/GN]0:;/!1L"6>F-"$<94SW[=W
M?XY:ZMP17FW8F=:KG >8RUT#/SA[/!W2;>=@3M_Z$5J/K0QK8_PY3O6876ZL
MYN0[/+[1GT;0N_'#(<'C3*TN9\N0\;M+G(\%6S:J7\J7[[*S5?]2ME>OL';T
M0&3RY93C[Z2^;/82Q/UY_?_C5=GUZC\4NM&]#]T>E.^P]YR:B'=]NB_6?I/=
MU62+][//,Q=S$B7\A'&?H"<JLHH6[ UJI _AKX 8H+.=J"IT+^I]X6><&L1"
M:#%F[T;$P:G)KE<&0A?\%AQ:4V:GY1J\P[;#]ZKW#)A7O9DX_7M.:=_#*\9)
M+FFLQ\6[][]C5OU1.VH_A^Z#DL32>%]P2K+A>D6E0RQS[E&>(]^_>6 -<AD]
M_F768J6S7P[T]R-U&UF=9Z]HR/>-I9H*N$KJ1N\3;FH_BPC5T<B8*3S3 $&Z
M(Y#,4D9- IG-4 9W+]*T#\31M)5$%;>17VL]&['K<<F#")+V;D"HK3]4Y^WN
M>,&<+A<4>< 2]V) _TOO@\RI]UMG!=SE[?Z+6]Y\V)YV:MYY*"%<[]RK-U=N
MQK3XGLO>]UQI1&@\;0JKC1_KFG+G8+NU KIR[3K(X&$WUG0A3XXCH1_RDT'-
M&6TE$T++U]XD%3 ;!IW)G'AF?N9!NBECQJ4A56U\Y*1@F(8LA0?P)_+X16 (
M6]Y?+.O/P8Z3^87@/29#=2;"VF102.2@MN$P'?FP@05F4%%869#U=NKPE1%]
M%V1M0<9G1T_UV/IOWJ<@\/^YNFD2=\-J2[OS^N]-'^6IT=)1-&T5K+1!5[\J
M*,U<@]#0,#P"W&A.LQPJQ6F,<4@T[)9 C<1XL7:PM5[S^_K!9>_%,L]C%Q;.
MU[VNSU8O(G8304/2O"]@P"G$;^"14P@[9[W$F2%,3_%N\%]NLBQA)[C @K8W
M@.0[\)S.<FPJ0[D541#LIP+H]:<6)WC>_K7L/:+*3S%>/O6Z\?:#-0B<GI-,
M,,-OYC4*MY6[B@JI041U_#I16Y&HS K&*V>.S:<#G!-4'JP=2O>;Z&F@J \(
M#V)>!&E0XTN'K8_@'-%O$WYVJHW5R/D#/W!76IICO]H_A-T$RWDZ'609:P5B
M.Y9XC4B7.I752:YWYX;Q+%F,=((,?O_#CC\"=U#"AN7<6*6=#%G< 6N5OI*9
ML0O-V5E,(FS&>M>00:/W'SS<[/Y*(\?)^WWK.RA7=<RU@9)"__'1_O?\ IS=
M7-<6ZU'4T-SX9$MF_X;,6O7=>]^T?K&JJ3WIFG=S@M *X]\%?K0P^^^M0399
M[64WOI7$",ESR(IA8)2?XZA^^.AM+#0H8C7OH'#B1_:/"QG?WKO&392P'GY=
M^=]GE+H0AU^;4%]<;2%NF*\-M%^5NT^[8=:_/-'4'N'@N6-?.,%$^ICSL03X
MZ;U<\=".6W4$-X>W=Z)DSQFK'AD?G79YIU!K>W!B_?Y%@\,_6ITB5J\E5\UV
MNKP>##7MD_9\2SHWK!1T??[,37M^8\Y-&\V/_#?;E%!\W-5,_VD=!TT9QGOD
M_!,!5CR&WM :B7V%OPM2>1B.- V6BI20 G.>&Y.-B^QB;"98$C[ ZADI%"CN
MH#>OZIET>U[_NF YGB8SRF.FV<TVBD72 #'.GJ5R)<6<6:A*:PSLJW,3>PK:
M:6%<S48I,FP+<%&=J^?YC=68NT6I 24S%GYY07K+HN613UWGZ%Z>76:?QES^
M/K#;8>QU/ ;:P9!',BNH@--"&N4P4-V)BD<W(-J),.$QWN>J7&B<$,8B*O26
MS4WKC.IZ%I%0@_.7:Q>-#0ZT&U40/#C)^!E=CY0FH2N(YJ"W!Z-K#>()!X4.
MDLV2Q\#[\P*X9($T88!RA$>:[ZJBX\+.#UKY5AT')"J,7\+8= D0580)#[T&
MP[1HN<:UV*HSHT,?I!*;U0C1K=9D"1[4@M*"2+"0CQ1EAX8+%K[F=:(W+?>/
MG_,$83U(.3$,,\JHP\8O3[EUY"@*#_(V$/:,PG^;*E?^TLCS=&3+<O4/-0*B
MHA/)1[)VP@8F(T955]SO<O-S-L^J#=!R&ALR/8P+[FQ1WA[A-W5B2R.FI(9[
M'K'W_(/*EX\V]3P8!SN96))5" <5UZ!!ZJQ6PPE8?=/I;'(R>NNNU)-C]8Q-
M_1PG$V^1\CD>X>%)FU-MH\S&?(R<R'G_&-_/ECYI&K8)%D]\#978P(5 1VH3
MI C]VGMYTRW/<>7\?: 3+[63"KBV/$.>)#F3NH@[3*EJP1)O5@OB&ENU[,5[
MLMJTL6D185Y&L?;U@9D%%Y+? 8P$\CHK<X&N>)@*^"$3T+4Q/%>>"FG>!D#V
M/ RFDY.6$2IX&QZ*!E7#F;,_-T:S'45WP_2K5HM'OGTR"MF5X8C1/%]?6YLQ
MO8=]&B): BT%YPE=:"5K'7"(V3B_!N%U,@-2*/JX8\%A()75TZD5V0D#,O-2
M@] .N=]F+**[6KW:/F=%!U@_BR265A5B2MH:^IS9 X_VKEZ(UK1Y.WJ;&UZG
M93SGT]A@#S<;*O;TF3M$#RLW^V1!J-9KUK3\#^$W\ZT^(:#Y[9;^+;A=AG\W
MB!*$*/;"/>5_IUM6OM9Q@H/B88G4VXX,0&E/XO5 -"#5D1MPW_H(7F5$HLBD
MQB6.F,WH#@-C)D$V3&'VCU,!WJF%-SM368 _9O%4V=/+<0<;VF9M1AA -N1P
MT1*BW4Z46K@MX35BV6A_WK^;H[I#3WB:[8UB'="6#4W6MI!X/79#D/;.03.L
M_)R?^J@5NF@FZ.B/Y[-94F:3ZW0W&6ANCR&>,,$13S>/Y*&'3>5-HB,&G"B/
M*_M+O/LK9T9KXSUVOAX)&&(_1!S>])!]N"K77CUMJ\\;Z4=OP0] IS-86HB7
M)??X::#2O-8@<<LP[1GT5H.12KN49:34+_>(U=!2]LNE_XIS?P^=?DT=J;CX
M<)8;\I#MT/%55/SBL;_8 WEU#4(B-C@_>4&@(>M*T]<@U[%)9.7?PLA_B8B\
MZGD[-CG1;_=0J[ZU-JZ<697(D2=VJFIDE 45V\I/,I0&H_6UG(G*E6-Y1S^E
MAZY>EU.'KV@_$1P6[A?E$9EMY"U6OLR_9G-K$$T\7I1$#"8GK4&4\.X<M%*P
M]=ZQ<#FR'-X9]/1G<2U1"9Z3,]:*P')V4_2F9\\#L_V\ZWY$)>LTITRKQR#=
M-,6;E050.QY.N Y%+V?^!]+-YHC2C9WK.)7[L.J=[$.!:5[;*-J>SD7-]^=,
M[J=-<$_1PNRK>(4"]RY2"DR6L@ZTE"R0"@&.6VB'R;9*%VE&,53 GB[ZL^RX
M0F_1ZY[ .)>V.R%]W<4OX74N0>V$L9N&WD?;:BR/>(E=K;>AP3B^WI"UHGA(
M@D3_:L6.^_/I0  7+K&3UHB55@5^._"SPU#+G'URE=K-T,1HZ+>]Q$&[5N=3
M>=9C[)R.QB$XMC[U*+8SHOEJ8V)=7LN3PJ$ZFM,I] @R!5TGW=E/TH"38HC,
M O*;!8F1_*GR.#0_%L0AKU 5Q",48P"60E#">XJ*X=?QH=9J=GM 7S91F>YE
M<_ERS@6+2-)O(;(0H^8V$=0</K_:_/H8]$N('+]:E%Z/BC44G XD:Q$V3>'E
M@$(4,8KW<()&4$_LT-Z>=39OWNL!=:3_(465.F(0A=%O:%-M_EQ\>R8T1'>*
MT@9EEG838Y!U&<FP;D3,&D21L$/H ?1]1+%Z$3MP^U:<1ZM"0EEZQ8.(<$M<
M0D&AS]Z'^W.=BW:&*=N%;S/*TC%?M!$8>HO["'(2?1G*B($!+B1EX6:>0?H\
ME?F<(6N]!Q?)#HTK]1LG?+3>+2IIO0,LN.0P<^)O2S9QA.4<:N.<MGH-L/P1
MU]/AM[_545-TRC&J9UCC]^]-U=5$9F8V11\H[4&!^TK?D9/NKL2V.O(RB"G:
M6F !#\I>>5<.FZ?><X4EYT,$T@GX RSX^@^_0UK-.+ -@1;A;0MI==];*4U-
MPWJQOQV+LN_L/@8=0TF+Z<@:=Y+8#+,&J6V,H0;![ON9@G]9CI9-9MC[S5!2
M'=RF^X);T*<OLW=OT_%J&WQ]@QZ66Y?[;WDX/7/U9//C^@HCW1 M:?ZDZ&$X
M-=TK9[[_.6$ )BN1T72I$YZ?:X%4!UY58A2G=R_<Q?&EMT/!<=R*N45E2F->
M5*&'7)O7MHL_WI?U$7>J:B"[H?%^$E^+#1,J M)Q:Y!K5!4_G(UX\Q/YL<YJ
M^AJ$!>MJD^ZB*B,#]U991;.?V74K3@J/U@Z&6*$+YR(.J<79@\/XF]$AA3-\
MK_,5KG#P9*;HX+L!H<$0]1(5-*A<B+D*%"'K!<1V_^NW!1\J0[E(5BB*!Q5K
M%-+V"\\.+5--D*!#R5!/#-/ Z_7P)8PM,/#F66&"E-)K:?[S<._P\R:&W;0]
M!YI.S.AF9'9);;N6UB_YI<)^OGW*YN)^/>>RZ[KV//T?FBE_0S7,]F3(%>[)
M]$W+?&'3V!\9?BYID?01/3'&68.DB^7^M:([4RT?2%5D =!.=)J$)5QBDI,'
MT"C_2T6XF@Y$HL7O2I9HTY^?KC<NWEE.=73#Z%I*36UP,S7J16?F,!JJN\GI
MC.UX3P%R@C!"3^Q$Q)*WK4&8%6@8-:"%2(>VK]S=<A:'9#$Z%J1],005T(!)
MU9BTBRZ8R>U)PSL$B<B%&(M'0"><=LL[:-'/STHU"T+TVH\VFDW_[J"^4]KS
M4$(R3_#^&_V32@'2J%"W\*(V3J'OU42[^8/9[N-RSA]+3"[HA11/12[8PN\[
M:%TPB#CG*:< 9:]!A(J+[#%)Z('YB*?SU_$6N' D]SR+$8.NSV@#LECN789E
M=7(M37AH86!V?\@+1K"?ALE,;E5YB4].X\BR_5,1A7\DP'#[+CLG 1;O+BIL
MQ0@""?WDUXWOH!D6 ?-=DGADR$SL(F40]H)OK0X6@=1NC1RA89N=PX I>A/.
MW6YT8>?0[MH<EQ'W"SRS^<SZ+X-PO83)4X-W7JU;Y9L=?L)RW<;YE'XU;'=2
MZW_??+H'C>*U&I&_DY.O*#:A#UY^GW;%XKYC&[XIU_ZKX<GRYK.;8VMD>CX-
M',S:_FA]?#ODJ8;8=PT2B)A \8M2SX":@'\'N>$^;!O%\A=RO;61\ 18<%/"
MMT3@+A8CF9Z8%H[=!.:Y 2L)UKMP##3XA /=(D1(P)CRX7:3*5%U/%A;-^=<
M,\]B%CG>H1D5>(82 .3Q_R4]QHKIS<AY. LM0QC0U@#75>$O_,_K5:&B8FL3
M,,L>)+(8RH[5X JSIXL;Q6K("RD^7N8SZ3DSZK6D<2Y26R?'J:EU4/BM)5J#
M[_$";26U6L93S601E3X4^V*:];->.;">N=8_DW89J;Q>-68_4EGP<')V]3R-
M?;*64K=H/$^_?.FAJN?)>)U OU#G/ZAX@AZO>#2N'"8U1U2J(\DWD*,+IXG^
MP023(:$.>SQ4R=%S:>)^R(6Q#LIN\>>WT'!X\XQ&1</BA.U-TX9/J4*VN)/:
M@.!R)1ZB26Q'6!O@;X("%ED+U!%OMF12271$"D4QD+IUJ7K+#')S_<)]U>Q.
M6UYIW/*WUF;J<'AT^"AFRF_(I5ZP?NJ,^(2)H;H[R[R]MW]<\G&$!)/N- +H
M#((!WHDG6A$J9[&07>7]24@%H1,R"1_R$NP0^(+<FQONNC0JT&<T#CW>=HC\
ME6Y[WW6[T].$_9_G]TBM*+.("6N02WU(]K7:?X7?[A+GBZ'=U9O,QL=,H0EP
M@$61D)RKF<_?OATU14#/B/4&V([ABI]75$=G:Q[J^FP]N@;I(6^5X,598)D1
M3]'#P3J12E:'K\;^0&T!J2>&A';%T2^&I;;P1W,?U_$=(K==5#8U"L@XI=!:
M\%^9V(+(S%^-J!183Q+;]8E!J#1J[<H[F%80K"Z]E.9!4,<QF$YKD!0L$9..
M9).2K0R1269P%#NA8D5Q'(^MX:57MHP'^\'(\V] Z?/'L;<YGSPUEVKY$GX3
MVPS.L;!)8CG"0 Y9GG*8T,^HJ1=2U<4;A*X F6L&Q$(3Q?!6D!'-S%N#;!/W
M4W2 0N.6*BV;SKODU'ENZZ[P6['3ELD(3KY+K-)VJ16[;K(L82M8_@[ R74C
MY5OEV,@$KRLW=;7E>0;Q=>4DZ: 'WB$*>;XPUQI?<U1]0Z/#6<N7PE2,IX<:
M#:Y3%5]2"XRQ>N)8;>(QP""6H(&+/#UPO6)Y5U0!B'FWJM503,26!E[(O<)V
MC-8>I*^X//S<W;WG6GIHN/30\UK'9.-'I&^;$!-S_"71:^JUZAWBWNDC(*E$
MJ ]^!Q#\TZ(:BB&Q_8097*WCD)K&0N)M$;+S I^ZOE6/%?[TN-:SE>2\+K[[
M+=^@2ET^/2*3&%%R/-2UK9?/$V5_YYD+%0/X#F [SY!3W05+LB"_DPAD\?OF
MGH16I&IY2 $(I5%V\8C=V+AF0CH;JO4KUR@=D:(/=).BPTO'94OS+6_^G%-S
M*9PPV2.]M,!3XU#;L7$/9AK1:F(3X1[P_%4VK-%8XF6*UCHX]_8#F$QZDA?F
MF0:'9C&5YLX[47MLK/IZ#;SFO>/;R5@GC"$I@:@X+]3D'73,:J<JU/5&Y_9W
M4M6#PF:L#8;@;N[V1MZ>0&E2I6Y3;8+\B>VTO2\[;\HT[X$_O^-W29.PB=A^
MC/@O<ZVNG]LCV6=X<U[IO":["%04* 5'9@GE1!+@!A/+)WQ!,BU"H_AGL@1@
M96)_GAD2JK"BB4X &Q>!3C;W2E\NR>*7EQG#_9-L?]SMG__7<M$"#.%!^0&B
M7+P)X\T85Y$)E16> Z]6!OI)K-..2(S(0?[K8*]E>&H-<K^\DV#<BDKI9<L?
MDE=K)V@Y&0N\:T=5NRA])9,VT=="O?84_B>U'&#+,YAOX_GW4(X _8GX2X !
M&T6;,K#-::<J+FDITZQE>-7I2U/K-4NS%SJTS0:6YB;Z%=M+[&Y:_UV:PJ(:
M4X[H>=A/W]L<)#XHRJ;LF5VA2ILB5?%RX+-RH=G;@=)6T+<83&WW.S!&@/G\
M.C819#*%._1Y5G .F.*GO<\>C9JO_%V19K@A4/^X@OC&;VLEH;KH$1++ /7[
MTPC; F$R>!V!LM!M@'(8OP^TX?7S";RT5487(VWZ(!C',FR+I'DM<*4JIBJ+
MM'4!;;)*2769-R[/L86WM:!T3G;'2@V=]IH]3)2F0,4?&8 + M1;@]"0][2W
M@[8!@AW"TSP2B:(A- )' /,>*!N=SM@AWH=W&*HW;/DEMO*9EL."9X3R5RM2
M6QJ'EUK:(A;.M*Q#<)=RSFU9)SHHM /_)1*./KY4B?<#FX )EG5FU$O;TE^K
M5!IU!RZR_8(&C?=:KC0HQT]ON,X[JO?[$WSU&^\/\.X3%0,;;\,-,@B'A6J@
M(\O7G*W6!4NARA.T01V/W'Z!0;?U(5YU EZ/->41?#-YZ8/I% 8]<KVNY7MK
M743+$+NF)=>[_% Z]ZS-/AW"O[P*&XHRQIP(N!#O$;>%]X]C;45MUNIT<=^T
M,7C'?)Y1BC\%^A?AQECDY.KE^[G$]##A(;"27;W%8U9[0WY73N==:NKUDA8J
ML)26XV)K6F0B]I$,:H@W+Q&/$%60%]$)Y ;I^*5^+;PAT#_?+@B80\N(M^-6
MV8QN,63Q-I(>US4M/X"][7OMA^X0/N F$Y5X892@ JPDN??U)!AQE].M#W/U
M$T ($6.!3;H]Y=6)&EX2)"&,PKWECCHZM=0VUU/JJ#746,M4[Q;#7O6J$*S1
MCX3 HH35T:"*'W:>N_+MWP<WT!\%5_1O>WX*&1VG^==D2Y8R]Y;CQK/?OYAZ
M,.T]8HAYU*]2'!B-E$ %;!!T0[;Y?;,^VZHU2$!O]40G2I1GE@=6F;VL%&O@
MU< X'L()M#1[.B1Z]=/WR^TUR-9 NH^JVI]-L2O.L7L+_GKN6^DA@WN)/=18
MNMU\  =NZ0F,9>3UD %G4@:L'DJKWC3N.?/!(*T5RR3%-T=066W7]E;D!U4(
M)7@D*S^4^K4"W_4''JJ3R;X:=@PV$#<;\2<G6?7$R9MJ!E<(:'K*W\USACI%
M-3U/SIK;/GB5V7CS//8>E5ET08XHV(WW;,CT?-'4T!#R:@=ER.ITJ:SF6V2S
MSBY-@PU2$W_&^)'@L@"+D^8W2U & \+8U=P\)H-NR:)R!P LN[1K83O.T1$P
MCU\J:T64S_A)-_ (J;!8L_ZMTU-^?CAE!XO87S_/#I^<72U.\:X;,'WN/@_C
M=OEKUPH.XVUK#F2G1,GY_F(E&ZH,)=]Z_?O6)E9C[X?0=S?1N;BN9 _D9N$I
M6DE68?N3^1]3;1\Q&Y.<0Q:VE\Q/Y?VI;>)3U-T3U&B,K3=-<N\#0FQG^,OI
M"S_*4*;M'P_X>C=3G9-;8&0T8!L2U9EKW@E+)6\5CT?DPV$[ZIW.W^[^4L_:
M<3<8;P6&?OJ#2W'2."J?BOC4\ +\=&K;+AVI%9^H)5U_&/\3\9=OV%A6!N9/
MG%@656)- @HY\-0-ZZR/,NI?'[!_*'<-# >^;O*^5?+K5-];H\&0]/>?UQ<J
MKU*:^K7'8;%0D;3TW%_W)TSG(]>TH6!T:MK(Z7"<O]3\;-?BB6"DU]F;CQ]S
M]0)PQ2].S[G/@Q-I^9?8"TFXU6;W+IZS1?%ML9[NZR\IT6I-*B$+T>/P;:[H
M:MA_\?\O37C^S\^!;^=T(H[MRL"]HYN$,4J?(\^$H5XUNM:^FM_E\SY)][W\
MCM 3[UV>QD[<.G?QV^)OR)%T&[;:O;JH+/]*L+-30_O%2[T0<R_>)E))L*%R
MMN)'OGO.&Q_=6URX<O.>\&^1ZTE".#H!;2[T0:W'E[<@@?_ L*P>V!^E]Q]V
M7HU17WC?#QBN0:25'0A4X.P:1,5.M;K2\YBUHM"*6/-U+K?OZ>8%%?Y5#Z.%
MD,I[CQ6LTA0<NCM;#&!QJU/%-(OP/@9_)966I/C:RI.]^[[=[EKY\O+UAS=L
M^BQK>7?1[4CW4Y^?>MO+_<Y&G.;:^H[3?SN$M#B^U(M6K5B#^!3RO%DIQE?
M5*;I=^D^#FSKEH5=YV+#]^__=,SUZ9N=>W3OG:5*]$KB_O^$:Q!MG/&4@7N4
MIP$O(-'?\2VGYXE>0[C)8(_ZWRLASPVW:!^I_A, (.)U>>ZIJ$3&!5[;:.%+
M>'I5EGQB6JN-K)/7I1W963ZMN45)HV]V?-@GT[O_;XRE#/(Y&G!YAK!O);'$
M]<6(E#J/D-:-)8&K\"YRJEG]H,ZPG]@!;R/?X8WNUOA>ZE$8RYHPRFQ0T_5W
M.''S9=EIY70'O3WM)25#[DYVW@8!F/KHZ_>F0BOGOA&+)$;')J!;^FFH]5(Z
MCUPE>YZ4\,=>_?"_=VSZEISZ,DYG]&%385M4(F%)^1OD8H];FP!?-L:IT&5'
M#CP\=?"I5/O.6$-A?/VO9<V]2Y+P<S^N*T93+O5Y)9NDM/,:K"E@BUG:1J6L
M_@U5*$ANGGW=P\4S ^D]2:WNLKF6 V$ZN&I:#.$'*[/!0?3*!O\-S[QR)2"_
MJ?MTN-YI^.DBWZ<Z%5F+OM;7$8WYTP&K7$?)0D33,.J2E3 SL8=<D"#+NG ?
MJ_B(X%N),NLFGU^)#XU)J,CF]7><;\LZB]+&F\>Y-F5,:_:"5FZL/69RJ9B0
MDFGU\(W-:F[>W3:M$7_>OZ\\J')I)?'O<UPG'S\J_0Z6:-&73?Y7TF1HZ9F-
M#T_9!^RG(5X&9Q^<]7K<]WC>D+^<.5#79/339?.WWVE/C;T7NV>G<:R,FY6X
M2LA80<,4(M7*,7/'SUOZ0^6L//]+0Z ]/2PETJ?F&</H:N]>SW&SYKM$WYZ/
M@H.B$#-X%#.T ',G)(H-C;N;WO9MT&]Z@C$KWM123VV]?YG._Z/9I)\0-;-;
M7QU1ZJ!W<N>WF(WF)T;%LK\4IA&)>"> :*-FTOJGD\5U>T<_&;F?=J!45#&3
MY95,__I )__8B0<RQPXCO[4$!47K)2;I:8REI'[%I7RDU5GOX:D_L"62#"Z%
MG(MKMDK4O20SD2*PXQ/ R"K,M!HXI!\O<8.(VJ [S-1GLO(+R69_53]^_Q9[
M[6'W3#UL"GU/^<&;FH;1G90#;MQ=P@$!C5ARH? 57F$TO 6A/*>]&SSX:F[U
M:&T/BXLY.]RJ3&3+RS@N3D[,T*>^T\8B+HPI;3W[V7[PR(%]>W2"]$<I<L%J
MJW[4:I#$["YC:\EJPW6\A^N14NC9!M4_C;F,2R-5WZ/FU)4N<_<VYA[^^1DH
MTSD(_8/G:2<>2GV)R^U8/,=+KUC5SCO\-E[HSD:9['7L?A7Q+,#H7I'ZI:\-
MQWMVA#X--5Y8>GMM5.BQ*^=,*_D[+S)9I??$\W(8F*?U'_.W9>QOK>,J(:?W
M\VO.GIMG6((AF&G10]1O@KOY &RN#]H%2PC95R!Q.>FKV>?22>EX,]U!VOM:
MR^W=Q>V>KC=B'KZ44EAWN)FJ9JVV?])Z-PB]-%Z#DI MX[.G;G5>5BS?4?/X
MR ;(E(ZQS<8U"!PYCFF_2VGD23L.,YMX?F^*@U;]7M.+<L1[QO)0M6VMC?MG
M;CH:Y7P_,W3FED+,L;]-$$X'WO7YK,76IC#,R[E\1-WP"][1R3!/F!KN7F5K
MUM%W)S/,AB%_QJ_HKW^[)5G'6"7,[<B^&Z5G2YLVOUKZJ3M\K6WJ,GW$^FK
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M&[^$(,R"EA:@X\%CD/XR^LR%[(%9V&PQS>@LM5^'-3.,9&41@\Y;]"0Q(IJ
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M-BQY_ YOSBUWS[>Q%XC;<87K-<\J7<[WJU)(RWR]1\3\^9(I);*I(X\C^1"
M\2XZDG]ET!I&Z'<5[N"9_9DC[ 3,/A>S)E)A"KAT#=5ZWM928F2%4]7D7',4
M?>)#0/4'/+V^W$;#^Z/.!?D9*H2B^*^,T$+L&H2U#I0NQ1N EUB6$ZG/,.=?
M Q(/7+I*]AXQ+O0(K4]W/]L\8HRH3QU_D6&)^[VL638J\R@>>6AD#6*4;FC/
MN]#(U@/XJ6QTDD9&X<OI\?:@DAFQ$4^VN4DIN2G%,UQ6][Z.U;6+-I>MWC O
MBB(%E\=Q7W ,QY'PHW;=%(TO\Q08&-GIY38.YOG%3O]>.3; O=CFG5TWS(X/
MS0W;FWLV_ON#[]TH".Q7&!,U;B"6%0"EG%-E AN\)1@D0.)L.!?:S);H.233
M9RB;AI&0T/H';K[40>ZW$=VANG*NG_[5X=]++8:.+3/:=@\Y1EX5@8P:ZCR,
M59UQ-Y&+8%4G4"%+5%)NEJ^?+]YAR P%[:HD!@>'7AZIQQS^.5ST>LC*IOS=
MM--8DM&\SHA^ZJVCC">+YG_QP:ARRSY#L+%G--\OL73JOK8IS_)WMH>G\%-5
MY:!KH\&ZXU:"Q>:(%O8']A!7K8NJ8.!I9GFAKKZ65YT<_WW^16!A^C'QR.3$
MC@+%N/ZC!V/7B2NHVM9;"1^)=6/WQE@K7.5BO"Y8R#J\4#@<LL10QN0Z3@2M
M=I5;RGO;-&O4>66DOGKU9&#A>M7@#2G#'_O?6RN*7A(O,NYK[P,U)3O[/KD&
MF8*\0HUI-G["LX EBP^ & Y1&@SH)DH3#.<4/-(M3O*RD_W9\N;>-:,Z#S6C
M>HG*O^X^RZ_6XM;=^K S;&<UVYMSF\XES[\!#G;D\ D6@V8+T,E90S9"M3I5
M>#+4[(@QUDS]!<GURO!C6DJ.ZXGOC/CW4BL!,#GN2&BNS#6>>>K(]]%ZF)E:
MEUAOU\4?/_9[.7D\[-)R'JA;[WSD1PQR,$\LFR[0P1\2Q1/4A<>!<T@U@AJX
MR(9U5R>+=X&]G/?6.X@=2!9RPXS7CYK,"CJLLU_&KI*!GJ$H?8%G7JH51'__
M_O?>EK'&L\XT\CG12\HZ0B>CX8JU2AR'T"CQ8;\1H514&?*^E2>+FK(:>1\?
MPF)PO<-*YYI#G[#16^<:5NLLKKT)OE([:EJFYQU5KW?MOH4AE%4MEOFP8X P
MZ:?:^';$3)#J8*V!/^^=Y[V@,*>1YGYA@:7E\#;E!S^0G:]R_N'>B.RMSXUE
M.'\'QM3.M?!@J0'6>WG1160@%V2]P%GYLL^_M>])-7.)== 9*4QG7+31'EX'
MH9LXO)->K9PC V<60'WWY*6%^+LGM>4!M80ZQGUKR+#$#.YG !CM#>N_>D3"
M:GZY<5,9SK+;+4ACTMSOP)=E^5 VQ[VU<?0J.:+@Z*<.-*.9[ 0Z"90)'3 I
MS7<+0'4'65YHANQ@Q&L?!=69EZYRHFQ4XP$R.S+E&X^:CM<,D.\NMIB8N9N3
M7 ]W<VFPD]=+=1YXQ]([L@;1H3: G:CABI!*PE[A!71]#[&EE_>_^#KKOR:_
M]X\/05) 03JF=",-4BI2(J @'5-"RC%20)#1W:DB3&DE)MV,#A&0D!BY(2FQ
M(<P;&./+^]?/#]\_X+X?CW.=<Z[K];SOZYS72EQWF,W\T*I.Q5?0D^OD<C<:
M<D&_&]XH=2.!Q\?(FX&O>PZPJ &Z%JE;&88Z:$WNP,]EZ:C)*S=3S\P2DP_O
MUR<Y40XN_B8_=VUG.Q,@#:PP5FF^3#2F=;._.BD)=]S %\/KIE^3[M2ZMK-X
MX"GG7^#S^J;<9=]60^V6[+U]JM/S HE($;V -[QYN"D";#)4,? /(;JF!<<<
M\@)(Q?WK@=!IW ZLW1S@E#@$4C'_(I *P4A&5W3,1W2DU<.T18_3[FNWT7]\
MU7SD<EA(FIVBTR21;7N!U@G/3@FBR]1[@6;OLD5@K6_FS/$,NNLZBC(=T>7K
M HD%W6+^E\MKVRF&?]MG[!<J132K:V_^!=VUU5I#W0P/<H/YQ=<&P1NIM;A4
M:Z4FV674E6^!_Z3B? G_->J'AH[#V:;6D#WCM$3-B1#OYR'&TC&C!WW]T^W"
M.!+DYG+#8/PZ$("!ZEJT3!"YO*O;JP2/9[(I9(M?0 .H(_C.4'LLN&""V7D5
MB6>!*'9>J(FQ"C'&"38EABBLZ=7;.0YP/K=4,\"H.]![])YVY/=Q?C7P;,SL
M2B)T2)F&,'- ES)0@V-33_#Y!W%2E;']L(19<]P?T_FJ;%2JFJE\DXP1[GU1
M@L OFJ (9;%(K@7^VV'C;_%YVOB7X<C%;6M8'R316K:[V.;=[5\A;M@%_1))
MVO+THK<6M-J]S]-VO7RGA,(T9Q(&"7[G\7YP;M($XD:E'R(J9UGNO*I=O0PP
M6"-\$4XZXB,IX4BYQ;:!KR59,9KUUQ>Z%9-]"'5T3]D7TQ\/'?9E1Y>&CH!K
M%+//)+=1-7%YW7=S=X\+[0/?_#'"6<1IB,R[;WR'T0!(8_QX+'2@3*/2G_7;
M1+ONYZU_K*]C E$3JXJ3D; .,#&XP=!T\*G[LG#]):\)*$\0-=V^HE4#__2+
M\>X;<,Q=R[<14^NR$> M^,VSPF +K)EGZC'BV;!/<Y_B"/D56;Q*>%ND>E]2
M=V&$3$6DP*38]XDRB=\B%)EI9*362\TVNVMZ1D6:M;\]T6Z%S]"D7 ZLN(\K
MN0"%30T47 ?*.RGQ0LA5>O<E205$+"_?=+M2I?4X,E#\F;:>M!_42/]Y(%**
ME8RKMN[<=#5/.AS"0.)Q1="V2U>$B.,V>R%T@>Y@JJU0^DG_"Q #.M# "-??
MD%:K 8[55UHVW5YQ[F\8ZG#[W9J"W=!?&/W8<@&ZC4R$T(7R$65QJ;WT[O\&
M5VZ^.CI@ 4P&3@]/-3F 9KJW3QNHHJND!:"F3FPF7'FZEI:Y?E8?K]]6.0G]
M:XOOKL,=P7%-H:+0Z8,0;<^=2Z6I]6#OY2VQRQ$U=%]3Q#".?E2Z/PJ"5XUW
MIP+" 41FQ"I;WSO2G1 Q7&K8*Z)%L186#-S?58#$/P52N^$,XXD;'R W-7M1
MU#NG'6.1&'*DY/IH8S':^6L0P83KF9-N5T W"A :)S*OK;+U2ZJN@7L0%("P
M%KXLIL'XQHX]U;=F(%JJ!L,8VQJ;>+ QW?[T:X@BKKKLZ^)V*-TO!9O$O!PK
M"0?G1BNKIP\^6IS<<BL0 ^*]7_ /XE.Q9G%3!PO&5\#<P&=KXVQG@;J=OKW#
MDP'9P76JI-DI3@$$^R?@A6:B F/\!8A[EW,'7S9YL!]BAFV&_JZS?2BH!$8_
M%%$-O3^&28E:!<$K$'OZ9RRA0ZA&Q<\8N^"UE-SBG5!QG'9C0VF@07\H$Y#L
MNPIA06_=/<NL NPAUP&X:>23-MQ^!S/%K_J\+U*2Q1F*&0*I/\AD2)+_8:P#
M,@5RC72=*(*']"*HT(#J*CAV,+KS1E/O.+M=()LY3B@.+6'-LA&.V8/WMD8W
M?O$H=#\-@;I46MJ.>J%C#AH6]26'TYI.!/] V#HUW5ZW[OV U.L.&)[*;26R
MIV(9X] BZ/W?-P[5E]>8^S*DSA>TKC.X=^:>/0R=%/O7J@:NSQTTH&\R,;R)
M(VK/6C/6MTF\JN6W9:JI& (YZ("&V4'7&0DF.,:N\4@4/8EV&UQW*><%5\^9
M5U$Q[332O3SB7>:3]Z5C,KM2RT9++T#.]EVSQNKHQ;EQB;M]_YC?%ID6N%67
M9/JFA5[#08A,%01>@.$T-0GELD?>LTP%U)2$R +AN$U,65((;(T+&?<&W'O.
M/VAM-H. 8X(UKP&YSQ"&N=T6.OXI9P]HN*$N&]J,.0O4%R Y1"28&^YA?+,1
MY7P!HM<ZTUZ:F]]2\GF,AB4=MS6;!-_3TA6UBH3)"CWS7#25O3'3;GVPAMAC
M"ZJHJKH [;'@(X*?$J(#2_ ;[9-#>Q2S-+? ;GI+$]=/,#'\SY_M+WP 78"T
M('.F)!J7 !PYH0F G#T-<<&S[:;COBX0WN*$^^#4@$7O"EF[&S9Q20ZK@<1S
MS'"AF'?,43<:3G8O"S1,M\;CRZMV.LQ]P4CW)KB;1W:,0@K*%^X&_N;Q7Q^X
M26O(SQWS-RGY-^I::W*X%@SJ7Y]9CT.]/01J;!_B]V^T,VSH<.D8T5PN2H!H
MA?>UG_A1< L8P<O9-+8W(48;47AD7*,^U] -)BWZPPP-9V%N?/*2Q_ES30>H
MRL$%:/6]9IU.P:&!+R*BDZTA.+'M2[6GP ?ETM<M2J9ZL_2BYC2=5E:1HN/"
MY'A(L9'PCCTET!!OG%U]91SS8RFCDZENP=#^B^I"9]P_9?NOO=X6M&M.>\>\
M_-]K$BS6GYQVBF5;B!H4/_]4(CQAT_D!A3-.!0%P/<0:)(DB( V()XGQT#Z8
M_1=?IAY+%#^(M;C#,B5\N):"S\]WNFW58D(SC)P6I!)6I^8)3DY@_)/RMA6?
M0#P\SPI1P=*!.4*\FQ/[)[0PP<8)A&^HR-G[C6Y7_Q'%X;$I_LQ8?8&W#YQ[
M6,ZDT]+)VJ3HR"&?KJ]T2VPL\XL;K_>+&HLD-_ZENKZHN N-T8EP,IE+:[VQ
M_D]#>L*&"0_13:7U:%Q T#W]UU#G<2,IP%[?]<CZ1'X%PK7F\MX[X,8&BV?%
MFMS'UWS%3AW[^K\*MPQW5B2M9<QN+<PHN4X6)HB?7C\)^_^.S)3J_],]PU^
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MK3FT+D^OE'Y]!'LIZ\Y9_F+TD_LLQ[%[(J$B'J$T4/Y>7O;)!@A#X&0/:7"
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MNXO,AHI&"S9/_@[_\2:+Z?LI+&L'%G#5%)*M24E2AO>0X32QTMWP>2WL!6C
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M+N.U!?C+?EAPZ9: 3LBO*<\FO8S%S V6Q:0?/O 4XP7$XXDC%'H*J_C^LU8
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M3E3R?3#UQ=]=T<N@TY8EIQ!MA;=ESR76US'7Y]YR8JK/*B2XG<I?@&YI5AT
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MVR4[3PW/$<*G+#]F"N['6$WO];;0,G"<,;<).*U>"X-G(8@W73 ,7W!P0B^
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M<*=ZD[()Z%?H7+3VM(^N8$>4M[:8FN./[&QSH>=<8:/1)W618?H4'RY =\&
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M-",[;P$> Q-NBF^.0J]/K\U4RU><Q336M[%F2%"*VL4Q_!SQRNP&?[]6P\_
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M>DDYH_*E4#MYQ2X?XFR&LQTF$_-WYOV:9[(E_4+.ZRPOD^A<WT0]7/Y>\_M
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MLY)'2 0Q-807;R"PK$\<(TIYZ'']W#^GWU>%]+^Y&)C' R&/ISKXD- 8&['
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MXR!*'*M_9I_L!S679VJ=LS+B9(LN1I@?4P]9O\' Y<4BS*-]"E+OUSF!O'^
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MV+GZ9?J_J?XVTP'!=)T9-#_[K_I[J1\LMR03W6___=O*&_I1.H"EK25QY/A
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M4$=T@!YX++"0)W]:WQ9Z+!L!NB8PG-<T*QQ2Q-CP)H? B*<1B&K_-(7PWJ?
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M7_;C\Z<H]AM18V$W+AQVN(!-^-5B!'1W:!;AU0R&W/5H[9>W-\1J-J>P5LY
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MC6)<.)?\6%NL7+R OOE,<1-XR4A55(=\$TAD'M._#M$H7(;OT7T8,VXC/QU
MKNO;\3MXT?#&1LC;K^'/"*I#*D5O Y8@AM-@E'21_@PF5,=S"JLY4W*A7D=K
MC7H64\OF*P#XPJ-5*=5,ZKC^6FC6__H<%,&<KP#9(#=<'"KS/5#&<*S<$/>#
M0DV3CI6/=9B:\8D:]W '6E>\_I!#DV^84MH2*'V[]<8MMZ/1LW!3]1UQGR1+
M5WL03>P/;Y9\&R^JN.&7-?.Z"I=9' YLM?NEK",[AN=:%IL]R:_GSGL\Y.L4
M]W>GLJJ)(>/29[#YQR>_/P8-G7_+L)\D:@A.KSBLE8FY5QG<2VYM6(YNH:*[
M$=O42D%'_>W'$XZ(WTSG$S%_D;2ZCG56[,F&E)3!)P>6A@L>&:#B=VA%_J3/
MZ1??5B(B0^]= $_!U]-R@QE=UL 4T9Q@U*HDCCJ&<V,W.VIPGOFT[7WQOX8-
M][D_#Z*]!50M@2+*:J0<F/H5("HH7-*C4.5:I!,A!,MB@B#$>>TSU'#-=A9F
M='NV:RF#*KG\("EP?>7I_%W!C_U#@]QD@-1S9G1J!6*RBP(]3ZT&8MZR-O3+
MPHUQW Y1AMR;Q9M+LUS[(,ELKD>EPH8]VEHOBO7,HK</7"ZZ-%N.S= D090/
M.9WKC"PU77FV)>9^;[TL91)*R_H )J16H+/YMX,]1=(DTUPES5U++RBWI^A/
M%#Y5?ZZ^Q4J^/8,-,MNL4*'_4$2 ^=[7VK9[!>7'IYR_J,,=AEE;P_D2K@!?
M+>^L#J" IR6=.W._[Q3F9G[.UO>?O.V<OKM1)1$Y=6=[GKL&B;- +/"CY_>#
ML3V*Z*/^ S^3WDDO-5YWGR (8E6C&GSNVO FR'XWP\YFA$\@I#@,_VOY4?J*
M]*;HG]3O2#(H<&"5=_KODQ)4]17 C0 WGFHQT(.^L3F<U^L-LF[>&TY@R* ,
M]F-)<?7^7/7#*F+^7V4<=/@M[TGK.@VMK\JLAW=J@C6U+-.7A3-JQ]>NP5S!
M$>=37]&/H"/'HY1J6&;#),?$)*Q6_I[(I<<9^+!]36S08D26C36 #=H]S(WJ
MB&4GC_5-?<C/;GG#=K=98--4=%:L/Y_#UG#BV4K:F10J]9<^QJ$%#:*'-AZ9
M& "''D U#/%2,2?0?72*P;-^)LS6G%2+5K5 [/V:^NFWA)<4=WI%\<.#W,Q$
M#<IJ:.,Q11%JE7,:QEO^&[>3W?D8&=<<QH>E??W22H-MV>#V[.!HRW1J_J%
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M4Q3^JI9VTIIUP44TG^Y5620JX!WBZJ# (1&,V&-Z$JT7Z[![Q5C)1"B4)^Z
MU27!0.%06OPT-\)5*T:F7LMG.7P)U/0&V90S **"2:=B:&)[!797^7 ";/VZ
M:#*&TUSJBEZ^[*_N3=T:(X6'W$!!\P]9K)X H7.I'9-!KAOSWZ%&RL.OI&$&
M1=Z8?A\XI1,!M/@TF_NVFB:'L_2C&CU&X7;'91&#$0SCIFY5AY[LBRN +CJ)
MF?'5;]>.-G:7R6_>K*Y\4 XN(\W!J7%'4W.>)K8$NER_2J;=2OB7\A;$\0^5
M0(03O$3@/'WY286F[(Z7BQ>'(CVJ1O'( /O(6+,-)Q8@V-!.GUK<+5C[BZ -
MFI+JY8'2T<0[T/7$F8%3R7=+($):>)'F"!Z5B@R$-IO^_?-G4\-<G[+_R#VU
M-A6YJ5H?_O,RZPJPG@UL+CH H1][#:K3X*50G-33?;G).7'HG"'+(*:VMOW3
M(DC:9FMKI*Z @H9X58*S*X_H^R?</^.OB4:$> /?MO\/)X:N3%8#8Q>Z#7 >
M-'2\^.$XJ0-Q\8"N"7:/7,\>;!'-LHWAZK/<-SFY+K46S)82G,LZ9 .Q+_AZ
MS09 E>1O3Z!^4<???^TNK!H5K&/:ARIL13.AI5&BKUZ5&\F=3XC;#F*E&1U9
M]&+<1Q<M$TW!N0(X+YH-&#NIZ46?:SHX7OI[R[/9/-,:M_HB-E_#'<4##DC=
M! 9Y^G&J6\@%HY]X=&-G;A$>(]\CVG^FW]#4'CK*>8?DHMTU)2DI$%BH'4WW
M942, ^TM\Q_BQD\)AIU&#U[&^OWZ5^W-NL:Z/>@LU_@/W]/$7YG;8P6M@^[\
MTP;. @_>73N?(H(C;E4IP"LBFXMW1KPX;R";2V62:![J@[D;8$0![U<-J![!
M&-"!H661XWO]YP5)3(W?#I,WQP><Z5.WZ"_N;!C<+HAR@K0<E"#9?:/W'>[R
M"W ](N=( XT@->\C(@1/ZM#J@NN&?-EB_!BU(%:+ZAR?9T*6B55#]?S,!X][
M0GXF84?8TDVS-%E"4PR.U=VA#D+H+UE0-_G8.R+5AB8F^JOI&?D2SH<GV=DI
M;5X51?_!5 A!>)K3 3SQRW,)YWG,3S+HM6I\F HN>VUS)ZMB^ .$;NXN'>]G
ME9(A24/%+EBM-U4P=U*W" 88X_ ('QCAY>0#*?NURZ1 MV2_Q-";O5"NP^0H
M'L]9$L3[RB<KD%>#<_:4?!]_8478/H7A(J':Z&NE54"W;3W[7\O\7WM7:]<9
MF%-5;_@P9YE%9/!@[3WS$5&&SQ".2+&HRT\!-"GP!P'(!X0++'>4%^PQADH#
M90,I+\P H_,.;J[.]X=P[JOD!RFL@2.%ZP_N1MS;I6M;9/$KV$X]\1LP5,,<
ML@_XC%M^=.'B0A/%1@C\"=YV-+D:2<?,0R?0] >#@[/E[\=C4S[K9Q_#FC?O
MK&\+"1'UUX\H"=A$O$?S'VK6."J"09JD'9#NCU962&.BIV^3/X3U32G+]Y%*
MIN5RKZR3*X#\CWDM:TE)R:B;K(:/_KL5,,'S7G=88-TI]W>\Q$>EBU(?%B'P
M;8&T?5_I93J==3=^ \==WQM"[H+Q+JK>TNW'VJHZM_Z\O<M.1\*(V#V@??.A
MR>?XK4R(,]G/]WZ%/NE^H#_!'S'A+07ZK,F6GK5U8[5Y :)Z<U,'HP[FY)()
M$E:D78BBBZ"8EVO>OW*1Q^:%#99;0,/K!,X'-NF%SY[/)YX4..FWS$G)7;0?
MO4&TA+K_35;@:?7MJW0__EH;-2+K] .$WMX4OXOP)'A=6#G ^QYW"V*D%O8&
MK@!-Q%RI82I9S-H[XA.LV!&# S*N6Y8IJFI\CL2:T4]#^?&C9W.->UF,K6@B
MS_/WLJ#/0)S&1$QN4"32S5K-1#V#'9HWE%LW5\SYSUAGLON]!-]*EK+U-]&R
M9-0NX-SK=.P:*_2(S)<=W?85,)U9HCV&.Q;)4#OP $SBP?U%G%ZVO9,SD*=3
MU9%_K&[T2*'TOJF]1$6Q:Z%!T7<AQY:&2^5U[81\UARXA[=0BGD[DG5]BR\I
MVSZF.+':] 6TWB2W_Y605I9>8S:3VOF?J>A@=&Q&]:B>:5Q+](_\1^E]D/%\
M)W!76QA]:PJQ2X)9H8<9C[^ $D. S5*I<E< 3F14K9H0^&'1QM+2TNZT!Z7W
MT[3M#LG=+8T_LF\_[V]4L2)"KN-77S/"<"^"T&<H"0V']BDY*K<7%_:UDR4E
MP\'WBKO:EO^[5_'R>\22>#NVY<W_&C<C78QND,;7Z/[2Q/7>B#TT$$.?YI5!
MX4;=<VXKZJTYV3Z&B^7K&DT'DG"X).,+O:EXDG'+#C=.&[@ QW GJ$L30-B'
MY<4..[TW<1]F/9OA='8-<<_Q]B<JF7-_-)P9PH]UGC_3Y <LO9 -FM@,EW;M
MY=I6"T@:)KB@\&C2+:O7/[^]>(6VL%KTCE&>RW]AE[EK7JF2X<DV7KN!"(/*
M*K_<C(_JJR@HR6M;--&S=%==U=/MJIM_ =<#<9F=@G!K P:*Z]Q#R <[*O 4
M^&LO<FA&?Q$ESXR<U($US R]9%T/"= WX#;V=V_N>44Y'W/(I[$I]VW\SJS\
M/]2%";Q/1)TI?'0-9\0=;W,6 S- @'-[&UR":Z!M)GCV&U4[(;-?Z-T7 W-*
M!\+'&$Z_-0P+GJ2]JS1HC -$PHO=2<P$FN%"'@($ V<E,*-RUY+":5<DYE&7
M<+OIDNZY$]:_O**>TXB-Y((W7A:"";@X]B,'W?B72WOX. S\( [+O9B]?=I_
MF1/.1QI5%R60N:VGDGODL"ET8+KV/D+D557)_,K7:!C47/4=P^I:&KIPF[--
M78G6=5D? 74XZS8&'QHR#$&;]T=[?8K1_MH#:)8&S0>38K-' YN&+XX[_SWS
MP'C/.F8;5^I3_3V7UM4SKN9V4ZWW>FI$G_"UW=%E5)ZE\D@PB)&!)"+4"?D^
M%Q+,3^C%#6Z<[KC!ZD=4!,3X;-,H/G(\*(X7[=HV=P.@BU3?<_F=E$#G!X+.
MM:);<Y,//D-=*5'H=C?DV^7?/FJ3=FE.$%&&"]G'7;W__'C$]1X]ANEKXJ([
M4Y-/)N)^CCTL>HC$_%(3R.&ETSUPZIG1RH%4QZ?\5Z0;<04(9/!2U8@801QI
MG(9=;V(/TL"Y5Q]-G 5)^;(01H\%,N^$A$=4>CC(S+\Y2M\;:+1>T+.UG-G4
M=6II[<IU+&H<CQ02#"+K17J?"U_RM7M]?<X47+@=K$WGL^I2./1"Q#E+F@$;
M_=U[-L][")T5DA:9'")C%NVN;'[J9Q(MZ9[C"K0<;6 1)?S;E,W(=#--2J\6
M<3#)LBA6Q.O]?;Q1L/A[8L-V?6(_ZT(#YHV+&P"Q$55Q@<58">Z^7HXYHGX-
M.,-.%^)>+6[YJ&6S-4KM6V(5-%HX[6U\SY=DUB<"^'5D2P&I0&C *%:A\Z:#
M>TYGT/XL6H+;N.%COYW[M1,\/P[34OU"0;MR5U]3>/A\ZWMRF>49$L\^"*+L
MI5V"J1,>HX]B;#9"@@;$($:H3O7$=3B%ME14-WO)Z],)/_%"X5E_.XTR]>;]
MTZH)?O&T]2[FY5)"^?4Z?@R?"(+? [XQT#"Q]7&[IKEW(3<]V,3YC&3FC1+8
MJUZE+S([ML0TW?P@Y/O6+]+/#J0S47;$!-U,>^F;/QSM[J+T'"E=Q(#;Z& ;
M-!W]P@AL_+)F4[4[NC3OGT7AU\D2;.IIG"^D4*DTB,')^>I9J4GH8L2,Z$,^
MO!/1,]]4=E"J[M,T5%\\+-]F&3+TT#.U +H@U]^%@%!>\<BFE"S,[Q.7.74E
M KT]$E<15>?Q4]O/IW1'I7ILT=VT/:B!^J/U6^FX5PM"2:0A6/!E,M -R#Y8
M#C,@-.':2/12S$3NW-$!!03:B ;U&8H="*P6</],\-FW'6V9?7,DV!&I#\Y#
MJ[IGV-H90#;>LR'YKBDHDG0#1&X#,X][/H.=J:L_:CZP1L?,9C,94Q(CVJ3&
M_8I<AS5 TPL=N)R%>L&Y10SETE\^Y81'R2[)@(0?_!PQ!3>;BR2EY]?^E2@?
M,>-(;LIP"-Z3,IZ)]>7GZ1B8%EN6>(%9EI)I\;VU%YFOQ1][I%5T\+.:=9OF
M6CH$-0^9>>::/Y[P74X/M-!;[LZQ, IB=)N50"9R$\1RB/1=H X\*%E=@4B&
MVQP;1M7Q:TW!=.L)>D]_[K%!HEMO_NT^3D _G-QPYYDMUO@RZGF1$)7Q3_^"
M2B<;R$64@M=R,H$-%/L+9?#<"RW_\7]!%@X_[79M6AP(UO6FA8Q\6_8;,AJ[
M;(;W::GID*@NT]2!X$Z!P%SS29Q4?'--38>)Q:J^@=9W'6QS5)+LW5^7_7[I
MNBP"<&XXSBAU8=O@LI@DJHO;)>%V%'NE<+-ML=?*AYMOLW1:/LQU!;)DD@V]
ML50Y<$8IB,'>%'A33VU4VO>A.XYF,/_Q1Q\J&T)M'.4 2S"V*<G/=V@3G\*7
MN?O=TU->R)2Y6L3P7A#$YFS^.:>UR9!I_O1INH>O@7K C^DM?8S[PD+5\=*!
M>\"?U %D/+PW]P\JQ#PU!B&O?XV"<NQ:V4=&4\[MR6Q;X^-"JXZWR1336/K3
M#7\^8?R=W>F:A_%:Z+I6"E*']9Z21.DZ@L0).]1E,"</[K?I(3.4U*>3+3.)
M]J6XW[Z^_1>$\2(^0)WB"9:UNPY*A(!@7 ;FM ']K&.F>:^.V2QVZ,),ZFY,
M^& 9V*>\933>$PCO@7W[)9<8E?L/>WJ-7Y'A1*W+#TB7Q 5B0/U K\*<U#43
M$I;ZS_5KSRT2+XN"Y0[*4?+MQY[/37\<'CUXC?7]5O9Y'5Z'U$5P=-\?5T]-
M^P9E3R)8QM?4/J3.NFM6*3]@_CGT5N7]D.J84A.+BO06:\/2JLNATOWIG(0:
MO!IA(E'ZP_GW2K+9;Z_+-0WIMP9)!Z:9CFP9F5< :$5>I:&>PEI;%;ROURWH
MH!KC&GC?=EUQX$W$T"^MN+#3@-\RMP0 PZS#9!SS6&#\(S5S3,2T.C^>^L8Z
M]@)NOA_,[?_W1/Y"XPIPAY04OMC[4.@[-]X1%O(AZ<%35,GJ,!<Q8L3D>+N0
MQJ$2'S0(/Y8GE)*&4NGA.Q=6"'R O51(9I4BHK%J.E-R2;>W;<O4P52_>$G1
MQM1T0'76NVSC*.QQ,K<K(BBP.E3@[V1%0:Z[)Y%GJF)>71*F_A,[_2; L09\
M;E_=.$/]35_7AX'OY?!1LV94L #ZG_A=!Z G<+VB\#9.*-)_8H&T9#@MZ8](
M>@0-@0@YY'M8AJ0451/TC>P6Q[PJY)(AY0^SU$L9GJX.R4$,ZB<W+,'^_+@:
MO=D6$!4T$14N/ G<D$ ?>$Z839GX]&)-HHM$)[7MGA<WDGL;F8!^@?;1%^H$
ML=/1N?![I)] CN['P7Z8B7M0IB%]FILK=L_E*#F-[1=&F'K\;G>1(PL5IM=?
M0VS#FKM6MNS>#!^L:2/I9. 4,&/TH<+XEV4-PT+-6,SS49K8KY8^*!^U/1>X
M>;!;TU;&J?$<1*](H-(08O\[U$XYI3)[6RFDY0H09Y.TW]F<9["+D#";5$\9
M4Y@8/_HE^W65$=_V%92PZ/ 1G<PEP3^H$%(4K1963,BQ5>@<0F##V/4[>MOP
M#_/0%QVE7;&KNQ,FT;<N'BFUWO9M1VPMV4[EZ<RU]-!)"X KH*D#(9!.^EXE
MJH*+)QP^K12+:9^,C1S38I2YE]>&X02!)_/(-^"B)?JO12SBX9Q0)X,I,UL\
M*&+?7QG1DG=$O_C:U[V-?B?9B6)*HBX@5*LM<G?Q]SO([3*JAN?U*$(U 5N^
MM -G4^?9R?89O=F'+:(?\Y]^E&Z><V%QO+:5#EP1:!3GLVA[<E&WRP+K;\&G
M(*A]5IT2\&212HDR&%A._&;,N-(25:[HU* WM2IW7*62"X.+*6V6'M1=^]>D
M_Z<C:ITJ$44]5=?,WZ\:6/(#&5<S=PW*:A<WSVQ]$O.2-_*:3()V#U.7BPB"
M00E$E[!UB--3@JP3QZIBXRQO##8WJ/&=ET!T8EZ&?W&T:7RF?%M^4AM-?T14
MT<^ZT-,5?-QU4KL;Q:PUK0V (M88Y>N"!O&V[HI%=/Y=(N@(PVK?3I\9_LA5
MH>GZDT35#NW3^DKQB,%<)>-&^M3D_Q&- V#NZ*]4(HFG0##U*7+FA-V :TO$
M@3S'I*4Y6[_N3_W0.U.^4N]#O2^FG[AWMY;Z>MD3G^.&HJ@+W+9V3IE'*W?I
MK 3__C#NCCW<9IZJSGV^IMOU4NE^$+7.Q)::6 K:+N/1T!R6FK//Q],6%">K
MIF"M_0C#X44#=]VFFK%^Z*AGI6>:+>I74CU7H/+]'EVW0(Y\*C^E0Y*;^8M$
MW\W9A>:L5L\QCQRM@]9S*70IB5(#9\$=">+B3=G6POT((DG<Q%KA@V(B$HYL
M5W^?3NYV.H2/@L4M#K>4(1EA4S5J2WEW$-?F04HMN'XO)'FM?T54!_+W ^0
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MM/(TA1!1!GM&Z @.4IZ)[<*$*:).N9B_S)0TKXA:VU#=Z1^_U6('^<7]4GP
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MOC]WNAB8Y0?%:T@MW,<^B*41OI?FQ7]G[5TO#\P4#^KWBKX" -2>%/^NU"(
M,8H=4W]?OV+S>K?9E4(Z%&K(UMULFCZ4A'@W:GEZF2K?$Q'=_0\X2;1?I[GC
M<Z!..2IB]JV:D/>U^W8$>E5XM+%7D#3RK?&^I!/*.O,1H;:&V;! UU7^D9VF
M$85I%LN?%PA!>" ;\GHE4X=@4O>A(#/5;TI@A3$_#H@'%_]+X:=>M!E&M/8H
M2A#-4<5GX^CE3\NU^4S#Y[1$F<N/2!?@PM& .I"PM"X5!Z0B/2#D7%OH@K.$
M7GZM;#;JCYQU8YV[#WKJ5K]\<>\TS*E"2?1L('^-=<EDON1"?N0FB$T0&=I0
M1<U99_%PM[6(7H&?L"<XOWZ+0#,/$&W@F@")!T_5V3$G5Z "_OW>X;7)ZL#0
MFD7+VJUCM)-O4BWTB" L160@&24C&^%]$Y'J9/-J/NZU2U SH^EP):-:ZS[7
M0LG4_D5G=>Z6/-,4X8KI%I:_.B?E<[P0,3/?6Y-JT6\7B(.$U,\D5.FI%(XZ
M#T<BL5Q[W!D#*C7=QW,9]1J?%\8%:.H7ENTI32HD4V^W2[PY-J3-Y^.1[$<F
M$H$X+8X;42A"#]95<[#;\:-;1Z$B+_I-CZ.86[<RZL-]A,!8M2-1'PL+L\D2
M11,<,H4G4[3-#;.4S)/95L=-DN7"XMA\O,[?%3FS4KTING2K&6CYDI;--#;,
M?[[BX9^MW.FST<J\V(G?RLT,=MX^LI?Z$$X)!6,D>["4523&6A]"4]\B*+[;
MK4+W846VWV)E5''Z,66!3+"55MOSGU&>74/_%#X!'R&N,91$L7,1"%,F_+FX
MY\'-6&3=WD:(P<7UA:Q&X!\.#]R96AO4QQQ0:K9W=<S(K5#9AE=",,$\BJ=3
MMLW)$HETY+>U<1VXFJ$09-\5@/&:)7W6SR9A3VJ7=L[/8MEUN[RSF]P79Y.J
M%O/W1YOYRE&/1M"9SGXQ>T2*SX0,5,@]3;= R.'AX5\JP] ">C,PF-T=D51>
MG U=\084E++<]PY,NJD9GHB^ DPZ/<1[]7%Q?A.=1_?28NU2N;/=OHR[&^;,
M-]E\'/+)G\&$6'\WM\T'N[0<EZ>-&YI4[)ID)$WG.RU%Q\73XIG?'><OB9BM
M/[>PS-R"4="\@[^>?-' \JNB4OCBD#X!*;:5;@$!GX'BU+CQ.:1[?OA0K-!P
MZ@.B'<X2=1$?,#?YRHC1KKRWKFZ7S;Y\@LC?^<PX2Z+RMPKC!UK#35,!\)2R
M0-2_OW7UQ>BU>*^*M>5?OPAYUU&?#K#5C56L&#W+,9]N$?YXZ#]K,"JS,A"1
M6>_7!8[A]<LFW9156RQ/39 '4J\UY.^F[:@D7T8W4C0ZN+OY< 1I]CVVRAX1
M$HKX9H4*YDZ!*3H5CW<.-%K9#=YN;KQL/#[D2 L01#FO?V-\MVS(7OA$B92+
M?9[#BYNGL("%#79S)N(J.3\0 OJ7V;\RM!O&6N=YUX-R-JV(3,&1/Z I\MMJ
MX?2JPY.(W%?+OX^_9S]$BE5L.@VL=Y,GL'HQ^JB[#%IC?T"].-4,U)"QG <1
M-=;F,:SE0I4-!3IMHR[0):?S_]TQIB&MVO3,#R6[G;[&IT150>/T"94!5834
M)_BPEK@%YO[%M;@#A15K:+*.Q6NI];3;E=3EC._?TW#/GKV#6:.1=Z"R@^&\
M>,\N-(*:H(^Z [ZT-.]%LD$*6GIJO1ZO# XD=%A]BA%(^VH!B5\7$=6$WR[Z
MXG(4'_Z M "Z4^_ZLUNK\RA^$PRG)@3I3V?;&UFS95(&W?F$U\$-*A15_GH2
M)% CD!99"H:,:R_!<9:@Q>G3-+P"4JJO(-0>5YB,BP*UX_U7N::[><5#7#NP
M[3!E>,F2!UMJ0K.R_.W99NO:>B]@$].SMO1AXP\>;V6U*("#7*J7; 2S5/6T
M?XKWH.!X=%)4+'0^MO'-4&FRA\DW]RF'<?/-+.&9:O)W!<+ JB$9DW+0;I;H
ML59^!=*X& 7]3! VHF<VK1/V&Q(1V'T1&5U*Q3FOMM->\;?'0*KA-[+YC,B
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M=;X>SY8(X\-%EG8+Q9+MH-Z658EHE\;,A42 DN##I\,WE'BB'9%30]>2C/P
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M%C9T\LM"2\,,V5"0I_6=[*:N#%$)-B73.:-V6O0\NJ'+BYI;.^%<;:WB"T2
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M4^<FTUTZ%4Z[-@DV\G0K][E"%!]R/;N=WO[4/X\J&?Z.9(+;*B "O[BP'9T
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M M+Z)A5@2OI-EU*5X\E=+T]UHJUS<_-SDJL-)_=T"3NWA%X@L%F@/]FD[Q)
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ME1)ZF9<)MDMPJKFA)Z?!0N5_>_-Z,E>-@"6KMZ'1:SUBL?Q$1@%27<HZ7YO
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M+#'9W*UF/]F<J,31Z150/."G$H'4[7-[[^U_7='O/6O.IOMOM5;(;X/3,>0
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M UD\MA&*:/%ER30(]=^2(2!TN.=&RBNGCU_&!\TPZX)#KX;5"AA<%3,#TE\
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M@_>Q])\A)RB;;9>"ES:6[#86L/M?&^OY1U]UB@GSE4;YU;I;]@1536?RWSO
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MNW%3!OB?YUL%$75PM)B#%_9)N.Z)I.=EX\U1WYZ,L&73K53Y1)MOC^W3^Z]
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M6]\P9V2PRJ</GS+"K6W$U#F'TPH:?[/VJ["SV6_1+W*@^6-UL7)K12:/\=0
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MUL%''>>5M?_8L^*'5\1IW&4#O[=R>F\4+3:9)$SK-UFRG)%X/S)(@BRY1T)
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M:BESRB29VOX#%Z,BMVCVA;C-=5'R$T#SQ(<>?;+P:T_5DI&?5?)C+],2075
M<$7/HA5%6W.T/R2T':'3).1,.E-_A.WF>QUZ3+@K#9?J7*C99CS\U2ZDTIQZ
M*MJ]'F_PEF^C9U7127;MJ%*WHWNH9:&RW!WVN]8/3K>!L]E8R=G<2(*I[&V
M$.X<=Z&RTRJDFQ<N9=?Z0:28]JE!YQ_R2;U+LIL0F!8O3-V_D\W @]K;T3(Q
MCKB\=7U$@D0Q AMP>4%+G"BXTUKM=-.K@*Z'/JA\-SLJ#]:E'4.]]5T\^U0Y
M3^X/6G.XH*;#SH0-\5D/N?.<E>;M@1.1@N%_5\)Y9Y=U5LL/JR\/?CM&V282
M&RM5V&5Q?&)N?1GY6LGP#PX?J9EM9:B^T"DE$OOB<4%$"I_+).(-H'D0)@6X
M7NC!EKHHFS<OG57]#9)F,1P1SQN[.V(=Y5I[6N/[\2,BM"+1D_<?<P8RW:]^
MO3!Y[&, KW66?O:M3] DB=G9>YMIO",RZJ.K(5.(8QF?1<;=04/JPJG]XGL*
M5:]]53.%Z1E6 Q1BQDH9!1:K<N)F)'T-U,Q;]$X=:+K5K8@"A*<XQD3N.1@K
MQ C5%:S4%DU2.Q(3O&>C-D59$%!1]?M7=JI6DTCXP);4BJ RP\[H9MLJ7- )
M%U" 0BRIHZW">TAPQ>CV<"+[GGH+?&BEEHW(3S">QK2G#4D"&@._7_GLG^2D
M!/XI2=MP&)')$2UT7I@.:WH JO^],@+_WP36*)A$TUQM"R()S@YEKO8&UT?+
MJKHXX+9[T:B%5OGO_ER]28LF75G(I+25R2 Z>7F)JB*=4_PA%1,D>1S.AMA<
M,_H1=)K0LE .E-9!7194 FI7)W@VZ'Q['A<N0[Y-?C6IE+"72Q'+;$LR"V[@
M2V>P6HDT*)"#V",E^K5:)!3V_2@5XKPRN12>.?*3@_\N2IGO:45Z>;7*E/)4
MSIN%;V=U5_=YE6KRRYH6Y;3^+.=5M#U7%!147?^S"\^.F4'CZY-[;OT7)JD;
M4 ,I'NQ2R+?\]Y+:Z[MR<R.OC6NL:^)<.!N/3^HCV?,/%R:P]0(.HO!D%91O
M5A8@LA*X<?0K +<A#AY)7<.%<"(?E[D"M>U0NM#6=HEL*OVKD!S@63S)01\!
M,HNG=W'?>M%PZB6H_V6-:P^NK++<J^U> )8*-$8R.9PBF*?_85/6=R:7L#)8
MQW+F(]$Z!\03*1PO(WJ,,!3>CEW V(7QRF3=KE7VT% )NSC.>8AU.6.L)\N%
M@X0UZG4H?QU3ZAU)^\"X-#\34_^:5/_JM;K:C<7Y#;FTWOG#PZ-JW\.UH]?G
M[:\O"G8LL":LMJN2#\Y(%@1U.E\(32@^UY_L%N6FN:/KDWO^LJ!6[2;Q![R%
M"HF(=01WS<*X'%9LQ-K1W:JAAN'C J87VJW=K:WZPCD=_VG(]L@5/[=Q.&;Z
M9XCN@/LJ%1# TE>@VX1Y?U.B4>)&:TW@<)1J)=;_1E.3RRU%'$.H^/T:I@=:
M >LE_QN)-D,%\/\?9>\9U%0;_8N&WD1ZKTKOHO06RPL(B#3I302D2>\2$HJ
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MR/HKS_RZ4#F%Y@T;(XJZ1&%&@[OM&\U)@#, D 4,%^AD0%E>RV%+!XMX\,5
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MGY%LT_/FYI(5*1198WTHZV*1*.R6(?\RXW2ZX%9T2I378264[$+L#YEC]@T
M;5V\]N/R*A'_CB!W1.!?( B&E8YO4R] =Y30'+%@@1.;M!SE1)R]BXE"K6;
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MTS$AA%OG8]61(R>!+VQZB!W,CR%?%9^I6FLHKH*7_RI8CWB3FN7"HC_+K^(
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MP< > WV'DT'S8[*M%X26M%?:J\+,'%?:# R5YMTPDI'YZI7>^L/KU$X6_RI
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MHMBX2/0&\!2-[M4CN?,40(B"(EJ!+3< E.;U2\(0A)5  9Z$L*4/0U*V!5=
M/'4>?[^<< QP:=V9!ZDBI?@";= ).)&W)H0Y].Z/JQ"9/8=16@<C6H]0VS?G
M;L%_6J^(#1>C<_0W[Y3D6@T\"T2;0^AQ6OBF 0D<Y_(O.,M1*$&QZ 8PP80E
M-;0Y#$Y/4'!DMY_VJ/'4*U]#=4*S]O=B+ASEOJ6N<"81SJ8!W1X OQ+Y6S]J
MNZWU[)Q:&O39 9,I0KX?'[VDMC5@<O\V;(JH&.DVUZ/=R/E7ATUCUDJ]ADR,
M(OZ%,:5LZDZ_T+ -^&.%.[O26XO$S\<A^?R%I<=7S3;'?WW2G;A'*JT\KIIW
M9#ZWOJ=^E:IED9)Z P@R3_4:97?@7Y0-]GY]:;08=*(RNMJ35A[I5>'1P2@/
M,(J 1"JPY\Z+AFIDZ[^GI#QM8FOW"ZG I&<',C\'\%C)"P9L/-IJ(WV^29*/
MBR%F8IPP 6^#H^:OQ<5.?U\K8<\'P21]JWW^7SSYU9=QD1%(*3IZ@V$UX^Z<
MH&MK#77A4#,^TQ](3A]D86IW#'-=REF<YK-TFESGR[I:BL*#B\G[( >G=R,'
M'S?O;^KX:E226+0))4V,2 W/%@G=R^7/4RA]5ZJR5"LA7/9!#.3/7,NMZ/J8
M?Z'E7:%DZ/YA?J>T7=UI4<W5P-\W1*SL/,2QC5SY$ \R9!TDWXWMZ[D!)'U"
MCN9Q%/&G[Z#J!UHRPBR-\E=633&I,Y=V]2E_-3@X_'0YVXOT#JGN)0)FP(EA
M/$C*3QB&82(_=\9]_^' C0%'5X1E:R^Q<T17+BHFJYR?%MF&O\^ENE9 ?V1-
M^/,[ZN$8),\258MNO$+A\Q0@9.!9@;;C19#Y3O&[;;'_9AB_^SO>7H9=WQUF
M7P]N_Y72,UN,L+>TL#WYJ$#7D3MKU&H8'L[H2N_JQJ).BT_ )_=1$8TR#<X1
M7PIQ@PEX@-57<$!BFG5'MZFX1P>4"W$B.SQ&"0)N\5YXV8EAY17V]89>7]GW
MKUI:NW0>=THQ6:W>:L=KCA-(_>(-=XSH_"L,1K&32'F5AOO5G_S9O:EW[O->
MTL1,[!S[@>U'_KS 0!Q'#KG*^)YIR1N<*/C-UDDNI7AHZ^%\+(O=.(N$1O>[
M"O@4XROUE*E?F%8G1'KJ2?KY2!P5E*W,[P?T0K:9[?2$2"LD[H9,J1WF&$[]
M(4<?BP]-CNL\*(@.?Z[CA3Z_\B268X4 @[19XMC(KO*(6\%8SP@K'P+=]XYB
M1+H W42V/C8;0S4B_163,,QMI_58.!1,NN2B%O)/V;9AA5> 4)_Q2/%&6<ZW
M1(&I,-GKP(MJ*I]'QP4Q6MU'4G^X30K59F_75M45-M;TI*4*U^V&!OV%E]?_
MIN@1_]()^)(D_C]1)@8H< ,4W*Y<S\V?V <^^76\_N&3B;?H5F'65J]2UJ6W
M<-\Z:69W!ALGE9_8/M>X5JQF_X,"?Y/IM_/LY %=NQZJ,(<H3,HE:KODM0FW
M7G<+U73<GFL+:2SAB#QDUD^E<;88*YZ 8XU P' LK3MY\0-W0?9-&(=^N52-
MIT4<Z/0X#0Y7^O':^A\F&[ JAW]]?+G>U.\L!ET;U":O= FF2]>0^MNKBAH5
M84+"L_WR:/=488P8BV#QQ<$]+KGFZGS+6O'N"#7_VJ_Z91LINYS5V@/6O>.2
MAS+Z\!?E::-(EQQN^B[5;?D4\X:-))_USM#0BKSO>%Z.%HX7+[B$$R8%S_@_
MDHEQ4LV1?&63W-*+%WD11:)Q\:"7C*SAX6RD*H(W?0SV'HZV:_SNO.,":8TD
MM@W.#(D]A7@4WW8GR*#'EOC9^W+APUH\*[YW%Z1_-7),V3//3I[<_R11]'U3
M)8VK8?F9_.II:ATAN.^!D%#9RK%:CPIHXBZ-DWC ?7XE'KK & ;A@A"W/IFQ
M32$#T=HQ.YE17F4#]5R?)O/ FGN5M+"$2YN/_,[<@0D*8I+AJ=QM4MH!/>;5
ML_?U9 *'G-%=Q\X6W/UJ4[&I'UQGOL[0E9<7G:!$?RTVSY%E,%117997Z 0D
M$XY.5N?<&C4"9[3ZRLX:X;AU_.WE"*GS&\ M5A-M^3A6DX<4_T\(1!%9QOX\
MND@*VXYH7#,:9R]N;2]&F:'AB+R)K2?C4,X!"BQT5RP!3 \2P[C%_$H'A,6.
M6+RM'"T,'<V/SW$* &DB;;?X+X?9%^T- ,O;ODHK$'E&7\B0(($CS'=P'O=Z
MZ2<#5N20:!T1A1)UAHB3<-O!&P '2 9CK26AVW)P1=Z7-_PWYY2;Y<C++S^N
MNMLJ#M5_\?3SAYC-"1Q',2*^$7,R"&S5B:Y8QPEBB[T^XVPPY3._3S,QK<AN
M[*,=AO60$TNL.9*/X7';(N[IZKIW^>]D JO7^L#'W1FZD?7RU>_!-*^R'M8'
MDHLO0Q&IP)90E/;_HNFZH]G^WG]:;2E%[3U:5&UJ:TB77=2NF8]:M6L'D;3V
M5A2ME=HUHP0U8VO-VL1,%+4J:8V4B%_Z/>?W;T[.^]Q[G_%ZO>YY[O/@@Y\3
M%PFIQQE$AV+8V*P :Z< E)X8C@6_*> AIOH2F+_;0H7QA(FCU(2<LD(F#PHV
M]E>)O)-R=OX-=W4[[M]X-V1=7WZG$&S1L6UC/XJ>JNGZ&TFF327XX 0&D/'[
MV&E*=%,R7K<V4&8=M& SH!9]T U?G#I^04CM2:4:=W:K7.QVJW*'\4RW^U=;
MNP47\!-HOWK*' HPV^CR+2X""V5U?-KA:XGV3!D]%X#+,)$52O9HV-JWQ$?B
ME!/)PJ.XU3@-"O22]+$@;J@-\0* &WVLURQ!$"3&=C=G=_+D:C4UOW9K"@JU
MO0#\UYBP4)0@+/*&A*8LJXX4)H"BWH_'YZY= /IEYBW)M!P$Y+'U>1[);7U8
M(,F>BFA5X@'C(0936&)H5G0YZ WY-L:]0(# GQ&\#KH.<?\5$KT2*;*<=^O]
MDKC.BUN=!,I7V7ZV%N2O,6+2YYX03<]T8>/@2^7$K1OP2^1+Y,G0IF8DI!Q[
M$,40^U_K*DGHM*D%_FF'G0(M&O7-H2D9)8F+GP[#=-,Y:T5<7%WUB:]V?R'1
M-F_FR/,@O!&:%?KD''FTFK1ZG23U@YB-.]F3.S.'4A/&!^@?V[8E2"D/\@/Q
MC;$Q9.:7$S:ZOH*3GH;%4J.+M:E7]#V"K-U* B6I-ZX@\(9(3+$QGKV!H.<S
MSZC)SZGV*QD;?!Z/&( Q>82;VDY< )PE4M]P7 !X]AU3, *T-DO+T"?99.;G
M6Q 0:M70L>9OK,F3+/3G*GW7MN;;_I\3AS>C(<O98W>>L3@L7LG"6:3<,X5T
MO7T]?UES,D*Z_\-QEN;?=QM%#WGU>9.JA>%+MQ)'9+YD_^%DOXRB^FMWCH"O
MY5P &N&]C)BJ8T\P-^G.]W8;T5X$-WD,S0;5/W.V@W2N;)E- 'GPB..P:1@G
M<7A-N.XK1Y]:L;O][>DU&X^7_.JTAVZ.YFU)2Y)>8 2<'0@G[%/"; ^]L+Z6
MVF^4DK/53]'7-PA!S00.BJUC NVDYYY.=3*[(9C:J6OMC-:2>36Y1\/Y4[(D
M6'9,=44Q[6M?]3XB?T7@OE>7A^D,W0YR8Z?O7EY^) C8NP>0?83,O9=E\8HS
MARP(=Y.ZTR-#O+]U[#@G=61T?7E'>87GNY?/X;F 51N:P%8T#P7.81LT;DT*
M-\<LZOG2Z?]0K)[*C7O\#31^D_72^=##B,G/ AU+G\A?J/RVR*>"KV2O+;UR
M'S5%O?W6DO!1^+*>\OOK-R;2>0%?-)[??W#5\+&?^ : [<KQ]BM6#1HMAH])
MK[LS,S^G#>UWC6F+"DX?/J->1^Z+7 "N?".N$\K7J9-@8D2*8U>=!4&OX$\2
M:K$%O5CMGF57+,G^$CXVXXHLT)J7>S5&QJ<HP>6Q4&Y5B[F]UF**/.DWU(+X
M&!0!7ZL T:%=\HW(M-L4Y2DT3?(O)X;"HZT1 VZ_.GF6=NQI",U]#7P7@&@H
M4ZE=,I.@&CC>ZXW=H[7GNL=6CUS,G];_FSW-6T@LENGU85'NUL+G0$T2G[;X
M4#A-3U#V).21EV[F@Z8Y#@.0%WO#M<56P!A"SG@0-!X;#W<P(M[=2H*[@VA@
M\SD'K_^-GI8G6>$M8YTF'#I^:XC0TUE/USK>?(BK,9D&O5^Y@Z^^6J,0=B"6
M[ZCQXFO*)>3'KZ_FQ1OZS48\/DV=E@DQQL8V95)S628%V(\]"V0M#0XYTRDO
M*5I[9SF-'Q 0RX1ZB\KG:U@YOQ]IS0NO*E3!?9:[ +CFY2MSZ<VU\VFK5'E<
M'_@.-H$J4Z+< /:]DXTP& VTJX!W.X+6BF#*D^WW<7P@<"=>.^YH-:8"N\IJ
M-6_WY/=/#<&4\1[?5?VR'3H63?_CL#CAEQOAU0S^9^$^+P7]!8-4EU\_&.,9
M_O;VM]T??OT??@>#>G_7CU\8I:YC-Y+0J$F2D@"[:#K>O0:?YR':_7D[:$X\
M1U)I'*E\_*;%QHUG])[@'X;GGR423G5#':=2AU]K?Q[\@Z0M%=7R*QTKYS9Y
M539;89+R;GW4:6NHMJ4T1#]W):/>=<0P2?;W:8?J(]]>\L80^X9?K++\5%"N
MI5?+_15#W(0FVY4T78[WI<'UI.[Z#JW[_O.'*H-L=OM<39D%3\2[-GS3[SWD
MO0#40PY/DW)1<,38N_3T!FN/IE2[(PMXO'Q"GIESI=$']QE$6!EBG6@'>@MW
MDUFP[%WE)/.XD]GP@_$RG70>F)0*KTHC AVV/*:=R6-=R;F-P[+N'&T](2,U
M[_Y4;T7_ML)DQ0NPKQ1X7+OW D 45MXC(IH9^VC:*1:X2M710:QP]0A&CA9!
M_)_@:8C[);NMU7HY9"1.72M,%R7U"+.C6I:XU\2M(&\=*R7L&^V'GF5 <G<D
M5?:MB[T&>/7QL]R@$1D?3K\GGT< )R*H06LI<'H8,VP5)G[^Y? @OD!Z1AKZ
MN!K2W!\:_+KQKA0P7[Z?7SGA9:._]&<6J:-?::[T?=OEV_[PXIX!Y4=<K(AJ
M[-*O,M.8$3-_J-;U=N#2W4_&?5H^6=^&GN<\C^^^+]SB5/BR Z&LO/0JFTE;
MM+!@HJJ/DT3O:6^U)_N%T[CWQ:>Y_*T+@(P<!*IIS9+KYO^LRM!+4YTYDYBZ
MX$JF^4!ASK[G*"FXQR5"=I_ S2.O.W9!9P931P>T/[D-T3)Q4&T?!>5FBJ!%
M5>G;V.G>2@GI;[<(PLL&T=^Z[PMNK[AD7\_\^+(LZRO6NS?N_Z#*HS#>3XM6
M?2DI= !.MOB% H7 KW>D^NHS_AR]4(_1]#B%Y^$]MGQ5,Z&39@0V@KF<H<+?
M6R:E:@&86-2[OR\JC(LYV)1%@]F/FN6M!>221QN ,PX@%(&1"7B-:ZUN\MW=
M_L$;G]E\F1*/S2K^**O59V2"W4SMP2^QG"(WDC>$.D/%O,/C2..B.[YFY!FE
M[WUWZ "^?[RNO,E(?1"RG]:M6L51:H%Q]7LD[#VF+7P[><0W[:WL]:TWMFN=
M*\<5WFFZ5WY+^ME2WU'Y?!WQMK+DP^TK3X:>PAQZF;KYM419N!4_><3EFI@@
M]=ZI%O("+P#!^SM#*WL.QB*_VI AC5Z&*I_4-S/0/1B#?BGK-NN5%<OZT(X@
MZQT+$Z7"JTUO_4_NO5JN,Z1>6>]X&.+F!7?U=0V_8FF1'?0'LXRQ?5+?[>\%
M]&Q8'&6-]*P;YTU)UUKW*+[J?4_<(>)R%I5J]]H&#<^#'9H?> 9&I*W.,78?
MHT3EL?'*[^&--L,0OO-NX*<! X]H\T\]9KOFD'BMZDH3I+39KG'EL@Y47$Q<
MMU*W!&7<L>B90$@5=Z?+D=)3VIRY4U#1U)R2];>#<6.13!M&2?":%&KUTB?I
M D!+OD,>T6 ^1P#9L&@:ZX=>.,98Z_$(A0L _8/LIE92ZZ(')B!'HX#@KMR*
MFOSF\RF\72<58'[I0QW4]3CF/ /M 5Y(Q1H-HA/)].>Q($<D'S$61]TG0[/;
M1(]%QEIK]\LPDY0G)4GJCD7NEAC0ZT8C1BL;][?NIO.-(UEX'6%4^HZN<,(#
MML$CM&+1WZ=\QY*O:GNZ[O5O1,9<ZE7[U//YF^#KA]U<M7YBS#M6-2L.8O%O
MARZM[]^('#IC6?R6QE/Q1\2-O,M\.675)A9G0:%W%;C?U1H.T4,E*[=>B/E$
M9C44FI1(R;A:5)8K+>^T/%+*2%Z7J>XA1$;?:*9/^8K_T$DMD_S9I-_!7/O&
MY2K:^EXU_+,*PWQ;.S6VOX4R[EMZ['E%I8;@7#3>@#&ZR8_"*ZYK*)">G6=K
MW"1=/R]1W+]VS,BBOV840^;&*\<Y3B /5E;N5WU26%0Y"'@?&':)=R['(=LI
M;$1/Z;7$4?(U]5 &N4'O@B^GOCD;ZZ@8SG<BW^Y5>NF6IBB_JY*;O^,?J?;$
M\,<C\\< "!=UA?WE%*(H_NOX'ZX+P)'EN$657JT0BYJ"&+;"O,^\;Z)03UQA
MVV%WN"!9Q4I,Y:&8IFJ+;FG0D88/AWV6$%M"S:,HV6F"2B7QJ\/V'S^3TOAW
M(GI,FR=Y#K3N3#Y[_6";E*($<897_Z]I+P"@;#TR!+36)-#,L6^.!PVN7KT
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M/ACT360BF50J(N S.^'.K..]#NGYYB;\LDO9/(NF7)M^#/^D3??I:[-3[@N
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M^8CC[X\WAM;>]NV)5^I^)8435_]5SA&070<IB$;17C@;;#PG.O9-YV7RD)(
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MW"WE-(ZZ7>Q44XII\-X:W6S)DE?H-ZQ5JU$[$ALS6Q</>#E15GS=,.=',FW
M^M=I%L.Y=[8V7O.L7N;@!]0_Y/0UV7I"NO^UVWYN22>T//()>Z6*5]"I0HHU
M7I*PKV+!P;YG7GJ#6_9+K_,[;X%I/S6X_0=>U^\Y@^WGN\,L]!< ,?.F9[4U
M+3@?E(Z9Y$2KP[N[KWANI6@+4OW5IFBP2'BW!5F!/+[:Z-,/CR0+4'Y"P+K
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M\$%$M0@,R3[5[4K;#J)Q[8L!,XT\3"B1F3P._/4B@[9WKV=(Z_]Z_4:HP);
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M+UHEM1S)[B/#%["ZXSAK'/M LFYP1*M0@/4RO:B6)W7ENX[?F/5+3XUP"O'
M)'$H;'IV+X1N)ZG#O]9W<2JY@+\K:B]D@'??.^:8JN7IQKB_<B,UO9>O_O%H
M_.-5(9"*Y+LDT/_9WD;1'/\U#=SR--V(&;3-U*/O?_0W8_'J9L8M+\]A?3&$
M"F*.,E;3=5ZB.X FZ '#Z!Q4?\D%6,3FXKX&BOKT(,Q9+JT.PY*JNGY%2V^3
MWQ4Y^-+W\8?U7V=ARRI#R1635:NKDS<,Y.8L!^[>;4+,6.J"DY"-+$0.X]]&
MLPAAHA6IO8</+K1 5H7? I:\<-X&6-0+"11.(0[!,XQ>I_=!4$^?U,FXH A:
MG>_VN-P$6W"T#0(9VN_GZI?N6FG=FJD\H(0>C1 I"1)DGM:.:F$YH [%+1"&
M(]K(X)A!+7%<_, :+Q855X']WO#M8;@IW>W&3A,YL/WU++'EG!36-;-0<#YO
M J2-PT6/+E=LU<F>@4]$.6VXZNH5KN7GVQ%#<P*-U)S&>,PJ3\Z22R#R):W'
M)];.0]N+W:U#?WEB,MX=N=]4IB+^1 XHKF/-&@7JP*DH_QTJ>3L5Z'(6IE_M
MM1B[K)(!S^*4UM3$F'0?Z+<JJSZ#Z#;+!61O'9AN^," ,CX(J\Y-XJ-YE.<X
MM \!3MZH[!\'XV.!3P$X\[XUI98H&YQ.^2:$W;26T=7;=.ZEJTX)$[NF,_4%
MK6 B16?HGH-:V@_RL)5XSP4XU1NXY2Q"= =3Z'8U'DWZ$]?-B9'S[R?+X!:>
MEX_5^)Z#F Y.#^1'-TUFX.&8C_>S82S_S<OO'VI!ZVY=SGB7W+5K]9U,6:4Q
MX<A> [@:P8OBH&H$Z^JJLQ-L<<,@N275VG!:0>LJIB2^1RX9G9<JYQ8@I, #
M4QCJ#,S "/(/KO'/UREH03"OZF4]4K[7%>*:[T0P98+@9I"-Q4E PDX=EW[P
MQ)RR_IGOX/[S/@?)Y#!1UM=#"2)'_3S3V"9XF914]C$)LIR,>94;<O5E+6O3
M7DVBFVXLM9=+?=]E-'1Z^F-"]+9,FMF& 776HB!(-IK3X<3:X6SK]%-/06B4
M,FYYV1=G'H6,B-!P<G3\YK0RKKTU3\QL<A^5\8H4]Q(;4KW[*&$ A!2'M"*)
M? ?82@I+ *(#"(+P, "] >%UA!M@U\IQ$K9 (^$_HA...:T96\^[J2.#/7SN
M'U!GSE6$4;]W34;FK^@*S6CO%C1G<<^ DBL\(1M%$7E!?+!^_&>3B*\?G$N6
M2S UW8JY(1*ORQ8;E>V9+#Z+IJE9#B3Q/ZJ?Q"=3+#SD2A0!=JMZL<U]:_1
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MD++7S;&8M7IRP$8)0RAJHRA!#<R#^*8K*9=!L"2:BP6,;/+A;]W<!&V*%NZ
M_Z6/Z_S-'8Z]H)SE0E7HX?.7P9E*)[S52K]RGXGI#K8'I*DIF@5LY=J\SA7+
M%[LO^HPZ,I'-5T2!]1Y3 CW=<3S!BA(DZ\WGH$0R#6Q'C_2R1Q&.Q+(<,#S*
MMT&Q$%UQ!O@$H+<>!C:.6[=^X<]<XVNQ9P\."- ?GDR;^#F &]:0-"SP?X@O
MH47V?EC_\*GR>;>X]V9) J3U0=UF0K?:.R?8L,T4Q/<H657#K %C&%;@<[I7
M1SL1 /M4D?7>K\2OP]D_=9SI[ONWMC8L%9! ,""-J,*:8.13L>OXJ%DR!S!Q
MU(]@[ %&-I/3A8##R7XG\R$%1IC)X'+Z<W@H%HR'+[SM/ XO618UZTY5@76K
MAXN)+.Z_]+6W+,>_#1(H*5]O]C[@I'16#<ALF*>C&!5.&;HY<-3&[5UM[8LM
MA.]T V<RSE\?$F^AUSE]SK(MW'P1$MB%!LZAUS6.W>X.]?<RZ*75+.@VU8BW
M_U*0^1<UV0"\?++QF/2^1_+W"<5P.Z?OS8G\#)2_;=W-H\ !_+9DQN8Y*.X-
M4.'L [FN&=[&>_/SK5RA%XLG#^71$PR/=L1$147;L4\YGVIELCT)A$N.!4/Y
M$4OGH#;(4Y3'T7.=FT!>S1UP,M$>#:;_57QSIH=G]TEY>7O2:0.+3YXJWDT4
MY[1K;2KT5N*Y%J?@TJ)6!(;^:FY_OQ!ORUSX@9MS@$9?5,)G2%')$HK,' *8
MH\]![(@I-4C+XK!YRIH.]G$S3O4<9$\J? /X$G3A[E,JYO1P*?]$J-D4/#14
MM5V ;SAI\&W*9)7PQS1%@=DQT6NJT7 *WJT#$M8@@Q2D_RHK"[&(DD@W?H_P
MH6DRYG[$1#;44XA?T;]GLKV$NT#[,*JY?<B98@06@C%<PKJA/:GGDO\,K&L#
M/+1^87WX81N2'4$'3#'(M?*[2FN;C1G@=.*5<;_6!.?E[1;M6F.B?Y4T^"M[
M2/]?;+U[/--]'/>_4DEBR:F<5A&5PTH.Y;!5DN224CG&DAR75A>RLK8B9UIR
MQ84K2P@YC!CEL&%8)9&SB=EV=7 8WV\QW\L.[O6X[_OQ^]V/^_[CLW_FL7T?
MW\_[_7H]7_/Y?CY><0_C+JL\.5S@UD_^\TC?3ICT%HFG*3/>X-^@GR1X*-\H
M0P[;'7V2I/<LXO&CWPN>_B2Q<)#E''=3N:QV[S(D!5(;<1A Z7"#0RSW)DDI
M <WO8QOQ-<IY?5IXW<)'ID8N@.6\SY>:T!AA3.$4=A2?[0=*@5=_8U99(#J#
M8#3=*W<1]$PC'"_!XYA:>^-GF[XGTRK>14VJGAS@>MRAV6,N-H7.+TUL5G=Q
MO1-CX0&D6[S>\\_H=&,Z8_KUJA%SD9U]S[A;Z+^N49(ED!J&H]?18I]I7\KQ
MA"33B.T3;'R,/\ 1J/*H<F$GY@2(U]1.1=SV<:]0J=G@U687E[_78+3J89-'
MJ[!_\Z5*1)EBW#YJ9A<@"MCV[QLC83%4<%;;])/@CE>MT9,3__R;F84I0]?$
MB%4;I\EB55:;U!*Z QBY0T7E/_1LP;O0J,<;J!R$^T#D2O;LXQ\C6ELFPMC4
M9+/JA?EY@\;!HF8-P*;RS]Y=5S_YD:>$K[OLJ^H!-]V/JL>WUGQA[NE5ZG0_
M1=4!_WA86?LAX9JSVM/H*VV/CY?_6+\O/KD?97U?+OW)X?1_#NTT*G#;]?A4
M[%#]_[TL8F.(WX3=@G+7$_.75B>^JC/C$ *YRLRR=D?,W];Z.]Y_?G$?!0-9
M\PD\W1CA"J0BPOS0*GT8)=.B0Y 3B.9RTEH.LJ,[48:@?P7_3E3?_+-P4X^I
M0[B;38ZT^%U:E4_.O#K3?? X]8$416I_2ZE!"O:"S2Q&O7RGC*O9ZE)]\3&0
M^)8?.^ER EKF5^T99;*[6RYBX/)A0/AZN'*7S3[?AS4_ S-O%_H].(^^-VN4
MMV_,^(V'<;/\Z_@,5O\U/JI^G7A2%L+::]& V[YUO\]0ZLI,O_6?X^]'4E."
MF"R:6K%QM9S!_.V,::6/+B%'+7^.=I(ARS[NRQ+1'^+-H_1MXIM0^W/I>[;9
M YXOFBW?5K!?\IQ^""-V )V2<PU0.G3@QMO RO]N*X8=S8RV+)C=B"*$9W[9
M4YNT6@FN9-AI3E=MQZGBY[I\$/$$9&E/H'(A#ZDZ:\4^]>#:ZE-):\*3R5GK
MGPX!.-/A+T![B,&O[@V?& ?7)1 U(&.IHC46+G!&Q*.,9U ;@378O(2_F.I_
M$%+E*BQAMNMB^)@V1"H#WA(0S77,$A8"T16NM[C())).X!#A$&\Q0<_D9_XI
M&XVW14HG5N5!Y33=-GF$O%A;[K<T9GLGR_2/>");H5E6F'GMZB5/!PX&CCH\
M2W[_,??3@MO?>E6D3B0%.$M=U2%A!]=@,8Z@C#9SGDJV_?AE5V'XGQWK6)QK
MF[%!NG7"Z;9-VAXI+[)']J/Q>W(^7M$X^>FOQH,=[Y[4IG_PTM]V0F.=LS9X
MGT7ZH*RX;6SF&.*3R6^T0,K08EP!926A%IG=+"8.D=3:#&Y6?FCZ$69U>-.E
MC5Y/-MF,OJ/+_C3>3[K#5715;#)*T 8G^&:Y(ITPAO*R")?&4:)1V8I\]=%N
M^'9(ZN+[PPY=B4=WSE2T/J5G192Y!9A^9; #1#K951NR1UW_U(//LGB(3HH<
M),?LX[EI014G@<2,C<O9_ZPFI= 4([9W8R7N_XZ'Y9WQ"\?A0B0EE?[/ZP=,
MOV;ZS,Z_8+[); ;XTYYBC;,3G9CZ;YG '$_Z;-IMB]@($O%T73I(&ZGBP]0&
M!@B?]NS"*&.MB4KY7#=!"C<-46_]P!*38M/:%(Z!VYWCVJ'OW+H5\=R%8&G\
MM_YSY>/HZ3$J9!0QN(/3Q:&M)O_TE)KG\)YO+@S$3#'-6OQNA!Q]XGGIXH?'
MQTQH_]O9UF"%K-\;+G2^@(K68#T?I$D6N<<CTLGT(T]W$L.T%+X431W7WRJ8
MV)U1Y+E77)VTQ1';$[UAB[\3;-/)(QL??;]2]*!@W=&K1\XI'&E_#O^^G2]5
M^KVN*,KKU=DII(0Z&3._CT+3['([N.AQ_H#:Z%\/PD\WYQS=M'GOAC^-OTZ0
M($OJ]#)'<.L6[RC=6GSCC23]&G1<*8',')84HI#P-!>0+#JU1[H/I^)2?4>N
MXTE8FKG57XN,3Z'IH6^"J;-./$H768YP ,CH2Q4'57O-Y-U\9B$Q4TR;\-5>
M@ZE"V<*IKV+;Z47%_!E!U3)2$RHZ]\""HA0:=K!YQ')_8&V]LU%T!N/W=D@,
MR'@)K4$*E4V#/C11@E=D-B$$>HU:E/F>:O&1D6K"I<AI\G8OJ_*0:FFO+*U.
MOJ[,P2@1[8M"?1XU%GO-WF3_6%TNUFRZG1MC__5A[7VXD8R]_7_[X[%T6:!J
ME9,_(F.]_8%'=2.KH^?ZKZRF_\D %;^+52ND20CVBLRMTWCD-1C2>-7,[\3X
MX],[@?'-+ZWA^HE!AU@[UTT=NQB7J@@_\]>7SB(3[S_-Y?9ON&]^=G/?!]0*
M NG0/RWW'[-)5M\!O[_/8UOK#)@CP%=</SE@_/N7#S73AYF[]:X9_COW_)CA
M^9H_6"H+&Q-M""M<F64."N^AZY,Z,[!=Z!U2M#^QIW%J,_ H'ZAKUXH1J(*W
M1WEZ*>"6]J"T;G9C2G1Y=-\!T=FA<?T(FZX=)34>!\IV8E=]H*\@JXVT08K
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M$/4 +!)^DN1(-Q".0Y% $N][-T(1C^ AN_+?5+7(<WMOC/H^L]2,<'?=PX[
M7!JL;^Z%=UAILENV_UCUJ.#K7C@VL&P?C)[OT>Y)Z[]"_1XC+)1D1O7)V'TG
M\3"^3G@V1Y@D>8XR@4J%3T912M+/GGH&P)!-2)NBQ/C<\-(:3/T+'M&E9P8V
M-'/OF(GE 9>3B:[&;7J'(8=B*([?(=U?_[I1Y!M\XABJ7E(J=N)3H7V+\SU5
MA&N2K.L3G3XKS!YD"D8>'8: C/H$VL^_X&_.^1LF#G"DV]V2Z*C^19ZK4P=)
MC[CSL@L\#:6*SW=KOJ?I=;J2NG3O1*SQF^JY&>2XD52A!U!MERI(<HG[\+^8
MQ,,C4G.\49M4;ZC%DX=#&*#T0,UT\27U/'\\UAUB%<_$L3G=/M^9^Y[?TVS+
M*="_YW"N7_P&%_BK]$VB@%@N><RXV@<CLJ:TP(5\KI)#=X$)"._L4Y^ ."PI
M&LKBQ5)W0&NPKJ;6ET\U<DM\L5*#-T^O#5GT*89]UM4_UA#U:_?@L#OOVY]S
M7V-)G3(?1\")"GC]3HXZW1AB. /(^V+]0+,*'EPU?-!UX]/"_)X$HS>) [:B
M"<&)&3;G[.>H"/.1-9C74'6I2ZSQSF]1[NM^K":6E_JP_2[[]^G<%C:,P@V.
MHVYZR/T9<>:(WTK=L:V/Q_A]3XE!Z677B=9B>QE-)N(UA9]R+DB>/2*#.*$'
M0_*B'J?;)=HO'?"Y7<%]%G,,RJ2*;89??K;S+(9(G73U8<M>=#MB)T&S+.Q@
MN VKG9&<QJ5HA!=HQ:8(+"KR\4@ME+5P? @="(?VR<>3@D2M1ORD+LK.,-(V
M)-&B1R339>&?_7:>97/TW5 .MTK[Y#U?%M%XP!\.]\>C97=!/GCPAH4$A4@Y
M# 7WN(R*/0/"B T_O]@%:@OE91<<WJO!D$DJVU.8#WSO=$&FK6IVRQIYHF-*
M&51N+ PE(L ;U*#K!--I'%N>)]/N3>%YG+AZ#CF&N.E.?0;.&QA>9L]F'J"_
M_,9SV'/_#N?W0<D;YL"^1]+#Q)';B$8GIB@"Z?Z3KCN&=^AD;#6Y+BO>!,0.
M<5C$UI\NHF ([IFJ4D:PEA01/$O;L5R23IC6EK"<O'.?V=)9GB1:[1GZ-DI%
MK '$M#'6SZ"5Z#M##_W04P+$FNN[1V*3AJC?AI!F6J*+(Y:FIX1WJ)89#C[T
M;.SDU97S3=X+-UYFW_ZE\'Z)8?K$EV3Y0L'@4Z#GJ6TW3GAK& 1O\WF_/B=T
MTB#LQKH_D]MUJ._O4@2CHET0N8NB(]TT0](C'+;N9#S4VP"B6D$$LRGZ$>-.
MV0^M4SFE?D[5?45NDL=-3AF69.5 +4X2 5&.;5H@_QDAB(Y ?< FGV^STQ3*
MC#7N,10I]($^EQ*,$.N))F*O""3WH"SH.GE#N+ BO]DI)0B)X_5@MD#Q+#U5
MX.FWW^>BIQV"=+Z@4PF>LFE)T/),MW-^\2/;4W.EZ?JYDS_A#QC72>,]_!"!
M$N@IO ,Q@0O=.9AZQ'P^N ;C(]H7DZ?TH/;IH-HA%(K8(9O7$)='(A9FP\+"
M?$":O^09\0#>1X&  ./;_0U.Z>D-B!VJPWT*TEY-=,6&_\VH^WT2>VPG6KU%
M"4 <?PME@/J\T?G<<HCD!TT"BL)$\.SOQ^1)#93Y6M"H"Q=K+\WEOK-4W#1L
MB4S J"SUGEWH^-568/"35&."\V'/=LRL2T1SW.(1&^T0@#RWE"E+46NPK4O!
M_2WRP,3Q@9;#W'OFMO$W=PU&O7%7C<0OG"^A,X[;^I^V?IY'*/[CS2ZY=W0%
M8B=I'2,$J05168A-=-T9E,9(R_EPMOT31^L<[N)Z?+CS[KSO3!*\Q5:--$Y7
MZT=:;@X<-8NZMX?-GOH)'7KS>$.RIZO(ASA UY8\)H4L(@@D,#BC B*? #8V
M9.JP48F9E8V>=Z6T4BC2A7*>T11::6&O*,*XU_GY=K)[NUX^>.XE*?48H2GJ
MFGWZN:#(J;<69(@.2S]HN25:,MBJO)%XH,\-3*QA(Y(F+M2-TFS3FI,O?!RR
MU,Y ,YO.UI6%$7?V%W46[ 4?56$#N4C%;O ]SQ3WAW-@B#A34B55PN<+$R35
M*'T\1W@!&H[E<<B433+?(VV!,"Q&'9HL-N5M)@62R.C-Q'VSC9Y-K Y2<@$*
MZRP^,*4/5C^(C+S#=?5E9H7GE294;RQNRA8</M>2?/^VU 2B\3G0/G0'20M"
M<]%"UORDR(_XB;[K]0AJ/_$] C%X M1D(E)]/%.7O$<&VV79-MI/"Z,"87F(
M>0F8=*S %[V%X 88%E5!P9R+!\\FAC2$]JF(9!?7;B95G\/4>7;X884IT%$^
M9BOA_*"=+Z\WQ <*X>4*HKH!H\0@\%+7)'D>Q/)L=YI%4Y+1,/'N.X&;2J;M
MC2X/+UK83AX5_)MJ>WJKU:%[XR(]8AMZ*_H:MC6DVU^A%DHR2FF)X)*4\?Y^
MB.XUV':D=!>U@[1NQCS#O6]Z]+YEJZ/@.VD=Y.O3VI)US.7UHGHE\:+_R:M'
MG'[ Q[^?.)WP-<2]?'^0\S:GCI*//\_^_/M?MG*@TW6=S'^J8&'L+O76JOIM
MQ><=MF[K4KMYLN:XSOGN<BV'+;#'G<F%@2G'O/H/[(.MNS"HOU4__<B6=C7S
M"HU+5XIV'8+5R,M>,M_#_OE?*UK_KT'^]=]2F<&;1"L%_?N^L$?-#MO7$4*N
M;C_4VO$2/UFP#Y;-VY?L8?)QK&./!3GNQ/>KFZY?^\4ZYG;L-#0A_""I%-N+
M]A/V9O&^2+6'4+O/2/< HW$$>^XS5??^):]EN ;$O^BGV9'!0VK@\T3.0%]<
MR][(<GB==7JTP(=Y,E7(FYKR;?]>:,M!K,&PC'&J\)Y,N1@*XF"HB\N X=-X
MQ')L,61\C$$;6=;U],Y;/-\PX!XKNH=P'K[ )&JWT%L:!S2[]/;Y(9CNLYZW
MA?+>SE]/HGN=!$4B?8(KM"+R)@ZA+"24:#<-:3]JUR#*C& /D-(L3@+4C*S3
M_57+%<91HVNP8+1F^)1MRV<9-S"G-?*?T[ZGT"9]VRD3Q#V 4W+@X'R4Q'39
M^<GI^^A3= O\($]3K.8KO O2J2+;L!SB-D@DLI^E6T&Q(B=2.XH1*M#XP&%.
M'6T9$>];?"76@MZ6.FXJ4N_.Y$7LY(&8]K[4 G6*!_")85$;;G.V]$C<'4$L
M>0PG5<@%_'N$)$DVP0\D<1<SS(@'(5OFB TY-8J2TA>AF7XU<<*C:=A.!>CC
M71L9_=-/[  DM<V5O?@L52-U^)5A^[!< ?),]MZ3&D(A)EC*8M1J,M'C^F?!
M!,Y#I/@6C[R3<,I- ;X#RN$ATY8IVG,->8CXI1X1<B->\?CH,F./&._0=GYV
MM?LI-[1Z4-"0=[)VXH]O.R*>H.OWX.OY%HV.+[SS#$QZ3+J^<7>*IZ\%JM[(
MT'>Z^//AGP?UO">/;?/J;CKRUOK/REN3DXL/#W4'1VWY_"(.\MYY.$+S']&>
M\0UAV[MKJ>\P#7V".Z7$]U/K@*34"#H"NP93$WOS^Y+9B ZWC7ACQV$[-'??
MHCB0OYE:W%_9<IR/V3E[5S.Q1;-TMM2Y8*!#Y#=L8KKL.U,I,"G)<RZ$CQ$B
M)-6R2:3&H56(:@0D5 MBF?X*4!+HL[J9K@?%^-2-%L>.4Y&_K7!VM>!9$2>,
M*/]ZF*9OF/0B7'J8 0CSJ[&;[JDZ-S</N8?ND5Y%V4N[*:I$6^DP1:<%!P1>
M!*T%B*)9"NT& V#R6I>TK#,L[(TO#E1KMN?(*.8P:'L1_%9>A#^SR$UJZ]TS
MBY?%TF.0-2(EN@>G9CJ2HC.RHF7Y[1CZ-#I4<H&%!MS1X]AS4*W(V)>1W!("
MO)S@67?@V!>D"BNBXV.^,WFD=,LN6B*GB[(9M6_&.OO[.0#3Q=CD9W"7U=&G
MX^5TJR2\5@E]OG8(<Y9.:T6?(+(H@"OG@0^"B1RG\C3)+4;\9R%\S7BQ$O>>
M6^<H247 ZV]QX.'40K^:M5AQ-.O]S$_/MT2_$INU7JH!7/M2OX^8F9B:5%%?
M/''.W8NI8%QCC,UQ6?,)7(;V#S2<VA+-DX3P-%.?@Z6/Q)&@===H@25(38G.
M=S4;/-8?,+2</]XR*)](.!08P)4<Z@YZ,O+AZ(VT/Q;M*'YM[X-NOK^YOO7]
M8P?]@T_NC*C^/$6\G>?Y:-O/AG<?G+9G!ZNMVX US?IC8#Y5-SGEEG[YUD\7
M-Z3?,%3+.)<R>/WTM?U?LQ4PFE+V&JQ!!_.:FD3<,8&/Y=Y@@!2>4S<F!0M0
MN:S[+;8\C"+>,IJTPQ>REA'DMI"!:(P6?M"SO\64V^KF#JS!'EIBT?(S[&YJ
MR#U>GZ;?#Z+>@&"AVG)]42M4(KI*[.$H22UD3/>,< _,ZI"J0X.@(>\3;@-T
M^'R\9QCR6[/W&NSUTB2V4V/5;S21H!O)HQ[@NP("<IIEA/9YT*^'GL_-]W.7
M#,B)?XC=)6D6N$<(=9IIH-"5+BDBA7K13:4#VV6?7V[G &IV,)TAU8HP&4L5
M%N&+.NG($7$,WQ1[ GRH-=K^;(]O&G+\.XLB;X>L=M1,7MI9I;?*/QL[ D-<
M)(X?EL4)Z185D<D<IQXY?W<%HT&PQ$TSU,6&LC=$F\7^ S=:]O,X2E!'!V\_
MCN 06#+5KEP'# HK)04$CVP]"^ O]ZITE '92=]E^*FEG_E/4A,Z& T9&;7!
M$V,P&Z2F?OC(3KJAC,@PZ_$!-)PJ_O6^)26W;L0VWN>B!ZC]A%/ IV>Z](PJ
ML>?GJ,DS:["3M2"*ICBGX>$6JTY;'FK,,6=\YKRFS&=,(\?1[5HRQ=<L@QJ[
M\G)2[?S*(4XW>IN8Q(NE:.#YW5/[AJ[4U32/B%VJ_8H]S2<-LP+#BGT3PE+J
M&AM5LZ^9H$KJ'SS/.UJ]YV>'X[Y?)?L,3DP?3OSK]-3- ZFH(.T-04D[+6#_
M[2G8,75!J\<D0A_7L7"S>?V[M,<:GA<,O^V(;-0W*FW'-) $E:0@;4:"_U:
MTD[=(8Z&LD#R>3"Z\0$=@3_<A5("LJNJ':<CM!#;H?BS_=%H/2Q=;R!Z$?%E
MYD\7Z\26=2%E+CPWU5Y5=IA-]-"_)^_%=,L^=+Y1!KN/[I+FRZO%MX"D)*(M
ME'7R[=!2GP)'UV/=UA.]"T7U65VEKBB%03O,WBP2-G0*/FSG%,+K/=MA.!PU
MN?UGA]$_I"-274EB%"Z=H2:60\_7W1(YB2]#1B"6KU%11AQ ;)/N&7?AHC=:
ME0-,EM[NI$LRIOW%0Z=%3VKS;F>"I<S1N^EW0Y@RFT5VP+D1P8-.CX;\)[V[
MOFV#/V?@7!5Y. %?9">S0$IM ^T.N#+MU(7<*H,[,*8-K3(3,[4#ZA%9R0JG
M@RT83EADH1_X&-8J/^4A-A '&.MH3UN2NO3D1DBO%Y$XB_VFW%]7LX\BEB.G
M<\2J'"$.L@6-.RB:!%NN[\0:+'G5*&%)9#M)G"==\9Z3'GW3'['$T1 '#HDU
M Y5SB]I!VV[A1P,PN"%*R+A3_;T>4V?>IR*$C^<+O0'K^1Q@!)V(439K<:X8
M\\,7^8&4%,(EOJD/'P/F9-C%\@0G7)TZB8?!L^7Z)YH*"BLX'W]QI LJ!B75
MF\,,#A"3D\W^(<SX'(DHRCM5</F)A[-7?OGW]K^*8U2SC@8'G=X-^P@^O *S
M6%!=^7._T^EW&3LVANSU?NJV^OQ?I5QEYL,=!O>5B+>(8Y3&R<;Y<CXGD:.\
MU/< O1UE@Z?RK!_:X4!YJ<IBDK6>;EIG?-L:3$EK?\OE N5^L6-E:!W!";R1
M69(SS.&NQ%\;L0LK#Q/^<@LHG,QX+OI$%442W^>YL70O"+%#4FO\61;_1M)S
M1LJRF]RD+[;#)<*&<R8)4\ 2187),U7QN5'[><,Y[2.K0U(S&T(Y/D^US0'Q
M>Q_V[\+U67S-AW1M1IQTK_@/:%*D+KX&EJ;1;68*C* 4HS3B%ND YO4:C'6'
M)KEP88!XB-@[FO>U)"=U2=;$!4M?QONX<XEQW3\_<,WFIUL'O[FV:2,:R1UN
MJ9@&ISB4-G& \IJ41D6'4L=QPOMH!;/%)8/$4+HYL<>&_J"ZY"E%8"DR;_WH
MD3>5Q9/ 7,OQ.!Z5J>LT?WXV33A&4[SCZ_;DHY0J5I(\D)DP+@ZM9DI'XN'M
M+T>[XYT;!RH?DM506L!*BEG4CQ<@)\."LC$,<.!2MQ(<H<RM'C@^>?L8.R/0
MTVO/X+_-<0-6M)QQ1@AE?+ =\WJEPVT300WR*^6P\?IMC\//LWM?823-/J/1
M?B'N.1='"$Z5X7I_-)K/L@N*8J/+_*8*/=\6.+L<5SY.O9OQW'EZ7;J[SE_I
MTPM!)+,[EP+WWC#XBVQ*,?1JTPLONW',JN1*YNGYYKBB0^>_K,L:71W]AA2D
MK<$V:@Z2@ABI_DJ04P#@R=/L-KW0B=XJF^;\SE$]V)M^7Z]^^DZ\R^77G^TN
M\'";(4]W63?'\KX5<C<QXCU ZSCZ3E]\?K?-V0>W0JJF0FMFK!L:LV)O5XEB
MB.^T2LDHI'A3G>2YW1[B/K$9@$RU<^%/JKJ1O>@HG<$H5]1DBX-N=J-R]M0.
M4#-5C%2N*IF<F]H$+-!>02S'M'.#0</UQOMP G],-WE\1:K03@)=VB@;H[!N
M*9CM=$LB2\]J@' >[.$BN^$ZX7HFT"'1%2)K#:8E=BG7SL!>@OPB*[T<>+Z<
M>,Z.>62IR"TN.H%&@KL&Z,,;PFQHC>/WS:3C%#FZ'7&PB=.&>T19+W:J(,IJ
MB\%"I* 5Q!$R(,"C78W!.:'VL-&@8#X:G899K[? [N!WHI7L(KEC1;\/>DEL
M*B(5MC1JLDL29A)YBO QMSA23<Z\2&0K/C9"-R#L!TZB=$"KVI=.1>/WTMZ1
M.Z3PSPN+.>Z@1L:TFT*;:11)W@O?[+\=RNHJ<GS=F.\Y=,/OY;//'I;+C/N<
M]01]D2W!!$"T+R:N7E\EQ1'6O6@@%T^$6[N6S<;L7=!:F%V#71SZ]L1[@4HS
MS@UI;0WM.#5Z_;:X4OW>PGTXA@3\[PV=__]#7:V.I=QWL&:J73/<]N>]V\81
MYXZ:C)T[:G"1ED]4_O$W3NYZA;$Q;+MIX<\/;I-W]$^O;*V9O'_0Z[X">_6S
ME<:SS8\?5SY\Q]BW-\TNX.GY0[^:U4]^6 PR>_L?2=@H*99J2WLX6PNA?+YP
MR/*HX? 5@/. H,A]5U5-B 8]64T#!X'O3!(L+";'ZN9<@2&XM6' !5=<U>GN
MB@VT9W],"R?T/5Z#31?)*(C1C1G',J5J=9 +H,_RMZ6]><+L8FC3D3,H#=0>
M0'/^/\!GPKNF#HQ)L\S04*RX=Z&KZ2OM85\T[OF,[;]DU_B+PR7FA@57T/DD
M#?I.:3\:.(=^M 93KD\6'T6D$[=  YPS] %T*#));T^$I_ TU"K:QYGRP^?_
M3ML6I;16O<.0L>BZ6 _\8X"\"4O7%EVTOOW+?VPNWV*XL>$YW')0L 8+(T,'
M2%W4S9!0&_XP[[I-4@<\C;0EJTLKY\$R/)FB0-"<ED'_7(P-II-R'ZV+TL)G
M^0S:10 NP@'H?*P<![K0>2CLUP\]PX&!@6]W(N9/NEDO98B.$M8#\/G):7O-
M=OJV^@9K#>D.H#N+Q]'V&_,>AR@\C2JNKD8?4T@W!4N67QV8]1GNRBASIE93
M/LIM6WB\+^ M0)I>24!MA:[\\-<1G2JI"#<-0*<3(LN90?)I]+W0BP\=2F;?
MNPM00S(K\UKF:,YM\SG)KJ;MK3?WRZ2[F[^BI[RZDQ&*V[TNQS7QF]1K=\K"
MSB=L!<Q\V/;$D+=O;]5O2OF"[%MO5WCQOAE#1J1A/_%$IB=HEE#LCR^]> _!
MU+C[DEHZTTC4'[[ZNFFH=+!>$?N>2_$>VC5P';?L63/XA,>M%QE7O$SW85J4
MBW\0QPKL)<5$!4(D0H-N#=4)(R7E=)5PA-IBBRX7-]9J"46@#N#ESH'!I5S.
M.L)1D-*A:^SR6RRP)$VSEHU\DO:LGMG@LG!@_KK8WF1@W$]NSZ1#&Y3/TUJ#
MM9^0FD$XX0,HHHK8CZY;$;B(C/'Z/&H"P4&TE^T;*B1I$7>)D2/+MI.'VS$[
M&,&Y+8&F24GUL6LP]3F;X-Q2*(DUX(V9/ XP/<"DQ+VT0>IR_E',\J)PO23?
MDO(0 ;,SKB $ =8/1X5/P(>CE&TR!VR<MUJ1'@"-.C..^VACML_99(Q.%-'
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M]3(L^[QOA:Q&R[S#;.[F_JLA!'O+PI_XCDWDYWYHBPN+.7QD7.?AJYH-_GM
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M&EP5$K$%=B>I SG.Z>0T_G.7VNY*8J+K/%)D9>4(=7$S0EB,AM&.4M H>9Z
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M!QA<CVQD/%!!QTA0]X<BY%?"I3G+:0L%/&9W3H973='-1QP4B\[[EE(6(C
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M+2)XACVX?RAB6JU7Q)\[=OGGK:*8U)6-])(!NI?/SVUY?+9+,SF,^>-9Z\^
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MQ)1O5EFI[/>U:G^?;"_^5LL%B- :/W[X7Q;W9NG-'P[CK/'Q\6-)^8M9^ P
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MD/BGI*52320%:C05KN(+),00HT<^8RA18IE8TD.L&E(K%>;^U?0I4BP6"J0
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M\VE'S+F8ER^%G(.S/ZZ:FXPD$".K<.>]@>:E^XR\LE^^&+*"A'7K6%-&C.X
M8Z._G=[Z[DWFY@#.7BAR++GR3S_P#[L0'*^C>5'K;Y?%89HP,!JH"1BXO&!!
M'PQ%D[?V+BOK?UX_*HQLG[21R\K32T@[USE;G";7?JXN*.Y1_(A7.=NC/-)
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M]<9C/8ED$@GN%B-;OCH")O:M7!5:P-+C6%SY;^$\F?LZ\HCJ^Q@!J$A)"/-
M".>/<UT$#R@OZIZ)WOYV!!<9ZT]49??XN?2T_-+,'D5I2V946[FDU1U+$LJK
M4*@(B9X\?P(*N:+/6+D^_97*DORDD(4EOD-B??RM G\>4EZ'>?/!,[B59,EH
MB<C>N ZS6FN:@.""WSK%C=7+_BN,5]R_M03*7T4>2<EI)](5C^B7G>S&SZ!F
M;[KT<$>?,-$-D0Y1*,JGW &^Q@N+>)HTF33RZ4HCZ!>'.Q2J_ZA(C]B;AF7V
MA'-[E OPW\B<N?*^>ZEQHYMQ!:T;"?(.[MG64X7U)YZ*H'JN5M#Z=P "FNAU
MX,->,:3:8%ZT\FVYS)GH$ )TZFP.14?LE.&C!=<7#@S1?[VKM?P_/D/5)/X!
M\5GWMA2&"Q>-L M]U?/($E&NO0/,*3YTB:$-NV3C3+>_>K<UF<)T1:WKRU%2
ME=TU:B!TF:FW G-R)(]>9A=!-U7/[J2JK1ONWG.*#/)@1%4\P0*D;KZ@+*9:
M'5!QR*#8FSW.62H@HW-V3M:5(I0$;[%&Y)S*CJK-V>K]92?4%=:-D4=8K>OP
M15;$<]A)Y?CCR^?_G"3(-YSV+A*9#8R$6X:[.<>-*G/]'-6,?Q7"$]/HBIU-
M3>/A4Z<*\W,5=9\)F:U4#%+ND)HH97-;<W-^K\< ](S)D"-P)!,&L4#_I'%[
M#9+W ;5NOG?6"_T"14T*U%J_HP=('!-P!!DTF:NZE!1V&\Q8UU];AD8MKXW=
M>C8;:]#V_X\/3?^Q6CO# -9/M9R_+O/$2K[W'UT"PL^6R U;%O3;WCG]O%@+
MMM\X[$XH<65LC#J:T!2<^&H[#ZH)<^T1F[>;.EY%*25S05U#)38T2U^^ZP-[
M1@<^  EE Y@V3Q_JVXZTJ[*W="]!-TY(2)08YR]$W8,>MN$ENADJ:CU:2UAD
M?EV5&WF0]NE7 G/LB).@:65BNF+N)XMZ^<$203//;XTV4![>=X\,2A0F U_Q
M,'PM:2U7:S M5PP^"7)JD1J$>QB\0R2/6*0&& _!5U5T)RLMJOF;MMK?.7]2
M8A;:AQ%@%R'DRI#:F2JTUD@T< G*?R[:N/#-NG#%,GO=+',J24_\<DM_I_PY
M/DZS4J9/R_(?EN0SKD(6_>QQU+>YMOA=_VS%CZ/.;9%Q#$[]I8"#3#FQ;U^*
MU]-)+<P+7K0JT_.M?Y+'X'.6"N$*OJN"*XK1Z-=JPA0#TAG(PV6\&[=K\O?"
M\XSS(6YN:]%2PB.]P@'!\,PA\\&G7_G8PUA5=)%QWBMQ(26"GI."6Y==2\8:
M=$?%.!JT1O\=(YB] [0EIF(DX!2Q,-H_ABR'[/RKRE0,,5 E()/&SCUO1'.D
M#MEL5JT;0",\*QK>ZM4-?#RR#"N,_RV[&%5_VKZ@!?(+D,X:A608HF52K]:6
MSR.M49E8HGFX&+G>9S0)O"P5*Q<9; ATE'Z;!9\)&NDVR(%?D*X=OC?>V#I:
MK\IQ'.$Y_O&#RD^RZ@$?H!F[ 1UWSKLBB$A>?H1#UJOAP%=J[A;CZ1PI %Y1
MX$KFEMS0Y@WBZ7JG+NV8Z,@4B7OS\ XP( 'SI$B!=/C%]/+)Q?4I82#HX"T\
ME-Q@$Q'$Y:B0(!U*V/NDZF1B-US:H[$Z<:@P?7.KA-B;.2.76]SNO;6E83AN
MR[;(9*L#QXR'RQHY!97P-YA8:[J@9/')S>0?CIS6]*+(A5SYJB(03]BN>Z16
MMG^?<9%[L5;JX.+DET\TPPAOBSIF_P$CXWV3^NEW/[/;W]7M\KA7B57<]N@-
ML.:TM>]+T$KHL.KS%4B.L?5F<A00^UC;OQY^JH-/ON,O#F&\ _@ 4]FY4!=)
M(884-MLS+^&V%)+\;2>>P\9;CQ= ,8&17S.%?R:*T_("2!BB.M48L/>3AG0H
M<;_//8"__1(AS-',:.]^1^)>G=#@811O>E2=5^%8PF>^'-_TD(;-+7N>KV>-
M,QM/G"'"LA:_!LB&IND?)_#=D%RMHH5V2S@V(AV19.O>T8#EX5<)-:[5\;VI
M6J6/*U:N5H[I! *J'&S'\<(DE$87QU,^C!587I,3[?P((T!]I!!#,(L/N3$>
M^^?9IHT\$>:5K$CUC2?N+9VP_-"HV\9]I"OC>KKT<5L*JX-JS1! )\)+N<21
ME^*YJJP#H^#/4AG$@26OK%4<(XA2"RNJK5^BS,R.Y]_Q+_D6LQX8%%T;QO4J
MA",@":6\\WT<Z- K>RGS.=\/>3.]^7@TZQNZ7_[*#?*_E.-\3.@F3$10HWP'
M> IIE3NCJ\!$HB&>C1N36>"$!?G3WB>5;2D=[:W]%0J^!<\\+(ATWS]V'B?
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MR]MO_0_JF4)QWC7;(4<-@S*%]I6>9'-$&ZU-U\J^?<+H<\;'!,A6:(J%[7P
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M;(CS1\AMV7YP1$8>KDR=@;=XI::(L\0/*78O:& :$,;N,XA*UV 'ZRZY>I4
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MH\AH-S6$!=8[,MGOM-!*-9UZ98![V12##Q06/B]6,YHT,BHR)A+GJH78-)B
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MS8L[SDF_D/\^*+R@W^>5O.JR?3>,7+'AI1GL&6^0B^A4S2(F67GDT?[XS5^
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M>=[;EK329+\/D4H.VT)K*],7(K,M\.\%5>6#FU$<3%![6)**"+Z@5WI?8K]
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M]'CU6Y#Y7"4IC3DW<LZBG*GUO:6&4WIK=.7 Y3]H_^<-_<&.AQ*![\!I.UQ
MTOBO2Y41(T8#57%Z">(L;NWN+UWFRW8IYNTM&*J-\K7]'\L9YT!W#]"JVP&#
MM"MMR+;87EJ<T8S(*<=-/!D4D!_^<[P[5.7:I"*%-]+/1#/BLRH9P$JR8LS6
M?<C;4NZTXC6N*#>RU<BF6X<L#J'';0("E\'MM<_6;E>0Y\R,7@.2OQWVYZ^!
ML(DW.J ?VB>#8\9:!W/,!P=NQTBMD^Y !PYYCPQ11S$\B1;0>ZY7;Y,NNX4@
M?0R4]M3=AXZ^0K!ZR>_T\=%<& ?4_&J)V<75N^I;ZHM7F<,PZ9HN!_5</><H
M!S_ED(EWJ:-@7A\'D]1G*\!O(8^\;)S[EL?,DVX9%T?D0^8'NIX+@UAUK?G_
M5,D&^0<<.%X#GB->7@-*W@%W+HAU>"?YZP[S>-P?$L>(S;<4EM^_-V!8IT"#
MAKX9F$L,$&S^L2=OFK$K[ZL'G1_!W;O1@A^E@ZRYSM7P14K:*9#P%V+[UP R
MG&^-/M^:-)8AM!\B:^'Z,=4_%\(L [^I:YJ0+"F>%5-$N7+ 8%8(QTP+C-YM
MJ?YWY\/8,NL_[_.'R[W9919;9=!*:1M676)O:G:>_6IB8GGMG1YW#9!2#9?4
MIST41MT_%J#8>(&.W\:5[6N9_^..'[KO:M:9ZN7)(F(P[A_3*"8$W*3%,4P&
MM-P,=%#(_!%5VC,OQ&VEUZD_N#(ZECNYH\=/0C=;H@*H3I52@2T0\-!*K>/
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MJ=\:4/A+VRET*H;JW>'(*ZIWYY6_*[T2,HH6YF>-@-_3&O46]PMS]);VZ\Y
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M9WJY$^%.4OR4V(<MC@!MEB'^&M!E8L/@0N5S+WI4\R1Q8_#T\"LI_#]W4J!
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M$>;D[![8C =,"(!8 ]WD)_@VVU9E('(ADNW88@1Y&J[?WNB>6?^\62Q,NHA
M9;/@@U<H<$585OA6F@C$M!9/"<ZX9.:^N^S4PW3,X?&5+TMVM.;-F[&4C=,V
MIBH& 8JR]S2_7=N67WJX:AW>%_3SND'/V;NOW-U$!!V4XJ$>:28S*^(W))@O
M!<P_J"T&?3*I=_.75-:2J!S:WMLO&I/R^U*-R&<&8NVTVEBX/670Y:![9L0
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MU<ZS*0@_,5#9T8U[$&/CZ?%(Y7OPFB8*A% GR;1O<:RZ,@&1A&,+,#S _(9
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M'@>H!=!N,XCQA0Z8$SC_?#;7-T\[>/@HE0>E]Y:=DO$&.F=!Y? ]8H06;<O
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M;%8B;1$%J_REJL59AYOM@B,_>L\K?#4>%+*H)*L^-4P)*5!\I%;LZ1;? UG
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M!],X)]9BY -+%SEN6VKD>,"3?_1"((@OR7F\W@N\A[&TN_^-#4U$U93?LU$
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M5(ZUY_K^8'?_&#?\ORPVB_393705D@\=S;GO<-W2 >0/IX=CBC$2]UG?H *
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MUNR95_]<3\;%+X6+R]L3WOMU$]IT1"LL]TNQRNN8NE3H_!O?1\"EDVXZHJ,
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MI\8-"SD+OU$#1VZ)N!H%DG[R/[7M^,0]V8[F S\2"?$>0?99^@_.'M$BOMZ
MDBM4GI#!LOUHZ35P-?48=/V?YI'[,>C;1_HXXL 7)W0,VF>9*M\-IG//'8/>
M***[)/NI<I+VZL>@ZMT>QKV?<ED5*R;I1ET\1?J0N7XGI\>DD&-0D&Q8J)+>
M0<^O3V4_NF_\X>5YBA3]&_ ^Z.O^)W\G#9*\'U_YAP<R&?@SW]ZK_UH2W^WH
MW/F)WJ$@<DZBVHDO 1>%>X9XD.<4IF4/7@+&9(4>#9/*LL&E Z!R<?88)#2-
MK-5MC3SWN7;$5WDS.%-O_$K51P_N'E>; D6? 27K7=XC)TSG"6PN$A1B(?6(
MK;]+E7H'D>3^GA::2H5\A<XYZJ7)(/@)P7/2(9A'3OVE#@-+0PRP8/:I,],B
M[!GS1&\G\*^:<!.,,[F\JS6^YY[C7=&AA'9Q(-@LU_SM8R4'Q]C!M:LH076+
M)+%(+1;3I"+U2:/>N\B8[_+=&8++<Q=#ON1>1=J8!9*;WL.RO5LU&V6*!+=5
MSN__GLTL6"^C]?;ZYR*-J1>"<SYX/V59FTYYT2&16#GD9&B?:ER-ZOCQG>W[
MQZ@'8'\6(]-?9Q:26(S1Y]#?\DYA%FO1K, FP9>?/HEIL-XB4!"+\O49M:RQ
M5,9%:)3=?,H2]T/B!ONY4=<Q%<Y9]\6Z3.,F]P'XDZ6?<;+PO&=>&^#9;$(C
M";(T0C8TH^5>W8>0,*S(+:_G$V_FK]23MU]5F29834[EJE5?#=+<YNGKF3L[
MDO]E?*_'J.IA8TIP)3HX;QG02I8T9WY!Y,J+_;PA-2K:KA?3_] ?_\>\DG7+
M\[?(%1QOT)8%24+YDO]$\>*?%9&#^Q6;HY&&MZHDZS)E?!-G27_VTDGM%+?I
M!0'Z=902 "WRP*_V*D@"OAU93F6EQ9G%3LAX,QC3N&^7_*\,,9241::PM:]G
M:DU'S".;Z+>])B*!:NW7R>WO")F4W"*BI.Q=,NK9Z0TSH.!^6UW="+W_:0,1
M3_:T3LH8GIT;\!-LP^&%455 PI5L7:K+"?P_]$T^R614&#E\@-A6DHBZFLL,
MX(A@,>I](-*;XJ9/\0,BB,)D7$S@&@I!7NUN/,B*0^IUV:7OKT2F'T9CSXSM
MLU4L"=5.?^I36IN'TEZ?]-H[8U!/7!3F],I8:PC9EW[Z*$SVP&:D?DBH$=]J
M6 :D'AE3GK6$4L2^!:YM/0D",R(S[QHK=$Y%S</NU+5$O:AX4(K@X6ZZL!T6
M//'G&(3MF*;IU@(%Y'^K_?+DC:&^=N$FRM"!?E7KO'##Y),+DYB:/Y:_845C
M5K[U;,99\CL_>JZ\;OYZEK<!_)$S*M!6\'/E(7(E&[)1A%#X8=#G\&2E^O6S
M)6A<+B\M&>.9QTD?G[\$1"_F\:VC!>HH85OS%Z "*E$C5"]"F%QW(X1#&<ZZ
MCN#VUI%"#'D1&8EY/,CFKEVKY-X&L<JDV+#\7V%O/0B.!15#?/1>3/U\V5)B
M,%&EL1<GL8%6T+E!V8YYD#I ?/,/&KFOG$F4C<PC;)1$$.J/A.*+; &IL1X%
MU33>G8@AP5+_DI#/T$<J>>* DFZ[QN-&8AOCW0F7X7H(OR34;&+KBB^4(#&Z
MI.B91<TP_]K(7NAA6JX].*/_DE?BZ_+^<B D$<>!TEL4WXZSLTYN50DEK\)@
M4^-4;ZE\)K1$-7T(GUDX[\ &Z_3<N6F'JOF2<RNQ(A]M2/MX$MO+\V(A(GM#
ML7C9[F,0-[)ATXR6HZ-"/4M9H1W&J8"Y/=%G:BD9:27VR( NU6!/6?JWD^T4
MH\*4:?;9L>$P^!3QSO=86 BX _H"6K?:M1V1*T->:8\@V-+%N1&(-G+>5CKE
MU.IMB@FN&+AK'Z;8-Z9W#(K$>3@+):G $JV&S"?JZB:5<\SZ[]2VC#VIRK%2
MQ3/\DW:E;"XVE <MTJ#&0,%BZ, Q"-(=$K#8<D/EB%$MUAS>E#JZ>:2H^"CT
MI>2RF>UGVJ_DR\VW*\_55.:)H-P!2S)]S*R-4M*3S(*TFSTQQ,"YY]ZACM75
M&MY_"GP/6AQUD-1QI,*C^G._V8JB;LD[&.L(/*)# <8#0UK!5F4[R#T3PK;G
M+37;C:C37^B+:?4(6-KFWM!8>$7E#Z"8VU!<MU_H7"U*2AT#)G?IO#2C*BWI
M4A1T7)FD(V\6Z&TP+Y@8T+@$#<>(J& 2%_BI+L4HE6QB7\$B+BF/;]_;O*NY
M=%A+.Z0","<F=R.XUZ'@UF#RP3&H+^7;HN/CW4Y66!N9]#N[:O#I:YLY1W&5
MI'_6OQC^.8<=F=-__@N.4]YF=D)Y Z'"\4&.JF-VHWLL%-4W^-R2_#F\]GX5
MUI,7CX>)+LZ<SRP]!CU*FKB=34C9=5SMAB8L<-*O>@3C<2=-)49'B+*2E!Y&
MR_GD"'B9-8Q_'*N:3F$2]C.\D?7#\39W;T7FV51D.W(YB,-KYP0Q<-4E?9>4
MCT%1&KA$+6ER\U'?O!3M-5J#>G:B/M1;0:\A8Z'?26U\F[5[3E$XPCCKNX@R
MZ2IQ?M9VTML[*ME;X^[GOQF/A']C'B!FY [* ?FJ#7S]Q'(>&U6^% A8S(RB
M6A:CC)O)F-[M&!W5+T 0X4Z=9)BRMU=G<H$[6HQ<21UI&J[:EY.K]!1_G#!8
M5\X,HG7$N6:>#>E87CZ-47 "2X3N_9AX5P)Z39([I[H;H23\S,Q0//8\^<:6
MXO6I[)UJB\>L3"YYP&E)@ I\8'[]V:&,(^#;C?6(?IT2J6.04SH8+UR\\@O$
M^F5(^L92DU:HM381?MJC'3):SQULAZL?4S:6ZEHUGU3A7,^:'^TVKDM<:6G-
MO0].%VSU'#4Z2W QE"W%OM9B/@8QL]+BZ.>!QFXZ.X Y,J$*4I+CJ8[RO=AH
M+6W"MNCZ87-)C,*5%61AQ+U::\4[(W?%U)>>$#HZ?QK+&O+:XN.>1;==P'[:
MVFHX!H4?J!3<:C]G*7@QX+*?F?>%H_D#.!S05M%9CGS7S=?9_H0+I,GX4Z=N
M9X.'$V3H65#\U;7Q\2/W7W>)=W)&YM5$N"K,7X:S,0XS6MEO-XYCUN1NM<#>
MV>[#"F;SX[RQ(3+R68YBWNB\&/%73,EZ21\"R_[M5=@G7[O!JR^>ZJ\'2TC+
MO;L:;F($Z1Y+>&"39'3>RO49 R.?$FUD=EH*O+[5YV%J>LOH7JK1K^[SJR_N
M",J#!$SU_T<)<DTSV+SF2+76_@D&!:OW[ZT*JE@WK>5M0VA,(PT5X-\%=!Y+
M<LX 58(6JZ..'#M)]NBKZ).=7IM)2B: 8Z'UT=UYW/8.GGP;.,["407E4I5*
MZSL-CS/-1ZDJY:W!P58D;S^Q0J+!=4%KZ/L\L@T&N+A*Y7>C<R".5%$7:&]Q
MSK-I1X;T6;'M7D1DY9&"/2!,.(P+A/.B.%KK*5+)H2>]Z+ GU</N2:[@:!T"
MK"<3E5]B[V12^XUG-?PB04GVP(58B>DXO?$<\K+5K1SIK$ _TUN^W@XAY\5>
M5=[1>J0\<+W4RTI(0[5,=J95]X!;*ZSAH$_<ON5MY<LO[I-SYSW_[K<+H/N@
M-?)Y"3KJG>2! PPMK_+*8M.XE@?EK@(;$MJQH\?&E49KZ3G=6>)X_E#AG$R-
MG</WL9:828FOGQS$VA.?D'PW&U.4)N05/FGKMSH6H,0 !2_B"7U=&:&JEZ"@
M9)Z7)]PFW=?<MF;,,;IK,+)U)2BT?UPV, WU+^NK]'51*?M84P:/7VZK+3C@
MXM26F@<YNA,J=17J@8N<A+"UGP,RMKO0W)3W_]9A<#XO/ K+4U8X8ZAE5*H?
M4@SG3]1]I]7B*N7=;<BK"$Z%+C;D@BC)_0A %A(#)=PW)B8^QT,EJ$Q 414"
MI5DOMAIW = O1*[>G&JU)D+9U^#>H:QQ/H$X, N%"0UIBH(YWL-7#O2K]/C9
M#P&L1#E,[&0['P"E=!.MNWSC%H0PC^\H0X#+LAW8%U**K0#X''*@/Q@BH:6]
M6 Z9V22R]D*BFEFCZP9HX'ZTYE2E%JS0 ZW43IY/6\7;;[U=+Q-M"LEG&^+=
M-M*7]\'#'-4PDU%)OZJG[-LT,=UYPPBJ<+QY[11T,1'2:%!6Z&CG:6=01&8T
MG:C+)NG<SL(?FHQ+S1,YIXMC<R\1<D]=2+KSKB#P\EJOC=@1G,Y._[3P.7/K
M26O D3)5!+3\#,#D\VF$<G$]3U(,H,X<@SKMCD%N". B)/*$M",7N .'N*AH
M\M")U4;AF''.I/^Z:_UV)T( *28?VHOCQYZM)K_"AR5%$_^NY/IR.@+/.;5A
ML'&7) _1O NJ[]">]+1CT -I!MH)F+O,2!N$J]&RZ&"1,_(M XT81G=%@\BI
MBX]BF)/55XS.)AD;>U[S+WV3YMVB/-8\.7BU7!^=B7YNM!_4^X;/6[&3ZT=+
MG.BY)$,'VK;\LF,I7-(V(($1H8S=PAPI=5+Z$'A+-"?  TGFGZE\E<>_1%Z)
MH0C/$."7S^SVV.;"I57_'+%SP#7]$*8A&T7C3>8B,MTLS)8&,-Z$&D%U'@8K
MT-(-8B8^/^19T41A N>EV\B9B >2D19IK4FQB;]R"L+E4+6B[U8&!.$,R;V+
M^4YORI:D[R+CGE9&9SF,8^\^M3RKG):C?DG_FR.MRAT98O&F2.2+C!?^JI&M
MK=J?@?2_#5&V>$..R_UN7B#Q%W<:O"W/-_0^8,"+I#6>OZ0=IN2+DB4,D&Q1
MNJ7N8LP_JYD3_CW1Z)W/= XMMY^&[_SR(/]JJTMKSPL1=5]I?"QC.BW9^5D#
MK'&>[7P0BX&^X\+5]?-60?<A3-4<W8UGRGX7P\I5=@I"SMF>O[66?*[O3WG.
MGY@5QXFG1JY,S,RU+_SZ+\G-?6N4:_I>@-JU]B$-6(<YX?Q,[\JEA^4%57W"
M>S9#+Z0WJ$LR=K5+D@?3T_.B4.KY2/1DGZC\UM9>HN("[,Z9U,=?O,05:J\\
MG)^I,LKR)EA9!S/H>.*\\]V?30[;&1;8]#,WY*N6>[M/?KX>89IJG1LZB_G[
MN-';GZ1QC2&>;T;2R]VSV2A*[F6(R_)0R[=,TOT0_U>B#Q-Q/*5L5[[? 87#
M5587^-KE4)J ;>'Z\^T>!2$@M*O9JK'*?5YTQ&=?TD#3:K)5#SMGZ/71O5G5
M?^I?<8GF)[L9NUC7G&#O6W)!-7N(5%&<,R&/9SW DU2TEF62IQ!;DG4,<O22
M5\3C'3UW?E\ZF[MMU7R3>;DF6N<!MVP&PUPC\@<9B=&#98<6CBIWD/4Y[(>D
M<D[-=:J\NC7"I"9^,]$E]J:5K&_&32?F$&S4"3A<H4PE41W)W5VYRC635%<"
MTQQ1_D*79AFN]D= O]O3<^TPYQ+XU9S@RWA/JX/,@"&7P)K.8 E%7<62CQMB
M?UX2!B]XN]E/[I&$#<>6,F!MAI:XAMJ:6.E?L $_OW,&N9CTBS%*/F]O#YX.
M$BUF>C[TBBI']++?-,9T:ZBVN%7V,WJ2/56%K#\[%B5$P2ZT,EW[8B.#F/M@
M/1VF%,'22%#@1L;?;2#_^4+(D;8?.9<ZWOG1T\XDK]3](.^1A=>ECZ-5?MR?
M;$FG1DC6@7=T7*U86O/ZCD%UAQU@AEFJP1>*82^48WT4=::./%E N=R%_[NO
MN<!FC^P=T9+GJ70IT@]%UGK]MBD<\WX8;I\=^4[R''[#\V?;D2[U$CFSFQNZ
M!(G7LKR02-YUC#!N&=F/SX'V\#HZ5I7^4%Y;&GDX!G%(LKJSG.5EJ[S<U%@?
M[C50^K$ASDB <?PLN3&Z0B4'WF.5*S7B/!44IL&M9CKY8,3;ZLAB+'"?(T,C
M<D<A.\##/<*[\DU5PZREE>R9" =$E X;2IZ,C4:I$1*5.C5D_J03Y+ULIK0@
M/(TN+#4H=0QVHU%CCM87[?>I<JOAM$Q?P5.MID+XI>$*_6>7)+:CH!Z^X?1K
ME/WD$[OCHAJ2Z?44CJ-N*RGYS\/R4FO=G]8TJG)<RO5+/?"M0I4E"-' 08.?
MQZ"MZCG5#PVC=35VGWJO)[/VX.JWM]8)H3BNZ8T\X3J1JR@/C)_SARNFGM:3
M75[R: SGSW^)$U%Y ;X?U]UZ5,<\.,LW^6S64W^]J)Z[$?@8=.CHUD47G/(.
M,E9 D/LBRM>S@%B5<FY?@]JVZBE"S.7+"WC'3BVE5J[3=H7#+=SQ5_16K*QZ
M%X]!'#-(*RC3+-+Z=GS7J<FPZUKROB6V_01*<:JH]Z-1H1N5*XD.+(%)L\\;
MP&9][>;9= [&(QG\!N[TGGU>_ 5N!$%^HBVS1UX'P0Z,&Q8LS#O]6O_G^L8?
M%]6U86V70ZNH]KCO/A1VM=!2ZIM;DOM,V^.I@]> 3!5*NAG8+@:.0??R".GO
MG\A2[CWU--#4ONDI5^2PKH:WK16;R&CD^3@R _LXYS'BZ>=@).'M*7:;:PO?
M;#)5OT5"3_T1H@8ZE93:(\4[)S,UI(K $505WU!"HJJQK$%[O&$-C"1MG'[/
MUZ/@^^=!/X_'#^4E&NX*^EAVO':^;L%/6'WY9"N0IC/6T2[0,*:E68'ITOLP
M8^LN9G':0VQYQUB9?F;LS'4]+^?ROXT*3P^?^CQ[:E&=H<CZV@-7G[RU7>8$
M"'U?(#Z+"('V*/#,(TNZU>LG,BX%>JOX9-%W[S=E]&DZ,I!Z(_&#7E4#)8X5
M&4/"*;@SB[/H64S-9#UA@1EH'B,.OB27]"CP_T*J=6;5_TPFRFL,]6BTY8P_
MLU9X<&AW^\H_9>'&T_AO1/8,;>['J2H:T3^STT8<UUK:A.=5LU"5*E<'E?=G
MX3I1F8E4M25L>!X3%5Z"_H[@;I5;6HBY5.DI=794Z])2GM \TJV;+C^E!<.V
M'8-B51P#>H;QB%;S >W>B;7!%H,*LXL1!I_L"<F ;#\)>^1,G]#1 <J+J8ZT
M]W1!JAP03([N=[H.&!$7> $XL:]R"7,:VK/-5/]V7/E(6VRWV\ZR+HMY"E\8
M+K=>9:)G$)SAG#QQDJ6!VNY<Q=%,!_(DUK5B'1P05"Q/BMKEF%]OCCX(F\NN
M2"E,F;-S[)2I_V$2MW[%A*TK#?$FCVQD85-Y#/+]MIQ\ 0Y<]"6Q2XDP=R0=
MW4F,_],W7"P,456T3EAVF^G04!RHAD_OMKO[#\J&?B\LD+?*:&X-G-@.>M26
MP$4>NO332P.U[S$6>4-_(<M28,4$%7?H?7X^=J8M<)B6^)\7<Z:?9WP1XO16
MEE$2*2OR[<:Y&I7XIKI-\;E;SX+J:QHR-E:6;*4L&QH,4A<[JB\]:]HQ@]=6
M.+\K9#NUPS!R9,']9F'7VTS8RXWK;CARV2TBKPQDH02+#+I?0=#S?GJ7^0KK
M3P;)FKMI[[G2+_HY2=X5J$\TT@^0%10UNK!=E#Y_HM'*9W5(/<Q@-$?]YQOY
MRW%J:8%C)AZV;80P[\/:';<N*-GV&#0-/K'5TR>@VZ@/Y!!;CD&20$'/,R?!
MS^1UP'KIR';*?'S?*T=JB+2IFB%L7)_Z>U1?;+_;L&1.D:7QW<@@NM56C:?B
M67J/JTW4PY':/OL?0S\X/C$SL3"=#EE$RZ'.C]9]Q2S6XNHMC)P+:1D+!W<!
M7OF*AZ/?C6Y_(_KR)ZOV\HH/M,16/DR7;DB G7??&3JGY2>''I[YU!,'.V6D
MV^F2V@*K/?6'L?;/0Y:QM+IP:]F90?+;)S)/U*H3LK'AW1;>[3Y.R("=EHNE
M.[.9]ANC\, PJ=#P@9U?)L+<F5VF13$#Y)E77[(RY1WN6109?S.X=%>XUKYE
MK]:@3<#4R8C(+&!Z\_\JME_E8>"=3Q$,##X\PSH^BG[]K%AX/TN5)>SE:\BG
M< :=;%A$O_FW+9Z0_"T:9)G%J?B>4'#P=7M:L[V7??S;*UW]TG-P7Z8T?9]8
MZ7.B%U*8[MB^X5NZ6L%H30XE+] Y!B@;_0<? 2PE;6F(=+2XS6H##!P8T7#U
M89"#!Q.D/05N0._ %*@EA_:E /:+B)<J"IP.WU6PPM2[%,&B""#>2"._,=NI
M<=Q'W"".XJQ.+X(N5N :=7#'(": %D_UHNQVYO)$]"_P;5--%Y-?0=E;Y4MK
M^_,74/>!-.RW J23=]!2JK"CV#R)F+572%9.T5_1NY32!?F*_2^[I(20EPY,
M +^3B"T[#EW,S:N&]_G.VA/2DU_J**+QS4ZU^0L74BH <^.1JJ#D&'/@5-]O
MX=IQ*IS[J#>$5E)9$6P5[ZI</>N$2E%3%9Z/]SO,R*JT)FQ(;H]AI ^Q=/9=
MBAH1T8>9;CFP!%HH&7W>"L22'L3+!3#5=FD35JD=&!]-N5K[ 3\86JKS]B5?
MA^?'BUC]^(_PAY(/W@D.6..O$RS^_/5'SO6A+8<<@K$GP.0ZE$#GHWW$N>%>
M+D!:N9UI:8O;\0O<6C)+<XQ&=T;.CM3-8>[5M32,Z(;/C\Z=&WG3D.-!C_=N
M%OEZ^ZPXQ  6[!N^?>ZC8=,=5Q;M:'1GTPTFUY3P5)#S]U2Y$C>W M+4'Y[,
M]862>=3<D<=KS",H/ID) O0OQ#OR8'X;3(7)[>;1N?%+=+:A(S:WDZ#(,6"U
MN7X,8E^-\=HS/_@9Z#O#>E!@*9<'N&W'1X=?,Z2>P4_+:G$]<M'6"!A$^Y^$
MFM:K)X&<R97V"NQ"[K?B>'X,^O&7R!5X.)?T'EQTFRZ^9^U]8.<[;6WELS%@
MM?UQUS?_R%SYY@O_)DVX:4*U+)/?+ZGWR?D=CQFO"EHPO+:U#S;Y(ETF21FZ
M%Y'B%+RT'8?C08MY'%@C>%N#"0J,>,],;M=B.'$. R=3-=*GC;>]G:_F^SVY
MNF*AF2./ZK>4B>%B@+Z%B)]$K"8H&8YY 14H M27X/%I&SJ7&NK(I#%/)_!(
M$<7PE1N"-P3QH!'.9_O+T:93)76(=YSQKFO$;[7+;&>"'R@Z#*BT71&R3^J[
M5.5%>)I>7FYH/Y^CVGQX#%)9?U CL:I>I_BK!9(086*>(<P>TV/PS7VVR,2O
MQGH>-O!X:G,\1F?GR<.1SS=MP[^*\@@'ANQ,)('0O$:;ZW^'3E:G&/"NDJH$
MF)=LS@L"M>74JY2<PJE_4Z\")14WNHV@_"J.JHY:)5%_]G/@)N.!1_VJ9@Y#
M;H20]MX HOK#AMKZ]H9,ON0*%/.1 8H=2"FS\W!B!KK)J[UB!P7.@BLE47L(
M87>UYWN3-?T2G[ ?\0M&@34?OQ:^B7&1#6?HK_#$"\565A:*_8XM]GHV&2SG
M]R K*<\-[?TX,LK5LC7.5_[C.Y:9<_=[7_M;"R8^T7XB;^2\.5)^JU+XVV7+
MLI]OEK[C:R/O=,$L#I/6#VYL.E-NV*5V$\O&B^SB U=,ZF1-"D/LK=Z<] OE
MOXTPBZ'5T%Y$G3!)-!2+'GXN@R5!/Z[MH PCX),H"+&<YF(SW*IT=-W]'T\+
M8?#R*N&P-X\[F0.Q /#WTJ&U60>.FGU64_BB@KK,Z[.5@P57EC"=)RE9F,2P
MI,#K+DT7BDZDRA![J^M.T)0N/-<655L,E!,2L2^U+*N0F0>189Z;W?_TY^OL
M>^D0C>+LJL)GD\]T),6<8I'R?_Z,JM$.,SO1 DT:4WBJ F$S#[ASVY@HE&TP
MEDWG8VF8/AC;9*A\V2*T8RC>4_..HV;Y5->78Y P2H/L&X>"EJYIM$<4&_J6
M(]&[794JD8E%.<L:0L6QS'_>E6SPSO;ZN7E._G8?G9^W0%PEZKN*GJM15#\&
MS8SUBT7W@L,7..AG-ZV2/2J ,<)4E$JEO]JK;MS]IE&"5W8343SCHF^QHN,M
M@<\[OSE$4IP6Y?M8?5A%I24";S"6Y%> P1X:;M%UF]J<!K71)B-[VM(F(W4M
M;/P#<?WPSXTP&.<=HNCEU_:& K9K=]-RO4KFV]1./35A^+:$%6! ?(LAEWX/
MY2MD2'J^E 0<*N/<I'#8W:7WAT-.^Q=33.;%?]\0-1_4?+YB@":??^X<HD57
M9F!]'3]A)-+!P<Y(9DRZQBK!D/2VX*O>]ZJ1,:8'%,!?78248AYM-JO+7/V>
M!^.45ZDV>(\Q+6(+T]98K'381-5Y YJ(O-EYN-[/M"JI+C6G71;U2V)W/'<Y
M:/T]SXE9;_3>>Z1_0Y9UC.D8=/:NJ'W^T+ $6E:$=7KW)@<+2.H%^'O^4TQ8
M9^=,4NL>JU1[5.'NZ==J_G<8(Q9*/ .XNUEG2ZI9_]UG5<#B[1=F'6<<9WI+
M;1%V,-=@5V53./-<$;Y.V&I73T-+L5N93RM _UQZJBQR^L4^8'G$AF("KA-P
MP,5C$%4@W)&3 .XV/@>/FI<#I"$O5L90O(10 W)B>R695#(!CN:NRE'IBYK:
MK?!%'A2S5SV^':(4,XC>7SACVA3$<8U5Y.P4CHA^E9;[ JV%[GE[#(I./O%'
MJ_0D4:HEF951$DZ5BW()!S]XM3LE(743:WXU[5^5K\C&I%2\AP_6[#))WFS%
MUWSV>SFQU/7]O5)56CLCMY1^<*A5@GW-%*P<M^+M> '=-<WWX-?M['=O:V&X
M4+5;@[^=Z=FIBBPL'==-X=)]RQES+U?/,5],Z4NY_'6WG>W-LI"^B%;D#;FO
M8Q4!RF=?N%VXJ?ZWP*5.(H$G3*DI>.CYE/7MCU=NLW-"KL^)IKB(,+/WBV?F
MA?WBV%D>?>\<-*3\7AKSW$L?68D?G7(TUU)^+POQW/K]8;SH8_9R4O6?JLJ@
MHC&HG,[E$YF/H \6(A"\5#@90V3M&1*<INJ2HZK#BKS$F*.[<#'X^OWYHA+'
ML*3]0*1RV[G%C88#:VXQ8[^2*Y/3J:Q\S%F*&!,M4:*Q0N^\Z C*]J/V>)9:
M;."1H]N]U)WO7IP--6WW1_I#//S+Y-NZHO]^3#?3%S5K>8G]77O02VO#N6Y'
M(,BVV)F3H$0YJ%3-70"CQ8!^ B8A%<+^K=2@_3HP5@K8*42-=+SN/[? ^0Z4
MY'C+)F[ZDKQ6QGK.PIAWM7%*B/,MQ9O5 DG:E?S>UWL%'AF\[I?2O0%ZH?BN
M QNJ^2W74D^F3$OJ<EHO82[H\IL2D0%\=ZZ)6GASW9*:7+U'W^3FWB_#E"O9
MG*^)<H3K-X(3.OO%12=?Y8O>:H;G\MQW&/_U2?\(MJ-F=DEY#/[\%%.(+&.
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M]?&7'J6(?KPY$LBP!N<,4QR5]MA",2/GVKUX'3#IVX)>RKR[FLS$F[A]HF0
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M_.LK>\W=O3.9K$,D?2XC99%O8UM^V)A<.^D98M78.@<^(?9H1B2L"GE*4Z-
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M$/FYF[H43,DTXE^SUQ/N>>H6?TOD9GLQ7PXIX=KQ\^?GSB.$!F[01A(/0:1
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ML+_&LJL1=DPUMU4^K$*GND0Y/XPUG(]S+3JW+"\@&2#ZS+WX&UM5G(Q&TW@
M42SINS<IHHYW'8%_ $==IKC*'Q3N7>V4S(Z5?6Y$%=JBA\\!,ZC"Q!D<+!XD
M-C=P#JJ'7Z9A<+(Z+P'.$C8_NGY91 U/3=+Z%!\> F:IK*B<K%XU+LW4Z7WK
M(OWIFLN-H'\T>4U_!J D@WWW5]3':1GJR#P9W%8U@D@!LH'DB3-C$%X=)VP
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MG4\HKYD^YQ'=ZY3]--;&QUU$!9YN20(4_77_-<TVK1I03?F./YP!6B.)G6>
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M&(ELEIN<9>8]&+_8%FB\1%"JW:-SM=5'I7ZVWKK:TS7)4L=U$64V=W'*_![
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M$FO^<\F;V:$]G684\U7VU2N#"-8!4>H,C$='DY ]7J).=,#W!\NF!8TB. :
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MGZ@J>ZQ2];U48T<1+/NNX0=&#+*W$_HK86]!;Y3C$^!6D]0YI_!E8ZC[DGW
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M[LJ3#.X)FO(:)_L]<OS+.?EF;5F?JWM_RCMC)CUB;(*N9'Y]=3)K@,DKE(]
M;N)4#V"#4+Z;1(3&Y['T8A<\\.N5U=O@#QL[A:>*VS]TSNTEM<PR=&BW6HK6
MR0IPXS7MSW7^.[AP#R=8SO*4ZL.PJ"+>Q&M_?CU1Y"%6-<?5V_EP)89^KW3B
MF"WA%ZS$E>F/-'=GFE]U/ *]_=XI82)X&IP:;)*<;ON\TJY0AM<RH-HQ)SG5
M)BN+,GL)W]P9_A@7XSPTBR29(Q?_S=+LLI);^\&DNQ9+TWTM.5!!Q"6'>U([
MBR0;2YN*>X@O$#9N][:I Z?Q?&&HZ':HF7]8M>M@S.&(<=&%P*L7$8RE)=WQ
MJ<=Z,M(O?%VZ7:]_K/H@?C?ABC/'%^/K'E=J%_0$4F7BW&W%']VU;#@!?E5_
M=@*4E.N9"CK=6W#",7#PI&EF?_R0Y/X)D3]_ZG/&&AT_O1>?R^:JG"ZE%[*=
M,[F6*LYW9D3)?G*0;?>3VI+O3N[@AF#AG3U1CD?ET@](,VXQO7C"54.NQ#(3
M^[C*VSK)/Y6L@G*5LY>Z"K.%?8QF-'[UFXP$G3]W%B38(]UV0OCNT+/3QXAI
MPK#9AT].O"BOE!+1*HCP$+PQK#-=)GS&ZN!>U<N=I>BA<M!=5HGH2S'7^#1Z
M-A#*V-F,C4%9;$@>@AKD-^?_;JGU[8;:4H<O^H;QRQ'9EZUO/I@6<(C\&;(I
MN(]X5S!M=/IV^=J0P&'&!+$@PZK(OK];8AHN7[:51^FHP&V*@2?E%$.Z?&R[
MM.6?CBM;M.9M[5E^>G+A N5%_V,4R#?)9>F; 78 POZO:_,'CT%_$4\HI^X%
MQ-SJ25HX$<WGTHTBH-A^B,DW?YIIWKV]*.E5\V="_'';IV..(>EG!(S<+FS&
M&/N-Z3H4/%8)%*AIE1U76I"[GC)&;M.Y8=(&K\J5W[2MM3XOQ6;>V.Y76NNY
M+"]TQ:9,]+*5@2FLPSM_LM:/L3N;T5&O>-E )DW@Q<U?,A=P7#D8A3$]>-RU
MP=-!M=@[L/HA-$Z;P+\S1)IV!3K(Q*$B42"81,1XBAV!^A'B7:;Z'9F6H_[O
M-R^,;097^:AGOO1Q?[^(N3$P-A9_TTZ 1J=_0N.KP9Q(]SV^S2-0XVJ?!?L6
MNEEQMXQXSW6T!]68@='/N#NG,KKI%CJ][Y]D;Q<4CF G4>^@O&84FM5:,F7O
MVVFT>ZQCGR%)IJB4U::P?NA9Q-P1B&2'Y5^$^P$EY5!'()_0NE->XF(&WOE.
MXMDM]).[!T,8#Z*(%OQ>9S[4?JFNP(2DW9*"'3.PA38/PWA98WOT4N"WQ_G/
MDF;#(3OPG$)P+1G%/Y]BNO57S+4@*H&G*MFVL68DFZ-1T2;;FT]9JWIK5-#M
M\MBFU?MU_%_G_<9)[9%Y^[D1I8/"=C#V"#2 S4"2+-%+)0QV?NHU!E.'-\RE
MD.T)1R",!1_4P9BJO8D\MY;1^\(;TC@?M[]\'9*&N-0U*97$3,\$,;)+<_;L
M#Z^^Y?'S+8.\.:KTPT5CV0'A.R/WHG-<=V[^YD/8"AMO#N[<)V<:KJ&&A(UV
MD/A6Y(?+.:@'OCZ<J)U$JL6])=RMDVJA=A_EYQ/RS5I:T@7%DU?FOFJ79^98
MOYYLN?7)B(_JY%>G]DQM['CXY&E#F4]'(.=XUK2UK)\QNC]V7^A')69T^IJF
M!+AR/PBJ.S.L82,SW,9_I??!U8GF)RY/1'5&M>(Y#"#\JO#0&].]UI37S6=D
M%D9>'Y*MTF"W13Z9<RU8<%O7.GRRK70-S6^T?E4N=3(GR37TNSE.WZFRB^7K
MB7I%["2ZSCLBAJM-MP'YXW9Y/<9SQ-ILN+6%Z<K/?V*2I6M[_D\3%!GVF+>W
M[K,.#T8I#8N(N,6BUF'*LSZH=C2S;DT(90 7$5S,?/L4_2A*FY((0*G:<-]N
M>A-3X[ Z(P:/0 )U" 5/E##<JL1Q*]01T57KB<'@GE[(=%E>ZL]#%?'MRNMT
MQ 9L2)X0D/BE2*ECDO]0Q@*2%PXAS5/NTIGW>/RR5+^K,+UN?3H$G CAH/F2
MJF]/[G0K.P%^VP9DSL*6Q"@/U=)WFKJ39:Y.7G,'H6N4X/-E=8*V]GM[@*9V
MWX$>@6OG%CE_$,6UCTU&-PSMD*F/ >4U^]U O#S/X.][R7L$K1\'AT]=+\T_
ME;V!K?RA*S!3ZK.L[\J?+/#HNO:EA.6_O4Q25,"T+8WY5U69-I5"&PU[L8LE
M%)&Y)BQ.F3(UWZT(ETZAV+>26)[!;Y5OKYZJ>])I6S9:Y6.SU;AI9PW8&TUW
M:CZBJ.-"VL8FWXU0R+T"(>MO([V.0!!;6F[G;CFBFB'PQA6' "M3;Y.X$I9Z
M5]A(87'N[6:W+=B82G]%.-?*R.Y8A?%;SQ8MMU6YB^A7"GFSY=S^;F+T^"3G
M>6?YX&&VH//<J3'G<RR#%C0D\=G8X#QBY[&RK4/#&!JX#);\S046:TS*3?BS
M'(K7^JP04@CY[V/33-V)2IEMU1UEDSKE+H$+U-G5L[$_9-\'FC05YO8*J^2D
M[SW.]</^.J]8NS>-WJ9[(M20O0@^>\:9;6J4GP@J.J)"A&-C=XXS:UHC-%0W
M+BO=9^<(!$@5@TE]D(_#0Q(4+T Q=A.5>'@V$"K '#T$^0AT-HC>S0^@"89;
M<1EK0TM//["*!F;?Y[I3'2%$A3!8?R"))Y'_URY@%0>?]]2_AP=R__-&,-L4
MR/GGC\#4/Q<5D#HOM!'ONQ_2:Q144R"+>T35U<3.P+751*VN1,P>SU;+BCJ
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M3TONFQE%&UO-6\>N_DF T19']Z(O ?59S)P4!."8 QXJ[(?N1J7YQTGT\Z3
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MIE55[?Q_ISCW4V@OM-7:%%[ !C)?" >+)_7N$C@%?8 5L)#G&W<B&,WW*L?
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MJF%ZDSME*WT0KF(;]@Z5XNCH>N3,GY7#5_9 E&WC9B)^[F'%)S13-?^+.YK
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M5^,$)$_39ZFC;N#;@\1Q^>R_?M>V(9/850\@";&%WX;XC<XUTPHS#.K6+5P
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MA]]6OD__&'92^_NYX(OG\J8BL^,B>/MVL.R&D G4Q@O)-&I:B>G6,XP$;Q1
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MYN?'6BWCKLO_N1?UZ)E?"L6CR,1?^4JD#Y0CRI5GV:W^Y*A@WB-V=H5A@U^
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M09_CH";-4NMDY3CZY//0:+,L8C&2L1+K=&;9/.C^^_$CPF3B\7^S >W9G?P
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M+JBYHR)F="!U4WA@'=096IMAR3#=UF+I.:!V]&H%T,F$]>)G92YAQ;BQ+/P
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M@/9$"_S^9AQ8,#YF?#;VS:K>';#D2)913@?O&+;W,"RT+I#=#89R+G$5P$9
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MG;D('+YD9F$&L+&Q 3=87X Y YS_Y]=_Z_//(/_=,=B8GP#!@\#" 2=VMN/
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M/VGI!B&:)WP7(<&:PIXT1Z7=DSG^*Z;N[R-;X>#G)+.0[-&<R&O[DV+N+N2
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M]#O[HX/=_DCYZ,RG8X2$K[J8K\?P^D]SV?D!HX5$E'08$TAD<)'6%UH,T$S
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M;00"*BQ:P(>D)?N)T#G1M>ND0^^9 );4OOFRK&3^@G#5R2^R]DR D_4@CUQ
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MR9P:73B$6RS 2#!$6,XA79T@.?9\A/,@!SU(5Y91*9(52<8J(8HY9-RB8Y]
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M95&U0EZ-"FN.JQSR+7M.R';,/\VA."A@Z[>5=/X;PI^5-8,T\7^F"H.7HA2
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MA"=@-6D!X%HM3814V^=QF*9 +Z2QH\A23B3S+HS0[]:@51#=K;T0T'K=1;]
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M9CW+(A='?5_9L,]CK]"KL<*,$0]Q&'0&#*:$T<NWX-Y#XC-@ A\5)^T"0LZ
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M"].#E.=B*@NL.OD'?-+E089?KE/5==">1=I:J_<5B<Z%%B"E>*\I6\.8?U$
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MI)G&0>ZR,5*'96]5 A>X#F$ 9PAWL<YV:*&"'UA,XV5*S2R6K)WFT@.<=<I
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MBM L^'1ZB+ZK:6LR$4WN761:_7#[$/X@2GJ^:M+ ^J&J"V7X)O'M$;L34_S
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MRO&%]]4;JF#B0(P[=6H1_C56;'\%DS"U03( C^SBQ5I'=/'M?E[T5T71]-T
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MJ,!<Z+=,=HB5ZCB"JLV!?=9D E.-5_[2(JO?7-8ZNN*[5!I.@GYU9WT,O@&
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M&^T)'ZQS,O^6PQBE8/HXY_O63L?TP>@YLM9<.]4S2**52U1-]J_^^2>U@\+
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MJTQ:7>3>'A-@7TE1VT+9TSJX-1.KB=GTK]@]+P)DCP9N-N0*@K^+RY$95&3
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MJNXB7B:DT@J>R3DW-[=A;>//WHOB^E)!Z+5$4MO;B)LF:SQ/CZ\H>%,7\U$
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MN$.+TC#/VNL48F<:(TV^>LYQ-CJV[TVVC':S*$M*C5P=#G[W8EB T:I!GA6
MZ_>*G9$,-YYDR+K6QH?TE1!5\L9FG::@0M8VV9DQF5AA<Y/(F2G'=DQIJ/=?
MX%I84#14;TU-.DCSO :Z'&\RK,I[ /"9O5-Y!I?5S:LI)\OK)G<>TVQ2Q7_L
M2/!9B6VZ@T+\=)%G@[^NGO$B#+293:6Z&?,G7LZ)XK8U-,TEM&Q,<%\1*=%I
M)F1_*>\2O57=/JXP^M7%O-TGJ:G<-,$U%2")%"S8IEUX&BVG<8;HQ4GGWOQ0
M\7[WS98QS@9H6W@ *+U%WP5_??YGA1&M.-*(FD-KN&/35-;E *IK(/BX5N5$
M-)^S"$3\=62(C[POVPL0(4^6*WW$J?AXF;M_Z]5M(M@Z9&44):1@O?V.X*,%
M!'.$HI8=C*EN[G-?8?67T-I8F*W;[9PB^ED73UB3/*P6$V?]J7Q>YT*SNCBD
MF,6$Y#0 7="F[,MEJ7_H.S0!^\]91&IWN=C\+HJ* )8 01%2F^FN$SU'\_-K
M^77Q94&43S<\_"9GB-*<SRSD#]_>2@-.^@& GR Z.1%%BDUHZ7UA>52?%SJ&
M&QX9$^M@ER<4#C1*FJR%_^J'%<MYTFT[A1^W?'4X<D-5J"A/@%]5S+Y73,36
M3FM]SEW^XQ-:!>4:B'#QO?^5D'L>YS[<..8WO:2%]3.#V166_R'@C1:HK5)@
M,!\95X=/>.M%CLH(K+FG3ID3\E/J!"6:/.^J2Y=UILX[3P3,=6#O-I=Y6GGN
ME7>':%OQ#T[IW:9ZTH*'$:?".I'9W/"J>5,*Y-OO0W=^?Q*CLGAU\><10A>Q
M-2ZGP:\GO.[B^T9QJ8VSH[*D!NL'J@C[?K^_CEM\")';F]1231I?/7^T+HL_
M(%;C?(VWTO7 Y<6:VVMFTU?O,!1%PC9  ULSI?2=R+U[>>&5W(\+U3\\7KLZ
MEW4F+0^ 0X+4;X1&GQ]4>:J:M[ULGN!QOUF2I[+ZS?NWRGN&1;3?4THSSY\6
MQ1+;YS>BA@\ )=GO_5JG+^6X!V(<C]NM_5[\G^].U'*SM)_?%_Q_!^?RON#Y
M79/XD4W,7@8XK&64PB1W'GN4MV_"U6#;W><:OH@O7/8'6Z>X#9^ZGC?F[+E&
M<<7CTT<U,L+LV[=RVASCDD4N)(W8 )#&!X#7C[@*HZNH23M2*/QZ#&M%,9ZQ
MB4W9/,7)W#6?]:I4&R;(!:V6]A"!G-S5MBV2SS?8CETRG&<R^P @'BH1[K7;
M&_\->1(U;M60_X-AKTS4/P \"#T ]!QB)NK[.LM@L2Z)K="+%,8:B'(EV<#T
M>M;'Q%ZP(EPI[MCH ^$+%HU-!B09:%M%1E9S9'#ADH:3V3ZH)Z$&OK66+XN\
M872)GR7*E:)L*NUAP1']Q).ST->NY$<"\?P]8P')4UU:%%-<MSA1$_XG.^\)
MRSG$69HNQ Y.-DTO)2O+T/2,+*HUQE)],M+KV)8J6IO*N+  B)7:ET/N*D#A
M&(^,NT4#$%^@RL9)B$%2]ZI3;LCFU8>AW<K[FE=08H@1']=<2YO$R98<GPIB
MUHXB=:YUUFO'LOM'G/RS8;7"GG?OJL?/>(/K.[5YMC6^@2<SD>VZ<,]5, 6I
M& X5)FIQ?0^':+)4!MFZ1795XJ!8.+(LU[<*\3762G3$TK2:ZYTX1%U^R;W&
M'/QQHL+0B19A+$F 3=^GCW_OM_@<8S"FK'2H9<0^PP3U"DSJ'LW>E\>]+3M6
MEPZ^OM#] "J)X.LF*?&0K20X*+;FK]ZRDM*8%AOV;27HA1%+O>H QGB/63JE
M9^NR0!&\T-""#'[V;Z-BK0> % 02-L&SB3BL'L1Q9&RB.2E3*Y+[ U!9A%3\
M BN#))JY;[K:CET]21KC3X5".H95.6#T=_B95R,,=^R;-WG"<MSS372[3=_L
M9!-?N5EC%$>]E"NIBABTTN;XU\+]J%2*# .GLB2^^[</C"[)66$Q,A!B;)E>
M9!:NS)TH]H6;6#T7<)38QB9T@GXX6U4SZY<)AHHGY)VJXPL_;0?&[K^>?2::
M#[ZZDLJ00_ C!AC'$;*(+^;=Z3$KV9627]"M;$3+Y(HXYP#P#J& QY=>PA.2
M[T[$L=)?LT05H7:P\#O"3Y+BKM" F4T?I$OY2"!W:,OL?W?4OZ>M!2D7#^5N
MW6 <XOT*)PL4F 4X&/T/4$L#!!0    ( &A\KUK\OQM:\*@  ,^O   0
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MQ0GQHX^(U$AP-WO'S_[T22N-L<#++\U=ID90<M"@.)X)\;0>0;@]6HPW:L:
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M*SQ)T 85=>.F]HXX6YX]M+3REDUK7WJ6$?G.W_'X$!$;ME1#(IRI\J1P0?)
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MK')HK8E36\*>U&.Y^U1YY14/,F)D*1HX1_).P,O64E5>=M):VV.USQS(](N
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M3-W@^7E8Q!Q2R]*0 U$V9OXY]&/P?ER/E1B$>52$[*ZH[+MI"Z<@^5>=#1+
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M*74-#.D\&QFJ%X]:$<'*1]6[,9SH3Q^;Z+?.PS1*%EQ.]EJB1MA09$K^)V4
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MQ?HO.*Y=R:'[S*[&0BGRH:O5'Y"VY8E28=%A.%?8PMO8P6^"\A47#QE$$IX
M;CV)&R;-NH.G]"-3JK/<_0SBG]*&4FHO;]20'"]^>/&>/_(%OV[O0M2-FO7K
M&R+\"DM<FK:1NKQUU^*UP@^FQM,YPP#K"O<O&Y&L=J\ CZM;(/[!P/#,6I14
ML;EP[[L,U1MBGND;Q1IW/7N#3#P>\@P@'CE]_QA]1;#@_*8#C=)950FUW;(#
MQ;1 3W/6@5GD^")[P=;M;,Z-'/\!A:>Y&=,?K#>-'9O2]F1'^C4)57HTH_GF
M"]03[%?--2].,CP<*ZUXK19SG/>007)6%^L(.;KFV=4%A>QW"WMPHU-"V&4P
M&+/?*?<7XMA%MR4F'$9MUY1NQJM,>YL2T'T;(<2%C9DEVKLW[2?T.&I%S,-
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MN&M&(F<=\,"+X$/>F%3H:;!T^EOZGRI?J@30?U2UUES[]>4GF>=5[U6G-X7
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M\7Z64DG?\5G=;>$&OM/U^ ^B.ZQ)MM)VQ 41>8=!!F'>:6L]C%+'O<N]G;?
MI>*BRL*>M;:P;#>1*^G L.B4=.RK,')0Q$C.[=NN+'HM,QG++6.4'%F#\PW\
M>0RVM6K4IP9!Z<9,0S\YT8!\#>AY,G-3%IC76V&1ZK"7LRDQI&<_32)CV)V&
MAPP8ES?TRIEZ7+'ZHR!^"(U-\E>AETUX'^HGJ*YF/,^/ J3GL8K0T>2I>0=8
M,K8CGP#+]%5B4<7+]5$K%YI!=<L3/6)*WAI=LFZ]<\'&?#X#Y2")%DX>E I4
M*K9@_FCAO8(S=)-= [<#E1L=723T"V:@4^P_;CN;?<1 "Y<$FYN!LJ$/#=80
M*UKY SWX?/]%2)V)V1_>]/UY:AR>^7$Z0?74#C,Z$N 9N@<N7>,SO\P)WOSJ
M+M7C31!'7:\3T(G.#;24[3Z?G![M5?8<&SS$U3$N,2:QWU#QJ42/CRL:QZWY
M#AKJ1@]&&M[+,8\60\X*NH!MD&#V8%QX@IL#,-="2+,M:WWL$;?'V?4ZY(UV
MF#A2F8J/PVGYYK=#/RDN(<_/4^9&R.E1+]ZA:6%LMQ+DE.5-4VLG7! D-=+(
M>[W<N+)R$_AE2R!&C9?9I*P]1R.LL21ZT;[4(\=?M\6+^ZBC6P2Z_LTN*!E7
MM=V?73D]1'+>A'J7A+LA7=7DPN!KR E Z[>09=!#/K 8=*_:,B_\RK7YCS1O
M);CXKWL^7J KI5%V9Y!9U7C"LXTQAD)FU@@_2:$FSZ3#O<HOBSML/CG+]S+W
MF9)+' PFIBO:VBQ+-4(WH,N'88GU-D\[0X=^0/ OM9V4H1*3RIM*0QX*_,N)
M"-J/.'11YC?@<"/T4AEO0^ZY*'.;C+8I]\)=.P6V9E+W2UL2]WZI>/'^]8O+
M"WLU_"9WQ)"=OFU3:R*#N8)\F("\(SBY:>HY48-Q_[O*RN<&$UQHK+G"!N$F
MKJ<&- (X9+[V:5:"V.2?"/?/>>P% 1@QFJ/R *_5$M&LO<B[#Z]MUB/%63,S
M)9ACY$V*#?0S=91_B[*OD^E@*&.E".8+!M;OA>-I$;)&>&FIB7-\QG(!]W_B
M&@6@?103H#9'K?(H^,W.'!QD/)H*O;_2><85C?;^ \$GOW.-?U06]>RULL*I
MI1*T7@[J$JQC!17=PIG<A1R\LRSJ>P*8_UVI,TI#?D1#:,!R_2DLL9EN,>_Y
M+M,.'ROE[B$ZF#6GNG,JN]R[?>",FZ*Y, <SPN='DF.QOH4D8SOX^L,4?@BG
M]+7A&V=H(8&+)6M7NF^GH=@K:<D@,ZKON'QJG- 8[>46V#:E[',4'W*OU/3/
M$X T^!5F_-64^/57GIV<LYN!JX-EG_M\#KV"^2#:*I,?.<=:79W-SD6?Q=5,
M?A?G6LA+/ 'BMAE0<O#;_IRZ!):616DKF!LW=&]VV,PJ)I0V1%2;\?@O6VU!
M9_1&CE^TKR>Z>NMG >?:MU5X!,7J6)AR<DBIFYT6A./H+%HP>QC@6)9N'A4"
MOQW<XI]#.<)RC]W8Q_26@PV@[=+Z;I!9 G0WWL)X:85B$_4I&-9I'>]TY0A3
M6X07>N'/8,I[&10WW"J6<8C&(<*7TTI]29CQU(KHE[0*S,F'WN;WX=^41""L
M:D>V"5ABL196)!*Q3?56A=;?/D6I\*0';KD^^DB(N.Z+2KW9_G3BRO./8#RK
M7;)I&&-GTDI$(\N.:<)B/?C+%CXL50OG@X--HT0;-C3<O2ZDW.P!?PWDN8JC
M6<M9R^_46/([#J@/"SPM%1 P\07(]O!T7$4A]I&K7[EY0W+C]"<QND^AKBF2
MMB][PI7)%:3B !32I&/ZU\>62HCC1]7MX=E[,A&A.\7]3W*D_.XUIVY,G\?/
M/H?O7VSD]\"]",O$,7RH1P)"JW:4\FO=/M@K8\9CI.?=4$]ES@BMY^6ASW>F
MDEA8*)41.R7&-I.\MI'X()F7=%#Z6@6=GKN_^N#+3(S_)4L?G?O[8?'3_EGQ
M(^U2J73T.;$Y,X0,B013AVB;46/Z&"W9),+-1GF%G3*I7C_RDF(&2T;3;G/S
MR,M\4[75S</%'L2H%W/-DB& ?K\; 1EO9!VV17O])OBK>!T78CMA+*:ZMNZ<
MPKFZJ!4;3\#K@EI6\3W_+VS\MH_NXM)T-+O=A @^&=!(<4B!4PL^WQP;4*,#
MK_7">;[<S.Z2UA-8;(/]/$=>?N)JM^;KA]>KU:*$Y(EE,75)R6K6.WHB-.45
MZL3Y>2S<I@9,+6W#-26S_L^'OM7*<8\=?.&TXIPL4:;.DM53S\(!Q1E4Q$8;
MEYW:'2LFF[Q9&W3FE'7(KSMWJWLKHD%KHK3TH[YU8T4@RJ']LM_J59;\7/F7
MUGF_9^CVJB_;FF?)\-7),T\<V_"E?V.Q&X\K -/3/[V0_U)^\&/V _>8M)7?
MC>CRK<.KK?V_XM_SR3LKF'4$& 4K#\Z9%268V] ,N]$KL5S?J_G+3-U=L.T-
MU_1 IL@3 %ACZ641]_X0NSYIWZX*=3[^3+/TTKQ,?:/]6'#C/&I"1A>BK.YI
MP)3W1[//.LYJ:%B9;SY3^%2XB%OI<I3OU$0XA/D[T<W**4!5;GY9+RTZV5(-
M2PVW\A/M+VK]+B;T_IH_[$YVS$MDCGC*Z)QTZ9A4+-2,\<<KG^%Y&9K.%>:"
MU6G?H,FD',F_,/-$/ZM9TDJ,JFB-;M6?$N!Y"5NW^^G/S&/;SBC+3_2/R73J
MZ"YO''<Z:W.=0<7UR@%)@@P!BO*[00<OVBM"N4&,&B#A,00=T<S178I97.;P
M=[C6O 35+G%XP3=TN9>/<PS2B\$L4(T:%>T<ZWT53[)LSTL>]"G7\>\ 7'9!
M #K'2@XJ/-(2F8@@L"(!=2FO6"=JP8<OUH7%FD1ZSDHAE%X1ROWBDQ4&Z.*C
MH+$7CM^@@GD\ N*5A</#*H0X1)K+&>G:8-;YV";-BZZIW%R[Y;*YCV,XCBC;
ME%'[#:GLV=<C'P2/.FKYB"K4<XK"?[Q2KG'D:HK(YH[J&9?0+"FVS'[,N+(B
ME_DG3.ZFP%<\);+VF2,]8U]'&0H%8[EGVP_/C?^>M?MCX+&V;5#O,-,34+T>
MY_*.!7OF,:#P5G8Q3\H0'J.!(WLQA0QU@3>W6,%3N!,4;^-_>#6N<PNZ$_=2
M7U"U33Y+V[XFV=8Q6^1EPGC6,$%\'Q[AHQ6UUR^CW0L06=,JD5R$ZN5]*1*O
M<%U(%=145BNIR0FT""AXKEKIG2\+FO0YT,LT'LNY.IK/^R'IM:^QE?3S9JY&
M7Y0C_PR/59,IR7R,:]3.NV$J6E9?B"):WJ.#]"7>QZ*2H"\\PV]/WJ6TSGV:
M;W"PC@$(IVB(8NF)">P2Y ,/7NT[+48YD @Q14><<4Z_+'8MHMMA3O%.P:8B
MOWJKVVTXQWIBLKRU_ KWK?Z!:*FA5#LZ'[H/M<P+ 4.%$F"E3$['EU' 7>-L
MBV+%!$;M/($XW?68^+1WSGD*2JB4N'QS4\EN4F'J5X$&D;;%+S//$S1TZ;PD
M(V98T');LZ_CERS##^7RCNB%/(Y)8F\V(@>.,*&QI[J(]9'EOYL/,?D'8#-C
MJX?LDP+7R&D3ME7L"6E."9O7\A,;DG$5XO-1E4L/FU3L>P95(R)5ALE[/BV!
M9A8X91K$<</6']O-9=YI!EMXV&KE<V LYE?O'JES9VY-3G==R7FJC*7B BD9
M;1=\@UZQIT60W^N=LFEST-9CG29YA6;^@0,_6ZXK[MNYU6=TL+(&Q#[7QK\^
M$8=D6$T%R[Y$9L,O/ B G0]74]:P -M%X8-Y=LIY,U8[L;4SWM_?B#3SI 3N
M +-T&?<2]Q+!6DO=VM![DVN+TLT=!5KZXX^K.&3-;I_1,,X.F,*/<_;Z]\5Y
M9I*.(< Q8N5\EZ\![Q.^Z%5II,U0Y&@A#J*O6CL9:OW3'/*DDE+0Q88TL!,*
M:%+XA$LXU;IE6<!!7-E1Q3WG]KJFM^:UQ[8GN<F:COF0[-N2IBP;+*<)0 4Z
M>I^Y[P"5](H"5+6$MTH2+Z9@332+&4>%-FZ*3[V+B96EG0^]'G]%FLS*L?!7
M>UQ'FOQJ&9UUN/0MM2P2\]!B.V(9%B"BMM,979.6R=I C<=^/^@5>B/_7'4S
MM;"LS'F7/E"350^][<O$LY>5:QB^AY^]?Q]<36N7(TL'N77X]X@K[=0.)#F3
M7.U)['8X0E\0J+!"($9B%>(D0L,SHAF?BZ-I=5,@W@4]32N+.*B+A[I>5I=0
M<OC&CIKSR,:1K: *=_(!4,!V CWZD4A"^L.\%NH)L*'6)W7S(O^PO$S,,#A>
M!=15$F!5U*?1QW(RK7T3A_2%=CP!&DL1>&C+"G1[CG'\7\T>T@GDQ_NE'5,^
M NOAA<.:8B,O]P\T%UWK3C0>H6[NY&6 R_MK1SD.S>H^ =<D6%^FXU(O,V@T
MC!(4J]&3H*'YC'VQY?EB79+^J,[)RR63WZKK2+!!KWG#^&Z(]CTG*A@A=M-2
M[?6-%P:<<LH!!Q2Z#3NB)6!P:9EY>WF.0QPZX.V5XM5*YL+V)T>Z:GW.S;6U
M'0'NUY<-I_MT4KGVJW0O;(WP3U\'1%6.)KOH)W__,ZWXLX*Z?<)4:^O$8O:/
MMOY2PL\FPHSI$ 1Z^^=V[O8#*95?JE3XHQ!E[MS%Z.8;KTWES^?IK^PD$@3_
M3!8Y;[RO!PB@O7'3;X_6-P[4JF$H<;;G2<O6:&?Q4F.S<4#_:/F&X2.!&L3N
MD[:DV"@WT"SSG1O(#),#$W!0L4/;@UE*2+ZP=5@EVG+AUU>TR4#SQ;[:KKAV
M:>D4U"52J:V<$\C8MX6FI(T!DN:4N^ &!7NI09Q%:Y(:.*H$4"& VLX.?C0[
M),O 00.\+;9>AO!&J33L*ZJJYKOU__NXLQB!;82*#K;!. 8)]G@_DV!&P5<\
M;F0/<L03H3U0"->OP=5"WL-F"8\L1;J0A1"S-;Z6/@J4Z#)K(U*K5R3&X]F?
MP)D:QJ$UA_DAF<V(PP*:WJ5"*P>GL% ;Q>.'@NU84?]GHDJ?1Q6%(Y25W%^;
MV+Q4'MCE(C*&^-?MY]YL/*3U\J$TGP 1*4@KV%GB/0W_<+**.L+QY#8 /K2C
MF01F9<0]E6:!XLM/(("/-)A:78AW-"E%L!I)F63X&6Q;?I%1D\(0ZQED'"!7
M3(4+M6]_SI?[X:LJA9*?Q30-%_@\<=)I2YY]C?%;WF=<FUXRA!R*5.R&!9'7
M1U2+<H3SJR->E"&X;O"UASM+R^I N7J+U<5MR_L(G#%HCY:FYAF*Q17<L[1Y
M/5(8RZB5 +&T&.+1)JN./=>P2SLS5?%Y2SJ93&9?3!)@WSO&'$RDUN;6A#[X
M%::C$I0]]]:MF. [BR0VEHG:.G>U7I[BF[TB/[TU\/>LL,\B@%!]$.Y H./0
M.9*+, )%"[4B.&:@_;=D/%8YC."WX<U?>7TTK !.RY(JPV$QX& :J^CO#=JG
MUWUFN"#P11B1W!?XVT/W=R<:H4TK>WQY8.=_0S@J'MY-YYN*M$XEIE=UUJPN
M2REITDYX A#,SQR,-)@?#,T[_8B+5<]5L0VYB7RV2<BI"KQV^=\/1$5 #3Z_
M0/ODR^+O8)[)LD$D<*Z_8&(00V7G*"[;O'QTCUW"YNQ2<//8@_<$8,.ZT\?T
MEIBPH6HC_&S\C%:Z8G(GR8BW#B2FM$S.D36*&V*(51?SK0(\R-+1T-'5E(/9
MF6SC-*_V3,*Z6]2<#V+$=,OPWO8G&E)/#<^K7(U(,@)+/^]9,5'8L^?VXI;J
M'QO3_<VWL@Z/1GNVH6T4K?[^VGNV>W7$2$JS6,U"K4+U5D1ME,\LKK-A@PM^
MF<Q#_[R(ZMGT]>.WBB+G#R:-?6FO4@.ST 1W:>Y*=R#LJ:4N0LA$2'9B2U\4
M.!=4!YOI*$<"WVGDICX'=0W_78DI,3Z7-H,^?/@F0@MT>"-<N.J>55W52HZ#
M5K>@YI;AA$UCR_&1DU9"JF.S !U_]3"/SN@5C!#;*1 V_+<V'W>"S)]8J?QM
MZ'2038;\;RE3B[>3-_NJNT[Y10,"3:_&Q:O+HJ/?;VK#0KZIO,U_U 9>R[P3
M=4XH8G3(,[?O$W23XJO8%/-@/3\ZOZM@'.Y+Z"-HUM#DWB$<7.^C1P9I_^[%
M<FZ3(WZD,%.H*"0!)1HMY?-[V"(#=[?^Y!"DN2!*3H^3!(4322F3TJ[\AV83
M.PD32=S>0(V&+5B&;UXCLV&6N97.V93:/*DU2)M3NU0EWQZ!(YI@4\VVOS+#
M%+I3= J9QI_("M\M]C(<!RIULPR9UA0O"X0-BI&LN@S'G5[5H.N*I2N*^+Z
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M[<P&U63S_+J0SANM74_,Y&\FTOJ-+4Y-?H1?[*(K_&LYVTOK$Q/QVZCJ#W
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MJZ'"Y[J;BZ6Y;I.6Q\>(OG[^M=-'.K/<38NB1'UCHP?JE.O6.#B#8'>\H'*
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M]I^PW)7^<]BE'=]E/E?K>5]F^O4I_$FPMER:#R,7!NSECUBFR[05=.G"NB>
MP_E:T'OXYN.WJF._:> -,YX9'U&'%%6]13?D9]HE<1[ZA$3=<E!A;,.;Q"?
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M'D%5R&\@Z7"QL:YS]KF3=X?!=+%AZQ%)BW)+A<RB%?7DD4JO10B<%,&6[CG
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M6B;1ZSL4[/O68,(W%$RG[XU5HI"%SOQ_-E\]./HVK$FOH'E/'V.\2K&#B75
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M0#?/. 8/>&,-U)R 6[Y(\I9::;-4R.3_XI3]7[EEIZ)W^6[(!).OP&Y#&*Y
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M[\]SP27K_A>;[_\P=? [K24YOEL L]<?#R,#51I_W87:OR+S$V_.K[;FOQS
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MZ9CG!1M&CC #S3BX'(&SV5LZ!WKI<U6K= '4V& Q:D#Q#:&P^(!WJW%7!W$
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M;='[L05ACY;_7RW^?\SP;A?^!U!+ P04    " !H?*]:I?F>X<@-  ";F0
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MQ%$S+<!-%\=I8+4H-0!5-CFV+Y1;(.NOF-/0E=1M!^M8V=505L\M-CLNS=)
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MTY0EJIE-&(VP6+G/#4%^9!/X)'^QJN[WAC29O^UEQ?->]"@-?/PO4$L#!!0
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ME5BYN5TE9GL:,*%1 W\!84-[:WKB@;K9^CU7#^P^<Q?4IURL#S5KJ=.5M[U
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M:Y+L'F,Y+_'YF/Q+_D_%X9N_ %!+ P04    " !H?*]:H+="DY0E   3CP(
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M_3!*8\ ^/]TS6R(4WR(H##,S8P3+S;CJ#8,B7_VLLF$0%<"E/ZV!I3_,ILQ
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MK[JW,!X2TT<B1F+5R%12P#ZA*#,+8M$)&"R#H00<ZV:F'GGV"DB%70B2UUU
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MVD#)D[+?L__<."&BO_E_4$L#!!0    ( &A\KUK'^4KXH5   $.O!  5
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M[JYL_17Y?*TO83&MC A:*XM,^V?G32W')&_8<2?PN]>YY\3 M6>TKC10LD@
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M@  O8JNE9>#JUN[_#J+%):#ZK<[$$)-SM!O_G.,X$[OOUF_61O8^G&8@KW\
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M0?=N;0ME 7%&"5!VA[O*^;&;&Y=:CJY8YIB^%Q$^X2LO]RIL4GMEXK8O5:I
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M^DCJ9XW>DY+I9(=)7&$?TUCT^J_?GR%2QA:S6[V1^Q&U%6^F/!ODQ*P> TI
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M;349P^L^#'CD;LQR,%(;?ON41N9!U7G,D=CHPZ]FY!UB[>"1UJC7GM;  .=
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M%+!B6NUZAH)=24X:V73Y=!*+IF%+)6#KHUY>NL])1(QEMWAGRY:;43C0P27
M:KU]X7/)O/I9(Y]8267.2-HC_;;?=>=DB^Q\Y7G;WR99AO/LLB"+M^[U(*'
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MZO44"XE_M]!'?;((E'WG/E)V((TZG!#I;+4*<^2"<(W<9?00LV5!GCD,%=H
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M8S_FUYZ;2H=++_Z>C@E]?%).KUV9^YZO:GBTCNJ]F]7&M>V5?&JO4UBY@^5
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MA/(OXO_=!PGAO_G_4$L! A0#%     @ :'RO6FB"95/T]@  %4<%  H
M         ( !     &5X,3 M,BYH=&U02P$"% ,4    " !H?*]:S-_#@S$(
M  !'5   "@              @ $<]P  97@S,2TQ+FAT;5!+ 0(4 Q0    (
M &A\KUKQ.'=&!P@   12   *              "  77_  !E>#,Q+3(N:'1M
M4$L! A0#%     @ :'RO6@(^P>(Z!   K1L   H              ( !I <!
M &5X,S(M,2YH=&U02P$"% ,4    " !H?*]:2#W< SL$  !T&0  "@
M        @ $&# $ 97@S,BTR+FAT;5!+ 0(4 Q0    ( &A\KUI)&!BZ>$,
M  -\ 0 )              "  6D0 0!E>#0M-BYH=&U02P$"% ,4    " !H
M?*]:(EDHE=A" 0"C8PX #               @ $(5 $ 9F]R;3$P+7$N:'1M
M4$L! A0#%     @ :'RO6GBOR4\&U@$ )?X! !               ( !"I<"
M &9O<FTQ,"UQ7S P,2YJ<&=02P$"% ,4    " !H?*]:O"\UGJ%\ P"7B@,
M$               @ $^;00 9F]R;3$P+7%?,# R+FIP9U!+ 0(4 Q0    (
M &A\KUJ0.%?;S.$  )7H   0              "  0WJ!P!F;W)M,3 M<5\P
M,#,N:G!G4$L! A0#%     @ :'RO6JDZCEY]# $ >A$! !
M ( !!\P( &9O<FTQ,"UQ7S P-"YJ<&=02P$"% ,4    " !H?*]:F66>RP/0
M  !/U0  $               @ &RV D 9F]R;3$P+7%?,# U+FIP9U!+ 0(4
M Q0    ( &A\KUK\OQM:\*@  ,^O   0              "  >.H"@!F;W)M
M,3 M<5\P,#8N:G!G4$L! A0#%     @ :'RO6J7YGN'(#0  FYD  !$
M         ( ! 5(+ &=T8G M,C R-3 S,S$N>'-D4$L! A0#%     @ :'RO
M6NOD;YHF"P  I7X  !4              ( !^%\+ &=T8G M,C R-3 S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( &A\KUJ@MT*3E"4  !./ @ 5
M  "  5%K"P!G=&)P+3(P,C4P,S,Q7V1E9BYX;6Q02P$"% ,4    " !H?*]:
MQ_E*^*%0  !#KP0 %0              @ $8D0L 9W1B<"TR,#(U,#,S,5]L
M86(N>&UL4$L! A0#%     @ :'RO6NCW38'7-@  "L@# !4
M ( ![.$+ &=T8G M,C R-3 S,S%?<')E+GAM;%!+!08     $@ 2 $@$  #V
%& P    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20250331.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-02-262025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_InducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2024-05-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-18</instant>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-13</instant>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-112025-05-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-11</startDate>
            <endDate>2025-05-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-14</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="From2025-04-012025-05-15_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-15_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-15</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-03-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-03-31" id="Fact000005">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-03-31" id="Fact000006">0000109657</dei:EntityCentralIndexKey>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:FairValueOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0522"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0524"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0613"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0615"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0731"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0733"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0735"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0737"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0739"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      id="xdx2ixbrl0741"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-03-31" id="Fact000012">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-03-31" id="Fact000013">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-03-31" id="Fact000014">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-03-31" id="Fact000015">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-03-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-03-31" id="Fact000017">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-03-31" id="Fact000018">GT BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-03-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-03-31" id="Fact000020">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-03-31" id="Fact000021">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-03-31" id="Fact000022">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-03-31" id="Fact000023">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-03-31" id="Fact000024">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-03-31" id="Fact000025">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-03-31" id="Fact000026">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-03-31" id="Fact000027">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-03-31" id="Fact000028">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-03-31" id="Fact000029">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-03-31" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-03-31" id="Fact000031">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-05-13"
      decimals="INF"
      id="Fact000032"
      unitRef="Shares">2586397</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-03-31" id="Fact000033">505 Montgomery Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-03-31" id="Fact000034">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-03-31" id="Fact000035">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-03-31" id="Fact000036">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-03-31" id="Fact000037">94111</dei:EntityAddressPostalZipCode>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">2365000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">3951000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">2658000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">4232000</us-gaap:AssetsCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">2380000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1132000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">1797000</us-gaap:AccruedLiabilitiesCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">126000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3638000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">5902000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000081"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000083"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000085"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000087"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000100"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000102"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000106"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000108"
      unitRef="Shares">2536397</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">2536397</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">695019000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">693554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">-696003000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">-695227000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">-980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">2658000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">4232000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">1099000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">777000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">3000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000142"
      unitRef="USD">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">833000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">2314000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">-1932000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">-3091000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">32000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">142000</us-gaap:InterestIncomeOther>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">-126000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">-658000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">998000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">-2000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">1156000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">-776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000171"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000173"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000175"
      unitRef="USDPShares">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000177"
      unitRef="USDPShares">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">2345087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">2345087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">1380633</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">1380633</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000187"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">2234328</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000188"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000189"
      unitRef="USD">693554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-695227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">302069</GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000198"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000199"
      unitRef="USD">615000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">616000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000207"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000213"
      unitRef="USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">-776000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000223"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">2536397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000224"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000225"
      unitRef="USD">695019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-696003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-980000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000239"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000233"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000241"
      unitRef="Shares">1380633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">1380633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">1380633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">689641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-684331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">5312000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">1380633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">689641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">-684331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">5312000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">3000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">102000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-126000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-658000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-2000</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">12000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-6000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-1291000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-1347000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">2000</GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-2202000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">-4163000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-5034000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">5034000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">616000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">616000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-1586000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">871000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">4044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">1079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">2458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">1950000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <GTBP:FairValueOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000360"
      unitRef="USD">847000</GTBP:FairValueOfPrefundedWarrantToSettleVendorPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000363">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zM6PIFrYAEv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_823_z23uQagtjm6i"&gt;Organization and Going Concern Analysis&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GT
Biopharma, Inc. (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#xae;) platforms. The Company&#x2019;s TriKE&#xae; and Dual Targeting TriKE&#xae; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#x2019;s own natural killer cells (NK cells).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Throughout
this Quarterly Report on Form 10-Q, the terms &#x201c;GTBP,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;the Company&#x201d;
and &#x201c;our Company&#x201d; refer to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
GT Biopharma logo, TriKE&#xae;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Going
Concern Analysis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible
debt instruments, and strategic collaborations. For the three months ended March 31, 2025, the Company recorded a net loss of approximately
$&lt;span id="xdx_90B_eus-gaap--ProfitLoss_iN_pid_di_c20250101__20250331_zt99e9axnC3l" title="Net loss"&gt;800,000&lt;/span&gt; and used cash in operations of approximately $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250331_zHl2q3qQWmh" title="Net cash used in operating activities"&gt;2.2&lt;/span&gt; million, and had a stockholders&#x2019; deficit of approximately $&lt;span id="xdx_906_eus-gaap--StockholdersEquity_iNI_pn6n6_di_c20250331_z31Ufg8ARuT" title="Stockholders deficit"&gt;1&lt;/span&gt; million
as of that date. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year
of the date that the financial statements are issued. In addition, the Company&#x2019;s independent registered public accounting firm,
in its report on the Company&#x2019;s December 31, 2024, financial statements, raised substantial doubt about the Company&#x2019;s ability
to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable
to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated the significance of the uncertainty regarding the Company&#x2019;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#x2019;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#x2019;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000365"
      unitRef="USD">-800000</us-gaap:ProfitLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="-5"
      id="Fact000367"
      unitRef="USD">-2200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-6"
      id="Fact000369"
      unitRef="USD">-1000000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000371">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zRhOk7ZRSfae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_828_zHweFq8hJnyg"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zmAmW8E5Bce8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z470qXIiS6Ld"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain
information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be
read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance
sheet as of December 31, 2024 included herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zqT8nlXirlld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zGi5OSuGphgl"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zI8cXo5tQFOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zjgXBdSxuVk7"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At March 31, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds, amounted to approximately $&lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zYOreHHvbRKg" title="Cash equivalents"&gt;2.2&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zBl9ncHWQPD1" title="Cash equivalents"&gt;3.8&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zv9OsLVptJsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zMMvlSpaDnai"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement
with the same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zacVsGESQNJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zUb8WajMASUb"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses
and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of
these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20250331_zOXvps7CxYa7" title="Warrant liability"&gt;126,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_zspCPHqNOLEj" title="Warrant liability"&gt;252,000&lt;/span&gt; at March 31, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--WarrantLiabilityPolicyTextBlock_zn4R7s00VTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zmB5wSBctree"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zqoRcRrNaNji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zaJjXnbQV6M8"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zCvsGIiEXn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zTSl9riVB5mk"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zbXPGAi80Qdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zRBQmeHnWnj5"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;304,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,894,494&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431,227&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z81CU68N4GFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zzhLpyzj6El3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOEuKYc0ZAPb"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20250331_zS9GZTGTB3dj" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University
of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwwaByBJlAOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zPIXApcRV3ug"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEag9Q3NM2M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zHfJBoclPqT7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85E_znT4gC9gGuDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000373">&lt;p id="xdx_84A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zmAmW8E5Bce8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z470qXIiS6Ld"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable
rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain
information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be
read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance
sheet as of December 31, 2024 included herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-03-31" id="Fact000375">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zqT8nlXirlld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zGi5OSuGphgl"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000377">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zI8cXo5tQFOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zjgXBdSxuVk7"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At March 31, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds, amounted to approximately $&lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250331_zYOreHHvbRKg" title="Cash equivalents"&gt;2.2&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zBl9ncHWQPD1" title="Cash equivalents"&gt;3.8&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000379"
      unitRef="USD">2200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000381"
      unitRef="USD">3800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2025-01-01to2025-03-31" id="Fact000383">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zv9OsLVptJsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zMMvlSpaDnai"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement
with the same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-03-31" id="Fact000385">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zacVsGESQNJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zUb8WajMASUb"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses
and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of
these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20250331_zOXvps7CxYa7" title="Warrant liability"&gt;126,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_zspCPHqNOLEj" title="Warrant liability"&gt;252,000&lt;/span&gt; at March 31, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">126000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000391">&lt;p id="xdx_843_ecustom--WarrantLiabilityPolicyTextBlock_zn4R7s00VTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zmB5wSBctree"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000393">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zqoRcRrNaNji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zaJjXnbQV6M8"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-03-31" id="Fact000395">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zCvsGIiEXn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zTSl9riVB5mk"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000397">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zbXPGAi80Qdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zRBQmeHnWnj5"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;304,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,894,494&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431,227&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z81CU68N4GFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000399">&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z8nEEifDJv74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_z9sQ3lkO6sp7" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250331_zzRSh0IMNCW8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240331_znuZCsPrwes1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March
                                            31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&#x202f;&#x202f;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zET941P3QPk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmY0i6Nezfn1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;304,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zti8wGMSNlw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,894,494&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431,227&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">124600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">126265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000404"
      unitRef="Shares">1769894</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">304962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">1894494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">431227</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-03-31" id="Fact000410">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zzhLpyzj6El3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOEuKYc0ZAPb"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20250331_zS9GZTGTB3dj" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University
of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000414">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwwaByBJlAOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zPIXApcRV3ug"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000416">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEag9Q3NM2M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zHfJBoclPqT7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000418">&lt;p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zOdI1DL8mQz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_821_zH2zM6gKBSR8"&gt;Accounts Payable and Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcZATHE2dRq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zKWYRga3cP4g" style="display: none"&gt;Schedule
of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250331_zqW0YFXn3lBf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_z1WqoC6Zg8B2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXLwOEOvO1m9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts payable
    to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F4E_z4UeE58erEQf"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;600,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z1dMePmOYD8g" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z5FJlFZ8isvd" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zjUsN19m6ata" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable to University of Minnesota&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zlDwu4Xead43" title="Accounts payable interest rate"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;712,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_ziZvvk7z22X5" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpehegdI0Lu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal services firm&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zztuRI6YJCde" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjRO9z2vDVGd" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zrHzT4rPEdff" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjDQo3GCFERe" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zB0I64IsCdH5" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zSNx52a28dp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;554,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zay1ppGKWtfh" title="Accounts payable interest rate"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;453,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z7TmpAgQIJT5" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zajFcUgdrSBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331_zqLF4pMHeNXi" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,853,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_z4rDXvrJuaIc" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td id="xdx_F01_zZsdS1E3ZXe4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zhrfQva32tsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
                                            Payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_znnEVNOy7KV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zALwPRMOQmf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zdNKQsxVbiCj" style="display: none"&gt;Schedule
of Accounts Payable to Related Party&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250331_z8nrJ4FJXso4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240331_zUA7eC4FzE6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zxID2R9FHfA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,515,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zUO0oBe3k6ni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Invoices, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;532,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;269,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTpHmaiJX623" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(268,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zhYuxYYBTK39" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in pre-funded
    warrants, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(847,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0477"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zevZ2mD2owff" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;600,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,984,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_ze56yxW8XcD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zd27Unshc0lk" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares of common stock exercisable
at $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zDYAuT8VtyV" title="Exercise price"&gt;0.0001&lt;/span&gt; per share with a fair value of approximately $&lt;span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgKhMJQaAxp5" title="Payments in pre-funded warrants, at fair value"&gt;847,000&lt;/span&gt; to Cytovance as partial payment of accounts payable. The pre-funded
warrants were valued at the market price on the last day of the month during the respective month that the invoices are due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#x2019;s prior year unpaid fees by approximately
$&lt;span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zzFXn5B72fE" title="Prior year unpaid fees"&gt;1&lt;/span&gt; million. The Company classified this transaction as other income during the period ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000420">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zcZATHE2dRq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zKWYRga3cP4g" style="display: none"&gt;Schedule
of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250331_zqW0YFXn3lBf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_z1WqoC6Zg8B2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXLwOEOvO1m9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts payable
    to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F4E_z4UeE58erEQf"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;600,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z1dMePmOYD8g" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_z5FJlFZ8isvd" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zjUsN19m6ata" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable to University of Minnesota&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zlDwu4Xead43" title="Accounts payable interest rate"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;712,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_ziZvvk7z22X5" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpehegdI0Lu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal services firm&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zztuRI6YJCde" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjRO9z2vDVGd" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zrHzT4rPEdff" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;597,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zjDQo3GCFERe" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zB0I64IsCdH5" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zSNx52a28dp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;554,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zay1ppGKWtfh" title="Accounts payable interest rate"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;453,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z7TmpAgQIJT5" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zajFcUgdrSBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250331_zqLF4pMHeNXi" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,853,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_z4rDXvrJuaIc" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td id="xdx_F01_zZsdS1E3ZXe4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zhrfQva32tsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
                                            Payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">600000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000425"
      unitRef="Pure">0.25</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Pure">0.31</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-03-31_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">629000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000432"
      unitRef="Pure">0.26</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">712000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000434"
      unitRef="Pure">0.18</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">597000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000439"
      unitRef="Pure">0.25</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000441"
      unitRef="Pure">0.39</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000443"
      unitRef="USD">597000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000446"
      unitRef="Pure">0.25</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Pure">0.39</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">554000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Pure">0.24</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">453000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000455"
      unitRef="Pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">2380000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000460"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000462"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000465">&lt;p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zALwPRMOQmf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zdNKQsxVbiCj" style="display: none"&gt;Schedule
of Accounts Payable to Related Party&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250331_z8nrJ4FJXso4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240331_zUA7eC4FzE6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zxID2R9FHfA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,515,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zUO0oBe3k6ni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Invoices, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;532,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;269,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTpHmaiJX623" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(268,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zhYuxYYBTK39" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in pre-funded
    warrants, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(847,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0477"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zevZ2mD2owff" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;600,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,984,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">3515000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">532000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">269000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">268000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1800000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000479"
      unitRef="USD">600000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">1984000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000484"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:PaymentsForFees
      contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember"
      decimals="-6"
      id="Fact000488"
      unitRef="USD">1000000</us-gaap:PaymentsForFees>
    <GTBP:WarrantLiabilityTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000490">&lt;p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zAPAMzLGFfWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_825_zqbd1GKbxbQ6"&gt;Warrant Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z9Wn8dAr8rt6" title="Warrants to purchase"&gt;216,667&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;2023 Common Warrants&#x201d;), and placement agent warrants to purchase
up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zmHfZSUpMuW6" title="Warrants to purchase"&gt;13,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;2023 Placement Agents Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#x201c;2023 Warrants&#x201d;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zrrIJOKaTQg4" title="Volatility amount utilized in the value calculation percentage"&gt;100&lt;/span&gt;% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#x2019;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrants were initially recorded at a fair value at $&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zUINDY4eEwbj" title="Warrant  fair value"&gt;5.8&lt;/span&gt; million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#x2019;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zq3ZcIXqQcel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a BlackScholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zqVMRczECXg3" style="display: none"&gt;Schedule
of Warrant Liability Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zxkZEcyMUNDg" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zI2ZKBePaDPh" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup id="xdx_F4D_zOwk5RhxxqZg"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zE5vJQEuvXPj" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zoeM54tNwsCl" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup id="xdx_F4E_zZXqpXDLWypd"&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z0D7SRTuVGF9" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zdmOdN0ZZFDl" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup id="xdx_F48_zvGlUa57Zhfc"&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zHmVUjPWfAQ6" title="Expected life (in years)"&gt;2.75&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z9EC9wV3sDtl" title="Expected life (in years)"&gt;3.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zIU4Ylbt9qG5" title="Expected life (in years)"&gt;3.00&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zZDwDxUEPSI1" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup id="xdx_F4F_zelfSlSVyIg3"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zDUZHAFyOnua" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0522"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zX8IAhNPrhq2" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zaFbvcMFMlB2" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z1VDfo10kQO" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0D_zYjOToFFH3vg" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_zTdv3qgvClSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0C_zvpQT0GH6Qs1" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zAnmwhI4d9ah" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0E_zIo5uGGv9OHb" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zLN7PkjyPcej" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F05_zOgBl70L1kif"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_za3P2XSlLMx8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AE_zm8VVcez7oXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zRTHSBQwv64b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zCApsygI1Ndi" style="display: none"&gt;Schedule
of Warrant  Liability Transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250331_zHEIIxNXu5Fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240331_z4UqUeGrsoh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zG7JU6ftL4me" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,052,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zKClTktTjRU2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance of warrants at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIhUaRRlmMC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zTwyAK8bjMql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0545"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0546"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zVUwC9mOynhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A4_zb0HKYT3ZeLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000492"
      unitRef="Shares">216667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000496"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="-5"
      id="Fact000498"
      unitRef="USD">5800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember"
      id="Fact000500">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zq3ZcIXqQcel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a BlackScholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zqVMRczECXg3" style="display: none"&gt;Schedule
of Warrant Liability Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zxkZEcyMUNDg" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zI2ZKBePaDPh" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup id="xdx_F4D_zOwk5RhxxqZg"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zE5vJQEuvXPj" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zoeM54tNwsCl" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup id="xdx_F4E_zZXqpXDLWypd"&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z0D7SRTuVGF9" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zdmOdN0ZZFDl" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup id="xdx_F48_zvGlUa57Zhfc"&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zHmVUjPWfAQ6" title="Expected life (in years)"&gt;2.75&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z9EC9wV3sDtl" title="Expected life (in years)"&gt;3.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zIU4Ylbt9qG5" title="Expected life (in years)"&gt;3.00&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zZDwDxUEPSI1" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup id="xdx_F4F_zelfSlSVyIg3"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zDUZHAFyOnua" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0522"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zX8IAhNPrhq2" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zaFbvcMFMlB2" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z1VDfo10kQO" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0D_zYjOToFFH3vg" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_zTdv3qgvClSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0C_zvpQT0GH6Qs1" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zAnmwhI4d9ah" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0E_zIo5uGGv9OHb" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zLN7PkjyPcej" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F05_zOgBl70L1kif"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_za3P2XSlLMx8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000502"
      unitRef="USDPShares">2.15</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000504"
      unitRef="USDPShares">3.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000506"
      unitRef="Pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000508"
      unitRef="Pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Pure">112</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000512"
      unitRef="Pure">114</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000514">P2Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000516">P3Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000518">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000520">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">126000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000534">&lt;p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zRTHSBQwv64b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zCApsygI1Ndi" style="display: none"&gt;Schedule
of Warrant  Liability Transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250331_zHEIIxNXu5Fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240331_z4UqUeGrsoh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zG7JU6ftL4me" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,052,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zKClTktTjRU2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance of warrants at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0540"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIhUaRRlmMC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zTwyAK8bjMql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0545"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0546"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zVUwC9mOynhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">1052000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">-126000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">-658000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">126000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">394000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000551">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHRGombDIUQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_823_zIGddV7QHat3"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s authorized capital as of March 31, 2025 was &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_zcYP3SOb3O65" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_zLTVgR4WAM6j" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_z19uG5FLWC61" title="Preferred stock, shares authorized"&gt;15,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zUNnKtJdz22g" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Warrant Inducement Transaction&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2025, the Company received gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zLS9bHQh7zra" title="Proceeds from private placement"&gt;686,000&lt;/span&gt;
before deducting placement agent fees and other offering expenses of $&lt;span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_z1VPm9iHPPz5" title="Other offering expenses"&gt;70,000&lt;/span&gt;
in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226_zXKpaejRaEC4" title="Issuance of warrants"&gt;302,069&lt;/span&gt;
shares of the Company&#x2019;s common stock at $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zblTL6afperg" title="Share price"&gt;4.35&lt;/span&gt;
per share. The holders agreed to exercise these existing warrants at a reduced exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z3pd9KePE9w8" title="Share price"&gt;2.27&lt;/span&gt;
per share in exchange for the Company&#x2019;s agreement to issue the holders new warrants (the &#x201c;Inducement Warrants&#x201d;)
exercisable for an aggregate of up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zeCdRkOxUqHe" title="Issuance of warrants"&gt;604,138&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inducement Warrants consist of i) new Series A Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zCO0MtQqnK61" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of Common
Stock at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zwAvPu6xgJr6" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_z5IzWdtryvi3" title="Warrant term"&gt;five years&lt;/span&gt; from the date of issuance, and ii) new Series
B Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zOvJ8KCsOzdh" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyNQ11svGdMa" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately
upon issuance with a term of &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_z6k5OlPMUh46" title="Warrant term"&gt;eighteen months&lt;/span&gt; from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240523_zTkrCPQiDXnd" title="Placement agents"&gt;21,145&lt;/span&gt; shares of common stock at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zwb6XRnUYg" title="Exercise price"&gt;2.8375&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zoGPjdbEHp2k" title="Warrant term"&gt;five years&lt;/span&gt; from the
date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#x2019;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $&lt;span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250331_zQz5MRAXQ7jf" title="Equity issuance cost"&gt;1.1&lt;/span&gt; million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
C Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, there were &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJySguInM01" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqxVdC8cGGm6" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt;&lt;/span&gt; shares of series C preferred stock, par value $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJMIh8i0dVvl" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share (the &#x201c;Series C Preferred Stock&#x201d;)
issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
&lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLvkRRo84uu4" title="Preferred stock, shares issued"&gt;96,230&lt;/span&gt; shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000555"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000559"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000561"
      unitRef="USD">686000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000563"
      unitRef="USD">70000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000565"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2025-02-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000567"
      unitRef="USDPShares">4.35</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000569"
      unitRef="USDPShares">2.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000571"
      unitRef="Shares">604138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000575"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      id="Fact000577">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000579"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000581"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      id="Fact000583">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-23"
      decimals="INF"
      id="Fact000585"
      unitRef="Shares">21145</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000587"
      unitRef="USDPShares">2.8375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-02-26" id="Fact000589">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000597"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <GTBP:CommonStockWarrantsAndOptionsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000601">&lt;p id="xdx_806_ecustom--CommonStockWarrantsAndOptionsTextBlock_zOx08Tl0c5w9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_82A_zOJ5liIIBDZ7"&gt;Common Stock Warrants and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zNijWn5Oqb17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zQZzAJUiSHbk" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zaOszPndsBcg" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,120,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zIS25OOpsxh1" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zDlP55hnZGb" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;951,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250331_zgmaCpNYvMPd" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250331_zV9d4w3rg8i8" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0613"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250331_zKgEw1yv7Ym1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331_zSi1crGnMMpj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(302,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250331_z3pBqM9iRRL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zsv46KVXYRMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_zHUFngovEUl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250331_zIGjOpokraA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zaaHhne0BtA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zSvMFSa0S0oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, all outstanding warrants were fully vested and exercisable and had an aggregate intrinsic value of approximately $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250331_zXrhk6maDCm1" title="Options outstanding intrinsic value"&gt;780,000&lt;/span&gt;
based on the fair value of the Company&#x2019;s common stock on March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z15bp3jr1SQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of March 31, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxvwGp0FxzI6" style="display: none"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding and Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXb3A1LpFlg" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zL6J8rmNonu3" style="width: 22%; text-align: right" title="Number of outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zr1mXiK5iCHk" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAJWDXzR0JOf" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zti4BJe7frof" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;604,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHAXH1kSa6i7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVmX3O1lUOo9" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ10iRdr6i78" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zt047FzdD05i" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zErWXMrasQOi" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z12UvnA63y2f" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgEe3Fz09W3j" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zG3ojNL9m2S6" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437,931&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_ziNZU4uDeHS8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTxNimT4MLA6" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTeOEsCSCMX9" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3y6w2gFVXj4" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zu6LytumgCfl" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zaL2hyh1NTn8" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTGwkPz2xG48" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBX7fOKkWOIf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4V6RH8XRZ" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zgCjWH6wHzU8" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUMhdzPuOyF2" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zVBRnY2D73Pa" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zkpTu0a2QLS7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zZGgLYt84Ws3" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4Thc450ADql" title="Range of exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zfXP9059l2D8" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zL8GybeHIOrf" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zg6Y8d4U2Wc1" title="Warrants weighted average exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zwAdIiRn3P99" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zY3Hr46dtLjl" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,316&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJXkHQlANyLd" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z1z77Gq6krb5" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zgP6M7hcSRmf" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zy6wQpztR4Oi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQ4ge4H0Enel" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZrzNVWbttfj" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUp7oXuCfEg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zkk3adYBfwAa" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlr2WDuWOEI3" title="Warrants weighted average exercise price"&gt;11.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zF2LG7OPp8dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zmgXZImSAPVb" title="Common stock awards granted"&gt;166,667&lt;/span&gt;.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under
the Plan. As of March 31, 2025, there were &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331_zPc73PT8vxSh" title="Stock option outstanding"&gt;124,600&lt;/span&gt; stock options outstanding and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250331_zz1TNoO99XNc" title="Rstricted stock granted"&gt;25,935&lt;/span&gt; shares of restricted stock granted in prior years
under the Plan, which left &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zAj24qQeubi5" title="Available for grant"&gt;16,132&lt;/span&gt; shares available for grant under the Plan. The following table summarizes stock option transactions
for the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwX7pgJKqPTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zAFYiX5utv6d" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331_zoyRoudq3b57" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_z06l8W2piFsh" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250331_z3b7CHLeCNgg" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zUt0FrITAJs7" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331_zPhtp7JDkKn8" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_z95YfFOnKPt" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331_zv5tGuY6zQ39" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zX4lrtnt3Yri" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331_zD65Ylh3Gdia" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_z57GoByABuV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250331_zFAS13N4juP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zejkIcCibhig" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zYndHl2ev1X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of March 31, 2025 was
&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331_zUudQ9v3hJMa" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term"&gt;8.0&lt;/span&gt; years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable as of March 31,
2025 was approximately $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250331_zTsBkWN4XW7k" title="Options outstanding intrinsic value"&gt;1,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250331_zeoTZW2zZsb8" title="Options vested and exercisable intrinsic value"&gt;0&lt;/span&gt;, respectively, in each case based on the fair value of the Company&#x2019;s common stock on March
31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total fair value of options that vested during the three months ended March 31, 2025 and 2024, was $&lt;span id="xdx_904_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250331_zVQPbU6eXn4a" title="Fair value of vested stock options"&gt;3,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240331_zHgq2xdQxEef" title="Fair value of vested stock options"&gt;102,000&lt;/span&gt;, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
March 31, 2025, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250331_zguKtE1oskkd" title="Stock option, exercisable"&gt;107,746&lt;/span&gt; stock options were vested and exercisable and unvested compensation expense amounted to approximately $&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250331_zUcR6eAmqd38" title="Stock option, unvested compensation"&gt;29,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zyjW5WJYy61a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of March 31, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zE9N8n3wJHgg" style="display: none"&gt;Schedule
of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Options Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSJscntedLyg" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zx9QbJXzLLpj" style="width: 22%; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQ0kMtC25rCf" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcO51nuYSHgj" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmzqmTT8fNo9" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z93huJfABi3b" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zt6FOBpqvvu5" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBNSj0IXaYZ4" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuSUHk5vpgY7" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNbwl6Pt93j2" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zA8tdYPN4d02" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDW3rlOB6ZMe" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwhfLDvXzjNl" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9BnGNSHZ0He" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,598&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFOtwcsmrZjg" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zncA8Sd9SxS9" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331_zuBHkw7zoKO" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zmMKfWSNQ2de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:CommonStockWarrantsAndOptionsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000603">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zNijWn5Oqb17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zQZzAJUiSHbk" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zaOszPndsBcg" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,120,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zIS25OOpsxh1" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zDlP55hnZGb" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;951,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250331_zgmaCpNYvMPd" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250331_zV9d4w3rg8i8" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0613"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250331_zKgEw1yv7Ym1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331_zSi1crGnMMpj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(302,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250331_z3pBqM9iRRL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zsv46KVXYRMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_zHUFngovEUl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250331_zIGjOpokraA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zaaHhne0BtA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">1120429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000607"
      unitRef="USDPShares">18.85</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">951534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000611"
      unitRef="USDPShares">2.05</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">302069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000619"
      unitRef="USDPShares">1.35</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">1769894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000623"
      unitRef="USDPShares">11.91</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">1769894</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000627"
      unitRef="USDPShares">11.91</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember"
      id="Fact000631">&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z15bp3jr1SQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of March 31, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxvwGp0FxzI6" style="display: none"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding and Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXb3A1LpFlg" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zL6J8rmNonu3" style="width: 22%; text-align: right" title="Number of outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zr1mXiK5iCHk" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAJWDXzR0JOf" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zti4BJe7frof" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;604,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHAXH1kSa6i7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVmX3O1lUOo9" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ10iRdr6i78" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zt047FzdD05i" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zErWXMrasQOi" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z12UvnA63y2f" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgEe3Fz09W3j" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zG3ojNL9m2S6" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437,931&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_ziNZU4uDeHS8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zTxNimT4MLA6" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zTeOEsCSCMX9" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z3y6w2gFVXj4" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zu6LytumgCfl" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zaL2hyh1NTn8" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTGwkPz2xG48" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBX7fOKkWOIf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4V6RH8XRZ" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zgCjWH6wHzU8" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUMhdzPuOyF2" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zVBRnY2D73Pa" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zkpTu0a2QLS7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zZGgLYt84Ws3" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4Thc450ADql" title="Range of exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zfXP9059l2D8" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zL8GybeHIOrf" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zg6Y8d4U2Wc1" title="Warrants weighted average exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zwAdIiRn3P99" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zY3Hr46dtLjl" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,316&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJXkHQlANyLd" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z1z77Gq6krb5" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zgP6M7hcSRmf" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zy6wQpztR4Oi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQ4ge4H0Enel" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZrzNVWbttfj" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUp7oXuCfEg3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,769,894&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zkk3adYBfwAa" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlr2WDuWOEI3" title="Warrants weighted average exercise price"&gt;11.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000633"
      unitRef="USDPShares">0.0001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">326251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">0.0001</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000639"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">604138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      id="Fact000643">P3Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">2.02</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000647"
      unitRef="USDPShares">2.8375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">21145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      id="Fact000651">P4Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000653"
      unitRef="USDPShares">2.8375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact000655"
      unitRef="USDPShares">4.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">437931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFourMember"
      id="Fact000659">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact000661"
      unitRef="USDPShares">4.35</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact000663"
      unitRef="USDPShares">5.4375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">88800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeFiveMember"
      id="Fact000667">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">5.4375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact000671"
      unitRef="USDPShares">30.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSixMember"
      id="Fact000675">P3Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact000677"
      unitRef="USDPShares">30.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">37.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeSevenMember"
      id="Fact000683">P2Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">37.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">102.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Shares">1867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeEightMember"
      id="Fact000691">P0Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact000693"
      unitRef="USDPShares">102.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">165.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">52316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeNineMember"
      id="Fact000699">P0Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">165.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">206.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact000705"
      unitRef="Shares">7780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember_custom_RangeTenMember"
      id="Fact000707">P0Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact000709"
      unitRef="USDPShares">206.25</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000711"
      unitRef="Shares">1769894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-03-31_custom_WarrantsMember"
      id="Fact000713">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">11.91</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">166667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">25935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">16132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000725">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwX7pgJKqPTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zAFYiX5utv6d" style="display: none"&gt;Schedule
of Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250331_zoyRoudq3b57" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_z06l8W2piFsh" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250331_z3b7CHLeCNgg" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zUt0FrITAJs7" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250331_zPhtp7JDkKn8" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_z95YfFOnKPt" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250331_zv5tGuY6zQ39" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zX4lrtnt3Yri" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0741"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250331_zD65Ylh3Gdia" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_z57GoByABuV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250331_zFAS13N4juP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250331_zejkIcCibhig" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000729"
      unitRef="USDPShares">32.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000745"
      unitRef="USDPShares">32.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">107746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">37.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-03-31" id="Fact000751">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000753"
      unitRef="USD">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000759"
      unitRef="USD">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">107746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">29000</GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000765">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zyjW5WJYy61a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of March 31, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zE9N8n3wJHgg" style="display: none"&gt;Schedule
of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Options Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSJscntedLyg" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zx9QbJXzLLpj" style="width: 22%; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zQ0kMtC25rCf" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcO51nuYSHgj" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmzqmTT8fNo9" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z93huJfABi3b" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zt6FOBpqvvu5" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBNSj0IXaYZ4" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuSUHk5vpgY7" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNbwl6Pt93j2" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zA8tdYPN4d02" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDW3rlOB6ZMe" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zwhfLDvXzjNl" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9BnGNSHZ0He" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,598&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zFOtwcsmrZjg" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zncA8Sd9SxS9" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250331_zuBHkw7zoKO" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">6482</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-03-31_custom_RangeOneMember"
      id="Fact000771">P9Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">2.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000775"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">16666</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-03-31_custom_RangeTwoMember"
      id="Fact000779">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000781"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000783"
      unitRef="USDPShares">25.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-03-31_custom_RangeThreeMember"
      id="Fact000787">P7Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">25.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-03-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact000791"
      unitRef="USDPShares">74.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-03-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Shares">34598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-03-31_custom_RangeFourMember"
      id="Fact000795">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-03-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact000797"
      unitRef="USDPShares">74.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">107746</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000801">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zc8SMVyfROOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_824_zyzj1qzzqKfd"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Litigation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ohri
Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#x2019;s termination as &#x201c;for cause&#x201d; under his Employment Agreement, and that the
Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#x2019;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#x2019;s violations, and attorneys&#x2019;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#x2019;s claims against
him and counterclaims for breach of his Employment Agreement and Separation Agreement. A final hearing is scheduled for June 10th through
June 12&lt;sup&gt;th&lt;/sup&gt;, 2025 in Los Angeles, California. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TWF
Global Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 24, 2023, TWF Global, LLC (&#x201c;TWF&#x201d;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#x201c;Notes&#x201d;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader
against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#x2019;s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against
TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released
from all associated liability and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further
briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal
of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company&#x2019;s shares of common
stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its
motion for entry of default. On November 14, 2024, the Court held a hearing on the parties&#x2019; motions, at which the Court found that
the motion for entry of default was mooted by the settlement agreement between Z-One and TWF. The Court ordered that the case be dismissed.
On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. Z-One
alleges that it was assigned TWF&#x2019;s rights under the Notes and seeks enforcement and damages. The Company intends to demand a complaint,
and seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will continue to vigorously
defend against these claims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Significant
Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cytovance
Biologics, Inc., a Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#x2019;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#x201c;SOWs&#x201d;) for the research and development of products for use
in clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#x2019;s common stock. The Agreement also set
Cytovance&#x2019;s beneficial ownership limitation at &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zfMcsPGWvxnl" title="Equity method investment, ownership percentage"&gt;4.9&lt;/span&gt;% of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#x2019;s
beneficial ownership limitation to &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zkp7b1QCa1yf" title="Equity method investment, ownership percentage"&gt;9.9&lt;/span&gt;% of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zTE98MUzPjo9" title="Equity method investment, ownership percentage"&gt;5&lt;/span&gt;% of the issued and outstanding shares of the
Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2025 and 2024, the Company recognized research and development expenses of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ztsFX4tZvack" title="Research and development expenses"&gt;532,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zO2EyNRGvkW9" title="Research and development expenses"&gt;269,000&lt;/span&gt;, respectively
and made cash payments amounting to $&lt;span id="xdx_905_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEDoDKfhFJla" title="Cash payments"&gt;268,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zVY4YmLT5XXi" title="Cash payments"&gt;1.8&lt;/span&gt; million, respectively to Cytovance. In addition, during the three months ended
March 31, 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCurDIOPHccl" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares of common stock exercisable at $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zpD7Rxv9VGS6" title="Exercise price"&gt;0.0001&lt;/span&gt; per share
to settle accounts payable valued at approximately $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zO2Ka33UbCR2" title="Fair value"&gt;847,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of March 31, 2025, amounted to approximately $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250331_z53srMILBFR8" title="Stock issued during period, value, issued for services"&gt;340,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Sponsored Research Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#x201c;2016
Exclusive Patent License Agreement&#x201d;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zh6DWCbwdbv3" title="Aggregate research and development expense"&gt;1.7&lt;/span&gt;
million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue
work with the Company with three major goals in mind: (1) support the Company&#x2019;s TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; product development and commercial
GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; constructs in support of the Company&#x2019;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#x2019;s native NK cell population as a result
of alteration of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform through formation of
immune complexes. Most studies will use TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; DNA/amino acid sequences created by the Company under existing licensing
terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense classified as research and development of approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zWZdkyXQkoZh" title="Research and development expense"&gt;216,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zXseZOlerf0a" title="Research and development expense"&gt;0&lt;/span&gt;, pursuant to the 2023 Sponsored Research
Agreement, for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately
$&lt;span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zLZJIjB5Cgk3" title="Unbilled and unaccrued amounts"&gt;431,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2016
Exclusive Patent License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#x201c;2016 Exclusive Patent License Agreement&#x201d;), to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;
&lt;/sup&gt;technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement,
the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology
worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses,
authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that
is responsible for the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology, including without limitation the FDA and
the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $&lt;span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaKAnwukyRc9" title="Proceeds from upfront amount"&gt;200,000&lt;/span&gt;,
and license maintenance fees of $&lt;span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zrXh9Dhcofh6" title="License maintenance fees"&gt;200,000&lt;/span&gt; for years 2017 through 2020, and $&lt;span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC4A8jhsmpf1" title="License maintenance fees"&gt;100,000&lt;/span&gt; per year beginning in year 2021 and each year thereafter.
The agreement also includes &lt;span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRmu9QtmMku7" title="Royalty fee percentage"&gt;4&lt;/span&gt;% royalty fees on the net sales of licensed products, not to exceed &lt;span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8diRgQ6C1x1" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements
or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zYH1rcxPToIj" title="Annual royalty payments"&gt;250,000&lt;/span&gt;
beginning in 2022, $&lt;span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zTZtSEr2gjfk" title="Annual royalty payments"&gt;2&lt;/span&gt; million beginning in 2025, and $&lt;span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zpsVCA0HSLgd" title="Annual royalty payments"&gt;5&lt;/span&gt; million beginning in 2027 throughout the remainder of the term. The agreement
also includes numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC52exVIqrUg" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time
sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4cTs8f3Kws2" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0X3KFkdir5l" title="Sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zGirNm8CUO4" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpDqzo0BCb59" title="Cumulative gross sales"&gt;500&lt;/span&gt; million
in cumulative gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $&lt;span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zeRgcHdKc9f9" title="Proceeds from upfront amount"&gt;145,000&lt;/span&gt; and amends the license maintenance fees to $&lt;span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zR3YMluBFCzl" title="License maintenance fees"&gt;50,000&lt;/span&gt; in 2025, and $&lt;span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzMEedMHqRi5" title="License maintenance fees"&gt;100,000&lt;/span&gt;
per year beginning in year 2026 and each year thereafter. The amendment also includes &lt;span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z12AY91gMeh3" title="Royalty fee percentage"&gt;1&lt;/span&gt;% to &lt;span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_ziMp5TbXWo3i" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed
products, not to exceed &lt;span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zM1KXx3x2d5c" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $&lt;span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zdCC7QaRZ8dj" title="Royalty expense year one"&gt;250,000&lt;/span&gt; in year one, $&lt;span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z2pNVMJjzdW3" title="Royalty expense years two through five"&gt;2&lt;/span&gt; million in years two through five, and $&lt;span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6S7suzfhzRe" title="Royalty expense year six and thereafter"&gt;5&lt;/span&gt; million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $&lt;span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zAzVnZtiVoPf" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone, and one-time sales milestone payments of $&lt;span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zK53mAG9qiv7" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zWzIY80Yh00c" title="Gross sales"&gt;250&lt;/span&gt;
million in cumulative gross sales, and $&lt;span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0jBDvMtM0h" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOOBR0g3DEW9" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2016 Exclusive Patent License Agreement, for
the three months ended March 31, 2025 and 2024, respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021
Exclusive License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#x201c;2021
Exclusive Patent License Agreement&#x201d;), specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. The agreement requires an upfront payment
of $&lt;span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znLmoDlx0DWl" title="Upfront license fee"&gt;20,000&lt;/span&gt;, and license maintenance fees of $&lt;span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zYdTsFu4Jvkg" title="License maintenance fees"&gt;5,000&lt;/span&gt; per year beginning in year 2022 and each year thereafter. The agreement also includes
&lt;span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_znbYlqDn5jzg" title="Royalty fee percentage"&gt;2.5&lt;/span&gt;% to &lt;span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zie4hXnFhB08" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $&lt;span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9iERo7RCfw9" title="Royalty expense year one though four"&gt;250,000&lt;/span&gt; in year one though four, and $&lt;span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zXrhXuADoEI5" title="Royalty expense year five and thereafter"&gt;2&lt;/span&gt; million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zQRII04gULUf" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million,
and one-time sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zUgOqKOynOSk" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zhYXIHztk9b6" title="Gross sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zECnFA4wSMag" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching
$&lt;span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0PrTzZxhM3k" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024
GTB-3650 Clinical Trial Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#x201c;Agreement&#x201d;) with
the Regents of the University of Minnesota (the &#x201c;University&#x201d;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#x201c;IND&#x201d;) application for IND 165546 GTB-3650 (the &#x201c;Research Program&#x201d;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#x201c;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#x201d; designed
by the University (the &#x201c;Study&#x201d;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJ2TWPY1a1I9" title="Annual royalty payments"&gt;2&lt;/span&gt; million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#x2019; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the three
months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of March 31, 2025, amounted to approximately $&lt;span id="xdx_908_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zwfUhapHa0bf" title="Unbilled and unaccrued amounts"&gt;1.9&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Contingency
&#x2013; NASDAQ Matters&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2024, we received a letter (the &#x201c;Notification Letter&#x201d;) from the Nasdaq Listing Qualifications Staff (the &#x201c;Staff&#x201d;)
notifying us that the amount of our stockholders&#x2019; equity had fallen below the $&lt;span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zWhIClx7GmW7" title="Contigency minimum required"&gt;2,500,000&lt;/span&gt; required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#x201c;Minimum Stockholders&#x2019; Equity Requirement&#x201d;). Nasdaq&#x2019;s determination
was based upon our stockholders&#x2019; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#x2019;s Listing Rules.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#x2019; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#x2019;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff has not, as yet, accepted our plan of compliance, and has requested additional information
regarding our financing plans. We can provide no assurance that the Staff will accept our plan of compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Staff does not accept our plan of compliance, or if the Staff accepts our plan but we do not regain compliance within the allotted
compliance period, Nasdaq will provide notice that our Common Stock will be subject to delisting. If our Common Stock is delisted from
Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected.
We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our Common Stock and could harm
our business and future prospects. In addition, we believe that, if our Common Stock is delisted, our stockholders would likely find
it more difficult to obtain accurate quotations as to the price of our Common Stock and it may be more difficult for stockholders to
buy or sell our Common Stock at competitive market prices, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As a result of the private placement
of preferred stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#x2019; equity on
an unaudited proforma basis of at least $&lt;span id="xdx_90F_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zBlgubIXYp27"&gt;2.5
&lt;/span&gt;million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#x2019; Equity Requirement, so if at the time of the filing of the Company&#x2019;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#x2019; Equity Requirement, the Company may be subject
to delisting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Pure">0.049</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Pure">0.099</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">532000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">269000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">268000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-03-31_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      id="Fact000815"
      unitRef="USD">1800000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000819"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000821"
      unitRef="USD">847000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="Fact000823"
      unitRef="USD">340000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="-5"
      id="Fact000825"
      unitRef="USD">1700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">216000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">431000</us-gaap:UnbilledReceivablesCurrent>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">200000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Pure">0.04</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="-6"
      id="Fact000845"
      unitRef="USD">2000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember"
      decimals="-6"
      id="Fact000847"
      unitRef="USD">5000000</us-gaap:RoyaltyExpense>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000849"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000851"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000853"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000855"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000857"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000859"
      unitRef="USD">145000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">50000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000865"
      unitRef="Pure">0.01</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOne
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000871"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOne>
    <GTBP:RoyaltyExpenseYearTwoThroughFive
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000873"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearTwoThroughFive>
    <GTBP:RoyaltyExpenseYearAfterSix
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000875"
      unitRef="USD">5000000</GTBP:RoyaltyExpenseYearAfterSix>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000877"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000879"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000881"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000883"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000885"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <us-gaap:CostMaintenance
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">5000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Pure">0.025</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOneThoughFour
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOneThoughFour>
    <GTBP:RoyaltyExpenseYearAfterFive
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000897"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearAfterFive>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000899"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000901"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000903"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000905"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000907"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-6"
      id="Fact000909"
      unitRef="USD">2000000</us-gaap:RoyaltyExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-5"
      id="Fact000911"
      unitRef="USD">1900000</us-gaap:UnbilledReceivablesCurrent>
    <GTBP:ContigencyMinimumRequired
      contextRef="AsOf2024-11-21"
      decimals="0"
      id="Fact000913"
      unitRef="USD">2500000</GTBP:ContigencyMinimumRequired>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="-5"
      id="Fact000914"
      unitRef="USD">2500000</us-gaap:StockholdersEquity>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000916">&lt;p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zymEbTqntKxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82F_zgmdGiGTFph7"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#xae;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z6BajPcYxsb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zWidqRMLRzE7"&gt;&#160;Schedule
of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zA4G2M2ZwHx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z1aFGXbjAcyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_z9cJNughFMI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,099,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_zz8H0owUszgh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;281,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;478,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zarglEP7naQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_z9nTiw93Kmcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_zZJZjr6CJWP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zU0BPIoETkBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,156,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(825,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_zWP7DprIbtAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,266,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_ziN8c525UXb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000918">&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z6BajPcYxsb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zWidqRMLRzE7"&gt;&#160;Schedule
of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zA4G2M2ZwHx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z1aFGXbjAcyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_z9cJNughFMI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,099,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_zz8H0owUszgh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;281,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;478,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zarglEP7naQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_z9nTiw93Kmcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_zZJZjr6CJWP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zU0BPIoETkBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,156,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(825,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_zWP7DprIbtAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,266,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">1099000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000921"
      unitRef="USD">777000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000923"
      unitRef="USD">281000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">478000</us-gaap:SalariesAndWages>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">61000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">76000</us-gaap:InsuranceCommissions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">3000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">102000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">488000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">1658000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000935"
      unitRef="USD">-1156000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">-825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_SegmentsMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">2266000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-03-31" id="Fact000941">&lt;p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zyGbQyvFd9x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_826_zWnD1FqdvU67"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Private
Placement of Preferred Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with the purchasers
identified therein (collectively, the &#x201c;Purchasers&#x201d;) providing for the issuance and sale to the Purchasers of (i) up to &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zz972VTyQWZ4" title="Issuance of shares"&gt;6,056&lt;/span&gt;
shares of the Company&#x2019;s Series L 10% Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;), (ii) warrants to purchase
up to a number of shares of common stock of the Company (the &#x201c;Common Stock&#x201d;) equal to 100% of the shares of the Company&#x2019;s
Common Stock issuable upon conversion of the shares of Preferred Stock (the &#x201c;Common Warrants&#x201d;), and (iii) warrants to purchase
up to a number of shares of Company&#x2019;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities
Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#x201c;Vesting Warrants&#x201d; and together
with the Common Warrants, the &#x201c;Warrants&#x201d;), with an aggregate stated value of $&lt;span id="xdx_900_ecustom--AggregateStatedValue_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z8mmq31JkZq8" title="Aggregate stated value"&gt;6,055,555.56&lt;/span&gt;, for an aggregate purchase price
of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp2d_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2cAQYuXz5Z3" title="Issuance of shares, value"&gt;5,450,000.00&lt;/span&gt; (the &#x201c;Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Preferred Stock with an aggregate stated value of
up to $&lt;span id="xdx_903_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zb2u2Ro1KElc" title="Aggregate stated value"&gt;22,000,000&lt;/span&gt; (the &#x201c;Greenshoe Rights&#x201d;) for an aggregate purchase price of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zkK2ri3mtiW8" title="Issuance of shares, value"&gt;19,800,000&lt;/span&gt;, subject to adjustments, as further
described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its respective Greenshoe Rights for an amount
of Preferred Stock equal to the ratio of such Purchaser&#x2019;s original subscription amount to the original aggregate subscription amount
of all Purchasers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of the State of Delaware. The Certificate of Designation
creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms and conditions on which shares of such
preferred stock would convert into shares of our Common Stock, as well as its liquidation preference.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Preferred Stock may be converted at any time at the
option of the Purchasers into shares of the Company&#x2019;s Common Stock at an initial conversion price of $&lt;span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zV3PxbyJaOvg" title="Conversion price per share"&gt;2.043&lt;/span&gt;, subject to certain
conditions, as further described in the Certificate of Designation. In addition, the holders of the Preferred Stock are entitled to receive
cumulative dividends at the rate per share (as a percentage of the stated value per share) of &lt;span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znds67Q5LTbd" title="Percentage of dividend"&gt;10&lt;/span&gt;% per annum until May 11, 2026, increasing
to &lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z1ZxQIBGo3Hf" title="Percentage of dividend"&gt;12&lt;/span&gt;% per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date
of issuance of the Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in cash, shares of the
Company&#x2019;s Common Stock (subject to the Company&#x2019;s satisfaction of the conditions set forth in the Certificate of Designation),
or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right to require the Company to redeem
the Preferred Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser will be issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#x2019;s Common Stock equal to 100% of the Conversion Shares underlying the Preferred Shares issued to such Purchaser and
(ii) a Vesting Warrant (the exercisability of which shall vest ratably from time to time in proportion to the Purchaser&#x2019;s (or its
permitted assigns&#x2019;) exercise of such Purchaser&#x2019;s Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement), each
to purchase up to a number of shares of the Company&#x2019;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined
in the Securities Purchase Agreement) applicable to such Purchaser, in accordance with the Securities Purchase Agreement. The Common
Warrants have an initial exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zkRxuMFo5CRc" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, are exercisable, subject to certain ownership limitations, immediately upon
issuance and have a term of exercise equal to &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zlK1aofvSut9" title="Warrants term"&gt;five years&lt;/span&gt;. The Vesting Warrants have an initial exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zrJFqDRUCFo1" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, are
exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_z6770Fcc7XY4" title="Warrants term"&gt;five years&lt;/span&gt; from the date that
the applicable warrant shares vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $&lt;span id="xdx_90E_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zNaBdThHfaPf" title="Floor price"&gt;0.454&lt;/span&gt; per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the Common Stock issuable upon conversion of the Preferred
Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement within 30 days after the initial closing
and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met, &lt;span id="xdx_900_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcZ3aywStsZj" title="Liable of liquidated damage percentage, description"&gt;the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser pursuant to the Securities Purchase Agreement. Further, if the Company fails to pay such liquidated
damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registerable
securities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than &lt;span id="xdx_90B_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmnSTL5m2KG3" title="Common stock shares outstanding percentage"&gt;19.99&lt;/span&gt;% of the number of shares of the Company&#x2019;s Common Stock outstanding on the date of the initial closing (&#x201c;Shareholder
Approval&#x201d;). In connection with the required Shareholder Approval, all of the Company&#x2019;s officers and directors (each a &#x201c;Voting
Agreement Party&#x201d;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;As a result of the private placement of preferred
stock and common stock warrants that occurred on May 12, 2025, the Company believes it has stockholders&#x2019; equity on an unaudited
proforma basis of at least $&lt;span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn5n6_c20250512__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zY4bT4X5pN59"&gt;2.5
&lt;/span&gt;million as of the date of the filing of this Form 10-Q. Nasdaq will continue to monitor the Company to ensure its ongoing compliance
with the Minimum Stockholders&#x2019; Equity Requirement, so if at the time of the filing of the Company&#x2019;s next periodic financial
statements the Company does not evidence compliance with the Minimum Stockholders&#x2019; Equity Requirement, the Company may be subject
to delisting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;Private Placement &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On May 14, 2025, the Company entered into a common
shares purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with investors (collectively, the &#x201c;Investors&#x201d;) relating to
a committed equity facility (the &#x201c;Facility&#x201d;). Pursuant to the Purchase Agreement, the Company has the right from time to time
at its option to sell to the Investors up to $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTqv6CHtzxRg" title="Warrants to purcahse"&gt;20&lt;/span&gt;&#160;million of its common stock subject to certain conditions and limitations set forth
in the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Sales of the shares of common stock to the Investors
under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion
and will depend on a variety of factors, including, among other things, market conditions, the trading price of the common stock and determinations
by the Company regarding the use of proceeds of such shares of common stock. The net proceeds from any sales under the Purchase Agreement
will depend on the frequency with, and prices at, which the shares of common stock are sold to The Investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The purchase price of the shares of common stock that
the Company elects to sell to the Investors pursuant to the Purchase Agreement will be &lt;span id="xdx_90E_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT8BiduZLyMj" title="Weighted average volume price of common stock percentage"&gt;93&lt;/span&gt;% of the volume weighted average price of the
shares of common stock during the applicable purchase date on which the Company has timely delivered written notice to the Investors directing
it to purchase shares of common stock under the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In connection with the execution of the Purchase
Agreement, the Company agreed to issue to the Investors a pre-funded warrant to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvKjJULH1Zpb" title="Warrants to purcahse"&gt;300,000&lt;/span&gt; shares of common stock as consideration
for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to the satisfaction of the conditions
set forth in the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Settlement
of Vendor Payable in Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to March 31, 2025, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdUMIZJwVhO4" title="Issuance of shares"&gt;50,000&lt;/span&gt; shares of common stock and warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHWhc5W0n8Qg" title="Warrants to purchase shares"&gt;50,000&lt;/span&gt; shares of common stock as settlement
of a vendor payable amounting to approximately $&lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20250401__20250515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgruVu5MrxD3" title="Issuance of warrant to settle vendor payable"&gt;200,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">6056</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="2"
      id="Fact000945"
      unitRef="USD">6055555.56</GTBP:AggregateStatedValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="2"
      id="Fact000947"
      unitRef="USD">5450000.00</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact000949"
      unitRef="USD">22000000</GTBP:AggregateStatedValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">19800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-112025-05-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Pure">0.10</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact000959"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      id="Fact000961">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember"
      id="Fact000965">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DerivativeFloorPrice
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="INF"
      id="Fact000967"
      unitRef="USDPShares">0.454</us-gaap:DerivativeFloorPrice>
    <GTBP:LiableOfLiquidatedDamagePercentageDescription
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember"
      id="Fact000969">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser pursuant to the Securities Purchase Agreement. Further, if the Company fails to pay such liquidated
damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registerable
securities.</GTBP:LiableOfLiquidatedDamagePercentageDescription>
    <GTBP:CommonStockSharesOutstandingPercentage
      contextRef="From2025-05-122025-05-12_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Pure">0.1999</GTBP:CommonStockSharesOutstandingPercentage>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-05-12_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="-5"
      id="Fact000972"
      unitRef="USD">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact000974"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:WeightedAverageVolumePriceOfCommonStockPercentage
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Pure">0.93</GTBP:WeightedAverageVolumePriceOfCommonStockPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-05-15_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-15_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-04-012025-05-15_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">200000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000422"
          xlink:label="Fact000422"
          xlink:type="locator"/>
        <link:footnote id="Footnote000463" xlink:label="Footnote000463" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accounts
                                            Payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), a Related Party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000422"
          xlink:to="Footnote000463"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000423"
          xlink:label="Fact000423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000423"
          xlink:to="Footnote000463"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000425"
          xlink:label="Fact000425"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000425"
          xlink:to="Footnote000463"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000427"
          xlink:label="Fact000427"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000427"
          xlink:to="Footnote000463"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000506"
          xlink:label="Fact000506"
          xlink:type="locator"/>
        <link:footnote id="Footnote000529" xlink:label="Footnote000529" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000506"
          xlink:to="Footnote000529"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000508"
          xlink:label="Fact000508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000508"
          xlink:to="Footnote000529"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000510"
          xlink:label="Fact000510"
          xlink:type="locator"/>
        <link:footnote id="Footnote000530" xlink:label="Footnote000530" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000510"
          xlink:to="Footnote000530"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000512"
          xlink:label="Fact000512"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000512"
          xlink:to="Footnote000530"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000514"
          xlink:label="Fact000514"
          xlink:type="locator"/>
        <link:footnote id="Footnote000531" xlink:label="Footnote000531" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000514"
          xlink:to="Footnote000531"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000516"
          xlink:label="Fact000516"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000516"
          xlink:to="Footnote000531"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000518"
          xlink:label="Fact000518"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000518"
          xlink:to="Footnote000531"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000520"
          xlink:label="Fact000520"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000520"
          xlink:to="Footnote000531"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0522"
          xlink:label="xdx2ixbrl0522"
          xlink:type="locator"/>
        <link:footnote id="Footnote000532" xlink:label="Footnote000532" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on no dividends
paid or expected to be paid</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0522"
          xlink:to="Footnote000532"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0524"
          xlink:label="xdx2ixbrl0524"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0524"
          xlink:to="Footnote000532"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
